<SEC-DOCUMENT>0001178670-19-000005.txt : 20191031
<SEC-HEADER>0001178670-19-000005.hdr.sgml : 20191031
<ACCEPTANCE-DATETIME>20191031160340
ACCESSION NUMBER:		0001178670-19-000005
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191031
DATE AS OF CHANGE:		20191031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36407
		FILM NUMBER:		191183650

	BUSINESS ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		STREET 2:		HENRI A. TERMEER SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		STREET 2:		HENRI A. TERMEER SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>alny-20190930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2019 Workiva--><!--r:5d2595a3-a26b-49fe-8f15-878ed8f526a8,g:8c29cc34-fc93-4a2b-96ed-ef5f86bbe907,d:24e82a76d5714f7fbfe5363b9e000fce--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:alny="http://www.alnylam.com/20190930" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y18yLTEtMS0xLTA_d841bbd0-351f-42ab-9f00-eb96e727fd5b">false</ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y180LTEtMS0xLTA_72add366-b9a9-407c-a3ed-eed3346a0d58">2019</ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y181LTEtMS0xLTA_7eed0625-d2c4-42d7-87d6-a47129c55022">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y184LTEtMS0xLTA_d78d2b9d-16c6-4d2a-8796-c04e4aec3d41">0001178670</ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y185LTEtMS0xLTA_31cdae7b-584a-4ca3-a1ac-a2d70615195d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="if894ca33791d422190136819871eb3fe_D20190401-20190630" name="alny:InvestorAgreementDescription" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81Mi9mcmFnOjkyYTNmM2QwMWY0YTRkNjc5YmE4NzE3Nzg4MDUyYjAxL3RhYmxlOjczNDM5MGE3ZmE5YjQ3M2VhODdkNjUxZjZkY2ViOWUzL3RhYmxlcmFuZ2U6NzM0MzkwYTdmYTliNDczZWE4N2Q2NTFmNmRjZWI5ZTNfMS0xLTEtMS0w_18763693-775a-4ab9-baf6-1386ca7cd19d">until the earlier of (i)&#160;the fifth anniversary of the expiration of the last to expire royalty term or the earlier termination of the collaboration agreement, as amended by the Collaboration Amendment, and (ii)&#160;the date after December&#160;31, 2021 on which the beneficial ownership of Sanofi Genzyme and its affiliates no longer represents at least 5% of the outstanding shares of common stock, Sanofi Genzyme and its affiliates will be bound by certain &#8220;standstill&#8221; provisions, including an agreement not to propose or support a proposal to acquire us.</ix:nonNumeric><ix:nonNumeric contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" name="alny:DiscoveryPeriodOfProgramsDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81Mi9mcmFnOjkyYTNmM2QwMWY0YTRkNjc5YmE4NzE3Nzg4MDUyYjAxL3RhYmxlOjczNDM5MGE3ZmE5YjQ3M2VhODdkNjUxZjZkY2ViOWUzL3RhYmxlcmFuZ2U6NzM0MzkwYTdmYTliNDczZWE4N2Q2NTFmNmRjZWI5ZTNfMi0xLTEtMS0w_16a7300e-935f-4b9e-a1a5-7090021e95f2">P5Y</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="i7f917e7daa184219863485fd13588358_D20190425-20190425" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81Mi9mcmFnOjkyYTNmM2QwMWY0YTRkNjc5YmE4NzE3Nzg4MDUyYjAxL3RhYmxlOjkxYjFkYTZhNTQ3ZjQyYmY4OGI1ZWZiYTY1NjlhYzM0L3RhYmxlcmFuZ2U6OTFiMWRhNmE1NDdmNDJiZjg4YjVlZmJhNjU2OWFjMzRfMS0xLTEtMS0w_48ece2a5-869c-45a6-b6e4-45e11b8a1288">4,444,445</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id9dfbac5853146558814da5e8f5ea8a7_D20190927-20190927" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMjg2L2ZyYWc6NmUyMzVlOWNiNmM5NDJmMWFlMWE0MjAwZGI2MmExM2YvdGFibGU6M2I5ZTllMThkODYzNGU0NGJmYmMxYjdlMGNiMDkwYmEvdGFibGVyYW5nZTozYjllOWUxOGQ4NjM0ZTQ0YmZiYzFiN2UwY2IwOTBiYV8wLTEtMS0xLTc5MzY_4263998f-4e5b-4ab4-a591-12c24b89dcec">0.2222</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="INF" format="ixt:zerodash" name="alny:ImpairmentOfMarketableDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82NC9mcmFnOjZlYzc3ZmI4ZTIzNjQyOTNhZWE4MTNiMTVjYWY4MDU4L3RhYmxlOjNmY2FiODQ2OTliZjQzNDhiODVlM2Y4ZWNjNjBlN2Q5L3RhYmxlcmFuZ2U6M2ZjYWI4NDY5OWJmNDM0OGI4NWUzZjhlY2M2MGU3ZDlfMS0xLTEtMS0w_4b0de892-bac3-4c6f-bfd0-ef997789beb3">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="alny:ImpairmentOfMarketableDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82NC9mcmFnOjZlYzc3ZmI4ZTIzNjQyOTNhZWE4MTNiMTVjYWY4MDU4L3RhYmxlOjNmY2FiODQ2OTliZjQzNDhiODVlM2Y4ZWNjNjBlN2Q5L3RhYmxlcmFuZ2U6M2ZjYWI4NDY5OWJmNDM0OGI4NWUzZjhlY2M2MGU3ZDlfMS0yLTEtMS0w_f523bd1f-8b88-491b-a9e9-3a9dfd10e0bd">&#8212;</ix:nonFraction><ix:nonNumeric contextRef="i65a3b729d2b6434facd1ef9436293344_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNC0xLTEtMS0w_26ea3475-eee6-4293-b588-649a04b1d793">true</ix:nonNumeric><ix:nonNumeric contextRef="i57addb2cc587477995144b49e9eba89b_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNS0xLTEtMS0w_52d0bb59-5900-47dd-828e-8fa6d876b6b8">true</ix:nonNumeric><ix:nonNumeric contextRef="i1997e78a21c14482b37dd96a0a0275a3_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNi0xLTEtMS0w_b1d38623-484e-42e0-9d9d-47290d5b9987">true</ix:nonNumeric><ix:nonFraction unitRef="renewaloption" contextRef="i16dd0de9646a4fda905e58f333423af5_D20150401-20150430" decimals="INF" name="alny:NumberOfLeaseExtensionOptions" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNy0xLTEtMS0w_38194835-fa70-4512-8c22-c1129eea568c">2</ix:nonFraction><ix:nonFraction unitRef="renewaloption" contextRef="i9fd9e2e99e294a098eb38e91d8de00b3_D20030925-20030926" decimals="INF" name="alny:NumberOfLeaseExtensionOptions" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOC0xLTEtMS0w_05abdb26-e2d5-4f03-b8df-94e345e29a41">2</ix:nonFraction><ix:nonFraction unitRef="renewaloption" contextRef="i9c1b26358b0c4c7dbcbb8cdd284463c8_D20150501-20150531" decimals="INF" name="alny:NumberOfLeaseExtensionOptions" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOS0xLTEtMS0w_45eca64b-0786-4d18-93e7-369388527a7b">1</ix:nonFraction><ix:nonNumeric contextRef="i8fc4dafdb8224f2fa05374c12dc848bb_I20190930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNy0xLTEtMS05ODU1_57b355f2-d2e2-4f2b-9c64-375d23cb492c">five years</ix:nonNumeric><ix:nonNumeric contextRef="i1856e4d8c9854c78af384a4826058c3a_I20190930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOC0xLTEtMS05ODU1_334241ae-5c93-4486-8ada-c3114b645efc">five years</ix:nonNumeric><ix:nonNumeric contextRef="i2a15eda5822d49eeae29c67db90ce4d3_I20190930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOS0xLTEtMS05ODU2_a6d6fd84-18ee-4e45-9041-1e638e3e3645">five years</ix:nonNumeric><ix:nonNumeric contextRef="i387bd39383dc463f807be6d966c8ee8a_D20150301-20150331" name="alny:ExtendedLeaseExpirationMonthAndYear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfMTAtMS0xLTEtMA_5db7cd60-8f75-4278-9c70-209721af81a5">2024-03</ix:nonNumeric><ix:nonNumeric contextRef="i9c1b26358b0c4c7dbcbb8cdd284463c8_D20150501-20150531" name="alny:ExtendedLeaseExpirationMonthAndYear" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfMTEtMS0xLTEtMA_a5f768fd-3f4a-478d-be2e-f25beb7d362f">2021-06</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alny-20190930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9a8cdc1b5f3342449f15e9e82f596399_I20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib290959e61784a1896b905564c991cdf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifd31099009a341cebcc213b46e1c6c76_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290fb1f9477f4b0dad6a294dbebe5fe0_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica700222a11442d3b8b92d9f887edb3c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4b5651a52648659bb33699e1f159aa_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc6569f4b7a54920b4b016ec2a2307d1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca8122b23ae48f2b7a30429c7434451_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia035051af8af48248146e9bb253e5b61_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id872e0d52c5f4349b6ad645fc3ff01c6_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaba2b198691462eb220d545c5071fa7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f94264251c43368c4771d54ce4fbd2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffcea211cbf84b608c3df605df16aac5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af99066d2354ca1a75dbe6369056527_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af6d69e893a4d178a9cfecc6e32e66d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220bc1041a80494185ddcfda3b0920a1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3341252d93974bdca224a07c275ae6cc_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibde364f980be4b1aa95846761f001d51_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb00a6eb479d40d3939afd5036703227_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib05e1ba0f35d45f5bd5774c207913ccb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd648aa81acc49a38c586a7482708782_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd48e7dae264b53b2ee1bacea526327_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a53da1f63ae4fd38c49af1968eb03e4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1d8229c0cc4d28a3d73367d8687475_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29880daf69f1436f8c9e07a5d1f26e39_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f06f86af24b4bb8b2e3262a34d11cd3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8e567ccacd4802a6318a2e2c459b14_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f18bc840ab43f281968996981ebe97_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092004fdf6b04a69ac3ae56810e7b8ef_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca4e4838440486c8f5a7b55f1575484_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875fbab980f042debc104cf45c8ae36a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efbe15735524508ab0312ffd4616e7b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i051b47be2e4f44b18624cfd7fb7d1e52_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10915d8296543898e5c6c6185f06b70_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a18a2febb21461088839dc562e86825_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000b407bc82d4af584eae0ea4da200e8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dda98ef75fa4c0cabaec8f6917de928_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8260434ced747a89db3a4a3760f382a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb8b45ba98c4ea79afcd93e804e2e31_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00290d9a0ceb4932b342087b2d02c362_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia298b62308334655b29761118e628026_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51590640cc3445e8236acd0882c53a5_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b902bb76314b22b35d3d375909326c_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017bcda5f3f84bd0b08d262246dc8609_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9375ef392e4486bbab8ee684ac7c28_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c50c0a9426f4d279cde7bc33c6203d6_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb5c2da414142a58bef1ad8643452f0_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9c4ad3ea6f43f8b03c5853acc51d01_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ed32556e304de6860f08c6da60b133_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic604e629a18e47f48644038e508838aa_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if084fb52c6fd4a039d5f4dc8424a4453_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079b65915ef04049ab59dcf69c973f75_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade6d453882449f8b0ad8daf7e4d39e5_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8833025058462db2992db44ec3934e_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibddc1e81c5e54e42822e1311df259ceb_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief21c0d90240476b8922ccee38864765_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3e88d620de4614b17853b7a58ca2e2_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b36842a761546ef807e31ee2522a096_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef4dd7f09d947d493d5f4436cf0c0e9_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15fa7b634fd4daea03b505c756c59bd_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb493b807d924cf39624accb949af88c_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a7aaddfaf542bbbf7a06985850a41f_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9f25a7c241a4588906a002ff847246a_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c54b97117a54dc9a2281403a9143f40_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a7f979d1744d46907e2fe5ef13d747_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib666c190ab3a4d4aa6556b9c46d1eb1d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ad1e878ba7413bba91fe1bdec91294_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5fc643144f4f66a3f3e5fbd015f089_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e5da0497604cffa89334d054aa8689_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47bf377672994a6989a0ffc4fda88279_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6977f9771bb9474f9b987ea4acb6e766_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58cef5166244621bfaed56c877e6047_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76fea3f3c89e4d38be0558a94f330d68_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedca81ec08d84b71974e26397c92d1df_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a9dd2ed7f84b8eabd7dbe77bd4bede_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5944d6095a8a4e978f43fe95bdf38b47_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib789d44f74694f1ba05ae665b85e3c8d_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94dc645833714139975f0211dc2191fb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida54ff3bad294ce5853890d30053bb7c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c27321c10b343b58de158e6d3db20e5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a1f0c21c27441983ec53e357768237_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd9ee786c8c474d9a7bb46eff4d0397_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97807f37924b4995a48c769fc07945fa_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a811b4311a4914940c20e54952a306_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie144870db8f9498eb7801f4559dd2d72_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i673aa3eee23e4a288c64b4dfedc553da_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e3a21a1c4c4bcdbb03dc8833f4924d_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5884d7e33e4b7d94d106059300af24_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21118dc8b808433e81625e7f2b7884b3_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b4cb7028ab4d418d05a21b47a3728a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ae16923f0f84a86ad6008c568b4b1eb_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c1d7dbd6c148efb6c9867f8e130af1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd904aabd6f4f08942cf7251614b26f_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18fdbb5b94847bb87d8d115277e9ea1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33bd68ff20fc4287ac9b1020d2779301_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1a333dbc9d46f196d16aaf2ceb4132_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c731ed1fbc417b9ee053536a59d9a6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb229db5707849d4a22b3c3e18621842_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841cbe61ae1c4ba5ac3531120ba0c867_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7569b264a69c48a88a61d8ec84e9025a_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ff16a733d64c5fae19a59891cce764_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc350c0de347466695b330f459fefc28_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide82e9762bef4fdeb0c81cbf70048f13_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7cf10b7b2548a080a4c2299f3c7795_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb70ef125a034aa0830cee0808b5cfa1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566f60a947954dc69ddaac57c3b30366_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0bf8fb6901c49edba6c2026ee58fcc4_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bea475b1bd4453e8b3b41aa9c9a011b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide622c05ddce4e44a17a894f34bccbba_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef633268a6c4fcc928100d0671ed5e9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd6cf1430e34457b82db167b81278ef_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc02df567f3e4ff6bf19fc1d69294ac4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia340b62c22e4415db15b4677cf672c04_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9a583b3eaa48f5ad28f2b7e2dc2657_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146c5c0497e044de8cd9a05912301c3c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9592e8ff40504f85af6d1939889fd11b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e703eff2264d08bab65003cdbeaad7_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475658c0ca9e4d928c433d121b265c82_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if449ef4bea9a40ae916cb93478c18048_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45dfd0bcbe484904a18240c95809b63d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5715163b5bd44e09ae21778e01a08ad6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50c807a1f0e4c1492220c3fbd4c4cac_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992ffaac88eb4d129a8f61d7f3155127_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae58e4687c76458cbd799a3532718cc8_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i828961f893674d5694c8381c4f2c012b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c0e609344340b0ac078896c7302e19_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if914afcf9e4744d0b11d5a1478378a35_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527af3a6a1a443b0b18b74a5866a3b90_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79eb574b077e440788e6310bda7ce3dc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39121bec9968473c89779780093452eb_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38c9fe25a9f40e79efe3342ecec48b2_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8470f847a3491dae7d1bcd2f3f6398_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657c2557d02741b08dc2a2dfbc051fd5_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie781c80188954ce28b5095c7ad86743a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89009e721c8458ea441dc7256bae44e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5faa958db3248cf8abd2d51854649c9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0133baa156a644908b72e47c2d43ec0a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66ba49548de4a899fd6450c151c30c3_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185ceb104d524ac2b0dd476c73f39d3b_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fd5aa0223e4864bd917a1eb955fbe1_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f0807ba74548b0a8cae142017dec3a_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1a8dc3c9da43c0b2be902403a125d8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib996cc6e2cef48baa147a3c936b7622d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209d8f822ea54215a8a5a92d1710e4fa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3677fbfc08e94d57801b8fbdfc4f3d18_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d661f5bbcaf4991993d92085c0405ea_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d79f61ae80486795459192eaa096a6_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9911e13cc954763aca179b898c772aa_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f229b2a3d4481b99dbd2a5d30a1bcf_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea900a9c6d3a4cbab86b5bc952e69203_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fae1adbaaf04d2681c00589c86c0041_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c35a882679b407281d6fe08e0b51a82_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a80641a47214d5f91ecd50a0a248023_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90acd6d92ec642f9b7b36589e3268571_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757b55bca5a64fd58f1fab4d5d19add2_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207df81799004a46ba28b23122e5111b_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice65c0bb2b5e417888fde2ff078b534c_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-08</xbrli:startDate><xbrli:endDate>2019-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3a888b47654db19c388966c89d70d3_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-08</xbrli:startDate><xbrli:endDate>2019-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>alny:Program</xbrli:measure></xbrli:unit><xbrli:context id="i910f04c70f8f42eaa89bc212b0fcede9_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtProgramInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6314e00fa4e4a639121892a2b493f92_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtLeadCandidateIdentificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e47a5ab3bd844aca1d5112c5e5bc4fe_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAnAnnualDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia89cc425b8ec4574a3b6d9187fd8d47b_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88df3d689a741d8b329bc0a7ffb25d6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f99093d364045fda1a43bb5fcbfce58_D20190630-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-30</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f1516e126c4492b1083718d689a0b5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e07bf9298b24bbcbbdd5c0c60d0efe0_D20190630-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-30</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb5ab21b5e394f12b80ee7c85f5a6436_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d830c7785d42eca47ab825a3dd466e_D20190630-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-30</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f42feab7e1d44078d72a7646ec908c5_D20190630-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-30</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaea32819b574ef28e3693d2eb5e6e5b_D20190930-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8fa0c4e76a42f2852aac811eb5477f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1583edbcfb14632bce947d08adc1711_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a37ee0addcc471cbc26952515d07305_D20190930-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a05588cdc94fe990de15bb14b81d2e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2478295fa07f441eb5430e16d67ec61e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b9efc823ea4a52a48884c8f7ef46ee_D20190930-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i561b9cbdf5134340b23a4852eff9113a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a69fc879d06480e8231d059d82c9ff1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53189462639a41ea94d96ecc0862a2c7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304e9e4a77f146f1b45c8803228f6a4d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128a21da539642528efe8070e11f3e47_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c55aec91dc4c59ba2a9a3f39ee2da2_I20190117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18255b8b8fa94a3c932e5d83d5508a09_I20190503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a3a0ee563f4e42ad4529debd4b818a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CollaborationAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if894ca33791d422190136819871eb3fe_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CollaborationAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f917e7daa184219863485fd13588358_D20190425-20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-25</xbrli:startDate><xbrli:endDate>2019-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab12e28db7e4641b70a2a645c6a28e8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f78360553254ee782ee02d789c9d889_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697b1bfc24074b85bf27cd5598d3b51b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c50e4c814e74c9491d54d5e4e91af0f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3163fef4430b47c28ff4777546273453_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45fc9bcd587c4f37b74ab016f6cbdefa_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01382b3f2664b17976086250fb17c01_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14a072a848f45a5a23bc9f805fbbd08_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239343e7b44f41dabd006bd02fa42bff_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if099e69b9be14094b333354d839f0f79_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic860375e3027429092c256d65a2d7780_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc53aba859045ecb0ca135b483634d7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe092ad14ecf40ecbc93697363251ede_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0949304a7dde4229b6e753cd9903c40e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0a82f69d8e49c7bf0facdafd02a08b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i891225af6803446f9581a304ba109390_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2fc5c6f5de44f4ad84017a9d68a878_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c36b06d4d7444b1b5923152fba320f9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i635b34a72c56410d8d1df7055596b6b8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99a29ede5ec418db5992d141e96e1af_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3189a838fac44b6aa80a5b0128eeea48_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe3d4c3f27649a5b8cffd56fc6d60d6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic657523a72064bf8a77241824eec1de4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea41bafdaa19451b99ca8455af31092b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e0f6431e4d44508c464f542f15baa9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb09fac19014b80be63710b35a8db33_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de1d13c04544ccda16e21d30fb14653_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782b647a38c84737b078e327971daeba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04ae69b490e4a07b9dd11c6a1a057d8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40aef21a5b0742b6919605b695cba83a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534eab2866fc4b1bb0f1e30546b2550e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d0c030ef7f6469c8c51584431c73bee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf54ff63ecd4190a0aebd37630638c0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51284ca40ae4f409a968f2a88ae537c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d596b8dc524e17b6c9b06b62b6040d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6219fb42fe014e16a1c218a1ab221110_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8081f4ca6b924dd5986fc5e0a2f8b585_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5938ec1fdaa449c2b1ecc81f9993204c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c3b43b17584cae8dac039f9d951a2b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8eaca78602548f881448af5a5dc5dc2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a256ed0c704bdaa3843a8e99ae65b0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786e48af2f8048819a014a47ad5f3590_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64cd7b4acbce48ee8c20aa3dc411db8a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a446afad065485689143f29fefeb88b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc9691ef8ec419190202c98ca260168_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a9ec62896246148cc11c6a75758e7d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc8b8cbc9dc4a3fa34ac39e8ac315bd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d00afa93a0d4d08987a2f888620c445_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f9758c7a5442eb909c35e568f89d1a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6809fdac18e942108fea8b72dfefb89d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563399d00a3f4495921402e83ebb9b19_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d6099e88b14f529fcdbf31508676b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie975d68357554af895cd61a0cde4dbcb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fdecb33a35d4e5eb7f0e714d9cd1534_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8d158421a74475a932f3e1697894c8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ecb9a3c8f1c431198624af0dce809c1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4533404dc7f419c81cf7e77f58ea8c5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6535ccbf5045358595e81d855d972e_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5e31efccf54c278eb1d25e678417d7_I20190926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd70bee38ec4be4894eb36e4bddfaf7_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9dfbac5853146558814da5e8f5ea8a7_D20190927-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-27</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74014017f8ee43b3b9a7e4ef08932177_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3020f4366f48a4bbcc014e09a08814_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21bcaecfc40942ca8fd4007f198b3c58_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63df20ed74a495096a637566cb09eeb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b98f93930b4ca1a7e47371e33fbf42_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d791afc3ff048e39ee8f08279c377d5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6057c3e479cc4cdba31104be591267b3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f2602865d142ab9138159f4fe344a7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16dd0de9646a4fda905e58f333423af5_D20150401-20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:BMRSixSevenFiveWestKendallLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57addb2cc587477995144b49e9eba89b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:BMRSixSevenFiveWestKendallLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd9e2e99e294a098eb38e91d8de00b3_D20030925-20030926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2003-09-25</xbrli:startDate><xbrli:endDate>2003-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a3b729d2b6434facd1ef9436293344_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1997e78a21c14482b37dd96a0a0275a3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>alny:RenewalOption</xbrli:measure></xbrli:unit><xbrli:context id="i9c1b26358b0c4c7dbcbb8cdd284463c8_D20150501-20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fc4dafdb8224f2fa05374c12dc848bb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:BMRSixSevenFiveWestKendallLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1856e4d8c9854c78af384a4826058c3a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a15eda5822d49eeae29c67db90ce4d3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387bd39383dc463f807be6d966c8ee8a_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice75d291b75345eeb04d09221d4ac4bc_D20160429-20160429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-29</xbrli:startDate><xbrli:endDate>2016-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12206eca6a84503bf5e9fcc26bd4ded_D20160429-20160429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-29</xbrli:startDate><xbrli:endDate>2016-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb3e8a8fa91c4e08a54b904445e3b904_D20160429-20160429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-29</xbrli:startDate><xbrli:endDate>2016-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8211fd2babc7426599d8a4da01554401_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436c9f5ba1394239990c555377c133a4_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-21</xbrli:startDate><xbrli:endDate>2019-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc8680a0470f4515bbbb63de4581db15_I20190521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41895d919e574902acb6169b0edb03fd_D20190408-20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-08</xbrli:startDate><xbrli:endDate>2019-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4dc572daa54cea9409b772eff6e606_I20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48cd17bd102c404d9c2fb188602a9b17_I20190425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0fb16a3a7a347cf97e568dd2a32d15f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756073bf9c7c485baa654d9c3b97871c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f962dd9c0f44fafacbd61a3c2eb05e8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6c2484c92b4de1af5da63f0a53a5a3_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27125284d00480e8f6436e54883feb0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c1e473ec654c44910204fe79355acb_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a903160824485588e14c40fe27e4f4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20fa348345c43e6aa0c88af9024338c_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76aae8848c0147d7b950df899aa1ee06_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a29165453f749cf90320576aab15e8e_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b94502431eb4c5aafa0614d51c18e74_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebaaccb3176d4aea882b953a0bfbd222_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i635ef6dc444f45e2a67366c5fb673343_I20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4abb8539eed44421b7213ceef0389203_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alny:LandAndCostsRelatedToConstructionOfManufacturingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20e2ef3281f455ba39063a9f09b371c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alny:LandAndCostsRelatedToConstructionOfManufacturingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:DicernaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-18</xbrli:startDate><xbrli:endDate>2018-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a9655ab33ba47a3b214bdd3432435d3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanFundingStatusAxis">us-gaap:UnfundedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i920d2d842f894f7e86890f2d0f76a285_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71b3c59a6854c088d21eef4ff92db76_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d215da162a4b1f870322c528da7252_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i668cb2e656af4447be63e110a6773f58_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c726db79a1419ca5405f2c9219f5d5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i730a5054c2f94c9685c25fdcab2d5d7a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14817b988c44e9f97cb96e8be08c094_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f8703c144249dfa1533aa08a4f503a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94bb522921334436b71c747686f4701a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35867a636295441082ae888c09b539e8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca4613a2da84898a3f92d22c8ec8558_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92b2ba692c74f76b138c30a332bc91c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d342895255493b9e648583464cf9bd_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954eab77f4f9402dbb8b521337506e81_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9fea367ee9d4fe88b485027bf9fcb91_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859a77e1c3ee4e5c8d583b9b6ac23528_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285826056b0946b7ba9a170eaa6cc107_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">____________________________________________</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjM5_a03a8c78-a0f5-45c3-b41c-3c2466fa05de">10-Q</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">____________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:3.172414%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.827586%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NmQwNjFlZTI3YzcwNGFkOTlhYWI4ZDZhN2QwMTMyYTQvdGFibGVyYW5nZTo2ZDA2MWVlMjdjNzA0YWQ5OWFhYjhkNmE3ZDAxMzJhNF8wLTAtMS0xLTU1OTE_74bbf66e-065d-49ec-8bfc-843643c83e5b">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN180OTQ3ODAyMzI3MzM2_36f29565-2d4e-476b-8feb-9328dbe11883">September&#160;30, 2019</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:3.172414%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.827586%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGUzZWRmMjYzNjA1NDAzM2JjZjQwMmVhNWRmMmQ4N2QvdGFibGVyYW5nZTo0ZTNlZGYyNjM2MDU0MDMzYmNmNDAyZWE1ZGYyZDg3ZF8wLTAtMS0xLTU1OTU_956155b1-7350-4db6-b028-c2074032111f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:120%;">For the transition period from ___________ to ___________</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:120%;">Commission File Number <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjYw_def41ee8-a7e2-4bda-81fd-046625a7202d">001-36407</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">__________________________________________</span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:24pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjYx_1fe5ab2e-09ce-4394-aa6e-bc17359e2a73">ALNYLAM PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">__________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDQzYTk5MzFlOTYzNGEwYTk0NDNlNjg3Njg1MGUxNjgvdGFibGVyYW5nZTowNDNhOTkzMWU5NjM0YTBhOTQ0M2U2ODc2ODUwZTE2OF8wLTAtMS0xLTU2MTAvdGV4dHJlZ2lvbjowYmNjMGU5ZDUwNmE0NjFiYjI5NjBlODcxNjA4NTM4NV83Njk2NTgxMzk0NTE3_76e391a3-42b6-480e-a01e-ae4d7b616049">Delaware</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(State or Other Jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Incorporation or Organization)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDQzYTk5MzFlOTYzNGEwYTk0NDNlNjg3Njg1MGUxNjgvdGFibGVyYW5nZTowNDNhOTkzMWU5NjM0YTBhOTQ0M2U2ODc2ODUwZTE2OF8wLTEtMS0xLTU2MDQvdGV4dHJlZ2lvbjo1NjAyODkxMmMyYzc0NzNmODg2Y2E2NjEyMWE1Yjc3M183Njk2NTgxMzk0NDk1_d85410b7-c591-4d37-8989-7aa925005101">77-0602661</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NTYz_8aa17cda-f6c3-45e5-a437-f334adc08f04">675 West Kendall Street,</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NTg4_8231dc9a-0b80-465a-862c-715f085e79b4">Henri A. Termeer Square</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NTk5_7a980b84-b540-42ca-9905-745b3f97dce0">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NjAz_3bb3fa6f-b04f-4799-92dd-5085e080d3eb">MA</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTEtMS0xLTU2NTAvdGV4dHJlZ2lvbjowMzAyZGJmOWZmZWM0ZjMxOWVjMWM2YWNiMGMxNDUxN183Njk2NTgxMzk0NDU5_9a70a2bf-6a45-4381-af20-37baf05538e3">02142</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjY4_7d24202a-b4c8-47f7-a039-335988c278e3"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjY4_cba741b9-46b2-4d8e-b3e9-787ee25b37f9">617</ix:nonNumeric></ix:nonNumeric>) <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2Njc4_12c3623a-e143-4084-8cbb-d07429e427e3"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2Njc4_adacebce-dd41-44ee-862c-06653e3d4f41">551-8200</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">__________________________________________</span></div><div style="padding-left:45pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:0.1%;"></td><td style="width:1.093103%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:26.160920%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.465517%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.160920%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.465517%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.160920%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.093103%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of Each Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of Each Exchange on Which Registered</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGNhNTUwMmJhNmZjNDkwODhlODkyZGU1YjIwNGNkZGMvdGFibGVyYW5nZTo0Y2E1NTAyYmE2ZmM0OTA4OGU4OTJkZTViMjA0Y2RkY18xLTEtMS0xLTU2NjQ_fafd858b-6df0-4388-b013-0735779261c6">Common Stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGNhNTUwMmJhNmZjNDkwODhlODkyZGU1YjIwNGNkZGMvdGFibGVyYW5nZTo0Y2E1NTAyYmE2ZmM0OTA4OGU4OTJkZTViMjA0Y2RkY18xLTMtMS0xLTU2NjE_aa35e2d9-fc07-4d5c-88cd-3a4467e23271">ALNY</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGNhNTUwMmJhNmZjNDkwODhlODkyZGU1YjIwNGNkZGMvdGFibGVyYW5nZTo0Y2E1NTAyYmE2ZmM0OTA4OGU4OTJkZTViMjA0Y2RkY18xLTUtMS0xLTU2NjY_a0d7888f-406a-4aac-9041-0794e79ab323">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2Njgz_60fc73b6-fce9-45c6-9da3-02c9641ca5f7">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN184MjQ2MzM3MjEwNTc2_ef7090bd-cd8b-4562-a182-f0ac0a36ab03">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:23.862069%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.396552%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.862069%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.879310%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDcyNWI5MDFhYWNiNGU5NzhhZmU1ZjE5YmVjNTY4YzQvdGFibGVyYW5nZTowNzI1YjkwMWFhY2I0ZTk3OGFmZTVmMTliZWM1NjhjNF8wLTAtMS0xLTU2OTA_daba9f11-a9db-44eb-95df-1ae3d26ad5e2">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDcyNWI5MDFhYWNiNGU5NzhhZmU1ZjE5YmVjNTY4YzQvdGFibGVyYW5nZTowNzI1YjkwMWFhY2I0ZTk3OGFmZTVmMTliZWM1NjhjNF8xLTMtMS0xLTU2OTI_6cf49de8-f2a5-4c92-82cb-93d13096ad3e">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDcyNWI5MDFhYWNiNGU5NzhhZmU1ZjE5YmVjNTY4YzQvdGFibGVyYW5nZTowNzI1YjkwMWFhY2I0ZTk3OGFmZTVmMTliZWM1NjhjNF8yLTEtMS0xLTU2OTQ_9ffed6a7-3204-4af2-8cda-563d111fb73d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN184MjQ2MzM3MjEwNTc5_bc3104f4-5883-444d-bccd-c2250a48d2e8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9pt;font-weight:400;line-height:120%;">x</span></div><div style="text-indent:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">At October&#160;25, 2019, the registrant had <ix:nonFraction unitRef="shares" contextRef="i9a8cdc1b5f3342449f15e9e82f596399_I20191025" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN18yNzQ4Nzc5MDcxNjI4_8e65eb00-0c71-49ac-a38a-f709ed895ac2">111,489,744</ix:nonFraction> shares of Common Stock, $0.01 par value per share, outstanding.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div id="i_0_7"></div><div style="text-align:center;margin-top:10pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:89.800878%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.199122%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">PAGE<br/>NUMBER</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">PART I.&#160; FINANCIAL INFORMATION</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_16">ITEM 1. FINANCIAL STATEMENTS (Unaudited)</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2019 AND DECEMBER 31, 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">THREE AND </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_31">8</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_106">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_106">23</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_127">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_127">32</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_130">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_130">33</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_133">PART II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_136">ITEM 1.LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_136">34</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_139">ITEM 1A.RISK FACTORS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_139">34</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_142">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_142">64</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_145">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_145">65</a></span></div></td></tr></table></div><div style="margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8220;Alnylam,&#8221; ONPATTRO</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#174;,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Alnylam Act</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#174; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">and Alnylam Assist</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#174;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> are registered trademarks of Alnylam Pharmaceuticals, Inc. Our logo, trademarks and service marks are property of Alnylam. All other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.</span></div><div id="i_0_10"></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_13"></div><div><span><br/></span></div><div id="i_0_16"></div><div style="text-indent:11.25pt;text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:82.8pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except per share amounts)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMy0xLTEtMS0w_f5e246dd-25ff-4ff6-a20b-eee09d9211d7">923,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMy0zLTEtMS0w_5e2e5141-962d-4475-8ea5-679648350755">420,146</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNC0xLTEtMS0w_3ed8334e-b006-4f00-b762-709cdecd59b0">797,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNC0zLTEtMS0w_e06e68ec-4d92-4444-9bc9-6e025d4d5f37">662,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNS0xLTEtMS0w_99ddf4ec-33c1-48bc-b424-74483aaa88aa">48,109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNS0zLTEtMS0w_e45dfe19-6c08-427d-b7b2-4d76e28fc5b5">18,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNi0xLTEtMS0w_01ab0886-95f1-4db6-a7df-839ae86daa7b">54,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNi0zLTEtMS0w_bb5e4c33-c893-4360-9e52-2a29dac54904">24,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNy0xLTEtMS0w_aa714bb6-44a3-4284-97ba-1658b0eec4c9">73,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNy0zLTEtMS0w_d93d253f-198b-4396-b349-87750118e01e">74,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOC0xLTEtMS0w_93d9862d-6dda-4c49-9d56-4dcb10695b36">1,897,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOC0zLTEtMS0w_90ceb5c1-a493-4618-9d21-7d3ee5d4cfe5">1,200,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOS0xLTEtMS0w_d87b04f7-75be-4910-8c53-34cbe5f8d818">396,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOS0zLTEtMS0w_a76f8484-1c94-4b53-92d8-c834500d9f0c">320,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTAtMS0xLTEtMA_63162a4a-7ccc-4e15-bb7c-2dc56ee2e77e">223,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTEtMS0xLTEtMA_2afa308f-97e8-46e3-9117-4f41ed8f1850">14,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTEtMy0xLTEtMA_1614e027-16b6-42a1-b27e-91d42f8c2887">44,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTItMS0xLTEtMA_01181ed3-16cf-4f75-9e42-395d5917154f">9,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTItMy0xLTEtMA_0b348047-a4e1-4021-bec2-ac17ef45967d">8,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTMtMS0xLTEtMA_51c4b41c-d7bf-48e8-9280-17d98ae79e9a">2,541,622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTMtMy0xLTEtMA_f69ff540-3de0-4568-8e91-dc86627c736e">1,574,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTYtMS0xLTEtMA_6993998a-1436-4cc5-bedd-da175b69fe85">39,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTYtMy0xLTEtMA_415afaa6-72ed-47fa-a1e3-402d534764b1">59,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTctMS0xLTEtMA_97498ab9-ddaf-4f45-bec2-8d2f3be7cd93">177,948</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTctMy0xLTEtMA_fa0fab48-fa29-44b9-9829-a7f37dd2071a">112,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTgtMS0xLTEtMA_ae0b4fbb-fb95-4338-aa66-27e87c4cb2ce">28,165</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTktMS0xLTEtMA_38b82136-ac48-432e-a08b-bdd5142516c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTktMy0xLTEtMA_c400a66a-7871-4bfb-bb58-37e75158d35f">3,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjAtMS0xLTEtMA_f30648f0-8a5e-42ba-80c4-3861d14e05b7">107,359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjAtMy0xLTEtMA_a1cb1025-1cf1-4870-9f2e-6925573337ab">3,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjEtMS0xLTEtMA_2e007876-3277-4574-be80-9ec72449da29">352,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjEtMy0xLTEtMA_67fe0407-bf2e-4dab-bcc5-19052989643c">179,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjItMS0xLTEtMA_f8c57b3e-b240-41f3-81f0-000c31f5ab56">276,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjMtMS0xLTEtMA_dc1e4cf3-f323-411c-854c-4c1456b46496">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjMtMy0xLTEtMA_0c2cb3f2-a15b-4df6-9f5b-ea5fbac4f055">57,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjQtMS0xLTEtMA_c6447645-316d-4578-9516-6cdd4826c3f7">296,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjQtMy0xLTEtMA_ded29d0b-872e-4740-9d46-f0509da29034">458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:SecuredLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjUtMS0xLTEtMA_1a2a7692-507c-4138-9c46-a5d5d673e871">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjUtMy0xLTEtMA_4d9bf921-64ea-43c3-9cb2-d089a66775a2">30,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjYtMS0xLTEtMA_072b9e0e-200b-430a-9fe1-8b97e3a383fd">9,036</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjYtMy0xLTEtMA_e8646ea7-c5ec-4cea-ba61-4eaed141ecce">4,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjctMS0xLTEtMA_21c849d2-7c2a-4b66-8391-2d81ec316ea7">934,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjctMy0xLTEtMA_70606bd3-ee09-4cdb-95a1-6f06d81ce61b">272,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjgtMS0xLTEtMA_ffa44f50-5806-4c33-89c0-49836775322c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjgtMy0xLTEtMA_79a98d28-3180-49de-b17d-134dbf090f0e"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjA_018679a5-754a-4b5c-b2cf-be84e0f059d9"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjA_0975cf92-c60c-43ae-a7de-1577968b0bbc">0.01</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="shares" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNTI_19ae5d8f-0d7a-47b2-ad4f-2177cb8960da"><ix:nonFraction unitRef="shares" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNTI_e3bf0285-7841-418a-945d-3fab01b44e94">5,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_40ccd47e-7f35-4183-b35e-1abaa8ce6e2b"><ix:nonFraction unitRef="shares" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_7a1ca825-948c-4d3b-b31f-9eece72c273c"><ix:nonFraction unitRef="shares" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_a888ec10-677f-4c7f-8b49-b875211708cd"><ix:nonFraction unitRef="shares" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_ff8bd4ed-b590-4dd9-9857-8122334a786a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2019 and December 31, 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMS0xLTEtMA_3802835f-0926-49c5-a947-079f0926c18c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMy0xLTEtMA_c78c92fb-c9fd-48f1-84ba-e6c10060dd8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MDc_73e52c20-c57e-4874-8a6d-c0da8302278e"><ix:nonFraction unitRef="usdPerShare" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MDc_74bd10f0-d74d-4474-a176-748c49623d36">0.01</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="shares" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MTY_2b6fc916-e6ae-4d8d-a7fc-1b08139bbd48">250,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MjY_2ebb89e0-9da2-4f22-983a-4f45c4a9ee9b">125,000</ix:nonFraction> shares authorized as of September 30, 2019 and December 31, 2018, respectively; <ix:nonFraction unitRef="shares" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MzY_3e101a77-6ba8-4033-b169-8a193d61e1f7"><ix:nonFraction unitRef="shares" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MzY_f9ba635f-0030-40f6-836f-c4f2ae307579">111,325</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2019; <ix:nonFraction unitRef="shares" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3NDY_50769c7b-6717-4a4a-92e5-e729958966bb"><ix:nonFraction unitRef="shares" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3NDY_feef3572-4521-4e40-b457-65fec1f1eefb">101,177</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMS0xLTEtMA_86dbcfd7-ca29-4ecc-abfc-3b79151af448">1,113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMy0xLTEtMA_e33dc866-8e18-4bf7-9a2d-8a540275a39f">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzItMS0xLTEtMA_d0c3b4a1-caf0-4c68-8567-1232a2de19d5">5,091,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzItMy0xLTEtMA_121b9833-3bef-429a-8d99-965207c7c00d">4,175,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzMtMS0xLTEtMA_15438dc6-99a4-4d25-b398-b48b29bf3dcf">34,371</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzMtMy0xLTEtMA_3253325c-7231-4e8f-a761-12bb6ebac4a1">33,213</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzQtMS0xLTEtMA_02ccbe99-17b9-437c-891e-5ea4190fdae9">3,450,903</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzQtMy0xLTEtMA_837146d7-7f1d-4f9e-bce1-db77496e4740">2,840,972</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzUtMS0xLTEtMA_77e0085c-c629-44da-86fe-f080e4d8ac87">1,607,087</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzUtMy0xLTEtMA_daab6aab-d7c4-42ae-b47c-2a87a87c2dfc">1,301,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzYtMS0xLTEtMA_151401a8-f32a-4f8d-9374-84d8a3a1d9fe">2,541,622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzYtMy0xLTEtMA_7ef17e86-7715-4a0b-92d6-b57ce49722d8">1,574,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div id="i_0_22"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:79.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except per share amounts)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.533724%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.316716%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.316716%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.316716%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.316716%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenues, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd31099009a341cebcc213b46e1c6c76_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy0xLTEtMS0w_e8d0d415-bb82-4034-83ad-51dafb686ff7">46,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i290fb1f9477f4b0dad6a294dbebe5fe0_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy0zLTEtMS0w_7ff6723b-4de9-4182-a917-04f45603e464">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica700222a11442d3b8b92d9f887edb3c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy01LTEtMS0w_67955aa3-3151-472a-b14a-68bed1f930a1">110,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e4b5651a52648659bb33699e1f159aa_D20180101-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy03LTEtMS0w_5ab455b4-5df1-4624-b941-4227c34a86c2">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenue from collaborators</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc6569f4b7a54920b4b016ec2a2307d1_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC0xLTEtMS0w_5e6c3bda-8509-4cfe-bf15-1dd4cd5a7ecf">23,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ca8122b23ae48f2b7a30429c7434451_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC0zLTEtMS0w_54e5d02b-7ddf-403d-a7a5-17fa608ab373">1,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia035051af8af48248146e9bb253e5b61_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC01LTEtMS0w_0786bebd-6be5-4ed3-9836-d8879fe3f435">37,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id872e0d52c5f4349b6ad645fc3ff01c6_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC03LTEtMS0w_3c5d79dc-e3c1-4304-b1d5-550b74947875">53,415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS0xLTEtMS0w_c9a2b140-38b2-43c2-8ed5-31003fd68edc">70,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS0zLTEtMS0w_6bcc3829-7b71-4c88-bed5-8c87388a04ea">2,069</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS01LTEtMS0w_ceab7c29-fc23-482d-9933-de25e541bdb0">148,069</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS03LTEtMS0w_37f43646-7d83-44c0-814e-bc1d097c6666">53,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy0xLTEtMS0w_6db34680-efd0-4a4c-be10-49f879c3982b">5,213</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy0zLTEtMS0w_9821d23a-48db-463b-a2d6-9c1095bb66c3">137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy01LTEtMS0w_001b81ad-0e79-42de-ad02-c5e00478ed43">12,886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy03LTEtMS0w_77968cec-7622-4c0b-97e7-80c6f3df1234">137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC0xLTEtMS0w_946cbff7-27ae-4c37-ab51-efad8f9a327c">160,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC0zLTEtMS0w_153fe748-14fe-49e9-a7ca-c19f8c057b7c">139,945</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC01LTEtMS0w_ff0b92bb-646f-43d5-9e20-ca7c8a104bf9">453,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC03LTEtMS0w_97749a03-3720-4841-b671-e7bb0858d4f0">374,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS0xLTEtMS0w_0476a779-5767-4f42-bada-1b46fedc11ea">120,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS0zLTEtMS0w_ef9a864a-8190-4867-ae03-48a412390cc1">116,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS01LTEtMS0w_fdcb7201-e828-4a7b-8f16-07717dfc9e2e">322,728</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS03LTEtMS0w_9af39ab4-8f97-4cde-8b40-e6bac1432ce6">273,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtMS0xLTEtMA_1b53cdc4-45b9-4472-801b-fd0df8072f99">286,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtMy0xLTEtMA_ea40c06f-8bb8-4c34-a32e-0cd56c1f2ed4">256,627</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtNS0xLTEtMA_65d9752a-b1e3-4e2b-8b9c-30b7393b186b">789,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtNy0xLTEtMA_c579f330-80e0-40a4-8fe4-b60cb43ee5a0">648,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtMS0xLTEtMA_20910e61-ddeb-472b-ab47-c9cd16ce0b66">216,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtMy0xLTEtMA_3e8d0d1a-648e-47f7-9f30-580aead3817b">254,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtNS0xLTEtMA_18adcd3c-559c-4698-b912-dd02210d2718">641,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtNy0xLTEtMA_647f740d-8f8c-4035-a846-6dac7549630a">594,317</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtMS0xLTEtMA_0aed29d4-3de7-41fd-bbab-a105b2ec5183">9,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtMy0xLTEtMA_d30855e2-f9c5-4113-a60d-0bfe17afc972">6,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtNS0xLTEtMA_c4f5dcc9-3bef-4a53-8106-cf75ff5f25e9">26,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtNy0xLTEtMA_bfce9bc5-34c5-4dce-8bcd-a5d0ceeaee4a">18,691</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other (expense) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtMS0xLTEtMA_87558b1f-0c81-4c37-9836-9b062a995221">2,519</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtMy0xLTEtMA_e64b1e95-1e5b-4cfd-984c-05e15012b221">2,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtNS0xLTEtMA_5b2323d0-5a4e-4ceb-87bc-114c69751500">2,929</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtNy0xLTEtMA_8fe33f42-64d3-4c9a-83ed-77dfd865fc44">5,468</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of liability obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="alny:ChangeInFairValueOfLiabilityObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtMS0xLTEtMA_7a1c6275-f74b-4a39-b609-b00e1630ea51">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="alny:ChangeInFairValueOfLiabilityObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtMy0xLTEtMA_897dc6d0-53b7-4825-8858-f103d59ae38f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:ChangeInFairValueOfLiabilityObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtNS0xLTEtMA_f4bd5a00-132f-435a-bc64-c30c3c5c0c29">9,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="alny:ChangeInFairValueOfLiabilityObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtNy0xLTEtMA_a4e97c13-7851-489b-b414-0e6dcf8e3e6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on litigation settlement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtMS0xLTEtMA_c894593b-3d4e-4448-bd23-0858aa5aa811">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtMy0xLTEtMA_b6674db0-2926-4b44-9384-5667f568c2d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtNS0xLTEtMA_6aec7726-d661-4e86-8b13-cf935bacf805">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtNy0xLTEtMA_9dda0b90-4458-4f67-9470-0f6efe4710f3">20,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctMS0xLTEtMA_407cf781-d776-46ce-a68f-85efe0a22354">7,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctMy0xLTEtMA_522fdc79-ef3c-472b-9e17-25c85ff1efd9">9,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctNS0xLTEtMA_7ad3d1a1-e6d4-4ba8-a1aa-76fe29a4bdd0">32,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctNy0xLTEtMA_fb209675-6ccf-40d5-8b2e-0643222e3428">44,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtMS0xLTEtMA_d3af2f6e-93c7-47e5-b45a-e676542c79b1">208,929</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtMy0xLTEtMA_1a923487-2e26-4700-8506-06a8878fa276">244,837</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtNS0xLTEtMA_5d2817cb-e7d0-4fbb-85c4-e4343f2d1e26">608,670</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtNy0xLTEtMA_f9864f5c-e8fd-49ac-b27c-21440ba6f7f3">549,594</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Benefit (provision) for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktMS0xLTEtMA_7101b1f8-028a-44cd-bf78-f4ee228990cc">394</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktMy0xLTEtMA_6183ca93-21d2-428d-b03f-a8d3a51fff8b">445</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktNS0xLTEtMA_a7677fef-2659-4a81-bbe9-adcc48290a8b">1,261</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktNy0xLTEtMA_208e0f8b-04a7-4cdb-8b1a-7b43ff0ebc92">462</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtMS0xLTEtMA_cffb5cab-81a9-4521-a724-cdb20e3583d3">208,535</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtMy0xLTEtMA_b7f324b1-dffe-47c8-a109-9f6adb1eedbd">245,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtNS0xLTEtMA_dc23a6f4-0429-4f45-9253-71a872ec5f71">609,931</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtNy0xLTEtMA_b6513247-5e86-4a8e-8fd3-f0ebe1cdae98">550,056</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share - basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtMS0xLTEtMA_b04eb59b-4308-4393-9c9f-9334ae3c85c5">1.92</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtMy0xLTEtMA_85111dc3-da66-4a1c-9bd2-e9d6ce0832ff">2.43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtNS0xLTEtMA_f6ee7ad2-0eab-4040-bd33-755b4e045876">5.63</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtNy0xLTEtMA_3dc5f339-d46f-48cb-8be2-a0a31dfa17a2">5.48</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average common shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItMS0xLTEtMA_86f02471-cf57-45ed-bef2-9da06db1b524">108,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItMy0xLTEtMA_e739eae7-7fac-43bd-8ad7-622bc2afe0cc">100,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItNS0xLTEtMA_7acc7a49-f5ad-4801-8fe8-39ba531dbbe7">108,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItNy0xLTEtMA_168fcdcc-fb0d-4b2f-a35a-7770fd50f76f">100,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtMS0xLTEtMA_dfa621a5-77ab-467f-93f1-aabf0fb1fdfa">208,535</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtMy0xLTEtMA_ff2825bb-8e43-405d-befc-d8b07e3d0ce3">245,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtNS0xLTEtMA_6fb80732-9c3a-4944-b586-bffa64a564a7">609,931</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtNy0xLTEtMA_9878388b-a957-4194-88d1-bb02ca2491c0">550,056</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (loss) gain on marketable securities, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtMS0xLTEtMA_e4f9cbaf-167e-46cf-a593-dd105cff1441">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtMy0xLTEtMA_aad6b794-566a-4818-ae56-6467cf16ed47">415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtNS0xLTEtMA_8cfde77b-e376-4d86-bb11-c3f7fb4ce81e">772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtNy0xLTEtMA_65413823-6099-48bc-8c25-1dd29e10d0c5">1,041</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtMS0xLTEtMA_79c22805-1415-4570-b1a1-37bfe4390a4e">1,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtMy0xLTEtMA_4391b1da-5227-47df-8e0e-adc75b23dcbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtNS0xLTEtMA_760335c8-4d03-4660-a9d2-6475a663d371">2,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtNy0xLTEtMA_a648e16a-f724-4e48-81d3-a53789862a44">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined benefit pension plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctMS0xLTEtMA_fafb910c-d5ac-407b-8262-cbd1671385cd">71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctMy0xLTEtMA_7177428e-d000-4252-b9a0-78df42937851">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctNS0xLTEtMA_008750e2-041d-47d4-903d-40a3bd185a74">4,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctNy0xLTEtMA_91cbd74f-8640-4a9a-8be4-3cde09c31e7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtMS0xLTEtMA_6e69aa9a-fba2-4280-87de-3341af045361">207,075</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtMy0xLTEtMA_e01289f3-066b-4b39-8a43-144b7c530da5">244,867</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtNS0xLTEtMA_c4c173a6-1216-4ffc-a3cd-0bcae9069b52">611,089</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtNy0xLTEtMA_f48fe766-9891-467f-b8c1-8def61bf7ed6">549,015</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div id="i_0_25"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:79.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:34.904762%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.848485%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.848485%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.064935%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.497835%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.064935%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.064935%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Comprehensive</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">(Loss) Income</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icaba2b198691462eb220d545c5071fa7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi0xLTEtMS01NDI_f5845ca4-c183-4de7-9f03-c3f103305949">101,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icaba2b198691462eb220d545c5071fa7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi0zLTEtMS01NDI_77cc3cd6-b416-40db-99dc-645e1b5d79f3">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31f94264251c43368c4771d54ce4fbd2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi01LTEtMS01NDI_39747f7a-7607-40c8-9bff-933ae5053dc8">4,175,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iffcea211cbf84b608c3df605df16aac5_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi03LTEtMS01NDI_ff6e9696-ba8a-4a3b-b7bf-521910632920">33,213</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4af99066d2354ca1a75dbe6369056527_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi05LTEtMS01NDI_557389a7-20a2-448f-be63-c9d848692fa3">2,840,972</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi0xMS0xLTEtNTQy_add762f2-565b-48bd-a5c6-1461ca3b9037">1,301,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy0xLTEtMS01NDI_41dabe39-82eb-44b0-afae-f826d991b59d">207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy0zLTEtMS01NDI_81e5bf5c-6960-4e9d-a29f-a4fe38cf4e0f">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy01LTEtMS01NDI_162079e0-68ab-4c49-b713-1b3e6d6108cb">11,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy0xMS0xLTEtNTQy_ceb24c49-768c-498a-b8dd-cae4d0097104">11,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under equity plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNC0xLTEtMS01NDI_0ca07f57-ec80-4417-8ec2-e428e04d57d5">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNC01LTEtMS01NDI_3a82cd6c-b08e-4e9d-8119-ca773db16cc6">58</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNC0xMS0xLTEtNTQy_4605d12c-97eb-418a-8e8e-4b806863fa37">58</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNS0xLTEtMS01NDI_30b63b96-1d18-4ab0-a174-44fe9919bfd7">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNS01LTEtMS01NDI_985a6ec0-f25d-4612-9422-19c8a321aaf5">784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNS0xMS0xLTEtNTQy_7ce42070-5d2a-4340-901a-c25e86b938d3">784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi0xLTEtMS01NDI_5231a77b-f3e7-4097-a031-e64462da7388">5,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi0zLTEtMS01NDI_e4617d25-7393-4ca1-b8c6-cf10a3e7e8ad">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi01LTEtMS01NDI_802d52f9-dec6-421b-ad21-747cf483c41f">381,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi0xMS0xLTEtNTQy_a965299f-832b-409d-805d-379dafd709f1">381,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNy01LTEtMS01NDI_042630e7-c456-4bb6-9d52-1cbca64c8b87">32,541</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNy0xMS0xLTEtNTQy_eb2b2be5-2cc3-4cf4-b644-690ae30ef8bb">32,541</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive gain, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1af6d69e893a4d178a9cfecc6e32e66d_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOC03LTEtMS01NDI_c1f431ee-e64d-437a-a94a-c2fe793e443c">360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOC0xMS0xLTEtNTQy_ea3c4384-488b-4289-9927-642f69788e59">360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i220bc1041a80494185ddcfda3b0920a1_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOS05LTEtMS01NDI_ffe772dc-1b77-453e-a284-101e107d53f6">181,915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOS0xMS0xLTEtNTQy_8d08b1a9-a108-40d2-9fbd-e0bc80654e14">181,915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3341252d93974bdca224a07c275ae6cc_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtMS0xLTEtNTQy_e5f4a689-02bd-4dc8-8a7b-eec1d3ff8f39">106,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3341252d93974bdca224a07c275ae6cc_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtMy0xLTEtNTQy_fe8dca6c-d81e-42ad-b354-0b8690d3adfd">1,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibde364f980be4b1aa95846761f001d51_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtNS0xLTEtNTQy_bc597501-9d3b-4c3d-82b2-7cfa4110d746">4,601,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb00a6eb479d40d3939afd5036703227_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtNy0xLTEtNTQy_f319515c-1d77-40ed-80b1-e9613817459b">32,853</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib05e1ba0f35d45f5bd5774c207913ccb_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtOS0xLTEtNTQy_535babb5-3eb1-4e59-97f4-03b805f910e3">3,022,887</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd648aa81acc49a38c586a7482708782_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtMTEtMS0xLTU0Mg_54863137-d20f-4287-8893-08babae2bf9d">1,546,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtMS0xLTEtNTQy_bb899cd0-235a-4c2d-bc1d-804fad569f2c">203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtMy0xLTEtNTQy_799f78dc-a7b7-4bf5-923f-4f83a058d567">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtNS0xLTEtNTQy_842f1044-8679-48c1-8cd3-8ce3e2dfaef9">6,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtMTEtMS0xLTU0Mg_6cb782d4-cb00-4938-a57e-65d6b98b6a69">6,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under equity plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTItMS0xLTEtNTQy_ca2bc661-30cf-48c9-867c-e9205aa82d9d">55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTItNS0xLTEtNTQy_363babad-34ed-49df-b5dc-4f8be1f733bb">4,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTItMTEtMS0xLTU0Mg_412435c7-e19a-4e06-9dca-e40e8fedea7f">4,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTMtMS0xLTEtNTQy_2ed36301-88a2-486d-96b0-46483cd6dba2">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTMtNS0xLTEtNTQy_72ab8e59-f4c1-400f-ad0e-415e38009338">1,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTMtMTEtMS0xLTU0Mg_458bfc5c-ff64-472f-a8fc-4fc16c6afaf4">1,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtMS0xLTEtNTQy_b16085b0-7bad-4830-b440-85e7340409b1">4,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtMy0xLTEtNTQy_086522d7-22f6-4fc5-9f88-b8c75ca49fe7">44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtNS0xLTEtNTQy_d78e8be1-9d27-49fa-bbda-7e5014797d46">390,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtMTEtMS0xLTU0Mg_9f20d5d9-c0bc-44af-a28b-48f36130a8dd">390,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTUtNS0xLTEtNTQy_3c35e2c8-6a64-4a56-a159-f35d5fc2af6d">30,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTUtMTEtMS0xLTU0Mg_be146674-36c4-4576-be04-b59f48b03ac0">30,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9fd48e7dae264b53b2ee1bacea526327_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTYtNy0xLTEtNTQy_71da63b0-cb3b-4a6f-859e-0efe0b2b9738">2,978</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTYtMTEtMS0xLTU0Mg_78ed8170-958c-4d9d-9483-3c0fe377703b">2,978</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5a53da1f63ae4fd38c49af1968eb03e4_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTctOS0xLTEtNTQy_49984ca0-4402-4110-98b1-bff7d6cb96e2">219,481</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTctMTEtMS0xLTU0Mg_86ee08cc-d585-488d-bd95-0ceb588c59e1">219,481</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3e1d8229c0cc4d28a3d73367d8687475_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtMS0xLTEtNTU4_a020572f-a3dd-4702-9421-d57f0ed43ec2">111,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e1d8229c0cc4d28a3d73367d8687475_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtMy0xLTEtNTQy_9533f997-2711-4ddc-a438-962cfca49b6e">1,110</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i29880daf69f1436f8c9e07a5d1f26e39_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtNS0xLTEtNTU4_07ab0a13-7d76-461a-9644-50a84d6ccf85">5,034,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f06f86af24b4bb8b2e3262a34d11cd3_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtNy0xLTEtNTQy_00901bbe-3105-4e2a-bceb-9087b70348a9">35,831</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaa8e567ccacd4802a6318a2e2c459b14_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtOS0xLTEtNTQy_c4bad202-48e0-4615-ba61-c9e4672b75e1">3,242,368</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1f18bc840ab43f281968996981ebe97_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtMTEtMS0xLTU0Mg_b44e8850-859e-4600-a609-d3478e294519">1,757,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktMS0xLTEtNTc1NQ_7b4fd297-fc0e-4808-a903-23e86e383c9a">191</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktMy0xLTEtNTQy_6e8d9887-d965-4cda-ad70-6d5c2f84c79f">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktNS0xLTEtNTc2Nw_74ad6e7f-98fe-4615-a09f-83ca3e1e6e72">9,298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktMTEtMS0xLTU0Mg_57845b48-6636-4861-be1b-63ee0ac54050">9,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under equity plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjAtMS0xLTEtNTc1OA_a1951ee6-144d-469d-99c2-fc06e74e8701">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtMS0xLTEtNTQy_b20ff0d5-d7e3-4a3b-9de4-686df1cd913a">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtMy0xLTEtNTQy_7ec3a149-f796-40d5-9d37-aa0aad41073d">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtNS0xLTEtNTc3Mw_45f94e3d-8c47-4fb2-8265-04a796adf8c3">1,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtMTEtMS0xLTU0Mg_225a4b42-1017-4587-a2cd-3824f5ed6d48">1,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjMtNS0xLTEtNTQy_4c65c43d-13db-4a6f-a67e-6687afc13400">46,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjMtMTEtMS0xLTU0Mg_987ff9c4-fe9d-4347-8ffb-6c4068b4cf5b">46,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive gain, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i092004fdf6b04a69ac3ae56810e7b8ef_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjQtNy0xLTEtNTQy_5951a26e-a4fa-43e8-a702-846cfd414b76">1,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjQtMTEtMS0xLTU0Mg_ae85a9c4-be9d-42e1-a265-232634316c80">1,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0ca4e4838440486c8f5a7b55f1575484_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjUtOS0xLTEtNTU4_8dd57d72-e299-42bd-a20a-818802a9b06a">208,535</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjUtMTEtMS0xLTU1OA_6cc4cf39-0165-4f2c-a6ae-ddd1a0c5d35c">208,535</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i875fbab980f042debc104cf45c8ae36a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtMS0xLTEtNTU4_a390f01e-ab3c-4ea0-93cc-156304abd6f7">111,325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i875fbab980f042debc104cf45c8ae36a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtMy0xLTEtNTU4_427e88bc-ef34-408c-acb6-ba09e673e21d">1,113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1efbe15735524508ab0312ffd4616e7b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtNS0xLTEtNTU4_c560c2a0-02c4-4a15-a925-0590adbecd44">5,091,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i051b47be2e4f44b18624cfd7fb7d1e52_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtNy0xLTEtNTU4_574654a2-e610-432a-b730-dce70c5b2d1d">34,371</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia10915d8296543898e5c6c6185f06b70_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtOS0xLTEtNTU4_0598eb5a-e3c9-4367-b3bf-84c4e7d12d28">3,450,903</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtMTEtMS0xLTU1OA_8575a108-a470-43a5-af70-01658c7dc6ae">1,607,087</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:79.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:34.904762%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.848485%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.848485%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.064935%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.497835%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.064935%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.341126%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.064935%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a18a2febb21461088839dc562e86825_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi0xLTEtMS01MDk_2d0660a8-8d03-4225-9d73-b7d1894142b9">99,667</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a18a2febb21461088839dc562e86825_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi0zLTEtMS01MDk_3112bd12-5230-4449-829a-a77c1408455d">997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i000b407bc82d4af584eae0ea4da200e8_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi01LTEtMS01MDk_b6afaea0-5d26-4aef-9c42-bfaac8422078">3,947,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4dda98ef75fa4c0cabaec8f6917de928_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi03LTEtMS01MDk_9ef76488-ce91-4592-b970-7a5e2d8cf9be">34,433</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if8260434ced747a89db3a4a3760f382a_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi05LTEtMS01MDk_adc2aa08-59a5-4259-a640-b40e48154825">2,147,685</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdb8b45ba98c4ea79afcd93e804e2e31_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi0xMS0xLTEtNTA5_d9ec4da6-de8f-4dff-930e-def00b5619ed">1,766,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative effect adjustment from the adoption of new revenue standard</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00290d9a0ceb4932b342087b2d02c362_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMy05LTEtMS01MDk_65953dc4-6344-4042-9af9-2293462b7542">68,210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMy0xMS0xLTEtNTA5_bd5dced0-73ac-45b4-9fed-b18f822dea41">68,210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC0xLTEtMS01MDk_fea64371-b778-4a1a-ab18-a79710aff578">795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC0zLTEtMS01MDk_dfa8ced9-2fe3-40c4-89be-0b546db6737c">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC01LTEtMS01MDk_5534cae7-8901-4e64-b18b-ccf21bfacd49">41,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC0xMS0xLTEtNTA5_ea9912ab-0a4c-4cbc-9017-bf8f6c5ba133">41,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under equity plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNS0xLTEtMS01MDk_51ad22b7-16f8-4850-95a0-6f8b4a476bb1">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNS01LTEtMS01MDk_c8218906-cd83-48bf-8f7e-0f7d34f40556">123</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNS0xMS0xLTEtNTA5_69fa89ec-736c-49e6-852f-7adafa9d1560">123</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNi0xLTEtMS01MDk_1e9d7193-ee93-4382-b539-7db4ec7e38a8">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNi01LTEtMS01MDk_94fac340-6951-42d5-b0ff-c3e409a48555">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNi0xMS0xLTEtNTA5_5301ea2d-a9df-4b0d-bce1-06bb51daf19a">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNy01LTEtMS01MDk_023a7d0f-0bed-4361-9b15-5361b8bc07cf">19,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNy0xMS0xLTEtNTA5_904a12d2-22be-43b7-9795-44c8f78da42d">19,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib6b902bb76314b22b35d3d375909326c_D20180101-20180331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOC03LTEtMS01MDk_3e368fca-0286-48b9-a14e-3e1da05eedfb">420</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOC0xMS0xLTEtNTA5_1cd95c7a-6b80-447b-bee0-38b5513c7fef">420</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i00290d9a0ceb4932b342087b2d02c362_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOS05LTEtMS01MDk_20c39494-c21c-4176-8337-3e7df91d71e9">141,214</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia298b62308334655b29761118e628026_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOS0xMS0xLTEtNTA5_d2730a4c-711a-4a12-9a02-f2b055106bd4">141,214</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of March 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i017bcda5f3f84bd0b08d262246dc8609_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtMS0xLTEtNTA5_d0769e88-c528-4467-9709-8eb17134e377">100,468</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i017bcda5f3f84bd0b08d262246dc8609_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtMy0xLTEtNTA5_4032e454-7b52-40fb-b540-18d1306b9b5b">1,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c9375ef392e4486bbab8ee684ac7c28_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtNS0xLTEtNTA5_8c846c0b-7276-42e1-b971-2ab529c0470e">4,009,342</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6c50c0a9426f4d279cde7bc33c6203d6_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtNy0xLTEtNTA5_35884b9b-fb66-49c2-817c-be12c0eb7d8f">34,853</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5cb5c2da414142a58bef1ad8643452f0_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtOS0xLTEtNTA5_4b08cc5f-8042-4921-a871-36996e37e8ec">2,220,689</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d9c4ad3ea6f43f8b03c5853acc51d01_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtMTEtMS0xLTUwOQ_ca26a6fe-088d-40c4-b8b5-e2eb84803033">1,754,805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTEtMS0xLTEtNTA5_a91f37d8-701e-4229-b14b-d7be4124580a">53</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTEtNS0xLTEtNTA5_32a93571-ddf4-4c77-be7a-349fe66000bd">2,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTEtMTEtMS0xLTUwOQ_9c7ada6c-9223-4199-96cb-c74b55898a6f">2,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under equity plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTItMS0xLTEtNTA5_0456ce41-ceb1-4125-8926-abe789569371">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTItNS0xLTEtNTA5_07777a72-ddbb-4005-89c9-3401e2e0427c">3,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTItMTEtMS0xLTUwOQ_14ccb239-7091-4ca6-89e1-15b230964bb6">3,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTMtMS0xLTEtNTA5_77422cdb-09ac-4560-931b-6d5fc2002686">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTMtNS0xLTEtNTA5_6412106a-477b-4bf0-b8dd-a7f9d67e0a91">829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTMtMTEtMS0xLTUwOQ_866ac059-21c0-404c-b96f-9b9e801975c8">829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTQtNS0xLTEtNTA5_3a241fe4-d3d6-49ec-94db-8ae09b327bb0">21,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTQtMTEtMS0xLTUwOQ_f7dd5e96-1136-4ffc-b25c-53e8be01c1dc">21,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive gain, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60ed32556e304de6860f08c6da60b133_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTUtNy0xLTEtNTA5_8b4847e5-270f-4d68-9447-682ed3416d95">1,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTUtMTEtMS0xLTUwOQ_91016200-3f26-4ec7-a478-7e53c0bc2eb9">1,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic604e629a18e47f48644038e508838aa_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTYtOS0xLTEtNTA5_592f7f4c-9470-4bf6-9e7e-84f71e6ca179">163,560</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTYtMTEtMS0xLTUwOQ_0eaa0402-3cf9-4202-9c19-9725b6fe2f4d">163,560</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of June 30, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if084fb52c6fd4a039d5f4dc8424a4453_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctMS0xLTEtNTA5_43a2b922-3ab7-490d-aaf3-b97557448472">100,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if084fb52c6fd4a039d5f4dc8424a4453_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctMy0xLTEtNTA5_e1722aaa-3f96-482a-bf34-25ce43ac3876">1,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i079b65915ef04049ab59dcf69c973f75_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctNS0xLTEtNTA5_71f9f1f6-996d-4676-b610-42c3abb70291">4,037,853</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iade6d453882449f8b0ad8daf7e4d39e5_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctNy0xLTEtNTA5_2ddf674d-e984-4a75-a9f7-17a40b8b5755">33,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a8833025058462db2992db44ec3934e_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctOS0xLTEtNTA5_2df1cdeb-e393-4fa4-ba50-048491b431d1">2,384,249</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibddc1e81c5e54e42822e1311df259ceb_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctMTEtMS0xLTUwOQ_7ff81dc1-7f95-4767-9b62-862d95993d76">1,620,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtMS0xLTEtMzg4Nw_2a864fac-1360-44a1-891d-aa9e9cc06130">261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtMy0xLTEtNTA5_710848a6-ff05-41eb-9e16-46b972da367e">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtNS0xLTEtNTgwMQ_c3ff0d8c-4c02-4e79-b0e1-ff1bdd4ebcae">13,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtMTEtMS0xLTUwOQ_56cf21c1-3adf-4ed1-84c4-89037d1d2166">13,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under equity plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktMS0xLTEtMzg4Nw_f7309858-6fc1-45ee-a64e-c1dee788dbd1">130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktMy0xLTEtNTA5_6b9778f2-36cf-423b-af1e-0fd5fd9dfc91">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktNS0xLTEtNTgwNA_84a967d1-e37b-4dff-8afe-1da4f3e4c7fa">546</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktMTEtMS0xLTUwOQ_938f6d42-a146-441c-b360-fe038a7be08f">545</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under benefit plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjAtMS0xLTEtMzg4OA_4400500e-7366-4549-942b-69ce25188a0c">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjAtNS0xLTEtNTgwNw_c06628d1-0736-47fb-b5cc-56116bad5181">820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjAtMTEtMS0xLTUwOQ_cdfa4afa-cc60-43ba-92a1-22333b0d4db0">820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjEtNS0xLTEtNTgxMA_cc4099f3-fa9a-4268-a294-26fb335bda2c">88,412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjEtMTEtMS0xLTUwOQ_f2952f8a-e177-4fca-96d1-0606e2d7ede4">88,412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive gain, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3e88d620de4614b17853b7a58ca2e2_D20180701-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjItNy0xLTEtNTgxMw_09961051-62e2-4a4b-b4e2-5d0de782d80c">415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjItMTEtMS0xLTUwOQ_4a7947a6-a668-43ba-be34-2ac7e9fd6961">415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8b36842a761546ef807e31ee2522a096_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjMtOS0xLTEtNTA5_48e2e59f-4049-4a97-bee2-d2cf0dfee403">245,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjMtMTEtMS0xLTUwOQ_f81142e1-6645-4a27-835d-be31f1d2e73c">245,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5ef4dd7f09d947d493d5f4436cf0c0e9_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtMS0xLTEtNTA5_4c82fc38-89c1-4762-a8d7-cfce3551d98c">100,968</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ef4dd7f09d947d493d5f4436cf0c0e9_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtMy0xLTEtNTA5_30e8f9ca-3ced-49d3-90fa-cf19f9f3af90">1,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib15fa7b634fd4daea03b505c756c59bd_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtNS0xLTEtNTA5_d07b500a-8e75-4c5e-be18-000d42bb31a3">4,140,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibb493b807d924cf39624accb949af88c_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtNy0xLTEtNTA5_1012f06c-c59a-4911-91fd-30e0bec32d78">33,392</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id5a7aaddfaf542bbbf7a06985850a41f_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtOS0xLTEtNTA5_8e9f1e19-fac8-4608-8cbf-1eb0867a185c">2,629,531</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtMTEtMS0xLTUwOQ_daa014e1-4174-4d4d-968d-3dd81f16b25c">1,478,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div id="i_0_28"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:73.584795%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.842105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.842105%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMy0xLTEtMS0w_b0688925-5369-40f8-b369-79b576314b2a">609,931</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMy0zLTEtMS0w_6b0bacf8-55ad-42b2-8cc7-980fb2f5c06a">550,056</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNS0xLTEtMS0w_ca515ddf-75a9-499e-be5b-9bc5f8a7495f">11,733</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNS0zLTEtMS0w_9ebce384-6e99-44b3-aed2-37a489682ca5">5,822</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization and interest accretion related to operating leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:AmortizationAndInterestAccretionRelatedToOperatingLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0xLTEtMS02NDE5_cfe6ae32-46d6-43c8-ba21-bf6ba92e3b81">27,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="alny:AmortizationAndInterestAccretionRelatedToOperatingLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0zLTEtMS02NDIy_24e7ab7b-9756-4916-8fa9-bef6e0b0832b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0xLTEtMS0w_7a049103-7bce-45f4-86a7-df558010a19f">108,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0zLTEtMS0w_f7951162-7906-4553-ae8e-2d14b4f35804">129,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on litigation settlement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="alny:NonCashGainOnLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNy0xLTEtMS0w_2183137a-87f5-442c-8c94-d2866401d5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="alny:NonCashGainOnLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNy0zLTEtMS0w_e36b5db5-db50-4fbb-b8ea-3b4b851a51e0">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Charge for 401(k) company stock match</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOC0xLTEtMS0w_6033300e-2377-4b41-9149-bc506cbabddd">3,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOC0zLTEtMS0w_e5d2d5b1-0328-4160-b90a-8bee995e7d0c">3,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of liability obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:ChangeInFairValueOfLiabilityObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOS0xLTEtMS0w_3fbfff12-ab8d-4120-93f3-73bcf3e5a129">9,422</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="alny:ChangeInFairValueOfLiabilityObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOS0zLTEtMS0w_c7ebaab4-59ec-4974-9d13-71a30d256be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTEtMS0xLTEtMA_2e678d17-493c-4b32-814f-198bacfdc430">4,415</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTEtMy0xLTEtMA_8257a70d-4d21-4e93-b981-26b483c0c8f1">2,163</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTMtMS0xLTEtMA_20027108-7cb2-402e-a9c0-dbec38d091a3">29,717</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTMtMy0xLTEtMA_402fedda-c071-4008-a8e9-ff742a04bcda">30,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from landlord lease incentive for tenant improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMS0xLTEtODY4Ng_958be091-b251-4d46-b19a-fb6bc53defa7">29,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMy0xLTEtODY4Ng_79b67be6-f592-4f15-9b9e-21732cdc3fbd">11,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMS0xLTEtMA_6ba18211-de8b-4550-85d9-37c0e5bec1b3">28,095</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMy0xLTEtMA_554af603-f969-4ab6-bcb1-56655d63cb00">10,354</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTYtMS0xLTEtMA_7b5256a1-53c9-4857-bfc3-302e385b9b6e">13,662</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTYtMy0xLTEtMA_483cd071-52e5-4f3e-9f62-55d5b928b476">34,125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTctMS0xLTEtMA_7730fec4-92d8-490e-9af7-1dd0f8bed389">3,719</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTctMy0xLTEtMA_095c2bab-da8f-43f4-a66d-c56d418fead1">650</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTgtMS0xLTEtMA_5d42ec3e-7aa0-4d37-9942-638115a66732">36,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTgtMy0xLTEtMA_2f169da0-b89c-43d1-a64e-b777c7fa9b53">25,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTktMS0xLTEtMA_0a236150-d4b5-432b-a716-793278ca6299">399,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTktMy0xLTEtMA_1842b880-bf0c-465c-afc4-9812fd93757c">11,503</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjAtMS0xLTEtMA_a919fe6d-6fec-4a07-b101-af7654968671">82,447</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjAtMy0xLTEtMA_cc512e3f-ff04-42ab-91bc-69dc0ee3fdb6">412,159</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property, plant and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjItMS0xLTEtMA_63d8504a-303b-4b36-a921-5eceb8ca9575">101,351</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjItMy0xLTEtMA_8ce1d058-ee22-441c-9b0b-6e83b2a4dbe9">89,374</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of restricted investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjMtMS0xLTEtMA_9e033774-61b5-4496-8862-2aa4d3135abd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjMtMy0xLTEtMA_07edb91c-d1c5-4e59-a576-4a21ea356223">14,825</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturity of restricted investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMS0xLTEtNjQzNA_da272b29-c4c0-4d99-9402-7c8056f101e0">30,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMy0xLTEtNjQzNw_0108cb76-a72f-4b02-b300-2157c4c93097">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjQtMS0xLTEtMA_a56628e8-7e6f-4e66-81db-29650a347426">1,445,632</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjQtMy0xLTEtMA_f92a453c-f96a-4430-bb1e-814cbe14f820">992,385</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sales and maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMS0xLTEtMA_54998a5f-f915-4975-8aa6-ab7feff9a174">1,320,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMy0xLTEtMA_dadbf003-7110-4428-b3db-797918d64feb">1,120,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjYtMS0xLTEtMA_7130f64d-8581-48a4-9464-638ee183f49c">196,827</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjYtMy0xLTEtMA_14665ec9-3df2-4d64-8b7d-016e610fa7ba">23,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of stock options and other types of equity, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjgtMS0xLTEtMA_0cb14d32-8a83-4cc6-acb6-b002ac51a8c9">30,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjgtMy0xLTEtMA_678a8fb1-32f9-4948-9e80-9d043e2b1685">60,092</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of term loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzEtMS0xLTEtNjY2NQ_6f7dea3b-194c-4368-94a1-342cc2b104d9">30,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzEtMy0xLTEtNjY2NQ_072a903b-dbfe-4a95-a549-9ff328d6c94c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Offering proceeds, net of costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjktMS0xLTEtMA_3c0950f9-e22b-4950-9236-a1068c04aac6">381,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjktMy0xLTEtMA_d00a86b8-b689-46cb-a4e5-61d38516c788">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock to Regeneron</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzAtMS0xLTEtMA_4f4a60cb-70d2-42f8-85bc-11610f294929">400,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzAtMy0xLTEtMA_0e77fadc-c79d-4896-991b-e6a06a8b57f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzItMS0xLTEtMA_dc4cb18f-a113-45fa-a82f-97d8da28e523">782,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzItMy0xLTEtMA_d1f468ad-1218-4a44-afed-8d860be98efd">60,092</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzMtMS0xLTEtMA_a32c7e6b-1e6c-4589-a924-1125cc0f1c20">449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzMtMy0xLTEtMA_65c4ad32-c22d-4825-abb8-5883915f523b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzQtMS0xLTEtMA_2806b09c-3476-4719-b90d-476b1b33c789">503,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzQtMy0xLTEtMA_6a379a0b-0135-41ce-a608-a4fe2bb3136b">328,086</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzUtMS0xLTEtMA_777de41a-73f2-4477-abd5-ba281eb4071c">422,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdb8b45ba98c4ea79afcd93e804e2e31_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzUtMy0xLTEtMA_9cc4e542-0217-4244-873b-bb24a7d65bd9">646,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzYtMS0xLTEtMA_0a6e71a5-df1e-4739-b51f-ebcb1cdfd469">925,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzYtMy0xLTEtMA_c803b7e0-d29c-470d-98a1-174418dcb7c5">318,746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of noncash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzgtMS0xLTEtMA_39f720ec-b994-4ee3-8ece-50da5d035584">18,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzgtMy0xLTEtMA_939260e7-5dfc-4011-9133-4eb8045402ca">19,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div id="i_0_31"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div></div><div id="i_0_34"></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNC9mcmFnOmNhYTYyNDg1Y2FiNDQ3MTY5ZGRjMGVlMDZkYjFhMDMzL3RleHRyZWdpb246Y2FhNjI0ODVjYWI0NDcxNjlkZGMwZWUwNmRiMWEwMzNfODI0NjMzNzIxMDM2MQ_38a0804d-739e-4e76-a7cf-601fccb7cc72" continuedAt="ic1a12c9d42f44c6c82627d679059a950" escape="true">NATURE OF BUSINESS</ix:nonNumeric></span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><ix:continuation id="ic1a12c9d42f44c6c82627d679059a950"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, commercial biopharmaceutical company with a sustainable pipeline of RNAi therapeutics to address the needs of patients who have limited or inadequate treatment options. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. In August 2018, we received approval for ONPATTRO</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#174;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (patisiran), our first product, from the United States Food and Drug Administration and began commercializing and generating product revenues in the U.S. In October 2018, we began commercializing and generating product revenues outside of the U.S. and, as of September 30, 2019, we have launched ONPATTRO in Japan, Canada and in several countries in Europe. Regulatory filings in additional markets in Europe and elsewhere are pending or planned for the remainder of 2019 and beyond.</span></ix:continuation></div><div id="i_0_37"></div><div style="text-align:justify;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzY5NjU4MTQwMjY1MQ_5158dbbf-4c4d-45a4-800d-4868b2146423" continuedAt="id5487f68fe4d4ab88951cd353fac50bd" escape="true">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</ix:nonNumeric></span></div><ix:continuation id="id5487f68fe4d4ab88951cd353fac50bd" continuedAt="i52bb980edbff49d8868d943069374ea2"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzY5NjU4MTQxMzcyNg_a977bf96-76dd-41e0-9353-1c6c74b71ef4" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2018, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 14, 2019. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018.&#160;Updates to our significant accounting policies, including the updated lease accounting policy due to the adoption of the new leasing accounting standard, are discussed below and under &#8220;Recent Accounting Pronouncements.&#8221;</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxOQ_89d45a83-ce3e-44f9-b489-cdadffde89cb" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassification</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:LiquidityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxNA_6f3ef34f-8c78-41f5-8ae3-08729ec610cf" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable debt securities as of September&#160;30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to enable us to advance our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:LeasesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxNQ_52ccbe41-4aff-49b4-aa14-3445697a350f" continuedAt="ifd5492c9b6ce4a2d92473ac20e47704c" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We determine whether a contract is, or contains, a lease at inception. We classify each of our leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the condensed consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.&#160;Costs determined to be variable and not based on an index or rate are not included in </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="i52bb980edbff49d8868d943069374ea2" continuedAt="icec4353fade447808ce0b61d9995c53c"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ifd5492c9b6ce4a2d92473ac20e47704c">the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. We record expense to recognize fixed lease payments on a straight-line basis over the expected lease term. We have elected the practical expedient not to separate lease and non-lease components for real estate leases.</ix:continuation></span></div><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxNg_0b120b24-050f-4bcd-a8be-edd04d42fe38" continuedAt="iaf8c0631e46b4fcd88c26070103619a7" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board, or FASB, issued a new leasing standard which generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the condensed consolidated balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new standard on January 1, 2019, using a modified retrospective basis and did not restate comparative periods. In addition, we did not elect the package of practical expedients permitted under the transition guidance that permits companies to carry forward prior conclusions related to (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. All our leases have been classified as operating leases under the new leasing standard.&#160;We elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the condensed consolidated balance sheets and recognize the associated lease payments in the condensed consolidated statements of comprehensive loss on a straight-line basis over the lease term. Please read Note 8 for additional disclosures related to accounting for leases under this new standard.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The adoption of ASC 842 had a material impact on our condensed consolidated balance sheet as the standard requires us to measure and recognize a right of use asset and lease liability.&#160;As most leases do not provide an implicit rate, our incremental borrowing rate was determined based on the information available at the date of adoption to measure our lease liability.&#160;Costs determined to be variable and not based on an index or rate were not included in the measurement of the lease liability.&#160;We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNTc0Ng_141a53e5-e662-4ffb-8c3d-94e63fde6029">290.0</ix:nonFraction> million of operating lease liabilities and approximately $<ix:nonFraction unitRef="usd" contextRef="id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNTc5OA_5f7ff493-9758-4359-ab9a-7d2b35704c07">230.0</ix:nonFraction> million of operating lease right-of-use assets on our condensed consolidated balance sheet as of January 1, 2019, which are presented as separate line items on the condensed consolidated balance sheet.&#160;Had we not adopted the new leasing standard, we would not have had operating lease right-of-use assets or operating lease liabilities on our condensed consolidated balance sheet. The adoption of the standard did not have a material impact on our condensed consolidated statement of comprehensive income.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued a new standard which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued a new standard that amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date.&#160;The new standard became effective for us on January 1, 2019. This standard did not have a significant impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued amendments that eliminate, add and modify certain disclosure requirements on fair value measurements. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued new accounting guidance to clarify the accounting for implementation costs in cloud computing arrangements (hosting arrangements). The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued guidance to clarify the interaction between the accounting guidance for collaborative arrangements and revenue from contracts with customers. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption, including adoption in any interim period, is permitted. This </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="icec4353fade447808ce0b61d9995c53c"><ix:continuation id="iaf8c0631e46b4fcd88c26070103619a7">guidance is required to be applied retrospectively as of the date of our adoption of the new revenue standard on January 1, 2018. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</ix:continuation></ix:continuation></span></div><div id="i_0_43"></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfNzY5NjU4MTM5NDcxNw_d762a457-288d-481c-8c9a-6cc003cb12bb" continuedAt="i864a19bc92434a49a03131ceedf55c4a" escape="true">PRODUCT REVENUES, NET</ix:nonNumeric></span></div><ix:continuation id="i864a19bc92434a49a03131ceedf55c4a"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfMjM2_027ea59d-2733-4b31-a1ec-8e439d039cd7" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net product revenues (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:46.684211%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c54b97117a54dc9a2281403a9143f40_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi0xLTEtMS0w_82641eb6-41bf-4d65-ac27-fde38598aa08">33,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20a7f979d1744d46907e2fe5ef13d747_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi0zLTEtMS0w_4a3f5dd8-dc47-415d-81bb-fe838233bc0e">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib666c190ab3a4d4aa6556b9c46d1eb1d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi01LTEtMS0w_f401784b-5ad7-4d44-8f54-22712f671a98">80,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49ad1e878ba7413bba91fe1bdec91294_D20180101-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi03LTEtMS0w_e85fbb22-624a-48d7-828f-fe9ac2040930">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of World</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d5fc643144f4f66a3f3e5fbd015f089_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy0xLTEtMS0w_b81e5476-3a37-410c-8112-d04062abed25">12,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54e5da0497604cffa89334d054aa8689_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy0zLTEtMS0w_30b9d837-0ec4-4e3e-8330-7766d92cf584">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47bf377672994a6989a0ffc4fda88279_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy01LTEtMS0w_f6604e8e-f7e3-440d-901a-c18d6114e588">30,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6977f9771bb9474f9b987ea4acb6e766_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy03LTEtMS0w_19d1b115-71a7-4640-9655-1242f8830434">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Product Revenues, Net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd31099009a341cebcc213b46e1c6c76_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC0xLTEtMS0w_de7fe889-becd-42d0-8b01-ed4752f63147">46,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i290fb1f9477f4b0dad6a294dbebe5fe0_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC0zLTEtMS0w_c72c1e12-8c46-441c-89d2-60d1e9cf013e">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica700222a11442d3b8b92d9f887edb3c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC01LTEtMS0w_8b0511fe-75d9-4194-9fa9-b5dbc350d2f0">110,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e4b5651a52648659bb33699e1f159aa_D20180101-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC03LTEtMS0w_4e3a7929-0b2a-4b4a-b25f-40c62a888ab5">460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019 and December&#160;31, 2018, net product revenue related receivables of $<ix:nonFraction unitRef="usd" contextRef="ia58cef5166244621bfaed56c877e6047_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfMTY3_10f7b5ab-2de8-4689-a5db-990c1366e06e">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i76fea3f3c89e4d38be0558a94f330d68_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfMTc0_e7c4b877-dc65-4bd3-b3ef-6aa91bcde58b">13.1</ix:nonFraction> million, respectively, were included in &#8220;Accounts receivable, net.&#8221;</span></div></ix:continuation><div id="i_0_49"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzY5NjU4MTQyMTcyOA_17fcec0f-44fe-4d87-b9ea-620979574edd" continuedAt="ia2a219b7cd72475da152dbdaafef812b" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ia2a219b7cd72475da152dbdaafef812b" continuedAt="i977d48e4487d43249ecb42859417bd1d"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTkwNTU_9af1af55-cd8c-47b5-86e3-3cab0f1357ab" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net revenues from collaborators (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:44.929825%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedca81ec08d84b71974e26397c92d1df_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi0xLTEtMS0w_dc5199d7-4325-43d8-91cd-298c4e4749e6">1,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic4a9dd2ed7f84b8eabd7dbe77bd4bede_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi0zLTEtMS0w_50ae2796-0ce7-4bf5-9dce-5a518f76dfd2">1,560</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5944d6095a8a4e978f43fe95bdf38b47_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi01LTEtMS0w_2fc28a87-14ee-404b-88b7-27eaf5a78296">10,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib789d44f74694f1ba05ae665b85e3c8d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi03LTEtMS0w_2f0cdb6d-5be9-4985-8b74-4598182f2dc7">40,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir Biotechnology (Vir)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94dc645833714139975f0211dc2191fb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy0xLTEtMS0w_431e3b9a-a154-4a67-9475-f5b60a95f0b8">5,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida54ff3bad294ce5853890d30053bb7c_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy0zLTEtMS0w_225b0d2a-a393-40ce-b41c-d72aff2f68dd">2,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c27321c10b343b58de158e6d3db20e5_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy01LTEtMS0w_08c6f2fb-2dd3-426a-947a-6468bc0a0252">7,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2a1f0c21c27441983ec53e357768237_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy03LTEtMS0w_cf112d4f-8990-4f94-a7ef-7db327d7e223">10,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">The Medicines Company (MDCO)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfd9ee786c8c474d9a7bb46eff4d0397_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC0xLTEtMS0w_00e77cfe-cd6f-4338-98d3-60ee6adf73dd">528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97807f37924b4995a48c769fc07945fa_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC0zLTEtMS0w_1c0d8fdf-ecdb-4531-bf1f-5eecffa9575a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64a811b4311a4914940c20e54952a306_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC01LTEtMS0w_42698a48-c6ea-4fd1-9982-b06eea198e15">2,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie144870db8f9498eb7801f4559dd2d72_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC03LTEtMS0w_cb208043-b3d0-4398-9589-d9d4d5665504">1,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i673aa3eee23e4a288c64b4dfedc553da_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS0xLTEtMS0w_ef995863-477a-4546-8dae-7d2f7929c394">15,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04e3a21a1c4c4bcdbb03dc8833f4924d_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS0zLTEtMS0w_f29b47f5-5451-47b2-91bd-9d7f3abfd08d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb5884d7e33e4b7d94d106059300af24_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS01LTEtMS0w_cd91d33c-d554-4565-8d0b-15f206a62034">15,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21118dc8b808433e81625e7f2b7884b3_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS03LTEtMS0w_264e41a3-4fce-4421-883a-73c1d0a52df5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0b4cb7028ab4d418d05a21b47a3728a_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi0xLTEtMS0w_85ff7c8b-d5d5-4433-8d72-9dc134dca8e8">455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ae16923f0f84a86ad6008c568b4b1eb_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi0zLTEtMS0w_c45721ab-d09a-4e3e-81fc-ede132900b41">212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83c1d7dbd6c148efb6c9867f8e130af1_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi01LTEtMS0w_c70016de-b992-4bae-95be-232f280cb023">977</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dd904aabd6f4f08942cf7251614b26f_D20180101-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi03LTEtMS0w_f1ae6078-b8ef-413b-94df-088a7a0e06d5">775</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues from collaborators</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc6569f4b7a54920b4b016ec2a2307d1_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy0xLTEtMS0w_d603b88b-cdec-4db8-b94a-7edc91ed0b0c">23,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ca8122b23ae48f2b7a30429c7434451_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy0zLTEtMS0w_1728d111-83fe-46b3-8235-528bd035ebcb">1,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia035051af8af48248146e9bb253e5b61_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy01LTEtMS0w_6d3bfe64-7af7-4099-9e00-6a4f4355b3e4">37,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id872e0d52c5f4349b6ad645fc3ff01c6_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy03LTEtMS0w_7e6e453e-250f-4bfe-bbab-24ad23dd1d66">53,415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTkwNTY_86eac86d-7d0d-4238-aa39-def1194edb5d" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:65.205882%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.029412%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.029412%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMS0xLTEtMS0w_c7ef4b83-c7d7-4fb3-b4c8-552c843a4e47">28,107</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMS0zLTEtMS0w_26f8d10b-937e-426c-ab5b-e7b516821a57">5,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMi0xLTEtMS0w_0ed4f64d-4b8b-4ee1-a1a9-d1f6888d202d">158,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMi0zLTEtMS0w_de91e79a-ea32-4b16-92c3-68a8d4023bd5">3,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three and nine months ended September&#160;30, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:65.794118%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.735294%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.735294%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Revenue recognized in the period from:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts included in contract liability at the beginning of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYzMjIwMDE3N2RjYjQzYmNhZGJlYTczYTY4NDhkNmFiL3RhYmxlcmFuZ2U6ZjMyMjAwMTc3ZGNiNDNiY2FkYmVhNzNhNjg0OGQ2YWJfMS0xLTEtMS0w_5391ffd3-40cc-498b-902e-85c686f7d8e3">12,333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYzMjIwMDE3N2RjYjQzYmNhZGJlYTczYTY4NDhkNmFiL3RhYmxlcmFuZ2U6ZjMyMjAwMTc3ZGNiNDNiY2FkYmVhNzNhNjg0OGQ2YWJfMS0zLTEtMS0w_a4ac17e1-b65c-499b-91af-095dc9d74b98">3,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTkwNTc_377dd9c0-9779-42ae-a19b-01757a53c96b" continuedAt="i97d65772443e4c17bf9e97a92d67ce89" escape="true">The following tables provide the research and development expenses incurred by type that are directly attributable to our collaboration agreements by our collaboration partners for the periods indicated, in thousands:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="i977d48e4487d43249ecb42859417bd1d" continuedAt="i9287eafc30fe44a7b74f49968729a043"><ix:continuation id="i97d65772443e4c17bf9e97a92d67ce89"><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:22.597365%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia18fdbb5b94847bb87d8d115277e9ea1_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xLTEtMS0w_0417a6d3-6cc7-4687-a528-919bb7a2e83c">3,262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33bd68ff20fc4287ac9b1020d2779301_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0zLTEtMS0w_b47de0ca-b52f-46d8-82bf-b2f1b4ab5786">347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a1a333dbc9d46f196d16aaf2ceb4132_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC01LTEtMS0w_a04f1ecb-89b1-489a-b8a5-f5ada53deeb4">4,843</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88c731ed1fbc417b9ee053536a59d9a6_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC03LTEtMS0w_d75df49a-adc7-4e97-98e5-dc591ee8df06">637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb229db5707849d4a22b3c3e18621842_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC05LTEtMS0w_aeeb5348-daf6-46dd-8a1e-04395399f7e0">4,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i841cbe61ae1c4ba5ac3531120ba0c867_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xMS0xLTEtMA_10a38c11-9b2b-4ea6-a688-244c2f1c89a8">937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7569b264a69c48a88a61d8ec84e9025a_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xMy0xLTEtMA_aa117279-f7ca-477b-9cc3-303c75911ea9">800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46ff16a733d64c5fae19a59891cce764_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xNS0xLTEtMA_2c98ab50-5d42-46f4-80f0-5923556182cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc350c0de347466695b330f459fefc28_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xLTEtMS0w_2fe4bb2c-b1c7-43fe-913a-4ae070683202">110</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide82e9762bef4fdeb0c81cbf70048f13_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0zLTEtMS0w_95965e1b-281e-4d52-bdf3-2116bd8a321c">5,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5d7cf10b7b2548a080a4c2299f3c7795_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS01LTEtMS0w_7f19928b-34c3-42b6-a099-108835925f28">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb70ef125a034aa0830cee0808b5cfa1_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS03LTEtMS0w_1f0c93ea-b0ac-4fa6-90a1-518945590f2e">959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i566f60a947954dc69ddaac57c3b30366_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS05LTEtMS0w_a2285e62-ff14-43ce-89e2-0032ff5fc695">588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0bf8fb6901c49edba6c2026ee58fcc4_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xMS0xLTEtMA_24d635d7-64fb-443d-a672-4f4daa6951d9">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3bea475b1bd4453e8b3b41aa9c9a011b_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xMy0xLTEtMA_5210a241-ca5f-4994-b876-b06e762adfd0">1,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide622c05ddce4e44a17a894f34bccbba_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xNS0xLTEtMA_60382ea2-ecae-4aca-94f1-c554d05e929e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icef633268a6c4fcc928100d0671ed5e9_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xLTEtMS0w_8da612a0-8241-48b4-9214-c2db5cc969b2">1,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfd6cf1430e34457b82db167b81278ef_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0zLTEtMS0w_9ae9eb9c-a1f5-4a68-b5f6-b2d3ea3ea5f8">398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc02df567f3e4ff6bf19fc1d69294ac4_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi01LTEtMS0w_1304204b-5553-4c07-bec7-f6593e934395">2,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia340b62c22e4415db15b4677cf672c04_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi03LTEtMS0w_800909fc-eb48-4145-ae17-05cbb14bb269">9,518</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf9a583b3eaa48f5ad28f2b7e2dc2657_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi05LTEtMS0w_e6e67e17-53eb-4d39-93a2-f54616e0f2fd">395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i146c5c0497e044de8cd9a05912301c3c_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xMS0xLTEtMA_a2bc2365-a4c0-4539-a566-067a15837d84">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9592e8ff40504f85af6d1939889fd11b_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xMy0xLTEtMA_0ac71c4f-da25-4eed-afcb-ec57449684a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7e703eff2264d08bab65003cdbeaad7_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xNS0xLTEtMA_69a6131c-dd33-43d5-8b4d-a5d07cd87980">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i475658c0ca9e4d928c433d121b265c82_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xLTEtMS0w_779b4a1e-f29e-48a5-8185-b0e6153eb5df">4,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if449ef4bea9a40ae916cb93478c18048_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0zLTEtMS0w_cf70ef2f-915d-4d2a-b257-325115a56abc">6,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45dfd0bcbe484904a18240c95809b63d_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy01LTEtMS0w_4370760b-9479-4ba0-9b41-77db083add4b">7,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5715163b5bd44e09ae21778e01a08ad6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy03LTEtMS0w_30ecfa18-9b03-4d76-8a21-fe889e365809">11,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if50c807a1f0e4c1492220c3fbd4c4cac_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy05LTEtMS0w_36697c9d-f94a-4082-804b-5b40934bc946">5,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i992ffaac88eb4d129a8f61d7f3155127_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xMS0xLTEtMA_97f73c68-9c4d-4e80-889b-8ee60c74a6bc">940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae58e4687c76458cbd799a3532718cc8_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xMy0xLTEtMA_24353234-8f0e-48e0-9333-21d7466a6056">1,823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i828961f893674d5694c8381c4f2c012b_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xNS0xLTEtMA_f522ae3c-097f-4f34-8a9f-c75a3c17a3f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:22.707602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2c0e609344340b0ac078896c7302e19_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xLTEtMS0w_a62684fa-51a9-4dda-b823-c4dd2ad3306b">11,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if914afcf9e4744d0b11d5a1478378a35_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0zLTEtMS0w_2daabcbf-1a24-499e-9063-4782c058c773">2,024</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i527af3a6a1a443b0b18b74a5866a3b90_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC01LTEtMS0w_174b62f2-63ad-486d-9fbd-29e84e19f029">5,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79eb574b077e440788e6310bda7ce3dc_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC03LTEtMS0w_e324ae5c-5997-470d-b1c8-afbec8cb5a6a">1,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39121bec9968473c89779780093452eb_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC05LTEtMS0w_b6d5458f-338a-4245-b33f-2457db68290a">32,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia38c9fe25a9f40e79efe3342ecec48b2_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xMS0xLTEtMA_888797f6-a381-4e4d-8743-254a3c41e99d">1,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae8470f847a3491dae7d1bcd2f3f6398_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xMy0xLTEtMA_cc3bc439-de55-4d3b-8e2b-44d0305fabc6">6,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i657c2557d02741b08dc2a2dfbc051fd5_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xNS0xLTEtMA_a2a40568-7f6f-4b51-beb8-336dbfa14aa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie781c80188954ce28b5095c7ad86743a_D20190101-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xLTEtMS0w_aef5f8e1-7342-4f3f-a00b-a087e1a30c0a">326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie89009e721c8458ea441dc7256bae44e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0zLTEtMS0w_d96e8d55-a820-4337-83f2-1635e3fe85ce">6,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5faa958db3248cf8abd2d51854649c9_D20190101-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS01LTEtMS0w_9b4fa0b7-af4c-4bfc-8d19-ec69bcba0119">268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0133baa156a644908b72e47c2d43ec0a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS03LTEtMS0w_261bd0d3-04f5-41ca-b085-f3584de40703">1,010</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id66ba49548de4a899fd6450c151c30c3_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS05LTEtMS0w_fe3b1c95-c74e-4ce9-b501-8a63488be7fa">5,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i185ceb104d524ac2b0dd476c73f39d3b_D20180101-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xMS0xLTEtMA_2efa94cd-a0bb-4bfd-a6cd-814237f6b489">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28fd5aa0223e4864bd917a1eb955fbe1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xMy0xLTEtMA_c05e511c-4c62-4d50-b016-9312e90366ed">7,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i80f0807ba74548b0a8cae142017dec3a_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xNS0xLTEtMA_729c4be1-850f-460e-acb8-11669d90ece0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b1a8dc3c9da43c0b2be902403a125d8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xLTEtMS0w_4b6f0f0e-940a-40d9-9683-19a68dd065e9">1,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib996cc6e2cef48baa147a3c936b7622d_D20190101-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0zLTEtMS0w_009a5246-9ef5-4e66-88f7-8b1ad699abc5">458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i209d8f822ea54215a8a5a92d1710e4fa_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi01LTEtMS0w_dac2c4b1-6ea7-4700-b71f-573de9f66d94">2,733</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3677fbfc08e94d57801b8fbdfc4f3d18_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi03LTEtMS0w_f4dd60ca-73b9-422d-98b2-b61cd81889a1">9,943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d661f5bbcaf4991993d92085c0405ea_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi05LTEtMS0w_42ca6077-4445-449b-9ecc-5ec11108fb2c">1,145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9d79f61ae80486795459192eaa096a6_D20180101-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xMS0xLTEtMA_cf823a25-f304-4727-85f9-662eba9876c0">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9911e13cc954763aca179b898c772aa_D20180101-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xMy0xLTEtMA_67273f49-2e82-43ac-b456-f0e092d2683e">980</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05f229b2a3d4481b99dbd2a5d30a1bcf_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xNS0xLTEtMA_e0e92904-2005-43b8-a376-e4feeb30c9a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea900a9c6d3a4cbab86b5bc952e69203_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xLTEtMS0w_433ad709-757f-4497-9ac2-be258338c947">13,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2fae1adbaaf04d2681c00589c86c0041_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0zLTEtMS0w_1d046e91-ff5e-4434-bb64-0bb0e1914722">8,484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c35a882679b407281d6fe08e0b51a82_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy01LTEtMS0w_5d646a57-62c5-4135-9a7f-800d9c350e4e">8,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a80641a47214d5f91ecd50a0a248023_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy03LTEtMS0w_acf5931d-9128-4fd3-8768-cc6c2553f422">12,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90acd6d92ec642f9b7b36589e3268571_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy05LTEtMS0w_983737b3-a0e1-4c11-9a02-02ba7986e119">38,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i757b55bca5a64fd58f1fab4d5d19add2_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xMS0xLTEtMA_40134867-cc56-4b92-9b5a-d639f807570a">1,581</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i207df81799004a46ba28b23122e5111b_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xMy0xLTEtMA_9a976ad6-767b-4e77-b7d1-2ccca913dc3d">15,205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice65c0bb2b5e417888fde2ff078b534c_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xNS0xLTEtMA_b7227736-5673-4ac0-bd15-b5d91f7cd72b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research and development expenses incurred for each agreement listed in the tables above consist of costs incurred for external development and manufacturing services for which we are reimbursed and licensing payments made to the counterparty to such agreement. In addition, these expenses include a reasonable estimate of compensation and related costs as billed to our counterparties. As part of our revenue recognition policy adopted on January 1, 2018, the costs in the above table are considered an input in our determination of transaction price when they relate to consideration received for the delivery of goods or services. For the three and nine months ended September&#160;30, 2019 and 2018, we did not incur material selling, general and administrative expenses related to our collaboration agreements.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regeneron Collaboration</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On April&#160;8, 2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019, or the Effective Date. Upon closing of the Stock Purchase Agreement dated April 8, 2019, referred to as the Regeneron SPA, we issued <ix:nonFraction unitRef="shares" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjc1Mg_bb85d702-c0d4-4636-96fa-afb84063d8c3">4,444,445</ix:nonFraction> shares of common stock to Regeneron for aggregate cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjg0NA_19379a62-9d1a-4fb9-bf38-91fa589440b7">400.0</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d3a888b47654db19c388966c89d70d3_I20190408" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjg1MQ_902da25d-3493-4d9f-9240-eb033fc9c473">90.00</ix:nonFraction> per share.&#160;Please read Note 10 for a full discussion regarding the Regeneron SPA. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 siRNA currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#8217;s pozelimab (REGN3918), currently in Phase 1 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Regeneron Collaboration, we will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial five-year research period, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional <ix:nonNumeric contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" format="ixt-sec:durwordsen" name="alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjc0ODc3OTA4ODY5NQ_513a6445-1e75-4daa-a6ad-762787106806">two years</ix:nonNumeric>, for a research term extension fee of up to $<ix:nonFraction unitRef="usd" contextRef="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:ResearchTermExtensionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMzQyOA_41694ed3-b83c-4f17-b9b5-9d71e881cf54">400.0</ix:nonFraction> million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously-announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-directed clinical and preclinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.</span></div></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="i9287eafc30fe44a7b74f49968729a043" continuedAt="i9b17a4a4ebb54e66ad91cd7f443a24c0"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Regeneron will lead development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron will alternate leadership on CNS and liver programs, with the lead party retaining global development and commercial responsibility. For CNS and liver programs, both we and Regeneron will have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#8220;Licensee&#8221; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#8220;Licensee&#8221; for the purposes of the license agreement.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Under the C5 co-co collaboration agreement, we and Regeneron equally share costs and potential future profits on any monotherapy program. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjIzMQ_61d804d9-6d97-4963-8b22-7ed673d748e7">325.0</ix:nonFraction> million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:UpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjU2OA_24f5fb03-9597-40fb-b86a-4f79098d62ce">400.0</ix:nonFraction> million. We are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjYyNA_aa043e89-3e4d-4ec9-950d-3b765e0998a3">200.0</ix:nonFraction> million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to <ix:nonFraction unitRef="program" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" name="alny:NumberOfTargetedPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjgwNg_00db62ac-22af-4c2a-94bf-8203c1e19145">30</ix:nonFraction> targets under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $<ix:nonFraction unitRef="usd" contextRef="i910f04c70f8f42eaa89bc212b0fcede9_I20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:PotentialProceedsFromCollaborationArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjkzNA_a4707b25-ed5a-4f2e-8617-afc4e61b726b">2.5</ix:nonFraction> million in funding at program initiation and an additional $<ix:nonFraction unitRef="usd" contextRef="ie6314e00fa4e4a639121892a2b493f92_I20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:PotentialProceedsFromCollaborationArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjk4OA_9e04e9c3-ef41-461b-9b1b-509db8c948d4">2.5</ix:nonFraction> million at lead candidate identification, with the potential for approximately $<ix:nonFraction unitRef="usd" contextRef="i3e47a5ab3bd844aca1d5112c5e5bc4fe_I20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:PotentialProceedsFromCollaborationArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzA2Mg_a0cebe66-5690-440f-bdbe-ec03c8390bf4">30.0</ix:nonFraction> million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#8217; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfODM5MQ_a03599f3-8728-4e2a-b4fe-a0a2b510fd7b">150.0</ix:nonFraction> million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to <ix:nonFraction unitRef="number" contextRef="ia89cc425b8ec4574a3b6d9187fd8d47b_I20190408" decimals="2" name="alny:RoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfODY0NQ_bc7cbb96-cf29-4233-85ee-00e2fefb8610">20</ix:nonFraction>%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to <ix:nonFraction unitRef="number" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" name="alny:PercentageOfMaximumRoyaltyPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfOTUzNA_40c3eb48-d1f8-4b30-a188-e1f017e7b0c0">20</ix:nonFraction>%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="i9b17a4a4ebb54e66ad91cd7f443a24c0" continuedAt="id519ba851e914221bf22b4a0870e58b8"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Separately, the cemdisiran monotherapy co-co collaboration agreement is under the scope of ASC 808 as we and Regeneron are both active participants in the development and manufacturing activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The development and manufacturing activities are a combined unit of account under the scope of ASC 808 and are not deliverables under ASC 606.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The total transaction price is comprised of the&#160;$<ix:nonFraction unitRef="usd" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:UpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTE4NDk_92bc266d-a6f3-49cb-bce5-4ed8d7462600">400.0</ix:nonFraction> million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain ocular, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. </span></div><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:ScheduleOfAllocatedTransactionPriceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzY5NjU4MTQyMTY4Ng_50bdb728-3f02-46b8-8052-b3d87df6115e" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467836%;"><tr><td style="width:1.0%;"></td><td style="width:34.906585%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.412557%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.836141%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.412557%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.836141%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.331394%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.664625%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Standalone Selling Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Guidance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88df3d689a741d8b329bc0a7ffb25d6_I20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:StandaloneSellingPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMi0yLTEtMS0xMTE0OA_c7d76e0c-b8db-4506-96dc-a690a66a795d">122,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f99093d364045fda1a43bb5fcbfce58_D20190630-20190630" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMi00LTEtMS0xMTE2NQ_9f277005-3c1d-4a84-ae8f-401a76fb8656">178,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19f1516e126c4492b1083718d689a0b5_I20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:StandaloneSellingPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMy0yLTEtMS0xMTE1Mw_e75916ae-a4cd-4162-9f1a-2d0c94866fac">97,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e07bf9298b24bbcbbdd5c0c60d0efe0_D20190630-20190630" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMy00LTEtMS0xMTE2OQ_8d633829-1ffd-4c9d-a19f-381a8f3c127f">93,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:95%;">ASC 606</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb5ab21b5e394f12b80ee7c85f5a6436_I20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:StandaloneSellingPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfNC0yLTEtMS0xMTE1OQ_7086984a-0008-4f2e-b1c0-14bbbf9369e3">364,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86d830c7785d42eca47ab825a3dd466e_D20190630-20190630" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfNC00LTEtMS0xMTE3Mg_9a42a07f-9cff-45aa-a7d0-3f292b756df8">249,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f42feab7e1d44078d72a7646ec908c5_D20190630-20190630" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfNS00LTEtMS0xMTE3Ng_e3c312b4-2ca6-4cca-8412-5c784ff5e3e4">521,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:14.619883%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, the expected number of targets or indications expected to be pursued under each license, the probability of success, and the time needed to develop a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the Research Services Obligation and the C5 License Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period and during the quarter ended September 30, 2019, the transaction price increased $<ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="alny:IncreaseDecreaseInTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTA5OTUxMTY4MTg3MQ_93bdacd7-db50-4c33-a315-74f4ac0eb4e4">18.5</ix:nonFraction> million from $<ix:nonFraction unitRef="usd" contextRef="i6f42feab7e1d44078d72a7646ec908c5_D20190630-20190630" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTA5OTUxMTY4MTg4MQ_6453ad78-f253-42d8-95fd-2ba320af5708">521.6</ix:nonFraction> million as of June 30, 2019 to $<ix:nonFraction unitRef="usd" contextRef="i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTA5OTUxMTY4MTg5MQ_ea253594-8bd2-41b0-bd63-2e549687bdd2">540.1</ix:nonFraction> million as of September 30, 2019 resulting from additional variable consideration we expect to receive. For the C5 Co-Co Obligation accounted for under ASC 808, the transaction price allocated to this obligation is recognized using a </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="id519ba851e914221bf22b4a0870e58b8"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">proportional performance method. Revenue recognized under this agreement, inclusive of the amount allocated to the C5 Co-Co Obligation and future cost reimbursements, is accounted for as collaboration revenue.</span></div><div style="margin-top:6pt;"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzY5NjU4MTQ2MTU3MQ_7a6afe8b-11ac-48ec-bd9a-3c3779ac1894" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.491228%;"><tr><td style="width:1.0%;"></td><td style="width:23.454545%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.406061%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.181818%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.406061%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.969697%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.406061%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.818182%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.406061%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.272727%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.406061%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.272727%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue Recognized During</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Guidance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idaea32819b574ef28e3693d2eb5e6e5b_D20190930-20190930" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi0yLTEtMS0xMTI1Ng_8fc2c362-8487-433e-b0b6-a34474b09006">182,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a8fa0c4e76a42f2852aac811eb5477f_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi00LTEtMS0xMTI2Mg_32dc4bd6-0aab-4bd2-9fb5-046fef90af80">11,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1583edbcfb14632bce947d08adc1711_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi02LTEtMS0xMTI2OA_a0c78bfb-2002-407f-9977-fcc2fc5903cb">11,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88df3d689a741d8b329bc0a7ffb25d6_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi04LTEtMS0xMTI3NA_74dcd8ff-c2e8-421b-8df4-557ef68fa3fa">90,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a37ee0addcc471cbc26952515d07305_D20190930-20190930" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy0yLTEtMS0xMTI1OA_effcf8c4-b4f9-489b-a58b-d0945d7cfe24">109,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0a05588cdc94fe990de15bb14b81d2e_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy00LTEtMS0xMTI2NA_293be37e-2b9d-4d78-8d9d-375891bfde4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2478295fa07f441eb5430e16d67ec61e_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy02LTEtMS0xMTI3MA_e2e0cbb8-f2df-4ac2-92c0-7c0036427b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19f1516e126c4492b1083718d689a0b5_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy04LTEtMS0xMTI3Ng_1929e634-f7ba-4307-86ba-dce714f63384">66,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3b9efc823ea4a52a48884c8f7ef46ee_D20190930-20190930" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC0yLTEtMS0xMTI2MA_0fc5ec08-d6a9-478b-91d0-7b7663c08201">248,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i561b9cbdf5134340b23a4852eff9113a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC00LTEtMS0xMTI2Ng_5c864ecb-5196-4232-8a38-3354277093ba">3,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a69fc879d06480e8231d059d82c9ff1_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC02LTEtMS0xMTI3Mg_f9de9d2a-8292-412f-9572-251ff3b2e9c6">3,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb5ab21b5e394f12b80ee7c85f5a6436_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC04LTEtMS0xMTI3OA_451aba0f-05d7-4bf3-84cb-b47e65c91ba1">245,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS0yLTEtMS0xMTY0Ng_5e7adf45-0bdc-4084-9142-f3e522ca0a72">540,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53189462639a41ea94d96ecc0862a2c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS00LTEtMS0xMTY0OA_ef392971-911f-4c2e-bb87-8d35f8201a51">14,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i304e9e4a77f146f1b45c8803228f6a4d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS02LTEtMS0xMTY1MA_ee26cabd-071e-4a23-892f-ba767c5bd590">15,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i128a21da539642528efe8070e11f3e47_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS04LTEtMS0xMTY1MQ_90efcea6-2c54-44f3-bdff-c34759cdcddc">402,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></ix:nonNumeric></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of&#160;September&#160;30, 2019, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation and C5 License Obligation that was unsatisfied is&#160;$<ix:nonFraction unitRef="usd" contextRef="i128a21da539642528efe8070e11f3e47_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTY0OTI2NzQ2NTk3Nw_a6910d15-982f-4801-ae9f-3c74af233380">279.8</ix:nonFraction> million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. This amount excludes the transaction price allocated to the C5 Co-Co Obligation accounted for under ASC 808. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi Genzyme Collaboration</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Amendment</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April&#160;8, 2019, we and Sanofi Genzyme entered into an amendment to our 2014 Sanofi Genzyme collaboration, which we refer to as the Collaboration Amendment.&#160;Under the Collaboration Amendment, we and Sanofi Genzyme agreed to conclude the research and option phase under our collaboration agreement. In connection and simultaneously with entering into the Collaboration Amendment, we and Sanofi Genzyme also entered into the Amended and Restated ALN-AT3 Global License Terms with respect to ALN-AT3 (fitusiran) and certain back-up products, which we refer to as the A&amp;R AT3 License Terms. The A&amp;R AT3 License Terms amend and restate the ALN-AT3 Global License Terms entered into by us and Sanofi Genzyme in January&#160;2018 to modify certain of the business terms. The material collaboration terms for fitusiran, as previously announced, will continue unchanged.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with entering into the Collaboration Amendment and the A&amp;R AT3 License Terms, we agreed to advance, at our cost, a selected investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies. Following completion of such studies, we will transition, at our cost, such asset to Sanofi Genzyme. Thereafter, Sanofi Genzyme will fund all potential future development and commercialization costs for such asset. If this asset is developed and approved, we will be eligible to receive tiered double-digit royalties on global net sales.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">No changes were made to our Exclusive License Agreement with Sanofi Genzyme, referred to as the Exclusive TTR License, pursuant to which we have global rights for the development and commercialization of ONPATTRO, together with vutrisiran and all back-up products, which remains in full force and effect.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amended and Restated Investor Agreement</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Collaboration Amendment, we and Sanofi Genzyme also entered into an Amended and Restated Investor Agreement, referred to as the A&amp;R Investor Agreement, which amended and restated the Investor Agreement entered into by us and Sanofi Genzyme in February 2014, referred to as the Original Investor Agreement. Pursuant to the A&amp;R Investor Agreement, Sanofi Genzyme was released from the lock-up restrictions under the Original Investor Agreement and was permitted to sell shares of our common stock in transactions approved by us or in fully bought block sale transactions satisfying the conditions set forth in the A&amp;R Investor Agreement. As of January 17, 2019, Sanofi Genzyme owned <ix:nonFraction unitRef="shares" contextRef="i56c55aec91dc4c59ba2a9a3f39ee2da2_I20190117" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTgzNTc_f83ffd44-85df-453f-97e3-4ed2f596b3ce">10,554,134</ix:nonFraction> shares of our common stock and as of May 3, 2019, Sanofi Genzyme reported owning <ix:nonFraction unitRef="shares" contextRef="i18255b8b8fa94a3c932e5d83d5508a09_I20190503" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTg0NDE_bc54bc72-550d-444b-809c-1e9d7687700b">no</ix:nonFraction> shares of our common stock.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the A&amp;R Investor Agreement, until the earlier of (i)&#160;the fifth anniversary of the expiration of the last to expire royalty term or the earlier termination of the collaboration agreement, as amended by the Collaboration Amendment, and (ii)&#160;the date after December&#160;31, 2021 on which the beneficial ownership of Sanofi Genzyme and its affiliates no longer represents at least <ix:nonFraction unitRef="number" contextRef="i23a3a0ee563f4e42ad4529debd4b818a_I20190930" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTg4NTE_8555dc55-bacd-49ec-a822-07a5e6881fec">5</ix:nonFraction>% of the outstanding shares of common stock, Sanofi Genzyme and its affiliates will be bound by certain &#8220;standstill&#8221; provisions, including an agreement not to propose or support a proposal to acquire us.</span></div></ix:continuation><div id="i_0_55"></div><div style="text-align:justify;margin-top:18pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RleHRyZWdpb246MmRkZmQxNTBhNmM4NDBmZjliOTkwYTkyZWVlY2UwMzBfNzY5NjU4MTM5NDUyNw_6e5dcd01-f689-4cab-9d91-ddd3dfb5acc5" continuedAt="i301aab3672544153b5dd4fa96b0783e5" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i301aab3672544153b5dd4fa96b0783e5"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RleHRyZWdpb246MmRkZmQxNTBhNmM4NDBmZjliOTkwYTkyZWVlY2UwMzBfOTI_c458ee80-e550-4839-b7f9-5cbfff1e9b57" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents our inventory as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:72.707602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMS0xLTEtMS0w_8b35e6f1-f73a-4dcd-b177-94ec298c63f0">11,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMS0zLTEtMS0w_b0a41ef5-e797-4d06-be10-644a396c5d6f">8,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMi0xLTEtMS0w_0d6977dc-feeb-49fd-a516-51ea31f0341f">42,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMi0zLTEtMS0w_b749284a-4f32-445e-8fb0-14e798a98ed6">15,262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMy0xLTEtMS0w_e4208ade-d1e1-4169-a590-e4e5ffaa65eb">579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMy0zLTEtMS0w_02c50fdf-7224-4230-a5f0-a9c45c0c4caa">97</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfNC0xLTEtMS0w_0796cb97-02e8-4e39-add5-69794ff54f7c">54,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfNC0zLTEtMS0w_48219671-b8ac-4adc-817b-496f868529ce">24,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_58"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfODI0NjMzNzIxNjE2Ng_7c0998f2-9f9d-411a-8d65-fae4e73ddb20" continuedAt="icdce8fc506be458ba6099995ab514cae" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="icdce8fc506be458ba6099995ab514cae" continuedAt="i38c12ac2b33644d0a9d3578051648e63"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfODI0NjMzNzIxNjE2Nw_ae77c576-e12b-4902-aa26-8ee847695a49" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables present information about our assets that are measured at fair value on a recurring basis as of September&#160;30, 2019 and December&#160;31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:48.073421%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab12e28db7e4641b70a2a645c6a28e8_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMi0yLTEtMS0w_0f687326-623c-4537-b4d7-9427f2c20a56">16,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f78360553254ee782ee02d789c9d889_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMi00LTEtMS0w_6774410f-0c9e-4734-a05a-5beac324946a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i697b1bfc24074b85bf27cd5598d3b51b_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMi04LTEtMS0w_1165b2c0-f813-432d-a76f-994ed97c93ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c50e4c814e74c9491d54d5e4e91af0f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy0yLTEtMS02Mjk5_c99d0d3a-bf4a-4341-bee9-2cc19e50d146">2,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3163fef4430b47c28ff4777546273453_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy00LTEtMS02MzAy_00962567-281c-4eb2-9b7b-4f333b76d1b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45fc9bcd587c4f37b74ab016f6cbdefa_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy02LTEtMS02MzE3_44871bad-7187-4d98-9e4e-10a5f2fd264b">2,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie01382b3f2664b17976086250fb17c01_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy04LTEtMS02MzIw_c1b1803f-8bb4-4cfa-b426-626c5be836d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie14a072a848f45a5a23bc9f805fbbd08_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy0yLTEtMS0w_194dae23-c545-48c2-8618-a64c5c1c18af">655,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i239343e7b44f41dabd006bd02fa42bff_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy00LTEtMS0w_f60f0252-ab4b-4ce8-a09d-b5e6b65f8aec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if099e69b9be14094b333354d839f0f79_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy02LTEtMS0w_5844c7e0-d195-4c92-95f1-c59a5fae518f">655,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic860375e3027429092c256d65a2d7780_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy04LTEtMS0w_15472882-3c57-4da1-8fa4-95148501b24e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdc53aba859045ecb0ca135b483634d7_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS0yLTEtMS0w_eb985dc5-036f-4ba3-9182-32abf72590f3">134,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe092ad14ecf40ecbc93697363251ede_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS00LTEtMS0w_850bea90-dd82-45cb-9997-7b0ceb49f6ee">134,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0949304a7dde4229b6e753cd9903c40e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS02LTEtMS0w_2adb0a7a-ea50-422e-bce0-75520284d2cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d0a82f69d8e49c7bf0facdafd02a08b_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS04LTEtMS0w_f2d89db4-3933-41d3-a16e-9db4ad5915f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i891225af6803446f9581a304ba109390_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy0yLTEtMS0w_8c34fe9e-68c2-4ee6-a2c7-769a474f0857">3,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd2fc5c6f5de44f4ad84017a9d68a878_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy00LTEtMS0w_5b2fcfaa-4779-4b4b-80c7-576a45280f34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c36b06d4d7444b1b5923152fba320f9_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy02LTEtMS0w_08cffbaf-54a4-488e-8484-e731e6298d0c">3,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i635b34a72c56410d8d1df7055596b6b8_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy04LTEtMS0w_6f373fdc-33e1-4424-ba4b-001344702f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ab12e28db7e4641b70a2a645c6a28e8_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC0yLTEtMS0w_119a7cd5-2505-4f16-be6b-1fbededab647">12,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f78360553254ee782ee02d789c9d889_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC00LTEtMS0w_ea5f956d-7409-4205-a04c-4e5ee88a11e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia99a29ede5ec418db5992d141e96e1af_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC02LTEtMS0w_7921e5c6-fbe9-4a38-b668-1651f8ad159b">12,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i697b1bfc24074b85bf27cd5598d3b51b_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC04LTEtMS0w_20f7ba94-692e-4366-8f0a-7140e5acc2df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c50e4c814e74c9491d54d5e4e91af0f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS0yLTEtMS0w_5f0958a9-19fa-4c4f-92ce-903e8b9fddb2">87,927</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3163fef4430b47c28ff4777546273453_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS00LTEtMS0w_1f129eaf-1c82-433e-82b6-a7bf5188a1e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45fc9bcd587c4f37b74ab016f6cbdefa_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS02LTEtMS0w_988137cc-9d39-4e37-9212-0983d5126486">87,927</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie01382b3f2664b17976086250fb17c01_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS04LTEtMS0w_7411b9fa-09bf-4437-bf0e-81758ae26390">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3189a838fac44b6aa80a5b0128eeea48_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtMi0xLTEtMA_dc542374-e4f8-406d-a894-79bc19c73eb0">59,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6fe3d4c3f27649a5b8cffd56fc6d60d6_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtNC0xLTEtMA_8e519531-d1ad-42ad-bd0d-e870a19dbc9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic657523a72064bf8a77241824eec1de4_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtNi0xLTEtMA_d2e3ea1d-6575-4d44-adb2-ada935acca7a">59,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea41bafdaa19451b99ca8455af31092b_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtOC0xLTEtMA_7e274c01-91d0-4733-9f14-7e42299edb22">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie14a072a848f45a5a23bc9f805fbbd08_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtMi0xLTEtMA_fbc91dab-cb82-4d42-8c11-c754b8617252">634,514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i239343e7b44f41dabd006bd02fa42bff_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtNC0xLTEtMA_c0ae0461-5441-4f9a-93ec-7624309ad348">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if099e69b9be14094b333354d839f0f79_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtNi0xLTEtMA_d5d39540-2d10-4d51-ad4e-482fb2244843">634,514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic860375e3027429092c256d65a2d7780_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtOC0xLTEtMA_5f78ffce-5b56-41a7-82df-5647119bbb27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdc53aba859045ecb0ca135b483634d7_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItMi0xLTEtMA_c4374db8-d5a5-4d2e-afd8-109e6f902de4">1,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe092ad14ecf40ecbc93697363251ede_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItNC0xLTEtMA_db9fcc3d-7ed7-481c-8615-f0ae418c39ac">1,481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0949304a7dde4229b6e753cd9903c40e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItNi0xLTEtMA_32e390df-77ff-4104-b5b0-35749b3e02ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d0a82f69d8e49c7bf0facdafd02a08b_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItOC0xLTEtMA_a305cd34-b23c-4aa9-b203-7c24d2e90e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16e0f6431e4d44508c464f542f15baa9_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtMi0xLTEtMA_fa271bab-afa5-4508-a89e-b53d7308bedf">1,607,818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4eb09fac19014b80be63710b35a8db33_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtNC0xLTEtMA_68344249-f15d-4dc1-9dde-d86aaf463ff7">135,921</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de1d13c04544ccda16e21d30fb14653_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtNi0xLTEtMA_72f7f6e2-de95-456d-818c-c8083f166600">1,471,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i782b647a38c84737b078e327971daeba_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtOC0xLTEtMA_1c170133-eb29-4d84-a4c9-edb8d68c51a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:48.073421%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.747430%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib04ae69b490e4a07b9dd11c6a1a057d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi0yLTEtMS0w_a6f3fcc1-2297-49c7-9c69-541a602c90ca">221,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40aef21a5b0742b6919605b695cba83a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi00LTEtMS0w_fabf867a-a1c7-4b68-a0d6-fe633c926e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i534eab2866fc4b1bb0f1e30546b2550e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi02LTEtMS0w_a20a582c-f7ca-451f-be2c-69c6459c69f1">221,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d0c030ef7f6469c8c51584431c73bee_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi04LTEtMS0w_a35ff95a-aa7a-41ca-aeb2-0f363b102c45">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedf54ff63ecd4190a0aebd37630638c0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy0yLTEtMS0w_92d2b94a-bb4f-4dd8-9b63-6f301ccee0aa">102,445</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib51284ca40ae4f409a968f2a88ae537c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy00LTEtMS0w_6b784180-cf91-48a9-b9c2-b6ee523b3cfd">102,445</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28d596b8dc524e17b6c9b06b62b6040d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy02LTEtMS0w_9753dbe0-ca61-4fe4-85bb-ffb6df2c40a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6219fb42fe014e16a1c218a1ab221110_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy04LTEtMS0w_067996e7-a6b0-468a-a10e-30cbf50f3da0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8081f4ca6b924dd5986fc5e0a2f8b585_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS0yLTEtMS0w_24f1e679-2ddf-4d3b-9789-86045022346f">8,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5938ec1fdaa449c2b1ecc81f9993204c_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS00LTEtMS0w_02e2edec-be43-4ef9-8ca8-e94f22599772">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94c3b43b17584cae8dac039f9d951a2b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS02LTEtMS0w_3ad7c2bb-63c5-451a-a130-704fc858e7c3">8,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8eaca78602548f881448af5a5dc5dc2_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS04LTEtMS0w_d8e679e5-7167-48fc-ab65-9cdbd8192550">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i13a256ed0c704bdaa3843a8e99ae65b0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi0yLTEtMS0w_f719a370-72ae-4b19-934d-5dea37b86be4">57,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i786e48af2f8048819a014a47ad5f3590_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi00LTEtMS0w_f258f3ae-282d-4b65-ace5-2e000e2a95e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64cd7b4acbce48ee8c20aa3dc411db8a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi02LTEtMS0w_51cc9733-bae8-42f2-9a74-f87b520222df">57,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a446afad065485689143f29fefeb88b_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi04LTEtMS0w_a38d7b95-7694-415f-9e32-7d61cd6048d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cc9691ef8ec419190202c98ca260168_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy0yLTEtMS0w_a854ba59-f047-47ba-80e4-859111e14cb5">232,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51a9ec62896246148cc11c6a75758e7d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy00LTEtMS0w_d21ed719-9ca1-44e6-87c5-c4c049a5385b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fc8b8cbc9dc4a3fa34ac39e8ac315bd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy02LTEtMS0w_1ac3f55a-c955-42e8-9281-593a60193b52">232,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d00afa93a0d4d08987a2f888620c445_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy04LTEtMS0w_5f6b4768-7ff2-40a6-bd0a-9c16b6b20eab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40f9758c7a5442eb909c35e568f89d1a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC0yLTEtMS0w_ca1661f7-6730-4713-921e-0018bef67fe8">39,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6809fdac18e942108fea8b72dfefb89d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC00LTEtMS0w_81aed436-df60-4794-80d6-a013fb3ff9a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i563399d00a3f4495921402e83ebb9b19_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC02LTEtMS0w_ade25e6f-3560-4dda-a115-0189ae2b0bf9">39,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77d6099e88b14f529fcdbf31508676b1_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC04LTEtMS0w_d4e5b170-1713-427a-a1b7-fcf03e63647d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib04ae69b490e4a07b9dd11c6a1a057d8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS0yLTEtMS0w_c2c240c2-375b-4c9f-98be-2e388788a749">325,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40aef21a5b0742b6919605b695cba83a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS00LTEtMS0w_8644cadb-8f5a-4cc3-9c5b-ef585864c9d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i534eab2866fc4b1bb0f1e30546b2550e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS02LTEtMS0w_ed3724f3-fdee-4e91-b65b-6bc50dc08ead">325,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d0c030ef7f6469c8c51584431c73bee_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS04LTEtMS0w_68966600-8039-4a20-96c2-414746f3609f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie975d68357554af895cd61a0cde4dbcb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtMi0xLTEtMA_ba377088-782a-43e5-9b20-a5bd652ae3f0">1,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fdecb33a35d4e5eb7f0e714d9cd1534_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtNC0xLTEtMA_516b7fbe-5be4-49e1-bb61-1ed004fb791f">1,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee8d158421a74475a932f3e1697894c8_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtNi0xLTEtMA_b08d4871-461f-4c3c-a3ed-f227e17fab7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ecb9a3c8f1c431198624af0dce809c1_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtOC0xLTEtMA_1634daf3-f1c6-4b12-9425-d06b47325f68">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedf54ff63ecd4190a0aebd37630638c0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtMi0xLTEtMA_b9cc1984-2af2-453a-817e-0556b71a0544">1,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib51284ca40ae4f409a968f2a88ae537c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtNC0xLTEtMA_8dd28453-a62e-4dd0-8d52-b64d09dd8197">1,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28d596b8dc524e17b6c9b06b62b6040d_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtNi0xLTEtMA_1af3c19e-e704-4a14-9013-3b3cb56dc825">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6219fb42fe014e16a1c218a1ab221110_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtOC0xLTEtMA_88470a46-a7c9-4aef-b8bd-e73ad2aef847">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie975d68357554af895cd61a0cde4dbcb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItMi0xLTEtMA_6ec07f20-bd52-4181-8b65-b1b23af2bb0f">989,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fdecb33a35d4e5eb7f0e714d9cd1534_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItNC0xLTEtMA_5cfb1ed8-e825-42f1-9f0f-58c1c25008d5">105,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iee8d158421a74475a932f3e1697894c8_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItNi0xLTEtMA_32a97c21-1610-4755-bcb1-e0da5e7fa323">884,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ecb9a3c8f1c431198624af0dce809c1_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItOC0xLTEtMA_35f5c104-0ffa-40d1-ac91-1c4077680484">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i38c12ac2b33644d0a9d3578051648e63" continuedAt="i5f4beecfe1624bcfb52e7bc749f750a7">During the nine months ended September&#160;30, 2019 and 2018, there were <ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfMjc0ODc3OTA3MDU2NA_3210a30f-64c0-4afe-8685-198469e73cb1"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfMjc0ODc3OTA3MDU2NA_55c91cd8-c464-4419-b7f0-c2020e28ee38">no</ix:nonFraction></ix:nonFraction> transfers between Level 1 and Level 2 financial assets. The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities. As of December&#160;31, 2018, the fair value of our long-term debt, computed pursuant to a discounted cash flow technique using a market interest rate, was $<ix:nonFraction unitRef="usd" contextRef="ib4533404dc7f419c81cf7e77f58ea8c5_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzU2_2cbeeaa1-1eee-4ce9-9e44-b8336add83ec">30.1</ix:nonFraction> million and was considered a Level 3 fair value measurement. The effective interest rate reflected the current market rate as of the fair value date. On September 27, 2019, we repaid in full the $<ix:nonFraction unitRef="usd" contextRef="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfMzI5ODUzNDg5MTgxMg_48a8a139-feda-4909-b41e-b3e0764c5c46">30.0</ix:nonFraction> million long-term balance under our Credit Agreement with Wells Fargo Bank, National Association. Please read Note 9 for additional information regarding the Credit Agreement.</ix:continuation></span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5f4beecfe1624bcfb52e7bc749f750a7">In October 2017, we entered into a collaboration and license agreement with Vir Biotechnology, Inc., or Vir, at the time a private clinical-stage immunology company. As part of our upfront consideration, we received <ix:nonFraction unitRef="shares" contextRef="i1f6535ccbf5045358595e81d855d972e_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzY5NjU4MTM5ODQ0Mg_c102b49b-f9e0-49d7-828e-94fd39d9c213">5,000,000</ix:nonFraction> shares of Vir common stock. On September 27, 2019, Vir implemented a 1-for-4.5 reverse split of its common stock, converting our <ix:nonFraction unitRef="shares" contextRef="i9c5e31efccf54c278eb1d25e678417d7_I20190926" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzY5NjU4MTM5ODQ1Mw_f6fe7c2e-adee-4627-8c26-e6a26c37c19f">5,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="iedd70bee38ec4be4894eb36e4bddfaf7_I20190927" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzY5NjU4MTM5ODQ2NA_c93a4fe4-2f3f-495e-ad36-b182e9cc861c">1,111,111</ix:nonFraction> shares. On October 10, 2019, Vir completed its initial public offering, or IPO. As a result of the IPO, our common stock is now publicly traded common shares and is subject to a 180-day lock-up period.</ix:continuation> </span></div><div id="i_0_61"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RleHRyZWdpb246MGU2MWVlNWZjMGI0NDZiNWJlNjJmNjk0YjBlYWM2N2NfODI0NjMzNzIxMDg5NA_560b2879-6238-465c-bf54-3fc623a68e87" continuedAt="i6186a260779f480084b4d227bd9f147b" escape="true">MARKETABLE DEBT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i6186a260779f480084b4d227bd9f147b" continuedAt="i36e11839212d45ed9e1fc9df86ecfc52"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We obtain fair value measurement data for our marketable debt securities from independent pricing services. We perform validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand the methods and data sources used. Additionally, we perform our own review of prices received from the independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets. We did not record any impairment charges related to our marketable debt securities during the nine months ended September&#160;30, 2019 or 2018.</span></div><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RleHRyZWdpb246MGU2MWVlNWZjMGI0NDZiNWJlNjJmNjk0YjBlYWM2N2NfNzY5NjU4MTM5NzI2MQ_92bb71df-86d7-49e5-bedd-209211d719d4" escape="true"><div style="text-indent:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize our marketable debt securities as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:48.879765%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi0xLTEtMS0w_236f8442-dc65-4a37-b007-9fa756fd73b8">3,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi0zLTEtMS0w_3c1b0190-b2ab-4be2-bbb0-8d0deee16b0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi01LTEtMS0w_7e4e0d08-84e8-478a-9908-6bece2c08543">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi03LTEtMS0w_662a65fa-3519-4d0a-b6af-b1399d1c0185">3,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy0xLTEtMS0w_0d5272a9-e99b-41d0-bf3f-e6911b2431ab">29,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy0zLTEtMS0w_7fdc8978-4850-4336-ba73-8a08b1f061a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy01LTEtMS0w_5fc6dbc1-3140-449a-a441-63483c82c5bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy03LTEtMS0w_eeb9db78-f9a8-40c7-ae46-6c994e1b3d81">29,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC0xLTEtMS0w_bb3b52c0-3872-41ec-bc26-53fb9f249674">89,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC0zLTEtMS0w_0c3cc6c0-c7c9-4190-9a53-c1f7c76c1ffd">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC01LTEtMS0w_475463fd-47f8-4cf4-b50b-34695d3ec404">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC03LTEtMS0w_0fdedb3a-b534-4025-9fa7-8e23fe594155">90,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS0xLTEtMS0w_6576637a-937b-4fbd-b63c-7d2f061d4a2b">59,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS0zLTEtMS0w_23c4d0b7-a8cb-485e-ae33-c5ecf93994f3">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS01LTEtMS0w_feab791d-5668-453c-be2d-2aa7fffaf036">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS03LTEtMS0w_a72fcba8-8cc4-4fac-8cbb-10c0568da743">59,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if63df20ed74a495096a637566cb09eeb_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi0xLTEtMS0w_45ccdd60-a78f-48aa-874a-693928dc6a38">1,289,294</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if63df20ed74a495096a637566cb09eeb_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi0zLTEtMS0w_614dc29d-e76f-4882-aecd-0a08e0b2d75f">298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if63df20ed74a495096a637566cb09eeb_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi01LTEtMS0w_7ddfe03d-d772-4a9f-856b-781a507d7f2d">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if63df20ed74a495096a637566cb09eeb_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi03LTEtMS0w_e6f064cf-8ea5-49f0-815b-c3d886571412">1,289,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy0xLTEtMS0w_6e3d4620-b857-4bd6-ab71-fc1658937bb7">1,471,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy0zLTEtMS0w_7d768717-3121-468f-9b5f-4441fea176be">395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy01LTEtMS0w_da493a52-ebaf-4aa2-b6e5-c8c2da270d11">44</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy03LTEtMS0w_90e3050e-8eff-4427-8f1e-9aa9dc7e13af">1,471,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:48.879765%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi0xLTEtMS0w_32b531f0-95b4-4bf1-a7f9-72d2531cdcd5">8,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi0zLTEtMS0w_d6a7089f-a98d-43f8-8f93-29deffc7c340">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi01LTEtMS0w_e18e19dd-379a-43ac-8ca1-bd37d03eac77">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi03LTEtMS0w_66f7abe4-54de-43c4-a23f-ece1d42f1690">8,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy0xLTEtMS0w_0e51b4bb-f76b-498a-b451-621ac9f81a4b">57,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy0zLTEtMS0w_015d8819-ae68-4d83-8aeb-f974e0e137c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy01LTEtMS0w_2b902612-9420-41a2-91a4-4fcccbbecf48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy03LTEtMS0w_28b09d32-5f87-4e5a-95c1-5cc58d774302">57,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC0xLTEtMS0w_6fe1d6ef-400e-44f1-8b9c-dace477a2363">232,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC0zLTEtMS0w_b0fc4108-480f-4e28-9538-a735707667b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC01LTEtMS0w_01c35c18-9c5b-4244-b3ae-4bb28d76671c">285</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC03LTEtMS0w_ae2d0742-8fcb-440d-9973-3aeca4859954">232,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS0xLTEtMS0w_d7cf0d90-efe0-407d-a4c8-32eb6d06d719">39,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS0zLTEtMS0w_97094c2f-8dcd-42ca-a551-9682dc9676e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS01LTEtMS0w_9c6e7e3c-a997-424d-9cce-81bdbdfb0c0a">13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS03LTEtMS0w_b65e922f-f83f-454e-bfb3-8b8eff7e1570">39,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi0xLTEtMS0w_1ed5d96e-7c8e-4af3-b29a-c8c0d72051ce">546,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi0zLTEtMS0w_10f32754-cd68-4e09-97c9-b3d7c865b56e">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi01LTEtMS0w_5a61384c-f03c-4f88-86e7-6e70e6a1f4ce">124</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi03LTEtMS0w_002a3ffb-0fa2-4f75-9bb9-e50440089a36">546,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy0xLTEtMS0w_5730b0ab-92a6-4124-8844-890376c75b95">884,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy0zLTEtMS0w_701a19d4-67dd-485f-87cd-20e251a246c5">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy01LTEtMS0w_b9d26853-8c34-4355-992b-ecc511d1e368">422</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy03LTEtMS0w_f1c22cae-a77c-4db4-9c68-510a9f3b1365">884,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="i36e11839212d45ed9e1fc9df86ecfc52"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RleHRyZWdpb246MGU2MWVlNWZjMGI0NDZiNWJlNjJmNjk0YjBlYWM2N2NfNzY5NjU4MTM5NzI2Mg_352e5c25-92cb-4cdc-8ae9-7418a87c8687" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:69.783626%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.742690%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.742690%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMS0xLTEtMS0w_f833a8a6-a2e8-414a-9973-317018c135b8">674,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMS0zLTEtMS0w_bfb32911-71ee-498c-babd-f00630f39dcd">221,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMi0xLTEtMS0w_d86e45a7-195d-4e20-8ab1-e576c73958d0">797,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMi0zLTEtMS0w_ae5aed73-173c-4c2b-93d3-f157717a501c">662,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMy0xLTEtMS0w_698c2009-b432-47b4-92e1-3f0f6b76cc8c">1,471,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMy0zLTEtMS0w_4eeafee6-9e3e-4d23-a2cf-d726ca72eba5">884,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We classify our debt security investments based on their contractual maturity dates. As of September&#160;30, 2019, the contract maturity for all of our available-for-sale debt securities was less than one year.</span></div></ix:continuation><div id="i_0_67"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfNzY5NjU4MTM5ODk5NA_fee092ca-04d7-4f54-b7d5-951e4a0335d0" continuedAt="i6dced1566312459c88a9dd5c2c92e930" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i6dced1566312459c88a9dd5c2c92e930" continuedAt="i53b6385a07da4f8ab68f0bd2e21bf574"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview of Significant Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease three facilities for office and laboratory space in Cambridge, Massachusetts that represent substantially all of our significant lease obligations.&#160;An overview of these significant leases are as follows:</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">675 West Kendall Street</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease office and laboratory space located at 675 West Kendall Street, Cambridge, Massachusetts under a non-cancelable real property lease. In September 2019, we moved our corporate headquarters and research facility to this location from our 300 Third Street location. The lease commenced on May 1, 2018 and monthly rent payments became due commencing on February 1, 2019 upon substantial completion of the building improvements, and continue for <ix:nonNumeric contextRef="i16dd0de9646a4fda905e58f333423af5_D20150401-20150430" format="ixt-sec:duryear" name="alny:LeaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfNzQ5_f3cb767d-5907-47e4-b3a8-f0b119000eda">15</ix:nonNumeric> years, with <ix:nonNumeric contextRef="i57addb2cc587477995144b49e9eba89b_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjc0ODc3OTA3Mjg2MQ_b8b39f9b-3d22-4bdc-b7a2-750359e53c2b">options to renew for two five-year terms each</ix:nonNumeric>. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">300 Third Street</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease office and laboratory space located at 300 Third Street, Cambridge, Massachusetts under a non-cancelable real property lease agreement dated as of September 26, 2003, as amended. The term of the lease expires on <ix:nonNumeric contextRef="i9fd9e2e99e294a098eb38e91d8de00b3_D20030925-20030926" format="ixt:datemonthdayyearen" name="alny:ExtendedLeaseExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMTMxMQ_2d4fd80f-6fb4-4cec-8f6d-1d62ebc57a37">January&#160;31, 2034</ix:nonNumeric>, with an <ix:nonNumeric contextRef="i65a3b729d2b6434facd1ef9436293344_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjc0ODc3OTA3MjkyNg_c971dc0d-d9b8-47fe-a332-d19830a564cc">option to extend for two additional five-year terms</ix:nonNumeric>. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">101 Main Street</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease office space located on several floors at 101 Main Street, Cambridge, Massachusetts under non-cancelable real property lease agreements entered into in March and May 2015 that will expire in March 2024 and June 2021, respectively, each with an <ix:nonNumeric contextRef="i1997e78a21c14482b37dd96a0a0275a3_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjc0ODc3OTA3Mjk4Nw_f4935b24-75ad-42bd-aa48-c3451ff33458">option to renew for one five-year term</ix:nonNumeric>. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Lease Disclosures</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our facility leases described above generally contain customary provisions allowing the landlords to terminate the leases if we fail to remedy a breach of any of our obligations under any such lease within specified time periods, or upon our bankruptcy or insolvency.</span></div><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMzM0NQ_68c24dc0-e7da-46b9-bece-e32a30fbc574" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The below table summarizes our costs included in operating expenses related to leases we have entered into through September&#160;30, 2019, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:65.349927%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.959004%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.959004%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Lease Cost</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMS0xLTEtMS0w_bbac65ed-7fb6-4290-af00-5475e2b90d62">9,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMS0zLTEtMS0w_c78e5689-6df8-490c-ae55-632e550d3dfa">27,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMi0xLTEtMS0w_c2cde969-91ea-49eb-a047-44ea3dd1e13f">3,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMi0zLTEtMS0w_0c6e20e6-8ea3-4a6a-9e0c-e908397bd530">12,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMy0xLTEtMS0w_10521210-443a-4bac-bebf-fe082d5f2518">12,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMy0zLTEtMS0w_07f8fc03-b3be-47c2-8300-865958a0577d">40,856</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Short-term lease costs were not material for the&#160;three and nine months ended September&#160;30, 2019.</span></div></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="i53b6385a07da4f8ab68f0bd2e21bf574"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash paid for the amounts included in the measurement of the operating lease liability in our condensed consolidated balance sheet and included in accrued expenses and other within operating activities in our condensed consolidated statement of cash flow was $<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjgxMA_79df0be3-5128-4b9f-b8c8-87e5a5bb53a1">24.8</ix:nonFraction> million for the nine months ended September&#160;30, 2019.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September&#160;30, 2019 was <ix:nonNumeric contextRef="ib290959e61784a1896b905564c991cdf_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjk0Nw_8398108e-26c2-493e-a360-226e7799f701">13.4</ix:nonNumeric> years and <ix:nonFraction unitRef="number" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjk1NA_8d99c8fb-98ca-47ea-94f6-af2b24fa785d">8.2</ix:nonFraction>%, respectively.</span></div><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMzM0Ng_71743cd6-b856-4964-aa9e-3e4528ae31a5" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Future lease payments for non-cancellable operating leases and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September&#160;30, 2019 is as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:86.286969%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.713031%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining three months)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMS0xLTEtMS0w_2ad40483-648d-439b-a1c4-036d6aa20b05">8,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMi0xLTEtMS0w_f62bb06d-1c79-4a1d-abb5-c927876c5876">28,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMy0xLTEtMS0w_d6bb1543-0a16-4303-bcdd-90d35032fae3">36,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNC0xLTEtMS0w_68663015-9355-402c-882f-561312dc0287">36,510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNS0xLTEtMS0w_218062c7-916a-48e0-8e67-2645024391c4">35,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNi0xLTEtMS0w_fd4270c9-c10e-48a1-8bbc-8a6d53fe601c">34,670</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="alny:LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNy0xLTEtMS0w_51842d92-fbdd-46b6-a55c-daba7bc5ee7a">356,208</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfOC0xLTEtMS0w_dab6d7f6-bd11-47ef-8683-3e0447bba1b6">536,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfOS0xLTEtMS0w_0eb797f5-63bc-4cba-ac17-09cb00bbc83c">231,654</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total discounted lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTAtMS0xLTEtMA_73e560ee-88a7-4751-8ca7-8408f64a58c1">304,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTItMS0xLTEtMA_049b4e96-299c-4b59-bd4a-8ae537d25889">28,165</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTMtMS0xLTEtMA_c84512f7-915f-4916-9036-62b2ca02bf5c">276,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTQtMS0xLTEtMA_406fd56a-674b-460f-8c40-0119f644874b">304,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMzM0Nw_341e1838-4f95-4678-ab5f-8553b5d5cdf1" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the prior lease guidance, minimum payments under our non-cancelable facility leases, as of December&#160;31, 2018, were as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:86.286969%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.713031%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfMS0xLTEtMS0w_f09cc295-8700-41e1-97f0-a1f675969b38">32,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfMi0xLTEtMS0w_dfe55d66-bc06-4c57-ba67-7f03af233f79">34,826</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfMy0xLTEtMS0w_8f798152-0414-4dd1-beaf-c06c829fac72">34,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNC0xLTEtMS0w_1955b4d6-9800-465a-bfb0-06c3e1ee3edf">34,826</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNS0xLTEtMS0w_2811f5c8-6b3a-4fc8-b426-0b905dbaac9f">35,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNi0xLTEtMS0w_c267727d-6681-4a11-8b5e-885795c4639f">390,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNy0xLTEtMS0w_97b4a321-1403-40c9-adf7-63e5cb58b2e5">562,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_73"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:CreditAgreementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfNzY5NjU4MTM5ODA1Mw_ade149ac-8877-45c8-9d78-2826a7305a24" continuedAt="i95b2f0575a2149a797fde9b3ed687c34" escape="true">CREDIT AGREEMENT</ix:nonNumeric></span></div><ix:continuation id="i95b2f0575a2149a797fde9b3ed687c34"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April&#160;29, 2016, we entered into a Credit Agreement by and among Alnylam U.S., Inc., as the borrower, us, as a guarantor, and Wells Fargo Bank, National Association, as the lender.&#160;The Credit Agreement was entered into in connection with the planned build out of our drug substance manufacturing facility.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfMzY5_d2979219-02b5-4905-8ae0-58b7f3ef3373">30.0</ix:nonFraction> million term loan facility and was scheduled to mature on <ix:nonNumeric contextRef="ice75d291b75345eeb04d09221d4ac4bc_D20160429-20160429" format="ixt:datemonthdayyearen" name="us-gaap:LineOfCreditFacilityExpirationDate1" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfNDA2_8e11f72f-3a49-4704-b8ba-28feec98f095">April&#160;29, 2021</ix:nonNumeric>. On September 27, 2019, we repaid in full the $<ix:nonFraction unitRef="usd" contextRef="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfMjc0ODc3OTA3NDE3Mw_48a8a139-feda-4909-b41e-b3e0764c5c46">30.0</ix:nonFraction> million outstanding principal amount under the Credit Agreement and the Credit Agreement terminated in accordance with its terms upon repayment of the outstanding indebtedness. Interest on borrowings under the Credit Agreement was calculated based on LIBOR plus <ix:nonFraction unitRef="number" contextRef="ia12206eca6a84503bf5e9fcc26bd4ded_D20160429-20160429" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfNjE4_2657429f-2dbd-4cd9-aec2-003908cb8a3b">0.45</ix:nonFraction>%, except in the event of default.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The obligations of the borrower and us under the Credit Agreement were secured by cash collateral in an amount equal to, at any given time, at least <ix:nonFraction unitRef="number" contextRef="ifb3e8a8fa91c4e08a54b904445e3b904_D20160429-20160429" decimals="INF" format="ixt:numdotdecimal" name="alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfOTY2_5ee57c72-a708-4419-9fe9-9f6f27d4ff4f">100</ix:nonFraction>% of the principal amount of all term loans outstanding under such Credit Agreement at such time. As of December&#160;31, 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="i8211fd2babc7426599d8a4da01554401_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfMTA5OQ_7aceda3c-8173-4734-b670-5ce5e1cc8cf5">30.0</ix:nonFraction> million of cash collateral in connection with the Credit Agreement as restricted investments.</span></div></ix:continuation><div id="i_0_79"></div><div style="text-align:justify;margin-top:18pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNzY5NjU4MTQwMDgyMg_908391dc-f669-40bb-8ec3-121a0dd377a2" continuedAt="ic35818f2b3d84124943a46409010e5ae" escape="true">EQUITY</ix:nonNumeric></span></div><ix:continuation id="ic35818f2b3d84124943a46409010e5ae"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offering</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, we sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNzM_27ad70fc-5234-481b-b898-f7a6114a9d9a">5,000,000</ix:nonFraction> shares of our common stock through an underwritten public offering at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i436c9f5ba1394239990c555377c133a4_I20190131" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMTcx_cf1f434e-9209-4b5b-87a1-2336d99e1bb8">77.50</ix:nonFraction> per share. As a result of the offering, we received aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMjUy_eaf3db34-f728-40c7-8ba3-71cf14558ac9">381.9</ix:nonFraction> million after deducting underwriting discounts and commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzU1_d0f53e7e-def3-44c2-b3b2-45b6cf213446">5.6</ix:nonFraction> million.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regeneron Equity Placement</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 8, 2019, we executed the Regeneron SPA with Regeneron to sell <ix:nonFraction unitRef="usd" contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDU3_69d8f71f-00bd-40e0-8c13-142006b73a83">4,444,445</ix:nonFraction> shares of our common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="idc8680a0470f4515bbbb63de4581db15_I20190521" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDk4_cd6982f3-db37-4dbc-b13b-869c1795e39c">0.01</ix:nonFraction> per share for aggregate cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNTQ3_cc95ed1b-57e2-420d-9a12-19896879556c">400.0</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="idc8680a0470f4515bbbb63de4581db15_I20190521" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNTU1_2100af95-a5d3-48a3-b315-588b4dafb4f5">90.00</ix:nonFraction> per share, which we refer to as the Equity Transaction.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As a condition to consummating the transactions contemplated by the Regeneron SPA, we and Regeneron entered into an Investor Agreement dated <ix:nonNumeric contextRef="i304e9e4a77f146f1b45c8803228f6a4d_D20190101-20190930" format="ixt:datemonthdayyearen" name="alny:DateOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMTQ0Nw_ec4ae51e-b81e-488e-8823-6dc415ca426c">April&#160;8, 2019</ix:nonNumeric>, or the Investor Agreement. Under the Investor Agreement, until the expiration or termination of the Research Term under the Regeneron Master Agreement subject to extension by one year if the Research Term or Regeneron Master Agreement is terminated by Regeneron at will, or by up to <ix:nonNumeric contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" format="ixt-sec:durwordsen" name="alny:AgreementExtensionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMjc0ODc3OTA3NTgzMw_3e0e3d3f-97d7-45d9-9c55-1731c97863b7">two years</ix:nonNumeric> if as of the expiration or termination of the Research Term Regeneron owns more than <ix:nonFraction unitRef="number" contextRef="i41895d919e574902acb6169b0edb03fd_D20190408-20190408" decimals="4" name="alny:OwnershipPercentageOfSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMTgyMg_cd2b33e4-3a9d-4c8d-a96a-10d17ea73783">19.99</ix:nonFraction>% of our outstanding shares, Regeneron and its affiliates will be bound by certain &#8220;standstill&#8221; provisions. The standstill provisions include agreements not to acquire more than <ix:nonFraction unitRef="number" contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408" decimals="2" name="alny:OwnershipPercentageSharesOfStocksOutstandingUpperLimit" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMjAwMQ_ffcb2518-5c60-41a0-bde2-572b1707b5b9">30</ix:nonFraction>% of our outstanding shares of common stock, call stockholder meetings, nominate directors other than those approved by our board of directors, subject to certain limited exceptions, or propose or support a proposal to acquire us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Further, under the Investor Agreement, Regeneron agreed to vote, and cause its affiliates to vote, all shares of our voting securities Regeneron is entitled to vote in a manner as recommended by our board of directors, except with respect to certain change of control transactions, liquidation or dissolution of our company, or, after the standstill term, any contested election of directors.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Investor Agreement, Regeneron agreed not to dispose of any of the purchased shares or any shares of common stock beneficially owned by it immediately after the closing of the Regeneron Master Agreement, until the earlier of (i)&#160;the four-year anniversary of the closing of the Equity Transaction and (ii)&#160;the termination of the Regeneron Collaboration, subject to limited exceptions, which we refer to as the Lock-Up Period. Following the expiration of the&#160;Lock-Up&#160;Period, if at any time Regeneron beneficially owns at least <ix:nonFraction unitRef="number" contextRef="i41895d919e574902acb6169b0edb03fd_D20190408-20190408" decimals="3" name="alny:BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzE2MA_668cebab-c84a-42a8-b8f6-66917c62893d">9.9</ix:nonFraction>% of our outstanding shares, then until such time as Regeneron beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408" decimals="2" name="alny:BeneficialOwnershipPercentageOfSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzI1Mg_08119abc-35bb-464f-8bb4-2405a2521c5a">5</ix:nonFraction>% of our outstanding shares, Regeneron will not dispose of any shares except (a)&#160;pursuant to a registered underwritten public offering pursuant to the Investor Agreement, (b)&#160;in a manner consistent with the volume limitations set forth in Rule 144 under the Securities Act, or (c)&#160;as otherwise approved by us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Investor Agreement, following the&#160;Lock-Up&#160;Period, Regeneron will have three demand rights to require us to conduct a registered underwritten public offering with respect to the shares of common stock beneficially owned by Regeneron immediately after the closing of the Equity Transaction. In addition, following the&#160;Lock-Up&#160;Period, subject to certain conditions, Regeneron will be entitled to participate in registered underwritten public offerings by us if other selling stockholders are included in the registration. The rights and restrictions under the Investor Agreement are subject to termination upon the occurrence of certain events.</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Under the terms of the Regeneron SPA, if at the time of closing of the Equity Transaction a sufficient number of authorized shares of common stock under our Restated Certificate of Incorporation was not available, the Equity Transaction would have been settled in the form of our Series A redeemable convertible preferred stock. On April 25, 2019, following the receipt of stockholder approval at our annual meeting, a Certificate of Amendment was filed to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i5c4dc572daa54cea9409b772eff6e606_I20190425" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDQ1MA_537ef148-6cbb-485e-b972-6d7df39c4e54">125,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i48cd17bd102c404d9c2fb188602a9b17_I20190425" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDQ1Ng_ee1c8b20-79c3-4734-93d9-624ede0f8c21">250,000,000</ix:nonFraction> shares, providing for a sufficient number of authorized shares of common stock available to be issued to Regeneron pursuant to the Equity Transaction.&#160;On May 21, 2019, subsequent to the expiration of the applicable pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Regeneron purchased <ix:nonFraction unitRef="usd" contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDc5Nw_ff285fb0-bb72-40dd-84a3-356b5a0e408f">4,444,445</ix:nonFraction> shares of our common stock for aggregate cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDg2Mw_d49c40ca-a83a-495c-b757-deb0f79bfc23">400.0</ix:nonFraction> million.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Because we had an obligation to Regeneron as of April 8, 2019 that may have resulted in the issuance of redeemable convertible preferred stock, we were required to follow the guidance in ASC 480 and mark-to-market the obligation to potentially issue this redeemable security until April 25, 2019, when it became known that the obligation would be fulfilled in common stock. The final mark-to-market adjustment of this obligation under ASC 480 resulted in us recording a gain of $<ix:nonFraction unitRef="usd" contextRef="i7f917e7daa184219863485fd13588358_D20190425-20190425" decimals="-5" format="ixt:numdotdecimal" name="alny:GainLossOnSaleOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNTM0NQ_59e95704-fbaa-4d86-a889-d469a1500674">9.4</ix:nonFraction> million included in other income in the consolidated statements of comprehensive loss with the offsetting adjustment to equity netting against the $<ix:nonFraction unitRef="usd" contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzI5ODUzNDg4ODk1NA_d49c40ca-a83a-495c-b757-deb0f79bfc23">400.0</ix:nonFraction> million proceeds that were received upon closing.</span></div></ix:continuation><div id="i_0_85"></div><div style="text-align:justify;margin-top:18pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">11. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RleHRyZWdpb246NWJkZGNjYmRlZGRkNDU1ZTg3ODhmMTg0NWE0ZDkyNDZfODI0NjMzNzIwODUwNg_dbfd66f1-6bf3-4b79-9a54-79ce810f51b5" continuedAt="i171412553ff74db7956f86b1ca99f72e" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i171412553ff74db7956f86b1ca99f72e"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RleHRyZWdpb246NWJkZGNjYmRlZGRkNDU1ZTg3ODhmMTg0NWE0ZDkyNDZfMTg0_397f5be3-2553-4a64-a367-af3da51f203e" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock-based compensation expenses included in operating costs and expenses, for the periods indicated, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:44.187683%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.903226%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.903226%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.903226%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.903226%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0fb16a3a7a347cf97e568dd2a32d15f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi0xLTEtMS0w_71beda30-8c8b-4387-93fb-19cce099f552">22,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i756073bf9c7c485baa654d9c3b97871c_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi0zLTEtMS0w_d1c12d44-dcda-4f10-bb26-735bf73d5fbb">45,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0f962dd9c0f44fafacbd61a3c2eb05e8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi01LTEtMS0w_8dcd59e2-aa6f-4436-974c-0f20413e14e8">54,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c6c2484c92b4de1af5da63f0a53a5a3_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi03LTEtMS0w_bae231af-95a0-4fa7-a847-712a0082b4a1">67,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie27125284d00480e8f6436e54883feb0_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy0xLTEtMS0w_5b818e9c-608a-43a5-8115-eed70cf5822a">23,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8c1e473ec654c44910204fe79355acb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy0zLTEtMS0w_c8421d9f-20f1-46c0-900c-133f705d4292">42,170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1a903160824485588e14c40fe27e4f4_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy01LTEtMS0w_60202d0c-efb8-4003-9a59-da5679efa3a8">54,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib20fa348345c43e6aa0c88af9024338c_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy03LTEtMS0w_24519e58-bea0-4ee3-ae3d-74b11598da07">62,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC0xLTEtMS0w_3d4eb521-35d5-4802-a18c-84ad482ca06a">46,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC0zLTEtMS0w_58d18d62-34e6-46dd-82c0-f25ed4089171">87,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC01LTEtMS0w_59fe5ee6-7224-4020-93e6-286e156b137a">108,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC03LTEtMS0w_f7d08312-f668-483d-90dc-3cf95c007b86">129,779</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_88"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">12. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RleHRyZWdpb246ZWQyNGFmYzZiNzY0NDY3MmEwYjE0NmY2YjBkM2Q3ZGZfNzY5NjU4MTM5NzE5Mw_e44d6676-f130-461a-8876-96107e398e4c" continuedAt="i66b88461809c46d7bf77627f0e435384" escape="true">NET LOSS PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="i66b88461809c46d7bf77627f0e435384"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding during the period. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. Potential common shares consist of shares issuable upon the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.</span></div><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RleHRyZWdpb246ZWQyNGFmYzZiNzY0NDY3MmEwYjE0NmY2YjBkM2Q3ZGZfODk5_53a7b632-c37d-49ad-99af-0f6d9473a4e2" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following common share equivalents (in thousands) were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i76aae8848c0147d7b950df899aa1ee06_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMi0xLTEtMS0w_553cf916-4e6c-4449-97e6-de0bcfca1c8e">13,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a29165453f749cf90320576aab15e8e_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMi0zLTEtMS0w_ab1e3e1b-e017-430a-9815-b45a1b8f626c">12,676</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9b94502431eb4c5aafa0614d51c18e74_D20190101-20190930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMy0xLTEtMS0w_6dc19446-cd74-4225-a517-688f0b47667b">668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iebaaccb3176d4aea882b953a0bfbd222_D20180101-20180930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMy0zLTEtMS0w_628e01d3-a75d-433e-bcf8-127315476aba">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfNC0xLTEtMS0w_fbf2fcd9-f292-481b-a5ef-faa2238363c9">14,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfNC0zLTEtMS0w_29caada3-360a-46e4-b077-16db3503aa1f">12,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_91"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">13. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RleHRyZWdpb246NGJjYjY0OWMyOTYxNGQxOWFhZDUwMzJmZTI5ZjkyMGZfODI0NjMzNzIwODY1OQ_dc8d08fc-27f4-4ecf-90f6-81183fc77aca" continuedAt="i93aacf1c58c04fd0a397c6ef70d3b7a8" escape="true">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</ix:nonNumeric></span></div><ix:continuation id="i93aacf1c58c04fd0a397c6ef70d3b7a8"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RleHRyZWdpb246NGJjYjY0OWMyOTYxNGQxOWFhZDUwMzJmZTI5ZjkyMGZfMzM2_993b42c3-11e3-4724-a3e3-a811ff8b020d" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMi0xLTEtMS0w_a4e36090-aa49-4f8f-b9fb-b5280885a4ef">923,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMi0zLTEtMS0w_d7860505-45b7-492f-9cf7-4b2c7b6984fc">316,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMy0xLTEtMS0w_85435244-0a98-4441-a26e-40c092852652">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMy0zLTEtMS0w_03596949-b2d5-4797-b1b0-e39565534406">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in long-term other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNC0xLTEtMS0w_15306ff9-f823-4344-bb4c-16178f4a59d1">2,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNC0zLTEtMS0w_3a3acd01-fd7d-481d-9100-b9039a55ba44">2,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib290959e61784a1896b905564c991cdf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNS0xLTEtMS0w_632dffa3-5b8e-4ac6-914e-a27f03980ab2">925,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f25a7c241a4588906a002ff847246a_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNS0zLTEtMS0w_77dc104d-f9ef-4bb9-afdd-9be23708ffad">318,746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_94"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">14. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfODI0NjMzNzIxMzc2OQ_f0273247-df79-4d41-83ed-d0d5dba8dab0" continuedAt="i463ebf51694e41c694c2ab5d69e273a5" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i463ebf51694e41c694c2ab5d69e273a5" continuedAt="id592786eda594099b24c24d9109ad341"><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Manufacturing Facility</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2016, we purchased <ix:nonFraction unitRef="sqft" contextRef="i635ef6dc444f45e2a67366c5fb673343_I20160430" decimals="0" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfOTA_155564fc-dd6a-4e3b-b92f-75a411433198">12</ix:nonFraction> acres of undeveloped land in Norton, Massachusetts. We are constructing a manufacturing facility at this site for drug substance for clinical and commercial use. As of September&#160;30, 2019 and December&#160;31, 2018, property, plant and equipment, net, on our condensed consolidated balance sheets reflect $<ix:nonFraction unitRef="usd" contextRef="i4abb8539eed44421b7213ceef0389203_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfMzU4_1c327830-9d92-4d51-9c46-21dee6f586c4">278.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id20e2ef3281f455ba39063a9f09b371c_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfMzY1_8ed06e19-137d-4980-8c0c-261e7d70e748">227.7</ix:nonFraction> million, respectively, of land and associated costs related to the construction of our drug substance manufacturing facility.</span></div></ix:continuation><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><ix:continuation id="id592786eda594099b24c24d9109ad341" continuedAt="i06d15114afed4f538f426cb63de41a00"><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are a party to legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred. </span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Securities Litigation</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On September 26, 2018, Caryl Hull Leavitt, individually and on behalf of all others similarly situated, filed a class action complaint for violation of federal securities laws against us, our Chief Executive Officer and our former Chief Financial Officer in the United States District Court for the Southern District of New York. By stipulation of the parties and Order of the Court dated November 20, 2018, the action was transferred to the United States District Court for the District of Massachusetts. On May 8, 2019, the Court entered an order appointing a&#160;lead&#160;plaintiff, and on July 3, 2019, lead&#160;plaintiff&#160;filed a consolidated class action complaint, or the Complaint. In addition to the originally named defendants, the Complaint also names as defendants certain of our other executive officers, and purports to be brought on behalf of a class of persons who acquired our securities&#160;between September 20, 2017 and September 12, 2018 and seeks to recover damages caused by defendants&#8217; alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The Complaint alleges, among other things, that the defendants made materially false and misleading statements related to the efficacy and safety of our product, ONPATTRO. The plaintiff seeks, among other things, the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed a motion to dismiss the Complaint in its entirety on July 31, 2019. The motion to dismiss was fully briefed on September 30, 2019.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. The complaint is brought on behalf of an alleged class of those who purchased our securities pursuant and/or traceable to our November 14, 2017 public stock offering. The complaint purports to allege claims arising under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, and generally alleges that the defendants violated the federal securities laws by, among other things, making material misstatements or omissions concerning the results of our APOLLO Phase 3 clinical trial of patisiran. The plaintiff seeks, among other things, the designation of the action as a class action, an award of unspecified compensatory damages, rescissory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that the allegations contained in the complaints are without merit and intend to defend the cases vigorously. We cannot predict at this point the length of time that these actions will be ongoing or the liabilities, if any, which may arise therefrom.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dicerna Litigation</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June&#160;10, 2015, we filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the Superior Court of Middlesex County, Massachusetts seeking to stop misappropriation by Dicerna of our confidential, proprietary and trade secret information related to the RNAi assets we purchased from Merck Sharp &amp; Dohme Corp., including certain N-acetylgalactosamine, or GalNAc, conjugate technology. In addition to permanent injunctive relief, we were also seeking monetary damages from Dicerna.</span></div></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i06d15114afed4f538f426cb63de41a00">On <ix:nonNumeric contextRef="i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418" name="us-gaap:LossContingencySettlementAgreementDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfNDAxMA_d69885fd-125c-451a-b6dd-2f811297fd55">April&#160;18, 2018</ix:nonNumeric>, we and Dicerna entered into a settlement agreement resolving all ongoing litigation between the companies. Under the terms of the settlement agreement, Dicerna was required to pay us an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfNDIxMw_88eed81a-5058-43cc-bbfc-790e14b302f6">25.0</ix:nonFraction> million, all of which we had received as of January 2019.</ix:continuation> </span></div><div id="i_0_100"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">15. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDAvZnJhZzpmNGE5ODlkMTVlNGU0ZTU1YmYzY2VjMDBlM2Q3YWQ5Zi90ZXh0cmVnaW9uOmY0YTk4OWQxNWU0ZTRlNTViZjNjZWMwMGUzZDdhZDlmXzgyNDYzMzcyMDkwNzM_f9d39085-d8a0-4df0-b918-03ef1ae5cba5" continuedAt="i2d53f25ace0142e68d6bb16d2ffdcdf1" escape="true">DEFINED BENEFIT PLANS</ix:nonNumeric></span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2d53f25ace0142e68d6bb16d2ffdcdf1" continuedAt="i5b73c3863339455b9db791c5d582dea6">We maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The unfunded benefit obligation corresponds to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases and pension adjustments, </ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5b73c3863339455b9db791c5d582dea6">offset by the fair value of the assets held by plan. The unfunded benefit obligation was approximately $<ix:nonFraction unitRef="usd" contextRef="i1a9655ab33ba47a3b214bdd3432435d3_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDAvZnJhZzpmNGE5ODlkMTVlNGU0ZTU1YmYzY2VjMDBlM2Q3YWQ5Zi90ZXh0cmVnaW9uOmY0YTk4OWQxNWU0ZTRlNTViZjNjZWMwMGUzZDdhZDlmXzUwOA_0dc909ca-4770-4945-9a7e-4a13b367f669">4.0</ix:nonFraction> million as of September&#160;30, 2019 and is recorded in other liabilities on the condensed consolidated balance sheet. The unfunded benefit obligation as of December&#160;31, 2018 and the total net periodic benefit cost for the three and nine months ended September&#160;30, 2019 and 2018 were not material.</ix:continuation></span></div><div id="i_0_103"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">16. <ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90ZXh0cmVnaW9uOjRmZjYyMzJiNzhkYjRmYzA5MGYyZmVmZWYzYTE4MDAzXzgyNDYzMzcyMDg3Nzc_a5c4e7bc-5702-4fdc-b04d-4325c69fae28" continuedAt="i7853384ce5eb40e780f86e4ad66daf24" escape="true">OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i7853384ce5eb40e780f86e4ad66daf24"><ix:nonNumeric contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90ZXh0cmVnaW9uOjRmZjYyMzJiNzhkYjRmYzA5MGYyZmVmZWYzYTE4MDAzXzQ1Mw_d8a341df-240f-4c45-bb1e-f243b323dd97" escape="true"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the changes in accumulated other comprehensive (loss) income, by component, for the nine months ended September&#160;30, 2019 and 2018, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:32.356725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.327485%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on Investment in Joint Venture</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Securities</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Total Accumulated Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Comprehensive (Loss) Income </span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i920d2d842f894f7e86890f2d0f76a285_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtMS0xLTEtMA_93ef4bb9-0d6d-4966-a2af-269dfd3971ec">32,792</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia71b3c59a6854c088d21eef4ff92db76_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtMy0xLTEtMA_849c44a7-3d9e-4e16-af8e-61cdc94fd4c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i22d215da162a4b1f870322c528da7252_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtNS0xLTEtMA_204d9182-5790-44ab-b7d6-b62ad5b89a6d">421</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i668cb2e656af4447be63e110a6773f58_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtNy0xLTEtMA_808cb8f4-9c9f-4289-ac29-4276c2da4539">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iffcea211cbf84b608c3df605df16aac5_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtOS0xLTEtMA_17ee9f84-658b-49d0-bbc7-8021cd426320">33,213</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItMS0xLTEtMA_1f991d44-117b-4f75-b140-2f87ea9a6d51">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItMy0xLTEtMA_f4dc51cd-15bc-4f46-b985-b58e5cb8c944">4,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItNS0xLTEtMA_a5ff62d3-ee89-4b93-ae49-9f692af59384">359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItNy0xLTEtMA_4996ac94-64ba-4a83-a99a-9d6b9d981fdf">2,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItOS0xLTEtMA_cbd7925c-035a-4343-af69-f00859c1757b">1,642</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtMS0xLTEtMA_023bddbe-7433-465b-94bd-d9431c30cdde">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtMy0xLTEtMA_c0813cc6-f6d3-4b41-9c48-7f24b4354de9">71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtNS0xLTEtMA_8110b9f3-1096-40f3-a52c-fa897ab516ab">413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtNy0xLTEtMA_5864b55b-1e90-4b56-beef-14187f0e4916">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtOS0xLTEtMA_0aecc36d-a61f-42cd-b065-a39d4c7fbb59">484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net other comprehensive (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtMS0xLTEtMA_dc190bca-330b-47d0-a02d-e039bf377fd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtMy0xLTEtMA_556c9b6e-061a-4f81-a228-d4d7fe16718c">4,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtNS0xLTEtMA_4f0be2c6-09dd-42c1-bdcf-142a983a4531">772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtNy0xLTEtMA_82b362d1-b1a8-4ff6-8a7d-7c93091f2a57">2,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtOS0xLTEtMA_f1204337-a7c7-4a59-b371-d23bdec8264e">1,158</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i40c726db79a1419ca5405f2c9219f5d5_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtMS0xLTEtMA_bafa6ce8-3ef4-4e73-8513-3879f17bfefb">32,792</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i730a5054c2f94c9685c25fdcab2d5d7a_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtMy0xLTEtMA_16446eaa-d4dd-4490-9172-77efe4e5c708">4,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if14817b988c44e9f97cb96e8be08c094_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtNS0xLTEtMA_91ac64e4-198d-4cc9-8cdd-77eb7004332a">351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92f8703c144249dfa1533aa08a4f503a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtNy0xLTEtMA_8dc7cbdc-26e5-4307-a9f9-4cfd8747b657">2,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i051b47be2e4f44b18624cfd7fb7d1e52_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtOS0xLTEtMA_c77046ca-739c-4e0e-9161-ecb680950c0a">34,371</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:32.356725%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695906%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.327485%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on Investment in Joint Venture</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (Losses) Gains from Debt<br/>Securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Accumulated Other<br/>Comprehensive (Loss) Income </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i94bb522921334436b71c747686f4701a_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtMS0xLTEtMA_9b1fc5ba-a575-4b3e-a2d8-6c26cd7ba630">32,792</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35867a636295441082ae888c09b539e8_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtMy0xLTEtMA_5c943923-1445-4f4f-b6be-e43fd62e97e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8ca4613a2da84898a3f92d22c8ec8558_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtNS0xLTEtMA_acdc3b5c-5128-4a04-a723-7f85b63380c6">1,641</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic92b2ba692c74f76b138c30a332bc91c_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtNy0xLTEtMA_c68ad6c2-f965-4a11-a70e-ca7704249fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4dda98ef75fa4c0cabaec8f6917de928_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtOS0xLTEtMA_e1a5727b-ff4b-4125-aa7e-c0b88945f8bb">34,433</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItMS0xLTEtMA_89c00004-1df2-4dcf-9863-2d710af4f755">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItMy0xLTEtMA_70761d8c-0184-49f5-a247-1bf3e00bafbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItNS0xLTEtMA_4e15b961-ea3c-4d8b-8e68-a01e7d51410e">590</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6d342895255493b9e648583464cf9bd_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItNy0xLTEtMA_c570e855-5d9d-4ba1-9376-40d0370a270e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItOS0xLTEtMA_f797d83f-6c5b-4771-82c0-74fa5afa97d1">590</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtMS0xLTEtMA_44f39125-daa2-4b7e-b2a3-d7ae187955c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtMy0xLTEtMA_d9aed92d-4c41-4aaa-8241-a1f13a34c1a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtNS0xLTEtMA_d6e5ee61-8a22-4fbd-870d-874433fdf506">1,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6d342895255493b9e648583464cf9bd_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtNy0xLTEtMA_f8ae2379-6521-4edf-84bd-77a8688fbc84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtOS0xLTEtMA_3303d7b7-7722-4505-a843-1ce4125f92d6">1,631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtMS0xLTEtMA_266ae74e-fc40-49a6-9b87-77da8ab43a1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtMy0xLTEtMA_162a7352-e8ed-46c5-b0c9-9e5d21fc90b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtNS0xLTEtMA_20f1207b-61ac-4330-8d2c-a2d7d4538c4c">1,041</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6d342895255493b9e648583464cf9bd_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtNy0xLTEtMA_0a4bc789-2ce5-4874-828d-3db30f3bd211">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtOS0xLTEtMA_80bc3251-b63b-45e0-ae65-ba2f6ba9bf70">1,041</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i954eab77f4f9402dbb8b521337506e81_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtMS0xLTEtMA_15797af7-c44f-47c8-9b15-6398f1cef356">32,792</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9fea367ee9d4fe88b485027bf9fcb91_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtMy0xLTEtMA_18945754-1b89-41a4-804c-1298044b589c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i859a77e1c3ee4e5c8d583b9b6ac23528_I20180930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtNS0xLTEtMA_91f2187b-7cf9-4c94-8cd6-e3828997d46e">600</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i285826056b0946b7ba9a170eaa6cc107_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtNy0xLTEtMA_4eb3a4f5-4f60-471c-bd9b-3a40fefdb8b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibb493b807d924cf39624accb949af88c_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtOS0xLTEtMA_592804ba-43ad-4963-b591-20c27aed3836">33,392</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Amounts reclassified out of accumulated other comprehensive (loss) income relate to settlements of debt securities and are recorded as interest income in the condensed consolidated statements of comprehensive loss.</span></div></ix:continuation><div id="i_0_106"></div><div style="text-align:justify;margin-top:18pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Without limiting the foregoing, the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;goal&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us up to, and including, the date of this document, and we expressly disclaim any obligation to update any such forward-looking statements to reflect events or circumstances that arise after the date hereof. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth in this Item&#160;2 &#8212; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as under Part&#160;II, Item&#160;1A &#8212; &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. You should carefully review those factors and also carefully review the risks outlined in other documents that we file from time to time with the Securities and Exchange Commission, or SEC.</span></div><div id="i_0_109"></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are a global commercial-stage biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have developed a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, and function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for disease-causing proteins, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. Our efforts to advance this revolutionary approach culminated with the approval in 2018 of the first ever RNAi therapeutic, ONPATTRO&#174; (patisiran), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis, in adults in the U.S. and for the treatment of hATTR amyloidosis in adult patients with Stage 1 or Stage 2 polyneuropathy in the European Union, or EU. In 2019 the Japanese Ministry of Health, Labour and Welfare approved ONPATTRO for the treatment of transthyretin, or TTR, type familial amyloidosis with polyneuropathy. In addition, we have obtained approvals in several other countries.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our research and development strategy is to target genetically validated genes that have been implicated in the cause or pathway of human disease. We utilize a lipid nanoparticle (LNP) or N-acetylgalactosamine (GalNAc) conjugate approach to enable hepatic delivery of siRNAs. For delivery to the central nervous system, or CNS, and the eye (ocular delivery), we intend to utilize an alternative conjugate approach. Our focus is on clinical indications where there is a high unmet need, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval, patient access and commercialization.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are committed to the advancement of our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy of building a multi-product, commercial biopharmaceutical company with a sustainable pipeline of RNAi therapeutics to address the needs of patients who have limited or inadequate treatment options.&#160;Specifically, our broad pipeline of investigational RNAi therapeutics is focused in four Strategic Therapeutic Areas, or &#8220;STArs:&#8221; Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases.&#160;Following regulatory approval, we began selling ONPATTRO in the U.S. in August 2018 and in Germany in October 2018, and are now marketing ONPATTRO in several additional countries outside the U.S. Regulatory filings in additional markets in Europe and elsewhere are pending or are planned for the remainder of 2019 and beyond.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to our first marketed product, we have five late-stage investigational programs advancing toward potential commercialization. Our most advanced investigational RNAi therapeutic, givosiran, targets aminolevulinic acid synthase 1, or ALAS1, for the treatment of patients with acute hepatic porphyria, or AHP. In mid-April 2019, we reported positive complete results from our ENVISION Phase 3 study of givosiran. Based on the positive ENVISION data, in June 2019 we submitted a new drug application, or NDA, and in August 2019, the United States Food and Drug Administration, or FDA, accepted our NDA and granted Priority Review for the NDA. The FDA has set an action date of February 4, 2020 under the Prescription Drug User Fee Act, or PDUFA, and has indicated that they are not currently planning an advisory committee meeting as part of the NDA review. Additionally, in July 2019, we filed a marketing authorisation application, or MAA, for givosiran. The European Medicines Agency, or EMA, has validated the MAA. Givosiran was previously granted an accelerated assessment by the EMA.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our other four late-stage investigational programs include our other wholly owned programs: lumasiran for the treatment of primary hyperoxaluria type 1, or PH1, and vutrisiran for the treatment of ATTR amyloidosis. Inclisiran for the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease is being advanced by our partner, The Medicines Company, or </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">MDCO, and fitusiran for the treatment of hemophilia is being advanced by our partner Sanofi Genzyme, the specialty care global business unit of Sanofi.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on our expertise in RNAi therapeutics and broad intellectual property estate, we have formed alliances with leading pharmaceutical and life sciences companies to support our development and commercialization efforts, including Sanofi Genzyme, MDCO, Vir Biotechnology, Inc., or Vir, and Regeneron Pharmaceuticals, Inc., or Regeneron.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and CNS, in addition to a select number of targets expressed in the liver. The transaction closed in May 2019, at which time we received a $400.0 million upfront payment from Regeneron and Regeneron purchased $400.0 million of our common stock. Please read Note 4 and Note 10 to our condensed consolidated financial statements included in Item&#160;1, &#8220;Financial Statements (Unaudited),&#8221; of this Quarterly Report on Form 10-Q for a detailed description of the Regeneron Collaboration and Regeneron SPA, respectively.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, we sold 5,000,000 shares of our common stock through an underwritten public offering at a price to the public of $77.50 per share. As a result of the offering, we received aggregate net proceeds of approximately $381.9 million.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant losses since we commenced operations in 2002 and expect such losses to continue for the foreseeable future. At September&#160;30, 2019, we had an accumulated deficit of $3.45 billion. Historically, we have generated losses principally from costs associated with research and development activities, acquiring, filing and expanding intellectual property rights, and selling, general and administrative costs. As a result of planned expenditures for research and development activities relating to our research platform, our drug development programs, including clinical trial and manufacturing costs, the establishment of late stage clinical and commercial capabilities, including global operations, continued management and growth of our patent portfolio, collaborations and general corporate activities, we expect to incur additional operating losses for the foreseeable future. We also anticipate that our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We currently have programs focused on a number of therapeutic areas and, as noted above, in August 2018, received regulatory approval from the FDA and the European Commission, or EC, for our first product, ONPATTRO. As a result of the regulatory approval of ONPATTRO, we began to generate net revenues from product sales during the third quarter of 2018. However, our ongoing development efforts may not be successful and we may not be able to commence sales of any other products and/or successfully market and sell ONPATTRO or any other approved products in the future. A substantial portion of our total revenues in recent years has been derived from collaboration revenues from strategic alliances with Regeneron, Sanofi Genzyme, Vir, and MDCO. In addition to revenues from the commercial sale of ONPATTRO and potentially from sales of future products, we expect our sources of potential funding for the next several years to continue to be derived in part from existing and new strategic alliances, including the Regeneron collaboration, which may include license and other fees, funded research and development, milestone payments and royalties on product sales by our licensors, and proceeds from the sale of equity or debt.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have focused on drug discovery and development programs. Research and development expenses represent a substantial percentage of our total operating expenses, as reflected by our broad pipeline of clinical development programs, which includes multiple programs in late-stage development.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our broad pipeline, including one approved product and multiple investigational RNAi therapeutics, is focused in four STArs: Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. The chart below is a summary of our product development programs as of September 30, 2019. It identifies those programs in which we have achieved human proof-of-concept, or POC, by demonstrating target gene knockdown and/or additional evidence of activity in clinical studies, those programs for which we have received Breakthrough Therapy Designation from the FDA, the stage of our programs and our commercial rights to such programs:</span></div><div style="text-align:center;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><img src="alny-20190930_g1.jpg" alt="alny-20190930_g1.jpg" style="height:356px;width:684px;"/></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the third quarter of 2019 and recent period, we reported the following updates from ONPATTRO commercialization and our late-stage clinical programs: </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commercial</span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt;">We achieved global ONPATTRO net product revenues for the third quarter of 2019 of $46.1 million, and continued global expansion with receipt of regulatory approval for ONPATTRO in Switzerland, and initiated commercial launches in Japan and Canada.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Late-Stage Clinical Development</span></div><div style="text-indent:-36pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt;">We continued to advance patisiran (the non-branded name for ONPATTRO) for the treatment of ATTR amyloidosis:</span></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.5pt;">Initiated the APOLLO-B Phase 3 study in ATTR amyloidosis patients with cardiomyopathy; and</span></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.5pt;">Filed a marketing authorization application with the Brazilian Health Regulatory Agency (ANVISA) for the treatment of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">hereditary ATTR amyloidosis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">with polyneuropathy.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">We continued to advance vutrisiran, a subcutaneously administered investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis:</span></div><div style="text-indent:-31.5pt;padding-left:94.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.96pt;">Continued enrollment in the HELIOS-A Phase 3 study of in hereditary ATTR amyloidosis patients with polyneuropathy; and</span></div><div style="text-indent:-31.5pt;padding-left:94.5pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri';font-size:11pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.5pt;">Aligned with regulatory agencies on the design of the HELIOS-B Phase 3 study of vutrisiran in patients with both hereditary and wild-type ATTR amyloidosis cardiomyopathy, which we expect to initiate in late 2019.</span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">We continued to advance givosiran, an investigational RNAi therapeutic in development for the treatment of AHP, and completed submissions of an NDA with the FDA and an MAA with the EMA for marketing </span></div><div style="padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">approval, each of which was accepted for filing. The FDA granted our request for Priority Review and set a PDUFA date of February 4, 2020.</span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">We continued to advance lumasiran, an investigational RNAi therapeutic in development for the treatment of PH1, and remain on track to report results of the ILLUMINATE-A Phase 3 study in PH1 patients six years of age or older with mild-to-moderate renal impairment by year-end 2019. We also continued enrollment in the ILLUMINATE-B Phase 3 pediatric study of lumasiran in PH1 patients under six years of age.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Our partner, MDCO, reported positive results for inclisiran, an investigational RNAi therapeutic in development for the treatment of hypercholesterolemia, including positive complete results from the ORION-11 Phase 3 study in patients with atherosclerotic cardiovascular disease, or ASCVD, (ex-U.S.), positive topline results from the ORION-9 Phase 3 study in patients with heterozygous familial hypercholesterolemia, and positive topline results from the ORION-10 Phase 3 study in patients with ASCVD (U.S.-based).</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There is a risk that any drug discovery or development program may not produce revenue for a variety of reasons, including the possibility that we will not be able to adequately demonstrate the safety and effectiveness of the product candidate. Moreover, there are uncertainties specific to any new field of drug discovery, including RNAi. The success of ONPATTRO or any other product candidate we develop is highly uncertain. Due to the numerous risks associated with developing drugs, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts necessary to complete the development of any potential product candidate, or the period, if any, in which material net cash inflows will commence from any approved product. Any failure to complete any stage of the development of any potential products in a timely manner or successfully launch, market and sell any approved product, including ONPATTRO, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our projects on schedule, or at all, and the potential consequences of failing to do so, are set forth in Part&#160;II, Item&#160;1A below under the heading &#8220;Risk Factors.&#8221;</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Strategic Alliances</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our business strategy is to develop and commercialize a broad pipeline of RNAi therapeutic products directed towards our four STArs. As part of this strategy, we have entered into, and expect to enter into additional, collaboration and licensing agreements as a means of obtaining resources, capabilities and funding to advance our investigational RNAi therapeutic programs.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our collaboration strategy is to form alliances that create significant value for ourselves and our collaborators in the advancement of RNAi therapeutics as a new class of innovative medicines. Specifically, with respect to our CNS/Ocular Disease pipeline, in April 2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and CNS, in addition to a select number of targets expressed in the liver. We, along with Regeneron, plan to advance programs directed to up to 30 targets during the initial five-year discovery period, which may be extended under certain circumstances for an additional two years. Regeneron has the option to extend the initial research term upon payment of a research term extension fee. Please read Note 4 to our condensed consolidated financial statements included in Item&#160;1, &#8220;Financial Statements (Unaudited),&#8221; of this Quarterly Report on Form 10-Q for a detailed description of the Regeneron collaboration.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to our Cardio-Metabolic Disease pipeline, we may seek future strategic alliances for these programs, under which we may retain certain product development and commercialization rights, or we may structure as global alliances, as we did in our collaboration with MDCO to advance inclisiran. In March 2018, we entered into a discovery collaboration with Regeneron to identify RNAi therapeutics for nonalcoholic steatohepatitis, or NASH, and potentially other related diseases, and in November 2018, we and Regeneron entered into a separate, fifty-fifty collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to our Hepatic Infectious Disease pipeline, in October 2017, we announced an exclusive licensing agreement with Vir for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus, or HBV, infection.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to our Genetic Medicine pipeline, we formed a broad strategic alliance with Sanofi Genzyme in 2014. In January 2018, we and Sanofi Genzyme amended our 2014 Sanofi Genzyme collaboration and entered into the Exclusive License Agreement, referred to as the Exclusive TTR License, under which we have the exclusive right to pursue the further global development and commercialization of all TTR products, including ONPATTRO, vutrisiran and any back-up products, and the ALN-AT3 Global License Terms, referred to as the AT3 License Terms, under which Sanofi Genzyme has the exclusive right to pursue the further global development and commercialization of fitusiran and any back-up products. In April 2019, we and Sanofi Genzyme agreed to further amend the 2014 Sanofi Genzyme collaboration to conclude the research and option phase and to amend and restate the AT3 License Terms, referred to as the A&amp;R AT3 License Terms, to modify certain of the business terms. The material collaboration terms for fitusiran will continue unchanged. In connection with entering into the 2019 amendment and the A&amp;R AT3 License Terms, we agreed to advance, at our cost, a selected investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies. Following completion of such studies, we will transition, at our cost, such asset to Sanofi Genzyme. Thereafter, Sanofi Genzyme will fund all potential future development and commercialization costs for such asset. If this asset is approved, we will be eligible to receive tiered double-digit royalties on global net sales.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual Property</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The strength of our intellectual property portfolio relating to the development and commercialization of siRNAs as therapeutics is essential to our business strategy. We own or license issued patents and pending patent applications in the U.S. and in key markets around the world claiming fundamental features of siRNAs and RNAi therapeutics as well as those claiming </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">crucial chemical modifications and promising delivery technologies. Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic and other uses; siRNAs directed to specific targets as treatments for particular diseases;&#160;delivery technologies, such as in the fields of carbohydrate conjugates and cationic liposomes; and all aspects of our specific development candidates.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that no other company possesses a portfolio of such broad and exclusive rights to the patents and patent applications required for the commercialization of RNAi therapeutics. In addition, we are very active in our evaluation of third-party technologies. Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise in this area.</span></div><div id="i_0_112"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our critical accounting policies are described in the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our Annual Report on Form 10-K for the year ended December 31, 2018, which we filed with the SEC on February 14, 2019.&#160;There have been no significant changes to our critical accounting policies since the beginning of this fiscal year.</span></div><div id="i_0_115"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following data summarizes the results of our operations for the periods indicated, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:22.082232%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.691630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.691630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.810573%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195301%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.691630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.691630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.810573%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195301%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">148,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">53,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Operating costs and expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">286,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">256,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">789,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">648,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">141,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(216,299)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(254,558)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(641,358)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(594,317)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(47,041)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(208,535)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(245,282)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(609,931)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(550,056)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(59,875)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Discussion of Results of Operations</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Total revenues (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:20.861357%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenues, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">45,606&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,914&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net revenue from collaborators</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,391&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">53,415&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">70,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">148,069&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">53,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">94,194&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:9pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product revenues, net</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We began to record net product&#160;revenues following&#160;regulatory approval of&#160;ONPATTRO in the U.S. and EU in August 2018&#160;and its subsequent commercial launch in the U.S. and in several countries in Europe during the third and fourth quarters of 2018, respectively. We began to record net product revenues of ONPATTRO in Japan in September 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net product revenues (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:20.861357%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,202%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">80,543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">80,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17,409%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of World</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total product revenues, net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">45,606&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,914%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,941%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We expect net product revenues to increase for the remainder of 2019 as compared to the same period in 2018 primarily due to increases in sales in the U.S., Europe, Japan and other geographies as we continue to execute on our global launch.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net revenues from collaborators</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net revenues from collaborators (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:20.861357%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,560)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(221)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(29,988)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(74)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,869&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,912&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,425)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">775&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues from collaborators</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,391&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">53,415&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net revenues from collaborators increased during the three months ended September&#160;30, 2019 as compared to the three months ended September&#160;30, 2018 due primarily to an increase in revenues in connection with our collaboration agreement with Regeneron.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net revenues from collaborators decreased during the nine months ended September&#160;30, 2019 as compared to the nine months ended September&#160;30, 2018 due primarily to a decrease in reimbursable activities in connection with our collaboration agreements with Sanofi Genzyme and Vir, offset by an increase in revenues in connection with our collaboration agreement with Regeneron. </span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating costs and expenses</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Operating costs and expenses (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:20.861357%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,213&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,705&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,749&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">160,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">139,945&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">453,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">374,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">79,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Selling, general and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">120,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">116,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">322,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">273,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">49,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total operating costs and expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">286,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">256,627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">789,427&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">648,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">141,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of goods sold. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold includes the cost of producing and distributing inventories that are related to&#160;product revenues and third-party royalties.&#160;Cost of goods sold increased during the three and nine months ended September&#160;30, 2019, compared to the same periods in the prior year, due to the increase in net product revenues. Prior to FDA approval, in the third quarter of 2018, ONPATTRO inventory (zero-cost inventory) costs were recorded as research and development expenses. The cost of goods sold during the three and nine months ended September&#160;30, 2019 and 2018 reflects only a portion of the manufacturing cost of ONPATTRO and third-party royalties.&#160;As of September&#160;30, 2019, we expect to continue selling zero-cost inventory over the next three to six months. We anticipate variability in our cost of goods sold as a percentage of net product revenues due to the timing of manufacturing runs and utilization as well as future product launches.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We expect that cost of goods sold will increase during the remainder of 2019 as compared to the same period in 2018 primarily as a result of an expected increase in net product sales.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.&#160;Research and development expenses (in thousands) consist on the following:</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:22.707602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,357&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">133,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">122,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation and related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">41,486&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">113,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">88,453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">24,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">45,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(23,047)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(13,393)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,302&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,401&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">51,311&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities-related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">License Fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">35,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,323&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">552&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lab supplies, materials, and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,311&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">160,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">139,945&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">453,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">374,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">79,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September&#160;30, 2019, the increase in research and development expenses, as compared to the same period in the prior year, was primarily related to the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased clinical trials and manufacturing and external services expenses as a result of increased preclinical and clinical services related to the advancement of our early and late stage programs to support our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy; and </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased compensation and related expenses as a result of growth in headcount to support our goals for 2020.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Partially offset by the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Decreased stock-based compensation expense due to the accounting for performance-based stock awards in the third quarter of 2018 as a result of the commercial launch of ONPATTRO and clinical achievements with respect to our givosiran Phase 3 study.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September&#160;30, 2019, the increase in research and development expenses, as compared to the same period in the prior year, was primarily related to the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased license fees resulting from our collaboration agreement with Regeneron;</span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased compensation and related expenses and facilities-related expenses, as a result of growth in headcount to support our goals for 2020; and</span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased clinical trials and manufacturing and external services expenses as a result of increased preclinical and clinical services related to the advancement of our early and late stage programs to support our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Partially offset by the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Decreased stock-based compensation expense due to the accounting for performance-based stock awards in the third quarter of 2018 as a result of the commercial launch of ONPATTRO and clinical achievements with respect to our Phase 3 study of givosiran.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three and nine months ended September&#160;30, 2019 and 2018, in connection with advancing activities under our collaboration agreements, we incurred research and development expenses, primarily related to external development and manufacturing services. The following table summarizes the expenses incurred under our collaboration agreements by collaboration partner for the periods indicated, in thousands:</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:46.023426%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.445095%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.445095%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.445095%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.445095%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,205&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,054&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">55,429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to devote a substantial portion of our resources to research and development expenses to support our goals for 2020. We expect that research and development expenses will continue to increase for the remainder of 2019 as compared to the same period in 2018 as we continue to develop our pipeline and advance our product candidates into later-stage development, hire additional employees and prepare regulatory submissions. However, we expect that certain expenses will be variable depending on the timing of manufacturing batches, clinical trial enrollment and results, regulatory review of our product candidates and programs, and stock-based compensation expenses due to our determination regarding the probability of vesting for performance-based awards.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, general and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;Selling, general and administrative expenses (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:22.707602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771930%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">% of<br/>Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation and related</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,968&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">107,706&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">78,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,887&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consulting and professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,670&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">92,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,170&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(18,898)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(45)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">62,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,742)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities-related</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">26,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,295&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,883&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,412&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total general and administrative expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">120,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">116,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">322,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">273,671&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">49,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September&#160;30, 2019, the increase in selling, general and administrative expenses, as compared to the same period in the prior year, was primarily related to the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased compensation and related and consulting and professional services expenses as a result of increased commercial and medical affairs headcount and commercial-related services to support corporate growth, the continued global launch of ONPATTRO and preparation for the potential launch of givosiran. </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Offset by the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Decreased stock-based compensation expense due to the accounting for performance-based stock awards in the third quarter of 2018 as a result of the commercial launch of ONPATTRO and clinical achievements with respect to our givosiran Phase 3 study.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September&#160;30, 2019, the increase in selling, general and administrative expenses, as compared to the same period in the prior year, was primarily related to the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Increased compensation and related, consulting and professional services, and facilities-related expenses, as a result of increased commercial and medical affairs headcount and commercial-related services to support corporate growth, the continued global launch of ONPATTRO and preparation for the potential launch of givosiran.</span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Partially offset by the following: </span></div><div style="text-indent:-36pt;padding-left:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Decreased stock-based compensation expense due to the accounting for performance-based stock awards in the third quarter of 2018 as a result of the commercial launch of ONPATTRO and clinical achievements with respect to our givosiran Phase 3 study.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We expect that selling, general and administrative expenses will increase for the remainder of 2019 as compared to the same period in 2018 as we continue to grow our operations, including the continued build-out of our global commercial infrastructure to support ONPATTRO and preparation for additional potential product launches, including the potential launch </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">of givosiran in 2020, but expect that stock-based compensation expenses will be variable due to our determination regarding the probability of vesting for performance-based awards.</span></div><div id="i_0_118"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flow activities for the periods indicated, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:71.538012%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(609,931)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(550,056)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">137,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">127,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">389,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(82,447)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(412,159)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(196,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">782,842&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">60,092&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(449)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">503,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(328,086)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash, cash equivalents and restricted cash, beginning of period</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">422,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">646,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">925,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">318,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Since we commenced operations in 2002, we have generated significant losses. As of September&#160;30, 2019, we had an accumulated deficit of $3.45 billion. As of September&#160;30, 2019, we had cash, cash equivalents and marketable debt securities of $1.72 billion, compared to $1.08 billion as of December&#160;31, 2018.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating activities</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities decreased during the nine months ended September&#160;30, 2019, compared to the same period in 2018, primarily due to the deferred revenue associated with consideration received from our strategic collaboration with Regeneron in May 2019 as well as an increase in net product revenues, partially offset by an increase in our net loss attributable to increased operating expenses to support overall growth.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investing activities</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities increased during the nine months ended September&#160;30, 2019, compared to the same period in the prior year, primarily due to net activities related to our marketable debt securities, partially offset from cash provided by proceeds of $30.0 million from the release of our restricted cash collateral, in connection with termination of the Credit Agreement.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing activities</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities increased during the nine months ended September&#160;30, 2019, compared to the same period in 2018, primarily due to proceeds of $400.0 million received from our issuance of common stock to Regeneron and aggregate net proceeds of $381.9 million received from our January 2019 underwritten public offering.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Capital Requirements</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We currently have programs focused on a number of therapeutic areas and, in August 2018, received our first product approvals in the U.S. and EU for ONPATTRO.&#160;As a result, we began to generate net revenues from product sales during the third quarter of 2018. However, our ongoing development efforts may not be successful and we may not be able to commence sales of any other products in the future. In addition, we anticipate that we will continue to generate significant losses for the foreseeable future as a result of planned expenditures for research and development activities relating to our research platform, our drug development programs, including clinical trial and manufacturing costs, the establishment of late stage clinical and commercial capabilities, including global operations, continued management and growth of our intellectual property including our patent portfolio, collaborations and general corporate activities. In addition, we are expanding our manufacturing capabilities, including through construction of a drug substance manufacturing facility in Norton, Massachusetts.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable debt securities as of September&#160;30, 2019, together with the cash we expect to generate from product sales and under our current alliances, including our recent collaboration with Regeneron, will be sufficient to enable us to advance our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy for multiple years from the filing of this Quarterly Report on Form 10-Q. For reasons discussed below, we may require significant additional </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">funds earlier than we currently expect in order to continue to commercialize ONPATTRO and to develop, conduct clinical trials for, manufacture and, if approved, commercialize additional product candidates.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the future, we may seek additional funding through new collaborative arrangements and public or private financings. Additional funding may not be available to us on acceptable terms or at all. Moreover, the terms of any additional financing may further adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to our existing stockholders will result. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we are unable to obtain funding on a timely basis, we may be required to significantly delay or curtail one or more of our research or development programs and our ability to achieve our goals for 2020 may be delayed or diminished. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own. Even if we are able to raise additional funds in a timely manner, our future capital requirements may vary from what we expect and will depend on many factors, including:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our continued progress in demonstrating that siRNAs can be active as drugs and achieve desired clinical effects;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">progress in our research and development programs, as well as what may be required by regulatory bodies to advance these programs;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the resources, time and costs required to successfully initiate and complete our pre-clinical and clinical trials, obtain regulatory approvals, prepare for global commercialization of our product candidates and obtain and maintain licenses to third-party intellectual property;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to establish, maintain and operate our own manufacturing facilities in a timely and cost-effective manner;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to manufacture, or contract with third-parties for the manufacture of, our product candidates for clinical testing and commercial sale;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the timing, receipt and amount of sales and royalties, if any, from ONPATTRO and our other potential products, including givosiran.</span></div><div id="i_0_121"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commitments</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The disclosure of our contractual obligations and commitments is set forth under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2018. There have been no material changes in our contractual obligations and commitments since December 31, 2018.</span></div><div id="i_0_124"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Please read Note 2 to our condensed consolidated financial statements included in Item&#160;1, &#8220;Financial Statements (Unaudited),&#8221; of this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our business.</span></div><div id="i_0_127"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Financial market risks related to interest rates are described in our Annual Report on Form 10-K for the year ended December 31, 2018. As of September 30, 2019, there have been no material changes to the financial market risks described as of December 31, 2018. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management&#8217;s objectives and strategies with respect to managing such exposures.</span></div><div id="i_0_130"></div><div style="text-align:justify;margin-top:18pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. CONTROLS AND PROCEDURES.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Disclosure Controls and Procedures</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our Chief Executive Officer (principal executive officer) and executive vice president, Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2019. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September&#160;30, 2019, our Chief Executive Officer and executive vice president, Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and executive vice president, Chief Financial Officer, of any changes to our internal control over financial reporting that occurred during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our evaluation did not identify significant changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September&#160;30, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i_0_133"></div><div></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="i_0_136"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1. LEGAL PROCEEDINGS.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For a discussion of material pending legal proceedings, please read Note 14, Commitments and Contingencies &#8211; Litigation, to our condensed consolidated financial statements included in Part I, Item I, &#8220;Financial Statements (Unaudited),&#8221; of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div id="i_0_139"></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1A. RISK FACTORS</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our business is subject to numerous risks. We caution you that the following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in filings with the SEC, press releases, communications with investors and oral statements. All statements other than statements relating to historical matters should be considered forward-looking statements. When used in this report, the words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;target,&#8221; &#8220;goal&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any or all of our forward-looking statements in this Quarterly Report on Form&#160;10-Q and in any other public statements we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in the discussion below will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from those anticipated in forward-looking statements. We explicitly disclaim any obligation to update any forward-looking statements to reflect events or circumstances that arise after the date hereof. You are advised, however, to consult any further disclosure we make in our reports filed with the SEC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Being a Commercial Company</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited experience as a commercial company and the marketing and sale of ONPATTRO or any future products may be unsuccessful or less successful than anticipated.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FDA approved ONPATTRO (patisiran) lipid complex injection for the treatment of the polyneuropathy of hATTR amyloidosis in adults in the U.S., and the EC granted marketing authorisation for ONPATTRO for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy in the EU and we have now received approval in several additional territories. While we have launched ONPATTRO in the U.S., Japan, Canada and in several countries in Europe, we have limited experience as a commercial company and there is limited information about our ability to successfully overcome many of the risks and uncertainties encountered by companies commercializing products in the biopharmaceutical industry. We also have several product candidates in late-stage clinical development, including givosiran, which is under review by the FDA and MAA for marketing approval. To execute our business plan, in addition to successfully marketing and selling ONPATTRO, we will need to successfully:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">execute product development activities using new technologies related to both RNAi and to the delivery of siRNAs to the relevant tissues and cells;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">build and maintain a strong intellectual property portfolio;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">gain regulatory acceptance for the development and commercialization of our product candidates and market success for ONPATTRO, as well as any other products we commercialize, including, in each case, givosiran;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">attract and retain customers for our products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">develop and maintain successful strategic alliances; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, commercialize ONPATTRO or any future products, including givosiran, raise capital, expand our business or continue our operations.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The approach we are taking to discover and develop novel RNAi therapeutics may not lead to products that achieve market acceptance.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have concentrated our efforts and therapeutic product research and development on RNAi technology and our future success depends on the successful development of this technology and products based on it. The scientific discoveries that form the basis for our efforts to discover and develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs based on these discoveries is still limited. Skepticism as to the feasibility of developing RNAi therapeutics </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics based on the so-called off-target effects and activation of the interferon response. In addition, decisions by other companies with respect to their RNAi development efforts or their adoption of different or related technologies and the potential success of any such different or related technologies may increase skepticism in the marketplace regarding the potential for RNAi therapeutics.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Relatively few product candidates based on these discoveries have ever been tested in humans. We have spent and expect to continue to spend large amounts of money developing siRNAs that possess the properties typically required of drugs, and to date, we have received regulatory approval for one product. In addition, the compounds we are developing may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways. For example, in October 2016, we discontinued development of revusiran, an investigational RNAi therapeutic that was in development for the treatment of patients with cardiomyopathy due to hATTR amyloidosis, due to safety concerns.&#160;We conducted a comprehensive evaluation of the revusiran data and reported the results of this evaluation in August 2017, however, our investigation did not result in a conclusive explanation regarding the cause of the mortality imbalance observed in the ENDEAVOUR Phase 3 study, although a role for revusiran and/or its metabolites cannot be excluded and is possible.&#160;Although we received regulatory approval for ONPATTRO in the U.S., the EU, Japan and Canada, if we do not succeed in developing multiple products that gain regulatory approval and succeed in the marketplace, we may not become profitable and the value of our common stock could decline.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Further, our focus solely on RNAi technology for developing drugs, as opposed to multiple, more proven technologies for drug development, increases the risks associated with the ownership of our common stock. If we are not successful in developing and commercializing additional products using RNAi technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Financial Results and Need for Financing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a history of losses and may never become and remain consistently profitable.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have experienced significant operating losses since our inception. As of September&#160;30, 2019, we had an accumulated deficit of $3.45 billion. Although we have launched ONPATTRO in the U.S., Japan, Canada and several countries in Europe, and expect to launch in additional countries during the remainder of 2019, we may never attain profitability or positive cash flow from operations. For the three and nine months ended September&#160;30, 2019, we recognized $46.1 million and $110.6 million in net product revenues from sales of ONPATTRO, respectively. We expect to continue to incur annual net operating losses over the next several years and will require substantial resources over the next several years as we expand our efforts to discover, develop and commercialize RNAi therapeutics. In addition to revenues derived from sales of ONPATTRO, and other product candidates that achieve regulatory approval, we anticipate that&#160;a portion of any revenues we generate over the next several years will continue to be from alliances with pharmaceutical and biotechnology companies. We cannot be certain that we will be able to maintain our existing alliances or secure and maintain new alliances, or meet the obligations or achieve any milestones that we may be required to meet or achieve to receive payments. We anticipate that revenues derived from such sources will not be sufficient to make us consistently profitable.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that to become and remain consistently profitable, we must succeed in discovering, developing and commercializing novel drugs with significant market potential. This will require us to be successful in a range of challenging activities, including pre-clinical testing and clinical trial stages of development, obtaining regulatory approval and reimbursement for these novel drugs and manufacturing, marketing and selling them. We may never succeed in these activities, and may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we cannot become and remain consistently profitable, the market price of our common stock could decline. In addition, we may be unable to raise capital, expand our business, develop additional product candidates or continue our operations.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect our operating results to fluctuate in future periods, which may adversely affect our stock price.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our quarterly operating results have fluctuated in the past, and we believe they will continue to do so in the future. Our operating results may fluctuate due to the level of success of our commercial efforts and resulting revenues, as well as the variable nature of our operating expenses as a result of the timing and magnitude of expenditures. In one or more future periods, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could decline.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will require substantial additional funds to complete our research, development and commercialization activities and if additional funds are not available, we may need to critically limit, significantly scale back or cease our operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have used substantial funds to develop our RNAi technologies and will require substantial funds to conduct further research and development, including pre-clinical testing and clinical trials of our product candidates, and to manufacture, </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">market and sell ONPATTRO or any other products that are approved for commercial sale. Because we cannot be certain of the length of time or activities associated with successful development of our product candidates, we are unable to estimate the actual funds we will require to develop and commercialize them.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements and the period for which we expect our existing resources to support our operations may vary from what we expect. We have based our expectations on a number of factors, many of which are difficult to predict or are outside of our control, including:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our continued progress in demonstrating that siRNAs can be active as drugs and achieve desired clinical effects;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">progress in our research and development programs, as well as what may be required by regulatory bodies to advance these programs;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the resources, time and costs required to successfully initiate and complete our pre-clinical and clinical studies, obtain regulatory approvals, prepare for global commercialization of our product candidates and obtain and maintain licenses to third-party intellectual property;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to establish, maintain and operate our own manufacturing facilities in a timely and cost-effective manner;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to manufacture, or contract with third parties for the manufacture of, our product candidates for clinical testing and commercial sale;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the timing, receipt and amount of sales and royalties, if any, from ONPATTRO and our other potential products, including givosiran.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If our estimates, predictions and financial guidance relating to these factors are incorrect, we may need to modify our operating plan.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Even if our estimates are correct, we will be required to seek additional funding in the future and intend to do so through either collaborative arrangements, public or private equity offerings or debt financings, or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. If we raise additional funds by issuing equity securities, further dilution to our existing stockholders will result. In addition, as a condition to providing additional funding to us, future investors may demand, and may be granted, rights superior to those of existing stockholders.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we are unable to obtain additional funding on a timely basis, we may be required to significantly delay or curtail one or more of our research or development programs, delay the build-out of our global commercial infrastructure or undergo future reductions in our workforce or other corporate restructuring activities, and our ability to achieve our strategy for 2020 may be delayed or diminished. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the estimates we make, or the assumptions on which we rely, in preparing our condensed consolidated financial statements and/or our projected guidance prove inaccurate, our actual results may vary from those reflected in our projections and accruals.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Further, from time to time we issue financial guidance relating to our expectations regarding our non-GAAP research and development and selling, general and administrative expenses, and expectations for our cash, cash equivalents and marketable debt securities available for operations, which guidance is based on estimates and the judgment of management. If, for any reason, our expenses differ materially from our guidance or we utilize our cash more quickly than anticipated, we may have to adjust our publicly announced financial guidance. If we fail to meet, or if we are required to change or update any element of, our publicly disclosed financial guidance or other expectations about our business, our stock price could decline.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The investment of our cash, cash equivalents and marketable debt securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, we had $1.72 billion in cash, cash equivalents and marketable debt securities, excluding the $14.8 million of restricted investments related to our security deposit for 675 West Kendall Street, Cambridge, Massachusetts. We historically have invested these amounts in high&#8211;grade corporate notes, commercial paper, securities issued or sponsored by the U.S. government, certificates of deposit and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. Corporate notes may also include foreign bonds denominated in U.S. dollars. These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our condensed consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The effect of comprehensive U.S. tax reform legislation on us, our subsidiaries and our affiliates, whether adverse or favorable, is uncertain.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. For example, on December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act of 2017, or the TCJA. Among a number of significant changes to the current U.S. federal income tax rules, the TCJA reduced the marginal U.S. corporate income tax rate from 35% to 21%, introduced a capital investment deduction, limited the current deduction for net interest expense, limited the use of net operating losses to offset future taxable income, and made extensive changes in the way in which income earned outside the U.S. is taxed in the U.S. We disclosed the estimated impact of the TCJA in our annual report on Form 10-K that was filed with the SEC on February 15, 2018.&#160;As of December 31, 2018, our analysis of the impact of the TCJA was complete and there were no material changes to the provisional amount recorded at December 31, 2017.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Dependence on Third Parties</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to execute our business strategy if we are unable to maintain existing or enter into new alliances with other companies that can provide business and scientific capabilities and funds for the development and commercialization of our product candidates. If we are unsuccessful in forming or maintaining these alliances on terms favorable to us, our business may not succeed.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are continuing to advance our sales and distribution capabilities and also have newly established capabilities for marketing, sales and market access, as well as limited capacity for drug development due to our growing pipeline of RNAi therapeutic opportunities. Accordingly, we have entered into alliances with other companies and collaborators that we believe can provide such capabilities in certain territories and/or for certain product candidates, and we intend to enter into additional such alliances in the future. Our collaboration strategy is to form alliances that create significant value for us and our collaborators in the advancement of RNAi therapeutics as a new class of innovative medicines. Specifically, with respect to our Genetic Medicine pipeline, we formed a broad strategic alliance with Sanofi Genzyme in 2014. In January 2018, we and Sanofi Genzyme amended our 2014 collaboration to provide that we would develop and commercialize ONPATTRO and vutrisiran globally and Sanofi Genzyme would develop and commercialize fitusiran globally. In April 2019, we and Sanofi Genzyme further amended our 2014 collaboration and agreed to conclude the research and option phase under the 2014 collaboration. The material collaboration terms for ONPATTRO, vutrisiran and fitusiran, as previously announced, will continue unchanged. With respect to our Cardio-Metabolic Disease pipeline, we may seek future strategic alliances for these programs, under which we may retain certain product development and commercialization rights, or we may structure as global alliances, as we did in our collaboration with MDCO to advance inclisiran. In March 2018, we entered into a discovery collaboration with Regeneron to identify RNAi therapeutics for NASH and potentially other related diseases, and in November 2018, we and Regeneron entered into a separate, fifty-fifty collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts. In October 2017, we announced an exclusive licensing agreement with Vir for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic HBV infection. With respect to our CNS/Ocular Disease pipeline, in April 2019, we announced a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">expressed in the eye and CNS, in addition to a select number of targets expressed in the liver.&#160;The Regeneron collaboration became effective in the second quarter of 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In such alliances, we expect our current, and may expect our future, collaborators to provide substantial capabilities in clinical development, regulatory affairs, and/or marketing, sales and distribution. Under certain of our alliances, we also may expect our collaborators to develop, market and/or sell certain of our product candidates. We may have limited or no control over the development, sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. For example, we will rely entirely on (i)&#160;Sanofi Genzyme for the development and commercialization of fitusiran worldwide, (ii)&#160;MDCO for all future development and commercialization of inclisiran worldwide, and (iii) Regeneron for the development and commercialization of all programs targeting eye diseases (subject to limited exceptions), and potentially other CNS and liver programs. If our collaborators are not successful in their development and/or commercialization efforts, our future revenues from RNAi therapeutics for these indications may be adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may not be successful in entering into future alliances on terms favorable to us due to various factors, including our ability to successfully demonstrate POC for our technology in humans, including our ESC+ GalNAc conjugate technology or our alternative conjugate approach for delivering CNS or ocular product candidates, our ability to demonstrate the safety and efficacy of our specific drug candidates, our ability to manufacture or have third parties manufacture RNAi therapeutics, the strength of our intellectual property and/or concerns around challenges to our intellectual property. For example, our decision in October 2016 to discontinue development of revusiran could make it more difficult for us to attract collaborators due to concerns around the safety and/or efficacy of our technology platform or product candidates. In addition, our decision in September 2017 to temporarily suspend dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic serious adverse event, or SAE, and agreement with regulatory authorities on a risk mitigation strategy could, notwithstanding the alignment reached with the FDA on a risk mitigation strategy in November 2017 and reinitiation of such studies, contribute to further concerns about the safety of our therapeutic candidates. Even if we do succeed in securing any such alliances, we may not be able to maintain them if, for example, development or approval of a product candidate is delayed, challenges are raised as to the validity or scope of our intellectual property, we are unable to secure adequate reimbursement from payors or sales of an approved drug are lower than we expected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Furthermore, any delay in entering into collaboration agreements would likely either delay the development and commercialization of certain of our product candidates and reduce their competitiveness even if they reach the market, or prevent the development of certain product candidates. Any such delay related to our collaborations could adversely affect our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For certain product candidates, we have formed collaborations to fund all or part of the costs of drug development and commercialization, such as our collaborations with Sanofi Genzyme, MDCO, Vir and Regeneron. We may not, however, be able to enter into additional collaborations for certain other programs, and the terms of any collaboration agreement we do secure may not be favorable to us. If we are not successful in our efforts to enter into future collaboration arrangements with respect to one or more of our product candidates, we may not have sufficient funds to develop these product candidates or other product candidates internally, or to bring our product candidates to market. If we do not have sufficient funds to develop and bring our product candidates to market, we will not be able to generate revenues from these product candidates, and this will substantially harm our business.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any collaborator materially amends, terminates or fails to perform its obligations under agreements with us, the development and commercialization of our product candidates could be delayed or terminated.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our dependence on collaborators for capabilities and funding means that our business could be adversely affected if any collaborator materially amends or terminates its collaboration agreement with us or fails to perform its obligations under that agreement. Our current or future collaborations, if any, may not be scientifically or commercially successful. Disputes may arise in the future with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and commercialize any affected product candidate. Our current collaborations allow, and we expect that any future collaborations will allow, either party to terminate the collaboration for a material breach by the other party. In addition, our collaborators may have additional termination rights for convenience with respect to the collaboration or a particular program under the collaboration, under certain circumstances.&#160;For example, our agreement with MDCO relating to the development and commercialization of inclisiran worldwide may be terminated by MDCO at any time upon four months&#8217; prior written notice. If we were to lose a commercialization collaborator, we would have to attract a new collaborator or develop expanded sales, distribution and marketing capabilities internally, which would require us to invest significant amounts of financial and management resources.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, if we have a dispute with a collaborator over the ownership of technology or other matters, or if a collaborator terminates its collaboration with us, for breach or otherwise, or determines not to pursue the research, development and/or commercialization of RNAi therapeutics, it could delay our development of product candidates, result in the need for additional </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">company resources to develop product candidates, require us to expend time and resources to develop expanded sales and marketing capabilities on a more expedited timeline, make it more difficult for us to attract new collaborators and could adversely affect how we are perceived in the business and financial communities.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moreover, a collaborator, or in the event of a change in control of a collaborator or the assignment of a collaboration agreement to a third party, the successor entity or assignee, could determine that it is in its interests to:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">pursue alternative technologies or develop alternative products, either on its own or jointly with others, that may be competitive with the products on which it is collaborating with us or which could affect its commitment to the collaboration with us;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">pursue higher-priority programs or change the focus of its development programs, which could affect the collaborator&#8217;s commitment to us; or</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">if it has marketing rights, choose to devote fewer resources to the marketing of our product candidates, if any are approved for marketing, than it does for product candidates developed without us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If any of these occur, the development and commercialization of one or more product candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, our development plans may be adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We rely on independent clinical investigators, contract research organizations, or CROs, and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We have contracted, and we plan to continue to contract with, certain third parties to provide certain services, including site selection, enrollment, monitoring, auditing and data management services. Although we depend heavily on these parties, we control only certain aspects of their activity and therefore, we cannot be assured that these third parties will adequately perform all of their contractual obligations to us in compliance with regulatory and other legal requirements and our internal policies and procedures. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with applicable good clinical practice, or GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development, and to implement timely corrective action to any non-compliance. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites, including in connection with the review of marketing applications. If we or any of our CROs fail to comply with applicable GCP requirements, or fail to take any such corrective action, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, the PMDA in Japan or comparable foreign regulatory authorities may require us to take additional action or perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority in the future, such regulatory authority will determine that any of our clinical trials comply with GCP regulations.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third party to adhere to our protocols or regulatory requirements or if such third parties otherwise fail to meet deadlines, our development plans and/or regulatory reviews for marketing approvals may be delayed or terminated. As a result, our stock price would likely be negatively impacted, and our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited manufacturing experience and resources and we must incur significant costs to develop this expertise and/or rely on third parties to manufacture our products.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have limited manufacturing experience. In order to continue to commercialize ONPATTRO, continue to develop our current product candidates, apply for regulatory approvals and, if approved, commercialize future products, including givosiran, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Historically, our internal manufacturing capabilities were limited to small-scale production of material for use in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vitro</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> experiments that is not required to be produced under current good manufacturing practice, or cGMP, standards. During 2012, we developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for late stage clinical trial use and commercial supply. In addition, in April 2016, we completed our purchase of a parcel of land in Norton, Massachusetts, where we are constructing a cGMP manufacturing facility for drug substance for clinical and commercial use.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may manufacture limited quantities of clinical trial materials ourselves, but otherwise we currently rely on third parties to manufacture the drug substance and finished product we will require for any clinical trials that we initiate and to support the commercial launch of ONPATTRO and any of our other product candidates, including givosiran. There are a limited number of </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">manufacturers that supply synthetic siRNAs. We currently rely on a limited number of contract manufacturing organizations, or CMOs, for our supply of synthetic siRNAs. For example, in July 2015, we amended our manufacturing services agreement with Agilent, to provide for Agilent to supply, subject to any conflicting obligations under our third-party agreements, a specified percentage of the active pharmaceutical ingredients required for certain of our product candidates in clinical development, as well as other products the parties may agree upon in the future. We currently rely on Agilent to supply the active pharmaceutical ingredient to support the commercial supply of ONPATTRO and in March 2018, we entered into a manufacturing services agreement with Agilent for such commercial supply. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our CMOs, including Agilent, to meet our delivery time requirements or provide adequate amounts of material to meet our needs. Included in these risks are potential synthesis and purification failures and/or contamination during the manufacturing process, as well as other issues with the CMO&#8217;s facility and ability to comply with the applicable manufacturing requirements, which could result in unusable product and cause delays in our manufacturing timelines and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA requirements, we will likely need to secure alternative suppliers of synthetic siRNAs and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. As noted above, in order to ensure long-term supply capabilities for our RNAi therapeutics, we are developing our own capabilities to manufacture drug substance for clinical and commercial use.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to the manufacture of the synthetic siRNAs, we may have additional manufacturing requirements related to the technology required to deliver the siRNA to the relevant cell or tissue type, such as LNPs or conjugates. In some cases, the delivery technology we utilize is highly specialized or proprietary, and for technical and/or legal reasons, we may have access to only one or a limited number of potential manufacturers for such delivery technology. In addition, the scale-up of our delivery technologies could be very difficult and/or take significant time. We also have very limited experience in such scale-up and manufacturing, requiring us to depend on a limited number of third parties, who might not be able to deliver in a timely manner, or at all. Failure by manufacturers to properly manufacture our delivery technology and/or formulate our siRNAs for delivery could result in unusable product. Furthermore, competition for supply from our manufacturers from other companies, a breach by such manufacturers of their contractual obligations or a dispute with such manufacturers would cause delays in our discovery and development efforts, as well as additional expense to us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Given the limited number of suppliers for our delivery technology and drug substance, we developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for late stage clinical use and commercial supply. During 2015, we scaled our cGMP manufacturing capacity for ONPATTRO and believe we have adequate resources to supply our commercial needs.&#160;In addition, as noted above, we are developing our own capabilities to manufacture drug substance for clinical and commercial use. In developing these manufacturing capabilities by building our own manufacturing facilities, we have incurred substantial expenditures, and expect to incur significant additional expenditures in the future. In addition, the construction and qualification of our drug substance facility is a lengthy process to complete and there are many risks inherent in the construction of a new facility that could result in delays and additional costs, including the need to obtain access to necessary equipment and third-party technology, if any. Also, we have had to, and will likely need to continue to, hire and train qualified employees to staff our facilities. We do not currently have a second source of supply for patisiran formulated bulk drug product. If we are unable to manufacture sufficient quantities of material or if we encounter problems with our facilities in the future, we may also need to secure alternative suppliers of patisiran formulated bulk drug product and drug substance, and such alternative suppliers may not be available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. Any delay or setback in the manufacture of ONPATTRO could impede ongoing commercial supply, which could significantly impact our revenues and operating results.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The manufacturing process for ONPATTRO and any other products that we may develop, including givosiran, is subject to the FDA and foreign regulatory authority approval process and we will need to meet, and will need to contract with CMOs who can meet, all applicable FDA and foreign regulatory authority requirements on an ongoing basis. In addition, if we receive the necessary regulatory approval for any product candidate, including givosiran, we also expect to rely on third parties, including potentially our commercial collaborators, to produce materials required for commercial supply. We may experience difficulty in obtaining adequate manufacturing capacity for our needs and the needs of our collaborators, who we have, in some instances, the obligation to supply. If we are unable to obtain or maintain CMOs for our product candidates, or to do so on commercially reasonable terms, we may not be able to successfully develop and commercialize our products.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we depend, and will depend in the future, on these third parties, including Agilent, to perform their obligations in a timely manner and consistent with contractual and regulatory requirements, including those related to quality control and quality assurance. The failure of Agilent or any other CMO to perform its obligations as expected, or, to the extent we manufacture all or a portion of our product candidates ourselves, our failure to execute on our manufacturing requirements, could adversely affect our business in a number of ways, including:</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we or our current or future collaborators may not be able to initiate or continue clinical trials of product candidates that are under development;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we or our current or future collaborators may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we may lose the cooperation of our collaborators;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our facilities and those of our CMOs, and our products could be the subject of inspections by regulatory authorities that could have a negative outcome and result in delays in supply;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we may be required to cease distribution or recall some or all batches of our products or take action to recover clinical trial material from clinical trial sites; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">ultimately, we may not be able to meet commercial demands for our products.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If any CMO with whom we contract, including Agilent, fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or product candidates.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited sales and distribution experience and newly established capabilities for marketing, sales and market access, and expect to continue to invest significant financial and management resources to continue to build these capabilities and to establish a global commercial infrastructure.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have limited sales and distribution experience and newly established capabilities for marketing, sales and market access. We currently expect to rely heavily on third parties to launch and market certain of our product candidates in certain geographies, if approved. However, as a result of the January 2018 amendment to our Sanofi Genzyme collaboration, we intend to commercialize ONPATTRO, as well as several of our late-stage product candidates if approved, including givosiran, lumasiran and vutrisiran, on our own globally. Accordingly, we have developed internal sales, distribution and marketing capabilities as part of our core product strategy initially in the U.S. and the EU, and with expansion ongoing in Canada, Switzerland, Central and Eastern Europe, Japan, Brazil and eventually in other major markets in the rest of the world, which will require significant financial and management resources. For those products for which we will perform sales, marketing and distribution functions ourselves, including ONPATTRO and, if approved, givosiran, lumasiran and vutrisiran, and for future products we successfully develop where we may retain certain product development and commercialization rights, we could face a number of additional risks, including:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we may not be able to attract and build a significant marketing or sales force;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we may not be able to establish our global capabilities and infrastructure in a timely manner;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the cost of establishing a marketing or sales force may not be justifiable in light of the revenues generated by any particular product and/or in any specific geographic region; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our direct sales and marketing efforts may not be successful.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we are unable to continue to develop and scale our own global sales, marketing and distribution capabilities for ONPATTRO and any future products, including givosiran, if approved, we will not be able to successfully commercialize our products without reliance on third parties.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit and financial market conditions may exacerbate certain risks affecting our business from time to time.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Due to tightening of global credit, there may be a disruption or delay in the performance of our third-party contractors, suppliers or collaborators. We rely on third parties for several important aspects of our business, including significant portions </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">of our manufacturing needs, development of product candidates and conduct of clinical trials. If such third parties are unable to satisfy their commitments to us, our business could be adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our ability to secure additional financing and to satisfy our financial obligations under indebtedness outstanding from time to time will depend upon our future operating performance, which is subject to then prevailing general economic and credit market conditions, including interest rate levels and the availability of credit generally, and financial, business and other factors, many of which are beyond our control. In light of periodic uncertainty in the capital and credit markets, there can be no assurance that sufficient financing will be available on desirable or even any terms to fund investments, acquisitions, stock repurchases, dividends, debt refinancing or extraordinary actions.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Managing Our Operations</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are highly dependent upon our senior management and our scientific, clinical and medical staff. The loss of the service of any of the members of our senior management, including Dr.&#160;John Maraganore, our Chief Executive Officer, may significantly delay or prevent the achievement of product development and commercialization, and other business objectives. Our employment arrangements with our key personnel are terminable without notice. We do not carry key person life insurance on any of our employees.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have grown our workforce significantly over the past several years and anticipate continuing to add a significant number of additional employees as we focus on achieving our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy. We face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other research institutions, many of which have substantially greater resources with which to attract and reward qualified individuals than we do. In addition, due to the risks associated with developing a new class of medicine, we may experience disappointing results in a clinical program and our stock price may decline as a result, as was the case following our decision in October 2016 to discontinue our revusiran program, and, to less of an extent, following our temporary suspension of dosing in our fitusiran program in September 2017.&#160;As a result, we may face additional challenges in attracting and retaining employees. In addition, we may not be successful commercializing our first product and as a result, we may be unable to attract and retain highly qualified sales and marketing professionals to support ONPATTRO and our future products, if approved, including givosiran. Accordingly, we may be unable to attract and retain suitably qualified individuals in order to support our growing research, development and global commercialization efforts and initiatives, and our failure to do so could have an adverse effect on our ability to implement our future business plan.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may have difficulty expanding our operations successfully as we evolve from a U.S.- and EU-based company primarily involved in discovery, pre-clinical testing and clinical development into a global company that develops and commercializes multiple drugs.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As we continue the commercial launch of ONPATTRO and increase the number of product candidates we are developing, we will also need to expand our operations in the U.S. and continue to build operations in the EU and other geographies, including Japan and Latin America. In August 2018, we received regulatory approval for ONPATTRO in the U.S. and EU, and as a result of the January 2018 amendment to our Sanofi Genzyme collaboration, we now have global development and commercialization rights for ONPATTRO. We have also received regulatory approval in Japan, Switzerland and Canada and have filed for regulatory approval in Brazil, and plan to file for additional regulatory approvals in additional countries during the remainder of 2019 and beyond.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As noted above, we grew our workforce significantly from 2016 through 2018, and anticipate continuing to hire additional employees during the remainder of 2019, including employees in the EU, Japan and other territories, as we focus on the commercialization of ONPATTRO and achieving our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy. This expected growth is placing a strain on our administrative and operational infrastructure, and we will need to continue to develop additional and/or new infrastructure and capabilities to support our growth and obtain additional space to conduct our operations in the U.S., the EU, Japan and other geographies. If we are unable to develop such additional infrastructure or obtain sufficient space to accommodate our growth in a timely manner and on commercially reasonable terms, our business could be negatively impacted. As product candidates we develop enter and advance through clinical trials, we will need to continue to expand our global development, regulatory, manufacturing, quality, compliance, and marketing and sales capabilities, or contract with other organizations to provide these capabilities for us. In addition, as our operations expand due to our development progress, we will need to continue to manage additional relationships with various collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls and systems, reporting systems and infrastructure, and policies and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Social media is increasingly being used to communicate about our clinical development programs and the diseases our investigational RNAi therapeutics are being developed to treat, and we are utilizing what we believe is appropriate social media in connection with our commercialization efforts for ONPATTRO and, we intend to do the same for our future products, if approved, including givosiran. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event, or AE. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable AE reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized or inappropriate access or use, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees, stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy and security of personal information, and the development and potential commercialization of our product candidates could be delayed.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The results of the United Kingdom&#8217;s referendum on withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the United Kingdom, or UK, held a referendum in which voters approved an exit from the EU, commonly referred to as &#8220;Brexit.&#8221; This referendum has created political and economic uncertainty, particularly in the UK and the EU, and this uncertainty may persist for years. A withdrawal could, among other outcomes, disrupt the free movement of goods, services and people between the UK and the EU, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. The UK&#8217;s vote to exit the EU could also result in similar referendums or votes in other European countries in which we do business. Given the lack of comparable precedent, it is unclear what financial, trade and legal implications the withdrawal of the UK from the EU would have and how such withdrawal would affect us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For example, Brexit could result in the UK or the EU significantly altering its regulations affecting the clearance or approval of our product candidates that are developed in the UK. Any new regulations could add time and expense to the conduct of our business, as well as the process by which our products receive regulatory approval in the UK, the EU and elsewhere. In addition, the announcement of Brexit and the withdrawal of the UK from the EU have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these effects of Brexit, among others, could adversely affect our business, our results of operations, liquidity and financial condition.</span></div><div style="text-align:center;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Industry</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any product candidates we or our partners develop may fail in development or be delayed to a point where they do not become commercially viable.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Before obtaining regulatory approval for the commercial distribution of our product candidates, we must conduct, at our own expense, extensive nonclinical tests and clinical trials to demonstrate the safety and/or efficacy in humans of our product candidates. Nonclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome, and the historical failure rate for product candidates is high. For example, in October 2016, we discontinued development of one of our product candidates, which included a Phase 3 clinical trial. We currently have multiple other programs in clinical development, including several internal programs and two partnered programs currently in Phase&#160;3 development, as well as several earlier stage clinical programs. In April 2019, we reported positive complete results from our ENVISION Phase 3 clinical trial for givosiran, an investigational RNAi therapeutic targeting ALAS1 in development for the treatment of AHP, and we filed an NDA in June 2019, which was accepted by the FDA and granted Priority Review, and an MAA in July 2019, which was validated by the EMA and granted an accelerated assessment. However, we may not be able to further advance this or any other product candidate through clinical trials and regulatory approval.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we enter into clinical trials, the results from nonclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in subsequent subjects or in subsequent human clinical trials of that product candidate or any other product candidate. There is a high failure rate for drugs proceeding through clinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results. Moreover, ONPATTRO and our current product candidates, including givosiran, lumasiran, vutrisiran, fitusiran and inclisiran, each employ novel delivery technologies that have yet to be extensively evaluated in human clinical trials and proven safe and effective.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, we, the FDA or other applicable regulatory authorities, or an institutional review board, or IRB, or similar foreign review board or committee, may delay initiation of or suspend clinical trials of a product candidate at any time for various reasons, including if we or they believe the healthy volunteer subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a product candidate or related product on healthy volunteer subjects or patients in a clinical trial could result in our decision, or a decision by the FDA or foreign regulatory authorities, to suspend or terminate the trial, or, in the case of regulatory agencies, a refusal to approve a particular product candidate for any or all indications of use. For example, in October 2016, we announced our decision to discontinue development of revusiran, an investigational RNAi therapeutic that was being developed for the treatment of patients with cardiomyopathy due to hATTR amyloidosis. Our decision followed the recommendation of the revusiran ENDEAVOUR Phase 3 study Data Monitoring Committee, or DMC, to suspend dosing and the observation of an imbalance in mortality in revusiran-treated patients as compared to those on placebo. We conducted a comprehensive evaluation of the revusiran data and reported the results of our evaluation in August&#160;2017.&#160;Following our evaluation, we continue to believe that the decision to discontinue development of revusiran does not affect ONPATTRO or any of our other investigational RNAi therapeutic programs in development.&#160;In September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic SAE and agreement with regulatory authorities on a risk mitigation strategy. In December 2017, we reached alignment with study investigators and the FDA on safety measures and a risk mitigation strategy to enable resumption of dosing in clinical studies with fitusiran, including our Phase 2 open-label extension, or OLE, study, and the ATLAS Phase 3 program, including protocol-specified guidelines and additional investigator and patient education concerning reduced doses of replacement factor or bypassing agent to treat any breakthrough bleeds in fitusiran studies.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the age and condition of the patients, the stage and severity of disease, the availability of clinical trials for other investigational drugs for the same disease or condition, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. For example, we or our partners may experience difficulty enrolling our clinical trials, including, but not limited to, the ongoing clinical trials for fitusiran, due to the availability of existing approved treatments, as well as other investigational treatments in development. Moreover, given the temporary suspension of dosing in our fitusiran studies in September 2017 due to a fatal thrombotic SAE, people with hemophilia may be more reluctant to enroll in the ATLAS Phase 3 program of fitusiran. In addition, in November 2018 we announced that due to recruitment challenges, we had discontinued a Phase 2 study of cemdisiran in atypical hemolytic uremic syndrome and now intend to focus our cemdisiran clinical development efforts in a different indication. Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments or safety concerns, can result in increased costs, longer development times or termination of a clinical trial.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Although our investigational RNAi therapeutics have been generally well-tolerated in our clinical trials to date, new safety findings may emerge. For example, as noted above, in September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic SAE that occurred in a patient with hemophilia A without inhibitors who was receiving fitusiran in our Phase 2 OLE study. In addition, in October 2016, we made the decision to discontinue our revusiran program. Following reports in the revusiran Phase 2 OLE study of new onset or worsening peripheral neuropathy, the revusiran ENDEAVOUR Phase 3 study DMC assembled in early October 2016 at our request to review these reports and ENDEAVOUR safety data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed us that the benefit-risk profile for revusiran no longer supported continued dosing. We subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo. Further, a review by us in 2017 of the ENDEAVOUR results subsequent to the completion of follow-up of the patients post-dosing discontinuation revealed an imbalance in new onset or worsening peripheral neuropathy in the revusiran arm as compared to placebo. We had previously reported, in July 2016, preliminary data from our revusiran Phase 2 OLE study for 12 patients who had reached the 12-month endpoint as of the data transfer date of May&#160;26, 2016. SAEs were observed in 14 patients, one of which, a case of lactic acidosis, was deemed possibly related to the study drug and the patient discontinued treatment. There were a total of seven deaths reported at that time in the revusiran OLE study, all of which were unrelated to the study drug.&#160;The majority of the AEs were mild or moderate in severity; injection site reactions, or ISRs, were reported in 12 patients. In August 2015, we reported that three patients had discontinued from the revusiran Phase 2 OLE study due to recurrent localized reactions at the injection site or a diffuse rash; no further discontinuations due to ISRs had occurred as of May&#160;26, 2016.&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In our ENVISION Phase 3 study of givosiran in patients with AHP, AEs were reported in 89.6% of givosiran patients and 80.4% of placebo patients; SAEs were reported in 20.8% of givosiran patients and 8.7% of placebo patients. Of the SAEs reported in givosiran patients, there were two cases of chronic kidney disease, or CKD, and one case each of asthma, device-related infection, gastroenteritis, hypoglycemia, abnormal liver function test, major depression, pain management and pyrexia. Three SAEs in givosiran patients were reported as related to study drug: pyrexia, abnormal liver function test and CKD. The two SAEs of CKD noted above were considered serious due to elective hospitalization for diagnostic evaluation. There were no deaths in the study. One patient in the givosiran arm discontinued treatment due to an increase in alanine aminotransferase, or ALT, level greater than eight times the upper limit of normal, a protocol-defined stopping rule. The increase in ALT levels subsequently resolved. AEs reported in greater than 10% of givosiran patients and seen more frequently compared to placebo were nausea, ISRs, CKD, and fatigue. Four of five of the patients with AEs reported as CKD had a prior history of CKD or a baseline estimated glomerular filtration rate less than 60 mL/min/1.73m2. No patients had clinically significant proteinuria and there were no treatment discontinuations due to renal AEs. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In our ALN-VSP clinical trial, one patient with advanced pancreatic neuroendocrine cancer with extensive involvement of the liver developed hepatic failure five days following the second dose of ALN-VSP and subsequently died; this was deemed possibly related to the study drug. As demonstrated by the discontinuation of our revusiran program in October 2016 and the temporary suspension of dosing in September 2017 in our fitusiran studies, the occurrence of SAEs and/or AEs can result in the suspension or termination of clinical trials of a product candidate by us or the FDA or a foreign regulatory authority. The occurrence of SAEs and/or AEs could also result in refusal by the FDA or a foreign regulatory authority to approve a particular product candidate for any or all indications of use.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Clinical trials also require the review, oversight and approval of IRBs or, outside of the U.S., an independent ethics committee, which continually review clinical investigations and protect the rights and welfare of human subjects. Inability to obtain or delay in obtaining IRB or ethics committee approval can prevent or delay the initiation and completion of clinical trials, and the FDA or foreign regulatory authorities may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB or ethics committee review and approval, as the case may be, in support of a marketing application.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our product candidates that we develop may encounter problems during clinical trials that will cause us, an IRB, ethics committee or regulatory authorities to delay, suspend or terminate these trials, or that will delay or confound the analysis of data from these trials. If we experience any such problems, we may not have the financial resources to continue development of the product candidate that is affected, or development of any of our other product candidates. We may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates we are developing.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, nonclinical testing and the clinical trial process that could delay or prevent regulatory approval or our ability to commercialize our product candidates, including:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our nonclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical testing or clinical trials, or we may abandon projects that we expect to be promising;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in filing IND applications or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs/ethics committees in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">conditions imposed on us by an IRB or ethics committee, or the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">problems in engaging IRBs or ethics committees to oversee clinical trials or problems in obtaining or maintaining IRB or ethics committee approval of trials;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in enrolling patients and volunteers into clinical trials, and variability in the number and types of patients and volunteers available for clinical trials;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">high drop-out rates for patients and volunteers in clinical trials;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">inadequate supply or quality of product candidate materials or other materials necessary for the conduct of our clinical trials;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">greater than anticipated clinical trial costs;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">poor or disappointing effectiveness of our product candidates during clinical trials;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or records of any clinical or nonclinical investigation;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">failure of our third-party contractors or investigators to comply with regulatory requirements, including GCP and cGMP, or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">interpretations of data by the FDA and similar foreign regulatory agencies that differ from ours.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Even if we successfully complete clinical trials of our product candidates, any given product candidate may not prove to be a safe and effective treatment for the disease for which it was being tested.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, pricing, marketing and distribution of drugs. Rigorous nonclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that the product candidates we are developing will not obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Because the drugs we are developing represent a new class of drug, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these drugs. The lack of policies, practices or guidelines may hinder or slow review by the FDA of any regulatory filings that we may submit. Moreover, the FDA may respond to these </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, or treatments in development which are approved by the time we apply for approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. In June 2019 we submitted an NDA for marketing approval for givosiran, which was accepted by the FDA in August 2019. The FDA has set a PDUFA date of February 4, 2020 and has indicated that they are not currently planning an advisory committee meeting as part of the NDA review. Additionally, in July 2019, we filed a MAA for givosiran. The EMA has validated the MAA and granted an accelerated assessment for givosiran. Any delay in the review or potential approval of givosiran by the FDA or EMA would adversely impact our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Any delay or failure in obtaining required approvals for our product candidates could have a material adverse effect on our ability to generate revenues from any product candidate for which we may seek approval in the future. Furthermore, any regulatory approval to market any product may be subject to limitations on the approved uses for which we may market the product or the labeling or other restrictions, which could limit each such product&#8217;s market opportunity and have a negative impact on our results of operations and our stock price. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy, or REMS, plan as part of an NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. In the EU, we could be required to adopt a similar plan, known as a risk management plan, and our products could be subject to specific risk minimization measures, such as restrictions on prescription and supply, the conduct of post-marketing safety or efficacy studies, or the distribution of patient and/or prescriber educational materials. In either instance, these limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we or our partners obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. If we or our partners fail to comply with continuing U.S. and foreign requirements, our approvals could be limited or withdrawn, we could be subject to other penalties, and our business would be seriously harmed.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Following any initial regulatory approval of drugs we or our partners may develop, including ONPATTRO, which was approved in the U.S. and EU in August 2018, and in several other geographies during 2019, including Japan and Canada, we will also be subject to continuing regulatory oversight, including the review of adverse drug experiences and clinical results that are reported after our drug products are made commercially available. This would include results from any post-marketing tests or surveillance to monitor the safety and efficacy of ONPATTRO or other drug products required as a condition of approval or agreed to by us. The regulatory approvals that we receive for ONPATTRO, as well as any regulatory approvals we receive for any other product candidates, including givosiran, may also be subject to limitations on the approved uses for which the product may be marketed. Other ongoing regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with good practice quality guidelines and regulations, including cGMP requirements and GCP requirements for any clinical trials that we conduct post-approval. In addition, we are conducting, and intend to continue to conduct, clinical trials for our product candidates, and we intend to seek approval to market our product candidates, in jurisdictions outside of the U.S., and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug and to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. As ONPATTRO is used commercially, we or others could identify previously unknown side effects or known side effects could be observed as being more frequent or severe than in clinical studies or earlier post-marketing periods, in which case:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">sales of ONPATTRO may be more modest than originally anticipated;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">regulatory approvals for ONPATTRO may be restricted or withdrawn;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">we may decide, or be required, to send product warning letters or field alerts to physicians, pharmacists and hospitals;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">additional nonclinical or clinical studies, changes in labeling, adoption of a REMS plan, or changes to manufacturing processes, specifications and/or facilities may be required; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">government investigations or lawsuits, including class action suits, may be brought against us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Any of the above occurrences could reduce or prevent sales of ONPATTRO, increase our expenses and impair our ability to successfully commercialize ONPATTRO.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The CMO and manufacturing facilities we use to make ONPATTRO and certain of our current product candidates, including our Cambridge facility, our future Norton facility, and Agilent and other CMOs, will also be subject to periodic review and inspection by the FDA and other regulatory agencies. For example, Agilent and our Cambridge-based facility were subject to regulatory inspection by the FDA, the EMA and potentially other regulatory authorities in connection with the review of our NDA and MAA for ONPATTRO, and may be subject to similar inspection in connection with any subsequent applications for regulatory approval of ONPATTRO filed in other territories or in connection with the pending FDA and EMA regulatory applications for givosiran. The discovery of any new or previously unknown problems with our facilities or our CMOs, or our or their manufacturing processes or facilities, may result in restrictions on the drug or CMO or facility, including delay in approval or, in the future, withdrawal of the drug from the market. We have developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for commercial use. In addition, in April 2016, we completed our purchase of a parcel of land in Norton, Massachusetts, where we are constructing a cGMP manufacturing facility for drug substance for clinical and commercial use. We may not have the ability or capacity to manufacture material at a broader commercial scale in the future. We may manufacture clinical trial materials or we may contract a third party to manufacture these materials for us. Reliance on CMOs entails risks to which we would not be subject if we manufactured products ourselves, including reliance on the CMO for regulatory compliance.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we or our collaborators, CMOs or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we may seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which will prevent us from becoming profitable.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The product candidates that we are developing are based upon new technologies or therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and consumers, may not accept a product intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for us to convince the medical community and third-party payors to accept and use our product, or to provide favorable reimbursement.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other factors that we believe will materially affect market acceptance of our product candidates include:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the safety and efficacy of our product candidates, as demonstrated in clinical trials and as compared with alternative treatments, if any;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">relative convenience and ease of administration of our product candidates;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the willingness of patients to accept potentially new routes of administration or new or different therapeutic approaches and mechanisms of action;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the success of our physician education programs;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the availability of adequate government and third-party payor reimbursement;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the pricing of our products, particularly as compared to alternative treatments, and the market perception of such prices and any price increase that we may implement in the future; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">availability of alternative effective treatments for the diseases that product candidates we develop are intended to treat and the relative risks, benefits and costs of those treatments.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For example, ONPATTRO utilizes an intravenous mode of administration with pre-medication that physicians and/or patients may not readily adopt, or which may not compete favorably with other available options, including inotersen, marketed by Akcea Therapeutics Inc., or Akcea, which is administered subcutaneously, or tafamidis, marketed by Pfizer, which is in pill form. In addition, fitusiran represents a new approach to treating hemophilia which may not be readily accepted by patients and their caregivers.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, our estimates regarding the potential market size for ONPATTRO, or any future products at the time we commence commercialization, may be materially different from the actual market size, including as a result of the indication approved by regulatory authorities, which could result in significant changes in our business plan and may have a material adverse effect on our results of operations and financial condition. For example, the indication approved by the FDA for ONPATTRO is for the treatment of the polyneuropathy of hATTR amyloidosis and not for the treatment of cardiomyopathy or other manifestations of the disease.&#160;In addition, the U.S. label does not include data from the exploratory cardiac endpoints included in our APOLLO Phase 3 study.&#160;This could have an adverse impact on the market opportunity for ONPATTRO in the U.S.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities or promoting ONPATTRO in a way that violates applicable regulations.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Physicians have the discretion to prescribe drug products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA or other applicable regulatory agencies. Off-label uses are common across medical specialties. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of treatments, the FDA and other regulatory agencies regulate a manufacturer&#8217;s communications regarding off-label use and prohibit off-label promotion, as well as the dissemination of false or&#160;misleading labeling or promotional materials. Manufacturers may not promote drugs for off-label uses. Accordingly, we may not promote ONPATTRO in the U.S. for use in any indications other than the treatment of the polyneuropathy of hATTR amyloidosis in adults. The FDA and other regulatory and enforcement authorities actively enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval has not been obtained. A company that is found to have improperly promoted off-label uses may be subject to significant liability, which may include civil and administrative remedies as well as criminal sanctions.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding regulations related to product promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading and non-promotional scientific exchange concerning their products. We intend to engage in medical education activities and communicate with healthcare providers in compliance with all applicable laws and regulatory guidance.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, we offer patient support services to assist patients receiving treatment with ONPATTRO. Manufacturers have increasingly become the focus of government investigation of patient support programs based on allegations that through such services illegal inducements are provided to physicians and/or patients, leading to improper utilization of government resources through Medicare, Medicaid and other government programs. Companies that are found to have violated laws such as the federal Anti-Kickback Statute and/or False Claims Act, or FCA, face significant liability, including civil and administrative penalties, criminal sanctions, and potential exclusion from participation in government programs. We have designed our programs in a manner that we believe complies with all applicable laws and regulations and have implemented a robust compliance program to support compliance with such laws.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or our collaborators, CMOs or service providers fail to comply with healthcare laws and regulations, or legal obligations related to privacy, data protection and information security, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As a manufacturer of pharmaceuticals, we are subject to federal, state, and comparable foreign healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights, in addition to legal obligations related to privacy, data protection and information security. These laws and regulations include:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The U.S. federal false claims laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented, claims for payment by government-funded programs such as Medicare or Medicaid that are false or fraudulent, making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which imposes requirements relating to the privacy, security, and transmission of individually identifiable health information; and requires notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The U.S. federal Open Payments requirements were implemented by the Centers for Medicare and Medicaid Services, or CMS, pursuant to the Patient Protections and Affordable Care Act, or ACA. Under the Open Payments Program, manufacturers of medical devices, medical supplies, biological products and drugs covered by Medicare, Medicaid and the Children&#8217;s Health Insurance Programs must report all transfers of value, including consulting fees, travel reimbursements, research grants, and other payments or gifts with values over $10 made to physicians and teaching hospitals as well as ownership and investment interests held by physicians and their immediate family members.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">State and foreign laws comparable to each of the above federal laws, including in the EU laws prohibiting giving healthcare professionals any gift or benefit in kind as an inducement to prescribe our products, national transparency laws requiring the public disclosure of payments made to healthcare professionals and institutions, and data privacy laws, in addition to anti-kickback and false claims laws applicable to commercial insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to government reimbursement programs, patient data privacy and security.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">European Privacy Laws including Regulation 2016/679, known as the General Data Protection Regulation, or the GDPR, and the e-Privacy Directive (202/58/EC), and the national laws implementing each of them, as well as the privacy laws of Japan and other territories. Failure to comply with our obligations under the privacy regime could expose us to significant fines and/or adverse publicity, which could have material adverse effects on our reputation and business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Some state laws also require pharmaceutical manufacturers to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring manufacturers to report information related to payments to physicians and other healthcare provides or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the EU, the GDPR replaced the EU Data Protection Directive on May 25, 2018. The GDPR introduced new data protection requirements in the EU, as well as potential fines for noncompliance of up to the greater of &#8364;20,000,000 or 4% of total annual global revenue. The regulation imposes numerous new requirements for the collection, use and disclosure of personal information, including: more stringent requirements relating to data subject consent; what information must be shared with data subjects regarding how their personal information is used; the obligation to notify regulators and affected individuals of personal data breaches; extensive new internal privacy governance obligations; and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR maintains the EU Data Protection Directive&#8217;s restrictions on cross-border data transfer. The GDPR increases the responsibility and liability of pharmaceutical companies in relation to processing personal data, and companies may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. Further, Brexit has created uncertainty with regard to the status of the UK as an &#8220;adequate country&#8221; for the purposes of data transfers outside the European Economic Area, or EEA. In particular, it is unclear how data transfers to and from the UK will be regulated. These changes may require us to find alternative bases for the compliant transfer of personal data from the UK to the U.S., and we are monitoring developments in this area.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If our operations are found to be in violation of any of the aforementioned requirements, we may be subject to penalties, including civil or criminal penalties, criminal prosecution, monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, or the imposition of a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services, any of which could adversely affect our financial results. We are continuing to establish our global compliance infrastructure following the launch of </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">ONPATTRO in the U.S. and EU in 2018, in Canada and Japan in 2019, and as we prepare for the launch in additional countries, assuming regulatory approvals. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we or our collaborators, CMOs or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell ONPATTRO, or any other future products, successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">adverse regulatory inspection findings;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">warning letters;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">restrictions on, or prohibitions against, marketing our products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">restrictions on, or prohibitions against, importation or exportation of our products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">suspension of review or refusal to approve pending applications or supplements to approved applications;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">exclusion from participation in government-funded healthcare programs;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">exclusion from eligibility for the award of government contracts for our products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">suspension or withdrawal of product approvals;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">product seizures;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">injunctions; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, CMOs and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or the legal structure.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. We are actively monitoring these regulations as we market and sell ONPATTRO in the U.S., the EU, Japan, Canada and Switzerland and as several of our other programs move through late stages of development, however, a number of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for such programs for a number of years. We might obtain regulatory approval for a product, including ONPATTRO, in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country and potentially in other countries due to reference pricing.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our ability to commercialize ONPATTRO or any future products, including givosiran, successfully also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. ONPATTRO and other products for which we are able to obtain marketing approval, including givosiran, may not be considered cost-effective, and the amount reimbursed may be insufficient to allow us to sell ONPATTRO or any future products, including givosiran, on a competitive basis. Increasingly, the third-party payors who pay for or reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. In the U.S., we have entered into more than ten value-based agreements and are negotiating additional value-based agreements for ONPATTRO with certain private health insurers. The goal of these agreements is to ensure that we are paid based on the ability of ONPATTRO to deliver results in the real world </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">setting comparable to those demonstrated in clinical trials. Partnering with payers on these agreements is intended to provide more certainty to them for their investment, and help accelerate coverage decisions for patients. The agreements are structured to link ONPATTRO&#8217;s performance in real-world use to financial terms. If the price we are able to charge for ONPATTRO or any other products we develop, including givosiran, or the reimbursement provided for such products, is inadequate in light of our development and other costs, or if reimbursement is denied, our return on investment could be adversely affected. In addition, we have stated publicly that we intend to grow through continued scientific innovation rather than arbitrary price increases. Specifically, we have stated that we will not raise the price of any product for which we receive marketing approval over the rate of inflation, as determined by the consumer price index for urban consumers (approximately 2.2% currently) absent a significant value driver. Our patient access philosophy could also negatively impact the revenues we are able to generate from the sale of one or more of our products in the future.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We currently expect that some of the drugs we develop may need to be administered under the supervision of a physician or other healthcare professional on an outpatient basis, including ONPATTRO. Under currently applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under the Medicare Part B program if:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">they are incident to a physician&#8217;s services;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">they have been approved by the FDA and meet other requirements of the statute.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or foreign regulatory authorities. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution or that covers a particular provider&#8217;s cost of acquiring the drug. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage or adequate reimbursement rates from both government-funded and private payors for ONPATTRO or other new drugs that we develop, including givosiran, and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A number of other legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed or enacted in recent months and years, and such efforts have expanded substantially in recent years. These developments have included prescription drug benefit legislation that was enacted in 2003 and took effect in January 2006, healthcare reform legislation enacted by certain states, and major healthcare reform legislation that was passed by Congress and enacted into law in the U.S. in 2010. These developments could, directly or indirectly, affect our ability to sell ONPATTRO or future products, if approved, including givosiran, at a favorable price.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In particular, in March 2010, the ACA was signed into law. This legislation changed the system of healthcare insurance and benefits intended to broaden coverage and control costs. The law also contains provisions that affect companies in the pharmaceutical industry and other healthcare related industries by imposing additional costs and changes to business practices. Among the provisions affecting pharmaceutical companies are the following:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Mandatory rebates for drugs sold into the Medicaid program were increased, and the rebate requirement was extended to drugs used in risk-based Medicaid managed care plans.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The 340B Drug Pricing Program under the Public Health Service Act was extended to require mandatory discounts for drug products sold to certain critical access hospitals, cancer hospitals and other covered entities.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Pharmaceutical companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part&#160;D coverage gap, commonly referred to as the &#8220;donut hole.&#8221;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">Pharmaceutical companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law provides that approval of an application for a follow-on biologic product may not become effective until 12 years after the date on which the reference innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric products. After this exclusivity ends, it will be easier for generic manufacturers to enter the market, which is likely to reduce the pricing for such products and could affect our profitability.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law creates a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law expands eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law expands the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law expands healthcare fraud and abuse laws, including the civil FCA and the federal Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law establishes new requirements to report financial arrangements with physicians and teaching hospitals and to annually report drug samples that manufacturers and distributors provide to physicians.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The law established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery methods.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for ONPATTRO or any of our product candidates for which we may obtain regulatory approval, including givosiran, or the frequency with which ONPATTRO or any future product, including givosiran, is prescribed or used.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The full effects of the U.S. healthcare reform legislation cannot be known until the law is fully implemented through regulations or guidance issued by the CMS and other federal and state healthcare agencies. The financial impact of the U.S. healthcare reform legislation over the next few years will depend on a number of factors, including, but not limited, to the policies reflected in implementing regulations and guidance, and changes in sales volumes for products affected by the new system of rebates, discounts and fees. This legislation may also have a positive impact on our future net sales, if any, by increasing the aggregate number of persons with healthcare coverage in the U.S.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Members of Congress and the Trump administration have expressed an intent to pass legislation or adopt executive orders to fundamentally change or repeal parts of the ACA. While Congress has not passed repeal legislation to date, the TCJA includes a provision repealing the individual insurance coverage mandate included in ACA, effective January 1, 2019. Further, on January 20, 2017, an Executive Order was signed directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October 13, 2017, an Executive Order was signed terminating the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">request for a restraining order was denied by a federal judge in California on October 25, 2017. Further, on June 14, 2018 the United States Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12.0 billion in ACA risk corridor payments to third-party payors. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and our business, are not yet known. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. The Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In July 2018, the CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Moreover, CMS issued a final rule in 2018 that will give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. While the Texas District Court Judge issued an order staying the judgment pending appeal in December 2018, and both the Trump Administration and CMS have stated the ruling will have no immediate impact, it is unclear how this decision, subsequent appeals and other efforts to repeal and replace the ACA will impact the ACA and our business. On July 9, 2019, the U.S. Court of Appeals for the Fifth Circuit held a hearing to determine whether certain states and the House of Representatives have standing to appeal the lower court decision, but it is unclear when the appellate court will render its decision on this hearing, and what effect it will have on the status of the ACA. Congress may consider other legislation to replace elements of the ACA. The implications of the ACA, its possible repeal, any legislation that may be proposed to replace the ACA, or the political uncertainty surrounding any repeal or replacement legislation for our business and financial condition, if any, are not yet clear.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The costs of prescription pharmaceuticals in the U.S. has also been the subject of considerable discussion in the U.S., and members of Congress and the Trump administration have stated that they will address such costs through new legislative and administrative measures. To date, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the Trump administration have each indicated that it will continue to pursue new legislative and/or administrative measures to control drug costs. The Trump administration released a &#8220;Blueprint,&#8221; or plan, to reduce the cost of drugs, increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Trump administration&#8217;s Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working to implement. For example, on October 25, 2018, CMS issued an Advanced Notice of Proposed Rulemaking, or ANPRM, indicating it was considering issuing a proposed rule in 2019 on a model called the International Pricing Index, with a potential start in the spring of 2020. This model would utilize a basket of other countries&#8217; prices as a reference for the Medicare program to use in reimbursing for drugs covered under Part B. The ANPRM also included an updated version of the Competitive Acquisition Program, as an alternative to current &#8220;buy and bill&#8221; payment methods for Part B drugs. Such a proposed rule could limit our product pricing and have material adverse effects on our business. Although some of these, and other, proposals related to the administration&#8217;s Blueprint may require additional authorization to become effective, may ultimately be withdrawn, or may face challenges in the courts, the Congress and the Trump administration have indicated that they will continue to seek new legislative and administrative measures to control drug costs. For example, on September 25, 2019, the Senate Finance Committee introduced the Prescription Drug Pricing Reduction Action of 2019, a bill intended to reduce Medicare and Medicaid prescription drug prices. The proposed legislation would restructure the Part D benefit, modify payment methodologies for certain drugs, and impose an inflation cap on drug price increases. Another bill, the Lower Drug Costs Now Act of 2019, was introduced in the House of Representatives on September 19, 2019, and would require the U.S. Department of Health and Human Services to directly negotiate drug prices with manufacturers. It is unclear whether either of these bills will make it through both chambers of Congress and be signed into law, and if either is enacted, what effect it would have on our business; however enactment of either of these bills could have a material adverse effect on our business and prospects. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. Some of these measures include price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from ONPATTRO or other product candidates that we may successfully develop and for which we may obtain regulatory approval, including givosiran, and may affect our overall financial condition and ability to develop drug candidates.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Governments outside the U.S. may impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The pricing of prescription pharmaceuticals is also subject to governmental control outside the U.S. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In some countries, including Member States of the EU, the pricing of prescription drugs is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of a product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval, which is time-consuming and costly. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic partners. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of ONPATTRO or any future products, including givosiran, in those countries would be negatively affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;special category data,&#8221; which includes health, biometric and genetic information of data subjects located in the EU. Further, GDPR provides a broad right for EU Member States to create supplemental national laws, such as laws relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedy in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the EU to the U.S. or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States, which may deviate slightly from the GDPR, may result in fines of up to 4% of total global annual revenue, or &#8364;20,000,000, whichever is greater, and in addition to such fines, we may be the subject of litigation and/or adverse publicity, which could have material adverse effect on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the new data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, may make it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification requirements throughout the EU, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are subject to the supervision of local data protection authorities in those jurisdictions where we are monitoring the behavior of individuals in the EU (i.e., undertaking clinical trials). We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we enter or intend to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct or intend to conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each European member state, without the need for further enactment. The draft ePrivacy Regulation imposes strict opt-in marketing rules with limited exceptions for business-to-business communications, alters rules on third-party cookies, web beacons and similar technology and significantly increases potential fines to the same levels as GDPR (i.e., the greater of &#8364;20,000,000 or 4% of total global annual revenue). While the e-Privacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process and commentators now expect it to be adopted during the middle or second half of 2020.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. Further, Brexit has created uncertainty with regard to the status of the UK as an &#8216;adequate country&#8217; for the purposes of data transfers outside the EEA. In particular, it is unclear how data transfers to and from the UK will be regulated. Enforcement uncertainty and the costs associated with ensuring GDPR and e-Privacy compliance may be onerous and may adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending and services, and any inability on our part to effectively adapt to such changes could substantially affect our financial position, results of operations and cash flows.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Budget Control Act of 2011, the failure of Congress to enact deficit reduction measures of at least $1.2&#160;trillion for the years 2013 through 2021 triggered automatic cuts to most federal programs. These cuts included aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year, starting in 2013. Certain of these automatic cuts have been implemented resulting in reductions in Medicare payments to physicians, hospitals, and other healthcare providers, among other things. Due to legislation amending the statute, including the BBA, these reductions will stay in effect through 2027 unless additional Congressional action is taken. The full impact on our business of these automatic cuts is uncertain.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If other federal spending is reduced, any budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell ONPATTRO and any other products we may develop, including givosiran.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, in the case of any U.S. federal government shutdown, now or in the future, that continued for a prolonged period of time, FDA review and approval processes, and FDA interactions during clinical development, could be delayed. Resolving such delays could force us or our collaborators to incur significant costs, could limit our allowed activities or the allowed activities of our collaborators, could diminish any competitive advantages that we or our collaborators may attain or could adversely affect our business, financial condition, results of operations and prospects, the value of our common stock and our ability to bring new products to market as forecasted. Even without such delay, there is no guarantee we will receive approval for our product candidates on a timely basis, or at all.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">There is a substantial risk of product liability claims in our business. If we are unable to obtain sufficient insurance, a product liability claim against us could adversely affect our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our business exposes us to significant potential product liability risks that are inherent in the development, testing, manufacturing and marketing of human therapeutic products. Product liability claims could delay or prevent completion of our clinical development programs. Following the decision to discontinue clinical development of revusiran, we conducted a comprehensive evaluation of available revusiran data. We reported the results of this evaluation in August 2017, however, our investigation did not result in a conclusive explanation regarding the cause of the mortality imbalance observed in the ENDEAVOUR Phase 3 study. In addition, in September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic SAE and agreement with regulatory authorities on a risk mitigation strategy. Notwithstanding the risks undertaken by all persons who participate in clinical trials, and the information on risks provided to study investigators and patients participating in our clinical trials, including the revusiran and fitusiran studies, it is possible that product liability claims will be asserted against us relating to the worsening of a patient&#8217;s condition, </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">injury or death alleged to have been caused by one of our product candidates, including revusiran or fitusiran. Such claims might not be fully covered by product liability insurance. If we succeed in marketing products, including ONPATTRO, product liability claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development, including the marketing and sale of ONPATTRO. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our research, development and manufacturing involve the use of hazardous materials, chemicals and various radioactive compounds. We maintain quantities of various flammable and toxic chemicals in our facilities in Cambridge that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Cambridge facilities comply with the relevant guidelines of the City of Cambridge, the Commonwealth of Massachusetts and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Patents, Licenses and Trade Secrets</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product candidates will be harmed.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our success depends, in part, on our ability to protect proprietary methods and technologies that we develop under the patent and other intellectual property laws of the U.S. and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to manufacture and commercialize our proposed products. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November 29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. Further, we may be required to obtain licenses under third-party patents to market ONPATTRO or future products or conduct our research and development or other activities. If licenses are not available to us on acceptable terms, we may not be able to market the affected products or conduct the desired activities.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. In addition, we may rely on third-party collaborators to file patent applications relating to proprietary technology that we develop jointly during certain collaborations. The process of obtaining patent protection is expensive and time-consuming. If our present or future collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected. Despite our efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. While issued patents are presumed valid, this does not guarantee that the patent will survive a validity challenge or be held enforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties attempting to design around our intellectual property. Moreover, third parties or the United States Patent and Trademark Office, or USPTO, may commence interference proceedings involving our patents or patent applications. Any challenge to, </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">finding of unenforceability or invalidation or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third party licensors and could have a material adverse effect on our business.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our pending patent applications may not result in issued patents. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the U.S. and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic discussions in the Congress of the United States and in international jurisdictions about modifying various aspects of patent law. For example, the America Invents Act included a number of changes to the patent laws of the U.S. If any of the enacted changes do not provide adequate protection for discoveries, including our ability to pursue infringers of our patents for substantial damages, our business could be adversely affected. One major provision of the America Invents Act, which took effect in March 2013, changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor&#8217;s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Failure to obtain and maintain all available regulatory exclusivities, broad patent scope and to maximize patent term restoration or extension on patents covering our products may lead to loss of exclusivity and early generic entry resulting in a loss of market share and/or revenue.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have obtained licenses from, among others, Cancer Research Technology Limited, Ionis Pharmaceuticals, Inc., or Ionis, the Massachusetts Institute of Technology, or MIT, Whitehead Institute for Biomedical Research, or Whitehead, Max Planck Innovation GmbH (formerly known as Garching Innovation GmbH), or Max Planck, and Arbutus Biopharma Corporation, or Arbutus (formerly Tekmira Pharmaceuticals Corporation). We also intend to enter into additional licenses to third-party intellectual property in the future.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">RNAi is a relatively new scientific field, the commercial exploitation of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain patent protection in the field. We have obtained grants and issuances of RNAi patents and have licensed many of these patents from third parties on an exclusive basis. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of RNAi therapeutics.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic and other uses; siRNAs directed to specific targets as </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">treatments for particular diseases; delivery technologies, such as in the fields of carbohydrate conjugates and cationic liposomes; and all aspects of our specific development candidates.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As the field of RNAi therapeutics is maturing, patent applications are being fully processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference, re-examination and opposition proceedings, as well as </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> and post-grant review proceedings introduced by provisions of the America Invents Act, which became available to third party challengers on September&#160;16, 2012, in various patent offices relating to patent rights in the RNAi field. For example, various third parties have initiated oppositions to patents in our McSwiggen, Kreutzer-Limmer and Tuschl&#160;II series in the European Patent Office, or EPO, and in other jurisdictions. We expect that additional oppositions will be filed in the EPO and elsewhere, and other challenges will be raised relating to other patents and patent applications in our portfolio. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete in the field of RNAi.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need for our siRNA therapeutic candidates or marketed products, including ONPATTRO. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for siRNA drugs we wish to develop. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for our siRNA therapeutic candidates or marketed products, including ONPATTRO.&#160;Thus, it is possible that one or more organizations will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. If those organizations refuse to grant us a license to such patent rights on reasonable terms and/or a court rules that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms, we may be unable to market products, including ONPATTRO, or perform research and development or other activities covered by such patents. For example, during 2017 and 2018, Silence Therapeutics plc, or Silence, filed claims in several jurisdictions, including the High Court of England and Wales, and named us and our wholly owned subsidiary Alnylam UK Ltd. as co-defendants. Silence alleged various claims, including that ONPATTRO infringed one or more Silence patents. There were also a number of related actions brought by us or Silence in connection with this intellectual property dispute. In December 2018, we entered into a Settlement and License Agreement with Silence, resolving all ongoing claims, administrative proceedings, and regulatory proceedings worldwide between us regarding, among other issues, patent infringement, patent invalidity and breach of contract.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Third parties may sue us for infringing their patent rights. For example, in October 2017 Silence sued us in the UK alleging that ONPATTRO and other investigational RNAi therapeutics we or MDCO are developing infringed one or more Silence patents. Likewise, we may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of proprietary rights of others or protect our proprietary information and trade secrets. For example, during the second quarter of 2015, we filed a trade secret misappropriation lawsuit against Dicerna to protect our rights in the RNAi assets we purchased from Merck Sharp &amp; Dohme Corp. We and Dicerna settled the ongoing litigation between us in April 2018 and in December 2018 we and Silence settled all ongoing litigation between us. A third party may also claim that we have improperly obtained or used its confidential or proprietary information. For example, in March 2011, Arbutus filed a civil complaint against us alleging, among other things, misappropriation of its confidential and proprietary information and trade secrets. In November 2012, we settled this litigation and restructured our contractual relationship with Arbutus. In connection with this restructuring, we incurred a $65.0&#160;million charge to operating expenses during the fourth quarter of 2012.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In protecting our intellectual patent rights through litigation or other means, a third party may claim that we have improperly asserted our rights against them. For example, in August 2017, Dicerna successfully added counterclaims against us in the above-referenced trade secret lawsuit alleging that our lawsuit represented abuse of process and claiming tortious interference with its business. In addition, in August 2017, Dicerna filed a lawsuit against us in the United States District Court of Massachusetts alleging attempted monopolization by us under the Sherman Antitrust Act. As noted above, in April 2018, we and Dicerna settled the ongoing litigation between us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Furthermore, third parties may challenge the inventorship of our patents or licensed patents. For example, in March 2011, The University of Utah, or Utah, filed a complaint against us, Max Planck Gesellschaft Zur Foerderung Der Wissenschaften </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">e.V. and Max Planck Innovation, together, Max Planck, Whitehead, MIT and the University of Massachusetts, claiming that a professor of Utah was the sole inventor, or in the alternative, a joint inventor of certain of our in-licensed patents. Utah was seeking correction of inventorship of the Tuschl patents, unspecified damages and other relief. After several years of court proceedings and discovery, the court granted our motions for summary judgment, and dismissed Utah&#8217;s state law damages claims as well.&#160;During the pendency of this litigation, as well as the Arbutus and Dicerna litigation described above, we incurred significant costs, and in each case, the litigation diverted the attention of our management and other resources that would otherwise have been engaged in other activities.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research, development and commercialization efforts and limit our ability to continue our operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If any parties successfully claim that our creation or use of proprietary technologies infringes upon or otherwise violates their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#8217; patent rights. In addition to any damages we might have to pay, a court could require us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties who have competing or superior intellectual property positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations under any licenses or related agreements, we may be required to pay damages and could lose license or other rights that are necessary for developing, commercializing and protecting our RNAi technology, as well as ONPATTRO and any other product candidates that we develop, or we could lose certain rights to grant sublicenses.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license or render the license non-exclusive, which could result in us being unable to develop, manufacture, market and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, we could incur significant costs and/or disruption to our business and distraction of our management defending against any breach of such licenses alleged by the licensor. For example, in June 2018, Ionis sent us a notice claiming that it is owed payments under our second amended and restated strategic collaboration and license agreement as a result of the January 2018 amendment of our collaboration agreement with Sanofi Genzyme and the related Exclusive TTR License and AT3 License Terms. Ionis claims it is owed technology access fees based on rights granted and amounts paid to us in connection with the Sanofi Genzyme restructuring. In November 2018, we received notice that Ionis had filed a Demand for Arbitration with the Boston office of the American Arbitration Association against us, asserting, among other things, breach of contract. In December 2018, we filed our answer to Ionis&#8217;s Demand for Arbitration, denying any liability to Ionis and the matter is currently in the discovery phase. The arbitration has been set for a five-day hearing in the first half of 2020. While we dispute that additional technology access fees are owed to Ionis, there can be no assurance that we will resolve this matter favorably or that it will not have a material adverse impact on our future results of operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we will be required to pay on sales of ONPATTRO or future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in ONPATTRO or other products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in such cases we could not assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Competition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">product candidates that are based on previously tested or accepted technologies;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">products that have been approved or are in late stages of development; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">collaborative arrangements in our target markets with leading companies and research institutions.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop drugs. We also expect to face competition from new drugs that enter the market. There are a number of drugs currently under development, which may become commercially available in the future, for the treatment of conditions for which we may try to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop. For example, we developed ONPATTRO for the treatment of hATTR amyloidosis. In August 2018, the FDA approved ONPATTRO lipid complex injection for the treatment of the polyneuropathy of hATTR amyloidosis in adults, and the EC granted marketing authorisation for ONPATTRO for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. We are aware of other approved products used to treat this disease, including tafamidis, marketed by Pfizer, which is now approved in the U.S., Europe and certain other countries outside the U.S.,&#160;and inotersen, developed by Ionis and licensed to Akcea, which is now approved in the U.S., the EU and Canada,&#160;as well as product candidates in various stages of clinical development, including an&#160;additional&#160;investigational drug being developed by Ionis. In addition, in August 2018, Pfizer announced the primary results from a Phase 3 study of tafamidis in patients with TTR cardiomyopathy. In June 2017 and May 2018, respectively, the FDA granted Fast Track and Breakthrough Therapy designations for tafamidis for TTR amyloid cardiomyopathy, and approved tafamidis for the treatment of the cardiomyopathy of wild-type or hereditary ATTR in May 2019. In March 2018, the Ministry of Labor Health and Welfare in Japan granted SAKIGAKE designation to tafamidis for this indication and in March 2019, Pfizer announced the additions of wild-type and mutant indications in Japan for TTR amyloid cardiomyopathy.&#160;Finally, we are aware that Eidos Therapeutics, Inc., or Eidos, initiated a Phase 3 clinical trial of AG10, a TTR stabilizer, in ATTR-CM in February 2019. Eidos also plans to initiate a Phase 3 clinical trial of AG10 in ATTR-PN patients by the end of 2019.&#160;While we believe that ONPATTRO will have a competitive product profile, it is possible it will not compete favorably with these products and product candidates, or others, and, as a result, may not achieve commercial success. Moreover, positive data and/or the commercial success of competitive products could negatively impact our stock price.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we continue to successfully develop product candidates, and obtain approval for them, we will face competition based on many different factors, including:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the safety and effectiveness of our products relative to alternative therapies, if any;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the timing and scope of regulatory approvals for these products;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the availability and cost of manufacturing, marketing and sales capabilities;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the price of our products relative to alternative approved therapies;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">reimbursement coverage; and</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">patent position.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are aware of product candidates in various stages of clinical development for the treatment of PH1 which would compete with lumasiran, our investigational RNAi therapeutic now in Phase 3 studies for the treatment of this disease, including Oxabact&#174;, a bacteria-based investigational therapy in Phase 3 development by Oxthera AB, reloxaliase an investigational enzyme therapy in Phase 2 development for primary or severe secondary hyperoxaluria by Allena Pharmaceuticals, and DCR-PHXC, an investigational RNAi therapeutic in development by Dicerna for the treatment of primary hyperoxaluria. In March 2019, Dicerna announced the initiation of screening for a pivotal study of DCR-PHXC for this indication, and in July 2019, the FDA granted a Breakthrough Therapy Designation to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1. Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop strategic alliances with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and the ability to execute on our business plan. Furthermore, we also face competition from existing and new treatment methods that reduce or eliminate the need for drugs, such as the use of advanced medical devices. The development of new medical devices or other treatment methods for the diseases we are targeting could make our product candidates noncompetitive, obsolete or uneconomical.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to the competition we face from competing drugs in general, we also face competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware of several other companies that are working to develop RNAi therapeutic products. Some of these companies are seeking, as we are, to develop chemically synthesized siRNAs as drugs. Others are following a gene therapy approach, with the goal of treating patients not with synthetic siRNAs but with synthetic, exogenously-introduced genes designed to produce siRNA-like molecules within cells. Companies working on chemically synthesized siRNAs include, but are not limited to, Takeda Pharmaceutical Company, or Takeda, Marina Biotech, Inc., Arrowhead Research Corporation, or Arrowhead, and its subsidiary, Calando Pharmaceuticals Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence, Arbutus, Sylentis S.A.U., Dicerna, WAVE Life Sciences Ltd., Arcturus Therapeutics, Inc., and Genevant Sciences, launched by Arbutus and Roivant Sciences. In addition, we granted licenses or options for licenses to Ionis, Benitec, Arrowhead, and its subsidiary, Calando, Arbutus, Quark, Sylentis and others under which these companies may independently develop RNAi therapeutics against a limited number of targets. Any one of these companies may develop its RNAi technology more rapidly and more effectively than us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, as a result of agreements that we have entered into, Takeda has obtained a non-exclusive license, and Arrowhead, as the assignee of Novartis Pharma AG, has obtained specific exclusive licenses for 30 gene targets, that include access to certain aspects of our technology. We also compete with companies working to develop antisense-based drugs. Like RNAi therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Akcea has received marketing approval for an antisense drug, inotersen that was developed by Ionis, in the U.S., the EU and Canada, for the treatment of hATTR amyloidosis. Several antisense drugs developed by Ionis have been approved and are currently marketed, and Ionis has multiple antisense product candidates in clinical trials. Ionis is also developing antisense drugs using ligand-conjugated GalNAc technology licensed from us, and these drugs have been shown to have increased potency at lower doses in clinical and pre-clinical studies, compared with antisense drugs that do not use such licensed GalNAc technology. The development of antisense drugs is more advanced than that of RNAi therapeutics, and antisense technology may become the preferred technology for drugs that target mRNAs to silence specific genes.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to competition with respect to RNAi and with respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver siRNAs to the relevant cell and tissue types. Safe and effective means to deliver siRNAs to the relevant cell and tissue types may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely affected. In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective means of delivering siRNAs into the relevant cell and tissue types, both in academic laboratories and in the corporate sector. Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates.</span></div><div style="text-align:center;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our stock price fluctuates, purchasers of our common stock could incur substantial losses.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The market price of our common stock has fluctuated significantly and may continue to fluctuate significantly in response to factors that are beyond our control. The stock market in general has from time to time experienced extreme price and volume fluctuations, and the biotechnology sector in particular has experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical and biotechnology companies have been extremely volatile, and have experienced fluctuations that often have been unrelated or disproportionate to the clinical development progress or operating performance of these companies, including as a result of adverse development events.&#160;These broad market and sector fluctuations have resulted and could in the future result in extreme fluctuations in the price of our common stock, which could cause purchasers of our common stock to incur substantial losses.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may incur significant costs from class action litigation.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development and commercialization efforts or the development and commercialization efforts of our collaborators and/or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. For example, in October 2016, we announced that we were discontinuing the development of revusiran and our stock price declined significantly as a result and in September 2017, following our temporary suspension of dosing in our fitusiran program, our stock also declined, although to a lesser extent.&#160;When the market price of a stock has been volatile as our stock price has been, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For example, a class action complaint was filed on September 26, 2018 in the United States District Court for the Southern District of New York, entitled Caryl Hull Leavitt v. Alnylam Pharmaceuticals, Inc., et. al., Case No. 18-CV-8845. The complaint, as further amended, alleges that we and our Chief Executive Officer, former Chief Financial Officer and certain of our other executive officers violated certain federal securities laws, specifically under Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The plaintiff seeks unspecified damages on behalf of a purported class of purchasers of our common stock between September 20, 2017 and September 12, 2018. We believe that the allegations contained in the Complaint are without merit and intend to defend the case vigorously. However, whether or not the plaintiff&#8217;s claims are successful, this type of litigation is often expensive and diverts management&#8217;s attention and resources, which could adversely affect the operation of our business. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may be the target of similar litigation in the future. For example, on September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. Any future litigation could result in substantial costs and divert our management&#8217;s attention and resources, which could cause serious harm to our business, operating results and financial condition. We maintain liability insurance; however, if any costs or expenses associated with this or any other litigation exceed our insurance coverage, we may be forced to bear some or all of these costs and expenses directly, which could be substantial.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future sales of shares of our common stock, including by our significant stockholders, us or our directors and officers, could cause the price of our common stock to decline.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A small number of our stockholders beneficially own a substantial amount of our common stock. As of September&#160;30, 2019, our six largest stockholders beneficially owned in excess of 50% of our outstanding shares of common stock. If our significant stockholders, or we or our officers and directors, sell substantial amounts of our common stock in the public market, or there is a perception that such sales may occur, the market price of our common stock could be adversely affected. Sales of common stock by our significant stockholders might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regeneron&#8217;s ownership of our common stock could delay or prevent a change in corporate control.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of May 21, 2019, the closing date of the stock purchase in connection with the 2019 Regeneron collaboration, Regeneron held approximately 4% of our outstanding common stock and has the right to increase its ownership up to 30%. This concentration of ownership could harm the market price of our common stock in the future by:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delaying, deferring or preventing a change in control of our company;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">impeding a merger, consolidation, takeover or other business combination involving our company; or</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Provisions in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">a classified board of directors;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">a prohibition on actions by our stockholders by written consent;</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">limitations on the removal of directors; and</span></div><div style="text-indent:-36pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span></div><div id="i_0_142"></div><div style="text-align:justify;margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 6. EXHIBITS.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:6.784773%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.215227%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="alnyq3201910-qex311.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="alnyq3201910-qex312.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="alnyq3201910-qex321.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="alnyq3201910-qex322.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code.</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td></tr></table></div><div><span><br/></span></div><div id="i_0_145"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:43.2pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:27pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:42.574780%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:52.692082%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ALNYLAM PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date: October 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ John M. Maraganore</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">John M. Maraganore, Ph.D.<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date: October 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Jeff Poulton</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Jeff Poulton<br/>Executive Vice President, Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>alnyq3201910-qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.1</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, John M. Maraganore, Ph.D., certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; October 31, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; John M. Maraganore</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">John M. Maraganore, Ph.D.&#160;<br>Chief Executive Officer&#160;</font></td></tr></table></div><div style="margin-top:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>alnyq3201910-qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.2</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I,&#160;Jeff Poulton, certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-45pt;padding-left:126pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; October 31, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jeff Poulton</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Jeff Poulton<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>alnyq3201910-qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 32.1</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the quarter ended September&#160;30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, John M. Maraganore, Ph.D., Chief Executive Officer of the Company, hereby certifies, pursuant to Section&#160;1350 of Chapter 63 of Title 18, United States Code, that to his knowledge&#58;</font></div><div style="text-indent:-40.5pt;padding-left:76.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:-40.5pt;padding-left:76.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; October 31, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; John M. Maraganore</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">John M. Maraganore, Ph.D.&#160;<br>Chief Executive Officer&#160;</font></td></tr></table></div><div style="padding-left:36pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>alnyq3201910-qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 32.2</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:36pt;text-align:justify;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the quarter ended September&#160;30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned,&#160;Jeff Poulton, Executive Vice President, Chief Financial Officer, hereby certifies, pursuant to Section&#160;1350 of Chapter&#160;63 of Title 18, United States Code, that to his knowledge&#58;</font></div><div style="text-indent:-40.5pt;padding-left:76.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:-40.5pt;padding-left:76.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; October 31, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jeff Poulton</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Jeff Poulton<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="padding-left:36pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>alny-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:5d2595a3-a26b-49fe-8f15-878ed8f526a8,g:8c29cc34-fc93-4a2b-96ed-ef5f86bbe907-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:alny="http://www.alnylam.com/20190930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alnylam.com/20190930">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="alny_BeneficialOwnershipPercentageOfSharesOutstanding" abstract="false" name="BeneficialOwnershipPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_VirBiotechnologyIncMember" abstract="true" name="VirBiotechnologyIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ExternalServicesMember" abstract="true" name="ExternalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_EquityTable" abstract="true" name="EquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alny_LeasesPolicyPolicyTextBlock" abstract="false" name="LeasesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_InvestorAgreementDescription" abstract="false" name="InvestorAgreementDescription" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_RoyaltyRate" abstract="false" name="RoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_OneHundredAndOneMainStreetLeasesMember" abstract="true" name="OneHundredAndOneMainStreetLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_NortonMassachusettsMember" abstract="true" name="NortonMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_TransactionPrice" abstract="false" name="TransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" abstract="false" name="ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" abstract="false" name="MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" abstract="false" name="CashCollateralRequiredForPrincipalAmountOutstandingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_NumberOfTargetedPrograms" abstract="false" name="NumberOfTargetedPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" abstract="false" name="InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_CreditAgreementDisclosureTextBlock" abstract="false" name="CreditAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_RegeneronPharmaceuticalsIncorporationMember" abstract="true" name="RegeneronPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_CashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="CashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_SanofiGenzymeMember" abstract="true" name="SanofiGenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_BMRSixSevenFiveWestKendallLeaseMember" abstract="true" name="BMRSixSevenFiveWestKendallLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ClinicalTrialAndManufacturingMember" abstract="true" name="ClinicalTrialAndManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ResearchServicesObligationMember" abstract="true" name="ResearchServicesObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_PercentageOfMaximumRoyaltyPayments" abstract="false" name="PercentageOfMaximumRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" abstract="true" name="LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_NumberOfLeaseExtensionOptions" abstract="false" name="NumberOfLeaseExtensionOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alny_MdcoMember" abstract="true" name="MdcoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ThirdStreetLeaseMember" abstract="true" name="ThirdStreetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_CollaborationAmendmentMember" abstract="true" name="CollaborationAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ChangeInFairValueOfLiabilityObligation" abstract="false" name="ChangeInFairValueOfLiabilityObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_AccumulatedLossOnInvestmentInJointVentureMember" abstract="true" name="AccumulatedLossOnInvestmentInJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_LeaseAgreementTerm" abstract="false" name="LeaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_FundingAtProgramInitiationMember" abstract="true" name="FundingAtProgramInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_FundingAnAnnualDiscoveryMember" abstract="true" name="FundingAnAnnualDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ImpairmentOfMarketableDebtSecurities" abstract="false" name="ImpairmentOfMarketableDebtSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_StandaloneSellingPrice" abstract="false" name="StandaloneSellingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_GlobalStrategicCollaborationMember" abstract="true" name="GlobalStrategicCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_FundingAtLeadCandidateIdentificationMember" abstract="true" name="FundingAtLeadCandidateIdentificationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_EquityLineItems" abstract="true" name="EquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_ResearchTermExtensionFee" abstract="false" name="ResearchTermExtensionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" abstract="false" name="OwnershipPercentageSharesOfStocksOutstandingUpperLimit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_WellsFargoCreditFacilityMember" abstract="true" name="WellsFargoCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_CollaborativeArrangementMilestonePayments" abstract="false" name="CollaborativeArrangementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_DateOfAgreement" abstract="false" name="DateOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" abstract="false" name="BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_AgreementExtensionPeriod" abstract="false" name="AgreementExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_NonCashGainOnLitigationSettlement" abstract="false" name="NonCashGainOnLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_DicernaPharmaceuticalsIncMember" abstract="true" name="DicernaPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_DiscoveryPeriodOfProgramsDevelopment" abstract="false" name="DiscoveryPeriodOfProgramsDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" abstract="false" name="ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" abstract="false" name="MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_PotentialProceedsFromCollaborationArrangement" abstract="false" name="PotentialProceedsFromCollaborationArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_OtherCollaborationsMember" abstract="true" name="OtherCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_UpfrontFeeReceived" abstract="false" name="UpfrontFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ExtendedLeaseExpirationDate" abstract="false" name="ExtendedLeaseExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="alny_C5CoCoObligationMember" abstract="true" name="C5CoCoObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" abstract="false" name="ScheduleOfAllocatedTransactionPriceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" abstract="false" name="AmortizationAndInterestAccretionRelatedToOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" abstract="false" name="ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_IncreaseDecreaseInTransactionPrice" abstract="false" name="IncreaseDecreaseInTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_OwnershipPercentageOfSharesOutstanding" abstract="false" name="OwnershipPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_C5LicenseObligationMember" abstract="true" name="C5LicenseObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ExtendedLeaseExpirationMonthAndYear" abstract="false" name="ExtendedLeaseExpirationMonthAndYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearMonthItemType"/>
  <xs:element id="alny_GainLossOnSaleOfCommonStock" abstract="false" name="GainLossOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.alnylam.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESS" roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS">
        <link:definition>2101101 - Disclosure - NATURE OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION">
        <link:definition>2102102 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies">
        <link:definition>2203201 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - Basis of Presentation and Principles of Consolidation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTREVENUESNET" roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNET">
        <link:definition>2105103 - Disclosure - PRODUCT REVENUES, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTREVENUESNETTables" roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNETTables">
        <link:definition>2306301 - Disclosure - PRODUCT REVENUES, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" roleURI="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail">
        <link:definition>2407402 - Disclosure - Product Revenues, Net - Summary of Net Product Revenues Of ONPATTRO (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenuesNetAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail">
        <link:definition>2408403 - Disclosure - Product Revenues, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONAGREEMENTS" roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS">
        <link:definition>2109104 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONAGREEMENTSTables" roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables">
        <link:definition>2310302 - Disclosure - COLLABORATION AGREEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRevenuefromCollaboratorsDetail" roleURI="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail">
        <link:definition>2411404 - Disclosure - Collaboration Agreements - Revenue from Collaborators (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail">
        <link:definition>2412405 - Disclosure - Collaboration Agreements - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail">
        <link:definition>2413406 - Disclosure - Collaboration Agreements - Change in Contract Liability Balance Related to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail">
        <link:definition>2414407 - Disclosure - Collaboration Agreements - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2415408 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails">
        <link:definition>2416409 - Disclosure - Collaboration Agreements - Schedule of Transaction Price Allocated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails">
        <link:definition>2417410 - Disclosure - Collaboration Agreements - Schedule of Revenue Recognized by Accounting Guidance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORY" roleURI="http://www.alnylam.com/role/INVENTORY">
        <link:definition>2118105 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYTables" roleURI="http://www.alnylam.com/role/INVENTORYTables">
        <link:definition>2319303 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetail" roleURI="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail">
        <link:definition>2420411 - Disclosure - Inventory - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2121106 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2322304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" roleURI="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail">
        <link:definition>2423412 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2424413 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIES" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES">
        <link:definition>2125107 - Disclosure - MARKETABLE DEBT SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESTables" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables">
        <link:definition>2326305 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableDebtSecuritiesAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail">
        <link:definition>2427414 - Disclosure - Marketable Debt Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail">
        <link:definition>2428415 - Disclosure - Marketable Debt Securities - Summary of Company's Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail">
        <link:definition>2429416 - Disclosure - Marketable Debt Securities - Summary of Fair Value of Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.alnylam.com/role/LEASES">
        <link:definition>2130108 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.alnylam.com/role/LEASESTables">
        <link:definition>2331306 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2432417 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" roleURI="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail">
        <link:definition>2433418 - Disclosure - Leases - Summary of Costs Included in Operating Expenses Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" roleURI="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail">
        <link:definition>2434419 - Disclosure - Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1" roleURI="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1">
        <link:definition>2434419 - Disclosure - Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" roleURI="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail">
        <link:definition>2435420 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENT" roleURI="http://www.alnylam.com/role/CREDITAGREEMENT">
        <link:definition>2136109 - Disclosure - CREDIT AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditAgreementAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail">
        <link:definition>2437421 - Disclosure - Credit Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITY" roleURI="http://www.alnylam.com/role/EQUITY">
        <link:definition>2138110 - Disclosure - EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/EquityAdditionalInformationDetail">
        <link:definition>2439422 - Disclosure - Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2140111 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2341307 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" roleURI="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARE" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE">
        <link:definition>2143112 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARETables" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables">
        <link:definition>2344308 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" roleURI="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail">
        <link:definition>2445424 - Disclosure - Net Loss Per Common Share - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH">
        <link:definition>2146113 - Disclosure - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables">
        <link:definition>2347309 - Disclosure - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>2448425 - Disclosure - Reconciliation of Cash, Cash Equivalents and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2149114 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2450426 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEFINEDBENEFITPLANS" roleURI="http://www.alnylam.com/role/DEFINEDBENEFITPLANS">
        <link:definition>2151115 - Disclosure - DEFINED BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedBenefitPlansAdditionalInformationDetails" roleURI="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails">
        <link:definition>2452427 - Disclosure - Defined Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>2153116 - Disclosure - OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>2354310 - Disclosure - OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail">
        <link:definition>2455428 - Disclosure - Other Comprehensive Loss and Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>alny-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:5d2595a3-a26b-49fe-8f15-878ed8f526a8,g:8c29cc34-fc93-4a2b-96ed-ef5f86bbe907-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alnylam.com/role/Cover" xlink:type="simple" xlink:href="alny-20190930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2d09ef87-a99e-4f12-8c40-cfebd8cef998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a2be1276-b85d-4af0-b386-50ff9e3b3e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d09ef87-a99e-4f12-8c40-cfebd8cef998" xlink:to="loc_us-gaap_AccountsPayableCurrent_a2be1276-b85d-4af0-b386-50ff9e3b3e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_491e5bbc-ec98-4feb-8342-07c577e8e5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d09ef87-a99e-4f12-8c40-cfebd8cef998" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_491e5bbc-ec98-4feb-8342-07c577e8e5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6028932-2da8-4a77-8133-894756b81563" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d09ef87-a99e-4f12-8c40-cfebd8cef998" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6028932-2da8-4a77-8133-894756b81563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_9170309c-95ae-4c21-b3e9-c799f436bdf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d09ef87-a99e-4f12-8c40-cfebd8cef998" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_9170309c-95ae-4c21-b3e9-c799f436bdf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_48559108-a9e4-4b3c-ba36-421d0fe96cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d09ef87-a99e-4f12-8c40-cfebd8cef998" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_48559108-a9e4-4b3c-ba36-421d0fe96cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd0016b7-a641-4058-baf4-0a3b8847ed0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2a740dd1-82ae-4eaf-acbc-9361e17b2abf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd0016b7-a641-4058-baf4-0a3b8847ed0c" xlink:to="loc_us-gaap_PreferredStockValue_2a740dd1-82ae-4eaf-acbc-9361e17b2abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_43f8c4d1-b9ff-4c77-84d4-71482400dceb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd0016b7-a641-4058-baf4-0a3b8847ed0c" xlink:to="loc_us-gaap_CommonStockValue_43f8c4d1-b9ff-4c77-84d4-71482400dceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_054874a4-775e-4cb7-8f82-bee277834311" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd0016b7-a641-4058-baf4-0a3b8847ed0c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_054874a4-775e-4cb7-8f82-bee277834311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62ea2b84-8db5-4a95-95c5-ca6be2fa964d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd0016b7-a641-4058-baf4-0a3b8847ed0c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62ea2b84-8db5-4a95-95c5-ca6be2fa964d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb3b4f0f-f37a-42da-96b0-843dbf8738b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd0016b7-a641-4058-baf4-0a3b8847ed0c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb3b4f0f-f37a-42da-96b0-843dbf8738b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fb5cb991-26ce-4f8b-9f66-333ec6b7303a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:to="loc_us-gaap_LiabilitiesCurrent_fb5cb991-26ce-4f8b-9f66-333ec6b7303a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4a4dda79-4212-44c1-80e1-8095fe267ead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4a4dda79-4212-44c1-80e1-8095fe267ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_d208ef97-008f-4b5e-88c3-e0f0331c97b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_d208ef97-008f-4b5e-88c3-e0f0331c97b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5ed7c958-0122-4a1f-bb28-b6f9355d563b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5ed7c958-0122-4a1f-bb28-b6f9355d563b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_8704e483-51c4-48bf-b9f2-c41fe4b3c7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:to="loc_us-gaap_SecuredLongTermDebt_8704e483-51c4-48bf-b9f2-c41fe4b3c7f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8cff26ea-b9bf-45a8-b92f-d3b96804532d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fe2ef58a-852f-4c86-b35c-af9dbcc9b8f9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8cff26ea-b9bf-45a8-b92f-d3b96804532d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d71db341-55c7-49e4-8cad-cf7b4e71e359" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2025e0ca-0930-414f-a1af-c1e2895c296b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d71db341-55c7-49e4-8cad-cf7b4e71e359" xlink:to="loc_us-gaap_Liabilities_2025e0ca-0930-414f-a1af-c1e2895c296b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e5ba0f4d-ea34-4ef6-9857-baf46d6b7629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d71db341-55c7-49e4-8cad-cf7b4e71e359" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e5ba0f4d-ea34-4ef6-9857-baf46d6b7629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61298b5f-45bd-4037-a95d-c41a0ba65545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d71db341-55c7-49e4-8cad-cf7b4e71e359" xlink:to="loc_us-gaap_StockholdersEquity_61298b5f-45bd-4037-a95d-c41a0ba65545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_787b342b-2c2e-48af-9f67-1e1d3c2e9aee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15000ed0-180f-420e-8932-8f9f9c9d42e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_787b342b-2c2e-48af-9f67-1e1d3c2e9aee" xlink:to="loc_us-gaap_AssetsCurrent_15000ed0-180f-420e-8932-8f9f9c9d42e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e1a17f07-bf0c-4538-a752-e445fca54ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_787b342b-2c2e-48af-9f67-1e1d3c2e9aee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e1a17f07-bf0c-4538-a752-e445fca54ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0bb86ec3-0e3c-406c-96e6-304bcb30cef2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_787b342b-2c2e-48af-9f67-1e1d3c2e9aee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0bb86ec3-0e3c-406c-96e6-304bcb30cef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_dd4df4dc-2016-4431-aadd-899503ad114d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_787b342b-2c2e-48af-9f67-1e1d3c2e9aee" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_dd4df4dc-2016-4431-aadd-899503ad114d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75dba810-3a01-43e4-bf65-43a8481477a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_787b342b-2c2e-48af-9f67-1e1d3c2e9aee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75dba810-3a01-43e4-bf65-43a8481477a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1ea0b25e-d82c-4993-a6a9-5a48d5786635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2f6234a-053c-49c1-8562-44ceaf6442e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea0b25e-d82c-4993-a6a9-5a48d5786635" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c2f6234a-053c-49c1-8562-44ceaf6442e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_19215ad5-6ee9-4154-b47f-bda1eda3859f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea0b25e-d82c-4993-a6a9-5a48d5786635" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_19215ad5-6ee9-4154-b47f-bda1eda3859f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_61a25892-e2ae-4416-802a-58e826f8183b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea0b25e-d82c-4993-a6a9-5a48d5786635" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_61a25892-e2ae-4416-802a-58e826f8183b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2709ba0c-5013-470f-bff6-7bdd0179e13b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea0b25e-d82c-4993-a6a9-5a48d5786635" xlink:to="loc_us-gaap_InventoryNet_2709ba0c-5013-470f-bff6-7bdd0179e13b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3c61ff62-73dc-4ff5-b575-90bf1bec74c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ea0b25e-d82c-4993-a6a9-5a48d5786635" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3c61ff62-73dc-4ff5-b575-90bf1bec74c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b163a37c-264e-49e4-8cea-13713a2c980a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6360a23f-490a-4469-b3f7-64f2f1534689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b163a37c-264e-49e4-8cea-13713a2c980a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6360a23f-490a-4469-b3f7-64f2f1534689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cc9f3a2f-2005-48a9-abbd-72bcb7185cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b163a37c-264e-49e4-8cea-13713a2c980a" xlink:to="loc_us-gaap_CostsAndExpenses_cc9f3a2f-2005-48a9-abbd-72bcb7185cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d01aedf0-da58-4b58-a43f-a1026354bde8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3de929fc-303b-4031-b917-ce301ef5fff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d01aedf0-da58-4b58-a43f-a1026354bde8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3de929fc-303b-4031-b917-ce301ef5fff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e8994142-2e89-4d8c-af39-65cb27c0d80e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d01aedf0-da58-4b58-a43f-a1026354bde8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e8994142-2e89-4d8c-af39-65cb27c0d80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f3a6c54e-af42-4948-9d99-f85327353f48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d01aedf0-da58-4b58-a43f-a1026354bde8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f3a6c54e-af42-4948-9d99-f85327353f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cf1b9f8-9a36-4490-bce7-abb41939555a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cdfb56ed-c85d-4386-b189-c9f391935048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cf1b9f8-9a36-4490-bce7-abb41939555a" xlink:to="loc_us-gaap_NetIncomeLoss_cdfb56ed-c85d-4386-b189-c9f391935048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_acaeb3fc-228c-4f10-8318-e1376e96a71b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cf1b9f8-9a36-4490-bce7-abb41939555a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_acaeb3fc-228c-4f10-8318-e1376e96a71b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_d8ae6837-d499-47fd-9257-5e75f7195606" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cf1b9f8-9a36-4490-bce7-abb41939555a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_d8ae6837-d499-47fd-9257-5e75f7195606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_4e331aa2-0ca8-4158-8f88-ee49805269c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1cf1b9f8-9a36-4490-bce7-abb41939555a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_4e331aa2-0ca8-4158-8f88-ee49805269c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1054548-84b7-4abc-a195-f583e8cb751a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a79163d2-b55e-4d3c-a85e-a3e94eb03505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1054548-84b7-4abc-a195-f583e8cb751a" xlink:to="loc_us-gaap_OperatingIncomeLoss_a79163d2-b55e-4d3c-a85e-a3e94eb03505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13583d86-986b-47de-bb35-d21d1a65eb91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1054548-84b7-4abc-a195-f583e8cb751a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13583d86-986b-47de-bb35-d21d1a65eb91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff322e8b-c3fc-4a67-a7bd-15cf63720b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71f794b8-1359-440f-9258-be50ddbba06a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ff322e8b-c3fc-4a67-a7bd-15cf63720b7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71f794b8-1359-440f-9258-be50ddbba06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a6b19a9-ebb3-4f5f-b9c3-feaaa9f0d963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ff322e8b-c3fc-4a67-a7bd-15cf63720b7f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4a6b19a9-ebb3-4f5f-b9c3-feaaa9f0d963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_237f0794-32b2-40f6-93ac-578476cf62a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_eb694079-575a-4561-ab15-ceb09412add5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_237f0794-32b2-40f6-93ac-578476cf62a8" xlink:to="loc_us-gaap_InvestmentIncomeNet_eb694079-575a-4561-ab15-ceb09412add5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4971c3c2-7379-40ce-9ba7-beb06a7bf708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_237f0794-32b2-40f6-93ac-578476cf62a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4971c3c2-7379-40ce-9ba7-beb06a7bf708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_3a165746-f88a-402a-b3b8-301dc978d591" xlink:href="alny-20190930.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_237f0794-32b2-40f6-93ac-578476cf62a8" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_3a165746-f88a-402a-b3b8-301dc978d591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f7df1e84-d83f-4ce7-b53c-b36edff80672" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_237f0794-32b2-40f6-93ac-578476cf62a8" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f7df1e84-d83f-4ce7-b53c-b36edff80672" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1fa6a27-d19b-4d64-9552-a34c2bdabb40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3093b926-755e-4ff5-8736-6a4e7d87c30a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1fa6a27-d19b-4d64-9552-a34c2bdabb40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3093b926-755e-4ff5-8736-6a4e7d87c30a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2121c507-ab03-4ac4-83ec-f47c46aba402" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1fa6a27-d19b-4d64-9552-a34c2bdabb40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2121c507-ab03-4ac4-83ec-f47c46aba402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2cf4dadc-5084-4ce2-a2bf-f011b55b1f16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1fa6a27-d19b-4d64-9552-a34c2bdabb40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2cf4dadc-5084-4ce2-a2bf-f011b55b1f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_524000bc-a570-4759-98d5-0bc453de5793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1fa6a27-d19b-4d64-9552-a34c2bdabb40" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_524000bc-a570-4759-98d5-0bc453de5793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_117cc5b4-469b-47a0-b4c9-04af0ffbf59b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_617d31f3-0069-49a7-85b0-48e710907500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_117cc5b4-469b-47a0-b4c9-04af0ffbf59b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_617d31f3-0069-49a7-85b0-48e710907500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6f0d94a-652d-4b94-82a3-28c408832991" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_117cc5b4-469b-47a0-b4c9-04af0ffbf59b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6f0d94a-652d-4b94-82a3-28c408832991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ad68f376-3931-4ae2-8f77-e8be1bb7f47e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_117cc5b4-469b-47a0-b4c9-04af0ffbf59b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ad68f376-3931-4ae2-8f77-e8be1bb7f47e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7c55a311-3e49-49e7-8b97-0998adf4a2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_117cc5b4-469b-47a0-b4c9-04af0ffbf59b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7c55a311-3e49-49e7-8b97-0998adf4a2ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_864e4430-3838-402d-ab6d-32ce79aaf7f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_981124b7-e65d-4b5e-bdb7-2355d67e4c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_864e4430-3838-402d-ab6d-32ce79aaf7f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_981124b7-e65d-4b5e-bdb7-2355d67e4c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_52927f56-0423-48b0-883a-5ca450aebf07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_864e4430-3838-402d-ab6d-32ce79aaf7f2" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_52927f56-0423-48b0-883a-5ca450aebf07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_84b91681-9a53-4ee3-93f5-5cff366e6dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_864e4430-3838-402d-ab6d-32ce79aaf7f2" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_84b91681-9a53-4ee3-93f5-5cff366e6dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8e42bb2e-8402-4163-965e-2f961bf68908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_864e4430-3838-402d-ab6d-32ce79aaf7f2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8e42bb2e-8402-4163-965e-2f961bf68908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_0874ed6c-3950-4cb8-997a-7851966c4965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_864e4430-3838-402d-ab6d-32ce79aaf7f2" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_0874ed6c-3950-4cb8-997a-7851966c4965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e963a1d4-8394-44d7-bffe-9c8729d0bcad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_ProfitLoss_e963a1d4-8394-44d7-bffe-9c8729d0bcad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_8538cd60-0691-4b6b-815e-4ad0a39013df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_8538cd60-0691-4b6b-815e-4ad0a39013df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9fddb416-11bc-4090-b2a8-aa39007d3e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_ShareBasedCompensation_9fddb416-11bc-4090-b2a8-aa39007d3e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashGainOnLitigationSettlement_ee9dfc69-fbde-4ebf-98c3-2e3a77805e80" xlink:href="alny-20190930.xsd#alny_NonCashGainOnLitigationSettlement"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_alny_NonCashGainOnLitigationSettlement_ee9dfc69-fbde-4ebf-98c3-2e3a77805e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_16e97e2d-f6f9-4c49-b73a-30776b395de5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_16e97e2d-f6f9-4c49-b73a-30776b395de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_05ebf022-bde3-460c-a5da-1fa6eb46e613" xlink:href="alny-20190930.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_05ebf022-bde3-460c-a5da-1fa6eb46e613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_367b2e71-ff36-4995-8850-7808b03cf0db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_367b2e71-ff36-4995-8850-7808b03cf0db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b92088f3-d422-4044-8e76-c73376b9ef51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b92088f3-d422-4044-8e76-c73376b9ef51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_93f51faf-ced9-490e-b7a5-8c93ab29c0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_93f51faf-ced9-490e-b7a5-8c93ab29c0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_84f609d3-0ada-49f6-8deb-17c4ef6754a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_84f609d3-0ada-49f6-8deb-17c4ef6754a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50d6fa20-5d33-47f9-9c77-e0d4994c12a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50d6fa20-5d33-47f9-9c77-e0d4994c12a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_045aecf8-ecba-48d0-9366-24453f4434f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_045aecf8-ecba-48d0-9366-24453f4434f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_09823df6-bd05-4f1c-ae5f-b477ce9cf147" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_09823df6-bd05-4f1c-ae5f-b477ce9cf147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f032a3ba-cce7-4277-a858-9ad1cd623b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f032a3ba-cce7-4277-a858-9ad1cd623b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_662bfd29-5ed6-46f9-8a5c-069888836b68" xlink:href="alny-20190930.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ed9349d-9c99-49ba-b7cd-e5ecd3511e4e" xlink:to="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_662bfd29-5ed6-46f9-8a5c-069888836b68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20190930.xsd#NATUREOFBUSINESS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20190930.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20190930.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNET" xlink:type="simple" xlink:href="alny-20190930.xsd#PRODUCTREVENUESNET"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/PRODUCTREVENUESNET" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNETTables" xlink:type="simple" xlink:href="alny-20190930.xsd#PRODUCTREVENUESNETTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/PRODUCTREVENUESNETTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ProductRevenuesNetAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS" xlink:type="simple" xlink:href="alny-20190930.xsd#COLLABORATIONAGREEMENTS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#COLLABORATIONAGREEMENTSTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsRevenuefromCollaboratorsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_db0ab0f0-1c0b-46e5-9598-66fb5522d40a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c4150665-0280-4f13-a457-4b8dd7f34b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_db0ab0f0-1c0b-46e5-9598-66fb5522d40a" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c4150665-0280-4f13-a457-4b8dd7f34b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9abd6008-9649-4b8f-8c9f-24318e8b29a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_db0ab0f0-1c0b-46e5-9598-66fb5522d40a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9abd6008-9649-4b8f-8c9f-24318e8b29a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/INVENTORY" xlink:type="simple" xlink:href="alny-20190930.xsd#INVENTORY"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/INVENTORY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/INVENTORYTables" xlink:type="simple" xlink:href="alny-20190930.xsd#INVENTORYTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/INVENTORYTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#InventoryScheduleofInventoryDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_51ecdc26-7fed-4f7e-8e8a-c64bcb736164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_72e23fd6-3964-497d-9367-34983d13202c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_51ecdc26-7fed-4f7e-8e8a-c64bcb736164" xlink:to="loc_us-gaap_InventoryRawMaterials_72e23fd6-3964-497d-9367-34983d13202c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5110f6cc-7486-42b0-b718-97bf11261ece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_51ecdc26-7fed-4f7e-8e8a-c64bcb736164" xlink:to="loc_us-gaap_InventoryWorkInProcess_5110f6cc-7486-42b0-b718-97bf11261ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_6121911b-b76c-452d-af94-c479b6193feb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_51ecdc26-7fed-4f7e-8e8a-c64bcb736164" xlink:to="loc_us-gaap_InventoryFinishedGoods_6121911b-b76c-452d-af94-c479b6193feb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20190930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_103901f4-b2a6-446f-a2bd-f46ed4c6f136" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4ea843a9-c6ae-4df9-84f9-87618db76573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_103901f4-b2a6-446f-a2bd-f46ed4c6f136" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4ea843a9-c6ae-4df9-84f9-87618db76573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_674148e0-fe1f-465f-b35b-f4a9a6019b58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_103901f4-b2a6-446f-a2bd-f46ed4c6f136" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_674148e0-fe1f-465f-b35b-f4a9a6019b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5f7c9101-9d60-4222-8960-5b355b68a9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_103901f4-b2a6-446f-a2bd-f46ed4c6f136" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5f7c9101-9d60-4222-8960-5b355b68a9bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_74464f1f-cc1e-4496-957e-4720fec411e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_103901f4-b2a6-446f-a2bd-f46ed4c6f136" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_74464f1f-cc1e-4496-957e-4720fec411e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20190930.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20190930.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58a7c140-678c-4e5a-88fe-aa7dadfd4a10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ddd96968-84e0-4b19-a621-e82ef357e016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58a7c140-678c-4e5a-88fe-aa7dadfd4a10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ddd96968-84e0-4b19-a621-e82ef357e016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f066f1d8-9bf7-4cfc-97f3-d231e7f5bdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58a7c140-678c-4e5a-88fe-aa7dadfd4a10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f066f1d8-9bf7-4cfc-97f3-d231e7f5bdbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e19fea5-17ee-4316-996e-f12b7a27438e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_58a7c140-678c-4e5a-88fe-aa7dadfd4a10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e19fea5-17ee-4316-996e-f12b7a27438e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dff3bf2b-2f26-4969-a36c-6804075552eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2a653fb3-edbf-459c-9157-f63a2bdc9136" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dff3bf2b-2f26-4969-a36c-6804075552eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2a653fb3-edbf-459c-9157-f63a2bdc9136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_50389eec-88e2-4d8e-a36e-39dd4e662d98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dff3bf2b-2f26-4969-a36c-6804075552eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_50389eec-88e2-4d8e-a36e-39dd4e662d98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LEASES" xlink:type="simple" xlink:href="alny-20190930.xsd#LEASES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LEASES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LEASESTables" xlink:type="simple" xlink:href="alny-20190930.xsd#LEASESTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LEASESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LeasesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e040f637-13c1-45a4-b094-d67e83e45401" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c84a28db-47da-40a0-92e6-6b0772434afa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_e040f637-13c1-45a4-b094-d67e83e45401" xlink:to="loc_us-gaap_OperatingLeaseCost_c84a28db-47da-40a0-92e6-6b0772434afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ff608f9f-5183-47e8-ab9b-436826fa5413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_e040f637-13c1-45a4-b094-d67e83e45401" xlink:to="loc_us-gaap_VariableLeaseCost_ff608f9f-5183-47e8-ab9b-436826fa5413" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5b248833-8c07-4de1-9604-2534c90ffaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_efd30e68-7e86-4d4d-89c7-3bfb2386d9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5b248833-8c07-4de1-9604-2534c90ffaf2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_efd30e68-7e86-4d4d-89c7-3bfb2386d9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_836d3a74-fd86-4b71-bae2-d9197abcc4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5b248833-8c07-4de1-9604-2534c90ffaf2" xlink:to="loc_us-gaap_OperatingLeaseLiability_836d3a74-fd86-4b71-bae2-d9197abcc4f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3676031b-bafc-4c2e-b717-aa0c0c86e2be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0503c4d3-5863-41e4-a53f-cd53675ca1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3676031b-bafc-4c2e-b717-aa0c0c86e2be" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0503c4d3-5863-41e4-a53f-cd53675ca1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbbe90ba-35ec-4008-940d-0a724556b3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3676031b-bafc-4c2e-b717-aa0c0c86e2be" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbbe90ba-35ec-4008-940d-0a724556b3a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_66549e47-d1ec-4936-9949-41ecc1c7f7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_66549e47-d1ec-4936-9949-41ecc1c7f7f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c767b162-04f4-40ce-99d3-0d20b7556945" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c767b162-04f4-40ce-99d3-0d20b7556945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a088d7e-fb64-4181-80cc-ae93ef273899" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a088d7e-fb64-4181-80cc-ae93ef273899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc2ac40d-1109-4ff6-9558-35da37d3b51c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cc2ac40d-1109-4ff6-9558-35da37d3b51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_838940a2-e27f-4948-aa1c-b413e3ce76b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_838940a2-e27f-4948-aa1c-b413e3ce76b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_8efa11bf-3024-4028-99c6-05c3726d8c44" xlink:href="alny-20190930.xsd#alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_8efa11bf-3024-4028-99c6-05c3726d8c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_b98c08b3-6e06-4256-aac2-9b1a1d023ebe" xlink:href="alny-20190930.xsd#alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9bf64b43-8ab4-4dc2-8a1a-9fc4e4f2ae1a" xlink:to="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_b98c08b3-6e06-4256-aac2-9b1a1d023ebe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_ea5eae87-17fb-4893-a2b2-060413111e07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_ea5eae87-17fb-4893-a2b2-060413111e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2fc99366-5cb8-4c26-9679-c67defa4a096" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2fc99366-5cb8-4c26-9679-c67defa4a096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0e8f0aa7-bde0-4035-a1a9-3e315b0ad89e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0e8f0aa7-bde0-4035-a1a9-3e315b0ad89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6760aa2c-19b5-4761-b58e-dabf5d1a9b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6760aa2c-19b5-4761-b58e-dabf5d1a9b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_af789c80-e13b-4494-b8df-28b121314fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_af789c80-e13b-4494-b8df-28b121314fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_9836c5e2-a0c9-43c6-a12c-4f6cef472069" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0705ed23-d130-4ab7-8bbb-357b251defb0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_9836c5e2-a0c9-43c6-a12c-4f6cef472069" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="alny-20190930.xsd#CREDITAGREEMENT"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CreditAgreementAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/EQUITY" xlink:type="simple" xlink:href="alny-20190930.xsd#EQUITY"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/EQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/EquityAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#EquityAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/EquityAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20190930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20190930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20190930.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20190930.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" xlink:type="simple" xlink:href="alny-20190930.xsd#RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" xlink:type="simple" xlink:href="alny-20190930.xsd#RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c36095b3-6f6e-47c0-b1cf-7ca640051d75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_976e9ed0-41e0-4870-ba3b-da216e668e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c36095b3-6f6e-47c0-b1cf-7ca640051d75" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_976e9ed0-41e0-4870-ba3b-da216e668e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_05c8483e-26ac-4723-94cf-d6880298519d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c36095b3-6f6e-47c0-b1cf-7ca640051d75" xlink:to="loc_us-gaap_RestrictedCashCurrent_05c8483e-26ac-4723-94cf-d6880298519d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e5174d8c-0bf6-4141-95a7-8df1a4646f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c36095b3-6f6e-47c0-b1cf-7ca640051d75" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e5174d8c-0bf6-4141-95a7-8df1a4646f2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20190930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEFINEDBENEFITPLANS" xlink:type="simple" xlink:href="alny-20190930.xsd#DEFINEDBENEFITPLANS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/DEFINEDBENEFITPLANS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#DefinedBenefitPlansAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20190930.xsd#OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>alny-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:5d2595a3-a26b-49fe-8f15-878ed8f526a8,g:8c29cc34-fc93-4a2b-96ed-ef5f86bbe907-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/Cover" xlink:type="simple" xlink:href="alny-20190930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/Cover" xlink:type="extended" id="ie1ee04abc9354cf19af3ec298a987eb3_59863d0a-a844-4e61-9e99-f9ed14190cd6"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i237430dd416847c482cecd1ed2712749_54778948-612d-417b-a486-10468734f17a"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i8af461c6ad5d48ab9ae9f596a2eefbf3_48b5ff89-6ed0-4f7f-b64c-a5805e35f642"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended" id="ifad1c47157a749c898992d122c5dfe86_1f2a09f5-a5e0-4668-9b45-a9a0eae07569">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f67cbac5-db01-4d77-880b-c06eb0ffd022" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_RevenuesAbstract_f67cbac5-db01-4d77-880b-c06eb0ffd022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0506d9f9-5a6e-4a45-b5ad-01afc67adc77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f67cbac5-db01-4d77-880b-c06eb0ffd022" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0506d9f9-5a6e-4a45-b5ad-01afc67adc77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_54bf4aa5-79d3-42ce-a594-efb7406ce495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_54bf4aa5-79d3-42ce-a594-efb7406ce495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b4f48ced-b251-4560-b342-a0063aa83932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b4f48ced-b251-4560-b342-a0063aa83932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3095f4af-ea9e-4e3f-bb5b-a3079878eab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3095f4af-ea9e-4e3f-bb5b-a3079878eab2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f0f0f870-0ea9-435d-b251-e74851c3c137" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_CostsAndExpenses_f0f0f870-0ea9-435d-b251-e74851c3c137" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b2851ba2-1abc-41fd-b8b7-850330bbdaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_OperatingIncomeLoss_b2851ba2-1abc-41fd-b8b7-850330bbdaf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7a888bfa-1da6-443d-9155-bc8099728ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_InvestmentIncomeNet_7a888bfa-1da6-443d-9155-bc8099728ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6c0c97ef-80f1-456d-be94-7f4f44c1fc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6c0c97ef-80f1-456d-be94-7f4f44c1fc1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_43919d33-e9cb-467d-bc44-9d90af097497" xlink:href="alny-20190930.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_43919d33-e9cb-467d-bc44-9d90af097497" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c6eb7e69-9a4c-4f94-9e54-7a7dc528ab6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c6eb7e69-9a4c-4f94-9e54-7a7dc528ab6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d49237b5-7a55-4bfb-a7d2-6c6846c99654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d49237b5-7a55-4bfb-a7d2-6c6846c99654" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1339d396-da2a-4d9c-9636-daf183a9dd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1339d396-da2a-4d9c-9636-daf183a9dd1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9a804b22-6cf7-491a-aad0-8fd3758ef9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9a804b22-6cf7-491a-aad0-8fd3758ef9ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b796883f-a9e6-47ca-9054-7b4e1e9ec3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_NetIncomeLoss_b796883f-a9e6-47ca-9054-7b4e1e9ec3e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2dddbc16-5e99-46bf-a379-e7183de94872" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2dddbc16-5e99-46bf-a379-e7183de94872" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_472dd9a8-d04a-4591-9842-792db66a822f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_472dd9a8-d04a-4591-9842-792db66a822f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea0f3b23-3de4-40a3-b56a-f3ba175ddf8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ffc56d5-73c0-452c-993e-0c1191cb1fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ffc56d5-73c0-452c-993e-0c1191cb1fdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3827c6cc-1ba5-44fb-bf98-64b7d46047fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3827c6cc-1ba5-44fb-bf98-64b7d46047fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1b721afe-1622-49e2-a05f-1ae6f6ed7f35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1b721afe-1622-49e2-a05f-1ae6f6ed7f35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_aa4fc025-0f1f-4fc4-ab05-09f184390492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_aa4fc025-0f1f-4fc4-ab05-09f184390492" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:to="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59714f2d-251a-40a9-b30d-458125f6a7f4_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:to="loc_srt_ProductsAndServicesDomain_59714f2d-251a-40a9-b30d-458125f6a7f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fbce21b-55f0-4b56-810c-ae00014a73a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:to="loc_srt_ProductsAndServicesDomain_4fbce21b-55f0-4b56-810c-ae00014a73a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fd899c0c-5d2c-42d6-b2d2-dac10831d280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4fbce21b-55f0-4b56-810c-ae00014a73a7" xlink:to="loc_us-gaap_ProductMember_fd899c0c-5d2c-42d6-b2d2-dac10831d280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f72ff703-12f2-4049-91f4-ff9217a0c384_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f72ff703-12f2-4049-91f4-ff9217a0c384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a024a925-1915-44b5-8344-55c1b3c680a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a024a925-1915-44b5-8344-55c1b3c680a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e1d80e97-6cc7-4952-a36c-d007dbb1baf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a024a925-1915-44b5-8344-55c1b3c680a2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e1d80e97-6cc7-4952-a36c-d007dbb1baf6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i23fdef4759b94e8f9077683e101e3cc4_0be54f44-6861-4c36-a7cb-b83459ea1df1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5903bbee-8950-42cd-92f1-d568831e09ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5903bbee-8950-42cd-92f1-d568831e09ab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fb942bb-31c3-45f2-9c02-39038a76fa6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockholdersEquity_9fb942bb-31c3-45f2-9c02-39038a76fa6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7c8594e4-8b01-483d-8da8-6274acfa9862" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7c8594e4-8b01-483d-8da8-6274acfa9862" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_fe8c82df-e768-4a0a-81fc-cbc97631c965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_fe8c82df-e768-4a0a-81fc-cbc97631c965" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3b1477fe-c278-47f0-bfb2-4c601dabcf13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3b1477fe-c278-47f0-bfb2-4c601dabcf13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9872c9c-2eab-4c6c-8c0e-42575c1f40f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9872c9c-2eab-4c6c-8c0e-42575c1f40f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_e7bf528c-8012-4701-bf23-52a4bb609c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_e7bf528c-8012-4701-bf23-52a4bb609c7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_0074d393-b870-446c-81fd-7bcbcfd396b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_0074d393-b870-446c-81fd-7bcbcfd396b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_22ee4266-039a-4deb-b726-f1a81c365e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_22ee4266-039a-4deb-b726-f1a81c365e20" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_471aaef8-c59b-416a-b02f-8d0705be8a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_471aaef8-c59b-416a-b02f-8d0705be8a4d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_383af93e-8428-456f-95c9-a5744a428054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_383af93e-8428-456f-95c9-a5744a428054" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a502e68-de55-43ac-965e-6eda2cb7f15b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a502e68-de55-43ac-965e-6eda2cb7f15b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_734a4a52-a03b-44da-9154-f8ac008ae9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_734a4a52-a03b-44da-9154-f8ac008ae9d6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_efb61729-1232-401c-931d-fa53e6b1195a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_efb61729-1232-401c-931d-fa53e6b1195a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e6da01d-2832-4301-8992-8b7ce44d6c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_NetIncomeLoss_0e6da01d-2832-4301-8992-8b7ce44d6c84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ce6e3bc1-6095-4ad3-b534-38da1ef6da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_837600cc-8a96-4b1a-8f0d-18cdcbc6ac3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5903bbee-8950-42cd-92f1-d568831e09ab" xlink:to="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c01c11a4-e35a-4439-8216-33929cdf0a5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:to="loc_us-gaap_EquityComponentDomain_c01c11a4-e35a-4439-8216-33929cdf0a5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:to="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_56b18a11-e773-435e-86e7-05d86329fb65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_CommonStockMember_56b18a11-e773-435e-86e7-05d86329fb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee3a45b1-c2d5-412d-8b1f-4cf0d464978f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee3a45b1-c2d5-412d-8b1f-4cf0d464978f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_be742780-1465-40c9-8725-dcd816b9ad54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_be742780-1465-40c9-8725-dcd816b9ad54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40b4ae6b-c1f5-4677-ae0f-4b392ff6ec61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_RetainedEarningsMember_40b4ae6b-c1f5-4677-ae0f-4b392ff6ec61" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ic8816bd6d6c54ad78c3d9406200f0d7d_ea09592a-7e0d-4b69-ad03-9d36ce1050c7"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20190930.xsd#NATUREOFBUSINESS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended" id="i69a848f36d104857910ed808d291a250_c8e3bc4d-570b-4b82-8bb9-966184fbf294"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20190930.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended" id="i58a4376c4d654822aee645764a792bbe_48951efb-d1a9-48df-bdaa-5f1d31fccc40"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20190930.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended" id="i2377db793cae4db6a50991b529ac849d_63a8e12e-fa0f-4a6c-9587-7a4630482ac0"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" xlink:type="extended" id="i111b0118d409406c9e0cdc032ff3d79a_2c8341b0-4f08-4ae9-8971-dd67344a8ab0"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNET" xlink:type="simple" xlink:href="alny-20190930.xsd#PRODUCTREVENUESNET"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/PRODUCTREVENUESNET" xlink:type="extended" id="i4795334fd01d4f54a3922b3257bee6d8_b22de6d0-d384-4488-8c37-8612d18b08d6"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNETTables" xlink:type="simple" xlink:href="alny-20190930.xsd#PRODUCTREVENUESNETTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/PRODUCTREVENUESNETTables" xlink:type="extended" id="iba7466baa3cd4942b88c6eaf9769fe8a_91920951-db54-4db3-aa0f-7a821739287a"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" xlink:type="extended" id="i176f6bec56194d2cba4b163f77f96e3b_58ed49e3-a416-4975-8cc4-43ab155c57c0">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fabe1e0f-3b2a-42c4-babd-98aeea820b94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45d87c8c-b9ec-4e59-a9b7-3703304e1074" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fabe1e0f-3b2a-42c4-babd-98aeea820b94" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45d87c8c-b9ec-4e59-a9b7-3703304e1074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fabe1e0f-3b2a-42c4-babd-98aeea820b94" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:to="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d5089be-ae6a-49b4-822e-b404f33bd727_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:to="loc_srt_ProductsAndServicesDomain_0d5089be-ae6a-49b4-822e-b404f33bd727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6efcfd94-3700-4843-bec2-7c79ec13b792" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:to="loc_srt_ProductsAndServicesDomain_6efcfd94-3700-4843-bec2-7c79ec13b792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_238c63dc-6e76-4217-a882-a0f4ad194917" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6efcfd94-3700-4843-bec2-7c79ec13b792" xlink:to="loc_us-gaap_ProductMember_238c63dc-6e76-4217-a882-a0f4ad194917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:to="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_aae407fd-53cc-43eb-8d74-09ec6491e337_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:to="loc_srt_SegmentGeographicalDomain_aae407fd-53cc-43eb-8d74-09ec6491e337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:to="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4f323873-d098-4b58-9bc9-c42a3532eb00" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:to="loc_country_US_4f323873-d098-4b58-9bc9-c42a3532eb00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_53ccd722-ebba-418a-b27b-a8796f02b3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:to="loc_us-gaap_NonUsMember_53ccd722-ebba-418a-b27b-a8796f02b3b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ProductRevenuesNetAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail" xlink:type="extended" id="i29d8b2f66a634b999acf0a2bed83f09b_e534f37d-8988-4d8e-a914-143382a5a3e2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_39bb9f28-1452-4b5c-b08e-98e5b5990cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8bbe1de4-d83a-42ac-9082-d9d80075e1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39bb9f28-1452-4b5c-b08e-98e5b5990cb6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8bbe1de4-d83a-42ac-9082-d9d80075e1aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39bb9f28-1452-4b5c-b08e-98e5b5990cb6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:to="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79690e33-c47b-42b4-bc04-f4988c631d40_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:to="loc_srt_ProductsAndServicesDomain_79690e33-c47b-42b4-bc04-f4988c631d40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3fc8dfd9-3e5f-4581-b030-d77f34ab0b34" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:to="loc_srt_ProductsAndServicesDomain_3fc8dfd9-3e5f-4581-b030-d77f34ab0b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_79185054-efc8-489e-a194-d075b4fbab03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fc8dfd9-3e5f-4581-b030-d77f34ab0b34" xlink:to="loc_us-gaap_ProductMember_79185054-efc8-489e-a194-d075b4fbab03" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS" xlink:type="simple" xlink:href="alny-20190930.xsd#COLLABORATIONAGREEMENTS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS" xlink:type="extended" id="i751657516a44440183f511505ad0ce6b_426f0ec7-f8b5-4d77-b8cb-67ffe06b6e13"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#COLLABORATIONAGREEMENTSTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables" xlink:type="extended" id="icce8960c335842bd9de4fcbf8f861d84_d7063423-8654-47df-af35-3de818071c93"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsRevenuefromCollaboratorsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail" xlink:type="extended" id="i8339d28b96e9438fb48efac00869ecc4_eb35104d-e089-4ce4-ac10-93117d2d9fb5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c9c6ac57-35d1-45d2-8c6a-8b8526ca96a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c9c6ac57-35d1-45d2-8c6a-8b8526ca96a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b2ce198-70f8-4950-8b54-182b1ed9df71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b2ce198-70f8-4950-8b54-182b1ed9df71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_3e033c51-2d0d-43b9-b03c-497bf4d96bee" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_alny_TransactionPrice_3e033c51-2d0d-43b9-b03c-497bf4d96bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2eff48ec-7216-4691-84b2-03a8fe6c1473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2eff48ec-7216-4691-84b2-03a8fe6c1473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_20ff4a70-3af2-4af4-b8df-472eb289e568" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_Revenues_20ff4a70-3af2-4af4-b8df-472eb289e568" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5beb7de4-4469-4ec5-b719-5fc3036a1293_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5beb7de4-4469-4ec5-b719-5fc3036a1293_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_58cf66fa-d440-468b-83fb-fb7749b2f08c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_58cf66fa-d440-468b-83fb-fb7749b2f08c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_d5341f23-d0f1-4a27-8a36-18fadf0473eb" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:to="loc_alny_GlobalStrategicCollaborationMember_d5341f23-d0f1-4a27-8a36-18fadf0473eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc26e0f7-1471-4255-8785-5be6e1567871_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fc26e0f7-1471-4255-8785-5be6e1567871_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_35af6b0d-bc8c-489b-b059-5cec2d265747" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_SanofiGenzymeMember_35af6b0d-bc8c-489b-b059-5cec2d265747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_03069cac-2dc9-4f95-9035-f52790ddf975" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_VirBiotechnologyIncMember_03069cac-2dc9-4f95-9035-f52790ddf975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MdcoMember_a92e731a-86d4-49a1-b200-219a730aceb4" xlink:href="alny-20190930.xsd#alny_MdcoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_MdcoMember_a92e731a-86d4-49a1-b200-219a730aceb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_de98ece8-6672-4a67-bcaf-abdac84522cd" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_de98ece8-6672-4a67-bcaf-abdac84522cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_84b349f2-05e5-4732-8cee-7e8186048a84" xlink:href="alny-20190930.xsd#alny_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_OtherCollaborationsMember_84b349f2-05e5-4732-8cee-7e8186048a84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4f5a70c-a05c-43d5-884a-b546fe6fb672_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:to="loc_srt_ProductsAndServicesDomain_a4f5a70c-a05c-43d5-884a-b546fe6fb672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:to="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_b5bf113e-3dae-4aad-9637-a900d2fe0d3f" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:to="loc_alny_ResearchServicesObligationMember_b5bf113e-3dae-4aad-9637-a900d2fe0d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_f08e8b33-bc23-41c1-a6a6-19c2dc17b8c2" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:to="loc_alny_C5LicenseObligationMember_f08e8b33-bc23-41c1-a6a6-19c2dc17b8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_3c55d172-bfec-4273-8358-578fc7ad5a5b" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:to="loc_alny_C5CoCoObligationMember_3c55d172-bfec-4273-8358-578fc7ad5a5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_773d2007-14e7-4277-b026-698d3f855243_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:to="loc_dei_EntityDomain_773d2007-14e7-4277-b026-698d3f855243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd06af7d-a80e-4d96-8b41-492b226b9913" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:to="loc_dei_EntityDomain_bd06af7d-a80e-4d96-8b41-492b226b9913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_19ce5fe0-0558-447d-bc67-a35a2797c191" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd06af7d-a80e-4d96-8b41-492b226b9913" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_19ce5fe0-0558-447d-bc67-a35a2797c191" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended" id="ifac9d08c04394ce89bb1a92e41761a04_3d38cc4d-3ab5-43a6-af4a-c72500093089"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" xlink:type="extended" id="if1df3a2723cb44e0a999f241aed3544a_4442b803-0d45-4d32-8d03-3676aa5fecf4"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended" id="ia17a512ae2574ed8a5ff2dd7e45a9a8e_84df1540-4e04-48dd-aa7a-690473c85b1d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2ac14491-2e45-4c4f-87be-911ee15203d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5c6046a8-8690-4ca5-8067-bdfebf0d1f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2ac14491-2e45-4c4f-87be-911ee15203d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5c6046a8-8690-4ca5-8067-bdfebf0d1f88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2ac14491-2e45-4c4f-87be-911ee15203d6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7b3db74f-1813-4a70-ae8b-94a9661f1e28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7b3db74f-1813-4a70-ae8b-94a9661f1e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember_7ac4f1f7-9067-44d7-b70e-1cc579b26985" xlink:href="alny-20190930.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:to="loc_alny_ClinicalTrialAndManufacturingMember_7ac4f1f7-9067-44d7-b70e-1cc579b26985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember_85588ffb-2a73-48a6-aaaf-28272b59118c" xlink:href="alny-20190930.xsd#alny_ExternalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:to="loc_alny_ExternalServicesMember_85588ffb-2a73-48a6-aaaf-28272b59118c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember_5d6bb327-426d-41de-8131-7c07ddb5c4bc" xlink:href="alny-20190930.xsd#alny_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:to="loc_alny_OtherMember_5d6bb327-426d-41de-8131-7c07ddb5c4bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:to="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba2b750c-9666-4e9a-953e-0219a0fcb393_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba2b750c-9666-4e9a-953e-0219a0fcb393_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_d41637db-1ca8-4f32-81cf-8ddf25a2fe83" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_SanofiGenzymeMember_d41637db-1ca8-4f32-81cf-8ddf25a2fe83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MdcoMember_6a16ca39-febf-4355-ad1f-51b583f9c92a" xlink:href="alny-20190930.xsd#alny_MdcoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_MdcoMember_6a16ca39-febf-4355-ad1f-51b583f9c92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_9916a397-bb2d-487f-bbec-482628ad5067" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_VirBiotechnologyIncMember_9916a397-bb2d-487f-bbec-482628ad5067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_4c78e5ab-07bf-4779-9d41-8b37340dc680" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_4c78e5ab-07bf-4779-9d41-8b37340dc680" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="i395519f0928448d4bd6c0201149819da_195ab319-4f57-4d18-826b-3960f4ead0d2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ff155e0-8878-4f4c-8c31-1393e41e5795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ff155e0-8878-4f4c-8c31-1393e41e5795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9be4d6c9-0ffa-44dc-801a-2962d663c63d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9be4d6c9-0ffa-44dc-801a-2962d663c63d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_189f9b06-ad11-4f3e-b175-974d5f592da5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_189f9b06-ad11-4f3e-b175-974d5f592da5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment_54454b2f-2bf7-4a51-a36e-47929317e70b" xlink:href="alny-20190930.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_DiscoveryPeriodOfProgramsDevelopment_54454b2f-2bf7-4a51-a36e-47929317e70b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_749667d0-fe2f-48aa-9b25-308166e00f8e" xlink:href="alny-20190930.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_749667d0-fe2f-48aa-9b25-308166e00f8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee_bd002a7f-fba3-4324-89e2-d688c3c9159e" xlink:href="alny-20190930.xsd#alny_ResearchTermExtensionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_ResearchTermExtensionFee_bd002a7f-fba3-4324-89e2-d688c3c9159e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_9f961ee8-e0b1-442d-ad9d-7000e374db99" xlink:href="alny-20190930.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_9f961ee8-e0b1-442d-ad9d-7000e374db99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_3e5eacde-e479-4984-8bea-db9272dc4ba5" xlink:href="alny-20190930.xsd#alny_UpfrontFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_UpfrontFeeReceived_3e5eacde-e479-4984-8bea-db9272dc4ba5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_d4b6cd39-ea2d-4672-bdc1-3309dca775c3" xlink:href="alny-20190930.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_d4b6cd39-ea2d-4672-bdc1-3309dca775c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms_4130f433-f64c-469e-8612-4273ed440a3a" xlink:href="alny-20190930.xsd#alny_NumberOfTargetedPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_NumberOfTargetedPrograms_4130f433-f64c-469e-8612-4273ed440a3a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement_08681a3c-e85c-42b2-a8b6-b5c3920b55af" xlink:href="alny-20190930.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_PotentialProceedsFromCollaborationArrangement_08681a3c-e85c-42b2-a8b6-b5c3920b55af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments_76f6d2f5-d485-4b97-8540-a7eba32a2b48" xlink:href="alny-20190930.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_CollaborativeArrangementMilestonePayments_76f6d2f5-d485-4b97-8540-a7eba32a2b48" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate_376cc9c0-c1df-42d5-891c-7b26144ec6ad" xlink:href="alny-20190930.xsd#alny_RoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_RoyaltyRate_376cc9c0-c1df-42d5-891c-7b26144ec6ad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments_8796f945-2590-48c8-838d-6c019eca27df" xlink:href="alny-20190930.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_PercentageOfMaximumRoyaltyPayments_8796f945-2590-48c8-838d-6c019eca27df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_d4cbc67f-887e-4767-ba73-4d6e06abccef" xlink:href="alny-20190930.xsd#alny_UpfrontFeeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_IncreaseDecreaseInTransactionPrice_83685ef3-3d36-43e3-a3bd-098daf7e4ce8" xlink:href="alny-20190930.xsd#alny_IncreaseDecreaseInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_IncreaseDecreaseInTransactionPrice_83685ef3-3d36-43e3-a3bd-098daf7e4ce8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_76aa6e01-723a-4b2d-8102-c45e190bc9c4" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_TransactionPrice_76aa6e01-723a-4b2d-8102-c45e190bc9c4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_db6e833b-6f7f-412e-aa77-5562490763ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_db6e833b-6f7f-412e-aa77-5562490763ec" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bfa099e4-58d2-4581-9798-8ef038056ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bfa099e4-58d2-4581-9798-8ef038056ed7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce31475e-54ec-4d75-8d4c-2d7a547673db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ce31475e-54ec-4d75-8d4c-2d7a547673db" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e68e2c2b-873c-49ee-ad6c-ccdac57ed17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e68e2c2b-873c-49ee-ad6c-ccdac57ed17a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestorAgreementDescription_d95fb813-1452-4663-af1c-0d688b432422" xlink:href="alny-20190930.xsd#alny_InvestorAgreementDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_InvestorAgreementDescription_d95fb813-1452-4663-af1c-0d688b432422" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0738e5f-2e85-40a2-8052-5e66b5a47720_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0738e5f-2e85-40a2-8052-5e66b5a47720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_bba07415-83c9-4178-867e-763477b5f386" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:to="loc_alny_GlobalStrategicCollaborationMember_bba07415-83c9-4178-867e-763477b5f386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborationAmendmentMember_f2254ca2-862b-48ed-a96c-0f15f4b11548" xlink:href="alny-20190930.xsd#alny_CollaborationAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:to="loc_alny_CollaborationAmendmentMember_f2254ca2-862b-48ed-a96c-0f15f4b11548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:to="loc_dei_EntityDomain_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3af8923d-45ab-4db5-898c-a5fb1007046b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:to="loc_dei_EntityDomain_3af8923d-45ab-4db5-898c-a5fb1007046b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f3f15db6-a9e0-4002-b644-b9f898f5da79" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3af8923d-45ab-4db5-898c-a5fb1007046b" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f3f15db6-a9e0-4002-b644-b9f898f5da79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7640edb3-09af-4f49-bec9-cb0c25030cde_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:to="loc_srt_RangeMember_7640edb3-09af-4f49-bec9-cb0c25030cde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:to="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c4b34bd-f9c1-4a6e-9b47-5846afc4f474" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:to="loc_srt_MaximumMember_6c4b34bd-f9c1-4a6e-9b47-5846afc4f474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44c8f020-97a7-4d0f-a3ff-65e6dac03d86" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:to="loc_srt_MinimumMember_44c8f020-97a7-4d0f-a3ff-65e6dac03d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_45463c37-42c4-4cd7-8f47-dc5ca1b42412_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_45463c37-42c4-4cd7-8f47-dc5ca1b42412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember_7b81cef9-f509-4aad-9891-6c628188d7e4" xlink:href="alny-20190930.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:to="loc_alny_FundingAtProgramInitiationMember_7b81cef9-f509-4aad-9891-6c628188d7e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember_f66f60a5-a1f1-4b1d-bd90-54e0946f726a" xlink:href="alny-20190930.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:to="loc_alny_FundingAtLeadCandidateIdentificationMember_f66f60a5-a1f1-4b1d-bd90-54e0946f726a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember_95f15bfd-2b81-47b3-ad78-4a784c644360" xlink:href="alny-20190930.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:to="loc_alny_FundingAnAnnualDiscoveryMember_95f15bfd-2b81-47b3-ad78-4a784c644360" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b3ae87b-e64c-4c1f-b774-7c1de412f07c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b3ae87b-e64c-4c1f-b774-7c1de412f07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91e0a5f3-383d-400b-bc4f-14b24ab4fc15" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91e0a5f3-383d-400b-bc4f-14b24ab4fc15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_3d475c97-2f62-4b18-aa45-421e5332a699" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91e0a5f3-383d-400b-bc4f-14b24ab4fc15" xlink:to="loc_alny_SanofiGenzymeMember_3d475c97-2f62-4b18-aa45-421e5332a699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0c363124-5971-4dd6-98f4-8d6da0ff2e29_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:to="loc_srt_OwnershipDomain_0c363124-5971-4dd6-98f4-8d6da0ff2e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9f8b5e43-0e42-4daf-b1b9-dbca0a632e19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:to="loc_srt_OwnershipDomain_9f8b5e43-0e42-4daf-b1b9-dbca0a632e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_3c9b0a41-1dbd-4fe3-9148-f4825a8c1a9b" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9f8b5e43-0e42-4daf-b1b9-dbca0a632e19" xlink:to="loc_alny_SanofiGenzymeMember_3c9b0a41-1dbd-4fe3-9148-f4825a8c1a9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" xlink:type="extended" id="ic45a27729c0c40d99dac11b561447976_24302418-700a-4199-8fde-88770300e19d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice_b2288ad5-035f-424c-95e4-cb42359f7c2c" xlink:href="alny-20190930.xsd#alny_StandaloneSellingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:to="loc_alny_StandaloneSellingPrice_b2288ad5-035f-424c-95e4-cb42359f7c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_e31f88bb-f9e3-4544-8c9d-184262f96748" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:to="loc_alny_TransactionPrice_e31f88bb-f9e3-4544-8c9d-184262f96748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67c8cb80-852d-4fce-8f2e-20554f2d67d5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:to="loc_srt_ProductsAndServicesDomain_67c8cb80-852d-4fce-8f2e-20554f2d67d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:to="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_0b232369-3aa5-440e-83c9-a85e1740b151" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:to="loc_alny_ResearchServicesObligationMember_0b232369-3aa5-440e-83c9-a85e1740b151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_88fe70f4-d74c-46bd-84e8-87e97cb0012c" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:to="loc_alny_C5LicenseObligationMember_88fe70f4-d74c-46bd-84e8-87e97cb0012c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_998a626e-27bf-4454-80e1-05708527dd25" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:to="loc_alny_C5CoCoObligationMember_998a626e-27bf-4454-80e1-05708527dd25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c646090b-60a7-466b-a3d2-086ee3e49edc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c646090b-60a7-466b-a3d2-086ee3e49edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_2bc01faa-7dc1-440a-9a59-7fca11b4b2c5" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c646090b-60a7-466b-a3d2-086ee3e49edc" xlink:to="loc_alny_GlobalStrategicCollaborationMember_2bc01faa-7dc1-440a-9a59-7fca11b4b2c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ecd76814-62f5-4bd7-8230-a92ea380785f_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:to="loc_dei_EntityDomain_ecd76814-62f5-4bd7-8230-a92ea380785f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4090e9ba-c6a4-43f0-a2c4-7496d7e26bcf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:to="loc_dei_EntityDomain_4090e9ba-c6a4-43f0-a2c4-7496d7e26bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c7af4583-a7ae-4b12-a7d2-73471f3d7611" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4090e9ba-c6a4-43f0-a2c4-7496d7e26bcf" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c7af4583-a7ae-4b12-a7d2-73471f3d7611" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended" id="i1c3b68292cf94fba976d271ca9b60d7b_9ce097cb-f96e-4f2c-b73c-a867fa18d48f">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_0bbd71bd-f3b8-4e06-99aa-cb7f229c05c2" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_alny_TransactionPrice_0bbd71bd-f3b8-4e06-99aa-cb7f229c05c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a71b8c8-94d6-4455-bbdc-4bd4fdf2ea58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a71b8c8-94d6-4455-bbdc-4bd4fdf2ea58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c93ba5d6-e926-44d7-841a-53ba4d85d11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c93ba5d6-e926-44d7-841a-53ba4d85d11b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c5906dbc-d425-407e-b1b3-3d3165b996ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_Revenues_c5906dbc-d425-407e-b1b3-3d3165b996ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c4dec3f-c722-45ea-8d82-bb66da463f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c4dec3f-c722-45ea-8d82-bb66da463f95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_560e27ff-5dc7-47a7-8dd4-77e3777f11c0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:to="loc_srt_ProductsAndServicesDomain_560e27ff-5dc7-47a7-8dd4-77e3777f11c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:to="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_54d1ebbb-b1da-4f2a-84b2-7017e69ec548" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:to="loc_alny_ResearchServicesObligationMember_54d1ebbb-b1da-4f2a-84b2-7017e69ec548" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_eaa0de39-6976-4a28-84a7-29e89749cc2a" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:to="loc_alny_C5LicenseObligationMember_eaa0de39-6976-4a28-84a7-29e89749cc2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_71c75a1d-2c29-4e02-80fc-c5e492a8af63" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:to="loc_alny_C5CoCoObligationMember_71c75a1d-2c29-4e02-80fc-c5e492a8af63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7e722821-9114-4370-8b21-3ef4e8fb4ad7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7e722821-9114-4370-8b21-3ef4e8fb4ad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2254a1-0bf6-466a-bbad-cad372cbeaea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2254a1-0bf6-466a-bbad-cad372cbeaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_63f974ae-4fd6-4261-9b5e-cb921660f531" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2254a1-0bf6-466a-bbad-cad372cbeaea" xlink:to="loc_alny_GlobalStrategicCollaborationMember_63f974ae-4fd6-4261-9b5e-cb921660f531" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4c3e68de-41ab-45b7-9843-663b4571953c_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:to="loc_dei_EntityDomain_4c3e68de-41ab-45b7-9843-663b4571953c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8826578d-be9f-4a77-b918-e3cbf3fc4176" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:to="loc_dei_EntityDomain_8826578d-be9f-4a77-b918-e3cbf3fc4176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_984b1fe4-a572-4c39-8ce9-b1b3f31ef8c2" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8826578d-be9f-4a77-b918-e3cbf3fc4176" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_984b1fe4-a572-4c39-8ce9-b1b3f31ef8c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/INVENTORY" xlink:type="simple" xlink:href="alny-20190930.xsd#INVENTORY"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/INVENTORY" xlink:type="extended" id="i06d4f8c0b09f49c0ab843c62c6c41cdf_62c3cc8c-92a9-4028-b2d7-8ae722989cec"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/INVENTORYTables" xlink:type="simple" xlink:href="alny-20190930.xsd#INVENTORYTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/INVENTORYTables" xlink:type="extended" id="ia545a61ce4e143eda70cb0e99d95a7fd_0613e1f9-e0c6-48ac-b137-7779161eaba6"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#InventoryScheduleofInventoryDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail" xlink:type="extended" id="i29d67f15ee5548e1b6aea893d85778d2_1d54d987-7bc3-4e89-9db5-107fc74dd08d"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20190930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended" id="ib85ebeb4864648d291d1db191ce808e7_fabe5f38-276a-47f7-9700-194a72ed3ffc"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended" id="ib947b2f1d72b42ecb06901394351c9c1_df4eb726-2f3f-4b6f-bf81-08f2139f5040"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended" id="i0055364e3d4e46eeabcf18ac77337806_0ee812f3-8437-4599-8e3e-635bbb1e3c53">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8bbb34d3-cdf8-4073-8105-c6e97bdfbf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8bbb34d3-cdf8-4073-8105-c6e97bdfbf5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dacda3e-3e43-4dbb-b016-ca922b6c1a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dacda3e-3e43-4dbb-b016-ca922b6c1a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_12d1b62e-ee2a-495c-9203-6dc6394ca1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_12d1b62e-ee2a-495c-9203-6dc6394ca1a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3ed007bd-9d9f-4e6a-9160-ae32e0ccb944" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3ed007bd-9d9f-4e6a-9160-ae32e0ccb944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c975e32d-e431-45d9-9ee1-3c1870c165d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c975e32d-e431-45d9-9ee1-3c1870c165d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_33ed9074-bd9f-41e1-bf76-100fd86e24f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_33ed9074-bd9f-41e1-bf76-100fd86e24f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_da169ce5-e95d-4523-8b2e-c8c0d60e8e76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_da169ce5-e95d-4523-8b2e-c8c0d60e8e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f2528369-9bb0-44d8-ba3d-a41a72dbcfda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_da169ce5-e95d-4523-8b2e-c8c0d60e8e76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f2528369-9bb0-44d8-ba3d-a41a72dbcfda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d48e5ba-ad18-4c50-996d-7dcb33885811_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8d48e5ba-ad18-4c50-996d-7dcb33885811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_86cf7835-2608-421d-9548-392d1a578499" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_CommercialPaperMember_86cf7835-2608-421d-9548-392d1a578499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b8324bac-01a9-4193-ac08-c2f3e92caa4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b8324bac-01a9-4193-ac08-c2f3e92caa4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_df4a2a0d-2ab5-4165-ac81-053775651381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_df4a2a0d-2ab5-4165-ac81-053775651381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4b956092-bce1-44be-805b-934fcfc171f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4b956092-bce1-44be-805b-934fcfc171f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1751e617-d508-4ac7-b1e7-1bf9bfde7703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1751e617-d508-4ac7-b1e7-1bf9bfde7703" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_73940ca1-7212-4fca-a65f-4fb73b668b64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_73940ca1-7212-4fca-a65f-4fb73b668b64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a10725c7-ad06-4944-b4fd-7f36c1de062d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a10725c7-ad06-4944-b4fd-7f36c1de062d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f1a39ae0-b42f-4041-b058-34471c9dc184" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f1a39ae0-b42f-4041-b058-34471c9dc184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_498af43c-9212-4de4-87c9-ae88128c50b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_498af43c-9212-4de4-87c9-ae88128c50b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c8646150-b78f-46ca-b8e4-4d8e0c9efb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c8646150-b78f-46ca-b8e4-4d8e0c9efb3d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i51f2d4e0fd174d7d8bb0daec62c458c5_5513f8e4-8523-45ae-acbb-fc768681b8aa">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_ac00ec7f-459f-414b-ab3e-7cad44b14fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_ac00ec7f-459f-414b-ab3e-7cad44b14fa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_25010557-7ee8-4f27-b366-e8f369e9a5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_LongTermDebtFairValue_25010557-7ee8-4f27-b366-e8f369e9a5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4806c119-7602-4fa1-a5c9-6b938b07bfff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4806c119-7602-4fa1-a5c9-6b938b07bfff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_28fff2b8-539a-4f04-967d-deb82f874bac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_28fff2b8-539a-4f04-967d-deb82f874bac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_63a7efc9-63ee-4f95-8257-124ccfdc1c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_63a7efc9-63ee-4f95-8257-124ccfdc1c7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_227c71fc-0ac5-4672-8872-384e424881e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:to="loc_us-gaap_CreditFacilityDomain_227c71fc-0ac5-4672-8872-384e424881e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2a867cb-1da6-406f-8bd4-d609cdc32c24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:to="loc_us-gaap_CreditFacilityDomain_e2a867cb-1da6-406f-8bd4-d609cdc32c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TermLoanFacilityMember_4654b1d3-af23-48eb-8ddf-f1c3e9ae3ad1" xlink:href="alny-20190930.xsd#alny_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e2a867cb-1da6-406f-8bd4-d609cdc32c24" xlink:to="loc_alny_TermLoanFacilityMember_4654b1d3-af23-48eb-8ddf-f1c3e9ae3ad1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0a9df63f-e84d-44b4-9856-e6168a3b74be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0a9df63f-e84d-44b4-9856-e6168a3b74be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2a912a6-3bc5-487a-ad6b-3297c5642b30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2a912a6-3bc5-487a-ad6b-3297c5642b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_WellsFargoCreditFacilityMember_8a4ffd9e-a1d3-49ac-8dd0-6dc8e24f4a42" xlink:href="alny-20190930.xsd#alny_WellsFargoCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2a912a6-3bc5-487a-ad6b-3297c5642b30" xlink:to="loc_alny_WellsFargoCreditFacilityMember_8a4ffd9e-a1d3-49ac-8dd0-6dc8e24f4a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748270da-be34-4549-acff-eaa05b5b81eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_748270da-be34-4549-acff-eaa05b5b81eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df2eb502-8406-4018-8f49-66c9449c8731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df2eb502-8406-4018-8f49-66c9449c8731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3c034c45-a23d-4f64-8ed7-2c4721d9c7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df2eb502-8406-4018-8f49-66c9449c8731" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3c034c45-a23d-4f64-8ed7-2c4721d9c7c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:to="loc_dei_EntityDomain_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4a2aa00e-c1e2-4854-ac4f-3719dc787f54" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:to="loc_dei_EntityDomain_4a2aa00e-c1e2-4854-ac4f-3719dc787f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_1f3bb30c-95d0-435a-9c58-d6f6adf5c8e3" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4a2aa00e-c1e2-4854-ac4f-3719dc787f54" xlink:to="loc_alny_VirBiotechnologyIncMember_1f3bb30c-95d0-435a-9c58-d6f6adf5c8e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20190930.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended" id="i4114bb564e994a8c8e9e0d85b17c6b1c_d4b718f4-4026-49d3-a04c-cfbb5c575a6d"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20190930.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended" id="i314fb36c0eb14985b08319690f0daf2a_5f2a4b74-273a-4e2f-8a77-2efe2785392d"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail" xlink:type="extended" id="i8857e56660be4403ab6beae9de3ed826_95eccea9-27c7-4166-a5ed-c057a1e3dfda"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" xlink:type="extended" id="if88fc19c74694500b0788105b625c5e5_998a583a-d2d2-4bdc-aa38-88e34c1e3f10">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dc948e2-a935-4569-bffa-76e6a2261f21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dc948e2-a935-4569-bffa-76e6a2261f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_766e3f05-bb48-434b-9c95-eb16ed79ebd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_766e3f05-bb48-434b-9c95-eb16ed79ebd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1214e4-de76-4305-a0aa-28f56e9eb43e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1214e4-de76-4305-a0aa-28f56e9eb43e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_809bc693-9822-4ef1-ad51-25d594ddb132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_809bc693-9822-4ef1-ad51-25d594ddb132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:to="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cda1b433-12cf-4475-b532-68bc2e37a2ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cda1b433-12cf-4475-b532-68bc2e37a2ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_bdb02e58-ebae-4304-831f-0420cebd6389" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:to="loc_us-gaap_CertificatesOfDepositMember_bdb02e58-ebae-4304-831f-0420cebd6389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7dd640ae-7fa9-4a2e-97dc-4c5dff4b1c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:to="loc_us-gaap_CommercialPaperMember_7dd640ae-7fa9-4a2e-97dc-4c5dff4b1c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0139b312-f175-4b3b-99c8-55f15412fc85_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0139b312-f175-4b3b-99c8-55f15412fc85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1cde83a8-29f4-41f2-b382-64217888d502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1cde83a8-29f4-41f2-b382-64217888d502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a76eb7e1-49b3-4415-bbc0-06c8f5237f58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a76eb7e1-49b3-4415-bbc0-06c8f5237f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6950124f-a248-4a39-ba79-0824d9d13a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6950124f-a248-4a39-ba79-0824d9d13a53" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended" id="ibdfdb3759eba481aa16f50ddf6778756_b97f800b-3bef-4156-ae32-8a322076860a"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LEASES" xlink:type="simple" xlink:href="alny-20190930.xsd#LEASES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LEASES" xlink:type="extended" id="i9c055f8354244d0885311c5c92e4651f_8245f61e-b5cb-40e5-8cab-cd9479781b9e"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LEASESTables" xlink:type="simple" xlink:href="alny-20190930.xsd#LEASESTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LEASESTables" xlink:type="extended" id="ie18bc0e248484b659422726c219e73b3_c632418a-1fc8-4c3b-9c8b-b8ce36b9b5e4"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="i64884d4e6a8b4b8f8465639a2b23db32_74b0410c-9e46-4484-a360-3c0ab220843b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LeaseAgreementTerm_71b40c37-04f6-40c5-9f66-d4f7f29680f6" xlink:href="alny-20190930.xsd#alny_LeaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_LeaseAgreementTerm_71b40c37-04f6-40c5-9f66-d4f7f29680f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfLeaseExtensionOptions_4afa9cb8-fbb2-4a3e-bbf3-9654789b07b9" xlink:href="alny-20190930.xsd#alny_NumberOfLeaseExtensionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_NumberOfLeaseExtensionOptions_4afa9cb8-fbb2-4a3e-bbf3-9654789b07b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_740deb07-e21b-4e40-b692-0570cae0af40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_740deb07-e21b-4e40-b692-0570cae0af40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_f725715b-8e85-4f0d-a597-3896a1884dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_f725715b-8e85-4f0d-a597-3896a1884dc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_092f0269-4128-4a56-9a5c-dbea7a12ee86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_092f0269-4128-4a56-9a5c-dbea7a12ee86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedLeaseExpirationDate_cc9b84ea-a0e2-43e0-97ae-b2e51964136d" xlink:href="alny-20190930.xsd#alny_ExtendedLeaseExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_ExtendedLeaseExpirationDate_cc9b84ea-a0e2-43e0-97ae-b2e51964136d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedLeaseExpirationMonthAndYear_587f3c35-a4a9-4c99-baa2-a895235a1e8a" xlink:href="alny-20190930.xsd#alny_ExtendedLeaseExpirationMonthAndYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_ExtendedLeaseExpirationMonthAndYear_587f3c35-a4a9-4c99-baa2-a895235a1e8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e8535803-82d8-4fd6-959c-7d29b51e9f06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_OperatingLeasePayments_e8535803-82d8-4fd6-959c-7d29b51e9f06" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fd0606c-ab62-4adc-b090-d851484781f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fd0606c-ab62-4adc-b090-d851484781f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5bd085f4-e374-4b2c-a051-1be177c889a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5bd085f4-e374-4b2c-a051-1be177c889a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_f89bb27e-2311-467f-82ab-c81082836cd3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_f89bb27e-2311-467f-82ab-c81082836cd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BMRSixSevenFiveWestKendallLeaseMember_62876396-3684-4251-9f41-1a96313156f2" xlink:href="alny-20190930.xsd#alny_BMRSixSevenFiveWestKendallLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:to="loc_alny_BMRSixSevenFiveWestKendallLeaseMember_62876396-3684-4251-9f41-1a96313156f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ThirdStreetLeaseMember_dc5e0ddf-856a-4add-a8f9-2a0d204f76b3" xlink:href="alny-20190930.xsd#alny_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:to="loc_alny_ThirdStreetLeaseMember_dc5e0ddf-856a-4add-a8f9-2a0d204f76b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OneHundredAndOneMainStreetLeasesMember_e75eb93c-b84e-404b-9987-146710af7819" xlink:href="alny-20190930.xsd#alny_OneHundredAndOneMainStreetLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:to="loc_alny_OneHundredAndOneMainStreetLeasesMember_e75eb93c-b84e-404b-9987-146710af7819" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" xlink:type="extended" id="i463460640bbf4368bc0cffdc061e576e_6ea75b64-9bcd-4f00-bc24-0fc8d136ff25"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" xlink:type="extended" id="iee12c098e3a7486f97a7452e9d9de50c_46df0552-a64d-4052-85b7-47700a246c54"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" xlink:type="extended" id="i7bead801335b42fe99800eaf37de6cf7_620443f1-8817-4720-bd35-910ecf26a5f3"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="alny-20190930.xsd#CREDITAGREEMENT"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="extended" id="i9b6c2ad3aa914f15adef3913f7ac4e6e_2f37ccea-6879-4542-815a-cb9a0b54c8fa"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CreditAgreementAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail" xlink:type="extended" id="i3f596d542faf45859b079d7221094585_ff8a949e-d25e-4581-874e-eaee37f9771e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bba53fa3-bc76-466b-a1d9-2113b812357e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bba53fa3-bc76-466b-a1d9-2113b812357e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_0c768ba5-162a-4ec4-b5ca-4d5ad0eaa753" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_0c768ba5-162a-4ec4-b5ca-4d5ad0eaa753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4b64f7f6-4271-44cd-a7b5-7a18fcf352d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4b64f7f6-4271-44cd-a7b5-7a18fcf352d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_c381cf66-2dbd-444f-8a9c-304e8938e975" xlink:href="alny-20190930.xsd#alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_c381cf66-2dbd-444f-8a9c-304e8938e975" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_8df228b1-673f-4282-88a4-98705fb1f25b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_8df228b1-673f-4282-88a4-98705fb1f25b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_630bc921-9d93-432a-b31f-5131b0f9834e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_630bc921-9d93-432a-b31f-5131b0f9834e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2f296cc-8481-4ad4-bc4b-92bb7d142edb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2f296cc-8481-4ad4-bc4b-92bb7d142edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_WellsFargoCreditFacilityMember_e3e3694f-d281-4917-b13f-ef9749f492d0" xlink:href="alny-20190930.xsd#alny_WellsFargoCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2f296cc-8481-4ad4-bc4b-92bb7d142edb" xlink:to="loc_alny_WellsFargoCreditFacilityMember_e3e3694f-d281-4917-b13f-ef9749f492d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b45ea807-c760-435a-a308-77e98bfbb69d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:to="loc_us-gaap_CreditFacilityDomain_b45ea807-c760-435a-a308-77e98bfbb69d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aec45e4e-d961-498e-a24a-8279199d063b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:to="loc_us-gaap_CreditFacilityDomain_aec45e4e-d961-498e-a24a-8279199d063b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TermLoanFacilityMember_984a4288-974c-4a8e-bc0e-636d1af873ba" xlink:href="alny-20190930.xsd#alny_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_aec45e4e-d961-498e-a24a-8279199d063b" xlink:to="loc_alny_TermLoanFacilityMember_984a4288-974c-4a8e-bc0e-636d1af873ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6edc3484-734a-4dbb-8b91-abf7e374b05b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:to="loc_us-gaap_VariableRateDomain_6edc3484-734a-4dbb-8b91-abf7e374b05b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_52804fe2-532e-4374-b22a-93b9126d254a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:to="loc_us-gaap_VariableRateDomain_52804fe2-532e-4374-b22a-93b9126d254a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f59107da-922c-4254-8523-ccd274af30ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_52804fe2-532e-4374-b22a-93b9126d254a" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f59107da-922c-4254-8523-ccd274af30ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/EQUITY" xlink:type="simple" xlink:href="alny-20190930.xsd#EQUITY"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/EQUITY" xlink:type="extended" id="if4a0299b54fa4b539a0ed0e38903a449_daa671be-a80b-4fca-9bd3-0c9b8b51e51f"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/EquityAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#EquityAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/EquityAdditionalInformationDetail" xlink:type="extended" id="iad58cd754e714a2db7f3fcdff9b9164d_4d683a29-5406-4c4b-a1e0-31b3db3ac6be">
    <link:loc xlink:type="locator" xlink:label="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:href="alny-20190930.xsd#alny_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25796b06-cb09-4b02-9378-80fe493f121a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25796b06-cb09-4b02-9378-80fe493f121a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5a29eca4-ed37-4094-a603-922c0b249e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_5a29eca4-ed37-4094-a603-922c0b249e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_081df620-8031-47b7-8d82-6ef2086c1c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_081df620-8031-47b7-8d82-6ef2086c1c3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_60940064-514b-4625-95a6-cb0aafcc1766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_60940064-514b-4625-95a6-cb0aafcc1766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eecee48d-267a-47c6-ba30-e4d79b9e470a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eecee48d-267a-47c6-ba30-e4d79b9e470a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a407a6f-0c4e-41af-b97c-670a394eb935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a407a6f-0c4e-41af-b97c-670a394eb935" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DateOfAgreement_0ab35135-8444-48e8-aac2-155c7ff41361" xlink:href="alny-20190930.xsd#alny_DateOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_DateOfAgreement_0ab35135-8444-48e8-aac2-155c7ff41361" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AgreementExtensionPeriod_74098e7d-4752-4055-a3b3-d94bea1d98a8" xlink:href="alny-20190930.xsd#alny_AgreementExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_AgreementExtensionPeriod_74098e7d-4752-4055-a3b3-d94bea1d98a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OwnershipPercentageOfSharesOutstanding_aed55aa8-3c90-4039-bcb5-280406212ae4" xlink:href="alny-20190930.xsd#alny_OwnershipPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_OwnershipPercentageOfSharesOutstanding_aed55aa8-3c90-4039-bcb5-280406212ae4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_183df591-0005-4659-b861-1b5343aa1e03" xlink:href="alny-20190930.xsd#alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_183df591-0005-4659-b861-1b5343aa1e03" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_adfa7741-5eff-4a56-8bb9-74be79d3c641" xlink:href="alny-20190930.xsd#alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_adfa7741-5eff-4a56-8bb9-74be79d3c641" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BeneficialOwnershipPercentageOfSharesOutstanding_8c4ff4a2-09df-4211-9638-bb64d3a172ad" xlink:href="alny-20190930.xsd#alny_BeneficialOwnershipPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_BeneficialOwnershipPercentageOfSharesOutstanding_8c4ff4a2-09df-4211-9638-bb64d3a172ad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_196168aa-66ea-4e9c-a0d9-fc6bafb08e94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_196168aa-66ea-4e9c-a0d9-fc6bafb08e94" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GainLossOnSaleOfCommonStock_418374d8-f98a-4e53-88cf-f97390b29ee2" xlink:href="alny-20190930.xsd#alny_GainLossOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_GainLossOnSaleOfCommonStock_418374d8-f98a-4e53-88cf-f97390b29ee2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:href="alny-20190930.xsd#alny_EquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4da57346-4679-4a44-a410-33119514ffbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4da57346-4679-4a44-a410-33119514ffbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b29e19a5-41ce-46f7-81a6-a8ac1ff3cdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b29e19a5-41ce-46f7-81a6-a8ac1ff3cdbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_1386460b-539d-4e0f-bece-e65bb1b18f35" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b29e19a5-41ce-46f7-81a6-a8ac1ff3cdbc" xlink:to="loc_alny_GlobalStrategicCollaborationMember_1386460b-539d-4e0f-bece-e65bb1b18f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:to="loc_dei_EntityDomain_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b8dfa1db-3a91-4e60-92e2-72f2ba1579c9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:to="loc_dei_EntityDomain_b8dfa1db-3a91-4e60-92e2-72f2ba1579c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_92bbefa8-165d-4390-a6a2-8191ece4842b" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b8dfa1db-3a91-4e60-92e2-72f2ba1579c9" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_92bbefa8-165d-4390-a6a2-8191ece4842b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:to="loc_srt_RangeMember_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:to="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_370148ce-e71d-41b8-9f1f-180432698a06" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:to="loc_srt_MinimumMember_370148ce-e71d-41b8-9f1f-180432698a06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7a29e193-5f78-46eb-ae25-4915dc617794" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:to="loc_srt_MaximumMember_7a29e193-5f78-46eb-ae25-4915dc617794" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20190930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended" id="i37a18a6e385843d981210d86d17037ad_2a594077-4e01-4aad-8f27-91eb6f5c4135"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20190930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended" id="icafea328cf904234a7507889e92e41d5_28613a22-79ca-4619-ade4-850f7d379c4a"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended" id="ib5a2f471f0c240638a9612bef4ef947f_1ee25ea1-cfb1-4218-940d-a83dc0644c4b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78b7dcdd-50d7-4345-a7aa-9b8f64e77b34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_484a7fec-fd50-4882-8503-e65deef9d2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78b7dcdd-50d7-4345-a7aa-9b8f64e77b34" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_484a7fec-fd50-4882-8503-e65deef9d2b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78b7dcdd-50d7-4345-a7aa-9b8f64e77b34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33ebc400-395e-4bd9-9923-722fa47d0985_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33ebc400-395e-4bd9-9923-722fa47d0985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cfa1add6-da2f-4643-9126-7ebc6bac4dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cfa1add6-da2f-4643-9126-7ebc6bac4dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8719d053-bdcc-4a15-8786-e0cb7b8665db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8719d053-bdcc-4a15-8786-e0cb7b8665db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20190930.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended" id="if6fadcc305734b7299df05f4ab85bea1_a580435b-5c8c-47de-9bf6-275570a26cfa"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20190930.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended" id="i20a8ec65bde841229fb2f5d3b6fc491a_22e1f3d7-f944-46b6-a42c-d921699d9423"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended" id="i14753da60cb74ba4a04648771955902c_e08935f7-ac0d-4aa8-8c12-43c6ded4d9a8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb5c7585-4048-4a7c-8407-d6047390505b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed332e2e-0c4d-4759-87f3-46c3bea506d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb5c7585-4048-4a7c-8407-d6047390505b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed332e2e-0c4d-4759-87f3-46c3bea506d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb5c7585-4048-4a7c-8407-d6047390505b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b8a00ce3-3210-4584-942a-31bf0c815af3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b8a00ce3-3210-4584-942a-31bf0c815af3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0b2cb58f-d523-4bef-814e-d8b54bad575e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0b2cb58f-d523-4bef-814e-d8b54bad575e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_43e983ed-1b67-439c-8083-a835a6c8b182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:to="loc_us-gaap_RestrictedStockMember_43e983ed-1b67-439c-8083-a835a6c8b182" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" xlink:type="simple" xlink:href="alny-20190930.xsd#RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" xlink:type="extended" id="i99e4b06f439d468f8f9a425ae4e15034_fbf07e65-6a2b-4c8d-8e74-89b751628834"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" xlink:type="simple" xlink:href="alny-20190930.xsd#RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" xlink:type="extended" id="i562fdca72f854af7ba2d047dd133989a_abd14b68-6e32-4a64-a771-510cf51ea439"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended" id="ia5b6c8082bb74660a49a976a02e4f6a1_945c61f1-b607-46d6-bea6-5c7e976617b3"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20190930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="ifb9b809215ea4d999f24071a1b018314_34ada259-b11a-4342-b500-786646ee88f8"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i9c227f0e7a6e4b3eb384345a57267b1c_6c63ccc3-2e8a-4e6f-82cb-8c12c06c66d4">
    <link:loc xlink:type="locator" xlink:label="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:href="alny-20190930.xsd#alny_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_478f58da-29bc-4a20-925c-f54c26c47a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_AreaOfLand_478f58da-29bc-4a20-925c-f54c26c47a0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7560626d-805a-464f-a527-adc565c940c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7560626d-805a-464f-a527-adc565c940c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencySettlementAgreementDate_d0edbbc3-c45a-4edd-919b-c954fdae1351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencySettlementAgreementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_LossContingencySettlementAgreementDate_d0edbbc3-c45a-4edd-919b-c954fdae1351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_aaca6bda-dd81-4b93-9fc8-22a5b651c636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_aaca6bda-dd81-4b93-9fc8-22a5b651c636" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:href="alny-20190930.xsd#alny_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_23f14eb1-d1a7-416f-b31c-749dd038d6f7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:to="loc_srt_SegmentGeographicalDomain_23f14eb1-d1a7-416f-b31c-749dd038d6f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef7fe3d9-26d2-4e7d-9492-0a6c12984db7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:to="loc_srt_SegmentGeographicalDomain_ef7fe3d9-26d2-4e7d-9492-0a6c12984db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NortonMassachusettsMember_0f9a0beb-e157-49c9-9344-539ed95988f3" xlink:href="alny-20190930.xsd#alny_NortonMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ef7fe3d9-26d2-4e7d-9492-0a6c12984db7" xlink:to="loc_alny_NortonMassachusettsMember_0f9a0beb-e157-49c9-9344-539ed95988f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b78baa5-7ca1-45fd-bf00-078a8b453b95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b78baa5-7ca1-45fd-bf00-078a8b453b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_a38c739d-970a-4917-b554-32fda21a7fd8" xlink:href="alny-20190930.xsd#alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b78baa5-7ca1-45fd-bf00-078a8b453b95" xlink:to="loc_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_a38c739d-970a-4917-b554-32fda21a7fd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5447301-d5b3-4288-a0ae-6a4ba0bf576c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5447301-d5b3-4288-a0ae-6a4ba0bf576c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DicernaPharmaceuticalsIncMember_9878852e-2375-4731-a9cd-6ee5d5b010cd" xlink:href="alny-20190930.xsd#alny_DicernaPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5447301-d5b3-4288-a0ae-6a4ba0bf576c" xlink:to="loc_alny_DicernaPharmaceuticalsIncMember_9878852e-2375-4731-a9cd-6ee5d5b010cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEFINEDBENEFITPLANS" xlink:type="simple" xlink:href="alny-20190930.xsd#DEFINEDBENEFITPLANS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEFINEDBENEFITPLANS" xlink:type="extended" id="ic90842c2a93c4e2e820817ed7a2fadcc_bce986ac-bb85-4972-8f51-b9aa9d5dc55c"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#DefinedBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails" xlink:type="extended" id="id7f48ba67d034d829eefb83da4f12a22_eff7fb7e-5533-42bd-9b6d-f2f3dc9352f9">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7d9a3c00-688e-472e-a4fe-fe6c7d393273" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f5efb8d5-cfec-43cf-b3c0-7f6522c7d7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7d9a3c00-688e-472e-a4fe-fe6c7d393273" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f5efb8d5-cfec-43cf-b3c0-7f6522c7d7b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7d9a3c00-688e-472e-a4fe-fe6c7d393273" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:to="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain_03c75d58-6ec6-4d88-afce-22955f3bb147_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:to="loc_us-gaap_RetirementPlanFundingStatusDomain_03c75d58-6ec6-4d88-afce-22955f3bb147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain_65f2837b-6e36-4426-b5d9-49743757b12e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:to="loc_us-gaap_RetirementPlanFundingStatusDomain_65f2837b-6e36-4426-b5d9-49743757b12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfundedPlanMember_03f0244a-f943-489e-9680-2fe92000646b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnfundedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanFundingStatusDomain_65f2837b-6e36-4426-b5d9-49743757b12e" xlink:to="loc_us-gaap_UnfundedPlanMember_03f0244a-f943-489e-9680-2fe92000646b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6857de66-d4f0-4b9e-9e6b-00098f29388d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6857de66-d4f0-4b9e-9e6b-00098f29388d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b5faa20f-a708-4317-a43f-88e9da88abfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b5faa20f-a708-4317-a43f-88e9da88abfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75240057-90a9-4726-96f5-c47c730a31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5faa20f-a708-4317-a43f-88e9da88abfb" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75240057-90a9-4726-96f5-c47c730a31f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20190930.xsd#OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended" id="i2952d20de6354a7bb7fee90d27c0ce24_139b6e17-4d1f-4d79-893b-13e7be9af6b4"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended" id="i9a5a228d5db04cfaafd0fb6b886e1879_5a126ea5-0478-4449-a787-a04b47b556b4"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" xlink:type="extended" id="i9891822b23c048acb4d422d7e2fcc164_7568abb6-480e-4b67-addb-2a9959155903">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85c219d0-ebeb-4af6-a4c4-9e984b930257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_85c219d0-ebeb-4af6-a4c4-9e984b930257" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f0954eb-7ec9-450d-97e8-49e6102cb940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_StockholdersEquity_3f0954eb-7ec9-450d-97e8-49e6102cb940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a7c1bdfc-0e55-4f19-a770-cf0e7220a33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a7c1bdfc-0e55-4f19-a770-cf0e7220a33b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_073ed3a0-bda4-48a9-b0fb-63431b0e2822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_073ed3a0-bda4-48a9-b0fb-63431b0e2822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c41d6b4a-c449-4ce7-a240-07184e02933c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c41d6b4a-c449-4ce7-a240-07184e02933c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5fa762c-9f38-4736-ab06-bebadbdbc7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_85c219d0-ebeb-4af6-a4c4-9e984b930257" xlink:to="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98b93ccd-a163-4a03-8dd0-5614e51111d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:to="loc_us-gaap_EquityComponentDomain_98b93ccd-a163-4a03-8dd0-5614e51111d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:to="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_0f6340ad-db61-4a27-b187-e9e0b5833bb3" xlink:href="alny-20190930.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_0f6340ad-db61-4a27-b187-e9e0b5833bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_db46ae8a-7f59-4cfc-a169-bad994e0a86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_db46ae8a-7f59-4cfc-a169-bad994e0a86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_13ba0f1d-668c-46f3-aee8-d0ba3f1e20a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_13ba0f1d-668c-46f3-aee8-d0ba3f1e20a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6d36d136-ef74-4a73-b44a-4db2cbdd5b96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6d36d136-ef74-4a73-b44a-4db2cbdd5b96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6687ac76-5923-437a-a27b-d46877281383" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6687ac76-5923-437a-a27b-d46877281383" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>alny-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:5d2595a3-a26b-49fe-8f15-878ed8f526a8,g:8c29cc34-fc93-4a2b-96ed-ef5f86bbe907-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_38858d55-893e-469b-890f-f8ea5603d7af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dacc08cf-443b-44e9-af8d-9f22dfabdf76_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d763cf08-7172-41e3-b02b-e6a7563778f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_aaf9dabe-7644-4787-8895-cba42b10b9b2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_8ea39a7f-7c80-40db-af32-d610e80cd898_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborators</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_60b91e98-a119-4d78-a597-25f313c9b6fd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DicernaPharmaceuticalsIncMember_d43a8791-11ba-4d12-9674-b2a86573d3bd_terseLabel_en-US" xlink:label="lab_alny_DicernaPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dicerna Pharmaceuticals, Inc</link:label>
    <link:label id="lab_alny_DicernaPharmaceuticalsIncMember_label_en-US" xlink:label="lab_alny_DicernaPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dicerna Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_alny_DicernaPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_alny_DicernaPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dicerna Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DicernaPharmaceuticalsIncMember" xlink:href="alny-20190930.xsd#alny_DicernaPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DicernaPharmaceuticalsIncMember" xlink:to="lab_alny_DicernaPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_23fe6b95-d6e1-40fe-83be-4225d9c32f43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Company's Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6b85f4e9-1336-4f83-9cfb-fe1daab4b25e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_10bddb5f-90d9-40de-8a67-4844a475bc9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_b51df02e-83b9-4ea1-b5ca-27e1af1247cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_fba76e7d-601b-4d96-9961-1da3d601021f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_94dd914d-9304-4b9d-a99d-3bb1f673129d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f691b29-a316-4634-a7fa-23d569931aaf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_0027d2c5-8cef-4342-8020-0358ddad505c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_20350095-d01e-414e-89b0-0f709ccb8e66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8711a1c7-9453-4f78-88f7-188480b470ab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4902cc3-9d73-49d5-b4dd-b62d34836478_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_2dea442d-b8ad-47a7-9268-dab453a3efab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_99c8e635-34ef-4fb6-b896-8ed855c41cb2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusDomain_0eaf9bb2-9d2b-4211-a272-c76c3ba3c1a3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Funding Status</link:label>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Funding Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanFundingStatusDomain" xlink:to="lab_us-gaap_RetirementPlanFundingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_29ddda02-d774-4c62-84cb-8c51263960ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ae46f762-1f9a-4ab0-87d7-1b3d7cfd63b8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_b13664e7-5143-47e1-b1de-872a6e1245f1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d1422183-e500-4844-b96f-6dcee068bf1e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f8306353-f752-4df5-8fec-5104c538a555_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a20718bc-f804-4af5-a983-48167f7e41ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bcb22926-4756-4669-b667-e4134f43fb9b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares owned</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_bd2113bf-b5a7-40ee-8328-b216966fe886_terseLabel_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional milestone payments to be receive upon achievement of certain criteria</link:label>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_label_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria</link:label>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_documentation_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional milestone payments to be receive upon achievement of certain criteria.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:href="alny-20190930.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:to="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37bc1d9c-94fd-4ab8-9082-511234235ab6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_83606ae7-70b4-46b7-8fb7-4dd8dc4a1c37_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_25565ddc-25f0-4540-a8a8-4f7d1ce320f9_terseLabel_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and interest accretion related to operating leases</link:label>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_label_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Interest Accretion Related to Operating Leases</link:label>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_documentation_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Interest Accretion Related to Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:href="alny-20190930.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:to="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00ac3a40-b78d-4a6b-b073-1cc646479fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in contract liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_ef7d9d74-fea8-4c04-9865-2fa50cd348a2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5980a245-7560-4268-8c3c-0dd3c6ea743c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2791098e-ce94-45dc-b349-15f5dd6e9fbb_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9aaaa5d6-f0fd-484e-b970-226c812ee1c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1a06f1ed-5703-4d59-821c-66e7e94a5f63_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_c21e9289-7ddc-4623-b4e1-7b1f10b98743_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues from Collaborators</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_234edb0a-102e-4294-8f45-49c2b6e202ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_238b0368-3cc8-4f88-b510-013d4224c37d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_67f24505-8226-4d5c-8cbd-3fc2b8c61cb5_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_3f4d76be-59f1-4bc7-b373-a865254a3673_terseLabel_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of royalty payments</link:label>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_label_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Maximum Royalty Payments</link:label>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_documentation_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of maximum royalty payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments" xlink:href="alny-20190930.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PercentageOfMaximumRoyaltyPayments" xlink:to="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_dfb74d0c-553e-4e0a-8582-2dac9f2805d6_terseLabel_en-US" xlink:label="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_label_en-US" xlink:label="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Six</link:label>
    <link:label id="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_documentation_en-US" xlink:label="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due year six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:href="alny-20190930.xsd#alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_a04e8ded-c4ec-4266-bbea-11abc12f6b8a_terseLabel_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum royalties and commercial milestone payments upon potential product sale</link:label>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_label_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale</link:label>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_documentation_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum royalties and commercial milestone payments upon potential product sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:href="alny-20190930.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:to="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiquidityPolicyTextBlock_2af50f6f-8d30-4077-b3c2-5852b0fbb935_terseLabel_en-US" xlink:label="lab_alny_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_alny_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_alny_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Policy [Text Block]</link:label>
    <link:label id="lab_alny_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_alny_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiquidityPolicyTextBlock" xlink:href="alny-20190930.xsd#alny_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiquidityPolicyTextBlock" xlink:to="lab_alny_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e9e864a3-24d6-4c23-984c-1b319b216db9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e8857f3-5f03-49d6-a2ad-efad25373520_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_db916aea-b1b3-4dc6-bcc7-85656733ec59_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_c28e1437-176c-45e2-8c01-e41d8a1086cd_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f1000a6e-8147-428f-bff2-fce95bbc3857_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5d213a70-6e40-4a9d-8999-3b36f8c10051_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fdcd39ef-abe3-4e8a-b257-3b5c7f76d2d0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DateOfAgreement_a4194c12-9e71-4c2b-a448-c9fe0cfa7ee3_verboseLabel_en-US" xlink:label="lab_alny_DateOfAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date of investor agreement</link:label>
    <link:label id="lab_alny_DateOfAgreement_label_en-US" xlink:label="lab_alny_DateOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date Of Agreement</link:label>
    <link:label id="lab_alny_DateOfAgreement_documentation_en-US" xlink:label="lab_alny_DateOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Date of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DateOfAgreement" xlink:href="alny-20190930.xsd#alny_DateOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DateOfAgreement" xlink:to="lab_alny_DateOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ae0c10a5-d57a-4e3b-89b9-a76ef81991f8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_22069d32-d52f-4138-b5d3-332358c9fc28_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_C5CoCoObligationMember_fd9c3f6a-1c71-4bb7-9511-713861365202_terseLabel_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co-Co Obligation</link:label>
    <link:label id="lab_alny_C5CoCoObligationMember_label_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co Co Obligation [Member]</link:label>
    <link:label id="lab_alny_C5CoCoObligationMember_documentation_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co-Co obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_C5CoCoObligationMember" xlink:to="lab_alny_C5CoCoObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock_d88e7a72-3292-43b7-ace9-10e052fe9378_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements</link:label>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Research And Development Expenses Incurred For Collaboration Agreements Table [Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of research and development expenses incurred for collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" xlink:href="alny-20190930.xsd#alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" xlink:to="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_23c0ac7f-033a-470d-94d5-b186c081fad6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_40f31046-3db7-4929-a51c-8eae202db4fb_terseLabel_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from collaboration arrangement</link:label>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_label_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Proceeds From Collaboration Arrangement</link:label>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_documentation_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from collaboration arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement" xlink:href="alny-20190930.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PotentialProceedsFromCollaborationArrangement" xlink:to="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_71834661-0840-485f-bd9f-a921130ee921_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_EquityLineItems_eee27012-9c8f-4941-a12c-192bbc1e8387_terseLabel_en-US" xlink:label="lab_alny_EquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Line Items]</link:label>
    <link:label id="lab_alny_EquityLineItems_label_en-US" xlink:label="lab_alny_EquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Line Items]</link:label>
    <link:label id="lab_alny_EquityLineItems_documentation_en-US" xlink:label="lab_alny_EquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_EquityLineItems" xlink:href="alny-20190930.xsd#alny_EquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_EquityLineItems" xlink:to="lab_alny_EquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExtendedLeaseExpirationDate_22bbea99-4912-4454-868a-a0ae10d6cd83_terseLabel_en-US" xlink:label="lab_alny_ExtendedLeaseExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extended expiration date</link:label>
    <link:label id="lab_alny_ExtendedLeaseExpirationDate_label_en-US" xlink:label="lab_alny_ExtendedLeaseExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Lease Expiration Date</link:label>
    <link:label id="lab_alny_ExtendedLeaseExpirationDate_documentation_en-US" xlink:label="lab_alny_ExtendedLeaseExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended lease expiration date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedLeaseExpirationDate" xlink:href="alny-20190930.xsd#alny_ExtendedLeaseExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExtendedLeaseExpirationDate" xlink:to="lab_alny_ExtendedLeaseExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_d06f2913-52d2-42ef-ad67-6a5fd055f27e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_bb44b5b6-40ac-4986-96ee-a92ea595d6c1_terseLabel_en-US" xlink:label="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of shares outstanding, upper limit</link:label>
    <link:label id="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_label_en-US" xlink:label="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage Shares Of Stocks Outstanding Upper Limit</link:label>
    <link:label id="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_documentation_en-US" xlink:label="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage shares of stocks outstanding upper limit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" xlink:href="alny-20190930.xsd#alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" xlink:to="lab_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AgreementExtensionPeriod_dab77d1a-8e63-47b2-bd76-75286d594460_terseLabel_en-US" xlink:label="lab_alny_AgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement extension period</link:label>
    <link:label id="lab_alny_AgreementExtensionPeriod_label_en-US" xlink:label="lab_alny_AgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Extension Period</link:label>
    <link:label id="lab_alny_AgreementExtensionPeriod_documentation_en-US" xlink:label="lab_alny_AgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement extension period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AgreementExtensionPeriod" xlink:href="alny-20190930.xsd#alny_AgreementExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AgreementExtensionPeriod" xlink:to="lab_alny_AgreementExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_13ae057c-8ade-422d-bed7-298ed49c783c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_8754f4ba-472f-49c9-b811-44da39c7997a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a92629-a92f-49f9-87ac-a87ad2272679_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_281443d6-11ba-4810-a4e2-77d0fd3f54cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8266e8b4-69c3-4300-af8e-b4db436f3b90_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2ec2052e-9325-4823-b515-3c23330ea24d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencySettlementAgreementDate_6f9f56f3-a591-454b-b728-1ef257eaccf1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencySettlementAgreementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, settlement agreement date</link:label>
    <link:label id="lab_us-gaap_LossContingencySettlementAgreementDate_label_en-US" xlink:label="lab_us-gaap_LossContingencySettlementAgreementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreement, Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencySettlementAgreementDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencySettlementAgreementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencySettlementAgreementDate" xlink:to="lab_us-gaap_LossContingencySettlementAgreementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_f12058ff-2f84-4ac4-a92d-faf82fe5238a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock at a price per share</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_deb628fd-80e0-4619-a742-09c00396cb18_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_f0a95c02-a232-477b-94ee-1ba290778c91_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eab42453-36a1-48c7-9013-e0570597a494_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1ec6878e-7751-4b6b-9566-91c6808038c8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d6f961f0-9501-401e-b7c0-6671236be9f0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8bac10c2-fc21-468a-8d56-f5e6d6632958_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7b6fb112-fb75-47d3-8d4e-3e8a99806ee6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e09640db-5cd9-4202-be41-3993e0a80129_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d9438f43-c0ea-426b-a5a3-6cc576bd914f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_IncreaseDecreaseInTransactionPrice_b5064eae-9b0a-4c61-b911-210aeea76453_terseLabel_en-US" xlink:label="lab_alny_IncreaseDecreaseInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Transaction Price</link:label>
    <link:label id="lab_alny_IncreaseDecreaseInTransactionPrice_label_en-US" xlink:label="lab_alny_IncreaseDecreaseInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Transaction Price</link:label>
    <link:label id="lab_alny_IncreaseDecreaseInTransactionPrice_documentation_en-US" xlink:label="lab_alny_IncreaseDecreaseInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_IncreaseDecreaseInTransactionPrice" xlink:href="alny-20190930.xsd#alny_IncreaseDecreaseInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_IncreaseDecreaseInTransactionPrice" xlink:to="lab_alny_IncreaseDecreaseInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2edb7b23-f2e1-47d5-afa8-31b4dfe3a81f_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfundedPlanMember_ab89a4de-11ef-4081-8e88-60d82b63427a_terseLabel_en-US" xlink:label="lab_us-gaap_UnfundedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plan</link:label>
    <link:label id="lab_us-gaap_UnfundedPlanMember_label_en-US" xlink:label="lab_us-gaap_UnfundedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfundedPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnfundedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfundedPlanMember" xlink:to="lab_us-gaap_UnfundedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6c4c32eb-c518-4b8c-b374-f92d031c6fc0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_105216f4-7247-4d59-93ba-71ecc7d11a84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f29ac79a-ab53-417c-aee1-df551702109f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_6ca999ed-3f07-49ae-baca-5e73eeae7299_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from landlord lease incentive for tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78696cf3-85a6-4246-8c6f-dfcf5a2a73c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_f74ecfe5-fdb2-49bd-b9bc-caab3acf7b57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers between Level 1 and Level 2 financial assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_11d6364b-3039-4d3b-a7e4-25ec255cfb52_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OwnershipPercentageOfSharesOutstanding_3a244a61-7b68-4f06-afc0-beeea1b66408_terseLabel_en-US" xlink:label="lab_alny_OwnershipPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of shares outstanding</link:label>
    <link:label id="lab_alny_OwnershipPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_alny_OwnershipPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_alny_OwnershipPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_alny_OwnershipPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OwnershipPercentageOfSharesOutstanding" xlink:href="alny-20190930.xsd#alny_OwnershipPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OwnershipPercentageOfSharesOutstanding" xlink:to="lab_alny_OwnershipPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8965b59e-3d13-4a45-95fc-a5cf391cb5fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5a424f1a-fed6-46e0-930c-dc834eb6a45d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b564cd30-2ac8-43a5-898e-a67d84bcc3d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4a7c411f-0dfa-4bf8-b387-ac8ba24c379b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_14bee904-186d-49b1-98f1-a15a0a8134d1_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash</link:label>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of reconciliation of cash, cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="alny-20190930.xsd#alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_97189e50-1de1-4954-9eed-22e8c22a7c55_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_c0d401ee-78b6-4dd0-8619-0ba52d05f938_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ea4fe16e-35ce-47b9-bd12-7277811ce64b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0e9c2c1a-55e6-415d-b497-b65df52ce8ea_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_f59e2d79-9da0-4e03-b851-33636f6983fc_terseLabel_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and manufacturing</link:label>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_label_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial And Manufacturing [Member]</link:label>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_documentation_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and manufacturing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember" xlink:href="alny-20190930.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ClinicalTrialAndManufacturingMember" xlink:to="lab_alny_ClinicalTrialAndManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e883de4e-40f6-4022-8ec2-29b2521d5552_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BMRSixSevenFiveWestKendallLeaseMember_9f870019-4f3d-4297-93d4-ecd2efe74ba0_terseLabel_en-US" xlink:label="lab_alny_BMRSixSevenFiveWestKendallLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMR-675 West Kendall Lease</link:label>
    <link:label id="lab_alny_BMRSixSevenFiveWestKendallLeaseMember_label_en-US" xlink:label="lab_alny_BMRSixSevenFiveWestKendallLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B M R Six Seven Five West Kendall Lease [Member]</link:label>
    <link:label id="lab_alny_BMRSixSevenFiveWestKendallLeaseMember_documentation_en-US" xlink:label="lab_alny_BMRSixSevenFiveWestKendallLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMR-675 West Kendall lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BMRSixSevenFiveWestKendallLeaseMember" xlink:href="alny-20190930.xsd#alny_BMRSixSevenFiveWestKendallLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BMRSixSevenFiveWestKendallLeaseMember" xlink:to="lab_alny_BMRSixSevenFiveWestKendallLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c4bce1e1-dec7-44ac-96c5-daec660dfefa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_012c56fd-f5c3-4c9b-89a9-a4f203ce913f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_a21dc5d3-5030-44e7-9660-63c72f2332f8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_df5d70dd-5852-4992-8592-50b6a195a6e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d119f3e0-5a68-4c31-a922-adcb9849ecb5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_0fad6303-015a-4291-9af1-07eb95eb8b11_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cf340182-c441-4dbb-b264-62f0bf5f6622_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_c03c437c-1ac0-460c-989d-867fb867907e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (money market funds)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8abfbb2d-8f07-4508-b623-040c4989b8b0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_175f4bb7-d2f7-4669-a815-ed5246fd2f16_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_ac4a80c5-f952-4939-a329-436d2f23ea6a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyRate_e7d126e7-6e59-4b3a-bffb-11fda2e4a29e_terseLabel_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_alny_RoyaltyRate_label_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate</link:label>
    <link:label id="lab_alny_RoyaltyRate_documentation_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential maximum royalty percentage that will received for sales completed by collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate" xlink:href="alny-20190930.xsd#alny_RoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyRate" xlink:to="lab_alny_RoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_1ac71250-f8f4-4bf9-bba9-b2b56a5d7d84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal options period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_c5f736c3-b244-49e6-952d-608aae41422d_terseLabel_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Investment in Joint Venture</link:label>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_label_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Loss On Investment In Joint Venture [Member]</link:label>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_documentation_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated loss on investment in joint venture.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:href="alny-20190930.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:to="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_51e3048d-363e-4457-8c5b-8814aa28a1f5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f1722f0-4ada-43e6-81a3-270f4a20843a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_b1940943-6466-4cdf-9c26-e11144512358_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_64d6a15c-ceb2-475d-8e45-f8fa6c96fd3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddcb58b8-dc79-474b-9049-fc12c22c7812_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_41bb1e37-8d5e-421f-82ee-2c0537131776_terseLabel_en-US" xlink:label="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Costs Related to the Construction of Manufacturing Facility</link:label>
    <link:label id="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_label_en-US" xlink:label="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land And Costs Related To Construction Of Manufacturing Facility [Member]</link:label>
    <link:label id="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_documentation_en-US" xlink:label="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and costs related to construction of manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" xlink:href="alny-20190930.xsd#alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" xlink:to="lab_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_474f0ff8-881c-456f-aa6c-ddfc5493b9cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ef343374-5f67-4cfd-851f-d717eea2ca6a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized under ASC 808</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4c83c88b-70c7-4f02-bee1-df7d3febeac8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NonCashGainOnLitigationSettlement_15c524aa-7587-48b9-a7c5-68ca39c4fb56_negatedLabel_en-US" xlink:label="lab_alny_NonCashGainOnLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on litigation settlement</link:label>
    <link:label id="lab_alny_NonCashGainOnLitigationSettlement_label_en-US" xlink:label="lab_alny_NonCashGainOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Gain On Litigation Settlement</link:label>
    <link:label id="lab_alny_NonCashGainOnLitigationSettlement_documentation_en-US" xlink:label="lab_alny_NonCashGainOnLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash gain on litigation settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashGainOnLitigationSettlement" xlink:href="alny-20190930.xsd#alny_NonCashGainOnLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NonCashGainOnLitigationSettlement" xlink:to="lab_alny_NonCashGainOnLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_3ef78215-8601-486f-894a-e8feadc36b88_terseLabel_en-US" xlink:label="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership percentage following the expiration of lock-up period</link:label>
    <link:label id="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_label_en-US" xlink:label="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Ownership Percentage Of Shares Outstanding Following The Expiration Of Lockup Period</link:label>
    <link:label id="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_documentation_en-US" xlink:label="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership percentage of shares outstanding following the expiration of lock-up period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" xlink:href="alny-20190930.xsd#alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" xlink:to="lab_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_b96cf960-1f8c-4707-a143-e7a6288a2e39_terseLabel_en-US" xlink:label="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral required for principal amount outstanding, percentage</link:label>
    <link:label id="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_label_en-US" xlink:label="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Required For Principal Amount Outstanding Percentage</link:label>
    <link:label id="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_documentation_en-US" xlink:label="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral required for principal amount outstanding, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:href="alny-20190930.xsd#alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:to="lab_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7e2f3506-ba13-43e4-8a5a-dca091f1e230_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering proceeds, net of costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_64063e90-31cd-47a7-89b4-9a9010da5397_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchTermExtensionFee_0741b5ba-08ad-42e1-9562-372e628fdd18_terseLabel_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research term extension fee</link:label>
    <link:label id="lab_alny_ResearchTermExtensionFee_label_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Term Extension Fee</link:label>
    <link:label id="lab_alny_ResearchTermExtensionFee_documentation_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research term extension fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee" xlink:href="alny-20190930.xsd#alny_ResearchTermExtensionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchTermExtensionFee" xlink:to="lab_alny_ResearchTermExtensionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_40977789-1e2b-4b64-9acd-dd90da0a8cd7_terseLabel_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended additional discovery period of programs development</link:label>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_label_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Additional Discovery Period Of Programs Development</link:label>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_documentation_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended additional discovery period of programs development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:href="alny-20190930.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:to="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f6c34973-51b1-4f45-aef7-ae4ad72654ce_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_4541b43b-28cd-4226-adc2-9c9c88945ecf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_bf396c39-08ac-4845-b027-957920230682_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Costs Included in Operating Expenses Related to Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MdcoMember_795d58da-6f2a-4655-b4b9-887c640850a1_verboseLabel_en-US" xlink:label="lab_alny_MdcoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Medicines Company</link:label>
    <link:label id="lab_alny_MdcoMember_d2d78604-7cdf-429a-86c8-6d7c71a4f326_terseLabel_en-US" xlink:label="lab_alny_MdcoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mdco</link:label>
    <link:label id="lab_alny_MdcoMember_label_en-US" xlink:label="lab_alny_MdcoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mdco [Member]</link:label>
    <link:label id="lab_alny_MdcoMember_documentation_en-US" xlink:label="lab_alny_MdcoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Medicines Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MdcoMember" xlink:href="alny-20190930.xsd#alny_MdcoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MdcoMember" xlink:to="lab_alny_MdcoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2bfc82fd-049d-4999-9095-6a5861325885_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_98a666b1-9a2a-4d8b-9369-2d260af20141_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d63e803b-6009-4c80-99cf-cc2b968329de_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding_1129047d-4380-405f-b639-ce7170363718_terseLabel_en-US" xlink:label="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership percentage of shares outstanding</link:label>
    <link:label id="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Ownership Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership percentage of shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BeneficialOwnershipPercentageOfSharesOutstanding" xlink:href="alny-20190930.xsd#alny_BeneficialOwnershipPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BeneficialOwnershipPercentageOfSharesOutstanding" xlink:to="lab_alny_BeneficialOwnershipPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_356ff481-6b3b-4a3b-9ee2-74fa16d56830_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3b402b0c-115e-4fc0-94c7-d2921c08a71a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored enterprise securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_StandaloneSellingPrice_1dd500c7-513b-4780-8b7a-216d55f99159_terseLabel_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:label id="lab_alny_StandaloneSellingPrice_label_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:label id="lab_alny_StandaloneSellingPrice_documentation_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice" xlink:href="alny-20190930.xsd#alny_StandaloneSellingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_StandaloneSellingPrice" xlink:to="lab_alny_StandaloneSellingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_089fd4a3-57c8-49c5-9e38-14068d8e8387_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dac89215-0d36-4716-aed5-94e1ded9918b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b44661b-2f10-429b-86ce-5985b587dc7a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_792f7559-cead-46b2-b4e6-bf35de14b5e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationDate1_3402ee6a-578c-4c11-9b79-5759e17702d0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, expiration date</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationDate1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9887ea41-e3dd-41e3-8945-7d0c03d20c3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid included in operating activities in cash flow</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_197caf10-f95f-4a45-ac30-7f10eb352348_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bd47652d-8f10-49ac-a0bd-a828e28cbcd9_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_06708731-b455-4687-baba-5b4af05a1957_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f08dee01-0feb-424b-b2dd-c8cadbab620f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7f6512f2-cd4a-4fc6-8147-c3c623a4c246_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d11962f3-8570-4d63-b188-ea585e05d31e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_99646800-f97b-4ba2-b7b9-3d29d3677825_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_9df202f6-98b2-41e1-83bc-b533dc9ec529_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0a977313-4d5b-4d5e-b4fa-edd0cf82082a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Losses) Gains from Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3e9c5870-40fd-4b36-bc73-f086f593066e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_42fa16b5-d901-446b-bb88-e3a7510b4536_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment from the adoption of new revenue standard</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_b0f4170d-46de-4625-ab76-f906982c68cb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NortonMassachusettsMember_e4c93228-be94-431e-a361-0eba5090561d_terseLabel_en-US" xlink:label="lab_alny_NortonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norton, Massachusetts</link:label>
    <link:label id="lab_alny_NortonMassachusettsMember_label_en-US" xlink:label="lab_alny_NortonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norton Massachusetts [Member]</link:label>
    <link:label id="lab_alny_NortonMassachusettsMember_documentation_en-US" xlink:label="lab_alny_NortonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norton, Massachusetts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NortonMassachusettsMember" xlink:href="alny-20190930.xsd#alny_NortonMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NortonMassachusettsMember" xlink:to="lab_alny_NortonMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cb587f-ce65-45bc-9ac2-00f977ee55a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_82ddfd14-92f9-4975-85ab-ddb6d89b95bf_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c944bd0a-e229-49ea-9e2e-9923860238f1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f19d42e0-8ba4-427e-a510-05d86467e1b0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_750feadc-8eb6-42c0-ae66-59f08c20af0c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_e607f8cd-2a63-42f4-89be-4f9ac0d4d59c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0b619532-2b49-4600-ae4d-f2c56d54e1ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfLeaseExtensionOptions_03f9ab4d-858c-4c8e-85c6-120a1270a779_terseLabel_en-US" xlink:label="lab_alny_NumberOfLeaseExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease extension options</link:label>
    <link:label id="lab_alny_NumberOfLeaseExtensionOptions_label_en-US" xlink:label="lab_alny_NumberOfLeaseExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lease Extension Options</link:label>
    <link:label id="lab_alny_NumberOfLeaseExtensionOptions_documentation_en-US" xlink:label="lab_alny_NumberOfLeaseExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease extension options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfLeaseExtensionOptions" xlink:href="alny-20190930.xsd#alny_NumberOfLeaseExtensionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfLeaseExtensionOptions" xlink:to="lab_alny_NumberOfLeaseExtensionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_f3023cd6-6fa3-4f85-b569-490fc63cb2fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6128a513-1910-4914-9ff5-8f14b42a5b5a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_16e10182-a57a-4450-a81d-dc315e8fd5b3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_0365d3fc-82dd-4a4c-b575-cf82e0525c75_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c5c6b010-b604-4f81-acc0-4e904f147813_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExtendedLeaseExpirationMonthAndYear_0c1d650c-7ac6-4868-85ca-0d9aa4726307_terseLabel_en-US" xlink:label="lab_alny_ExtendedLeaseExpirationMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extended expiration month and year</link:label>
    <link:label id="lab_alny_ExtendedLeaseExpirationMonthAndYear_label_en-US" xlink:label="lab_alny_ExtendedLeaseExpirationMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Lease Expiration Month And Year</link:label>
    <link:label id="lab_alny_ExtendedLeaseExpirationMonthAndYear_documentation_en-US" xlink:label="lab_alny_ExtendedLeaseExpirationMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended lease expiration month and year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedLeaseExpirationMonthAndYear" xlink:href="alny-20190930.xsd#alny_ExtendedLeaseExpirationMonthAndYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExtendedLeaseExpirationMonthAndYear" xlink:to="lab_alny_ExtendedLeaseExpirationMonthAndYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAbstract_c045f657-9203-4f84-a91a-7fb8ee53f0b5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Abstract]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAbstract_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract" xlink:to="lab_us-gaap_LineOfCreditFacilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bcbaabd6-8ae0-4fcd-89bc-895bb9dc441b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_3b08d1f4-27a6-4d13-9ad0-87da39887ee5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa99c794-1485-4068-a603-3422255925d4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_675796d9-8ff0-4bed-b415-ccfac52f9917_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_bf4ba963-5b84-49f7-8656-01ce039b37be_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2b008b4a-5217-4326-b415-3315463256d5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5e9f968c-bc4d-42b2-95d6-641837d1f630_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c84c68d8-9ece-4a4e-97bc-b7ba6a5828c7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ThirdStreetLeaseMember_227d70e6-a3a1-4f05-9c1d-bd3a19e3184f_terseLabel_en-US" xlink:label="lab_alny_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Lease</link:label>
    <link:label id="lab_alny_ThirdStreetLeaseMember_label_en-US" xlink:label="lab_alny_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Lease [Member]</link:label>
    <link:label id="lab_alny_ThirdStreetLeaseMember_documentation_en-US" xlink:label="lab_alny_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third street lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ThirdStreetLeaseMember" xlink:href="alny-20190930.xsd#alny_ThirdStreetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ThirdStreetLeaseMember" xlink:to="lab_alny_ThirdStreetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_1a22bee5-3670-4fff-af76-72e8a1484f31_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_98911205-d056-4804-a1f6-31a5539f8f17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_d3ddd95d-5f78-4404-b846-453e32e62d8b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_cddc6496-e05c-4f75-bffb-e4b4ae600989_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f4e34402-618b-422c-a392-b18600168f16_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_42036cde-4cf3-4dba-bdc8-15bbf796d4f7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_c7d93a1b-11f8-4830-9af5-8ba35ab7f940_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_0651f7f8-389e-440a-95b1-9162bee246c1_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in the period from:</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9fda24b0-ec24-40bb-bb46-a41a58e9c5f3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ae74739c-0ca2-467c-a008-8b27c2b4a4b4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9ae821d9-2f10-4672-80eb-7c4374b5fa4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0e1793e3-a98d-4bc2-880d-29be75e39fb6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3381b13e-34e2-4195-af67-6082f2a4263a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_GainLossOnSaleOfCommonStock_6aa3aeec-8878-4029-8f78-2f0354929a4d_terseLabel_en-US" xlink:label="lab_alny_GainLossOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of common stock</link:label>
    <link:label id="lab_alny_GainLossOnSaleOfCommonStock_label_en-US" xlink:label="lab_alny_GainLossOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Loss On Sale Of Common Stock</link:label>
    <link:label id="lab_alny_GainLossOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_alny_GainLossOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GainLossOnSaleOfCommonStock" xlink:href="alny-20190930.xsd#alny_GainLossOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_GainLossOnSaleOfCommonStock" xlink:to="lab_alny_GainLossOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_24c3bdd6-7d28-4dca-adf6-1b45fdae834e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRODUCT REVENUES, NET</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_ecf4148c-5433-45f4-8be7-cf33348cd4fd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ff3d1fb7-1443-4564-b791-c21bd29c9107_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79c0a577-962a-4500-a0a0-ae445619c5ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_b3355034-758c-440b-8c38-5eaadef10f71_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4510c450-0f7f-424d-af2b-5b2dedda3dd8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_e6a8ce72-2381-4819-b871-1e305ac434f0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_65bf8f91-e255-49a8-8cfa-c397b9c9ca44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_bae4c696-84d4-44c2-8d4b-a3bbb55d850d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1a028696-8191-464c-bb2c-666b35ce47f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_0f8a1dea-04f7-4cb7-b285-3aca3c02e884_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_04e9b272-4c9a-443f-b9d4-c9ca8eb97012_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_26f76e80-cf82-4d29-a8e4-03de171df86e_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6733c52d-e5fa-4bff-b8e5-ea69f2135dc9_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_bc38a284-1bb3-4181-8113-c15d83c7b8e7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_c3d149e4-c1da-415d-9271-e53f908bd34d_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance</link:label>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:href="alny-20190930.xsd#alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:to="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract_ddd1d401-f048-429b-b2ff-92447310f1d2_terseLabel_en-US" xlink:label="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract" xlink:href="alny-20190930.xsd#alny_CashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_alny_CashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_24593bb6-1844-4d6c-bb9a-4c00dc05f425_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_63be26ef-0b18-4899-901c-d135cbbe8a47_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_522f2ec2-37de-4476-894d-c4d88efd8a83_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, option to extend</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_8d9bbd30-0eba-45c1-910d-0d5f9c1f0e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d3a5c4c4-0ea5-4cfc-ae90-a4f21c936fce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4dbc1426-8295-45c9-8d61-bf4e06dcaa9f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4115d7c2-824f-48c3-96eb-b0f3920662a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and other types of equity, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d44bbfbc-18f9-4925-a032-c16d901a5648_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_ed129439-e267-4441-b449-ed8842a2effd_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OneHundredAndOneMainStreetLeasesMember_926d361c-da4f-4291-9469-08c772b42e11_terseLabel_en-US" xlink:label="lab_alny_OneHundredAndOneMainStreetLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">101 Main Street Lease</link:label>
    <link:label id="lab_alny_OneHundredAndOneMainStreetLeasesMember_label_en-US" xlink:label="lab_alny_OneHundredAndOneMainStreetLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred And One Main Street Leases [Member]</link:label>
    <link:label id="lab_alny_OneHundredAndOneMainStreetLeasesMember_documentation_en-US" xlink:label="lab_alny_OneHundredAndOneMainStreetLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">101 Main Street leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OneHundredAndOneMainStreetLeasesMember" xlink:href="alny-20190930.xsd#alny_OneHundredAndOneMainStreetLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OneHundredAndOneMainStreetLeasesMember" xlink:to="lab_alny_OneHundredAndOneMainStreetLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_72b72ecf-8f2e-4280-95f3-5f731376f2a5_verboseLabel_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_2973aaff-9337-4636-9360-e19d164622ee_terseLabel_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:to="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7f4b3efe-67a2-48e6-a03f-8b1f1a5645da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d89c4d7-f776-4e0f-b1a4-76741d80fa86_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_27c82dcf-76f0-4ee5-b9f5-e9cf8eb0ccae_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4d55e6b-012b-47d4-bd53-8414fdf611e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ff65a033-8d06-4c33-a069-0ecd012f70f0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_62020a2d-b049-46a5-9edd-38e4bd2ef628_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_622d413a-11ec-463a-9e0e-7a6078353133_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c63fd37f-6409-4967-8dce-151ceaa36d52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_c0285a46-0a03-4c95-ac62-d0ed703774e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, existence of option to terminate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_665b14d0-d2db-4c99-982a-cbdeec4942f6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_24305b08-e06d-4092-8af7-e62c71c031d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_394df470-a69e-4284-a250-566e822b2814_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total discounted lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_TransactionPrice_09ee7132-6d4d-4c76-96b1-dd20d25097d6_terseLabel_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_alny_TransactionPrice_label_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price</link:label>
    <link:label id="lab_alny_TransactionPrice_documentation_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_TransactionPrice" xlink:to="lab_alny_TransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3565984b-077a-4f91-a342-06ad093214c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7ee40a06-8357-4fb1-ada7-8866e3a22998_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_641b987d-1afd-40b5-9035-787b31da164b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_492a87cb-6bde-42e0-b7f8-cef85b5f1c12_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for 401(k) company stock match</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2f999e65-4deb-468d-810f-709c3d3d7a95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Payments Under Non-cancelable Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_48f23e08-3905-4080-84b0-4d883ffe7a3f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8078dd27-c683-46dd-92af-768dd2c0e3b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OtherMember_52f1ed56-a920-467a-a55b-3684a9d88614_terseLabel_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_OtherMember_label_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_alny_OtherMember_documentation_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember" xlink:href="alny-20190930.xsd#alny_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OtherMember" xlink:to="lab_alny_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ed350ae1-35d5-42e6-a423-d05ff43b8f37_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_aebecab2-ace5-4da4-a5ad-1574ffa20bca_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3eb193eb-f4f3-4811-9e08-5f5213504dee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_52e4a8f7-87e3-4c02-abb3-1db95be4cec6_terseLabel_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration</link:label>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_label_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration [Member]</link:label>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_documentation_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global strategic collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_GlobalStrategicCollaborationMember" xlink:to="lab_alny_GlobalStrategicCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_06d79b68-2a71-4bcb-85c7-87cde8500a69_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_e528835d-1962-48c5-ad32-758fd4986520_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_f575ea12-474c-467f-a952-d82126ec1836_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of restricted investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_fc88f795-57b0-4369-b0bb-79e3419a4c41_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in long-term other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_747167c6-77e3-4bf5-9412-babf74343fe6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2ace345-c751-4891-a0da-2e9d7485d573_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_14daaa7a-690c-4379-beeb-c4dca1946135_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d62dbabb-6287-40f0-9f5d-1033484fe750_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_9544a874-d1fb-477f-930a-bb366096efce_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_05f493a0-cba9-456d-b8ed-73313d999d76_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_98504509-c531-4b1d-bdb3-28c93a8f6203_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e024026e-09aa-4a4e-9f08-eb025c90d1c6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e88f51e1-1559-4d6f-810a-5a78a7976aee_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_5c571a32-f698-440e-abf0-06d5fb5fe549_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_80443a4a-f679-45b9-81d1-d672fed12571_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_a9805181-626b-4022-a79b-a93b77ef8c04_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in &#8220;Accounts receivable, net&#8221;</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29052120-cc6e-4a73-b013-1e87316ae5de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_91e11416-305c-4bb4-b677-b4f1d66cdba1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities included in &#8220;Deferred revenue&#8221;</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4352fd8e-0b74-4e4f-91a3-3be5dd150dab_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_35b903fb-3bd7-4b66-9d3e-1677ad0d8927_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_a82d8187-6482-4dd2-8df8-aa1f94c194d0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_b13d860d-dd1b-4217-a23f-55da814fc961_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9bc02f12-6ca6-48f2-83c8-5104723afe6c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value per share, 250,000 and 125,000 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 111,325 shares issued and outstanding as of September 30, 2019; 101,177 shares issued and outstanding as of December 31, 2018</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_44523d99-93b1-4749-ad7b-47581ae8acc4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of restricted investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_582d6b79-0622-4e60-8ce2-e9e270121f20_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_82e58b5f-62e9-4ce1-a4bd-8ede93bdd153_terseLabel_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liability obligation</link:label>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_e71c5d5f-4ecf-4585-8443-1b869bc8a808_negatedTerseLabel_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liability obligation</link:label>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_label_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Liability Obligation</link:label>
    <link:label id="lab_alny_ChangeInFairValueOfLiabilityObligation_documentation_en-US" xlink:label="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liability obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation" xlink:href="alny-20190930.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ChangeInFairValueOfLiabilityObligation" xlink:to="lab_alny_ChangeInFairValueOfLiabilityObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_29226d08-a70a-44f5-ad15-c43b7006575a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1bc9dd9c-466f-46bf-9e02-1c55cefc04d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to equity-classified awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a39d5cb6-d97e-451d-ae8b-379a6aee4894_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_77037116-42ee-4bd0-9a94-12ce17422d2c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2994b94-0363-4a6e-bbf3-979f1f0cfe63_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04eefd80-72cb-4c5e-948b-71d8050d301d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_093c62fc-e246-4bfa-a281-f3e6c2431fb9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_07b7603a-66c8-4518-bb59-f9898b7c2165_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_5256c01d-9e72-4103-994c-da8d877a69c2_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_089b1349-c3ed-4e64-8936-16161a3a9a00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactional price remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_032ecaa5-479b-4d09-b191-07ef3a1a8b63_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a72bae7c-9598-4357-9b17-0a7eeae14249_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_UpfrontFeeReceived_79b74fa1-d98b-48df-9107-2642034537f4_terseLabel_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee received</link:label>
    <link:label id="lab_alny_UpfrontFeeReceived_label_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Fee Received</link:label>
    <link:label id="lab_alny_UpfrontFeeReceived_documentation_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived" xlink:href="alny-20190930.xsd#alny_UpfrontFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_UpfrontFeeReceived" xlink:to="lab_alny_UpfrontFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CommitmentsAndContingenciesLineItems_8c1ce6f2-ee2b-4d69-947c-032552f8bc94_terseLabel_en-US" xlink:label="lab_alny_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_alny_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_alny_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_alny_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_alny_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CommitmentsAndContingenciesLineItems" xlink:href="alny-20190930.xsd#alny_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems" xlink:to="lab_alny_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_c91e92c7-e4a6-4c58-b008-f480701454d4_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price Based on Accounting Guidance</link:label>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:href="alny-20190930.xsd#alny_ScheduleOfAllocatedTransactionPriceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:to="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_006899c7-d403-4604-b94d-ff59071adfff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_793bf68c-43fd-4e0e-96a1-bfb2e15606de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bfd9729e-75ec-463c-bfa1-ebe5fc948140_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CommitmentsAndContingenciesTable_cbbbae0f-3717-4fd9-a089-a4f1cd41fd4f_terseLabel_en-US" xlink:label="lab_alny_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_alny_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_alny_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_alny_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_alny_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CommitmentsAndContingenciesTable" xlink:href="alny-20190930.xsd#alny_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CommitmentsAndContingenciesTable" xlink:to="lab_alny_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7d51391b-eaa6-4c44-ba9a-88abba51a430_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OtherCollaborationsMember_d4ea77e1-9a98-457c-a1c4-2999a43f08b4_terseLabel_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_OtherCollaborationsMember_label_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborations [Member]</link:label>
    <link:label id="lab_alny_OtherCollaborationsMember_documentation_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember" xlink:href="alny-20190930.xsd#alny_OtherCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OtherCollaborationsMember" xlink:to="lab_alny_OtherCollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7d1a6258-c079-4f14-9f21-e826ffc125f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bee095c6-a6ac-4fc5-9e71-ee15f097a169_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8ce2586a-5904-4a94-8768-b69db0125619_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_d46990fc-54b4-4414-bc73-462d60890453_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues, Net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_233ea17c-4825-4ae9-af4f-80262fe8f878_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ba70997f-c447-43b9-a8a6-512d09760e6b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_e729f238-a408-42bd-b66a-714330d129b5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c28aa638-1621-41c0-88a5-23481a53ae45_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_21367fab-fa5c-481c-9216-404b92653102_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2a954427-466a-4512-8f17-cfa7e91902fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c31afcdb-3e4f-4a3c-a284-3d218a8f0fdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d3ed18e3-271d-4a4d-b345-ed452c091f30_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_82ebb2a3-619e-4e03-a199-9e47f0ed490a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4e69a5f9-ee68-402b-a96a-31bc45a16fcf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_79a267ad-6f8c-49f3-a697-c89516625368_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LeasesPolicyPolicyTextBlock_b3d4f29c-5f0d-4d3d-8bdf-fc1d88e4a11b_terseLabel_en-US" xlink:label="lab_alny_LeasesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_alny_LeasesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_alny_LeasesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Policy Policy [Text Block]</link:label>
    <link:label id="lab_alny_LeasesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_alny_LeasesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LeasesPolicyPolicyTextBlock" xlink:href="alny-20190930.xsd#alny_LeasesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LeasesPolicyPolicyTextBlock" xlink:to="lab_alny_LeasesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f9a4ece5-e8c6-49d6-b201-bf753ecdced0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchServicesObligationMember_acae3b91-afa0-4331-9285-49d891a0af65_terseLabel_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Obligation</link:label>
    <link:label id="lab_alny_ResearchServicesObligationMember_label_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Obligation [Member]</link:label>
    <link:label id="lab_alny_ResearchServicesObligationMember_documentation_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchServicesObligationMember" xlink:to="lab_alny_ResearchServicesObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1c0ebddc-c5c9-488e-be83-b94fa6dafe8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_75b4631c-f45e-49f6-a9f9-dfa3504ebff7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_e9f0cc3b-7ad9-444c-84cd-51ea282a42ff_terseLabel_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE DEBT SECURITIES</link:label>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_label_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Marketable Debt Securities Disclosure [Text Block]</link:label>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable debt securities disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:href="alny-20190930.xsd#alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:to="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7d834f5f-0289-41ba-a2a3-a0a9519a2fa1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5e53a3be-3813-4625-b14b-30be8a366bff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_InvestorAgreementDescription_f2288547-5dc0-4479-8642-2d110d716609_terseLabel_en-US" xlink:label="lab_alny_InvestorAgreementDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor agreement description</link:label>
    <link:label id="lab_alny_InvestorAgreementDescription_label_en-US" xlink:label="lab_alny_InvestorAgreementDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor Agreement Description</link:label>
    <link:label id="lab_alny_InvestorAgreementDescription_documentation_en-US" xlink:label="lab_alny_InvestorAgreementDescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor agreement description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestorAgreementDescription" xlink:href="alny-20190930.xsd#alny_InvestorAgreementDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_InvestorAgreementDescription" xlink:to="lab_alny_InvestorAgreementDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_078e3368-3475-4441-bb03-d3137d31cd06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7e91075a-c7b6-4926-9ad7-75b92a7f3fc9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3aabea3b-b772-4659-a15d-e43f53278499_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_6bee9e13-3618-4a0a-95cb-9b8fa83287e4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f2e2724f-0bb1-4c13-a941-526e6d8efc23_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage ownership interest owned by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9aa39fd-545d-4203-b96e-f2d1acb7bcc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8a04239e-6d0e-4382-a37a-16cef30528c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_efe5e1a7-cdc5-4295-b2c3-a08af6e7b986_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fa5e1853-bf70-49b0-8aa5-aa196707aa1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_3d1bb141-448d-4ba3-9815-b127a7fa2088_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under benefit plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_50bf9b79-90a8-4a1e-a404-2fd1012d382e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEFINED BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3da58e35-2570-4ce5-8010-18b7655716c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_89c3dbc4-b1ac-44e9-86d5-a156050609d7_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_a1925d0a-5dac-4b19-bbb5-940ff99a6c3f_terseLabel_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Lead Candidate Identification</link:label>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_label_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Lead Candidate Identification [Member]</link:label>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_documentation_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding at lead candidate identification.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember" xlink:href="alny-20190930.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAtLeadCandidateIdentificationMember" xlink:to="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b538c2a1-148f-40a2-a31d-ed2555b8febf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_09f4dac6-2ebb-40b3-8048-5a74d5e22cf4_terseLabel_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Program Initiation</link:label>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_label_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Program Initiation [Member]</link:label>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_documentation_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding at program initiation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember" xlink:href="alny-20190930.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAtProgramInitiationMember" xlink:to="lab_alny_FundingAtProgramInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0439bb0a-6a62-4736-baa5-57d6ffb28d4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_bb9dcbb4-6cbf-44d9-85d5-b078813f803f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock to Regeneron</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusAxis_1d18b242-60fd-42d1-a99c-19ab2858ac4c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Funding Status</link:label>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Funding Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis" xlink:to="lab_us-gaap_RetirementPlanFundingStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3d532f0c-0c2f-45e7-96af-72cef662c3e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9f00312e-e61f-40e3-bb4a-576d92e58a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_SanofiGenzymeMember_aa6c4789-edab-4119-a2f5-f91b08573750_terseLabel_en-US" xlink:label="lab_alny_SanofiGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme</link:label>
    <link:label id="lab_alny_SanofiGenzymeMember_label_en-US" xlink:label="lab_alny_SanofiGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme [Member]</link:label>
    <link:label id="lab_alny_SanofiGenzymeMember_documentation_en-US" xlink:label="lab_alny_SanofiGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_SanofiGenzymeMember" xlink:to="lab_alny_SanofiGenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_eb33fd38-6500-440f-aae0-e47825180e6c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_51f84a2f-171d-4ec5-93de-80128c12d8a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LeaseAgreementTerm_8117b2a3-d9ab-47ea-8522-1c843b9a5449_terseLabel_en-US" xlink:label="lab_alny_LeaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_alny_LeaseAgreementTerm_label_en-US" xlink:label="lab_alny_LeaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreement Term</link:label>
    <link:label id="lab_alny_LeaseAgreementTerm_documentation_en-US" xlink:label="lab_alny_LeaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LeaseAgreementTerm" xlink:href="alny-20190930.xsd#alny_LeaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LeaseAgreementTerm" xlink:to="lab_alny_LeaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d82a13c2-e048-4486-a942-4ad79af7f184_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2019 and December 31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExternalServicesMember_8f593451-d4c1-4b72-b268-f7d6834d078f_terseLabel_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External services</link:label>
    <link:label id="lab_alny_ExternalServicesMember_label_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Services [Member]</link:label>
    <link:label id="lab_alny_ExternalServicesMember_documentation_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember" xlink:href="alny-20190930.xsd#alny_ExternalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExternalServicesMember" xlink:to="lab_alny_ExternalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7bd58c9f-5097-4869-90ac-0bcd56cd2ce0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fd24ac3e-d98b-4a0c-958d-c318f9bdb984_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_5da2626c-bcc6-46b3-b307-41655485de8d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborationAmendmentMember_f6f01477-ee7f-42db-ba14-7e9db495e0c5_terseLabel_en-US" xlink:label="lab_alny_CollaborationAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Amendment</link:label>
    <link:label id="lab_alny_CollaborationAmendmentMember_label_en-US" xlink:label="lab_alny_CollaborationAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Amendment [Member]</link:label>
    <link:label id="lab_alny_CollaborationAmendmentMember_documentation_en-US" xlink:label="lab_alny_CollaborationAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborationAmendmentMember" xlink:href="alny-20190930.xsd#alny_CollaborationAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborationAmendmentMember" xlink:to="lab_alny_CollaborationAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50089a9f-4fa3-4637-b08d-13c9fa2f90ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8dce3666-11f4-4b0b-883d-af29b52d3387_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3fba5486-ef5c-4ef8-babe-08d5c3ca5d4e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_46e7cc73-8c46-4a0e-a4bf-f11a6e9805c5_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c63a8022-0b65-4e3b-b47c-8ae423e3943f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_14e8e18d-f1d8-411f-8882-9b44d041b849_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2b222e71-0342-4ed3-bd9b-cff0bbd42257_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_96c80e1f-b8e3-4d41-8099-bd9113a33ccd_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4b73e31d-944d-4552-a781-5ad60a98a561_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_91c97cd6-53d0-471c-be8c-92e3867ba43a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4fb0fd2a-3248-492e-bc24-d2883edd3cbb_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b9b61d80-28d4-49f7-9343-1346343d0d4b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_cb86e23b-1db7-4c61-81cf-b0da92882002_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_a9a8b5d3-a92a-4d35-810f-2517b406f330_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f3d3d393-cafb-49bf-a8bc-6b942e110eef_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fcf50f05-dacd-465c-a102-08213744b900_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_d94fb1e5-5fb3-4322-9678-72e96fc4bd45_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fe1b7e26-2753-497e-aca1-97128f276976_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_469c3646-1c5c-416d-882a-a01948245853_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0029fc64-934d-4f4e-ac88-d339732397c2_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfTargetedPrograms_54271936-197e-489f-9fef-eef096d937e5_terseLabel_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targeted programs</link:label>
    <link:label id="lab_alny_NumberOfTargetedPrograms_label_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targeted Programs</link:label>
    <link:label id="lab_alny_NumberOfTargetedPrograms_documentation_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targeted programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms" xlink:href="alny-20190930.xsd#alny_NumberOfTargetedPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfTargetedPrograms" xlink:to="lab_alny_NumberOfTargetedPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_12ebacba-3185-4109-ad0d-963038e28ab2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CreditAgreementDisclosureTextBlock_344e8ff1-e3a6-413a-9161-644c69be7504_terseLabel_en-US" xlink:label="lab_alny_CreditAgreementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CREDIT AGREEMENT</link:label>
    <link:label id="lab_alny_CreditAgreementDisclosureTextBlock_label_en-US" xlink:label="lab_alny_CreditAgreementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement Disclosure [Text Block]</link:label>
    <link:label id="lab_alny_CreditAgreementDisclosureTextBlock_documentation_en-US" xlink:label="lab_alny_CreditAgreementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit agreement disclosure text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CreditAgreementDisclosureTextBlock" xlink:href="alny-20190930.xsd#alny_CreditAgreementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CreditAgreementDisclosureTextBlock" xlink:to="lab_alny_CreditAgreementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_24325f64-5970-4aca-aafb-50da5d1d6ed2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e2aa472d-8c28-4b59-b58f-83aa61a5ef42_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5c71ee33-1800-48b5-90f8-63555d5516e6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_99690d0a-d949-4de8-a1f0-dfde74826caf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_EquityTable_6418617e-ed70-4769-8d0a-f3fc705225ab_terseLabel_en-US" xlink:label="lab_alny_EquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Table]</link:label>
    <link:label id="lab_alny_EquityTable_label_en-US" xlink:label="lab_alny_EquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Table]</link:label>
    <link:label id="lab_alny_EquityTable_documentation_en-US" xlink:label="lab_alny_EquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_EquityTable" xlink:href="alny-20190930.xsd#alny_EquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_EquityTable" xlink:to="lab_alny_EquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9f51f13f-4335-498a-a6f5-fbd4ea228d08_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_72e76226-d2a2-4ed4-8513-2510d30dbc00_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5b5980e5-187c-46ad-8d48-e0edbb2e3cd8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options, net of tax withholdings (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79c7b00d-15ec-419c-8cb4-a9ed08a05a25_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_C5LicenseObligationMember_55b367de-1150-4a78-80e7-1f28578c6180_terseLabel_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 License Obligation</link:label>
    <link:label id="lab_alny_C5LicenseObligationMember_label_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 License Obligation [Member]</link:label>
    <link:label id="lab_alny_C5LicenseObligationMember_documentation_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 license obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_C5LicenseObligationMember" xlink:to="lab_alny_C5LicenseObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_54a3de53-fb7d-4347-9841-624474e60293_terseLabel_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery period of programs development</link:label>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_label_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Period Of Programs Development</link:label>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_documentation_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery period of programs development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:href="alny-20190930.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:to="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18b23085-ac77-4b06-828a-3b5ccef15e96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_04e21c50-8c4b-4346-a739-952c70744c51_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized under ASC 606</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_70408c29-485d-4fa6-8f2a-f0a763d9d9b7_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undeveloped land acquired (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0d0cf203-589b-48b4-b55b-c054f4428fe0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4d894c3f-19a1-4f39-9c63-75959f94623a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f9ac6424-3f0f-4054-8627-e6f9ed49baba_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_b55e8964-7a61-4d64-9d93-1dcb868c3e8b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization, net</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_61901bf7-cbe3-42cd-873e-0b4f68f82f57_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8e81df4f-1466-4039-ad59-65441903cd96_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_4c2ef389-9658-4170-aa2c-e3cd51c75ee8_negatedTerseLabel_en-US" xlink:label="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_label_en-US" xlink:label="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Seven And Thereafter</link:label>
    <link:label id="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_documentation_en-US" xlink:label="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due year seven and thereafter.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" xlink:href="alny-20190930.xsd#alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" xlink:to="lab_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_5e0fd893-04e9-4f83-87ae-8f4b701132a9_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e4309bda-e3c1-4519-a680-edfcfe0f249f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c10a99ad-9c52-4830-83ea-1500a9c3bdb0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_VirBiotechnologyIncMember_a6ac2980-5c27-4137-9ca2-5cc217d89fb3_terseLabel_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir Biotechnology</link:label>
    <link:label id="lab_alny_VirBiotechnologyIncMember_8512706a-9f29-427a-99e9-c1c4e3684f1b_verboseLabel_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir</link:label>
    <link:label id="lab_alny_VirBiotechnologyIncMember_label_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir Biotechnology Inc [Member]</link:label>
    <link:label id="lab_alny_VirBiotechnologyIncMember_documentation_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir biotechnology Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_VirBiotechnologyIncMember" xlink:to="lab_alny_VirBiotechnologyIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_554c057c-266f-41c2-b6ca-5c9dc058a121_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4256aa2c-75e6-4085-af4c-a0e389dd651a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_948a937b-7cc1-4ff3-9a1d-9cd738efc70c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_d1248cec-a550-4c52-875e-1cc9f3b8eb76_terseLabel_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Steady State</link:label>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_label_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding An Annual Discovery [Member]</link:label>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_documentation_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding an annual discovery.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember" xlink:href="alny-20190930.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAnAnnualDiscoveryMember" xlink:to="lab_alny_FundingAnAnnualDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_42866684-d512-4d5b-88b9-90e032dcb43a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_169629ab-9650-4a61-9422-23d74f5daa56_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c739e8b3-ea62-4bdd-ba4e-366357bcb9d8_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d55dbd09-fe9e-473a-b21c-5b5979091b45_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_e9e1b594-d5ca-4e97-818a-22ed8f544878_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3ad57e87-f53f-42a6-81e6-053f0fd06dfe_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cb1c63f6-f7f6-4782-ad5c-7fd7e01b34d4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_09953da3-fc10-4bab-8cc9-853189643039_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8ed4e773-3185-4c9b-929a-f945a575f9db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_667fe8d2-27a2-40a9-a6b5-b8eac24be22b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d2735618-3a5d-42ff-85ca-54e3671b9c3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_e2f70dcb-2838-4658-9a21-96b1396f9966_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_950bccbb-491e-408c-a02e-2fb8c9d6dbec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_327aa566-5184-4f17-8f16-e1eefa62fb65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d2d1863e-9ff5-45aa-aca5-3184f38e3ef9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_de92329d-ae4e-45dc-a07a-f72474c08ecd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9202bb1b-ded9-42bf-a35f-29f26fcf074a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options, net of tax withholdings</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_e249adcc-ed58-40cc-894f-49dfb82fbd57_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Vir common stock</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_391d4416-afec-4f73-8b09-b4c2f17e7056_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_2a376e0b-ac74-4d0d-89da-cbd59416ff78_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_4d1ad9ea-041f-467f-87ed-8b343d390ca3_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_622097a8-c1e9-4e45-9d9d-52bad2146e75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_WellsFargoCreditFacilityMember_989553b1-746a-4013-ac18-c6aecf6fd942_terseLabel_en-US" xlink:label="lab_alny_WellsFargoCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wells Fargo Bank, National Association</link:label>
    <link:label id="lab_alny_WellsFargoCreditFacilityMember_label_en-US" xlink:label="lab_alny_WellsFargoCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wells Fargo Credit Facility [Member]</link:label>
    <link:label id="lab_alny_WellsFargoCreditFacilityMember_documentation_en-US" xlink:label="lab_alny_WellsFargoCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wells Fargo credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_WellsFargoCreditFacilityMember" xlink:href="alny-20190930.xsd#alny_WellsFargoCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_WellsFargoCreditFacilityMember" xlink:to="lab_alny_WellsFargoCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_706d51c4-bd19-4334-9d36-9a8a1a77f605_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_TermLoanFacilityMember_a0c02434-0314-4cf6-9ed0-f99c352164e8_terseLabel_en-US" xlink:label="lab_alny_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_alny_TermLoanFacilityMember_label_en-US" xlink:label="lab_alny_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_alny_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_alny_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TermLoanFacilityMember" xlink:href="alny-20190930.xsd#alny_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_TermLoanFacilityMember" xlink:to="lab_alny_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_43bc792a-2278-4347-9114-56abea8e8b64_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_28b76af0-ca80-4daa-b228-2f69ae842d4a_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement milestone payments</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_label_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Milestone Payments</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments" xlink:href="alny-20190930.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementMilestonePayments" xlink:to="lab_alny_CollaborativeArrangementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3b1cdec5-f5dc-4816-8812-b369543ed710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1f92503c-2a48-437a-8f44-215d4ac9ea08_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fd2fe43a-7a57-4fd0-b092-86f5e31f30d3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ImpairmentOfMarketableDebtSecurities_ea4a5d8a-c570-450f-a5ce-8eab19dae285_terseLabel_en-US" xlink:label="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges of marketable debt securities</link:label>
    <link:label id="lab_alny_ImpairmentOfMarketableDebtSecurities_label_en-US" xlink:label="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Marketable Debt Securities</link:label>
    <link:label id="lab_alny_ImpairmentOfMarketableDebtSecurities_documentation_en-US" xlink:label="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of marketable debt securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ImpairmentOfMarketableDebtSecurities" xlink:href="alny-20190930.xsd#alny_ImpairmentOfMarketableDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ImpairmentOfMarketableDebtSecurities" xlink:to="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_16e40a68-57a7-4e2a-80a3-a019fbef9f60_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>alny-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:5d2595a3-a26b-49fe-8f15-878ed8f526a8,g:8c29cc34-fc93-4a2b-96ed-ef5f86bbe907-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alnylam.com/role/Cover" xlink:type="simple" xlink:href="alny-20190930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_263aebef-43d1-4fe2-8bde-d071e915f5fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_DocumentType_263aebef-43d1-4fe2-8bde-d071e915f5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c9627ad9-73ae-449b-a744-2cb8f9dd22a8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_DocumentQuarterlyReport_c9627ad9-73ae-449b-a744-2cb8f9dd22a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_82857e0b-2034-4c6c-b404-21753ebdf8d2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_DocumentPeriodEndDate_82857e0b-2034-4c6c-b404-21753ebdf8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_29e23f98-c830-4b3b-9f26-1ca2028218f1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_DocumentTransitionReport_29e23f98-c830-4b3b-9f26-1ca2028218f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_77faa06b-e722-4933-9fc8-6a4ce2964361" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityFileNumber_77faa06b-e722-4933-9fc8-6a4ce2964361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3763c2ff-2e97-43ad-abce-e1933789cd92" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityRegistrantName_3763c2ff-2e97-43ad-abce-e1933789cd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_61ef574d-6cf0-4108-9e35-7be937990cfb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityIncorporationStateCountryCode_61ef574d-6cf0-4108-9e35-7be937990cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_858734f2-72fc-4ea6-bd4a-b5aef27d0c9b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityTaxIdentificationNumber_858734f2-72fc-4ea6-bd4a-b5aef27d0c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d3e66aaa-aeec-4d21-91c6-805064a33d71" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityAddressAddressLine1_d3e66aaa-aeec-4d21-91c6-805064a33d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_067ff602-3cec-4eed-9815-ce29faa291fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityAddressAddressLine2_067ff602-3cec-4eed-9815-ce29faa291fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_98f42bb5-84c7-44fd-b938-8e93916caca4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityAddressCityOrTown_98f42bb5-84c7-44fd-b938-8e93916caca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f080bf3c-d42e-4cd4-ad73-2e1eb6819773" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityAddressStateOrProvince_f080bf3c-d42e-4cd4-ad73-2e1eb6819773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7b12dc3-88d9-4a40-ad96-d259628ed363" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityAddressPostalZipCode_d7b12dc3-88d9-4a40-ad96-d259628ed363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_05470d8d-4929-41d4-8864-5edc02d03014" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_CityAreaCode_05470d8d-4929-41d4-8864-5edc02d03014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a664ccf2-9d57-467b-a07f-63fc328927c9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_LocalPhoneNumber_a664ccf2-9d57-467b-a07f-63fc328927c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d1f5ac96-0b7b-4c2a-80f4-141df588439f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_Security12bTitle_d1f5ac96-0b7b-4c2a-80f4-141df588439f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_94f8d841-394f-4a45-8cf0-eb5423da3029" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_TradingSymbol_94f8d841-394f-4a45-8cf0-eb5423da3029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fcfe0b6f-44e8-4b5c-b729-6e79a42d2dd0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_SecurityExchangeName_fcfe0b6f-44e8-4b5c-b729-6e79a42d2dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7489976d-b514-42c9-abef-d5ed757aa6c4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityCurrentReportingStatus_7489976d-b514-42c9-abef-d5ed757aa6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c1f37a6d-69b8-4b2e-ae37-21b5cc6ebdfc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityInteractiveDataCurrent_c1f37a6d-69b8-4b2e-ae37-21b5cc6ebdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_992aeecd-9b82-49c9-a5ba-eee6d7e0c2dc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityFilerCategory_992aeecd-9b82-49c9-a5ba-eee6d7e0c2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_97f434ef-93ed-4e51-a57b-6e2bec65eee2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntitySmallBusiness_97f434ef-93ed-4e51-a57b-6e2bec65eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b0f82f86-263f-435c-a419-8f8daf6328cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityEmergingGrowthCompany_b0f82f86-263f-435c-a419-8f8daf6328cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8ee89b36-5e2b-4911-be90-c3763c67377c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityShellCompany_8ee89b36-5e2b-4911-be90-c3763c67377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_db174629-193d-4ce4-bfa9-76872bb638c8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_db174629-193d-4ce4-bfa9-76872bb638c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d17cdf83-0563-494d-8cb9-04b154b9213c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_EntityCentralIndexKey_d17cdf83-0563-494d-8cb9-04b154b9213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_53831917-be78-4d00-8145-5a2f54436d40" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_CurrentFiscalYearEndDate_53831917-be78-4d00-8145-5a2f54436d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fcac18a7-043d-4d62-b49c-0ad7a4aaed04" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_DocumentFiscalYearFocus_fcac18a7-043d-4d62-b49c-0ad7a4aaed04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1179bb1e-9c87-4a72-83da-beac49d836be" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1179bb1e-9c87-4a72-83da-beac49d836be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_024b806e-5b9b-4df7-9121-bc622a64a4fd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_06a8d0d7-5abc-4de7-bd65-c8950a2f6f10" xlink:to="loc_dei_AmendmentFlag_024b806e-5b9b-4df7-9121-bc622a64a4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_984e2397-e40e-45fc-9a85-c0d89e1c1424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_984e2397-e40e-45fc-9a85-c0d89e1c1424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8d774082-93bb-4511-ae9b-70801f8f955b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8d774082-93bb-4511-ae9b-70801f8f955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_92b9267a-d30c-4d8d-a6e2-403d9e6da735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_92b9267a-d30c-4d8d-a6e2-403d9e6da735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_605d182d-c716-4af5-80af-d4ee7e30225f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:to="loc_us-gaap_InventoryNet_605d182d-c716-4af5-80af-d4ee7e30225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d190568-7c4a-420e-b781-afa776ae3f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d190568-7c4a-420e-b781-afa776ae3f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d4d59a94-a3b1-4967-9928-1dc9cdfcc5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f059948-ef07-40c3-8f4d-46c27d9fb454" xlink:to="loc_us-gaap_AssetsCurrent_d4d59a94-a3b1-4967-9928-1dc9cdfcc5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_185b0203-7449-4d61-aa10-45af07f354b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_185b0203-7449-4d61-aa10-45af07f354b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1923c87f-b388-4772-9caf-a590e5d07dff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1923c87f-b388-4772-9caf-a590e5d07dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_1005dc3d-c27c-4e06-b6f0-77452df1cbec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_1005dc3d-c27c-4e06-b6f0-77452df1cbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f769a816-46ac-4d47-a794-31d08a62a30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f769a816-46ac-4d47-a794-31d08a62a30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ee6b5847-aaa0-48be-aa2e-58e593a95234" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_064924c5-4dcb-4cb1-975d-8f42c4b7971a" xlink:to="loc_us-gaap_Assets_ee6b5847-aaa0-48be-aa2e-58e593a95234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6c904e34-3c81-465e-8008-aafa3718ca51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:to="loc_us-gaap_AccountsPayableCurrent_6c904e34-3c81-465e-8008-aafa3718ca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d005fe9d-fdcb-411a-a78b-ece4fa4ba551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d005fe9d-fdcb-411a-a78b-ece4fa4ba551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_88cbf9c2-6497-4d79-9fb8-a825def01201" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_88cbf9c2-6497-4d79-9fb8-a825def01201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_1c018f5b-5856-4287-884f-9238237f6de5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_1c018f5b-5856-4287-884f-9238237f6de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df05cde2-0cd1-42e5-ab7d-d09ae127fee7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df05cde2-0cd1-42e5-ab7d-d09ae127fee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bc912db1-4457-4617-9737-49da08903762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19de568f-0f89-4fb8-a808-7dcd2f5f2593" xlink:to="loc_us-gaap_LiabilitiesCurrent_bc912db1-4457-4617-9737-49da08903762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac9592a3-cd16-4785-bbc8-07ed2eb35757" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac9592a3-cd16-4785-bbc8-07ed2eb35757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_6f31b8c6-c352-413f-9809-f9a2d8856cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_6f31b8c6-c352-413f-9809-f9a2d8856cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_72d48a84-0027-4e26-8023-593583834e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_72d48a84-0027-4e26-8023-593583834e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_b851a568-a98f-490e-8435-989a9b93004d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_SecuredLongTermDebt_b851a568-a98f-490e-8435-989a9b93004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e0e49c04-78c3-4a97-bf19-50cf8e255700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e0e49c04-78c3-4a97-bf19-50cf8e255700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_913571f8-76bf-4e30-84ee-ab37e74a16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_Liabilities_913571f8-76bf-4e30-84ee-ab37e74a16c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0f5dccd7-ec6e-46f9-8acb-207b5cb1b269" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0f5dccd7-ec6e-46f9-8acb-207b5cb1b269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7d0e0303-83b1-425e-a051-ab495ac77e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:to="loc_us-gaap_PreferredStockValue_7d0e0303-83b1-425e-a051-ab495ac77e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9022fe3c-fd8e-44c2-86b1-c85bb9c7a9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:to="loc_us-gaap_CommonStockValue_9022fe3c-fd8e-44c2-86b1-c85bb9c7a9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e743184d-2171-4c5a-ae63-f21f302c7d50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e743184d-2171-4c5a-ae63-f21f302c7d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7b1ca97-beb0-4ef0-acb8-37b48425394f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7b1ca97-beb0-4ef0-acb8-37b48425394f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12aa9da0-9a86-472d-a1ce-89869a51d217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12aa9da0-9a86-472d-a1ce-89869a51d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2172a9de-fc08-4204-9e55-92f1df4efc0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b2abc41f-8c8b-400a-ad59-a72df4eaee4b" xlink:to="loc_us-gaap_StockholdersEquity_2172a9de-fc08-4204-9e55-92f1df4efc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d978144d-37a1-4490-9958-0547fd92e66e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e54b26b-74e5-4572-bf2d-3dad54e4835e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d978144d-37a1-4490-9958-0547fd92e66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6defbe16-6a54-4ec1-891a-ac44fb6c8769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6defbe16-6a54-4ec1-891a-ac44fb6c8769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_adaeba83-0611-4323-bc70-7aa430d95c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_adaeba83-0611-4323-bc70-7aa430d95c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6d6e723d-2ee9-426b-8721-76c256662c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6d6e723d-2ee9-426b-8721-76c256662c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_86096e11-7b7e-43f5-9fcc-333fbf2088de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_86096e11-7b7e-43f5-9fcc-333fbf2088de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17817539-6750-49ae-9081-6305aa7df5f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17817539-6750-49ae-9081-6305aa7df5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_bf890264-2a74-40da-9907-72e512b4c516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_bf890264-2a74-40da-9907-72e512b4c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_8c0b6f67-ebb6-428a-a0de-69e317781821" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7a439cf5-0a4c-4660-89fc-f5da36ed11ca" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_8c0b6f67-ebb6-428a-a0de-69e317781821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_42290a3b-ab57-4538-986d-b0eab5537025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_42290a3b-ab57-4538-986d-b0eab5537025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f1c07609-b904-4d2c-868f-3ec7e9d5f7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f1c07609-b904-4d2c-868f-3ec7e9d5f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b6569628-d656-421c-bf73-349266c16d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b6569628-d656-421c-bf73-349266c16d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3bc9740c-40d5-4b00-a0d5-5b57fb57a6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3bc9740c-40d5-4b00-a0d5-5b57fb57a6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b1a9309-41c5-4be1-8948-6f68c9673f04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b1a9309-41c5-4be1-8948-6f68c9673f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d05779fc-560f-4448-8a0a-096f10da3327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d05779fc-560f-4448-8a0a-096f10da3327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_22af9a20-0afc-461d-812d-c84165b2fdd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_CommonStockSharesIssued_22af9a20-0afc-461d-812d-c84165b2fdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f85c03f2-1f45-4a60-b9a9-7dbdb15c9432" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf77f5e6-2e89-4644-9d8a-6b5ad9b6ca4c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f85c03f2-1f45-4a60-b9a9-7dbdb15c9432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c331d405-88d8-4a7e-8e13-a931e05c5fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c331d405-88d8-4a7e-8e13-a931e05c5fdc" xlink:to="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:to="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4fbce21b-55f0-4b56-810c-ae00014a73a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_59714f2d-251a-40a9-b30d-458125f6a7f4" xlink:to="loc_srt_ProductsAndServicesDomain_4fbce21b-55f0-4b56-810c-ae00014a73a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fd899c0c-5d2c-42d6-b2d2-dac10831d280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4fbce21b-55f0-4b56-810c-ae00014a73a7" xlink:to="loc_us-gaap_ProductMember_fd899c0c-5d2c-42d6-b2d2-dac10831d280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a024a925-1915-44b5-8344-55c1b3c680a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f72ff703-12f2-4049-91f4-ff9217a0c384" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a024a925-1915-44b5-8344-55c1b3c680a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e1d80e97-6cc7-4952-a36c-d007dbb1baf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a024a925-1915-44b5-8344-55c1b3c680a2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e1d80e97-6cc7-4952-a36c-d007dbb1baf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_268de6df-9267-4ca9-bb87-07d4246a5237" xlink:to="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f67cbac5-db01-4d77-880b-c06eb0ffd022" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_RevenuesAbstract_f67cbac5-db01-4d77-880b-c06eb0ffd022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0506d9f9-5a6e-4a45-b5ad-01afc67adc77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f67cbac5-db01-4d77-880b-c06eb0ffd022" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0506d9f9-5a6e-4a45-b5ad-01afc67adc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_54bf4aa5-79d3-42ce-a594-efb7406ce495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_54bf4aa5-79d3-42ce-a594-efb7406ce495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b4f48ced-b251-4560-b342-a0063aa83932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b4f48ced-b251-4560-b342-a0063aa83932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3095f4af-ea9e-4e3f-bb5b-a3079878eab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3095f4af-ea9e-4e3f-bb5b-a3079878eab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f0f0f870-0ea9-435d-b251-e74851c3c137" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_71034dd3-b6a3-42a5-a216-492b92662525" xlink:to="loc_us-gaap_CostsAndExpenses_f0f0f870-0ea9-435d-b251-e74851c3c137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b2851ba2-1abc-41fd-b8b7-850330bbdaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_OperatingIncomeLoss_b2851ba2-1abc-41fd-b8b7-850330bbdaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7a888bfa-1da6-443d-9155-bc8099728ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_InvestmentIncomeNet_7a888bfa-1da6-443d-9155-bc8099728ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6c0c97ef-80f1-456d-be94-7f4f44c1fc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6c0c97ef-80f1-456d-be94-7f4f44c1fc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_43919d33-e9cb-467d-bc44-9d90af097497" xlink:href="alny-20190930.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_43919d33-e9cb-467d-bc44-9d90af097497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c6eb7e69-9a4c-4f94-9e54-7a7dc528ab6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c6eb7e69-9a4c-4f94-9e54-7a7dc528ab6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d49237b5-7a55-4bfb-a7d2-6c6846c99654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7009ceee-a7d5-45db-a27d-b1529d7d2883" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d49237b5-7a55-4bfb-a7d2-6c6846c99654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1339d396-da2a-4d9c-9636-daf183a9dd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1339d396-da2a-4d9c-9636-daf183a9dd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9a804b22-6cf7-491a-aad0-8fd3758ef9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9a804b22-6cf7-491a-aad0-8fd3758ef9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b796883f-a9e6-47ca-9054-7b4e1e9ec3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_NetIncomeLoss_b796883f-a9e6-47ca-9054-7b4e1e9ec3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2dddbc16-5e99-46bf-a379-e7183de94872" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2dddbc16-5e99-46bf-a379-e7183de94872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_472dd9a8-d04a-4591-9842-792db66a822f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_472dd9a8-d04a-4591-9842-792db66a822f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104b75ef-32cd-42ca-8a22-9623855cbb07" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea0f3b23-3de4-40a3-b56a-f3ba175ddf8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_NetIncomeLoss_ea0f3b23-3de4-40a3-b56a-f3ba175ddf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ffc56d5-73c0-452c-993e-0c1191cb1fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ffc56d5-73c0-452c-993e-0c1191cb1fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3827c6cc-1ba5-44fb-bf98-64b7d46047fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3827c6cc-1ba5-44fb-bf98-64b7d46047fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1b721afe-1622-49e2-a05f-1ae6f6ed7f35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1b721afe-1622-49e2-a05f-1ae6f6ed7f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_aa4fc025-0f1f-4fc4-ab05-09f184390492" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_38bcae06-5d89-4fca-87ab-85b2f2c606c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_aa4fc025-0f1f-4fc4-ab05-09f184390492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ce6932c8-55d3-4ab5-b6f6-b82e83a57943" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ce6932c8-55d3-4ab5-b6f6-b82e83a57943" xlink:to="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c01c11a4-e35a-4439-8216-33929cdf0a5a" xlink:to="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_56b18a11-e773-435e-86e7-05d86329fb65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_CommonStockMember_56b18a11-e773-435e-86e7-05d86329fb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee3a45b1-c2d5-412d-8b1f-4cf0d464978f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee3a45b1-c2d5-412d-8b1f-4cf0d464978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_be742780-1465-40c9-8725-dcd816b9ad54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_be742780-1465-40c9-8725-dcd816b9ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40b4ae6b-c1f5-4677-ae0f-4b392ff6ec61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16132a8a-8367-4c28-b854-9499a6494ad9" xlink:to="loc_us-gaap_RetainedEarningsMember_40b4ae6b-c1f5-4677-ae0f-4b392ff6ec61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5903bbee-8950-42cd-92f1-d568831e09ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c91f81b2-c4fa-41da-bf53-5e512453fd54" xlink:to="loc_us-gaap_StatementLineItems_5903bbee-8950-42cd-92f1-d568831e09ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5903bbee-8950-42cd-92f1-d568831e09ab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fb942bb-31c3-45f2-9c02-39038a76fa6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockholdersEquity_9fb942bb-31c3-45f2-9c02-39038a76fa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7c8594e4-8b01-483d-8da8-6274acfa9862" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7c8594e4-8b01-483d-8da8-6274acfa9862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_fe8c82df-e768-4a0a-81fc-cbc97631c965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_fe8c82df-e768-4a0a-81fc-cbc97631c965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3b1477fe-c278-47f0-bfb2-4c601dabcf13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3b1477fe-c278-47f0-bfb2-4c601dabcf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9872c9c-2eab-4c6c-8c0e-42575c1f40f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9872c9c-2eab-4c6c-8c0e-42575c1f40f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_e7bf528c-8012-4701-bf23-52a4bb609c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_e7bf528c-8012-4701-bf23-52a4bb609c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_0074d393-b870-446c-81fd-7bcbcfd396b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_0074d393-b870-446c-81fd-7bcbcfd396b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_22ee4266-039a-4deb-b726-f1a81c365e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_22ee4266-039a-4deb-b726-f1a81c365e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_471aaef8-c59b-416a-b02f-8d0705be8a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_471aaef8-c59b-416a-b02f-8d0705be8a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_383af93e-8428-456f-95c9-a5744a428054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_383af93e-8428-456f-95c9-a5744a428054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a502e68-de55-43ac-965e-6eda2cb7f15b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2a502e68-de55-43ac-965e-6eda2cb7f15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_734a4a52-a03b-44da-9154-f8ac008ae9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_734a4a52-a03b-44da-9154-f8ac008ae9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_efb61729-1232-401c-931d-fa53e6b1195a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_efb61729-1232-401c-931d-fa53e6b1195a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e6da01d-2832-4301-8992-8b7ce44d6c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_NetIncomeLoss_0e6da01d-2832-4301-8992-8b7ce44d6c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ce6e3bc1-6095-4ad3-b534-38da1ef6da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_StockholdersEquity_ce6e3bc1-6095-4ad3-b534-38da1ef6da9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_837600cc-8a96-4b1a-8f0d-18cdcbc6ac3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a19995bc-5194-4f0b-af2f-57f67ea5b1ba" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_837600cc-8a96-4b1a-8f0d-18cdcbc6ac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20190930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0b9ff84-40c2-40fc-96e2-7e64f7da056f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0b9ff84-40c2-40fc-96e2-7e64f7da056f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f0b69b5f-e40a-48f4-a05b-7fe6c3c69794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0b9ff84-40c2-40fc-96e2-7e64f7da056f" xlink:to="loc_us-gaap_ProfitLoss_f0b69b5f-e40a-48f4-a05b-7fe6c3c69794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0b9ff84-40c2-40fc-96e2-7e64f7da056f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_015e88f7-3e37-453c-bbfe-e0d13d241630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_015e88f7-3e37-453c-bbfe-e0d13d241630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_78ab5abe-dc47-4e37-a4ce-7ff32fdec3f4" xlink:href="alny-20190930.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_78ab5abe-dc47-4e37-a4ce-7ff32fdec3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bf31396f-23f2-451e-8f42-b1e452cbd5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_us-gaap_ShareBasedCompensation_bf31396f-23f2-451e-8f42-b1e452cbd5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashGainOnLitigationSettlement_c605b370-76ff-4902-b9e3-37b04ba0ca4d" xlink:href="alny-20190930.xsd#alny_NonCashGainOnLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_alny_NonCashGainOnLitigationSettlement_c605b370-76ff-4902-b9e3-37b04ba0ca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_e87de49f-06fc-44e7-936e-8a1049c542ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_e87de49f-06fc-44e7-936e-8a1049c542ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ChangeInFairValueOfLiabilityObligation_477dc3c5-9e7b-49c5-9bf8-2e1b5775ecfd" xlink:href="alny-20190930.xsd#alny_ChangeInFairValueOfLiabilityObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_alny_ChangeInFairValueOfLiabilityObligation_477dc3c5-9e7b-49c5-9bf8-2e1b5775ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_cea898c0-37d3-4bb1-be5e-d160424c81ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_cea898c0-37d3-4bb1-be5e-d160424c81ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0fb7624-0beb-4973-ad81-99529ae6935f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c91eaffa-6722-4c66-a00c-859fdb270237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c91eaffa-6722-4c66-a00c-859fdb270237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_df6814b8-c29f-447e-8d28-4b824830f2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_df6814b8-c29f-447e-8d28-4b824830f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ab180257-18ee-4f0b-965c-1e1f55755618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ab180257-18ee-4f0b-965c-1e1f55755618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9479bab1-345c-4711-bb8f-e5573d4f72d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9479bab1-345c-4711-bb8f-e5573d4f72d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2afb270b-bcf6-4597-92c6-6d15ec48aa70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2afb270b-bcf6-4597-92c6-6d15ec48aa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d3477468-a7a8-4fcf-9a44-2a29ac35b15f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d3477468-a7a8-4fcf-9a44-2a29ac35b15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_809c5e12-a98f-45c6-a6ae-35343a1e31cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_edcb4c18-4c4f-4042-88b9-a02570acdb4c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_809c5e12-a98f-45c6-a6ae-35343a1e31cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14339da5-171b-404b-aa0c-138e08353b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0b9ff84-40c2-40fc-96e2-7e64f7da056f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14339da5-171b-404b-aa0c-138e08353b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2476729c-db76-48f1-96e1-ca18443865dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2476729c-db76-48f1-96e1-ca18443865dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_93e8acf5-497c-4b21-8203-ffce4cab6029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_93e8acf5-497c-4b21-8203-ffce4cab6029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_3f7979d8-9b28-40a2-befd-238426add1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_3f7979d8-9b28-40a2-befd-238426add1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a36c88bb-f0f9-420c-973d-dbfbbc151c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a36c88bb-f0f9-420c-973d-dbfbbc151c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f19f0dce-a405-4b4b-86c4-6d143818be1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f19f0dce-a405-4b4b-86c4-6d143818be1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c2aebeb-2871-48ca-8351-af9cdf65b957" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62b64f1d-e208-47e8-803e-c3d2fb73a87d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c2aebeb-2871-48ca-8351-af9cdf65b957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_aac2c9f3-98b7-4f03-9f79-4b3bf25dfb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_aac2c9f3-98b7-4f03-9f79-4b3bf25dfb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ba6a6804-18a4-43a4-b718-ad66729ee45f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ba6a6804-18a4-43a4-b718-ad66729ee45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7fe0f10f-659b-4dea-8fd5-e4c3626a7c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7fe0f10f-659b-4dea-8fd5-e4c3626a7c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c47f5f40-4b97-4af8-9107-91b1e7fd0d13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c47f5f40-4b97-4af8-9107-91b1e7fd0d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5ff75d8-9ab7-4927-b14e-fd2c0fac7e45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_680fb3c1-61a9-486e-9582-4aece7b862dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5ff75d8-9ab7-4927-b14e-fd2c0fac7e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea8137c4-c29b-4cff-aacb-5941796e6d93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea8137c4-c29b-4cff-aacb-5941796e6d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_57ace4e6-4691-4ea3-95cd-446b5cdab368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_57ace4e6-4691-4ea3-95cd-446b5cdab368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c29bdafa-ea82-467f-b9c4-95d056baac83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c29bdafa-ea82-467f-b9c4-95d056baac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bf32c69f-df12-4f0b-9462-a9abb1d855cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bf32c69f-df12-4f0b-9462-a9abb1d855cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2ebd157b-c22a-4b3c-bfe7-3a75eda6c29f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d7536e6f-ea7d-4d01-9618-af712962bff4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2ebd157b-c22a-4b3c-bfe7-3a75eda6c29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_135b197a-4f6b-42f6-a26e-47f58c747b03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2ebd157b-c22a-4b3c-bfe7-3a75eda6c29f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_135b197a-4f6b-42f6-a26e-47f58c747b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20190930.xsd#NATUREOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c9de74e-3759-4c2c-9e01-5f232f9e58c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_fad04603-a467-40ca-9267-be598248fcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c9de74e-3759-4c2c-9e01-5f232f9e58c6" xlink:to="loc_us-gaap_NatureOfOperations_fad04603-a467-40ca-9267-be598248fcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20190930.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5be34975-84f0-42e2-83aa-d7f269941d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_819f7013-6da2-46d3-b3b7-4ec9ea2002ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5be34975-84f0-42e2-83aa-d7f269941d4f" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_819f7013-6da2-46d3-b3b7-4ec9ea2002ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20190930.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f229125c-bba6-4ac1-a70b-1949f05fd146" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_825df24a-42e9-4072-86a9-ec6459565450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f229125c-bba6-4ac1-a70b-1949f05fd146" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_825df24a-42e9-4072-86a9-ec6459565450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f8f86fcd-55ba-4743-972d-ddf4dbe196d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f229125c-bba6-4ac1-a70b-1949f05fd146" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f8f86fcd-55ba-4743-972d-ddf4dbe196d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiquidityPolicyTextBlock_f8122fdf-844b-4283-91c0-1db655e6f6ed" xlink:href="alny-20190930.xsd#alny_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f229125c-bba6-4ac1-a70b-1949f05fd146" xlink:to="loc_alny_LiquidityPolicyTextBlock_f8122fdf-844b-4283-91c0-1db655e6f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LeasesPolicyPolicyTextBlock_ade3cc09-bd3e-4d97-b93b-f590d03b1288" xlink:href="alny-20190930.xsd#alny_LeasesPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f229125c-bba6-4ac1-a70b-1949f05fd146" xlink:to="loc_alny_LeasesPolicyPolicyTextBlock_ade3cc09-bd3e-4d97-b93b-f590d03b1288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ffe5e0a-4922-4154-af81-2b8ad9b5a9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f229125c-bba6-4ac1-a70b-1949f05fd146" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ffe5e0a-4922-4154-af81-2b8ad9b5a9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e26beeab-cc69-46af-a3ec-b279342501c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c51b5d3c-0500-438f-a526-5a89928cb14b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e26beeab-cc69-46af-a3ec-b279342501c2" xlink:to="loc_us-gaap_OperatingLeaseLiability_c51b5d3c-0500-438f-a526-5a89928cb14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_670e9c21-af05-4ad3-8383-797342f83756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e26beeab-cc69-46af-a3ec-b279342501c2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_670e9c21-af05-4ad3-8383-797342f83756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNET" xlink:type="simple" xlink:href="alny-20190930.xsd#PRODUCTREVENUESNET"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/PRODUCTREVENUESNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5834d3c-65ba-4c92-8425-4279aa5eb7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7513df99-066d-48e0-8c10-c594f67f5a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5834d3c-65ba-4c92-8425-4279aa5eb7a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7513df99-066d-48e0-8c10-c594f67f5a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/PRODUCTREVENUESNETTables" xlink:type="simple" xlink:href="alny-20190930.xsd#PRODUCTREVENUESNETTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/PRODUCTREVENUESNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbae15da-04bc-4927-a6fc-3c589964f77d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_9f20eba2-fb60-4f35-b297-00f457af31d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbae15da-04bc-4927-a6fc-3c589964f77d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_9f20eba2-fb60-4f35-b297-00f457af31d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2a1f5119-6cbd-4108-a7fb-6255df36dd62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2a1f5119-6cbd-4108-a7fb-6255df36dd62" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:to="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6efcfd94-3700-4843-bec2-7c79ec13b792" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0d5089be-ae6a-49b4-822e-b404f33bd727" xlink:to="loc_srt_ProductsAndServicesDomain_6efcfd94-3700-4843-bec2-7c79ec13b792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_238c63dc-6e76-4217-a882-a0f4ad194917" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6efcfd94-3700-4843-bec2-7c79ec13b792" xlink:to="loc_us-gaap_ProductMember_238c63dc-6e76-4217-a882-a0f4ad194917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:to="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_aae407fd-53cc-43eb-8d74-09ec6491e337" xlink:to="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4f323873-d098-4b58-9bc9-c42a3532eb00" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:to="loc_country_US_4f323873-d098-4b58-9bc9-c42a3532eb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_53ccd722-ebba-418a-b27b-a8796f02b3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e5581c4-729c-43a2-9efa-2d24b69f1344" xlink:to="loc_us-gaap_NonUsMember_53ccd722-ebba-418a-b27b-a8796f02b3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fabe1e0f-3b2a-42c4-babd-98aeea820b94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28b293a7-b8e1-4842-b365-07d607457af0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fabe1e0f-3b2a-42c4-babd-98aeea820b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45d87c8c-b9ec-4e59-a9b7-3703304e1074" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fabe1e0f-3b2a-42c4-babd-98aeea820b94" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45d87c8c-b9ec-4e59-a9b7-3703304e1074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ProductRevenuesNetAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_53ffccdc-26f1-4bc2-8e8e-03410d02391d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_53ffccdc-26f1-4bc2-8e8e-03410d02391d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:to="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3fc8dfd9-3e5f-4581-b030-d77f34ab0b34" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_79690e33-c47b-42b4-bc04-f4988c631d40" xlink:to="loc_srt_ProductsAndServicesDomain_3fc8dfd9-3e5f-4581-b030-d77f34ab0b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_79185054-efc8-489e-a194-d075b4fbab03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fc8dfd9-3e5f-4581-b030-d77f34ab0b34" xlink:to="loc_us-gaap_ProductMember_79185054-efc8-489e-a194-d075b4fbab03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_39bb9f28-1452-4b5c-b08e-98e5b5990cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f407dba5-53eb-4b90-9895-85fc43dd3d54" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_39bb9f28-1452-4b5c-b08e-98e5b5990cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8bbe1de4-d83a-42ac-9082-d9d80075e1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39bb9f28-1452-4b5c-b08e-98e5b5990cb6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8bbe1de4-d83a-42ac-9082-d9d80075e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS" xlink:type="simple" xlink:href="alny-20190930.xsd#COLLABORATIONAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/COLLABORATIONAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67c08442-096f-436a-b44d-18fb510196d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_67f5ce44-e903-4fd4-877f-f19d57ddeeac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67c08442-096f-436a-b44d-18fb510196d8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_67f5ce44-e903-4fd4-877f-f19d57ddeeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#COLLABORATIONAGREEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb8d19f-8493-41ff-ba62-858b32729080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_caea7108-ad1d-4f91-b727-b2e085ecec44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb8d19f-8493-41ff-ba62-858b32729080" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_caea7108-ad1d-4f91-b727-b2e085ecec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_660b4cc1-1ba4-42b9-9c50-64e4bee99be9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb8d19f-8493-41ff-ba62-858b32729080" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_660b4cc1-1ba4-42b9-9c50-64e4bee99be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock_021330ff-c8a8-47a1-baed-fab749859def" xlink:href="alny-20190930.xsd#alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb8d19f-8493-41ff-ba62-858b32729080" xlink:to="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock_021330ff-c8a8-47a1-baed-fab749859def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_c5c7c689-d0f1-4f45-9746-684affe2a5de" xlink:href="alny-20190930.xsd#alny_ScheduleOfAllocatedTransactionPriceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb8d19f-8493-41ff-ba62-858b32729080" xlink:to="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_c5c7c689-d0f1-4f45-9746-684affe2a5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_9863cb21-f953-468e-8b5c-3a804676df11" xlink:href="alny-20190930.xsd#alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb8d19f-8493-41ff-ba62-858b32729080" xlink:to="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_9863cb21-f953-468e-8b5c-3a804676df11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsRevenuefromCollaboratorsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e6c8961-165d-430f-b062-829d599802b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e6c8961-165d-430f-b062-829d599802b2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5beb7de4-4469-4ec5-b719-5fc3036a1293" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_58cf66fa-d440-468b-83fb-fb7749b2f08c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_58cf66fa-d440-468b-83fb-fb7749b2f08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_d5341f23-d0f1-4a27-8a36-18fadf0473eb" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311dd54c-00bf-423a-a23c-c11d34c0c7c3" xlink:to="loc_alny_GlobalStrategicCollaborationMember_d5341f23-d0f1-4a27-8a36-18fadf0473eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fc26e0f7-1471-4255-8785-5be6e1567871" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_35af6b0d-bc8c-489b-b059-5cec2d265747" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_SanofiGenzymeMember_35af6b0d-bc8c-489b-b059-5cec2d265747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_03069cac-2dc9-4f95-9035-f52790ddf975" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_VirBiotechnologyIncMember_03069cac-2dc9-4f95-9035-f52790ddf975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MdcoMember_a92e731a-86d4-49a1-b200-219a730aceb4" xlink:href="alny-20190930.xsd#alny_MdcoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_MdcoMember_a92e731a-86d4-49a1-b200-219a730aceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_de98ece8-6672-4a67-bcaf-abdac84522cd" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_de98ece8-6672-4a67-bcaf-abdac84522cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_84b349f2-05e5-4732-8cee-7e8186048a84" xlink:href="alny-20190930.xsd#alny_OtherCollaborationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_44a9bae8-ab3d-4dc3-b3fd-5ed651c62554" xlink:to="loc_alny_OtherCollaborationsMember_84b349f2-05e5-4732-8cee-7e8186048a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a4f5a70c-a05c-43d5-884a-b546fe6fb672" xlink:to="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_b5bf113e-3dae-4aad-9637-a900d2fe0d3f" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:to="loc_alny_ResearchServicesObligationMember_b5bf113e-3dae-4aad-9637-a900d2fe0d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_f08e8b33-bc23-41c1-a6a6-19c2dc17b8c2" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:to="loc_alny_C5LicenseObligationMember_f08e8b33-bc23-41c1-a6a6-19c2dc17b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_3c55d172-bfec-4273-8358-578fc7ad5a5b" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e8f60e6-49d1-4024-9476-cdb2cc07c318" xlink:to="loc_alny_C5CoCoObligationMember_3c55d172-bfec-4273-8358-578fc7ad5a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd06af7d-a80e-4d96-8b41-492b226b9913" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_773d2007-14e7-4277-b026-698d3f855243" xlink:to="loc_dei_EntityDomain_bd06af7d-a80e-4d96-8b41-492b226b9913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_19ce5fe0-0558-447d-bc67-a35a2797c191" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd06af7d-a80e-4d96-8b41-492b226b9913" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_19ce5fe0-0558-447d-bc67-a35a2797c191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_477d348e-dadf-4219-b933-09ddd17438d9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c9c6ac57-35d1-45d2-8c6a-8b8526ca96a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c9c6ac57-35d1-45d2-8c6a-8b8526ca96a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b2ce198-70f8-4950-8b54-182b1ed9df71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4b2ce198-70f8-4950-8b54-182b1ed9df71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_3e033c51-2d0d-43b9-b03c-497bf4d96bee" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_alny_TransactionPrice_3e033c51-2d0d-43b9-b03c-497bf4d96bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2eff48ec-7216-4691-84b2-03a8fe6c1473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2eff48ec-7216-4691-84b2-03a8fe6c1473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_20ff4a70-3af2-4af4-b8df-472eb289e568" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b20c831-7146-4a39-959e-34d0b50aa4de" xlink:to="loc_us-gaap_Revenues_20ff4a70-3af2-4af4-b8df-472eb289e568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9adf8f-d5bc-469f-9f4d-4ee2be77b230" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_13e5968b-657c-405c-ab8b-1745f6a43219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9adf8f-d5bc-469f-9f4d-4ee2be77b230" xlink:to="loc_us-gaap_AccountsReceivableNet_13e5968b-657c-405c-ab8b-1745f6a43219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_98acb5d5-5620-486f-8554-012d5ef7c6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9adf8f-d5bc-469f-9f4d-4ee2be77b230" xlink:to="loc_us-gaap_ContractWithCustomerLiability_98acb5d5-5620-486f-8554-012d5ef7c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad483821-65f3-4b58-8324-12ac7295d3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_d7910ecd-294b-44b3-91c7-cfd3543fcf40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad483821-65f3-4b58-8324-12ac7295d3cb" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_d7910ecd-294b-44b3-91c7-cfd3543fcf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7029e6e6-eb4c-40ae-b58d-9acd0e14533e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad483821-65f3-4b58-8324-12ac7295d3cb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7029e6e6-eb4c-40ae-b58d-9acd0e14533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd3e1357-46a5-4720-a0c2-09620d64cfad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd3e1357-46a5-4720-a0c2-09620d64cfad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7b3db74f-1813-4a70-ae8b-94a9661f1e28" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember_7ac4f1f7-9067-44d7-b70e-1cc579b26985" xlink:href="alny-20190930.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:to="loc_alny_ClinicalTrialAndManufacturingMember_7ac4f1f7-9067-44d7-b70e-1cc579b26985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember_85588ffb-2a73-48a6-aaaf-28272b59118c" xlink:href="alny-20190930.xsd#alny_ExternalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:to="loc_alny_ExternalServicesMember_85588ffb-2a73-48a6-aaaf-28272b59118c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember_5d6bb327-426d-41de-8131-7c07ddb5c4bc" xlink:href="alny-20190930.xsd#alny_OtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9748ebf-8ca5-4c0e-98ff-55212a166016" xlink:to="loc_alny_OtherMember_5d6bb327-426d-41de-8131-7c07ddb5c4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:to="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ba2b750c-9666-4e9a-953e-0219a0fcb393" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_d41637db-1ca8-4f32-81cf-8ddf25a2fe83" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_SanofiGenzymeMember_d41637db-1ca8-4f32-81cf-8ddf25a2fe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MdcoMember_6a16ca39-febf-4355-ad1f-51b583f9c92a" xlink:href="alny-20190930.xsd#alny_MdcoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_MdcoMember_6a16ca39-febf-4355-ad1f-51b583f9c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_9916a397-bb2d-487f-bbec-482628ad5067" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_VirBiotechnologyIncMember_9916a397-bb2d-487f-bbec-482628ad5067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_4c78e5ab-07bf-4779-9d41-8b37340dc680" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc772f29-1025-4d63-b2cf-96c74ef44cd9" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_4c78e5ab-07bf-4779-9d41-8b37340dc680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2ac14491-2e45-4c4f-87be-911ee15203d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4cf8cf92-c369-4b5f-a166-3eb9314d77c9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2ac14491-2e45-4c4f-87be-911ee15203d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5c6046a8-8690-4ca5-8067-bdfebf0d1f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2ac14491-2e45-4c4f-87be-911ee15203d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5c6046a8-8690-4ca5-8067-bdfebf0d1f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_395a3906-1bcf-436a-b782-288bd42028f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_395a3906-1bcf-436a-b782-288bd42028f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f0738e5f-2e85-40a2-8052-5e66b5a47720" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_bba07415-83c9-4178-867e-763477b5f386" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:to="loc_alny_GlobalStrategicCollaborationMember_bba07415-83c9-4178-867e-763477b5f386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborationAmendmentMember_f2254ca2-862b-48ed-a96c-0f15f4b11548" xlink:href="alny-20190930.xsd#alny_CollaborationAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d34fe81-34f9-4afc-9b40-e9db2cd4ed31" xlink:to="loc_alny_CollaborationAmendmentMember_f2254ca2-862b-48ed-a96c-0f15f4b11548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3af8923d-45ab-4db5-898c-a5fb1007046b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ca756c7e-c1a0-43a2-a3aa-59d8fb80d37a" xlink:to="loc_dei_EntityDomain_3af8923d-45ab-4db5-898c-a5fb1007046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f3f15db6-a9e0-4002-b644-b9f898f5da79" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3af8923d-45ab-4db5-898c-a5fb1007046b" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f3f15db6-a9e0-4002-b644-b9f898f5da79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7640edb3-09af-4f49-bec9-cb0c25030cde" xlink:to="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c4b34bd-f9c1-4a6e-9b47-5846afc4f474" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:to="loc_srt_MaximumMember_6c4b34bd-f9c1-4a6e-9b47-5846afc4f474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44c8f020-97a7-4d0f-a3ff-65e6dac03d86" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65e4ce85-b4d9-4224-8587-cd247be017a9" xlink:to="loc_srt_MinimumMember_44c8f020-97a7-4d0f-a3ff-65e6dac03d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_45463c37-42c4-4cd7-8f47-dc5ca1b42412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember_7b81cef9-f509-4aad-9891-6c628188d7e4" xlink:href="alny-20190930.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:to="loc_alny_FundingAtProgramInitiationMember_7b81cef9-f509-4aad-9891-6c628188d7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember_f66f60a5-a1f1-4b1d-bd90-54e0946f726a" xlink:href="alny-20190930.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:to="loc_alny_FundingAtLeadCandidateIdentificationMember_f66f60a5-a1f1-4b1d-bd90-54e0946f726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember_95f15bfd-2b81-47b3-ad78-4a784c644360" xlink:href="alny-20190930.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5e632d4e-fbf8-4446-aceb-077441c0ce8c" xlink:to="loc_alny_FundingAnAnnualDiscoveryMember_95f15bfd-2b81-47b3-ad78-4a784c644360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91e0a5f3-383d-400b-bc4f-14b24ab4fc15" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7b3ae87b-e64c-4c1f-b774-7c1de412f07c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91e0a5f3-383d-400b-bc4f-14b24ab4fc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_3d475c97-2f62-4b18-aa45-421e5332a699" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91e0a5f3-383d-400b-bc4f-14b24ab4fc15" xlink:to="loc_alny_SanofiGenzymeMember_3d475c97-2f62-4b18-aa45-421e5332a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9f8b5e43-0e42-4daf-b1b9-dbca0a632e19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0c363124-5971-4dd6-98f4-8d6da0ff2e29" xlink:to="loc_srt_OwnershipDomain_9f8b5e43-0e42-4daf-b1b9-dbca0a632e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_3c9b0a41-1dbd-4fe3-9148-f4825a8c1a9b" xlink:href="alny-20190930.xsd#alny_SanofiGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9f8b5e43-0e42-4daf-b1b9-dbca0a632e19" xlink:to="loc_alny_SanofiGenzymeMember_3c9b0a41-1dbd-4fe3-9148-f4825a8c1a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4dcba3a-b461-4ea3-b476-8d02af2564d9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ff155e0-8878-4f4c-8c31-1393e41e5795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ff155e0-8878-4f4c-8c31-1393e41e5795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9be4d6c9-0ffa-44dc-801a-2962d663c63d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9be4d6c9-0ffa-44dc-801a-2962d663c63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_189f9b06-ad11-4f3e-b175-974d5f592da5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_189f9b06-ad11-4f3e-b175-974d5f592da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment_54454b2f-2bf7-4a51-a36e-47929317e70b" xlink:href="alny-20190930.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_DiscoveryPeriodOfProgramsDevelopment_54454b2f-2bf7-4a51-a36e-47929317e70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_749667d0-fe2f-48aa-9b25-308166e00f8e" xlink:href="alny-20190930.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_749667d0-fe2f-48aa-9b25-308166e00f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee_bd002a7f-fba3-4324-89e2-d688c3c9159e" xlink:href="alny-20190930.xsd#alny_ResearchTermExtensionFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_ResearchTermExtensionFee_bd002a7f-fba3-4324-89e2-d688c3c9159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_9f961ee8-e0b1-442d-ad9d-7000e374db99" xlink:href="alny-20190930.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_9f961ee8-e0b1-442d-ad9d-7000e374db99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_3e5eacde-e479-4984-8bea-db9272dc4ba5" xlink:href="alny-20190930.xsd#alny_UpfrontFeeReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_UpfrontFeeReceived_3e5eacde-e479-4984-8bea-db9272dc4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_d4b6cd39-ea2d-4672-bdc1-3309dca775c3" xlink:href="alny-20190930.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_d4b6cd39-ea2d-4672-bdc1-3309dca775c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms_4130f433-f64c-469e-8612-4273ed440a3a" xlink:href="alny-20190930.xsd#alny_NumberOfTargetedPrograms"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_NumberOfTargetedPrograms_4130f433-f64c-469e-8612-4273ed440a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement_08681a3c-e85c-42b2-a8b6-b5c3920b55af" xlink:href="alny-20190930.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_PotentialProceedsFromCollaborationArrangement_08681a3c-e85c-42b2-a8b6-b5c3920b55af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments_76f6d2f5-d485-4b97-8540-a7eba32a2b48" xlink:href="alny-20190930.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_CollaborativeArrangementMilestonePayments_76f6d2f5-d485-4b97-8540-a7eba32a2b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate_376cc9c0-c1df-42d5-891c-7b26144ec6ad" xlink:href="alny-20190930.xsd#alny_RoyaltyRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_RoyaltyRate_376cc9c0-c1df-42d5-891c-7b26144ec6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments_8796f945-2590-48c8-838d-6c019eca27df" xlink:href="alny-20190930.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_PercentageOfMaximumRoyaltyPayments_8796f945-2590-48c8-838d-6c019eca27df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_d4cbc67f-887e-4767-ba73-4d6e06abccef" xlink:href="alny-20190930.xsd#alny_UpfrontFeeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_IncreaseDecreaseInTransactionPrice_83685ef3-3d36-43e3-a3bd-098daf7e4ce8" xlink:href="alny-20190930.xsd#alny_IncreaseDecreaseInTransactionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_IncreaseDecreaseInTransactionPrice_83685ef3-3d36-43e3-a3bd-098daf7e4ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_76aa6e01-723a-4b2d-8102-c45e190bc9c4" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_TransactionPrice_76aa6e01-723a-4b2d-8102-c45e190bc9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_db6e833b-6f7f-412e-aa77-5562490763ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_db6e833b-6f7f-412e-aa77-5562490763ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bfa099e4-58d2-4581-9798-8ef038056ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bfa099e4-58d2-4581-9798-8ef038056ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce31475e-54ec-4d75-8d4c-2d7a547673db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ce31475e-54ec-4d75-8d4c-2d7a547673db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e68e2c2b-873c-49ee-ad6c-ccdac57ed17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e68e2c2b-873c-49ee-ad6c-ccdac57ed17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestorAgreementDescription_d95fb813-1452-4663-af1c-0d688b432422" xlink:href="alny-20190930.xsd#alny_InvestorAgreementDescription"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a9599771-619f-4a72-9e52-bd874024c6f1" xlink:to="loc_alny_InvestorAgreementDescription_d95fb813-1452-4663-af1c-0d688b432422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d82293b0-678a-4c6a-a67e-870697beb9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d82293b0-678a-4c6a-a67e-870697beb9f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_67c8cb80-852d-4fce-8f2e-20554f2d67d5" xlink:to="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_0b232369-3aa5-440e-83c9-a85e1740b151" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:to="loc_alny_ResearchServicesObligationMember_0b232369-3aa5-440e-83c9-a85e1740b151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_88fe70f4-d74c-46bd-84e8-87e97cb0012c" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:to="loc_alny_C5LicenseObligationMember_88fe70f4-d74c-46bd-84e8-87e97cb0012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_998a626e-27bf-4454-80e1-05708527dd25" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a56290d3-73a9-483a-8f7c-1d3f5dc15e71" xlink:to="loc_alny_C5CoCoObligationMember_998a626e-27bf-4454-80e1-05708527dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c646090b-60a7-466b-a3d2-086ee3e49edc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15a7f9a4-ebbe-4185-8feb-c5f47bf9c796" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c646090b-60a7-466b-a3d2-086ee3e49edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_2bc01faa-7dc1-440a-9a59-7fca11b4b2c5" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c646090b-60a7-466b-a3d2-086ee3e49edc" xlink:to="loc_alny_GlobalStrategicCollaborationMember_2bc01faa-7dc1-440a-9a59-7fca11b4b2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4090e9ba-c6a4-43f0-a2c4-7496d7e26bcf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ecd76814-62f5-4bd7-8230-a92ea380785f" xlink:to="loc_dei_EntityDomain_4090e9ba-c6a4-43f0-a2c4-7496d7e26bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c7af4583-a7ae-4b12-a7d2-73471f3d7611" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4090e9ba-c6a4-43f0-a2c4-7496d7e26bcf" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c7af4583-a7ae-4b12-a7d2-73471f3d7611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7436d0-1494-4a05-a043-2e2ace2b683d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice_b2288ad5-035f-424c-95e4-cb42359f7c2c" xlink:href="alny-20190930.xsd#alny_StandaloneSellingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:to="loc_alny_StandaloneSellingPrice_b2288ad5-035f-424c-95e4-cb42359f7c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_e31f88bb-f9e3-4544-8c9d-184262f96748" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fcf69e04-d5f5-4bac-bbef-37d910eb5ead" xlink:to="loc_alny_TransactionPrice_e31f88bb-f9e3-4544-8c9d-184262f96748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29314a1d-a853-4f25-8c96-fa176cc3fecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29314a1d-a853-4f25-8c96-fa176cc3fecd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_560e27ff-5dc7-47a7-8dd4-77e3777f11c0" xlink:to="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_54d1ebbb-b1da-4f2a-84b2-7017e69ec548" xlink:href="alny-20190930.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:to="loc_alny_ResearchServicesObligationMember_54d1ebbb-b1da-4f2a-84b2-7017e69ec548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_eaa0de39-6976-4a28-84a7-29e89749cc2a" xlink:href="alny-20190930.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:to="loc_alny_C5LicenseObligationMember_eaa0de39-6976-4a28-84a7-29e89749cc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_71c75a1d-2c29-4e02-80fc-c5e492a8af63" xlink:href="alny-20190930.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_34ec10eb-ff69-49ca-bd7a-1b5d1cb2b6cb" xlink:to="loc_alny_C5CoCoObligationMember_71c75a1d-2c29-4e02-80fc-c5e492a8af63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2254a1-0bf6-466a-bbad-cad372cbeaea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e722821-9114-4370-8b21-3ef4e8fb4ad7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2254a1-0bf6-466a-bbad-cad372cbeaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_63f974ae-4fd6-4261-9b5e-cb921660f531" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e2254a1-0bf6-466a-bbad-cad372cbeaea" xlink:to="loc_alny_GlobalStrategicCollaborationMember_63f974ae-4fd6-4261-9b5e-cb921660f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8826578d-be9f-4a77-b918-e3cbf3fc4176" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4c3e68de-41ab-45b7-9843-663b4571953c" xlink:to="loc_dei_EntityDomain_8826578d-be9f-4a77-b918-e3cbf3fc4176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_984b1fe4-a572-4c39-8ce9-b1b3f31ef8c2" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8826578d-be9f-4a77-b918-e3cbf3fc4176" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_984b1fe4-a572-4c39-8ce9-b1b3f31ef8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89f2aff2-2aef-4a89-9a3e-208bd62fbbdd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_0bbd71bd-f3b8-4e06-99aa-cb7f229c05c2" xlink:href="alny-20190930.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_alny_TransactionPrice_0bbd71bd-f3b8-4e06-99aa-cb7f229c05c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a71b8c8-94d6-4455-bbdc-4bd4fdf2ea58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a71b8c8-94d6-4455-bbdc-4bd4fdf2ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c93ba5d6-e926-44d7-841a-53ba4d85d11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c93ba5d6-e926-44d7-841a-53ba4d85d11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c5906dbc-d425-407e-b1b3-3d3165b996ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_Revenues_c5906dbc-d425-407e-b1b3-3d3165b996ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c4dec3f-c722-45ea-8d82-bb66da463f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_655ea670-af48-4cd1-9e86-a57a163f6b0a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c4dec3f-c722-45ea-8d82-bb66da463f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/INVENTORY" xlink:type="simple" xlink:href="alny-20190930.xsd#INVENTORY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/INVENTORY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b0d25111-db8d-4e39-98a1-2ab807e563ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_909edb16-7cfe-4557-ab52-f6f52e1f9cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b0d25111-db8d-4e39-98a1-2ab807e563ac" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_909edb16-7cfe-4557-ab52-f6f52e1f9cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/INVENTORYTables" xlink:type="simple" xlink:href="alny-20190930.xsd#INVENTORYTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/INVENTORYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1bf574c0-815f-47c7-9303-3331c5c01421" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ce0be98d-ba3e-4a78-95ca-de82a4268abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1bf574c0-815f-47c7-9303-3331c5c01421" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ce0be98d-ba3e-4a78-95ca-de82a4268abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#InventoryScheduleofInventoryDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/InventoryScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6fe54360-b7aa-4cca-b50f-3d557bbaff07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d067056e-0d4a-4a26-9ffb-b18459e1e3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6fe54360-b7aa-4cca-b50f-3d557bbaff07" xlink:to="loc_us-gaap_InventoryRawMaterials_d067056e-0d4a-4a26-9ffb-b18459e1e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_45a36738-2488-4cfa-9cc5-04489f479bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6fe54360-b7aa-4cca-b50f-3d557bbaff07" xlink:to="loc_us-gaap_InventoryWorkInProcess_45a36738-2488-4cfa-9cc5-04489f479bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_56415726-b4b2-422d-b9a4-8613e76a2a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6fe54360-b7aa-4cca-b50f-3d557bbaff07" xlink:to="loc_us-gaap_InventoryFinishedGoods_56415726-b4b2-422d-b9a4-8613e76a2a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5e3d51d9-7c77-42cf-b18c-0f8bdd8906a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6fe54360-b7aa-4cca-b50f-3d557bbaff07" xlink:to="loc_us-gaap_InventoryNet_5e3d51d9-7c77-42cf-b18c-0f8bdd8906a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20190930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7505272c-aa7c-46fa-b080-977220f59941" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5b3d85ad-54e5-46bc-b202-f482246931e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7505272c-aa7c-46fa-b080-977220f59941" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5b3d85ad-54e5-46bc-b202-f482246931e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566ecf9d-f869-4b02-9b4f-1b034af08b18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_013f21f0-982a-4d42-9d2d-3da654aa7293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566ecf9d-f869-4b02-9b4f-1b034af08b18" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_013f21f0-982a-4d42-9d2d-3da654aa7293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_da9de263-8616-42c7-8412-28e69932cd87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_da9de263-8616-42c7-8412-28e69932cd87" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_da169ce5-e95d-4523-8b2e-c8c0d60e8e76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33ed9074-bd9f-41e1-bf76-100fd86e24f7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_da169ce5-e95d-4523-8b2e-c8c0d60e8e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f2528369-9bb0-44d8-ba3d-a41a72dbcfda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_da169ce5-e95d-4523-8b2e-c8c0d60e8e76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f2528369-9bb0-44d8-ba3d-a41a72dbcfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8d48e5ba-ad18-4c50-996d-7dcb33885811" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_86cf7835-2608-421d-9548-392d1a578499" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_CommercialPaperMember_86cf7835-2608-421d-9548-392d1a578499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b8324bac-01a9-4193-ac08-c2f3e92caa4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b8324bac-01a9-4193-ac08-c2f3e92caa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_df4a2a0d-2ab5-4165-ac81-053775651381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_df4a2a0d-2ab5-4165-ac81-053775651381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4b956092-bce1-44be-805b-934fcfc171f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4b956092-bce1-44be-805b-934fcfc171f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1751e617-d508-4ac7-b1e7-1bf9bfde7703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1751e617-d508-4ac7-b1e7-1bf9bfde7703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_73940ca1-7212-4fca-a65f-4fb73b668b64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5215173e-4be9-41cf-a54c-f9eb35f2f3cd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_73940ca1-7212-4fca-a65f-4fb73b668b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a10725c7-ad06-4944-b4fd-7f36c1de062d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f1a39ae0-b42f-4041-b058-34471c9dc184" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f1a39ae0-b42f-4041-b058-34471c9dc184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_498af43c-9212-4de4-87c9-ae88128c50b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_498af43c-9212-4de4-87c9-ae88128c50b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c8646150-b78f-46ca-b8e4-4d8e0c9efb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8aaca986-3677-41fa-8e10-70596efd27c7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c8646150-b78f-46ca-b8e4-4d8e0c9efb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2dcfcbc-d516-485b-93d1-55090ca22bfc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8bbb34d3-cdf8-4073-8105-c6e97bdfbf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8bbb34d3-cdf8-4073-8105-c6e97bdfbf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dacda3e-3e43-4dbb-b016-ca922b6c1a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9dacda3e-3e43-4dbb-b016-ca922b6c1a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_12d1b62e-ee2a-495c-9203-6dc6394ca1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_12d1b62e-ee2a-495c-9203-6dc6394ca1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3ed007bd-9d9f-4e6a-9160-ae32e0ccb944" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3ed007bd-9d9f-4e6a-9160-ae32e0ccb944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c975e32d-e431-45d9-9ee1-3c1870c165d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3308843-6ebe-453a-9459-19c78af14c3d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c975e32d-e431-45d9-9ee1-3c1870c165d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_fba1c955-7bd5-44ac-8ebd-f71f12da2ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_da9de263-8616-42c7-8412-28e69932cd87" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_fba1c955-7bd5-44ac-8ebd-f71f12da2ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a10e9a6d-d3f0-4051-ba64-6d049de95e33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a10e9a6d-d3f0-4051-ba64-6d049de95e33" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2a867cb-1da6-406f-8bd4-d609cdc32c24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_227c71fc-0ac5-4672-8872-384e424881e1" xlink:to="loc_us-gaap_CreditFacilityDomain_e2a867cb-1da6-406f-8bd4-d609cdc32c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TermLoanFacilityMember_4654b1d3-af23-48eb-8ddf-f1c3e9ae3ad1" xlink:href="alny-20190930.xsd#alny_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e2a867cb-1da6-406f-8bd4-d609cdc32c24" xlink:to="loc_alny_TermLoanFacilityMember_4654b1d3-af23-48eb-8ddf-f1c3e9ae3ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2a912a6-3bc5-487a-ad6b-3297c5642b30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_0a9df63f-e84d-44b4-9856-e6168a3b74be" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2a912a6-3bc5-487a-ad6b-3297c5642b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_WellsFargoCreditFacilityMember_8a4ffd9e-a1d3-49ac-8dd0-6dc8e24f4a42" xlink:href="alny-20190930.xsd#alny_WellsFargoCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2a912a6-3bc5-487a-ad6b-3297c5642b30" xlink:to="loc_alny_WellsFargoCreditFacilityMember_8a4ffd9e-a1d3-49ac-8dd0-6dc8e24f4a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df2eb502-8406-4018-8f49-66c9449c8731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748270da-be34-4549-acff-eaa05b5b81eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df2eb502-8406-4018-8f49-66c9449c8731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3c034c45-a23d-4f64-8ed7-2c4721d9c7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df2eb502-8406-4018-8f49-66c9449c8731" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3c034c45-a23d-4f64-8ed7-2c4721d9c7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4a2aa00e-c1e2-4854-ac4f-3719dc787f54" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5ec37b3f-cf14-4b24-b497-dbdc39fd0f83" xlink:to="loc_dei_EntityDomain_4a2aa00e-c1e2-4854-ac4f-3719dc787f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_1f3bb30c-95d0-435a-9c58-d6f6adf5c8e3" xlink:href="alny-20190930.xsd#alny_VirBiotechnologyIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4a2aa00e-c1e2-4854-ac4f-3719dc787f54" xlink:to="loc_alny_VirBiotechnologyIncMember_1f3bb30c-95d0-435a-9c58-d6f6adf5c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1f66f6b9-ba5e-4309-a5f6-b317f0bcf424" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_ac00ec7f-459f-414b-ab3e-7cad44b14fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_ac00ec7f-459f-414b-ab3e-7cad44b14fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_25010557-7ee8-4f27-b366-e8f369e9a5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_LongTermDebtFairValue_25010557-7ee8-4f27-b366-e8f369e9a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4806c119-7602-4fa1-a5c9-6b938b07bfff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4806c119-7602-4fa1-a5c9-6b938b07bfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_28fff2b8-539a-4f04-967d-deb82f874bac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_28fff2b8-539a-4f04-967d-deb82f874bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_63a7efc9-63ee-4f95-8257-124ccfdc1c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a997839b-0a80-4cff-a8f8-023887102ae9" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_63a7efc9-63ee-4f95-8257-124ccfdc1c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20190930.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_67b63b49-dbc6-4f0d-9c18-2c61f75e1bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_008e1f73-ff97-498e-b018-7ae487e95a30" xlink:href="alny-20190930.xsd#alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_67b63b49-dbc6-4f0d-9c18-2c61f75e1bbd" xlink:to="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_008e1f73-ff97-498e-b018-7ae487e95a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20190930.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33d11e-30f5-47cd-80dc-c7b26e5fc5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_030bc081-285d-40c8-9eff-b0b038d6690d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33d11e-30f5-47cd-80dc-c7b26e5fc5c0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_030bc081-285d-40c8-9eff-b0b038d6690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_27f2f2f3-4424-495f-a3c5-539aa77268a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc33d11e-30f5-47cd-80dc-c7b26e5fc5c0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_27f2f2f3-4424-495f-a3c5-539aa77268a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_54978500-ee99-421b-8cca-99a6c751a3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ImpairmentOfMarketableDebtSecurities_51287428-4fa2-49bb-a23c-04a9d4ed2037" xlink:href="alny-20190930.xsd#alny_ImpairmentOfMarketableDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_54978500-ee99-421b-8cca-99a6c751a3a5" xlink:to="loc_alny_ImpairmentOfMarketableDebtSecurities_51287428-4fa2-49bb-a23c-04a9d4ed2037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3c6f0685-fd29-4a0d-b8b4-c8998962fee5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3c6f0685-fd29-4a0d-b8b4-c8998962fee5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:to="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_cda1b433-12cf-4475-b532-68bc2e37a2ba" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_bdb02e58-ebae-4304-831f-0420cebd6389" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:to="loc_us-gaap_CertificatesOfDepositMember_bdb02e58-ebae-4304-831f-0420cebd6389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7dd640ae-7fa9-4a2e-97dc-4c5dff4b1c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fc128083-bd91-4f75-a9b8-02e14ebd8a31" xlink:to="loc_us-gaap_CommercialPaperMember_7dd640ae-7fa9-4a2e-97dc-4c5dff4b1c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0139b312-f175-4b3b-99c8-55f15412fc85" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1cde83a8-29f4-41f2-b382-64217888d502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1cde83a8-29f4-41f2-b382-64217888d502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a76eb7e1-49b3-4415-bbc0-06c8f5237f58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a76eb7e1-49b3-4415-bbc0-06c8f5237f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6950124f-a248-4a39-ba79-0824d9d13a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c91adf69-a67e-4b58-885d-eb5386fb7932" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6950124f-a248-4a39-ba79-0824d9d13a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_dde78e42-438a-4348-bede-ab0f8e088d44" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dc948e2-a935-4569-bffa-76e6a2261f21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dc948e2-a935-4569-bffa-76e6a2261f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_766e3f05-bb48-434b-9c95-eb16ed79ebd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_766e3f05-bb48-434b-9c95-eb16ed79ebd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1214e4-de76-4305-a0aa-28f56e9eb43e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1214e4-de76-4305-a0aa-28f56e9eb43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_809bc693-9822-4ef1-ad51-25d594ddb132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8db43e8b-115f-42b5-b0a1-dfe26f0b1396" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_809bc693-9822-4ef1-ad51-25d594ddb132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ace3e0e-6960-49bf-b9b9-7d2b2e17c49a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1aba9f38-24d6-4479-9b6c-7e0721e25eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ace3e0e-6960-49bf-b9b9-7d2b2e17c49a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1aba9f38-24d6-4479-9b6c-7e0721e25eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fe09c788-8833-4fa1-ab50-cbe8e75eaa43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ace3e0e-6960-49bf-b9b9-7d2b2e17c49a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fe09c788-8833-4fa1-ab50-cbe8e75eaa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_602516e7-422c-440f-918d-3af9e0273e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ace3e0e-6960-49bf-b9b9-7d2b2e17c49a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_602516e7-422c-440f-918d-3af9e0273e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LEASES" xlink:type="simple" xlink:href="alny-20190930.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b3ce77f2-25b4-44ba-a3da-ba1f520bdcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e3a3e745-6da9-41b5-9852-eb5b0b878040" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3ce77f2-25b4-44ba-a3da-ba1f520bdcfd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e3a3e745-6da9-41b5-9852-eb5b0b878040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LEASESTables" xlink:type="simple" xlink:href="alny-20190930.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dfc7e26c-df33-42e7-8981-96cbb9350458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_280ffa71-d6a4-4336-92fa-fb97ddb895d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfc7e26c-df33-42e7-8981-96cbb9350458" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_280ffa71-d6a4-4336-92fa-fb97ddb895d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b108f8b-0d43-45a4-89eb-70efde1bf323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfc7e26c-df33-42e7-8981-96cbb9350458" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b108f8b-0d43-45a4-89eb-70efde1bf323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_e91d2c88-aaad-440d-bf92-40c368e4fcb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfc7e26c-df33-42e7-8981-96cbb9350458" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_e91d2c88-aaad-440d-bf92-40c368e4fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_7b1d4175-4d32-438f-9cc0-79ce5e959aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_7b1d4175-4d32-438f-9cc0-79ce5e959aa5" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_f89bb27e-2311-467f-82ab-c81082836cd3" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BMRSixSevenFiveWestKendallLeaseMember_62876396-3684-4251-9f41-1a96313156f2" xlink:href="alny-20190930.xsd#alny_BMRSixSevenFiveWestKendallLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:to="loc_alny_BMRSixSevenFiveWestKendallLeaseMember_62876396-3684-4251-9f41-1a96313156f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ThirdStreetLeaseMember_dc5e0ddf-856a-4add-a8f9-2a0d204f76b3" xlink:href="alny-20190930.xsd#alny_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:to="loc_alny_ThirdStreetLeaseMember_dc5e0ddf-856a-4add-a8f9-2a0d204f76b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OneHundredAndOneMainStreetLeasesMember_e75eb93c-b84e-404b-9987-146710af7819" xlink:href="alny-20190930.xsd#alny_OneHundredAndOneMainStreetLeasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49b85729-e13c-4803-8bb9-6ae2739afbf9" xlink:to="loc_alny_OneHundredAndOneMainStreetLeasesMember_e75eb93c-b84e-404b-9987-146710af7819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_5def66f6-8137-4a63-b594-ed7c8254e6f1" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LeaseAgreementTerm_71b40c37-04f6-40c5-9f66-d4f7f29680f6" xlink:href="alny-20190930.xsd#alny_LeaseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_LeaseAgreementTerm_71b40c37-04f6-40c5-9f66-d4f7f29680f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfLeaseExtensionOptions_4afa9cb8-fbb2-4a3e-bbf3-9654789b07b9" xlink:href="alny-20190930.xsd#alny_NumberOfLeaseExtensionOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_NumberOfLeaseExtensionOptions_4afa9cb8-fbb2-4a3e-bbf3-9654789b07b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_740deb07-e21b-4e40-b692-0570cae0af40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_740deb07-e21b-4e40-b692-0570cae0af40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_f725715b-8e85-4f0d-a597-3896a1884dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_f725715b-8e85-4f0d-a597-3896a1884dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_092f0269-4128-4a56-9a5c-dbea7a12ee86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_092f0269-4128-4a56-9a5c-dbea7a12ee86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedLeaseExpirationDate_cc9b84ea-a0e2-43e0-97ae-b2e51964136d" xlink:href="alny-20190930.xsd#alny_ExtendedLeaseExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_ExtendedLeaseExpirationDate_cc9b84ea-a0e2-43e0-97ae-b2e51964136d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedLeaseExpirationMonthAndYear_587f3c35-a4a9-4c99-baa2-a895235a1e8a" xlink:href="alny-20190930.xsd#alny_ExtendedLeaseExpirationMonthAndYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_alny_ExtendedLeaseExpirationMonthAndYear_587f3c35-a4a9-4c99-baa2-a895235a1e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e8535803-82d8-4fd6-959c-7d29b51e9f06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_OperatingLeasePayments_e8535803-82d8-4fd6-959c-7d29b51e9f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fd0606c-ab62-4adc-b090-d851484781f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fd0606c-ab62-4adc-b090-d851484781f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5bd085f4-e374-4b2c-a051-1be177c889a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_33b97d2f-4e0c-4ca4-84a6-f46936f083d5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5bd085f4-e374-4b2c-a051-1be177c889a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_764fa768-5c56-408b-b569-d0553624d38a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_86975fea-c037-4e32-bc86-126080994095" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_764fa768-5c56-408b-b569-d0553624d38a" xlink:to="loc_us-gaap_OperatingLeaseCost_86975fea-c037-4e32-bc86-126080994095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_3a545f2b-bc9f-46e0-a63e-9c727831ffef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_764fa768-5c56-408b-b569-d0553624d38a" xlink:to="loc_us-gaap_VariableLeaseCost_3a545f2b-bc9f-46e0-a63e-9c727831ffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8c2bf23b-f3f9-40e3-ae6b-3d422d423737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_764fa768-5c56-408b-b569-d0553624d38a" xlink:to="loc_us-gaap_LeaseCost_8c2bf23b-f3f9-40e3-ae6b-3d422d423737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b0b6d7a-84b2-48cf-99f0-90b1c88ef562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b0b6d7a-84b2-48cf-99f0-90b1c88ef562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d98a3fd-7f4c-41ed-a674-c8938c4764ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d98a3fd-7f4c-41ed-a674-c8938c4764ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66045284-1c34-4d2c-9738-2f8d09ca8b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66045284-1c34-4d2c-9738-2f8d09ca8b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e754a0e1-56b5-413e-8bba-575f1c522932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e754a0e1-56b5-413e-8bba-575f1c522932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7035eb19-783a-4d77-994f-b6da822ad584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7035eb19-783a-4d77-994f-b6da822ad584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_6a86600b-2611-4792-a908-e3d7fa112082" xlink:href="alny-20190930.xsd#alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_6a86600b-2611-4792-a908-e3d7fa112082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_61d74c6d-b31d-4731-b9c4-63b5982f711c" xlink:href="alny-20190930.xsd#alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter_61d74c6d-b31d-4731-b9c4-63b5982f711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2afc1bb3-83ee-42bb-8777-e516f92ca93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2afc1bb3-83ee-42bb-8777-e516f92ca93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c743c523-82a4-45ec-b1b3-e9193f71d01a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c743c523-82a4-45ec-b1b3-e9193f71d01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e49264c0-0a9e-4ec9-80c1-4f24aa814387" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_OperatingLeaseLiability_e49264c0-0a9e-4ec9-80c1-4f24aa814387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca695b06-859c-4d93-85ad-f8890b82be90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca695b06-859c-4d93-85ad-f8890b82be90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf3156f5-9575-4a4e-8de2-3d6213d3b280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_b79d7b6f-0411-46a9-868d-8d67c4099491" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cf3156f5-9575-4a4e-8de2-3d6213d3b280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_fd7b7d5b-17e6-4455-95e0-1d16340e2b24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_fd7b7d5b-17e6-4455-95e0-1d16340e2b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_df9e0e9c-2ff3-4f79-9a31-cfd4b2812d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_df9e0e9c-2ff3-4f79-9a31-cfd4b2812d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_cecb32d4-a7f2-4c05-97d0-2d392897c8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_cecb32d4-a7f2-4c05-97d0-2d392897c8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1a8c4c0d-b553-4f7a-9898-c849809ca12e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_1a8c4c0d-b553-4f7a-9898-c849809ca12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_f7d82167-3a69-4268-8a5e-653e9c6cf6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_f7d82167-3a69-4268-8a5e-653e9c6cf6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b4aee853-779a-43f3-9e28-83b7e75cb6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b4aee853-779a-43f3-9e28-83b7e75cb6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4a713149-c8c8-4132-8fc5-61d01e0788d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_562ebced-b9a0-4e0c-8464-4584e0d28b9b" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_4a713149-c8c8-4132-8fc5-61d01e0788d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="alny-20190930.xsd#CREDITAGREEMENT"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract_d342c2fc-d083-495f-b31e-6c68e03f9b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CreditAgreementDisclosureTextBlock_c1874e4c-dc1d-4784-8dbb-fa80d136eae8" xlink:href="alny-20190930.xsd#alny_CreditAgreementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract_d342c2fc-d083-495f-b31e-6c68e03f9b0a" xlink:to="loc_alny_CreditAgreementDisclosureTextBlock_c1874e4c-dc1d-4784-8dbb-fa80d136eae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CreditAgreementAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract_c3e6b60d-1f8d-4918-8657-e37dd8fc5e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract_c3e6b60d-1f8d-4918-8657-e37dd8fc5e8c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2f296cc-8481-4ad4-bc4b-92bb7d142edb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_630bc921-9d93-432a-b31f-5131b0f9834e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2f296cc-8481-4ad4-bc4b-92bb7d142edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_WellsFargoCreditFacilityMember_e3e3694f-d281-4917-b13f-ef9749f492d0" xlink:href="alny-20190930.xsd#alny_WellsFargoCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b2f296cc-8481-4ad4-bc4b-92bb7d142edb" xlink:to="loc_alny_WellsFargoCreditFacilityMember_e3e3694f-d281-4917-b13f-ef9749f492d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aec45e4e-d961-498e-a24a-8279199d063b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b45ea807-c760-435a-a308-77e98bfbb69d" xlink:to="loc_us-gaap_CreditFacilityDomain_aec45e4e-d961-498e-a24a-8279199d063b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TermLoanFacilityMember_984a4288-974c-4a8e-bc0e-636d1af873ba" xlink:href="alny-20190930.xsd#alny_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_aec45e4e-d961-498e-a24a-8279199d063b" xlink:to="loc_alny_TermLoanFacilityMember_984a4288-974c-4a8e-bc0e-636d1af873ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_52804fe2-532e-4374-b22a-93b9126d254a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6edc3484-734a-4dbb-8b91-abf7e374b05b" xlink:to="loc_us-gaap_VariableRateDomain_52804fe2-532e-4374-b22a-93b9126d254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f59107da-922c-4254-8523-ccd274af30ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_52804fe2-532e-4374-b22a-93b9126d254a" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f59107da-922c-4254-8523-ccd274af30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_459587c5-8db7-478f-8bea-ff80950f6249" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bba53fa3-bc76-466b-a1d9-2113b812357e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bba53fa3-bc76-466b-a1d9-2113b812357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_0c768ba5-162a-4ec4-b5ca-4d5ad0eaa753" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_0c768ba5-162a-4ec4-b5ca-4d5ad0eaa753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4b64f7f6-4271-44cd-a7b5-7a18fcf352d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4b64f7f6-4271-44cd-a7b5-7a18fcf352d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_c381cf66-2dbd-444f-8a9c-304e8938e975" xlink:href="alny-20190930.xsd#alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage_c381cf66-2dbd-444f-8a9c-304e8938e975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_8df228b1-673f-4282-88a4-98705fb1f25b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e67c814d-cf9a-404b-8390-7c2153df4128" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_8df228b1-673f-4282-88a4-98705fb1f25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/EQUITY" xlink:type="simple" xlink:href="alny-20190930.xsd#EQUITY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/EQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_eeeddce2-b4cf-41bc-a54c-78f3dbeb3c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_94b7c749-02db-49c2-819f-baebe7933e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eeeddce2-b4cf-41bc-a54c-78f3dbeb3c1a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_94b7c749-02db-49c2-819f-baebe7933e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/EquityAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#EquityAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/EquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_87b3d501-9efa-4925-88f0-b5afa5da4053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:href="alny-20190930.xsd#alny_EquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_87b3d501-9efa-4925-88f0-b5afa5da4053" xlink:to="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b29e19a5-41ce-46f7-81a6-a8ac1ff3cdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4da57346-4679-4a44-a410-33119514ffbe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b29e19a5-41ce-46f7-81a6-a8ac1ff3cdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_1386460b-539d-4e0f-bece-e65bb1b18f35" xlink:href="alny-20190930.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b29e19a5-41ce-46f7-81a6-a8ac1ff3cdbc" xlink:to="loc_alny_GlobalStrategicCollaborationMember_1386460b-539d-4e0f-bece-e65bb1b18f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b8dfa1db-3a91-4e60-92e2-72f2ba1579c9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f6c1fce2-2c72-4d0a-a10e-04b4e523e90a" xlink:to="loc_dei_EntityDomain_b8dfa1db-3a91-4e60-92e2-72f2ba1579c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_92bbefa8-165d-4390-a6a2-8191ece4842b" xlink:href="alny-20190930.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b8dfa1db-3a91-4e60-92e2-72f2ba1579c9" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_92bbefa8-165d-4390-a6a2-8191ece4842b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d5d11d1d-64ae-49e2-8ef9-95a3065ca31f" xlink:to="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_370148ce-e71d-41b8-9f1f-180432698a06" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:to="loc_srt_MinimumMember_370148ce-e71d-41b8-9f1f-180432698a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7a29e193-5f78-46eb-ae25-4915dc617794" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6aa6acf-0bd6-4b2e-8be2-cf4fa14ae748" xlink:to="loc_srt_MaximumMember_7a29e193-5f78-46eb-ae25-4915dc617794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:href="alny-20190930.xsd#alny_EquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityTable_dd6f32a0-b095-4b23-b239-b1a141f197be" xlink:to="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25796b06-cb09-4b02-9378-80fe493f121a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25796b06-cb09-4b02-9378-80fe493f121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5a29eca4-ed37-4094-a603-922c0b249e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_5a29eca4-ed37-4094-a603-922c0b249e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_081df620-8031-47b7-8d82-6ef2086c1c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_081df620-8031-47b7-8d82-6ef2086c1c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_60940064-514b-4625-95a6-cb0aafcc1766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_60940064-514b-4625-95a6-cb0aafcc1766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eecee48d-267a-47c6-ba30-e4d79b9e470a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eecee48d-267a-47c6-ba30-e4d79b9e470a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a407a6f-0c4e-41af-b97c-670a394eb935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a407a6f-0c4e-41af-b97c-670a394eb935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DateOfAgreement_0ab35135-8444-48e8-aac2-155c7ff41361" xlink:href="alny-20190930.xsd#alny_DateOfAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_DateOfAgreement_0ab35135-8444-48e8-aac2-155c7ff41361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AgreementExtensionPeriod_74098e7d-4752-4055-a3b3-d94bea1d98a8" xlink:href="alny-20190930.xsd#alny_AgreementExtensionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_AgreementExtensionPeriod_74098e7d-4752-4055-a3b3-d94bea1d98a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OwnershipPercentageOfSharesOutstanding_aed55aa8-3c90-4039-bcb5-280406212ae4" xlink:href="alny-20190930.xsd#alny_OwnershipPercentageOfSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_OwnershipPercentageOfSharesOutstanding_aed55aa8-3c90-4039-bcb5-280406212ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_183df591-0005-4659-b861-1b5343aa1e03" xlink:href="alny-20190930.xsd#alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit_183df591-0005-4659-b861-1b5343aa1e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_adfa7741-5eff-4a56-8bb9-74be79d3c641" xlink:href="alny-20190930.xsd#alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod_adfa7741-5eff-4a56-8bb9-74be79d3c641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BeneficialOwnershipPercentageOfSharesOutstanding_8c4ff4a2-09df-4211-9638-bb64d3a172ad" xlink:href="alny-20190930.xsd#alny_BeneficialOwnershipPercentageOfSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_BeneficialOwnershipPercentageOfSharesOutstanding_8c4ff4a2-09df-4211-9638-bb64d3a172ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_196168aa-66ea-4e9c-a0d9-fc6bafb08e94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_196168aa-66ea-4e9c-a0d9-fc6bafb08e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GainLossOnSaleOfCommonStock_418374d8-f98a-4e53-88cf-f97390b29ee2" xlink:href="alny-20190930.xsd#alny_GainLossOnSaleOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_EquityLineItems_e3b3b7a6-5903-4eac-a731-5a9c4a4175e8" xlink:to="loc_alny_GainLossOnSaleOfCommonStock_418374d8-f98a-4e53-88cf-f97390b29ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20190930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_126514d6-f8f9-4289-b633-357442a7b2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_82a96fac-de5e-4670-b540-fbd6fd00cec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_126514d6-f8f9-4289-b633-357442a7b2da" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_82a96fac-de5e-4670-b540-fbd6fd00cec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20190930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bab047cc-5180-44f2-b04e-73b8df666b56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_e97997fa-d1bf-4d62-97a8-c8a385f7e5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bab047cc-5180-44f2-b04e-73b8df666b56" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_e97997fa-d1bf-4d62-97a8-c8a385f7e5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_192e4419-3987-4b62-970c-a1c7ed00ed93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_192e4419-3987-4b62-970c-a1c7ed00ed93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33ebc400-395e-4bd9-9923-722fa47d0985" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cfa1add6-da2f-4643-9126-7ebc6bac4dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cfa1add6-da2f-4643-9126-7ebc6bac4dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8719d053-bdcc-4a15-8786-e0cb7b8665db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b76f6cf3-4539-464b-80d1-0e00a8bbf552" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8719d053-bdcc-4a15-8786-e0cb7b8665db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78b7dcdd-50d7-4345-a7aa-9b8f64e77b34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02f548b2-0e06-4f24-8531-a2b4ca21d9bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78b7dcdd-50d7-4345-a7aa-9b8f64e77b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_484a7fec-fd50-4882-8503-e65deef9d2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78b7dcdd-50d7-4345-a7aa-9b8f64e77b34" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_484a7fec-fd50-4882-8503-e65deef9d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20190930.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b2b7bdda-3fe5-483f-bbea-15f381904fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d81c3abb-fba1-4b04-9b64-77a2249e0d14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2b7bdda-3fe5-483f-bbea-15f381904fe9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d81c3abb-fba1-4b04-9b64-77a2249e0d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20190930.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d89eaf44-a5ae-4c37-bacc-bed61c2ecc5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_edc87141-bb9b-4ef2-8006-d26f998543a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d89eaf44-a5ae-4c37-bacc-bed61c2ecc5b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_edc87141-bb9b-4ef2-8006-d26f998543a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a26d5e9c-b13d-4dc5-a8e9-204547d250f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a26d5e9c-b13d-4dc5-a8e9-204547d250f2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b8a00ce3-3210-4584-942a-31bf0c815af3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0b2cb58f-d523-4bef-814e-d8b54bad575e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0b2cb58f-d523-4bef-814e-d8b54bad575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_43e983ed-1b67-439c-8083-a835a6c8b182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f95f568f-c710-4f7d-a85d-90a693124555" xlink:to="loc_us-gaap_RestrictedStockMember_43e983ed-1b67-439c-8083-a835a6c8b182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb5c7585-4048-4a7c-8407-d6047390505b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_435b1af1-259c-4ef3-90be-a04c7b855c5c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb5c7585-4048-4a7c-8407-d6047390505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed332e2e-0c4d-4759-87f3-46c3bea506d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb5c7585-4048-4a7c-8407-d6047390505b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed332e2e-0c4d-4759-87f3-46c3bea506d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" xlink:type="simple" xlink:href="alny-20190930.xsd#RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_2fc46743-1808-48c3-9c4b-f904848f54ef" xlink:href="alny-20190930.xsd#alny_CashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_b7181bbd-2d64-47c9-9e0a-a0e7f4f6372d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_2fc46743-1808-48c3-9c4b-f904848f54ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_b7181bbd-2d64-47c9-9e0a-a0e7f4f6372d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" xlink:type="simple" xlink:href="alny-20190930.xsd#RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_d5ad05f7-230f-41ac-a3a5-fdcf743cd958" xlink:href="alny-20190930.xsd#alny_CashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_a02ee58f-44f7-4a68-80d6-a1e516afe83a" xlink:href="alny-20190930.xsd#alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_d5ad05f7-230f-41ac-a3a5-fdcf743cd958" xlink:to="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_a02ee58f-44f7-4a68-80d6-a1e516afe83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_7f2f4782-453a-442c-b61b-b8c432af80ac" xlink:href="alny-20190930.xsd#alny_CashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdc441ea-1e0d-47e7-b451-3f69a9a05a55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_7f2f4782-453a-442c-b61b-b8c432af80ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdc441ea-1e0d-47e7-b451-3f69a9a05a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_a5af7bc4-3db7-492c-b17f-684f2a70ae60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_7f2f4782-453a-442c-b61b-b8c432af80ac" xlink:to="loc_us-gaap_RestrictedCashCurrent_a5af7bc4-3db7-492c-b17f-684f2a70ae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_229ff8f9-609e-40b9-8fae-0b78f9aeb8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_7f2f4782-453a-442c-b61b-b8c432af80ac" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_229ff8f9-609e-40b9-8fae-0b78f9aeb8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0304b3aa-9d71-487b-b39d-6f38bb6e83b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CashCashEquivalentsAndRestrictedCashAbstract_7f2f4782-453a-442c-b61b-b8c432af80ac" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0304b3aa-9d71-487b-b39d-6f38bb6e83b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20190930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36c693c8-e5ca-4ce2-b8ba-c26630cf412a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bbedcedc-b321-45a7-a20e-e1078cdc9af2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_36c693c8-e5ca-4ce2-b8ba-c26630cf412a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bbedcedc-b321-45a7-a20e-e1078cdc9af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e017338-6814-48c7-b0af-80ebc578bf96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:href="alny-20190930.xsd#alny_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e017338-6814-48c7-b0af-80ebc578bf96" xlink:to="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef7fe3d9-26d2-4e7d-9492-0a6c12984db7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_23f14eb1-d1a7-416f-b31c-749dd038d6f7" xlink:to="loc_srt_SegmentGeographicalDomain_ef7fe3d9-26d2-4e7d-9492-0a6c12984db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NortonMassachusettsMember_0f9a0beb-e157-49c9-9344-539ed95988f3" xlink:href="alny-20190930.xsd#alny_NortonMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ef7fe3d9-26d2-4e7d-9492-0a6c12984db7" xlink:to="loc_alny_NortonMassachusettsMember_0f9a0beb-e157-49c9-9344-539ed95988f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b78baa5-7ca1-45fd-bf00-078a8b453b95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cf5e578c-c057-4ef8-bbfb-5d37f5847ca3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b78baa5-7ca1-45fd-bf00-078a8b453b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_a38c739d-970a-4917-b554-32fda21a7fd8" xlink:href="alny-20190930.xsd#alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b78baa5-7ca1-45fd-bf00-078a8b453b95" xlink:to="loc_alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember_a38c739d-970a-4917-b554-32fda21a7fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5447301-d5b3-4288-a0ae-6a4ba0bf576c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_40ed5d3c-2bbb-4aec-88f3-d2b3ba626e17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5447301-d5b3-4288-a0ae-6a4ba0bf576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DicernaPharmaceuticalsIncMember_9878852e-2375-4731-a9cd-6ee5d5b010cd" xlink:href="alny-20190930.xsd#alny_DicernaPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5447301-d5b3-4288-a0ae-6a4ba0bf576c" xlink:to="loc_alny_DicernaPharmaceuticalsIncMember_9878852e-2375-4731-a9cd-6ee5d5b010cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:href="alny-20190930.xsd#alny_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesTable_b428d9b6-bdb4-4ecc-9802-30ce7df76c39" xlink:to="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_478f58da-29bc-4a20-925c-f54c26c47a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_AreaOfLand_478f58da-29bc-4a20-925c-f54c26c47a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7560626d-805a-464f-a527-adc565c940c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7560626d-805a-464f-a527-adc565c940c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencySettlementAgreementDate_d0edbbc3-c45a-4edd-919b-c954fdae1351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencySettlementAgreementDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_LossContingencySettlementAgreementDate_d0edbbc3-c45a-4edd-919b-c954fdae1351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_aaca6bda-dd81-4b93-9fc8-22a5b651c636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_CommitmentsAndContingenciesLineItems_9e449204-b459-480e-b153-5299d2b27484" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_aaca6bda-dd81-4b93-9fc8-22a5b651c636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEFINEDBENEFITPLANS" xlink:type="simple" xlink:href="alny-20190930.xsd#DEFINEDBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEFINEDBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_32edebc2-9e21-4e44-8104-de57ee96addd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2557513a-be2a-4fa0-ba1f-71a960aea385" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_32edebc2-9e21-4e44-8104-de57ee96addd" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2557513a-be2a-4fa0-ba1f-71a960aea385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="alny-20190930.xsd#DefinedBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_491f2fa4-215d-4176-9ffb-301fb3101130" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_491f2fa4-215d-4176-9ffb-301fb3101130" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:to="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain_65f2837b-6e36-4426-b5d9-49743757b12e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis_03c75d58-6ec6-4d88-afce-22955f3bb147" xlink:to="loc_us-gaap_RetirementPlanFundingStatusDomain_65f2837b-6e36-4426-b5d9-49743757b12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfundedPlanMember_03f0244a-f943-489e-9680-2fe92000646b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnfundedPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanFundingStatusDomain_65f2837b-6e36-4426-b5d9-49743757b12e" xlink:to="loc_us-gaap_UnfundedPlanMember_03f0244a-f943-489e-9680-2fe92000646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b5faa20f-a708-4317-a43f-88e9da88abfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6857de66-d4f0-4b9e-9e6b-00098f29388d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b5faa20f-a708-4317-a43f-88e9da88abfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75240057-90a9-4726-96f5-c47c730a31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b5faa20f-a708-4317-a43f-88e9da88abfb" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75240057-90a9-4726-96f5-c47c730a31f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7d9a3c00-688e-472e-a4fe-fe6c7d393273" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36846170-7748-495c-8cb3-6ca26a5bf94b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7d9a3c00-688e-472e-a4fe-fe6c7d393273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f5efb8d5-cfec-43cf-b3c0-7f6522c7d7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7d9a3c00-688e-472e-a4fe-fe6c7d393273" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f5efb8d5-cfec-43cf-b3c0-7f6522c7d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20190930.xsd#OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_4400fdbc-5284-4e17-8636-c678ea39adcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_4e2351d3-7c3d-4e88-a6fe-e8fd11c9e955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_4400fdbc-5284-4e17-8636-c678ea39adcd" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_4e2351d3-7c3d-4e88-a6fe-e8fd11c9e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="alny-20190930.xsd#OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5b9fa6db-482e-4ba3-9709-a13726a0d1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b0519cdd-3460-4dd1-8426-fc5ab3eb0243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5b9fa6db-482e-4ba3-9709-a13726a0d1a9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b0519cdd-3460-4dd1-8426-fc5ab3eb0243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" xlink:type="simple" xlink:href="alny-20190930.xsd#OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ed7db976-0b68-4fec-a0b6-0a21ba474eab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ed7db976-0b68-4fec-a0b6-0a21ba474eab" xlink:to="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_98b93ccd-a163-4a03-8dd0-5614e51111d4" xlink:to="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_0f6340ad-db61-4a27-b187-e9e0b5833bb3" xlink:href="alny-20190930.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_0f6340ad-db61-4a27-b187-e9e0b5833bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_db46ae8a-7f59-4cfc-a169-bad994e0a86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_db46ae8a-7f59-4cfc-a169-bad994e0a86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_13ba0f1d-668c-46f3-aee8-d0ba3f1e20a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_13ba0f1d-668c-46f3-aee8-d0ba3f1e20a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6d36d136-ef74-4a73-b44a-4db2cbdd5b96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6d36d136-ef74-4a73-b44a-4db2cbdd5b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6687ac76-5923-437a-a27b-d46877281383" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_730dedf2-b3e4-4071-9122-3ce5aa7df87b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6687ac76-5923-437a-a27b-d46877281383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_85c219d0-ebeb-4af6-a4c4-9e984b930257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0591a964-9478-4ba3-8bb6-8422b62c2774" xlink:to="loc_us-gaap_StatementLineItems_85c219d0-ebeb-4af6-a4c4-9e984b930257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_85c219d0-ebeb-4af6-a4c4-9e984b930257" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f0954eb-7ec9-450d-97e8-49e6102cb940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_StockholdersEquity_3f0954eb-7ec9-450d-97e8-49e6102cb940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a7c1bdfc-0e55-4f19-a770-cf0e7220a33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a7c1bdfc-0e55-4f19-a770-cf0e7220a33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_073ed3a0-bda4-48a9-b0fb-63431b0e2822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_073ed3a0-bda4-48a9-b0fb-63431b0e2822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c41d6b4a-c449-4ce7-a240-07184e02933c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c41d6b4a-c449-4ce7-a240-07184e02933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5fa762c-9f38-4736-ab06-bebadbdbc7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_824b1dd5-4c16-4c41-a597-23f73acd67bf" xlink:to="loc_us-gaap_StockholdersEquity_d5fa762c-9f38-4736-ab06-bebadbdbc7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>alny-20190930_g1.jpg
<TEXT>
begin 644 alny-20190930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +)!5<# 2(  A$! Q$!_\0
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M1B<1R.-N''?/7BJ=*:BY-:)V^9/M(.2BGJ]3TVBBBLC0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_.;_ (*Y?%25K'P5\+M-=Y;J^E.L7MO$,LR@F*V7 Y.YS,<>J+U[?/7[1WP?
MO?V'_C%\(_$FC*R2)IMC?RLK?++J%ML6\3CC:_R$CTE/U/+?&/\ :/L?$W[:
M5Y\3[O3/^$HT'1]9C;3]--UY*7%O:D+!A]CA59D$A&TYW,.^:Z']K[]NBS_:
MP\&Z+H\OP^/AF^TJ^-W!J UG[7\C(5>,I]G3ACL.=W&P<<U]91HU*2IP4?=L
M^;YGS%6K3J.I-OWKJWR/V4\-^(++Q9X=TO7--E\_3M2M8KVVE_OQ2('1OQ5A
M7Y7?!S_E+A?_ /8Q:[_Z1W=?4/\ P2[^+7_"P?V<H_#UU,9-3\)73:>VXY8V
MSYD@;Z %XQ[15\O?!S_E+A?_ /8Q:[_Z1W=>;0INE*O!](L]"M4]JJ,UU:/H
M#]K+]O;Q1^S?^T9HGA"+2=&O/!SV]E>ZE/+;327XA>9UG$1$RIN"(=NY2,]<
MBO)?%_\ P5$^,>BRV7B%/A-9:-X%OY<6-QK%G>9NEZXCNMR1LVWGY4./>N-_
MX*16$&J_MN>%[*ZC$MM<V&EPRQGHR-<2!A^()K[._P""DFE6DG[&/C4F! +%
M].DMU4 ",_;8(^!V^5V'XUI&-&"HJ4+N1$I5I.JU.RB'B3]K+6_%'[&\_P :
M/AKI>GR:E9IYUYI.M)).D*QR;+E/W;QDE1\X;(!49QS@:O[#?[3^H?M1?"[4
M=9UVVTZP\1:9J+V=U:Z9'(D/EE%>*0*[N1D%A]X\H>E>8?\ !+W1[3Q-^R#K
M.CZE$+K3K[6+^SG@?E7BD@A5U^A#'\Z^;OV,_'P_8[_:2^*W@CQ/*RZ=!87V
M[>^P3R6*R3POZ?/ )=O?]XOKBLG0A*-6G!>]%W7H:*M.,J523TDM?4^DO%7[
M;7CO4/VUK3X+^!M)\/WFBI?PV5[?WUK/+<(%02WCJ4G1?W:AP 5^\ASUKYR_
MX*)?\GU^#O\ KUTG_P!*I*[?_@E?X'O?B!\3OB-\9M=3S[MYI+2&=N0]W<OY
M]RX_V@I0?28UQ'_!1+_D^OP=_P!>ND_^E4E=5*,*>)]G!;1U]3GJRG4P_M)/
M>6GH?;?[97[8FF?LI^&=-,>FC7?%.L%Q8:>TGEQ*B8WRRL 2%!8  <L>,C!(
M^1M2_P""F7[0'A"UL=<\3_"?2].\-7S?Z+<W.D:A9I< _,!'/)*48[>X4^N*
M^D/VY?VL/"?P/;1?"=_X%L_B+XFU6'[5;Z5J,2/;P1ERB.P9'+%G1@%49.P\
MCC/S1^V/KO[3GC3X"W^K?$O1/#'@SP0+FV=M(M&5[V5VD7RADO*0P)R1N0X#
M CM7/A:4'&//!:]6]_1&V)J34I<DWIT2V]6?9L?[4D7C#]D/6/C-X3L(X;JV
MTFZO(].U,&1(KF$LK1R;"I9=RGD%200>,XKY%\&_\%3/BEXT\,2Z7H?PQL_%
M'Q!:XEE1-&LKJ6UALUC3:S0)(\KOO,FX[T4*%ZDFMW]G/_E%7\1/^O;6/_01
M5S_@CMIEJO@OXCZB($%[)J%K;M/CYC&L;L%^F78_C3]E1I0JR<;\LM ]I5JS
MIQ4K<RU,[X8_\%;+@Z5X@MOB'X,CC\1VL6=-@T%98TO+C>$^SNDA=HF&2VXL
M1A&&-VT-EV__  5,^)W@?QY:6?Q+^%]KH6B7!24V@M+NSOTMV/$JF9B)!CD?
M(H;'45Y]\-_#MCX@_P""L%[97<$<ENOBS5KP1E 1YD4-Q.C8]=Z*<^O->B_\
M%E+.%+SX2W2Q@7$D>JQ/)W*J;0J/P+M^=='LL/[:-+D^)7]/3[C#VE?V4JG/
M\+MZGZ4Z?J%OJVGVU]:2B>UN8EFAE7.'1@"I&?4$5S'Q?\?)\+/A9XL\7O$M
MQ_8FF7%\D+' E=(R40_[S #\:K_ UFD^"?P_9B69O#VGDDG))^S1US?[6WAF
M\\7_ +,_Q*TNP0R7DNB7$D4:C)D,:^9L ]3LP/<UX,8KVBB]KGM2D_9N2WL?
MG3^P!\!;']K#XJ>-?'WQ-+^)+;3I8YI;>ZD;%[>3L[!GP>418S\G0[E'0$5]
MG_M$_L!_#?XL?#N\T_PIX5T'P9XKAC!TW4M.M%M(PX(.V=8E^=6&0259AG(Z
M8KY[_P""._C*R6U^(OA629$U%I+74H(3PTD>'CD(YY"GR\\<;QZ\??WQ.^(V
MC?"/X?Z[XQ\02O%I&CVS7,_E &1\<+&@) +NQ55!(!9AR.M>EC*M6.*Y8/:U
MD>?A:=*6'O);WN>7?L;_  !\4?LW_"N3PCXC\4VWB2-;M[FSCM8'1+)' +QJ
MS'+*7RWW5P6;KGCX5_X)7_\ )V_CK_L7;_\ ]+[2OT1^ ?[2/@O]I+0;_5O!
MD]])!82K#=1WUHT#1.R[@N3E6..NUCC(SU%?G=_P2O\ ^3M_'7_8NW__ *7V
ME.FYNG7=1:Z"J*"G04-M3U;5OVA/L_\ P42C\!_\*T^'DF=;@MO^$FDT'.M<
MVZ-YGVGS/OC. VWH *[K]MG]MSQ;^S#\6O"7A_1],T.\T+4;".]OIM0MII;A
M 9W1_+*3(OW$R,@\_E7S7KW_ "ENB_[&2V_])$J3_@K_ /\ );O!G_8NC_TI
MFKHC1IRK4HR6CB82K3C2J23U4CK/&W_!43XN6J1>)]"^%%MIOP]GG\JUU+6[
M*[D%R,\ 7".D0<@'Y0&Q[XK[<_9=_:$T[]IGX2V?C&QLVTRY$SV5_8,_F?9[
ME I90V!E2KHP. <.,C-<M^VIX;TVR_8S\>Z3#:1QZ?I^CQ);0*/EB$+Q^6!Z
M;=J_E7AW_!']C_PI7QHN3M'B'(';_CVB_P !7)4C2JX9U80Y6G8ZH2JT\0J<
MY731E?L!_M!?\+2_:)\6:#_PK7X>^$/LFC7=Q_:?A70?L5[-MN[=/+DE\QMR
M'?N(QRRJ>U=Q^UM_P4.7X)^./^$ \">'HO%OC&,QK<O.SM;V\CC*P!(SOED(
M*Y *XW <G('S=_P2O_Y.W\=?]B[?_P#I?:5!^R;Y>L?\%-/$LVO 3ZDFK:])
M#]J&&6X5I1PO8JF_ QP!QC%==2A3]M.4E=1C>QRTZU3V4(Q=G)VN>D^"O^"H
M'COP?\0++0/C=\.8O"]K<L@EFMK*ZL;FTC8X$S07#.9$'4X(. 2,D8/U/^UE
M^UGHG[,'P[L=<:T&OZMK#&+2+&*8)'/A0S2M( <1J&4Y ))90,9R.C^,_P +
M_@_X\USPW=_$VPT&\U&U$T6E+K5V(?,#%#(JH742XPAP0VW/&-QSY;^VA^TU
MX#_9L\%:!H=]X,T_QG=ZC"5TW09HXQ9PV\:A0[%D8!!E5557G!&1C-<*]E6J
M0Y*>O5=&=K]I1A/GJ>C['S#??\%,/V@M#TFU\3:K\*-*L_"%T0;?4)]'U"&&
M93]W9<M+Y;9]0.:^\/V9/V@--_:5^$]CXRT^QDTN1II+2\L9'#F"X3&Y0PQN
M4AE8' .&&0#7PW^TMXH_:>^('[-^OZGXM\+^%OA]\-5M;:2;2XPOVR2'SH_)
M3:S2%&WF/C$9&T# Z'UO_@D1_P FV^)/^QMN?_2.SKHQ%*FZ#J1BDT[:.YA0
MJ5%64&VTUU5CY\_X) ?\EN\9_P#8NG_TIAK]8Z_)S_@D!_R6[QG_ -BZ?_2F
M&OUCK#,O]X?R-LO_ ("^9^2G_!1RUAO?VXO"=O<11SV\UEI4<D4JAD=3<R J
M0>"".,&OT1UK]DKX+>(-.ELKKX5^$HH9 0S66D0VDHR".)(E5UZ]B/7M7YY?
M\%$O^3Z_!W_7KI/_ *525^L]7B9RC1H\KMH1AXQE5J\ROJ?CU\/H;G]B[_@H
MA%X4TV]N!X>N-5@TJ192<36-X(VBW_WO+,L9W?WHC[BOOG]L3]LK1OV4]!T^
M/^SO[?\ %6JAFL=+\WRT6-3AII6P2%R<  98@CC!(^$/VAI!\2O^"GUC8:+_
M *2T/B'1[)G4Y :!8//)]D*R9_W#3/\ @H9-KM]^W9IL%I96^I7L4>DPZ397
MS*+>X)8,L;[F50C3,X.648)R1UKME1CB*E)U/Y;OS..-65"G45/^:R/2=-_X
M*@?%[P;?:;J?Q&^$UO9^$]28&VGMK&\L))8^NZ*6=W24@<X  ..HSQ]-_M)?
MM0:_X1_9GTOXP_">+1_$&D32P2W']L6LSJMK*3'O CEC*NLI1&!SU/3%?//Q
MUTG]LK]H7X<7W@OQ/\&?",.G74L,XN;"^MEN8)(W#!HV?4'520"I.T_*[#C.
M:]K_ &3/V=?%.E?L>ZY\*OB?I7]D3W\M_;1VQN8KGR[>95*R!HG=01(SL!G(
M(SBN6K&A%1J65T]4G>Z.FG*M)RIW=FM&U;4]2_9)^/#_ +1WP/T;QC=0VUKJ
M[O+::E:V88117$;8(4,S$ J4< DG#CFO"/@]^VQX\^-G[8&L?#GP_I/AY_ &
MEW-XTVJ&VN&O#:P?NQ('\[9EY2@&4X#CC(KY1_93_:#U']E7PK\?/!.M2&QU
MBRL99=.A9ROEZI'(+0A1C)),L;GH=L!Z5]'_ /!)+X1_V#\,?$7Q#O(O]+\1
M7?V*SD89(M8"0[ _[4I<'_KB*=7#PH*K-K3:/S_R%3KSK.G!/7K\O\SI?VL_
M^"AC_!GQZ?A[X \-Q^+?&491;EYR[P02.N5A6.,AY9,%20&7&<<G('#?"S_@
MIOXHT?XB6?A/XZ> T\%&[95^W0VES9M:;CA'EMYRS&,GJP88P3@U\N?";6OB
MC#^VSXNU?P!X:TOQ5\08M3U>46&MRHL:YE=96#--%\RAB!A\X)X(S7K_ .TK
M\%_VM?VIFT&3Q7\(?#NG7&C^<L%QHNHVD4CK)MRCM)?294% 0!C!+>M='U?#
MT[4YVU6KO9W]##ZQ7G>I"^CT5M#W#_@KJP;]FOPTRD$'Q9;$$=_]#O*](_8M
M\5:5X'_89\%^(-<O(]/TC3-+NKJZN9,XCC2XF+' Y)P. .2< <UX5_P48T[6
M='_83^$MAXCB,'B&UU'2(-2B,BR%+E=+N5E7<I(;#AN02#V)KF?B#>7EI_P2
M)\)):R21Q7$L,5SY?1H_M\K8;VWJGXXKFC3Y\-"G?>=CH=3DQ$YVVB6]<_X*
M?_$[XA>)[ZS^#7PI&MZ?:'<6NK&ZU&Y:/G$CQVS*(@<="6Z'GT]:_9._X**6
M?QM\9+X%\<:%'X/\8RLT=H86?[/=2KG=#M<;HI.#A6)!P1D' -__ ()8Z7I-
MG^RO:W=C%"+^[U6[;4)(\;VD5PJ!S[1B/ ]#GO7RC_P4,M[3P[^W5X6OO"P6
M/79;?2KRZ^S\-]N%PZH3C'S&-+<_B.:T5.A5J2PZA:U]?0CVE:G3C7<[WZ>I
M]*_MR?MO>-/V8/B?X9T#P]I6@WVEZAIJWUU)JEM/+,I\]T(0I,@QM0=0>>]>
M1^+/^"GWQ@\E_%7A[X206?PZ\\QQ:GJUC>2K(N[ S<HR1*QXX ;!.,GJ>1_X
M*_\ _);O!G_8NC_TIFK](O$N@>%9/@'J>D10VQ\&#PY)!''M'DBS%L0I QT"
M $<=JBU&C1I2E"[D7^]JU:D8SLD<Y^RW^TQH7[4/P[_X2+2K=]-U&UE^S:GI
M4KAVM9L9&&P-R,.5; S@C (-?#WP_P#^"L7Q$UR/4-.N_A_I?B+Q-=&*+1;#
MP_;7*;W.XR&13+*[X 7:B $_-DC%)_P1UN+Q?&GQ)@1G_L]M/LWE4?=\P22!
M"??!D_6N8_X)$:7:W7Q[\47DT"R7-IX>D,$C<F,M<0JQ'N1QGT)]36GU>C1=
M:\;J-K?,S]O5JJE:5F[W/2/AO_P56\2:#XXOM"^-'@BWT"*!9 _]E6=Q;W=I
M*J%ECDMYW8DL<+U7&X$\9K*\4?\ !4KXL^&]8L-8O/A/::1X'U)C)I_]J6UW
M%/=P@]8[HD1L<8Y6,@>]<'^WIHEIKW_!0+0],NXE>UU!]&M[A=H^=7=4;/K\
MO%?4/_!6+3[8_LOZ6WD(#:^(K7R=HQY?[B=<#';!QBJY,/S4_P!W\?X$\]?E
MJ>_\'XGTCX4^.OACQ-\#K3XJO<'3O#,NEMJDSW'WH%0'S$..K*RLN!U(XZBO
MA/5/^"G_ ,5_'6N:E-\*_A/%JGAS3_GFDN;"[U"=(A_'*;=U6+//!W >IQ5'
M6KZ_M_\ @CKH M6<QS7CPW3!L8A_MB? Z]-RQC'O6'^Q7XP_:;\*_!5(?A'\
M,_"GB/PK/J$\S:EJ-Q$EQ)/\JN'!O8CP%4#*=,<D8K.GAZ<(SFTG:32N[(TJ
M8BI.4()M75W979]@?L;_ +;>B_M465]IMSIP\/>,M-B\^XTU93)%/#D+YT+$
M X#$ J>5W+RV<UY-^T?_ ,%#?$W[/W[3UWX*N-$T>^\%6,5O-<2);S'47$EN
M)"J/YPC!+D $I@#KFN'_ &4_V9?CKX/_ &Q+;XD>+O =GX5T/4IM1FU7^S=0
MM&MH?/AE94CB2X=]OG&/ ^;'X9'GG[6.E6NO?\%//#VF7T*W%C>:WX=MIX7&
M5DC<VZLI]B"13A0H/$22UCRWWO84JU;V";TES6VM<Z_Q-_P5%^,WA74=/U;5
M?A-8:+X3U']Y9+J=I>Q2W4?7,=RS*C\$<K&17T!^TE^TAXB\6?L8Z;X]^%OA
MJ37[?Q6DEEJ5M+937;Z?9/;72W4C>2PV&*2+89&R@[CD5%_P54L8+K]E>2:6
M-7EM=:LY(6(Y1CO0D?\  68?C6#^QZQ;_@FGK8))"Z5KX&>W^O-9VI2I0KQA
M:TK6+_>QJ2HRG?2Y\9_L'?&#XK?"[Q)K5G\-_!'_  EVGZS=Z=%K=Q_9-W>_
M88U>8(VZ!U$>1),<OD'9QT-?M=7YJ?\ !&G_ )J__P!P?_V]K]*ZQS*2==I+
M;\=$:Y?%JBFWO^&I^:G_  66_P":0?\ <8_]LJ^JOA'^S3\)/$'P7\$S:C\,
M?"%S<WF@6,EQ<MHEL)I':W0LYD";MQ))+9SDU\J_\%EO^:0?]QC_ -LJYWPC
M^Q1^U-XR^'^A3VOQIBA\-ZEIUM-;Z=-XIU4)';O&K1QF(0E!M4J-H.!C KJ4
M5+"4KSY=_P SG<G'$U+0YMOR/,?A#I=G\*/^"DEAH7@6>231K7Q1-ID2QS^8
M/LK;DEC+?Q!%+#G)^0=^:^D?V_/V@O\ A5O[1/A/0?\ A6OP]\7_ &O1K2X_
MM/Q5H/VV]AW7=PGEQR^8NU!LW 8X9F/>O0OV.O\ @GG9?LZ>*/\ A,_$VMP^
M)?%J120VBVL12ULMXPSJ6^9W*[EW$* '88)YKYD_X*H?\G;^!?\ L7;#_P!+
M[NM8SIXC$Q2U2COW,W"I0P[;T;>W8^J/V_OVO/&/[*O_  @G_")Z;H>H?V]]
MO^T_VS!-+L\C[/LV>7+'C/G-G.>@QCG/A'B+_@IY\7=8TR7Q#X)^$\,O@^Q"
MK>:SJ&GWEQ#N"C>3)$ZQPC.<*S.0,9)J?_@LM_S2#_N,?^V5?:_[-.D:$O[-
M/PZL=,M[:;19_#EGF$*&CE\R!6EW@]2S,Y8'N6S7*O8TL-3J2A=N_P"9TOVM
M7$3IQG9*WY''_L>_M>Z/^U7X3OIEL1HGB?22BZCI?F;UPV=DL3<$H=I'(RI&
M#G()\3_:,_X*1:KX3^*%W\._A)X0B\9^(+*=K6XNIXY;E'N%^_%#!"0\FT@@
MMN'((Q@9/S]_P3/DN--_:N\<6WAK-SIJZ'J(BCW9CDC6YA\@DG'?8,\?>/J:
M\T_8AU[XP:7\5_$6K_"CPGHWC/Q:VG2"]CUZ5$,43S(7D4O<0G<7"@X)^]R.
M:Z/JE*%6<K:))I-VW[G/]:J2IP5]6W=I=C[*_9[_ ."DFJ^(OBA;?#SXP^#X
M_!.O7DZVD-U#%-;+%<.0$BGMYB7CW$@!MQY(R #D97_!8?\ Y)Q\/?\ L+7'
M_HD5Y)^T+^SY^UA^TCXQTGQ1X@^%&BZ-K.FVXMH[C0=3LX"ZJY="Y>]<DJ2<
M$$8S7J7_  5T:Y?X3_#)KQ EX=0E,RKC ?R%W 8]\TH0I1Q%*5.UW>Z3O8<I
MU)4*D:E]+6;5CT#5O&__  KG_@F!X?\ $7]@:'XH^Q^']'_XE/B2S^UV$^^Y
MMX_WL6Y=VW?N7GAE4]JT_P!C_P"-USXF_9!\8^.;+PCX3\)WFDR:G-#I?AK3
M#96#O#;)(KO$')+,<!B&!( Z8KAOB]_RB-L/^Q?T/_TMM*S_ -A/_E'A\3/^
MXY_Z0I6+A%T92:UYS92DJL4OY#BO O\ P55^(_BK0[C2[7X<V/B?Q[<W.W3[
M+0;.Z,*P!,LSQB2221MW0*5  ))Z5V?[-_\ P4L\3^,OC)IWP]^*/A+3] O=
M2NQIT-QI\,]L]M=,0L<4T,SNWS-\N<@@L..M<C_P1MTJUFU;XK:F\*M?6\&F
M6T4V/F6.1KIG4>Q,49_X"*XC]M"SAT__ (*0^&9K=!#+<7^A3R,G!9Q)&N[Z
MX1?RKIE2H2K3H*%K*]SFC4K1I0K.>[M8^]OVMOVLM"_95\&6FH7EFVLZ_JCO
M%IFDI*(_-*@%Y';!VQKN7) ))8 =<CX[M?\ @J#\9O#8T[Q%XN^$EG#X(U"0
M"VNHK*]L_/4C.(KF1GC<[>>%YKC?^"KDVIWG[3_A6S>%)+9= M?L4,S@12%K
MJ?<6R0!E@%.2.%'UKUCXM1_MF?&;X:ZKX&UWX*>"XM%U")(F-G>6ZRP;&5D:
M(MJ#*K*5&#M.*RI4*,*4)32?-O=V^XUJ5JLJDU!M<NUE?[S[F^$OQ4T#XU?#
M[2/&/AFX:XTG4HRZ"1=LD3@E7C=>S*P(/;C()!!KKZ^4O^"<_P 'OB%\#O@_
MKOAOX@:.=%N&UI[RRMS>07/[IX8E8AHI' &Y#P2#DD]Z^K:\>M&,*DHP=T>K
M1E*=-2DK,****Q-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O//VA(_%US\%?%]IX#TUM5\6WE@]I86ZSQ0D/+B,R;Y75!L5F
M?D_PX&3Q7H=%5&7*TR9+F31\5?\ !-O]E'Q3^S]I7C#6O'FC+H_B359HK2VM
M_M4-PR6L:[RVZ)V4!W?&,Y_=#@9Y^O\ Q9X9L?&GA;6/#^IQ^=IVJV<UC<QD
M9W1R(48?DQK6HK6K6E6J.I+<SITHTH*G'8_.O]@7]FGXU?LV?'+6!XA\+>7X
M(U:TEL[C4H]2M'3?&Q>WG\I9C)SAE VY'G<XP:M?#7]E7XI>'_\ @HI>?$^_
M\+^1X&DUG5KM=5_M"U;,4UM<)$WE"4R?,TB#&W(SSC!K]"J*Z)8RI*4I-*\E
M9F$<)",8QN_==S\\OVSOV4_BG\6/VL/#7C+PKX7_ +5\-V=OIZ3WO]H6L.QH
MIW>0;))5<X4@\+SVS7T[^VQ\-_$?Q<_9D\9>$_">G?VMX@U#[%]FL_/CA\SR
M[V"5_GD95&$1CR1TP.<"O<**S>)F^31>YL:+#Q7/K\6Y\R_\$]O@[XO^!WP&
MN/#OC;2/[%UEM9N+L6WVF&XS$T<05MT3LO)5N,YXKXK_ ."MG@/3_#OQR\/^
M)K.>);WQ%I7^FVJM^\#P$1K*P[!HRB#U\EJ_43XK>&=5\:?#7Q/H>@ZK)H6N
M7^G3P6&IPRO$UK<%#Y4F]/F7#[3E>1VYKX+^&_\ P3%\>:[\4-.\4_&KQ]:>
M*K:SECEDA@O+J_N+U4.5BDFN$0JF>N-W&0,9R.W"UHJK+$5)6\NYQXBC)THT
M*<;^?8^KOV+?A-_PIK]FWP;HDT/DZE<VHU/4%/WA<3XD96]T!5/^ 5\Q?MG?
MLI_%/XL?M8>&O&7A7PO_ &KX;L[?3TGO?[0M8=C13N\@V22JYPI!X7GMFOT-
MHKBAB9TZKJK=W_$[)X>$Z:IO9?H?"O\ P4&_8E\7?'7Q7HWCWX?/;W&O6=FM
MC=:;-<"W>54=GBEBD8A=P+L"&*\!2#UKRGQ+^R;^UE\?_ -[#\4/$F8=&MFF
MTGPW)>6AEO[I5(CWM"1%G!;]Y*Y89QQDD?J!16L,;4IQ44D[;.VIE/!TYR<F
MWKOKH?#?P(^ /Q/\,_L)?$7X8:_X2.F^*KI+]-+M?[0M9!=K-$NWYTE*(=^X
M?,5XQ6__ ,$VO@#X]^ /@GQE8>/-!_L*[U#4(9[:/[9;W'F(L94G,,C@<^N*
M^Q:*SGBISC.+2]YW-(X:$91DF_=5C\]?AK^RK\4O#_\ P44O/B??^%_(\#2:
MSJUVNJ_VA:MF*:VN$B;RA*9/F:1!C;D9YQ@UU7_!3#]F_P"(O[07_"N/^$ \
M._V]_9']I?;?]-MK;RO-^R^7_KI$W9\I_NYQMYQD5]P457URI[2-6RO%6)^J
MP]G*G=VD[G*_"?1+WPS\+?!VD:E#]FU'3]&L[2YAWJ_ERQP(KKN4D'# C()'
MI74LH92K $$8(/>EHKB;N[G6E96/SD^-G_!.OQUX%^)LGQ _9[UM=)FDF:<:
M.+K[)-:.QRR0N?D>(G_EFY&!Q\PZ<?XE_9D_;)_:4:RT/XG:O%IN@12K(WVZ
M^LE@! X<PV6?,8 G&X=3U'6OU+HKT(XZJDKI-KJUJ<,L%3;=FTGT3T/,_P!G
M?X"Z%^SC\,-/\':$S70B9I[S4)$"27MPV-\K $XX"J%R<*JC)QD_(/[ ?[*O
MQ2^"?[1/BSQ/XT\+_P!C:'?:-=VEO=?VA:S[Y7N[>15V12LPRD;G) ''J17Z
M%45A'$32FGKS;F\J$&X/;EV/SRU;]E/XIW7_  42C^)T7A?=X'&MP79U3^T+
M4?NEMT0MY7F^9]X$8VYI_P#P4?\ V5?BE\>OBEX9U?P)X7_MW3K/1A:3S?VA
M:V^R7SY6V[9I4)^5E.0,<U^A5%:QQE2,XS25XJQD\)"490N]7<\J_:G\$ZU\
M2/V>O'7AGP[9?VCK>I:>T%I:^:D7F/N4XW.RJ. >I%>.?\$W_@3XY^ GPQ\4
M:3X[T/\ L+4+W6/M4$/VN"XWQ>1&N[,+N!RI&"<\5]<45@JTHTG1Z-W-G1BZ
MBJ]4?GK^P'^RK\4O@G^T3XL\3^-/"_\ 8VAWVC7=I;W7]H6L^^5[NWD5=D4K
M,,I&YR0!QZD59_:Q_8/\=:C\9#\7?@KJ4=GXAFF6[N-/^TBVF2Z PTT,C'80
MX^\C$<ENH; _0&BM_KE7VOM=+VMY&/U2G[/V>MM_,_+&Y_8M_:<_:A\;Z/=?
M&W5H]*TK3SY1N+BYM))(X3@OY$%IF/>VU02VW. 23@"O:OVY/V#]4^+WAGP5
M/\-EM([[PIIJZ-'I-U*(A/9H!Y020_*'4@\-@$,>01@_<E%-XZKS1DK*VR6P
ME@Z?+*+N[]7N?F$W[*/[6GQP\!W'ASXF^*'TWP]I-E))8://>6LLU_<QQL;>
M-V@.U@9 H+S2$KU )''T+_P3?^#WQ"^!/PP\4>%_'WAG_A'Y)-8_M.SD^VV]
MSYXD@CC<?N97QM\A?O8SOXSSCZXHJ:F,G4@Z;22?9%4\+"G-33;:[GYZ_P#!
M.#]E7XI? 7XI>)M7\=^%_P"PM.O-&-I!-_:%K<;Y?/B;;MAE<CY58Y(QQ7Z%
M445A7K2Q$^>6YM1HQHPY(['YP?MZ?LI_&3XL?M&:?XR^'OA?^U;&STRT2*]_
MM"SAV7$4DCXV32J3C*GE<'WK,OM)_P""AFNVSV-U<2VL$PVO-!<:% ZCU#Q$
M.OU4YK],J*ZHXV2C&#A%V[HYI8.+DY*35^S/BK]BC]@B]^!_BFX^(7Q"U*WU
MSQQ,L@M8K>1YH[-I,^;*TK &29@2I.,#<W+9R-?]N[]B.Z_:3_LOQ5X2OK?3
MO&VE0?9MEVQ2*]@#%U4N 2CJS,5.,'<0<<$?7U%8_6JOM?;7U-?JU/V?LK:'
MYCV_PS_;X\2KI^@W_B*ZT;3K1P$U)]7L(R0O ,DMN3/*.^'W9[BOT(^$OA7Q
M#X+^'NCZ1XJ\43^,?$%O&?MFL7$21F9R22%50/E7.T$Y) R37844JV(=9)<J
M7HATJ"I._,WZL_,3]N?]@OXC?$3X_7_BWX<>&H]8TG7+>&XO6%_;6WD78'ER
M#;+(I(941\@')=J_0_X3_#ZS^%'PS\,>#[##6VBV$-GY@_Y:,JC?(?=FW,?=
MJZRBBIB:E6$:<MHA3P\*<Y5([L_/C]J/]@_X@I\:IOB]\#M4CM==NK@WMQIW
MVE;:>*Z((DDA=\(RR<ED<CEF^\&PN;X+^$?[</Q"\;:?=^,?'MQX&L(&VRW"
MW=DR[."2MK:9CD;L-^._/K^C-%:K&U.51:3MI=K4S>$AS.2;5^B>A\H_\%#O
M@9XV^-WP&\.^&?!&FR>)M9LM>M[N=9KJWMW:%+6YC:5FD:-"=TB9"_WN!@<=
M#\%?V=YK[]BO1OA)\1=,:PN9M.FM+^U2:.5H'-Q)+&ZNC,A93Y;@@D9 KZ-H
MK'ZQ/V:IK9.YK[&/M'4?56/RVTG]D/\ :O\ V7=;U6U^#NNQ:QH=])N,EG<V
MD:R  @/);WAVI)C@E"W;YN./2OV6_P!@/QA;_%I/BQ\<-5CU;Q'#<"\MM-^T
M_:I'N0 $FGE'R_)@;40D95>0%VG[_HK>6.JRBU9)O=VU,8X.G%IW;2V5]#\G
M/^"O_P#R6[P9_P!BZ/\ TIFKHO'G[+?[7V@^&9_A1X>\2-XJ^&+9@@FCOK2V
M/V8](I3*5G5<<&)69, @9%>Q_MW_ +$/CK]J#XB>']?\*ZMX>T^ST_2OL,J:
MQ<SQR%_.D?*B.&0;<..I!SGBOMZNEXM4Z-)0LVKWOT['.L+[2K4<[I.VWXGS
MO^Q1^RG'^RS\.;NQO;R'4O%.LRI<ZK=6X/E+L!$<,><$J@9_F(!)=C@# KY]
M_P""<'[*OQ2^ OQ2\3:OX[\+_P!A:=>:,;2";^T+6XWR^?$VW;#*Y'RJQR1C
MBOT*HKA^M5&IIZ\^_P CL^KP3A;[.Q^>7[4G[*?Q3^(W[:GAWQYX=\+_ -H>
M%+2XTEYM0_M"UBV+#(K2GRWE5SM /1>>V:]S_P""A/P=\7_''X#6_AWP3I']
MM:RNLV]V;;[3#;XB6.4,VZ5U7@LO&<\U]-44_K4[P=E[FP?5H6FK_%N?,?[/
MO[-MY)^P_IGP@^).FOI5Y<6U];WUM%/%,]N9+Z>:&171F0LNZ.0<D @ ]Q7R
M=X?_ &5_VOOV8;_5M'^$^K0ZKX?O9"YGL;JR6*3@ .8;T_NI"  2F>F-Q !K
M]3:*J&,G%R=DU)WL]B986$E%7::5KK<^4OV._@]\?/!VIWVN?&'XAW>IV\R.
ML'AMKE;P"1B#YDDI!V@?,!'&<<CD ;3Y%\=/V5?BEXQ_;^\.?$C1_"_VSP7:
M:SH=W-J?]H6J;(K=H#,WE-*)#MV-P%R<<9XK]"J*F.*G&HZB2NU;8;PT)04&
MWH[GSE^WS\)?%?QJ_9[N_#/@S2O[9UM]1M9UM?M$4&41B6.Z5U7C/3.:K?L@
M_ SQ%X)_9'3X=>.-/.B:M=)J-M<VXGBN#''.\@#;HG93\KYP&_*OI:BL_;R5
M+V72]S3V,?:>UZVL?E+\'OV1_P!K']G?QW?V?@I;6TT34;B"/4=2M=0LVMKN
M&*0E3ME/G+PS\J@8!R.YK]6J**JOB)8AJ4DK^0J-"-!-1;L?#_\ P4P_9O\
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ML6",%4C;F>,FY9>.ASD#!':OU HHIXN=."@TFEM=7L%3"PJ2<[M-[V>YY_\
M OP7XN\!_#FPTKQSXOE\;>)0S276IR1JB@G&(X\*"54#[S?,22>,@#T"BBN.
M4G)MLZHKE5D%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?CK_D2/$/_8.N
M/_135N51UW3/[:T/4-.\SR?M=O);^9MW;-ZE<XR,XSTS0!^;O[,W@7X4>*/
M?A&+Q'\$/'WB37;RY>&?Q1IUI=G2V)NG5)/,2Y50D:[5<A."C9R1D_4'BCXX
M?$[QE\6/%O@SX2:)X;G3PC!&=4U#Q0\X6XGE7<D,"Q%=I^609?Y25/*@ MZA
M\!?A3_PI#X3Z%X*_M3^VO[+\_P#T[[/Y'F>9/)-]S<V,>9C[QSC/?%<%XZ_9
MCUJ\^(VN>,_A[\1KSX=:GXAMUM]9BBTR*]AN=JJJ.BLR^4X .6&6RQ(*Y;<
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MN>$(Y?'OAZW\.>)(IGAF@LKE)[>=5QMFB*NQ5&S]USN&#GM7FGB7]EJ\N/\
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M&C[6&2&Q@X.#P:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!S3K76+"]U"]L+>^MI[ZRV?:K:*56D@WKN3>H.5W#D9QD<B@"Y1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@#Q+]J?]J;0/V8/!]OJ.H6S:KK>HLT>FZ5$X0S,H&YW;G:BY&3@G)
M]/BGP_\ \%;_ !E'XB237/!.A7&@E_FM]/DFBNE7/42.[*Q [;!GU%'_  5P
M\/ZK%\2_!&N.DAT2?2'LH6R2BW$<SO(/0$K)%]=O?''P57J4:,)03:O<]S#8
M:E*DI25VS^@_X8_$K0OB]X$TCQ=X;N6NM'U.+S(FD78Z$,5='7LRLK*1R,@X
M)&#6EI/BS2M<UK7-(LKKS]0T66*"_A\MU\EY(EE09( ;*.I^4G&<'GBOEO\
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MD9![$UYO\"-8\):AYB>%_&^K>+96TRUFOH;O4YM3@@E.[+F63?Y,S\AH!(
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MMN(UDYW<$KW..] '%ZAX]T;P3\.?AE):^'-!U[P]<O81V)DO%2>"[.098X3
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M"Q2,A#N5N#\I0E?O<!1QV^EO!.AKX?T-;5= TCPV3(SM8Z(VZWR?XL^5%DD
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M35O@WINCVMS--/X]\5SW6I6.FV<LKZ?"KK+=0)$BF1MBJG 7D,3TY/T/X?\
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MK#_GO_XXW^%']O6'_/?_ ,<;_"BS T**S_[>L/\ GO\ ^.-_A1_;UA_SW_\
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MK#_GO_XXW^%']O6'_/?_ ,<;_"BS T**S_[>L/\ GO\ ^.-_A1_;UA_SW_\
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M,#PKQ)^T!X@TG4=8@MY=!EAAOOLL4^Q5BM1ME(CN'GNX!YQ:%E,;",@?,OF
MXKN/&_Q&UC3=9\$Z18:9=6T^LW5LUW=):R7,,498-) LB*4WE5DRQ.%16;C(
M9>]_MZP_Y[_^.-_A575+S2=8T^XL;J5WMKA#'(J&2,E3U&Y<$?@:+,"#X?ZK
M>:YX)T2_OR6N[BU2220J%,F1P^  !N&&X '/ KH:S(M:TV"-(XY%CC0!518V
M 4#H ,<"G_V]8?\ /?\ \<;_  HLQFA16?\ V]8?\]__ !QO\*/[>L/^>_\
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MHKT"BCF \_HKT"BCF \_HKT"BCF \_HKT"BCF \_HKT"BCF \^(# @C(/44
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MC#91PK"TD0MVMA [R@8=@?/8DA<\$$  ]IHHHH&%%%% !1110 4444 %%%%
M!7C?QX\57UG=6>CVTSP6\L/GS&,D%\L5"D^GRGCWKV2O'_C[J&@1VL$=X[KJ
MT*&1'C("QQGKYA/;C([\=@: .'^%WBR_T/Q5I]M'-(]G=S+;RVY8E3N( 8#L
M03G-?1>LZU8>'=+NM2U2\@T_3[5#)/=7,@CCC4=2S'@"OFGX>^+O"'A&X?7_
M !+>?9;2UB,\5ZQ!MT&,ACCDD]L=R/:J/PVMM:_;%\6+XW\56TEE\)=+N6_X
M1_PW,,#4YD; NKD#[ZJ1PIRN>.0&+ 'TGX*\96?CS0H]9TZWO(M-G;_19KR
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M.->&&I1Q+O445S-=96U?WGSE9P=23IJT;NWIT"BBBNPQ"BBB@ HHHH ****
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M7T-JB3S#(.'<#<W('4]A5V"QMK6XN9X;>*&:Y8//)&@5I6"A06(^\0JJ,GL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9O\ OX?\:KT4 6/[0N_^?F;_ +^'_&C^T+O_ )^9O^_A_P :KT4 6/[0N_\
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M '\/^-']H7?_ #\S?]_#_C5>B@"Q_:%W_P _,W_?P_XT?VA=_P#/S-_W\/\
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MYO-=/)D9=K-A6 ;CLP(JUL!\P^"_"OBCX-^%O%,QN1\'+/Q'JMC9>']!0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !4=Q_J)/\ =/\ *I*CN/\
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M.)+F:-W#2L !ECN]OYGN:ZZVMX[.WB@A79%$@1%R3A0, <^U=K_8%A_SP_\
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MG_X\?\:/[/M_^>?_ (\?\: ,6BMK^S[?_GG_ ./'_&C^S[?_ )Y_^/'_ !H
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M"_\ 0C1_8%A_SP_\?;_&KEO;QVL*Q1+M1>@R3WS2;N!)1114@%%%% !1110
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MJ6.Q&AOM'U=-0MW8C+1,=B,DB?+D%<?,/F[4#.UHHHH **** "BBB@ HHHH
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MNI;QKWF%0)5.4.3@'+ FF6_Q1\;W?AK2]9VZ+##J6Z\\BWL9;JYM-.!;;=-
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M8XYU?'7PPC^(+:FNI:@RV\VES:;9QPP@&U:;'FS$DG>Q"Q@<+A0XYWFNXHH
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M )YP_P#?)_QH_P"$HN_^></_ 'R?\:QZ*+(#8_X2B[_YYP_]\G_&C_A*+O\
MYYP_]\G_ !K'HHL@-C_A*+O_ )YP_P#?)_QH_P"$HN_^></_ 'R?\:QZ*+(#
M8_X2B[_YYP_]\G_&C_A*+O\ YYP_]\G_ !K'HHL@-C_A*+O_ )YP_P#?)_QH
M_P"$HN_^></_ 'R?\:QZ*+(#8_X2B[_YYP_]\G_&C_A*+O\ YYP_]\G_ !K'
MHHL@-C_A*+O_ )YP_P#?)_QH_P"$HN_^></_ 'R?\:QZ*+(#8_X2B[_YYP_]
M\G_&C_A*+O\ YYP_]\G_ !K'HHL@-C_A*+O_ )YP_P#?)_QH_P"$HN_^></_
M 'R?\:QZ*+(#8_X2B[_YYP_]\G_&C_A*+O\ YYP_]\G_ !K'HHL@-C_A*+O_
M )YP_P#?)_QH_P"$HN_^></_ 'R?\:QZ*+(#8_X2B[_YYP_]\G_&C_A*+O\
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MW_SSA_[Y/^-'_"47?_/.'_OD_P"-8]%%D!L?\)1=_P#/.'_OD_XT?\)1=_\
M/.'_ +Y/^-8]%%D!L?\ "47?_/.'_OD_XT?\)1=_\\X?^^3_ (UCT460&Q_P
ME%W_ ,\X?^^3_C1_PE%W_P \X?\ OD_XUCT460&Q_P )1=_\\X?^^3_C1_PE
M%W_SSA_[Y/\ C6/119 ;'_"47?\ SSA_[Y/^-'_"47?_ #SA_P"^3_C6/119
M ;'_  E%W_SSA_[Y/^-'_"47?_/.'_OD_P"-8]%%D!L?\)1=_P#/.'_OD_XT
M?\)1=_\ /.'_ +Y/^-8]%%D!L?\ "47?_/.'_OD_XU9L]?N+C?N2,;<= ?\
M&N>J]I?_ "U_#^M)K0#<_M:;^ZGY'_&C^UIO[J?D?\:I45 %W^UIO[J?D?\
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M_P"-+<?ZB3_=/\JQJJ(&Q_PE%W_SSA_[Y/\ C1_PE%W_ ,\X?^^3_C6/7/\
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M!6MS2_VFK'Q1X)\0:]9>&/%F@VVGZ3)JEOJ&MZ$3:W$:KG,;+,$D.,':9$W
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M[T>A(/\ P$JQXP*^U_@/\)M+^#_P]L-)L-MQ=S*+F^O\?/=3L,LY/7 Z*.P
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MO1_PB?\ T]?^0_\ Z]%T!S]%=!_PB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O1=
M<_170?\ ")_]/7_D/_Z]'_")_P#3U_Y#_P#KT70'/T5T'_")_P#3U_Y#_P#K
MT?\ ")_]/7_D/_Z]%T!S]%=!_P (G_T]?^0__KT?\(G_ -/7_D/_ .O1= <_
M170?\(G_ -/7_D/_ .O1_P (G_T]?^0__KT70'/T5T'_  B?_3U_Y#_^O1_P
MB?\ T]?^0_\ Z]%T!S]%=!_PB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O1= <_17
M0?\ ")_]/7_D/_Z]'_")_P#3U_Y#_P#KT70'/T5T'_")_P#3U_Y#_P#KT?\
M")_]/7_D/_Z]%T!S]%=!_P (G_T]?^0__KT?\(G_ -/7_D/_ .O1= <_170?
M\(G_ -/7_D/_ .O1_P (G_T]?^0__KT70'/T5T'_  B?_3U_Y#_^O1_PB?\
MT]?^0_\ Z]%T!S]<'JGPN_M+4KJ[_M/R_/E:39]GSMR<XSNKUS_A$_\ IZ_\
MA_\ UZ/^$3_Z>O\ R'_]>E= ?+GA/]C?P[X1\8:IXDM=1=[^\E>2)7MQLM@_
M+*@#]SGGL#@>_O6FVG]GZ?:VN_S/(B6+?C&[: ,X[=*ZG_A$_P#IZ_\ (?\
M]>C_ (1/_IZ_\A__ %Z- .?HKH/^$3_Z>O\ R'_]>C_A$_\ IZ_\A_\ UZ=T
M!S]%=!_PB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O1= <_170?\ ")_]/7_D/_Z]
M'_")_P#3U_Y#_P#KT70'/T5T'_")_P#3U_Y#_P#KT?\ ")_]/7_D/_Z]%T!S
M]%=!_P (G_T]?^0__KT?\(G_ -/7_D/_ .O1= <_170?\(G_ -/7_D/_ .O1
M_P (G_T]?^0__KT70'/T5T'_  B?_3U_Y#_^O1_PB?\ T]?^0_\ Z]%T!S]%
M=!_PB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O1= <_170?\ ")_]/7_D/_Z]'_")
M_P#3U_Y#_P#KT70'/T5T'_")_P#3U_Y#_P#KT?\ ")_]/7_D/_Z]%T!S]%=!
M_P (G_T]?^0__KT?\(G_ -/7_D/_ .O1= <_170?\(G_ -/7_D/_ .O1_P (
MG_T]?^0__KT70'/U>TO_ ):_A_6M+_A$_P#IZ_\ (?\ ]>I[7P[]FW?Z1NW8
M_@Q_6DVK 5:*T?['_P"FW_CO_P!>C^Q_^FW_ ([_ /7J ,ZBM'^Q_P#IM_X[
M_P#7H_L?_IM_X[_]>@#.HK1_L?\ Z;?^._\ UZ/['_Z;?^.__7H SJ*T?['_
M .FW_CO_ ->C^Q_^FW_CO_UZ ,ZBM'^Q_P#IM_X[_P#7H_L?_IM_X[_]>@#.
MHK1_L?\ Z;?^._\ UZ/['_Z;?^.__7H SJ*T?['_ .FW_CO_ ->C^Q_^FW_C
MO_UZ ,ZBM'^Q_P#IM_X[_P#7H_L?_IM_X[_]>@#.HK1_L?\ Z;?^._\ UZ/[
M'_Z;?^.__7H SJCN/]1)_NG^5:O]C_\ 3;_QW_Z]))HOF1LOG8W#'W?_ *]
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MG/T5T'_")_\ 3U_Y#_\ KT?\(G_T]?\ D/\ ^O1= <_170?\(G_T]?\ D/\
M^O1_PB?_ $]?^0__ *]%T!S]%=!_PB?_ $]?^0__ *]'_")_]/7_ )#_ /KT
M70%'3?\ 4-_O?T%6ZN6V@?9XROG[N<_<Q_6I?['_ .FW_CO_ ->H8&=16C_8
M_P#TV_\ '?\ Z]']C_\ 3;_QW_Z](#.HK1_L?_IM_P"._P#UZ/['_P"FW_CO
M_P!>@#.HK1_L?_IM_P"._P#UZ/['_P"FW_CO_P!>@#.HK1_L?_IM_P"._P#U
MZ/['_P"FW_CO_P!>@#.HK1_L?_IM_P"._P#UZ/['_P"FW_CO_P!>@#.HK1_L
M?_IM_P"._P#UZ/['_P"FW_CO_P!>@#.HK1_L?_IM_P"._P#UZ/['_P"FW_CO
M_P!>@#.HK1_L?_IM_P"._P#UZ/['_P"FW_CO_P!>@#.HK1_L?_IM_P"._P#U
MZ/['_P"FW_CO_P!>@#*N/]1)_NG^58U=;)HOF1LOG8W#'W?_ *]4O^$3_P"G
MK_R'_P#7JDP.?HKH/^$3_P"GK_R'_P#7H_X1/_IZ_P#(?_UZJZ Y^LKQ1?:G
MIWA^^N-&TX:MJJ1_Z-9M*L8D<D 99B  ,Y//0<<UVO\ PB?_ $]?^0__ *]'
M_")_]/7_ )#_ /KT70'S\O@O6-8\&Z_:3:5J4?B;4!#=3:GJTMJ([F:&17CA
M00S2>6@P0HQ@ DDDDYZ71=%O_$WB[4-;UO1&TNRDTI=*73KUX9VG#.SRLXC9
MEV<JH!.3\V0.*]<_X1/_ *>O_(?_ ->C_A$_^GK_ ,A__7I70CYXUGP'KT:I
M?:;I=Q90//-!_8^BW4=E+!:K'(+<*Z2(H'G,9757Y+CAMN*[G7]%UC4_A+J.
MDSE;W7[C0Y+5]C!1-<M;E3@G  +GO@<UZ=_PB?\ T]?^0_\ Z]'_  B?_3U_
MY#_^O1= >/7&BZMX?\1:#KMKI4NKQQ:0=*N;&UEB2:$Y1UD7S'5&7*%2-P(R
MI&><<5JWP]UC2_#?A2V62.UU?4KV[TZ^BMVW+':WKR33(AQD^6$!X[JQ!'6O
MI;_A$_\ IZ_\A_\ UZJ2?#VQFU*'4)%MY+^%&CBNFME,L:GJJMG(![@&BZ \
M3^(OAWQ/K5]JEC;VNI7>C26*Q:;;Z7?Q65M'*4='-R=RRL!E2%7<A'5<UC2?
M#OQ'_P (WK$(TQC<3:3H,,4/GQ;GEM9&:>,'?@$# R2%)/!KZ0_X1/\ Z>O_
M "'_ /7H_P"$3_Z>O_(?_P!>BZ ^==4^'NNWVO7VN'3KLQKKBWZZ?;Z@+:XG
M@>S2!RDL<JA9$.[@NH8!AG!YNS>!R]D]T/!>K1337K2F>'Q(S:O#B!HEG$CR
M[,X^4IYQ&W:2&QM'OO\ PB?_ $]?^0__ *]'_")_]/7_ )#_ /KT:!8\Z^'M
MOKMKX;CC\0RRRWHED\O[0T;SK!N/E+*T8"-(%QDKP3W/6NEKH/\ A$_^GK_R
M'_\ 7H_X1/\ Z>O_ "'_ /7IW0SGZ*Z#_A$_^GK_ ,A__7H_X1/_ *>O_(?_
M ->BZ Y^NPT#_D$P?\"_]"-9_P#PB?\ T]?^0_\ Z];&GVGV&TC@W[]N?FQC
MJ2?ZTFP+%%%%0 4444 %%%% !1110 445YY\1_BW_P *_P#''P^\._V5]O\
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MXZ@\2^*]9TFUB5[:QLK&]BOHY=RW"7(E*X&. !$#G)SN[8Y .HHHHH ****
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M_CC?X4?V]8?\]_\ QQO\*X^BCE [#^WK#_GO_P".-_A1_;UA_P ]_P#QQO\
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MA_SW_P#'&_PH_MZP_P">_P#XXW^%<?11R@=I'JUI,NY)<C./NG_"G_VA;_\
M/3_QT_X5S6F_ZAO][^@JW4@;7]H6_P#ST_\ '3_A1_:%O_ST_P#'3_A6+12
MVO[0M_\ GI_XZ?\ "C^T+?\ YZ?^.G_"L6B@#:_M"W_YZ?\ CI_PH_M"W_YZ
M?^.G_"L6B@#:_M"W_P">G_CI_P */[0M_P#GI_XZ?\*Q:* -K^T+?_GI_P".
MG_"C^T+?_GI_XZ?\*Q:* -K^T+?_ )Z?^.G_  H_M"W_ .>G_CI_PK%HH VO
M[0M_^>G_ (Z?\*/[0M_^>G_CI_PK%HH VO[0M_\ GI_XZ?\ "C^T+?\ YZ?^
M.G_"L6B@#:_M"W_YZ?\ CI_PH_M"W_YZ?^.G_"L6B@#9;4K95+&3  R?E/\
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MG_"C^S[O_GVF_P"_9_PH KT58_L^[_Y]IO\ OV?\*/[/N_\ GVF_[]G_  H
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M3?\ 4-_O?T%6ZBT^SN$A8-!(IW=T(["K/V:;_GD__?)K-[@1T5)]FF_YY/\
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MZ$:Y?^S[O_GVF_[]G_"NJT2-X=+A1U9&&[*L,'[QJ9 7J***@ HHHH ****
M"BBB@ HHKF_B!\1_#7PK\-RZ_P"*]7@T72HW6,SS;B7<YPB(H+.Q )VJ"< G
M& : .DHKB/A;\:_!/QJT^]O?!>OP:W#92+%<JL<D,L)894M'(JN%;!PV,':P
M!.TX[>@ HHK&\8>,-(\ ^&=0\0Z]=_8-'T^/SKFY\MY/+7(&=J L>2.@- &S
M16+H7B[3O$D\L=@+QU2"&X$\UA<0P21RIO0QRN@20X(R$8E3PP!XJSKFO6WA
M^VBGNHKR5)9D@46-C/=N&8X!*PHS*OJQ 4=R* -&BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***\U\:6=MXK^*.A>&M< ET!M-GOUT^9L0ZC<)
M+$ DB'B41J=^PY&6#$?** /2J*\4T^^TVSU^V\.>#?$,WAWPU<-J&I3W4,47
MDP&W,4<EO9&:-HQ'YDC2.0&52'"E<G;S<OQ*\;ZYX1FU2TUT:9+INAVL\BQ6
M,1-[>7$\B6Y(D1MJ.B1.P7M*-N.P(^CZ*\/G\3>+(?$4_A>'Q7NN9]=M]/BU
M:XLX 4 LFNKE(T5 IQA%4-N8&0 LV*Y7Q#\1M>CMXK^&X&N7?A^35)+&^FCB
M7[2&N([&VF8+MC;'GSY(V*PB)XR: N?35%>$0>,O'$4=YH1O[BWU*;5M.L;6
M]U9=/EO(#(C2W"R0VCF,*(HBRA@&(D// 800^/O%/AV.#5+G7[G7[-;W6DAL
MVMK9!<V=E%<D2NT<:GS#-'$H*;4*$?*2<D"Y[]17SSI_Q(\=:=H6JRW\T[WE
MSH,=U;G4#IP,%[/,L5N8(K=W<P%I#@S DF(#=DD59U]O$^M:TW@^[\2W=Y&?
M$&FV[7J6UM$Q9+9[VXC5?**^6H2%@K;FY"LSAL, >^T5X9\?M0U'QI\.9-!?
M1-1T*?49Y!Y=]);LTD<-O+<%U\F608#0H/F(.2.#7*Z]\2-3U+7HO&T=JERN
M@:)=7&GVDZE5:7$<$DQY "O+,ZYX(6U?D;S0!].T5X'#XZ\:Z;>2Z#=7EXEQ
M?76GZ>FI:M_9INK">;S#*WD6KNNUHXP8Q+SN;DN!BN?L_%$OA_Q'X@U?4-3C
MUV"#5;V:6^N+.&5FM]/LUCC.$555A<72 LFSE>H#&@#Z<HKYJUSQ%XJUZV\1
M^$+W5M7MYY4TJQE;4(]/2=)[NX9)%3[+YBK$80[%7+. HY^;YM?2_B5XP?Q!
M%=2&_DTY=;N--6VN'TR.">UMP\<K;=ZW+768VDVJH7' 3;R0+GOU%>"^&[[6
M/&7C7X8WVI:^NJ)?65SXDETB.*$0V'[KRX=A50Y4?:MN9"Q+)D$8(KWJ@844
M44 %%%% !1110 4444 %%%% !4=Q<16L+2S2)#$HRSR,%4#U)-25XA^T#JEV
M-3T[3@[K9>1YY4?==]Q'/K@ ?G0![+8ZI9ZI&9+*[@NXP<%H)%<#\0:M5\N?
M#35;O2_&VE&U9OW\Z02H.C(Q ;(]AS^%?07CKQ]H'PU\.W&N>)-2ATS38<#S
M),EG8]$11R['LJ@DT =#16!X)\17_BK08M4OM#N/#WVAM]O97K@W(A(&UI4'
M$;GGY,L0,9(.5&_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>=^(OVA/AWX4U>3
M2]3\46L5]&VR2.)))@C=PS(K!2.X)XK>C0K8A\M&#D_)-_D<N(Q6'PD5/$5%
M!/K)I?F>B451T37-/\2:7!J.E7L&H6,Z[H[BW<.C?B._MVJ]6,HN+<9*S1T1
ME&<5*+NF%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P= \?>&/%5V]KHGB/2=
M8N8T\UX=/OHIW5,@;BJ,2!D@9]Q0!O45DZ%XLT/Q0;D:-K.GZN;9@LXL;J.;
MRF.<!MI.T\'KZ&CQ!XNT+PG'#)KFM:?HT<Q*Q/J%U' '(ZA2Y&3]* -:BL*]
M\>>&=-T>UU:[\1:3:Z7=G%O?37T203'!.$<MM;@'H>QK:BE2>-)(W62-P&5U
M.0P/0@]Q0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<_P!J
MAU\+_$#X/^/M9L9[[P1X9U*\;66A@:<6;30JMM=.B@G;%(I;< 2#C') /T91
M0!\.?%KXEZ3\6_ OQE\1?"7POJ!G>TT^VU#QS;VLL:ZE K*+F!0RB1?+B*[]
MJY* EL!8RWA^G:?)<_"+Q#'H^N:*_@^Z\1Z.B67A8:ND%G=ERKO')?Q B1DV
MEMLC$80D ;:_5.B@#\T_B)\'?#7A;2_VB;;28]0L;+P+=Z3>>';2/4KCRK"X
MN%C\Z907^:0A%7<V2 !CH"*OQZN/#5UJGQ8F^(+ZO)\3)+2R?PBZ_:=C6!@4
MN8_+_=>7M\[S-_'^LQ\^ZOTVHH _/;5M'TO7+CXVVFL^(;CPOIC:!X2>?4(;
M*>[C"K:(2DT<'SF)L;6((QD$GC!YG0-:TV^^!9T_1=!L;#2['QYHNW5=#NM2
MDTO4)7W,XACOSYD;Q@(K]-Q93TVD_I?10!\#:;X8\(Z'IO[2'Q,USPK>^+-2
MTGQ5J6G+9VFI7%H3:RR1I, T1^4%96+O@G8I'3.?(=4;1--^&?QXT[PG<1_\
M(E=:5HE_916MO>V]M*?[1@1Y(TNY'E?:VZ,R' 8J<*HP*_5>B@#Y9^!?@?3/
MA+^UCX^\*>'3=PZ+/X=L]1FAN;N2=I;DR;6F9G8DLVYB3ZL<8'%?4U%% !11
M10 4444 %%%% !1110 4444 %%%% !7(_$2\\)I9V%EXKTV/68KF<FUL7TF3
M4F>148EEB2-SD*6^;' )YYKKJ\U\4ZTFD_%S3+K4=/U:;3K'1Y3;SV&D75XG
MVB:90P+0QN P2'H<8$GO0!JPIX(\=>'],C_L>RUC2K>X-E;6EQI)<64J J4:
M%H\VY4+M^=5QP.,C/3R:'ILTD\DFGVKR3R132NT*DR21$&)V..60JI4GD%1C
M&*\'U7P_KLUYJ&JR>'-49+I=4UEK&U/ESHLT=O9QHL@# 7'D+-+L&3NPHR3Q
MA?\ "&WMII<%EIVDRP>#EUK-RT_AN[9=0C2U4PO<:9&8V;$ORLZ(BR-'&S)M
M6@1[SKGPQ\-^)-4M+O4=+MKJ. SNUE)!&UO<22B,-)*A4[W C7!/J>O&-<>&
M='6W: :38B%K06#1_9DVFV ($)&/]6 3\G3D\5\V^)?#NMV7A/2M+N?#K:M9
MPV-]>Z?:W7AB>\1)II3LM1;Q7+);F-"-CS.Q57*C:5*UL2>&;BY\1^&(K_P]
MJEYJEG;:/8)/=V<L\+P+L>:ZCNT56LKB-C*&'F?O B@H=P*@'N^F>$]#T6WM
M(-.T;3[""SD:6VCM;6.-8792K,@4#:2&8$CJ"?6I[70=,L6M6MM.M+<VJNEN
M8H%7R5<@N$P/E#%02!U(&:^=/ GAGQ/I.I?VS-IMS>^)K.#4;C5(XM'FL9;^
M5E8+;2:A),5F4ML,9AC95\M?N#!/<_ /PW;Z'<ZS]ATJ\L].CAMH+>^U#39-
M-NKLX=G%Q$0J2R)N4?:!&I;<02VTD@'HVF>!_#FBVK6VG^']+L+=ITN6AM;*
M.-#,A!20A5 W*0"&Z@@5-<>%=%NIHY9]'L)I8[H7R/):HS+<  "8$CB3  W]
M>!S6K10,J7FDV.HR1R7=G;W4D:NB--$KE%<;7 )' 8<'U'6J]OX9T>SA\F#2
M;&"+[,++RX[9%7[.,XAP!]P9/R].3Q6G10!A1> _#4&@S:''X=TF/19G\R73
M5L8A;.V0=S1[=I.54Y(ZJ/2I;/P;H&G6_D6FAZ;:P>3);^7#:1HOE.09$P!]
MUBJY'0X&>E;%% '-V_PU\(VMC)9P^%=%ALY&1WMX].A6-F0DH2H7!*EF(/8L
M<=:T+7PMHMCKESK5OI%A;ZQ<IY<^H16R+<2K\ORM(!N8?*O!/\(]*U** ,;1
M?!?A[PY=2W6DZ%IFEW,VX2365G'"[[B"V6503DJ"<]<#TK9HHH **** "BBB
M@ HHHH **** "BBB@ KQ']HSQ]X<T'3?LNJB!);9?-:^GE\M;;=T&?XBPQ\O
MTZU[=7R#\:-#L?'&N>)M-U:!;JTGN)(65QDKM)564]F&!@]L4 .\%?&OP9\.
M](D\8:L4O=)\DO!J%L^]LG@*B]"Q/R^HYZ8-:WP#\(^(/C[XJM_C/\1HFBL5
M9F\(^&9,M#8Q$\73*1@R, -K8R?O<#9CXE^'_P '_%&M>*/^$4UQ;C_A#]!U
M&2>0296*=L#"IW(88/'0.QX+5^M7A%UD\*:*ZHL:M90D(@ "CRUX '04 :U%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!Y]\?_$%_P"%_@YXIU+3)&AO8[4)'*GW
MDWNJ%AZ$!B0>V*_,MF+,23DGDDU^M.KZ39Z]I=WINH6ZW5C=Q-#/"_1T88(_
M(U\A^)OV#]2;6I6\/^(;,:2[Y1-05Q-$O]TE00^/7C/I7Z)POFN#P-*I2Q#Y
M6W>_=6V^7ZGY!QQD68YG6I5\''GBE:U]G>]]>^WR(OV#_$5^/$GB+0C*S:8U
MF+P1,252575,CTR&Y]=H]*^S:\T^!WP.TOX*Z#-;V\S:AJMX5:\OW7;OQG:B
MK_"@R>Y))))Z >EU\QGF+HX['SKT%[KM\[+<^VX9R_$Y9E=+#8I^^KZ;VN[V
M^04445X1]2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 8OC9HU\&Z\TUX=/B%A<%[P0M,8
M%\MLR>6O+[1SM')Q@5X5XSO-;\)^")_#.D>(Y/%ECJ/@R[N8R]O#$]G'#$BK
M+%Y2*1'(LC*%?<V47#DA@?H^LC0?"&A>%3<G1=$T[1S<D&<V%I'!YI&<%M@&
M[&3U]30(\TFOK2Q^)7@NY\+V,NJ1IX5N3+:V#1"22S\RU^R@&1TCQN\PCYAT
M?'%7M:CE\6^//#\LVN:EX$U.WTZ\>/2Y+2TEN9(R\0DD$Q,\( V)E1E\'JH)
MSWV@^$="\*_:/[%T73]'^T$--]@M8X/-(S@ML R1D]?4TOB#PIHGBRWB@UO1
M]/UF&)M\<>H6J3JC8QD!P<''>@#Q;X:^*7\8^./#VK>)'M))+CPM=)!,R!(9
M]EZ4EE122!OB2)R ?NMZ5W?[/V__ (4_X<W;O+\N7R-W_/#SG\K'^SY>S'MB
MNKUGP=H'B.QM[/5M#TW5+.VP8+>\M(YHXL# VJP(7CCCM6K%$D$:1QHL<: *
MJ*,!0.@ ["@!]%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y_Q
M9_RZ_P# OZ5R>K:Q8>']-GU#5+ZVTVP@&Z6ZNY5BBC&<99F( &2.I[U5@/3*
M*\K\.^*M%\7V+7N@ZQ8:W9K(8FN-.N4N(PX )4LA(R 0<>XK4I\H'H%%>?U4
MU75K'0=/GO\ 4KVWTZPMUWS75U*L44:^K,Q  ^M'*!Z717EFF^)M'UB^N+*P
MU6QOKRVCCEGM[:Y222))%W1LR@DJ&7E2>HY%2:QKVF>';>*?5=1M-,@EE6".
M6\G6)7D;A4!8@%CV'4T<H'I]%>?T4<H'H%%>=W%Q%:6\L\\B0P1*7DDD8*J*
M!DDD] !WKDKSXS?#_3IEBN_'/ANUE:..94FU>W1BCH'1P"_W61E8'H0P(X-'
M*![C17G=O<17=O%/!(DT$JAXY(V#*ZD9!!'4$=ZDHY0/0**\_K"N/'OAFSDN
M8Y_$6DP26MPEG.LE]$IBG?[D3@M\KMCA3R>U'*!Z[17G]%'*!Z!17F&I:]IF
MBS646H:C:6$M],+>U2YG6-KB4](XPQ&YC_=&35^CE ] HKS^BCE ] HKS^BC
ME ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BC
ME ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BC
ME ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BC
ME ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BC
ME ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^BCE ] HKS^KVE_\M?P_K2<
M0.RHKG**D#HZ*YRB@#HZ*YRB@#HZ*YRB@#HZ*YRB@#HZ*YRB@#HZ*YRB@#HZ
M*YRB@#HZ*YRB@#HZ*YRH[C_42?[I_E0!T]%>?T5?*!Z!17G]%'*!Z!17G]%'
M*!Z!17G]%'*!Z!17G]%'*!Z!17G]%'*!Z!17G]%'*!Z!17G]%'*!Z!17G]%'
M*!Z!17G]%'*!Z!17(Z;_ *AO][^@JW4@='17.44@.CHKG** .CHKG** .CHK
MG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKG** .CHKF+C_ %$G^Z?Y
M5C525P/0**\_HI\H'H%%>?T4<H'H%%>?T4<H'H%%>?T4<H'H%%>?T4<H'H%%
M>?T4<H'H%%>?T4<H'H%%>?T4<H'H%%>?T4<H'H%%>?UV&@?\@F#_ (%_Z$:3
M5@-"BBBI **** "BBB@ HHHH Y_Q9_RZ_P# OZ5\N?M/?V9_PGGPB_X2WR_^
M%??VK=?VI]K_ ./3[3Y ^Q^=GY=N_P S.[Y<;L\9KZC\6?\ +K_P+^E<GJVC
MV'B#39]/U2QMM2L)QMEM;N)98I!G.&5@01D#J.U:+8#Y"^('C+P-X&T7XL:E
M\&9OL^O?9=,BO[G1"JZ5!%(_E[[<Q_NED"L<M_"S$J<B2N$C^('Q!MO >MVE
MOXJOX+$ZOIGV.^_X3"TUR_MGD=DD1YK9@?+; (1U"_*1SDY^ZM(\%>'O#^C7
M.D:7H.F:;I-SN,]C9V<<4$NY0K;HU4*V5 !R.0,54M?AGX/L-*;3+;PIH=OI
MK7"W1LXM.A6$S+C;)L"XWC PV,C HL!\<>,(?&'A/3_C%#9_$[QC)!X!NM/N
M=-^TZCYDL[W(CWBXDV[I$ 7B/A<DG!R<U?C5XLG\76?Q7N/$GQ!U#0M3TJ*S
MM=*\)QWBPVM[#)$A9FMB,S%]Y;<.4R&S@*!]MW?@?PY?KJPN?#^EW(U;R_[1
M$UE&WVW9]SSLK^\V]MV<=JK:O\-?"/B"]2\U3PMHNI7<<'V9+B\TZ&618L$>
M6&920N&8;>G)]:+ ?*D^O>)M0;XEZ18>/!X5CM='\-_8YM2U4V=M 'MD:5(I
M&R('D /S*,DXSUR,?3?BIJ)^&,ECI_B/Q4NKV'BS28KR:]\20ZLOE3ER(X;Z
MV5?,1E3YXSD*>.N:^RI/ ?AF5-01_#NDNFH11V]XK6,1%S'&-L:2?+\ZJ  H
M.0 .*S_^$,\"Z):V.@?V%X=L+:ZNS<VFE_8X(TFN43<9(XL -(JIG<!D!<]!
M18#YJL=8FL8_C5XX\4>//'%MI&@^(;W2+?3]%U $0QR2)&ICCERNX&50G0)C
M<,'!'GNI?$7Q+H'@GXRZ?I7C[5M7M=.L])N;'45\1G4YH'DNX5<)=HD>"58J
MRI\H.1EN2?NP>#M 6SU2T&AZ:+359'FU"#[)'LO)'^^\JXQ(S8Y+9)K/'PL\
M%BRELQX0T$6DL"VTEO\ V9!Y;Q+)YBQE=N"H?YPO0-SUHL!\M^*M2\0_#OQ!
M\4? DWC#6O$\>JZ'9Q6DFM3^=(EU>3"V;R@  B_O68*N  HZX!JM??"?7?$G
MQX^+&B^$]!\"ZI:Z?::-9E_&=I)/);(=/"1FV**=IPIW$]U3TKZ\N_!GA^_U
M<:K<Z%IMQJ@,9%]-9QM/F-MT9WD;OE;D<\'D5;M-"TW3]4O]2M=/M;;4=0\O
M[9=PP*LUSY:[8_,<#+[5) R3@<"BP'R%J&B3>!O$GA[X7>)_BIJG@;PYHGAC
M[9;ZGIUX-/-_=M,P<>:WWE0' BSDA1C!KC/$_P 2M8\:>#/AI#/\2-=\-^.]
M6A:*6Y_MC^RM+CL([F<+?7*_+F5T4!0&!8+G^Z&^Y?$G@OP_XRAAA\0:%INN
MQ0,7BCU*SCN%C8C!*AP<''I5'6_A;X,\37,5QK'A'0M5N(HE@CEOM-AF=(US
MM0%E)"C)P.@S18#XD\=_$[QS#\0M2M=$\97$Z>'XK"#2+R;QC9:=97<:Q(_V
MB>"=A]M\[)8N'Q\P!)&!70:]XBUG0]=^)%W9WEUHM_/XZT2*X^QW#1MM>-M\
M19#RIZ$9(.*^OI/AKX1FN]+NG\*Z*]UI21QZ?,VG0E[-8VW1K$VW,84\@+C!
MY%3W'@/PS>27,D_AW29Y+JX2\G:2QB8RSI]R5R5^9USPQY'8T6 ^+K[5/&GV
M34_%5K\1?$UK<I\29?#EO8_;3)9Q6SL<DQ/D,1D;0?E4#@<Y&VWC1O!]KX\\
M#^(OB!XP-K!XGM=.TK5EU>.&\0O"SXN+V53Y4 *J691D <*064_6Q\!^&6MF
MMSX=TDV[7O\ :31?88MAN_\ GX(VX\W_ &_O>]1ZA\//"NK1W\=]X9T>\34)
MEN+Q;BPBD%S(HPKR K\[ $X)R118#X3;Q9=>(O"/ARU\0>-KPZ;I?Q(>QA\2
M-J/VN:WM?)!WI=NB[P-S%960 ;MVT  #Z0_97\27FI:A\0M%7Q1>^-/#NBZI
M'#I6MW]R+J69'0LZF8?ZP*0.1QSQP0*]7F^&/@ZXC:.7PGH<B-*)V5]-A(,@
M38'(V_>V_+GKCCI6KH/AS2?"NG+I^BZ79:/8*Q=;6PMT@B#'DD*@ R:+ :-%
M%%, HHHH *XGQ-)<^(/&^G^&EO;K3].%C)J-VUG*89;C;*B)&)%PZ*"26*D$
M\#."<]M7+^.K7PNT5C=^);Z#2C!(PM;U]1:PD5F7#(DJNC88#E0<':"1P, '
M/VNH:CIFNIX5\/Z[;ZF\DEQ=-<ZIOO&TZ&,1AH&(E5Y7,DHQN<%5.#G"YP)_
MB]XDOO#[ZGIEII<:V6E)>W@G623?.TLD:11X=<!_*)!.=H92<Y&>QD\)^"=:
MT+18XFMSIJ^9!I\UCJ#Q>;YF?,198W!DW[26!)W%23D\UM'P3H?EW$8TZ-(I
MVMB\2%E3_1RIA4*#@*I4?*  >00<FD(XR3QUXJBU*XT18](N-9_M*WLXI%CE
M2!%>V:XDR"Y9S&B]05W;E^5<UA:Y\5-6L?+N)D6YNM&FU!;B.P$D<-XR21VT
M&4RQP7N!E<N08R1G KN]9^&&F:SK5I>L\]O%%//=S16\\L<DMQ(D:"42JX9"
MJ(5PN,AL<#(-U?AWX=6S:T&F1BW:S%@4WO\ ZH.7ZYR&WDMO^\6P<Y - :G&
MP_$CQ-]@GMSI\,^IR7UG:V5U<Z9=Z?;3F4DR+Y<WS_NUC<E@3P5.WC!9#\3O
M$&DLMUK TV;3H[S4;1Q9VLJ2S):13N\ZEI&"#="(]AW9))W=AW.G^ ]$TV:"
M:*TD>XAN/M8N+BYEFE>7RVB#N[L6<A&*C<3M'3&!4EOX)T2VCM(TL$:.UCGC
MB21VD4+,<R@AB0VX]=V>I]30!YYI_P 6O$7]B:G?7FE[F&EF]MF_LN[M(H;D
ML%CMG>; FR9$^=-O"MQTI=:\4^+KR\;P]]JT^VU+^U;"W-U96TVQ5>-[B6(?
MO0S;4BY<%=RLWRH>1V]G\-?#MC%Y:64DO,)#W5W-.X6%Q)$@9W+"-7 81@[<
M]N:MS>"](N+Y+UK>07:7W]HB5+F5&\_RQ%N.&&1Y:A=I^4@8Q0!PGQ>\87&I
M^ YX/#T^J:;J-Q,8DF>UN+*9?+BDG8IYB*Q&(<$KQSC/-8VL?%:YF\00ZY#Y
M\NBZ1IT]PUG:S,@O)PD:N&4?>"R3Q(I.0"LIP2HQZ_JGA^PUJ:"2]@\YX%D2
M/YV4 2(4?@$9RI(YZ9XQ6;!\._#MO9M:+IB-;M9?V>T<DCN# 6+%3DG)+,26
M^\3R3Q0!Q-K\3O$:*UC<6*2ZA>26MO8WLFD7EA:K-*7\Q'6<AW$:IORI&[(&
M$/-9=IXVU;3_ !'JLNN7L,T,.I31L89IK>W2&TM-Y=$#MMWRRQAE.\'!!#';
MCT;_ (5MX?:QGM7M)Y//FCN'NI+V=[HR1_ZMA<%_-!7H,-P"1T)RRV^%_ABU
MLYK5-+#P317$$BS3R2;UG9&FW%F))8QH2QY^4<T:@>>:I\1/$^K:9K.D07,%
MOJ;0V,<=S'I5U9-!+=3F'RU6=U9R!EA*-HPC':,<:FF_%C6;O6-QLFN-)CU%
M]/E,.C7@S''E)+L7/,2J)%;]WR0HY;/%=9'\+/#D?VAOLUV\UQ+!/+<2:E<O
M,SPEO*;S#(7RNXXYZ8'0"KD'@'0;?6I-46QW7;N\NV2:1X4D?[\B1,QC1VYR
MRJ"=S9/S')J&IQ.F^)O$OB3Q-X%ENI;:TTC5DN-56SLQ(DR0K#B-)GWD2 ^?
M$QP% 9<8/!KU>N;\._#O0/"M^M[IMG)#<I;FTC:2ZFF$4)96\M [D(F5!"J
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M<R&R2Y$@V"1HE64D)'N89<[BN%ZY-?4.H?"+PEJM]KEY=:3YMSK>G+I6H/\
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M?^S[7_GVA_[]C_"C^S[7_GVA_P"_8_PJQ10!7_L^U_Y]H?\ OV/\*/[/M?\
MGVA_[]C_  JQ10!7_L^U_P"?:'_OV/\ "C^S[7_GVA_[]C_"K%% %?\ L^U_
MY]H?^_8_PH_L^U_Y]H?^_8_PJQ10!7_L^U_Y]H?^_8_PH_L^U_Y]H?\ OV/\
M*L44 5_[/M?^?:'_ +]C_"C^S[7_ )]H?^_8_P *L44 5_[/M?\ GVA_[]C_
M  H_L^U_Y]H?^_8_PJQ10!7_ +/M?^?:'_OV/\*/[/M?^?:'_OV/\*L44 5_
M[/M?^?:'_OV/\*/[/M?^?:'_ +]C_"K%% %?^S[7_GVA_P"_8_PH_L^U_P"?
M:'_OV/\ "K%% %?^S[7_ )]H?^_8_P */[/M?^?:'_OV/\*L44 5_P"S[7_G
MVA_[]C_"C^S[7_GVA_[]C_"K%% %?^S[7_GVA_[]C_"C^S[7_GVA_P"_8_PJ
MQ10!7_L^U_Y]H?\ OV/\*/[/M?\ GVA_[]C_  JQ10!7_L^U_P"?:'_OV/\
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MH_L^U_Y]H?\ OV/\*L44 5_[/M?^?:'_ +]C_"C^S[7_ )]H?^_8_P *L44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK;YGWW"]/&TLII0Q]^?7?=*^B?R^[8****\ ^K"BBB@ HHHH **** "BBB@
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M+M5=8V^51\Q$C;NQXP!0!U5%%% PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **Q_$&H3V/V?R)-F[=G@'ICU^M8_P#;U_\ \]__ !Q?\*JP'845Q_\
M;U__ ,]__'%_PH_MZ_\ ^>__ (XO^%'*P.PHKC_[>O\ _GO_ ..+_A1_;U__
M ,]__'%_PHY6!V%%<?\ V]?_ //?_P <7_"C^WK_ /Y[_P#CB_X4<K ["BN/
M_MZ__P">_P#XXO\ A1_;U_\ \]__ !Q?\*.5@=A17'_V]?\ _/?_ ,<7_"C^
MWK__ )[_ /CB_P"%'*P.PHKC_P"WK_\ Y[_^.+_A1_;U_P#\]_\ QQ?\*.5@
M=A17'_V]?_\ /?\ \<7_  H_MZ__ .>__CB_X4<K ["BN/\ [>O_ /GO_P".
M+_A1_;U__P ]_P#QQ?\ "CE8'845Q_\ ;U__ ,]__'%_PH_MZ_\ ^>__ (XO
M^%'*P.PHKC_[>O\ _GO_ ..+_A1_;U__ ,]__'%_PHY6!V%%<?\ V]?_ //?
M_P <7_"C^WK_ /Y[_P#CB_X4<K ["BN/_MZ__P">_P#XXO\ A1_;U_\ \]__
M !Q?\*.5@=A17'_V]?\ _/?_ ,<7_"C^WK__ )[_ /CB_P"%'*P.PHKC_P"W
MK_\ Y[_^.+_A1_;U_P#\]_\ QQ?\*.5@=A17'_V]?_\ /?\ \<7_  H_MZ__
M .>__CB_X4<K ["BN/\ [>O_ /GO_P".+_A1_;U__P ]_P#QQ?\ "CE8'845
MQ_\ ;U__ ,]__'%_PH_MZ_\ ^>__ (XO^%'*P.PHKC_[>O\ _GO_ ..+_A1_
M;U__ ,]__'%_PHY6!V%%<?\ V]?_ //?_P <7_"C^WK_ /Y[_P#CB_X4<K [
M"BN/_MZ__P">_P#XXO\ A1_;U_\ \]__ !Q?\*.5@=A17'_V]?\ _/?_ ,<7
M_"C^WK__ )[_ /CB_P"%'*P.PHKC_P"WK_\ Y[_^.+_A1_;U_P#\]_\ QQ?\
M*.5@=A17'_V]?_\ /?\ \<7_  H_MZ__ .>__CB_X4<K ["BN/\ [>O_ /GO
M_P".+_A1_;U__P ]_P#QQ?\ "CE8'845Q_\ ;U__ ,]__'%_PH_MZ_\ ^>__
M (XO^%'*P.PHKC_[>O\ _GO_ ..+_A1_;U__ ,]__'%_PHY6!V%%<?\ V]?_
M //?_P <7_"C^WK_ /Y[_P#CB_X4<K ["BN/_MZ__P">_P#XXO\ A1_;U_\
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M ,<7_"C^WK__ )[_ /CB_P"%'*P.PHKC_P"WK_\ Y[_^.+_A1_;U_P#\]_\
MQQ?\*.5@=A17'_V]?_\ /?\ \<7_  H_MZ__ .>__CB_X4<K ["BN/\ [>O_
M /GO_P".+_A5NPUB[FW[YMV,8^4>_M18#I:*Q?[0N/\ GI_XZ/\ "C^T+C_G
MI_XZ/\*D#:HK%_M"X_YZ?^.C_"C^T+C_ )Z?^.C_  H VJ*Q?[0N/^>G_CH_
MPH_M"X_YZ?\ CH_PH VJ*Q?[0N/^>G_CH_PH_M"X_P">G_CH_P * -JBL7^T
M+C_GI_XZ/\*/[0N/^>G_ (Z/\* -JBL7^T+C_GI_XZ/\*/[0N/\ GI_XZ/\
M"@#:HK%_M"X_YZ?^.C_"C^T+C_GI_P".C_"@#:HK%_M"X_YZ?^.C_"C^T+C_
M )Z?^.C_  H VJ*Q?[0N/^>G_CH_PH_M"X_YZ?\ CH_PH VJ*Q?[0N/^>G_C
MH_PIDVI7*PNPDP0I(^4?X4 ;M%<?_;U__P ]_P#QQ?\ "C^WK_\ Y[_^.+_A
M5<K ["BN/_MZ_P#^>_\ XXO^%']O7_\ SW_\<7_"CE8'845Q_P#;U_\ \]__
M !Q?\*/[>O\ _GO_ ..+_A1RL#L**X_^WK__ )[_ /CB_P"%']O7_P#SW_\
M'%_PHY6!V%%<?_;U_P#\]_\ QQ?\*/[>O_\ GO\ ^.+_ (4<K ["BN/_ +>O
M_P#GO_XXO^%']O7_ /SW_P#'%_PHY6!V%%<?_;U__P ]_P#QQ?\ "C^WK_\
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M_'1_A0!M45A3:E<K"["3!"DCY1_A69_;U_\ \]__ !Q?\*:5P.PHKC_[>O\
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M ["BN/\ [>O_ /GO_P".+_A72:1<276GQ2RMN=LY.,=R*35@+E%%%( HHHH
M**** "BBB@#G_%G_ "Z_\"_I7B?[0WC_ %+X??#>:;06QXFU2Z@TG1UV*^;N
M9]JX5@02%#M@@@[>E>V>+/\ EU_X%_2O#OBU\!].^-'B3PW/XCO&N/#6D"=Y
M-"5'C^US2+M5VF2164)@$ #GGG!(K1; >977QK\7V'[-7CV[N]46+XB>#[U]
M-O+Y;:+YW%R@241%=FUHG '&#@D5Z7\;/&NM>$?V?=:\2Z3>?9-;M].AGBNO
M*1]KLR G:RE3]X]1CFN*O/V.=)L=+\;Z+X6UIO#GASQ/8VUN^F-;R78MYX90
MXF#O-N;(#+M./O9SQBK.I?L]_$+Q)X1U7PSXA^+_ /:^C7ME]D6W_P"$9MX/
M*(9"K[DD#'&W&,\YHU Y#PM^TGXD\43?"[2IKG^R_$;:X=(\46!@C/F@1[HY
M!E3M60#<&3 SN ) !/5_&W]I#2/"Y\$ZGX=\::7<:&VOPVVNS:;)#?A;4HS,
MK! [+D*2-N&X.*V->_9ATO5OBAX(\<VVI_8-4\/QQ17:K:[EU%8E"QD_./+8
M#(S\V1M'\-:WB;]GGP[J&J>$[OP_9Z7X231-9AU>:'3=+CC%Z8PP"-L*8^\<
M,0V,GBC4#QKQ3^U3<^*/$?CZ?P!XH^TZ!I/@UK^V;^SPGE7ZW**7_?1!F^1P
M,'*\],US_P /?V@_$NM>-O!&EV7QCM_&4VMS"VU'2[CPY%IOV /&2729E42N
MC<*HSO( P<XKWCXD?L]?\+!\5^)]:_M_[!_;?AG_ (1WR/L?F>3^_$OG;O,&
M[IC;@>N[M6#IO[-7BJ^NO"=MXO\ BA+XG\-^'+RWO[72(M!@LCYL"%8<S(Y;
M SR#G(ST."#4#CX_C[XU'PCD\/-?QM\6_P#A*/\ A%%N1;Q8$AEW?:#'M\O9
MY61G&W^*HM=^,WQ%TK6M:\5Q>(;=O"'ASQ;%X5N-!ET^+??*NQ)K@S ;D<EP
MP"X7IQ@%6]83]G/25_:!D^*!O6+M; #2O)P@N]GE?:-^[!/EY&W;U.[=VK#U
MO]EG^U_'5WJ">+KJV\(:AK,6OZAX76S0BXO$YW?:-VY49@"5P<\\YP5-0,'7
MO&WQ:T/XL:"]UJEG;66L>)SIMEX'^R02R2Z2J'?J#3QLTBE0-Y7.%.,\?(?I
M>O!M+_9]\;:3\6-4\;P?%%!+J=RANK5O#D,C?8UDW"TCE>5FC3;\ORXR0&.2
M,U[S3 **** "BBB@ HHHH **** "BBB@ HHHH ***Y'Q5X^LO"OBC0].OM1T
MW3;2\AN)YYM0G6+ C\M552S 9+2=\Y"MZ4 ==17GNG_%JWU#4;N.R@.NQ37K
MVNEQ:28W>X6*&-YY3(\BQ[%:3;G<.<#DFI;GXR:3':QW%KI^J:E%_9PU69K6
M!/\ 1[?<ZEGW.O(*,-HRQP< X. #O:*Y2^^(=K8:M;VK:;J,EG-/!:C5%C06
MPEF \M?F<.V=RY*HP&[DC!QR=S\:+JUT:\U*;1YH4CFU![:'$3^?;VH*,=XG
MPI\W'.#D?*JMN5J!'J]%>>2?%0Z1MCU6PN%O5:TLI+&)(4;[9-&\A42M/Y>-
MJC )') #,6 &[KWC-=+^'NH>)%MIK1H+*2X2VU"(Q.L@4[4=21CYL#KCN#CF
M@9TU%<!X'\:ZAKWB26P;5M$\16*60N)+[0HF6*WFWA1$S&:0,6&YA]TX4Y'(
MJ]J'CJ31=0\5QWMNKQ:7!:SVD<2D27'G!D1,G(+-*C(" .H';- '8T5YW;_$
MRYTR\33=3M)=4UAIDL?LVCVH"FY%N)Y0KR38*!709;;M/7@Y&U;_ !&TVXAL
MY/L]XGVJ\N;-%,:DYMQ(99/E8Y0&)@",DDK@<T".JHKF?!?CNV\<6HN;73[Z
MTMI(EG@GN%C:*=&+#*O&[KN!4@H2'7C*BLH?$Y;>[N(9=/NK^6;5YM,T^VT^
M(-+((H@9&<LX4 2!QNR  5SP"U SNZ*\LU+XS9OM,N+*TFAT+[ =1O[F>V65
MP#((XX459@0[2"1,[7&[;@,I+#H?^%G6:^=;2Z7J4.M1W,=JNC%86N9'=#(I
M4K(8]NP.Q8N  C9QB@1V5%>;ZI\6Y;._"?V+J%C:P:5=ZE>M>P()8#&VQ$">
M:-VYE;!7(;='M."S+K6WQ*M?[0ALI[.\>/[8-+DU5(46U^V;>8P/,,GWOER%
M90WR[C@T =E17'>&_B?I_B;4K:U@L-0MH[O[1]DN[J)%BN#"P5]F'+8P0P8J
M%([YXKL:!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5[2_\ EK^']:HU
M>TO_ ):_A_6D]@+]%%%9@%%%% !1110 4444 %%<E\6?B)9_";X;^(O%]]$T
M]OI-HUQY*G!E?HB9[;G*KGMFOR$\:_MG?&'QIXDEU8^-]4T93(7AL-(N&M;:
M%>R;$(W@#N^XGN:Z*5&575'71P\J]VMC]J**^1/V!?VK-:^.NEZOX9\72)=>
M)-&B2XCU!4"&[MV;:2ZJ  Z-M!( R''&02?KNLIQ<)<K,*E.5*3C(****@S"
MBBB@ HHHH *CN/\ 42?[I_E4E1W'^HD_W3_*@#&HHHK4 HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#2TW_4-_O?T%6ZJ:;_J&_P![^@JW
M6;W ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W'^HD_W
M3_*L:MFX_P!1)_NG^58U7$ K \>:G?Z/X,UF\TN">XU..V?[+';0&:3S2,(0
M@!W8)!QCH#6_6;XCTB37M#N["&_N=+FF3$=Y:/MDB8$$,/7D#([C([U0'F>H
M>.M2\-Z+KL+7FM#Q#'';?9[7Q%!9%46:=85F0VJA7 9^06."HX&>>J\.ZEJ6
ME^.K_P -7^I3:U#]@CU*WN[J.))H\NT;Q-Y2(K#*JP.T'YF!SQ5+4OA;<>)1
MK$^O:RMSJ-[:QVD$UA:?9X[5(Y!*I5&>0LWF ,26YP  *O6?PYBU"_O=0\6/
M8^)KRXABME1]/6.VBAC)8 1.TF6+LS%BW]T #'*$9OCO6/$,/BR.TT^'Q$-+
MATXW,LNA6MHY>0R$;2UR"I(53\B98[AQ5-/$VI>-+[4(?#OB.2VT_3='M[N&
M^2"%WO9IED9&E#QD! (QE45#ESR,8'0ZCX)U"UF!\,:Q%X>M6M#:-8FS,UO$
M,DK)#&LB+%(-S9."#\N5XYS!\)Y-$C6/PQK']CQOI::3<BYMOM)DCCW>7*I#
MIME7?)R=RG</EXI@:5I\1(5^%MGXQO;=PDEA%=R6\ Y+NH^1<GNQP,GOS6-K
M'Q8U'PO:ZJNM^'([?4K33?[4@M[2_,\<\8=4=-YB4JZLZY&T@[A@FNFOO >G
M7G@/_A$U,L&G+:):1O&1YB! -C9Q@L"H/3DUPOQ"^'^M7'A7Q%JE]J#:_KK:
M5_9UK%IU@8 $,B.Y$>^0L[,JDD''RC % #O'GQ/\2:+X?URV_LFWT778-.74
M;:1;T7">3Y@1\YBQYBEE!7!4[N&XK3N_B5>Z/K&KV5QI[7.II)I]I;6,=VA@
M-Q.CG"R&)651L)+-N.!PHZ%^J?"F]\36^KMKFOK>7]YIATN">VLA D";@Y=D
M+MO8NJDX91@8 7K4FH?"VYU2^O\ 4YM:2/5YY;*ZAG@L]L<,]NKJ&V-(Q9&W
MG*[@0#][O2 KZA\6K_2Q<V4_AU6U^WU&UL#917V87%P#Y4JRF,94[2""@(P:
MZ;PAXLN/$%UK5A?V$>G:GI-RMO/#!<>?&P>-9$=7*(2"KC@J,$&L+_A5D]Y>
M'4M0UE;G5I=4M-0GFBM/+B*6^?+A2,NQ489OF+,<DGVKHM#\*_V+XD\2:M]J
M\[^V)H)O)\O;Y/EPK%C.3NSMST&,X]Z8''ZQ\3M4;3?$=U%I0M-/TG4DTW[7
M'?+Y\LGVB)"5C:!E"%9.23GJ!V83:E\6KVU$E]:^'TN]#76%T47AOMDID\T1
M/+Y?ED>6'W*#OR2!P <C0O/AC]J\.:_I7]I;?[5U8:IYWD9\K]]')Y>-WS?Z
MO&<CKG'%<'K&@:I>ZH?#^E+J<&GMXG34'M;K1W1403"661;L-Y+0DAG5,"3)
M5>V*0&]I/Q.UNQOM1;4K"*[T9?$KZ,E\URL4L0:4)&!$(\,BY4%F<-R>#C)J
MV'Q:UG1;'49=;M].+/X@N-,MI[B_\BUMU0,VV67R/E4!<*Q!+D\XQ71WGPK^
MU:1=V/\ :FS[1KXUSS/L^=N)ED\K&[G[N-WOG%/A\ :QIRZLFG>(+:&WOM1F
MOS;W6F">-UE!\R*4&0%US@@J4(Q@[@:-0U.H\-ZI=:QHUO=WMBNGW$@),,=P
MEPA&>&21>&5AA@< X/(%:=<YX#\&Q>!M#?3XI8Y/-N9;IQ;P""%&D8L4BC!.
MQ!T"Y/U-='3&%=AH'_()@_X%_P"A&N/KL- _Y!,'_ O_ $(U,M@-"BBBH **
M** "BBB@ HHHH Y_Q9_RZ_\  OZ5Y;XY\07UMKWA3P]I<YM+O6+MWFN@BL8K
M6!/,EVA@1N8^7'R.!(Q&"!7J7BS_ )=?^!?TKR3X@:7<V_BWP7XFMK66]33+
MJ:SNXK>)I)%M[E AD55!)VR)"2 .%+MT6M%L!YTOQ,\6?\*M;2#J8_X6!_PE
M!\)#4S!%CS?.WBX\O9LP+3]YC;VZ5E^(/BQKUG*D-_XR/AS3CX]N]$GU5H[.
M,PV26K2(FZ:)HQ\X'S,N><9KTP?!>V_X78?B =3D,?V;C2?)&P7GE^0;KS,Y
MSY'[O;CU.>U58/@?Y.N6NH_VUGR/%=QXG\O[+][S;=H?(SOXQNW;\<XQM'6@
M"/X/^,+SQ#XK\6V$'B8^./#-BMHUGK^+8CSW1C-;>9;HD4FP"-N%ROFX8G(I
MOQBU+Q-X-MI/$&G>*I1-)>V=GI7AN.Q@:"[=Y$#Q2,4:9W8>:VZ-XPJJ#M.U
MBVS'\'M*_P"$@U^2[AL=4\+ZTZ7D_AW4;!9X8[\$[[F,L=J^8""R["2XW!@2
MP.7)\)]?L?&PUS2-<T"ULK2W6RTC3+KP_)+'I4&T!T@\N[B52^/F;9G 5?N@
M"@"/QIJ/B;PCXR\,RP^*9-2DUS74M$\-BQ@6W6QV,974A#/OB4"1I#)LW<;5
M#*H=I?C3Q=)\<M2T+58M/L-#CT2>^L;2*7>TFVY6-)II2@V%ER=BY"AN2QZ6
MM%^''BK2?'VI^))?$VC:@U_.JM]JT.8W,%B&!%I#*+P)&H&3N$?S.=S!N -K
M5/AS#K'CRX\0W-V6M[C0I-#DL5CP2KRAR_F;N..,8]\]J8'DWPG\=^,O&FHI
MIMQXJD>ZU+0)[N6:6TM8X[*^6950V!"8N[?#-F3]\ORI^\!;:?9OAQXL?QQX
M'T?6IH%MKJYAQ<P(<K'.A*2HI[J)%< ]P!7#:'\,;[P#_9.M:OK4OB:U\(:3
M-8Z+8:?I31W'ELJ+^\VNYFE*11H-JH.IVY/'7_"?PO=>#?A[HVEWX1=16-I[
MM(R"J3RNTLJJ1U >1@#W S2 ZZBBBF 4444 %%%% !1110 4444 %%%% !11
M10 5D1^'U7Q=/KCS;V:QCLHX=N/+ D=W;.>=V8QC''E]\\:]% 'F.J_!.'4!
M:SFXTVZU&-[QII=4TE;R&3[1-YI98FD 5T( 5LGC((.>(;7X6ZG)<>(-/2]B
MTKP]>);Z<8DM(_.N+6.(;VC,3(D)=Y)P1Y9ZY"KW]4HHL*QY>?@E'_PF$&LB
M]L!%#J?]I)_Q*U-WTP(3<;\^6O\ "H48  YQ2?\ "F[Q]#CL)=?ADDALFLX9
M/L#!!NN4GD9E\WYB_EJK8(SC/'2O4:* .!OOAOJ4TM[<V^O1+=7US-)=Q75B
M9[.XADA2+RI(?-&[:(UVDM@98$'<:T-0\"2S> -/\,VFH)']C6T07-Y TPD$
M#HV&0.G#>6 0&'!(%==10,YC1/"NH0>))==UC4K>_OOL@LHELK-K:)(]^]B5
M:20LQ..=P  Z<DF+5O ,>L>.]-\137C"&SA"-8B/Y99$9S$[-G^ R.0N.I!S
MQ7644 <AHOP_&E^)CK$M\+EO-O9Q'Y.WY[AXL'.X_<CB6,<<Y)XZ5A:;\(=1
MM[6&VN?%$ABM+&YL[%[&U-M+!),RL;@OYC;I.".P^8X YSZ910(Y?P;X/N/#
MEYJ]_?7UO?:AJ;QM,]G9_98CL3:&V;WRY))9MW/RC Q532/A_<:5-93_ -K"
M6XM+>]6.0VV!]HN9A*\Y&[G!&-ON>>:[.B@9YL_P7M9/#]UI;WL<J-::?;0>
M=:AXT^R$NI="V)%=V<LIQD,PSSFG6'PC;1S8WVFWFEZ=K-K=27 >UT6.&S*O
M&T?E^3&ZN0%;(+2L=V><':/1Z*!' WOPSOM4FN6U#7Q?+=VEG:W#R62K*PAN
M#,^TJP55D#NA7:2/E.3MP2+X8W<<X@_MM?[&MKV?4[&R^Q_/%<R.TBF23?\
MO$221W"A5.=N6(&#WU% '*Z!X$30K[1)A=^?'I.D_P!EP1M%@Y)C+RYR>6\I
M./8\G-=5110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M445F9!1110 4444 %1W'^HD_W3_*I*CN/]1)_NG^5 &-1116H!1110 4444
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M\O/\.<YQ[^U9_P#PB?\ T]?^0_\ Z]=!13NP.?\ ^$3_ .GK_P A_P#UZ/\
MA$_^GK_R'_\ 7KH**+L#G_\ A$_^GK_R'_\ 7H_X1/\ Z>O_ "'_ /7KH**+
ML#G_ /A$_P#IZ_\ (?\ ]>C_ (1/_IZ_\A__ %ZZ"BB[ Y__ (1/_IZ_\A__
M %Z/^$3_ .GK_P A_P#UZZ"BB[ Y_P#X1/\ Z>O_ "'_ /7H_P"$3_Z>O_(?
M_P!>N@HHNP.?_P"$3_Z>O_(?_P!>C_A$_P#IZ_\ (?\ ]>N@HHNP.?\ ^$3_
M .GK_P A_P#UZ/\ A$_^GK_R'_\ 7KH**+L#G_\ A$_^GK_R'_\ 7H_X1/\
MZ>O_ "'_ /7KH**+L#G_ /A$_P#IZ_\ (?\ ]>C_ (1/_IZ_\A__ %ZZ"BB[
M Y__ (1/_IZ_\A__ %Z/^$3_ .GK_P A_P#UZZ"BB[ Y_P#X1/\ Z>O_ "'_
M /7H_P"$3_Z>O_(?_P!>N@HHNP.?_P"$3_Z>O_(?_P!>C_A$_P#IZ_\ (?\
M]>N@HHNP.?\ ^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\ 7KH**+L#G_\ A$_^
MGK_R'_\ 7H_X1/\ Z>O_ "'_ /7KH**+L#G_ /A$_P#IZ_\ (?\ ]>C_ (1/
M_IZ_\A__ %ZZ"BB[ Y__ (1/_IZ_\A__ %Z/^$3_ .GK_P A_P#UZZ"BB[ Y
M_P#X1/\ Z>O_ "'_ /7H_P"$3_Z>O_(?_P!>N@HHNP.?_P"$3_Z>O_(?_P!>
MC_A$_P#IZ_\ (?\ ]>N@HHNP.?\ ^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\
M7KH**+L#G_\ A$_^GK_R'_\ 7H_X1/\ Z>O_ "'_ /7KH**+L#G_ /A$_P#I
MZ_\ (?\ ]>C_ (1/_IZ_\A__ %ZZ"BB[ Y__ (1/_IZ_\A__ %Z/^$3_ .GK
M_P A_P#UZZ"BB[ Y_P#X1/\ Z>O_ "'_ /7H_P"$3_Z>O_(?_P!>N@HHNP.?
M_P"$3_Z>O_(?_P!>C_A$_P#IZ_\ (?\ ]>N@HHNP.?\ ^$3_ .GK_P A_P#U
MZ/\ A$_^GK_R'_\ 7KH**+L#G_\ A$_^GK_R'_\ 7H_X1/\ Z>O_ "'_ /7K
MH**+L#G_ /A$_P#IZ_\ (?\ ]>C_ (1/_IZ_\A__ %ZZ"BB[ Y__ (1/_IZ_
M\A__ %Z/^$3_ .GK_P A_P#UZZ"BB[ Y_P#X1/\ Z>O_ "'_ /7H_P"$3_Z>
MO_(?_P!>N@HHNP.?_P"$3_Z>O_(?_P!>C_A$_P#IZ_\ (?\ ]>N@HHNP.?\
M^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\ 7KH**+L#G_\ A$_^GK_R'_\ 7H_X
M1/\ Z>O_ "'_ /7KH**+L#G_ /A$_P#IZ_\ (?\ ]>C_ (1/_IZ_\A__ %ZZ
M"BB[ Y__ (1/_IZ_\A__ %Z/^$3_ .GK_P A_P#UZZ"BB[ Y_P#X1/\ Z>O_
M "'_ /7H_P"$3_Z>O_(?_P!>N@HHNP.?_P"$3_Z>O_(?_P!>C_A$_P#IZ_\
M(?\ ]>N@HHNP.?\ ^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\ 7KH**+L#G_\
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M /7H_P"$3_Z>O_(?_P!>N@HHNP.?_P"$3_Z>O_(?_P!>C_A$_P#IZ_\ (?\
M]>N@HHNP.?\ ^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\ 7KH**+L#G_\ A$_^
MGK_R'_\ 7H_X1/\ Z>O_ "'_ /7KH**+L#G_ /A$_P#IZ_\ (?\ ]>C_ (1/
M_IZ_\A__ %ZZ"BB[ Y__ (1/_IZ_\A__ %Z/^$3_ .GK_P A_P#UZZ"BB[ Y
M_P#X1/\ Z>O_ "'_ /7H_P"$3_Z>O_(?_P!>N@HHNP.?_P"$3_Z>O_(?_P!>
MC_A$_P#IZ_\ (?\ ]>N@HHNP.?\ ^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\
M7KH**+L#(MM ^SQE?/W<Y^YC^M2_V/\ ]-O_ !W_ .O6E12 S?['_P"FW_CO
M_P!>C^Q_^FW_ ([_ /7K2HH S?['_P"FW_CO_P!>C^Q_^FW_ ([_ /7K2HH
MS?['_P"FW_CO_P!>C^Q_^FW_ ([_ /7K2HH S?['_P"FW_CO_P!>C^Q_^FW_
M ([_ /7K2HH S?['_P"FW_CO_P!>C^Q_^FW_ ([_ /7K2HH S?['_P"FW_CO
M_P!>C^Q_^FW_ ([_ /7K2HH S?['_P"FW_CO_P!>C^Q_^FW_ ([_ /7K2HH
MS?['_P"FW_CO_P!>C^Q_^FW_ ([_ /7K2HH S?['_P"FW_CO_P!>C^Q_^FW_
M ([_ /7K2HH S)-%\R-E\[&X8^[_ /7JE_PB?_3U_P"0_P#Z]=!13N!S_P#P
MB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O704478'/_\ ")_]/7_D/_Z]'_")_P#3
MU_Y#_P#KUT%%%V!S_P#PB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O704478'/_\
M")_]/7_D/_Z]'_")_P#3U_Y#_P#KUT%%%V!S_P#PB?\ T]?^0_\ Z]'_  B?
M_3U_Y#_^O704478'/_\ ")_]/7_D/_Z]'_")_P#3U_Y#_P#KUT%%%V!S_P#P
MB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O704478'/_\ ")_]/7_D/_Z]'_")_P#3
MU_Y#_P#KUT%%%V!S_P#PB?\ T]?^0_\ Z]'_  B?_3U_Y#_^O704478'/_\
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M2O)O _[-?B_P+X5\%+;:QI=WX@\!ZO?-H?VB23R+S2;DXDMKAQ%F*4J>'5)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>>>*/V>_AUXRUJ35]7\)V-UJ,C;Y)U#1F1
MO5PA 8^YS7H=%-2<=CHH8FOA9<]";B^Z;7Y%+1]&L/#VEV^G:99P:?86Z[(;
M:VC"1QKZ!1P/_KU=HHI&,I.3<I.[84444$A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\M=C;_%;0=(\&^'M:\8:OIG@^75;6.98=8OH+;YRBLRJ3(5.,]F; (K$T?\
M9[\-6>KZY?ZD;O66U&[DN$AN+VY\F%7M5MCNC,I22;RPZ_:"OF$/C=Q7H>AZ
M+:^'-'LM+L1*MG9Q+!"L\\D[A%& "\C,S<=V)- '.:Q\4M'M?#NE:OHP?QA%
MJ]U]CTV+P_-!.;R0+(S".1I$BPJPRLQ9P (V'7BO,]'_ &NO#=NNC67B,?8M
M7OG/G(LMO +5'NY;>'=%-.)9&_=_,(5D*\E@H(KV3Q5X1TOQIIBV&JPS21)*
ML\4MK<RVT\,B]'CFB99(VP2,HP)5F4\,0>;L_@?X0TMK%M/M=2TMK-!&C:=K
M=];&51(\H6;RYE\\!Y)"!+NQO8#@D4 >:>"OVFM5NY';Q#X?O#<7]W)%I>BZ
M;96ZS[#=RV\2O.U\T;MF%PQ*Q#/(^7!.Y/\ M<>"+/4M*L+Q;NPN[S8L\-Y/
M9PR63-<26X5XVN \I$D3@_9UEV@ G ()[>W^#?@^UOK&\BT?;<V,GFV[_:9C
ML;SY)\XWX/[V:1N<_>QT  ;_ ,*9\*QWT5Y:V^HZ;<QNSL^F:Q>V?G$S23XF
M$4RB4"264A9-P'F,  "10!E>%/C"_C3Q]IVE6.BWMGH5UIE_?0ZE?Q(HO?(N
M+:*.2 I*Q"$32$B15?\ U9P ><?4OVJ/"6E^(/$>CS6NH?;-$AN9I462T+2"
M"18Y/W?G^9"N7#"2X6)&0%PQ3YJ[;PY\*?#'A/Q%+KFEV,]OJ#Q30+NOKB2&
M&.619)(XH7D,<2ET5MJ*H!'&,FL[_A1?A :A<WT<.KV]S,T[AK;7]0B$!GD\
MR;R%2<"#>_)\H+F@#+UOXV)/\%;CQYX>M4N"DD:):R3P7@.;E(6 >VF>)S@D
MC9*<$@-@AE&9XF_:F\.>#=%6_P!;T76-+E6ZNK2XLKR6QADMW@6-G!=[D1.Q
M65&6.*1Y'!;:IVMCO+;X8^'+7PG+X;%E-/I4T_VF9;J]GGGFE\T2[Y)W<RNV
MY5Y9CPH7[H K.\0?!'P?XGN;BXOK"\6:Y>=[AK/5;NU\\3+$LJ2>5*N^-A#'
MF-LK\O3DY .?\3_M#:/IMC.EG!?+J$<LR.KV:3?9XXF@_?21^=&?+D6ZMRGS
M XG0D#! 6V_:.TFXA>5O#7B&&.5';3FDBMC_ &FR7D5F8X0LY*MY]Q"G[WRQ
M\X;.W)KI[CX.^$+RXU&>;1U>;4;6WLKI_M$N9(8"#$OW^"-JY88+;%#$[1C+
M\8? _1=>\'_V-I0&BW,,,L5E>$RS?9Q)=0W4O'F*QW2V\9W*ZNF,QNAP: +=
MG\8--G\%ZWXBN=*U735TBY>QN--NHHC=&X4JHB0)(R,6=U53OVDG.[;\U<!J
M?[66D^#[G6(O%6E76CW,.I2VUKIMQ/96URD$5I9RRO*TMTL3MYEW\JQ.S.I4
MJK;6-=SX%^#MCX9^'M_X7U>X/B"/4KB>YOII/.7S7E;)*F2624%<+AFE=\KN
MW9QA8_@/X.@AVPV^K6]P9Y+EK^WU_4([UWD2))-URLXE96%O!E2Y4F)"1D T
M 8DG[2&DSZB]MI7ACQ%KL33M:6UY8QVJPW4RVZW+1H9;A",0-YFYPJ$*5#%\
M(98?VCO#]Q#'>P:5K$^ALD ?68XX#;13S6R7,5NP\WS/,*21<A"@:107'..N
MM?AGX<LYTGCL',ZW<E_YLEU-(QG>W^S/(2SDDF+Y>?K][FLB'X"^![>:T>/2
M)ECM;>*VCM1J-U]F*QP?9XW>'S/+>18@$$K*7 5?FRH( .9O/VHM"TW0SJ6H
M>'=<TM6%G+#%J$MA;B6"Z2=X)_->Z$,:,+:48DD1MP5=NY@"W3_VBI+KQ5=:
M</"6K7MM<75C9Z2=/DLY'N7GL9+QBS&Y"!5CB<YSC@8)SQVU[\(_#=Y##&L>
MIZ?Y-I:V*OI>M7MC)Y%N)?)C+P3(S!?/EZDYW G.U<,TGX-^$-!UBPU2PTI[
M:[L3"UOMO)_*C:*VDM8V\HOL+"&:1-Q7)W DD@$ 'G'B#]K32Q)K6G^'M"O]
M3US2[RWMWM))K,%T:_CM)&*?:0\+!I %2=8F)=21M#E=.V_:T\$7VLZGI=I]
MJO;VU9XK>&UFM)9;Z5;A+?RHXEG,D;-+(BKYZQ!LY!V@D="O[//@58;B+^SM
M0:.:+R K:W?,($\^.<+!F;]P!+#$X\K;M*\8!.;[?!?PF_\ :2FUU#[+J D\
MZP&L7@LU9W\QGBMQ-Y4+A_G#QJK*WS*0>: .6NOC9K%K\*OB+XL;P[)#?^&[
MBYAM])N-B2CRX8V_?$2LC89V),;X*K\N21E=4_:?\,Z'XKOO#NH:=JEGJEG9
MS74MO(]H9<Q6ANI(Q$+@R\1JP$FSR69<+(<@GL['X4^&+#PCK/AE+&>;1]9\
M[^T([J^N+B6X,J!)&::21I-Q4#Y@V<C(.>:R9/@#X)FO);B:QU&Y:43!X[C6
M[Z6$M+;M;ROY;3%/,>)W5I,;B6+$[N: *"_M 6 N+5)O"WB*VADGLK:YNI$M
M3%8R7<RQVZS%;@D;E>.0E P59%#$.=E<C'^V!H'B6QB;PCIL^M7KW^FQ+;+=
MV3M):W-TD)E"I<DQM\P41S>6ZM(FY  ^WHO$G[/PU[XE:3XBBUQK+2+-["9]
M)2*;=)):,S1'<LZQ,,[,F:&5P%(5U!&WH8?@;X1M]+ETU(-5&G,T#Q6?]O7Y
MAM3!*LL/V9#/BW",B;1$$P%"_=XH /B!\8K#X?WT]M-HFL:NMG9I?W\^F1PL
MEE#)(T<32>9*A.]HY  @8C8Q;:!FN0E_:Z\#)JVM:?']JNI]-\X!;6>TDDN6
MAF6&14A$_FQD,W'G)&& )4L,9TOBU\!W^*7BC3]2.OMIEBEO':7MG'#-ON(D
MG$N \<\:D]0!.DZ+G*HI+%NBF^"OA.XDOR]MJ/V:^=Y)]/76;U;(LT@E9EMA
M-Y*$O\Q*H#DL>I.0#B_$?[6?A3P?'Y>N:;J6CZG'-<0W&EW]Q8030"%8F=BS
MW0BDRL\15(G=VW'"G:<;WQ'^-5GX!U/P2^8KO2?$1ECB$8_?W,I1#;10%F50
MTCNHRY"@'<S(H9AMZQ\'_"^M:A/?RVU]9ZA/.]Q)>Z7JUW8SLSI$C@R02HVP
MB"'*9VYC4XSS6CXC^'GA_P 706L.LZ?_ &C':P36T7GS2$B.5/+D!.[+$J!\
MQR0>00>: .(NOVC]$TNYOQJ>@Z[IEC9/=P2:C/';/";BV@:>6!1'.TA?8K8^
M3:Q& Q/%6;CX]6]O,^G'P=XED\3I(ROX;B2S>\$0B\TS;A<^0R;2!A92Q8@;
M<UOO\(/"4VG-8SZ3]KM7FN+B1+JYFF\V2>!K>9G+N2^^)V4[B>I/7FJ$WP&\
M&7%@UM)::F\C3FY:_;7+XW[,8_*(-WYWGE"GR^67V8 XH Y;0?VE+"ZNO%UO
M=6%U>SZ%>/')%I\ CDBC=E2SCE2:16\^=RR!0,*0#)Y092TFF?M"3FYUFVO?
M"6LRZE:WURB:19);?:[:TM[>U>::<O<",X>Y 'ENVX,NT-@FNK;X&^!VADB3
M0([>*19U,=M/+"H679O4!'  !BC90.(V163:P!JK+^S_ ."9M/-HUCJ6&FFG
M>X76[Y;F5I4C2423B;S75UBC#(S%6V*2"1F@#G+G]K+P5;7!A\C5I"8[MT9;
M=-LAA3S$09D'SSI\T2G!(^]L/%=/X'^,EEXZUV/38="UC3%N(;R>TO+];?R;
MI;6X2WN-GES.ZE9)4'SJNX'*Y J34/@3X#U36'U2Y\.6\EX]U97I822*@EM$
M*6Q"!@H"(2NT### 8' K=T7P'H7AVXL9M/L?L\ME'=Q6[>=(VQ;F9)YQ\S'.
MZ2-&YSC&!@$B@#SO7/VJ/"/A[Q5XAT&\M=1%YHL$\THC-LSS>2$9U2$3><N0
M^5:6-$<*2K-E=UC5_P!H);2QU*"W\'^(!XCLOM0FTF5+5Y+58+>WG>>1DN3&
MT86\MN(W9SYF I((&UJ'P#\$ZK>7ES>:=>7)NGN9'@DU>\-NK7!8SF.'SO+C
M+EV+;%7).>O-7O$GP=\)^+)[N?4=/G^T7<[7$\UKJ%S:R2%X(H'1FBD4F-HX
M(5:/.QO+4E21F@#E]+^.%U*]HC:)<:U=WD-G#;Z=HXB6XDNVM!=W)S/-'&L2
M12V^,N#EB,L2 .A^'_Q>TSXE:I=VVC:;J9L[6WAGDU.X2*.#=+%'*D6WS/-W
M[9.?DV@HP)^[NGG^#WA2;1+/2EL;JTMK.X:ZMY;+4KJVN89"A0E;B.190"A*
MX#8VX&, "M7PIX$T'P/'<)H6G)IT=PL*R)&[%2(HEAC !) PB*..N,G))- '
MG-I^U1X5U#7=8T6VT_5+C5K"86\=C$UHT]U(;E;8((Q/N@;S&7BY$)VG<> V
M,;4?VEM0L_!?BF\C\+7\VOZ9%JEQ]D6",QZ=';N\<37G[\;@70AC S@A'887
M#'N;?]GWP-;^84TZ^;=$88_,UF]?[,IECF M]TQ^SE9(HV4Q;2I7Y<4RZ_9W
M\!WVE?V=-I5XULPG68KJ]ZLMR)FWRB>03;YPS_-B0L-Q+#DDT <;)^T5?+XN
MU/21ILG]G6=P(#JGV*,J)#K/]GB/ROM88C (\SC)._8 /+.\O[2.CMI\%V/#
MGB#;?K;RZ,GEVV[6(9[A((I8#Y^%4O-#_KC$0LJG&,XZ*;X(^#+C47OGTF47
M#S-.^R^N%1Y#>"]W,@DVMBX'F#(XR0,*2*;IOP-\%Z3,TMOI4Q;SX+B)9]0N
M9DMC#.)XD@5Y"((Q*%;RXPJ':H*D*  #E->_:I\+>&(-'?5M,U;3I-0N+FVD
MANFM(GM9(+D6\JG=< 3L'.=ML9FVX.,,N[3A^.5GH'PJF\9>*!% B:M>::D=
MJR0K(T=_-;0C=-(J(2L:EF=U4'<<J.*T]8^ W@K7;BXFNM.O%:Y,IN%M=6O+
M=+CS)GF82I'*JR#S)'8!@0I8[<5M3_#;P[<>%W\/-8.FEM=27H2*YECECG>=
MIVECE5Q)&_FNS!E8%<\8'% '&:3^TQX5UK18M1M+>_G6>/\ T:& V\S7,WVM
M;1K>)XYFC>199(<E7*;9XV#D$XR8?VC#?:3IK:;I5YJ$CZEIUE?:LUG'!8VG
MVB^2$HZFX:17\HE@R[T!:/<1G97H4?PJ\-JV@O/;7FH3:'</=6%QJ6I75Y-%
M(XPQ,DLC,XZ$*Y(!52 "H(SH_@/X(M[O3[B'29X&L989XHX=1NDB:2*4S122
M1B0)*RN<AI Q ^7[O% '&Z#^U[X,\46\S:/:ZAJESOM5M;*SGL9IKL7$OE1,
M MR1#\Y4%+@Q.N\;E&#CI--^.UGJUQ:06?A;Q)<S[F748H+>"1M*VWDMH3.%
MF)<>;;S_ .H\WY8F;[N"=33/@OX4TA8([>VU$VMO-!/;64^LWLUK:M"X>$0P
M/,8XE0JN%10H "XV\4Z^^"W@[4+Z"[FTN3S8II9V6.^N$CG:2Y:Z=9XUD"SI
MYSNX20,JECM !Q0!C_"?]HGPE\9-7OM.T"9FGMX!=Q[[BVE\^ OM\P+#-(T7
M.WY)EC?YQ\O7'.^.?VE&TWP?JE_X?\-ZE->-!+-HUU?);FUU!([B*"29%%RK
M[%::,[9/*9PV5R Q7TGPE\-]#\#7$TFC+J%O%(GEK9RZK=SVD*YR%AMY)6BA
M Z 1JH X&!Q66OP-\%B2_8Z7/(MZLB/#)J-R\,*O,D\BP1F0K K21QLRQ! Q
M1<YP* ,OXD_'?2O@SHNBS^++>X:YO+5IIFMS;6R(8U0RX\^X"LV7^6&)Y9#@
M[0^":S/'G[0Q\/\ A_Q+?:'X4UK6$TQ9(K?4Q#$+":Y4QJ\9)E$B[/,))=45
MO*=5<L5![;QO\*_#?Q$EADURVNY7CMY;0_8]2N;,2P2[?,BE$$B>;&VQ?D?<
M.O')SF:A\!? ^K7&H2W>D33?;HFCEA.HW0A4LBH\L<8DV13,J &:,+(<MEOF
M;(!BV?[0&G6[:M#J5AJ0O+>Z>"VMH[2*-[AQ=);?9X_](<22I)-"&;*J?-0C
M'.,CP1^T>=;URZM]3TBZBT6(6,2ZXL,,,*RW$MQ&IE0W#M&A>..)?O?.23@,
MN/0(?A#X3@NM,N1I1DN--OY=3MIIKJ:1UN91B21BSDOG .&R-RJV,@$<UXH_
M9W\/:IX;U+2-%']AQZI!#87TC/<7 DM4F:4JB&8*LNYWVS$,R;NA&!0!>U[X
MR6.G>!/#7BU(+RWTS5YD9(9K-7G>%HI)1\OG*$++&"&);&0"O)VZ'@3XL6/C
MB/4F;2-4T!K&VM[YDU98<R6TRNT4RF&60;2(WX8AAMY45M>)/ NA>+=*M=,U
M33UGL+5Q)!!&[Q+&0C1C&PC@*[#'3GV%2:/X-T?09I9;&R$+RV=O8/ND=PT$
M <1)AB1\HD?GJ<\D\4 >1>,/VD;G3="L-5L_#VIZ)87%K=7_ -JUFP2;S[5=
M,O+N*:!8KD*S;K4;HG>-PK ,(]ZM6GXF_:.T_2H=;1-'UBQ6Q:_@AU:XM8)[
M6:>T;;,BQK<K(>,L-WE@@'Y@>*V_^&=? #64EI)HLUQ T#V@6XU.[E,=N]O-
M;F"-FE)CB$5Q,JQH0J>82H!P:UM4^#WA#6K*:TO-(\ZWFGN[ET^TS+F2Y),[
M9#@_-D\=!VQ0!@:C^T#I>EZ7JFJS^'M?71;-I5AU8Q6ZVEV8[E;9]LAF A D
M8?-<>2I57<$JK$)\-_C?;?%+Q1;1:/&@T.;29KS=(R23+/%=M;NOF12/$Z?*
M2&0L#P0Q%:5Y\!O!5_/=S2Z;>+)<2M.K0ZK>1_99&G6=WMMLH^S%I45V,.S<
M1\V:UO"?PN\-^![S[7I%E-#=F*2%KBXO9[F1UDE,TA9I78LS2$L6.223SS0!
MYO-^U'9:MMA\.Z!>7]ZFNV>D3P27E@TL:2S.CNT271>(CRRH6<1MN=3M(5PO
M1R?M!:%_9VC7%OI>KWD^LVPN+"RABA$TS&X2 19:4(K%G!RS!0H)+#&*TO\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W"LT$BH-SE2
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M''5=#^!/A/QBO]DZ?JVM"T65KTK]EB9XFDD*^;/ G1&VB6XC'(&YFVH_MU%
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M'"_0WAGPSIW@_18=*TJ%X+*)Y) )9I)I&>21I)'>21F=W9W9F9B22Q)/-:M
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MSTZ5I4 >._!SXG>*?&6K:<FOG1WM-6T>35;9--M)8)+<QW"PE'9YI!)D,&!
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M@&)F.X8!\]L_VEO&/C32;5I;_0O"^W5-(EO)#);&2PCDNU26UN(H]0DE !9
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MX )..!6A0!X'X#\9^/\ 4?BGI%OJ_P#;$NE7=I$UU:_V5-:6MD_V)7?>TE@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9-#'<PR0S1K+%(I1XW *LI&""#U%/HH XG6/A/HMQX&
M\1>&]%MX?#\6L^9*[VT68TG95 D\O(!'R)E 5! QQG-<+\0/A_\ $SXK>%9]
M.U=_#>@K&D)^PZ;=/>)J#K-&\BRRSVFV*(K&5\LP3@ELMN"[3TVE_'+2+C5O
M%L=_ ^FZ3HD;SP:D6,JW\43M#<-&B*6+1SH8]J[BQ9,9+;1T\/Q!T23PG=^)
M)I;O3])M%=YVU+3[BSFC"]<PRQK)D\8&W+9&W.10!X)9?LIZE<Z2L6IQ:5)/
M;V*06"S78N/L,POVN&:%HK.W6)?+9E7RXE*[BH^7FI/%G[+^J7>E:OINF:7X
M5O-,G&J0:5IU[));6^BBY9&CNK=8X& E0JV54)UXD&3GT:?X^Z;>^,/"V@:'
MIUYJ$^KW4]O=-?65[9/IXBCCD;S(WMBRN5EC8+)Y8*NK;@&4DUKXT7.D_$QO
M"O\ 9VC1@7-O;Q1ZAKR6>I7RR(C&>TM9(ML\2%V4D3*2T,RA25 8 \[OOV;?
M$S^*M-U2!-">>VU>6^74+BX28V\;W*R_)!-82D2*JYW0SV[$D#?\JL"S_9=U
M6W\)^)K>X@T"_P!<OK:TM;.XDD8&.);AI+B/S&@?8)$*C!CD1BH$D;H"I]7E
M^/7@>&WO[B35;A+>S* S-IET$N TZVZM;-Y6+E?-DC3=#O4%UR<,"<V3]H[P
MDNO6]COOUM'TVZU":\DTVZ3R&AG2'[.\9BWK,SLP$; .6\M0K&5 0#RS1OV3
M=7;PWJ5CK4>@7<Z:1J5OHJLPD33;R>42P2Q[+6%(O+8M\\42$9)51N(KTSXX
M?"C4_B1>6<UE#8W=O#I-Y826MY=_9]\DMYIT\;9:VN$9 +)]RO&RME5*E68C
M6O\ ]H#P-I=C:75YJEW;)<+=/Y4NDWBS0+;%!<-/%Y6^!4$L;,TJJ KAON\U
MEZE^TCX8L=0TE(8M2NK"ZDNH+B9-*O?M-M)###-C[+Y!E=6CG1]P7:%(;)'-
M %:W^$NMK\"+3P=<)HT]_;W44[:> L6GW$"7JW!M)#%;QKL>-?*9EMU4[CF(
MKE6YG_A1OBZR2[@TO3O"VF6.K1:?#<6=MJ%T(=+2UU*YO!';J86\T,MR4_Y8
M*A7Y8PN%'IO_  N[P7]L:W35WE01F3[9#97$EF<0>?L%RL9B,GE?/Y8??CG;
M5W_A.)_$'@^'6_!VDR:])=2(EM%J'FZ7&RE@#*[31;Q&%RP98W+#&T$'- 'E
M6E_LO)%'I32QZ/9:C;Z=KB/JUI!ON(M0N[BW:TO$)52TD,<3@,6#*=H4XY&)
M\/?V5K[2WT>T\2Z=H=WH-MJ2WUYH[3P75E/BQN(-ZV\>FVL8<R20,2X<D1*=
MV47/81_M%7]QITU[!X7MI[;2;=KW7IH]6RD%M]JFMTELSY/^EAOLMQ(-WD@J
MB\Y; Z#Q!\:7T.X\9P'PW>*^@V]D]JUW.D*ZA)=7$]O'C[QBA$D(!D<9P68(
M5"EP#R[3?V7[[3;BSEU>RT&_L$M=+34[B(S2W5Q':VLUO-"%$.Z161X]OS9.
MP#;P*['X7?#_ %R^^"WB$:O+(?%'B>SF@,VI1/!(L2V_V6U\U"-R$QHDCJ5R
MKRR#&:]$\ ^,;CQ=:ZK%?V$.FZOI%^VG7]M:W?VJ!91''*#'*40NICFC/**0
MQ92/ER>IH \,^'?[/<_@WQ)HVO2PZ/\ VQ;ZI=3W>H6P;SYK.2T:)(-Y0%@)
M=K["=HQD<UTMG\$=/O?&WBW7M=>[NTU35[>_M+.#5[R.U,<5E:0@3VJNL,C>
M;;NWS(^5V9/&U?3J* /F>?\ 9;U.P\+?9=)M] CU.[T^2VU5O,:(:A(=1@N(
MS(Y@D#A8DE0>;'(OS;#&\;,*SK/]F+Q=:V'A6'R?#[7>CWEQ-%=37<$T=G%+
M=+,$BMVTO8"F#AK<VA)/50%V_5-% 'A/P5^!>O\ PW^(6JZSJ=Y!>PW,5RC7
M\-U );YI)UD5[B%+"-V< '#R74Q3+!>')'4^%?#GC67XD7VN>*[+1;BS0S0Z
M5-9:M,YL;=B-JK;-:HOF.%7S)#*QSD+A3MKTVB@#YP\5_LX>(==\3:S=6+Z)
MI4UX^J2#Q3#/*-5N!=02)#%+'Y6W;!O$:GS6_=H" A)4U-%_9J\3Z7X4N;6Q
MN-/T#5I;N2,-;7L4D$=E<6_D72Q);Z=:)&Y BE $9W201DL,FOIJB@#Y9US]
ME+7Y->\8OI=S8"RU33=2L+"Y>\B@>**>Q>W@M9D73VF>"(F,!?M94")&"94)
M2_%3X%>)18>-]3L=/TU[FYCU.X76-,>:36-56X_U-G-$L:_NX=R[=LK_ /'M
M%A5))'U+10!\TW/[+][KC7C7>B^%=&T^2#4OLGAW3Y'EL;">:UMHH9(LP1C/
MF0-*Q$:[692H9@6JOXL_98UFZBDM]%;18M'^VPWIT)O)2VN9OL:0RSR">RNH
MS+O3<&,+,VXDLIZ_3U% 'SO9?LPS2RQWFIQZ7>ZHL^F@7][)]KNEM8K".VNH
M6F,$?F;R'!^51(""P4G U-2^"NNW'[./AGP!!8Z##J&G1VD5Y:QW)6RG$)R[
M!GM9$8NRB0B6VD4EFR"<./=** /FGPW^RWJEGI<#ZL-$N];TZSTVWTB]W%WL
M&M]5O+IS$X@3R\P30(/+51E&7:J 9ZOX5_!?5O _Q%76[NRT***/3[^SGU2Q
MGE:^U>6>Z@F6XN4:)55]L3 _.YR1\Q& OM=% 'RSI?P#\2>)?^$IO(M.TGPW
M+=ZGX@!O7>9+W689=3D:*WNU\H;;9D3A@TF4D4J@R=UC6OV<=;U>TM+.;P'\
M/;G11JDNHG0S?21I81F.!5M;6?[ Q2)Y(7FE"1QEFDV]-Q?Z>HH ^6;O]EWQ
M9/KGBB[%WIY?5C>%;W[=%&SI-/YJ0S(FG"61(@%1=URX'EJ51%Q&NI8_LJRW
M,U[/KD&BZE<-<V+6LCM(YA@75KFYO(P2@QYUM.(B!P_S*WR\GZ2HH ^6O&O[
M+_BG6+?2+32?^$?MK;2;C4)=.(G$0L%FU*6Y@6)&LY@FV'[.F8&MW4H1OD54
M"]M\+/@GJW@GQZ^L7%AH.GQK-JDLVI:7<2O>:L+JZ\Z)+E6B0*(5X'SR<CY0
M@)%>WT4 ?-^I?L[>))O']AKMM%H;O;ZY-J:WUU<1S-#$]^UP%6WEL)&#A#@M
M#<0,2<%L(K5V_P 2?A3J/BWX@Z;KD&FZ#JT$5O;P17&L3SQSZ-)'<&5KBT$2
MY9Y%958"2(_N8P6()%>LT4 ?-EO^SKXIU*ST72-:B\.RZ)I,5C8>7]JFN#?V
MT.H17$IEC:!57?$C)Y677)P6()Q%XK_95N[S2W72+;08YGUZ]OY[$QV\<%W;
M2-)]E61IK*Y3= KL%4PL%\Q]K+G)^F** /GC2?V8YEN([[48],N]6%Y8YU"\
ME-W=BS32H[.Y@:?R(S)O97R-JK(I!8*3M'(O\!?$W@GPKI-G906>G^);B#3=
M"M9?#T,UQ# GD36U]<2R>2BQ*4F-R"XYEC4?,<;OK6B@#QWXU?!.\\>>&]#T
M;PXUCIUIIEG=6<<5S)(BHCVQAC52JL<#C/L.]:-O\'ET7P3\3/#FA6NEZ/8>
M(FG.EV=FGDVUJ)-.@MR&1$PF9HY'(0'._=RQ(KU&B@#Q?6OV;](O/#>DV$43
MZC<+>::VH'7M5O-122U@F62:"/[0\FU' .8P%1\*&X QP?B[]EWQ+?7.CIHO
M]A6EKI-S=3::PN1$=/5]4GNXEB1[.;9MB:W0&W>W92A!:11&%^I** /EW5OV
M8_%.I7'BQ[,Z-HUMJUP;IX5N;>ZDU _:UG,<\S:8K;"HD!$_VP9=1C"D/['\
M'_A]<>"OAU;^'=9A@FV32R?9?M$=U!&K2%PB;+6V0(">$6%0O0< 5W]% 'F/
M_"K]4;X%R>"C=VJZDUL\3.&<V\N92YB<X#>6ZYC;CH[<'H?(O$7[+'B/7-.9
M(+#PWI5F^K75Z/#.GW:?88DEM+.%'22XTZ=5DC:VEV[;=2!.=KIRI^JZ* /G
MGQ!^SCX@UM=0MHM>CM+)]-DFM"\[2SQZO-!';W$KOY0#(T<<F7V@LUW.3&.
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M'=V^EV+K9P:&RPSS0NX01Q,TUOY:QYY^UR%1@N1GZW^S+XQO=>TB\M[C1/\
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M#^K_ !$UN&\L+;1;_.FR6%O-K$TD<NAW#2!A?V>V)]TPXXW1',,>'&37LM%
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MO#I&K:;>ZWJ$5U:/JTD^HVSJUQ(T!C=VAAEPT9NH\$!P4/E-I6?[)OB2#1Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6591967888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock', window );">MARKETABLE DEBT SECURITIES</a></td>
<td class="text">MARKETABLE DEBT SECURITIES<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We obtain fair value measurement data for our marketable debt securities from independent pricing services. We perform validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand the methods and data sources used. Additionally, we perform our own review of prices received from the independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets. We did not record any impairment charges related to our marketable debt securities during the nine months ended September&#160;30, 2019 or 2018.</span></div><div style="text-indent:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize our marketable debt securities as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:48.879765%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">90,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,289,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,289,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(44)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:48.879765%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(285)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">546,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">546,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(422)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:69.783626%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.742690%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.742690%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">674,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">221,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">797,754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">662,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We classify our debt security investments based on their contractual maturity dates. As of September&#160;30, 2019, the contract maturity for all of our available-for-sale debt securities was less than one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in marketable debt securities disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789338080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock-based compensation expenses included in operating costs and expenses, for the periods indicated, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:44.187683%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">45,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,170&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">62,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">108,644&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">129,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774918368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 304,621<span></span>
</td>
<td class="nump">$ 290,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 223,444<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781260432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock Based Compensation</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock-based compensation expenses included in operating costs and expenses, for the periods indicated, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:44.187683%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.903226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">45,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,170&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">62,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">108,644&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">129,779&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776329552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 28,107<span></span>
</td>
<td class="nump">$ 5,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in &#8220;Deferred revenue&#8221;</a></td>
<td class="nump">$ 158,446<span></span>
</td>
<td class="nump">$ 3,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787216752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 18, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396,456<span></span>
</td>
<td class="nump">$ 320,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_DicernaPharmaceuticalsIncMember', window );">Dicerna Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Litigation settlement, settlement agreement date</a></td>
<td class="text">April&#160;18, 2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Litigation settlement amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NortonMassachusettsMember', window );">Norton, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Undeveloped land acquired (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NortonMassachusettsMember', window );">Norton, Massachusetts | Land and Costs Related to the Construction of Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,200<span></span>
</td>
<td class="nump">$ 227,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencySettlementAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective date of a duly executed litigation settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencySettlementAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_DicernaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_DicernaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alny_NortonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alny_NortonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778156976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Costs Included in Operating Expenses Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 9,282<span></span>
</td>
<td class="nump">$ 27,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">3,460<span></span>
</td>
<td class="nump">12,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 12,742<span></span>
</td>
<td class="nump">$ 40,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776283968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 21, 2019</div></th>
<th class="th"><div>Apr. 25, 2019</div></th>
<th class="th"><div>Apr. 08, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,900,000<span></span>
</td>
<td class="nump">$ 390,577,000<span></span>
</td>
<td class="nump">$ 381,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Offering proceeds, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444,445,000<span></span>
</td>
<td class="nump">4,444,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in usd per share)</a></td>
<td class="nump">$ 90.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 4,444,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Offering proceeds, net of costs</a></td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DateOfAgreement', window );">Date of investor agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  08,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_AgreementExtensionPeriod', window );">Agreement extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit', window );">Ownership percentage of shares outstanding, upper limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_GainLossOnSaleOfCommonStock', window );">Gain on sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_OwnershipPercentageOfSharesOutstanding', window );">Ownership percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod', window );">Beneficial ownership percentage following the expiration of lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_BeneficialOwnershipPercentageOfSharesOutstanding', window );">Beneficial ownership percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AgreementExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement extension period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AgreementExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_BeneficialOwnershipPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_BeneficialOwnershipPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership percentage of shares outstanding following the expiration of lock-up period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DateOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DateOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_GainLossOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_GainLossOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_OwnershipPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_OwnershipPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage shares of stocks outstanding upper limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>21
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW<']8^.KH&K@UUVH+U!+ P04    " !R@%]/F5R<(Q &  "<)P
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M=BCIG5V)1]LOCQ>EVION=&K/F[YI["^,/@T-<3)VY:L_4$L#!!0    ( '*
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M4+Y<3+W_+;R%.LH')S''4U-WX__%TVO7-X>IE6CE4'T_?^Z/X^?[U/Y'F!P
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M,^S^S?:,.QXG:<,2(R%M^'P%#&49F_G+\Y%.- 6H*0!-;+BS(#OQ*D0VECG
M3(S6,6$2L^E6\DZ7$C/!FLQB<1D4EP%QEHG+0)Z5<7PN TQ[)\1)S! %8OO
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M32&23H>&LH3-  $S(.9Z#UV>ZQ!$<QV!<*XC\.Q<Q[: D"W@GH=DJ;YRO.
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M3@OB5V]45"*M(Y,/P)V ZDC9(-S$"@A;-QY5X&,!=,9&,E1:)QC0%@#:"3:
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MC.?M:1?W=-$WQVF'>GG>)K_Y'U!+ P04    " !R@%]/IY!TCK !  #2 P
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MCS<;YU\;XP%+26YPA5I\8(LCH?;!_(BVG=9L<KSIYQ?$EF=<_ %02P,$%
M  @ <H!?3_WU/-^T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL?5-A;]P@#/TKB!]0+B3=JE,2J==JVJ1-.G7:^IE+G 050@;DTOW[&9)F
MV1;M"V#C]_QL3#X9^^(Z $]>M>I=03OOAR-CKNI "W=C!NCQIC%6"X^F;9D;
M+(@Z@K1B_'!XQ[20/2WSZ#O;,C>C5[*'LR5NU%K8GR=09BIH0M\<3[+M?'"P
M,A]$"U_!?QO.%BVVLM120^^DZ8F%IJ#WR?&4A?@8\%W"Y#9G$BJY&/,2C$]U
M00]!$"BH?& 0N%WA 90*1"CCQ\))UY0!N#V_L7^(M6,M%^'@P:AG6?NNH'>4
MU-"(4?DG,WV$I9Y;2I;B/\,5%(8')9BC,LK%E52C\T8O+"A%B]=YEWW<I_DF
MY0ML'\ 7 %\!=S$/FQ-%Y8_"BS*W9B)V[OT@PA,G1XZ]J8(SMB+>H7B'WFO)
M$YZS:R!:8DYS#-_$)&L$0_8U!=]+<>+_P/D^/-U5F$9X^H?"=)\@VR7((D'V
MWQ+W8K*_DK!-3S78-DZ3(Y49^SC)&^\ZL/?Q$=GO\'G:OPC;RMZ1B_'XLK'_
MC3$>4,KA!D>HPP^V&@H:'X[O\6SG,9L-;X;E!['U&Y>_ %!+ P04    " !R
M@%]/(P0I^K4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q]
M4]MNW" 0_17$!X0UZURTLBUE4U6MU$BK1&V?67M\48!Q :^3OP]@QW5;JR_
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M3/6\HV0J_@M<06%X5((Y2JM\6DG9^V#UQ()2M'@>=VG2/DPWAPFV#N 3@,^
M0\K#QD1)^;T(HLB<'8@;>]^)^,3;(\?>E-&96I'N4+Q'[[7@?)NQ:R2:8DYC
M#%_$O$8P9)]3\+44)_X/G*_#=ZL*=PF^^T/A?PCVJP3[1+!_L\2UF-U?2=BB
MIQI<DZ;)D]+V)DWRPCL/["U/;_(:/D[[5^$::3RYV( OF_I?6QL I6QN<(1:
M_&"SH: .\?@!SVX<L]$(MIM^$)N_<?$;4$L#!!0    ( '* 7T\Z#M(ZM0$
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MQUM_-M.838;#/OT@-G_CX@]02P,$%     @ <H!?3ZOPOJ2S 0  T@,  !D
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M)1?$EV!\J@MZ"() 0>4"@_#;%1Y J4#D9?Q8..F:,@"WYS?V#[%V7\M%6'A
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M&9U_V=C_"M&!E[*Y\B/4^ \V&PHJ%XXW_FS&,1L-A]WT@]C\C?/?4$L#!!0
M   ( '* 7T^H,@DX[ $  &8%   9    >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;'54VXZ;,!#]%<0'K D!0B- VFQ5M5(K15NU?79@N&AM3&T3MG]?V["4
MTNE+;(_/9<9D)IN$?%$M@/9>.>M5[K=:#V="5-D"I^I!#-";FUI(3K4YRH:H
M00*M'(DS$@9!0CCM>K_(7.PJBTR,FG4]7*6G1LZI_'4!)J;</_AO@>>N:;4-
MD"(;: -?07\;KM*<R*I2=1QZU8G>DU#G_N/A?$DMW@&^=S"IS=ZSE=R$>+&'
M3U7N!S8A8%!JJT#-<H<G8,P*F31^+IK^:FF)V_V;^@=7NZGE1A4\"?:CJW2;
M^ZGO55#3D>EG,7V$I9[8]Y;B/\,=F(';3(Q'*9AROUXY*BWXHF)2X?1U7KO>
MK=-\D\0+#2>$"R%<":GS(;.1R_P]U;3(I)@\.;_]0.TG/IQ#\S:E#;JG<'<F
M>66B]R*,THS<K=""N<R8<(,YK ABU%>+$+.XA/_00YQ^1#,\.OIQ2P]B7"!"
M!2(G$/U5XKM=B0@F#G"3&#6)$8'#S@3#_.<I$M0D002..Q,,$^$F)]3DA C$
M.Q,,D^ F*6J2(@*GG0F&27<F9/,_YR ;U^'**\78N^FRB:Y#Y#%T??('/D^@
M+U0V7:^\F]"FVUQ/U$)H,*D$#^;3M6;HK0<&M;;;D]G+N?7G@Q;#,M7(.EJ+
MWU!+ P04    " !R@%]/XHBO)[<!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6QM4]MNW" 0_17$!P0OZR3;E6TIFRAJI59:I6K[S-IC&P4\
M+N!U^O<%[+A6ZA=@AG/.7!BR$<VK;0$<>=.JLSEMG>N/C-FR!2WL#?;0^9L:
MC1;.FZ9AMC<@JDC2BO$DN6-:R(X66?2=39'AX)3LX&R(';06YL\)%(XYW=%W
MQXML6A<<K,AZT<!W<#_ZL_$66U0JJ:&S$CMBH,[IP^YX2@,^ GY*&.WJ3$(E
M%\378'RI<IJ$A$!!Z8*"\-L5'D&I(.33^#UKTB5D(*[/[^K/L79?RT58>$3U
M2U:NS>F!D@IJ,2CW@N-GF.NYI60N_BM<07EXR,3'*%'9N))RL [UK.)3T>)M
MVF47]W&Z2>]GVC:!SP2^$ XQ#IL"Q<R?A!-%9G D9NI]+\(3[X[<]Z8,SMB*
M>.>3M]Y[+?CMIXQ=@]",.4T8OL+L%@3SZDL(OA7BQ/^C\VWZ?C/#?:3OU_3D
ML"V0;@JD42!="]PE'TK<PGPLDJUZJL$T<9HL*7'HXB2OO,O /O#X)O_@T[1_
M$Z:1G247=/YE8_]K1 <^E>3&CU#K/]AB**A=.-[[LYG&;#(<]O,/8LLW+OX"
M4$L#!!0    ( '* 7T]R_&OQZ0$  &8%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;'54VXZ;,!#]%<0'K,%)((T :;.K52NU4K15VV>'#!>MC:GM
MA.W?US:$4CI]B>WA7&;LS&2#5&^Z 3#!N^"=SL/&F/Y B"X;$$P_R!XZ^Z62
M2C!CCZHFNE? +IXD.*%1E!#!VBXL,A\[J2*35\/;#DXJT%<AF/IU!"Z'/(S#
M>^"UK1OC J3(>E;#5S#?^I.R)S*K7%H!G6YE%RBH\O Q/ASW#N\!WUL8]&(?
MN$K.4KZYPZ=+'D8N(>!0&J? ['*#)^#<"=DT?DZ:X6SIB,O]7?W%UVYK.3,-
M3Y+_:"^FR<-]&%R@8E=N7N7P$:9Z=F$P%?\9;L MW&5B/4K)M?\-RJLV4DPJ
M-A7!WL>U[?PZ3/IW&DZ@$X&N"&0T\ID_,\.*3,DA4./=]\P]<7R@]FY*%_17
MX;_9Y+6-W@J:T(S<G-"$.8X8NL#$,X)8]=F"8A9'^@^=XO0-FN'&TS=+>O0?
M@2TJL/4"V[]*W*Q*Q#!;W&2'FNP0@=W*!,,DN$F"FB2(0+HRP3![W"1%35)$
MX,/*!,&D$6ZR1TWVB$"\,L$PZX<GB_^Y %7[#M=!*:^=GRZ+Z#Q$'JGODS_P
M<0)]8:IN.QV<I;'=YGNBDM* 325ZL$_7V*$W'SA4QFU3NU=CZX\'(_MIJI%Y
MM!:_ 5!+ P04    " !R@%]/<-K'F;8!  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6QM4]MNG# 0_17+'Q OAC31"I"RJ:I6:J55JK;/7A@N
MBB_4-DOZ]QT;0FC*B^T9GW/FXG$^&?OL.@!/7I34KJ"=]\.1,5=UH(2[,0-H
MO&F,5<*C:5OF!@NBCB0E&3\</C E>DW+//K.MLS-Z&6OX6R)&Y42]L\)I)D*
MFM!7QU/?=CXX6)D/HH7OX'\,9XL66U7J7H%VO='$0E/0A^1XR@(^ G[V,+G-
MF81*+L8\!^-+7=!#2 @D5#XH"-RN\ A2!B%,X_>B2=>0@;@]OZI_BK5C+1?A
MX-'(7WWMNX+>4U)#(T;IG\ST&99Z;BE9BO\*5Y (#YE@C,I(%U=2C<X;M:A@
M*DJ\S'NOXS[--RE?:/L$OA#X2KB/<=@<*&;^47A1YM9,Q,Z]'T1XXN3(L3=5
M<,96Q#M,WJ'W6O*[-&?7(+1@3C.&;S#)BF"HOH;@>R%._#\ZWZ>GNQFFD9YN
MZ4FZ+Y#M"F11(/NGQ.Q=B7N8VW=!V*:G"FP;I\F1RHPZ3O+&NP[L0WQ$]@:?
MI_V;L&VO';D8CR\;^]\8XP%3.=S@"'7XP59#0N/#\0[/=AZSV?!F6'X06[]Q
M^1=02P,$%     @ <H!?3\S"G6"W 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL;5/M;ML@%'T5Q .4F*1)%-F6FE;5)FU2U&G;;V)?VZA@
M/,!Q]_:[8-?S.O\![N6<<S^XI(.QKZX!\.1-J]9EM/&^.S'FB@:T<'>F@Q9O
M*F.U\&C:FKG.@B@C22O&-YL]TT*V-$^C[V+SU/1>R18NEKA>:V%_GT&9(:,)
M?7>\R+KQP<'RM!,U? /_O;M8M-BL4DH-K9.F)1:JC#XDI_,NX"/@AX3!+<XD
M5'(UYC48G\N,;D)"H*#P04'@=H-'4"H(81J_)DTZAPS$Y?E=_3G6CK5<A8-'
MHW[*TC<9/5)20B5ZY5_,\ FF>NXIF8K_ C=0" ^98(S"*!=74O3.&SVI8"I:
MO(V[;.,^C#?WR41;)_")P&?",<9A8Z"8^9/P(D^M&8@=>]^)\,3)B6-OBN",
MK8AWF+Q#[RWGAWW*;D%HPIQ'#%]@DAG!4'T.P=="G/E_=+Y.WZYFN(WT[9*>
M[-<%=JL"NRBP^Z?$PX<2US#'#T'8HJ<:;!VGR9'"]&V<Y(5W'M@''M_D+WR<
M]J_"UK)UY&H\OFSL?V6,!TQE<X<CU. 'FPT%E0_' Y[M.&:CX4TW_2 V?^/\
M#U!+ P04    " !R@%]/W+%P#<4!   W!   &0   'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6QU5&&/G" 0_2N$'W HN_;V-FIR>TW3)FVRN:;7SZR.2@[$
M J[7?U] SYHM_2(SPWMO9H QGY1^-1V 16]2]*; G;7#D1!3=2"9N5,#]&ZG
M45HRZUS=$C-H8'4@24%HDGP@DO$>EWF(G769J]$*WL-9(S-*R?3O$P@U%3C%
M[X%GWG;6!TB9#ZR%[V!_#&?M/+*JU%Q";[CJD8:FP(_I\91Y? "\<)C,QD:^
MDXM2K][Y4A<X\06!@,IZ!>:6*SR!$%[(E?%KT<1K2D_<VN_JGT+OKI<+,_"D
MQ$]>VZ[ !XQJ:-@H[+.:/L/23X;1TOQ7N()P<%^)RU$I8<(75:.Q2BXJKA3)
MWN:5]V&=YIV,+K0X@2X$NA(.(0^9$X7*/S++RERK">GY[ ?FKS@]4G<VE0^&
MHPA[KGCCHM>2WC_DY.J%%LQIQM -)ET1Q*FO*6@LQ8G^0Z=Q^BY:X2[0=UMZ
M^A 7V$<%]D%@OQ4X)#<MQC#_:3*+)LDB O0F20RSNTE"-A<G0;?AR1I4J;$/
MX[*)KE/Q&%X*^0N?1^H;TRWO#;HHZYY/N.1&*0NNE.3.U=*Y*5X= 8WUYKVS
M]?R69\>J81E3LOXKRC]02P,$%     @ <H!?3Z/D]KO/ 0  G 0  !D   !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL=51M;]L@$/XKB!]0')*X:61;:EI-
MF[1)4:=UGXE]?E'!>(#C[M\/L.-Y'OT2N//S<D<XDD&J-UT#&/0N>*M37!O3
M'0G1>0V"Z3O906N_E%()9FRH*J([!:SP),$)C:*8"-:T.$M\[JRR1/:&-RV<
M%=*]$$S]/@&70XHW^)9X::K:N 3)DHY5\!W,C^ZL;$1FE:(1T.I&MDA!F>+'
MS?$4.[P'O#8PZ,4>N4XN4KZYX$N1XL@5!!QRXQ287:[P!)P[(5O&KTD3SY:.
MN-S?U#_YWFTO%Z;A2?*?36'J%!\P*J!D/3<O<O@,4S][C*;FO\(5N(6[2JQ'
M+KGVORCOM9%B4K&E"/8^KDWKUV'2O]'"!#H1Z(I 1B-?^3,S+$N4') :S[YC
M[B_>'*D]F]PE_5'X;[9X;;/7C!YV";DZH0ES&C%T@=G,"&+59PL:LCC1_^@T
M3-\&*]QZ^G9)IQ\([((".R^P^Z?%_:K%$"8.F^R#)ON P/W*)(0YA$WBH$D<
M$'A8F00P#]'*A"QNAP!5^;G0*)=]ZV=RD9U'[Y'ZV_47/L[M-Z:JIM7H(HV]
MH_XFE5(:L*5$=[;AVCX5<\"A-&Y[;_=J')@Q,+*;W@(R/TC9'U!+ P04
M" !R@%]/2?K()[8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6QU4]MNW" 0_17$!X1=[#;IRK:4356U4B*M4K5]9NVQC0(>%_ Z^?L"=APW
M=5^ &<XY<V'(1C1/M@5PY%FKSN:T=:X_,&;+%K2P5]A#YV]J-%HX;YJ&V=Z
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M_:\1'?A4=E=^A%K_P19#0>W"\=J?S31FD^&PGW\06[YQ\0=02P,$%     @
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MT6*K2MTKT*XWFEAH"OJ0'D]9P$? SQXFMSF34,G%F.=@?*D+FH2$0$+E@X+
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MD?<N9BIY^J-[/9[:UTOO_SD,#Q#] '$=8.Y];X#L!\B? ^CN .H'T-@[J'Z
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M,OU:-V\C\[[L3H"Z#W5Q[D^W@NL1V^H_4$L#!!0    ( '* 7T_ M1<0I00
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M%8E/Y^MD,)HEW@%+LWA)3N:4DSEL+^0M=Q+DZQ,/0G=)A2M2;T%CLWFZ>,C
M0O&"%<FWH$E:PQS.LN_ Y6@Q^\!=QP ZO*,%"G<E _0?.^"N/N JO]D.1#._
M*(F6M\!=IR!>LP7Q[$J!T>1DVRUPX?*YI&!TN^OG]AOFEZH1WH%)]5"8Z_S,
MF"2*,WQ2G*5ZX8<!)6>INZGJ\_Z9ZP>2M?8)#X;_$=N_4$L#!!0    ( '*
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MOLG:R <GYAX[5??CWV#WVFO53%6,E:;\?OFLVO'S/-5_'X8'T#2 K@-8<G<
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MQA!BC!WA231/I_WC!$7D^:TFC"M"RRD[PP362J99:6[3!@A-L]+8$V/"_"/
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MJTSWD=.89.AAA4;,<<"0&6:!.*T1<3!!D#$PN2";+HCCA_,)>+<M$&X*A$Z
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MAELA)%>$X8W*;:_^8(9!R;=27V;JNND^X[N!%(?^%R48_I.6_P!02P,$%
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M-?KO_,BS&MY$4G.L1%:U_\[J4$F1*R]U*'GRUEW3HKV>NB<A4V:P 5$&Y&R
M@ZL&5!G0#P/_JH&O#/RA#$P9L*$,@3((AAJ$RB <:A I@^C#X/JTQLH@'LJ
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M]^-X<DF*].W=Q024ZO']Y<UU,+X^AR\NK\\N;Z\NQ#>H5'#XW:,*X49Q/;?
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MCTK5)$51WC'&31121&J;IR =,:&C9YO-',V&P"W2VBI_2NA::]I)8\/4:('
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M87O40=]?2I+"#)X$6'',SJ/[!BMAECQD1&D[.*QTPBTL@/KN&:&.)BL4^ON
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M2VWVP5"2A=STZF+T&OD:&[7G$Y)K12U.8,TG:(UQS#ZPA[7)3^'T%W&.*]N
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M4S9->3D4$>FNT55KA%>[:F/N/X8:<Z+$P0.V65^FS2-X75JGP4+>.O#?D$]
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M1,W8F1EF>:>J8C\C(Z4=/X%XLU)%3?),:ATK+8$[RQ]BNR.P4DKU2?YX@KD
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M.B0%9Y<Q%@ '].N'HX'-SSU?G4D?' JK2+!8,0H'QE9B?\(R$%8U=N/N[/>
M9O2-+%K_#/0TV4B@?H#5 T"FQ:15D$_4_^O4ZW-C5/]W=C,?R:<D'ST0L%;/
M3%K]Y( 'Q*!>VPC%M8]UL&#[A&B@?ZY]), \H9,C0S'L!.--RQP1ERH8+JER
MC 6OWB@<=(U%JO:Q&<P JU[;"(_US_7:U$<+!^['(.RAZ8G_]6L$;*<:A$/*
MGVUW0/6(2#P,NP/@3*.!A3XN+KM4\6!4;@0 MM1H2WJWP6GW.Q^^M2)J&J3^
M_Q[X-@Q'/0/$ZB<'WWJ#L#TR*%/[Z%Q#U#K:YEK4/Q^*<9U1B$>A[T;U8R/
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MYW>7VMF)HZ+8T)5Q;\ A!9[J;V\MU#.>_77-2S:O_:$L5W_\?P!02P,$%
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M;,]$GFTT,U_]'+[GFYFX?9OG<]BV+I>5Z%Y=,]=X>O/ORW]02P,$%     @
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ME0<-3ZU/]\.^6;\:ON][X5_%P(;#_][Z\7((D!P2)(<"R:%!<DQ!<IR#Y+@
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M+RYR96QS4$L! A0#%     @ <H!?3R?HAPZ"    L0   !
M ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !R@%]/YP,M!NX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ <H!?3Z98I$]  @
MN <  !@              ( !AA$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( '* 7T\,T*Q10@4  &T:   8              "  ?P3
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !R@%]/*64J
M?G,)  "4.P  &               @ %T&0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ <H!?3W>A+3_4!   ,A<  !@
M ( !'2,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '*
M7T^GD'2.L $  -(#   8              "  2<H  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !R@%]/0$ JJK4!  #2 P  &
M        @ $-*@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
M  @ <H!?3WY?=X&U 0  T@,  !@              ( !^"L  'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( '* 7T\2A&DYKP$  -(#   9
M              "  >,M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L!
M A0#%     @ <H!?3_WU/-^T 0  T@,  !D              ( !R2\  'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !R@%]/(P0I^K4!
M  #2 P  &0              @ &T,0  >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;%!+ 0(4 Q0    ( '* 7T]'O$\QM@$  -(#   9              "
M : S  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ <H!?
M3[89L"NS 0  T@,  !D              ( !C34  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !R@%]/.@[2.K4!  #2 P  &0
M        @ %W-P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( '* 7T\BGH3?M $  -(#   9              "  6,Y  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ <H!?3ZOPOJ2S 0  T@,
M !D              ( !3CL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !R@%]/D'B@LK0!  #2 P  &0              @ $X/0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( '* 7T_/!RT[
MM0$  -(#   9              "  2,_  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ <H!?3X1$]SRT 0  T@,  !D
M ( !#T$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !R
M@%]/@MIR<K0!  #2 P  &0              @ 'Z0@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( '* 7T_"SJW?M0$  -(#   9
M          "  >5$  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ <H!?3Z@R"3CL 0  9@4  !D              ( !T48  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !R@%]/XHBO)[<!  #2
M P  &0              @ 'T2   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( '* 7T]R_&OQZ0$  &8%   9              "  >)*
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ <H!?3W#:
MQYFV 0  T@,  !D              ( ! DT  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    " !R@%]/S,*=8+<!  #2 P  &0
M    @ 'O3@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M '* 7T_<L7 -Q0$  #<$   9              "  =U0  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ <H!?3Z/D]KO/ 0  G 0  !D
M             ( !V5(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !R@%]/2?K()[8!  #2 P  &0              @ '?5   >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( '* 7T\1  !XLP$
M -(#   9              "  <Q6  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ <H!?3S43E)BX 0  T@,  !D              ( !
MME@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !R@%]/
MU&B$U[8!  #2 P  &0              @ &E6@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( '* 7T\XE)5WS0$  &0$   9
M      "  9)<  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ <H!?3SVXR3VJ @  J@D  !D              ( !EEX  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !R@%]/"?5>W-L!  #A!
M&0              @ %W80  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( '* 7T^5&09\? 0  %(8   9              "  8EC  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ <H!?3^1H0.7.
M 0  8 0  !D              ( !/&@  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !R@%]/4S>YP-D!  !P!   &0
M@ %!:@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( '*
M7T_<A JC\00  &X;   9              "  5%L  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ <H!?3\"U%Q"E!   (1D  !D
M         ( !>7$  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " !R@%]/9"B&G%@"  !3"   &0              @ %5=@  >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( '* 7T]@Z%UH70,   X0
M   9              "  >1X  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ <H!?3YB@F T! @  =04  !D              ( !>'P
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !R@%]/XD/2
MG7\&  !0*P  &0              @ &P?@  >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( '* 7T]VK(:U<0(  -D(   9
M  "  6:%  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M<H!?3]0OD0+: 0  7P0  !D              ( !#H@  'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " !R@%]/'>&U+M(#   I$P  &0
M            @ $?B@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( '* 7T^(?P(-[0$  /,$   9              "  2B.  !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ <H!?3_8F:F+Q @
M,PT  !D              ( !3)   'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " !R@%]/)QWR-PP"  ")!0  &0              @ %T
MDP  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( '* 7T]%
MKYX/>0(  %@(   9              "  ;>5  !X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ <H!?3^"_U" $ @  QP4  !D
M     ( !9Y@  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '* 7T_5 &PV,@(  ),&   9              "
M 4RF  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ <H!?
M3ULK)?I/ @  T@<  !D              ( !M:@  'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " !R@%]/0(TQWZ8!  "9 P  &0
M        @ $[JP  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( '* 7T\=K;#?<P4  *P?   9              "  1BM  !X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ <H!?3Z9Q#% Q:P  $; !
M !0              ( !PK(  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ <H!?3W5?_05' @  O H   T              ( !)1X! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !R@%]/-@I32J$%  !]*   #P
M    @ &7( $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ <H!?3[$$^+H8
M @  ["0  !H              ( !928! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ <H!?3Y>*BVSH 0  :R0  !,
M ( !M2@! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $8 1@ <$P  SBH!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6959673264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="nump">$ 8,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">42,383<span></span>
</td>
<td class="nump">15,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 54,562<span></span>
</td>
<td class="nump">$ 24,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6958817264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 160,796<span></span>
</td>
<td class="nump">$ 139,945<span></span>
</td>
<td class="nump">$ 453,813<span></span>
</td>
<td class="nump">$ 374,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,960<span></span>
</td>
<td class="nump">5,291<span></span>
</td>
<td class="nump">13,040<span></span>
</td>
<td class="nump">38,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_MdcoMember', window );">Mdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">6,737<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="nump">8,484<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember', window );">Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">7,256<span></span>
</td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">8,386<span></span>
</td>
<td class="nump">15,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">11,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,105<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical trial and manufacturing | Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">4,308<span></span>
</td>
<td class="nump">11,033<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical trial and manufacturing | Mdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical trial and manufacturing | Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,843<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">5,385<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical trial and manufacturing | Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External services | Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External services | Mdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">5,992<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">6,002<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External services | Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">7,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External services | Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">959<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,588<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Mdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">2,393<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 9,518<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,943<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_MdcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_MdcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6792732240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Debt Securities - Summary of Company's Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,471,546<span></span>
</td>
<td class="nump">$ 884,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,471,897<span></span>
</td>
<td class="nump">884,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">89,975<span></span>
</td>
<td class="nump">232,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">90,032<span></span>
</td>
<td class="nump">232,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">59,737<span></span>
</td>
<td class="nump">39,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">59,748<span></span>
</td>
<td class="nump">39,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,289,294<span></span>
</td>
<td class="nump">546,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,289,577<span></span>
</td>
<td class="nump">546,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="nump">8,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="nump">8,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,487<span></span>
</td>
<td class="nump">57,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 29,487<span></span>
</td>
<td class="nump">$ 57,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6958005360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Costs Included in Operating Expenses Related to Leases</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The below table summarizes our costs included in operating expenses related to leases we have entered into through September&#160;30, 2019, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:65.349927%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.959004%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.959004%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Lease Cost</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Future lease payments for non-cancellable operating leases and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September&#160;30, 2019 is as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:86.286969%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining three months)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">35,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,670&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">356,208&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">536,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(231,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total discounted lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">304,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">276,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">304,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Payments Under Non-cancelable Leases</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the prior lease guidance, minimum payments under our non-cancelable facility leases, as of December&#160;31, 2018, were as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:86.286969%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">35,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">390,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">562,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6959316368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 923,304<span></span>
</td>
<td class="nump">$ 420,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">797,754<span></span>
</td>
<td class="nump">662,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">48,109<span></span>
</td>
<td class="nump">18,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">54,562<span></span>
</td>
<td class="nump">24,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">73,536<span></span>
</td>
<td class="nump">74,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,897,265<span></span>
</td>
<td class="nump">1,200,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">396,456<span></span>
</td>
<td class="nump">320,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">223,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">14,825<span></span>
</td>
<td class="nump">44,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,632<span></span>
</td>
<td class="nump">8,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,541,622<span></span>
</td>
<td class="nump">1,574,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">39,392<span></span>
</td>
<td class="nump">59,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">177,948<span></span>
</td>
<td class="nump">112,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">28,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">107,359<span></span>
</td>
<td class="nump">3,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">352,864<span></span>
</td>
<td class="nump">179,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">276,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">296,179<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">9,036<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">934,535<span></span>
</td>
<td class="nump">272,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2019 and December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share, 250,000 and 125,000 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 111,325 shares issued and outstanding as of September 30, 2019; 101,177 shares issued and outstanding as of December 31, 2018</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">5,091,248<span></span>
</td>
<td class="nump">4,175,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(34,371)<span></span>
</td>
<td class="num">(33,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,450,903)<span></span>
</td>
<td class="num">(2,840,972)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,607,087<span></span>
</td>
<td class="nump">1,301,965<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,541,622<span></span>
</td>
<td class="nump">$ 1,574,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">111,325,000<span></span>
</td>
<td class="nump">101,177,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 57,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781278896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEFINED BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">DEFINED BENEFIT PLANS</a></td>
<td class="text">DEFINED BENEFIT PLANSWe maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The unfunded benefit obligation corresponds to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases and pension adjustments, offset by the fair value of the assets held by plan. The unfunded benefit obligation was approximately $4.0 million as of September&#160;30, 2019 and is recorded in other liabilities on the condensed consolidated balance sheet. The unfunded benefit obligation as of December&#160;31, 2018 and the total net periodic benefit cost for the three and nine months ended September&#160;30, 2019 and 2018 were not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6957672320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenue from Collaborators</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net revenues from collaborators (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.929825%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,560)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir Biotechnology (Vir)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,869&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">The Medicines Company (MDCO)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">775&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues from collaborators</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">53,415&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:65.205882%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.029412%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.029412%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,107&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">158,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three and nine months ended September&#160;30, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:65.794118%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.735294%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.735294%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Revenue recognized in the period from:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts included in contract liability at the beginning of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock', window );">Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements</a></td>
<td class="text">The following tables provide the research and development expenses incurred by type that are directly attributable to our collaboration agreements by our collaboration partners for the periods indicated, in thousands:<div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:22.597365%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,518&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:22.707602%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,033&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,578&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,205&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock', window );">Schedule of Allocated Transaction Price Based on Accounting Guidance</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467836%;"><tr><td style="width:1.0%;"/><td style="width:34.906585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.412557%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.836141%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.412557%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.836141%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.331394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.664625%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Standalone Selling Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Guidance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">122,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">178,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">93,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:95%;">ASC 606</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">364,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">249,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">521,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock', window );">Schedule of Revenue Recognized Based on Accounting Guidance</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.491228%;"><tr><td style="width:1.0%;"/><td style="width:23.454545%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.181818%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.969697%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.818182%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.272727%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.272727%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue Recognized During</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Guidance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">182,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">90,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">109,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">66,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">248,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">245,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">540,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">402,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Allocated Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfAllocatedTransactionPriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of research and development expenses incurred for collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Revenue Recognized Based on Accounting Guidance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786225568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (609,931)<span></span>
</td>
<td class="num">$ (550,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization, net</a></td>
<td class="nump">11,733<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases', window );">Amortization and interest accretion related to operating leases</a></td>
<td class="nump">27,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">108,644<span></span>
</td>
<td class="nump">129,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashGainOnLitigationSettlement', window );">Gain on litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Charge for 401(k) company stock match</a></td>
<td class="nump">3,268<span></span>
</td>
<td class="nump">3,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ChangeInFairValueOfLiabilityObligation', window );">Change in fair value of liability obligation</a></td>
<td class="num">(9,422)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(4,415)<span></span>
</td>
<td class="num">(2,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(29,717)<span></span>
</td>
<td class="nump">30,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Proceeds from landlord lease incentive for tenant improvements</a></td>
<td class="nump">29,064<span></span>
</td>
<td class="nump">11,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(28,095)<span></span>
</td>
<td class="num">(10,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(13,662)<span></span>
</td>
<td class="num">(34,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,719)<span></span>
</td>
<td class="num">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">36,348<span></span>
</td>
<td class="nump">25,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">399,584<span></span>
</td>
<td class="num">(11,503)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(82,447)<span></span>
</td>
<td class="num">(412,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(101,351)<span></span>
</td>
<td class="num">(89,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of restricted investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from maturity of restricted investments</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities</a></td>
<td class="num">(1,445,632)<span></span>
</td>
<td class="num">(992,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">1,320,156<span></span>
</td>
<td class="nump">1,120,565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(196,827)<span></span>
</td>
<td class="nump">23,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and other types of equity, net</a></td>
<td class="nump">30,942<span></span>
</td>
<td class="nump">60,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Offering proceeds, net of costs</a></td>
<td class="nump">381,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock to Regeneron</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">782,842<span></span>
</td>
<td class="nump">60,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(449)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">503,119<span></span>
</td>
<td class="num">(328,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">422,631<span></span>
</td>
<td class="nump">646,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">925,750<span></span>
</td>
<td class="nump">318,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 18,923<span></span>
</td>
<td class="nump">$ 19,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Interest Accretion Related to Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AmortizationAndInterestAccretionRelatedToOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ChangeInFairValueOfLiabilityObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ChangeInFairValueOfLiabilityObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashGainOnLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash gain on litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NonCashGainOnLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6604664528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Debt Securities - Summary of Fair Value of Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 674,143<span></span>
</td>
<td class="nump">$ 221,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">797,754<span></span>
</td>
<td class="nump">662,803<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 1,471,897<span></span>
</td>
<td class="nump">$ 884,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776158880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 674,143<span></span>
</td>
<td class="nump">$ 221,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,471,897<span></span>
</td>
<td class="nump">884,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,607,818<span></span>
</td>
<td class="nump">989,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">135,921<span></span>
</td>
<td class="nump">105,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,471,897<span></span>
</td>
<td class="nump">884,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">16,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">12,512<span></span>
</td>
<td class="nump">57,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">12,512<span></span>
</td>
<td class="nump">57,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">87,927<span></span>
</td>
<td class="nump">232,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">87,927<span></span>
</td>
<td class="nump">232,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">655,063<span></span>
</td>
<td class="nump">221,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">634,514<span></span>
</td>
<td class="nump">325,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">655,063<span></span>
</td>
<td class="nump">221,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">634,514<span></span>
</td>
<td class="nump">325,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">134,440<span></span>
</td>
<td class="nump">102,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">134,440<span></span>
</td>
<td class="nump">102,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="nump">8,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="nump">8,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificates of deposit | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">59,748<span></span>
</td>
<td class="nump">39,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">59,748<span></span>
</td>
<td class="nump">39,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791603808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 21, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 25, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 08, 2019 </div>
<div>USD ($) </div>
<div>Program </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 03, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 17, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Offering proceeds, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock at a price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_IncreaseDecreaseInTransactionPrice', window );">Change in Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 158,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,954,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares owned | shares</a></td>
<td class="nump">111,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,177,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_SanofiGenzymeMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,554,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444,445,000<span></span>
</td>
<td class="nump">4,444,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Offering proceeds, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock at a price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DiscoveryPeriodOfProgramsDevelopment', window );">Discovery period of programs development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment', window );">Extended additional discovery period of programs development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale', window );">Maximum royalties and commercial milestone payments upon potential product sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_UpfrontFeeReceived', window );">Upfront fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria', window );">Maximum additional milestone payments to be receive upon achievement of certain criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfTargetedPrograms', window );">Number of targeted programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfMaximumRoyaltyPayments', window );">Maximum percentage of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 540,100,000<span></span>
</td>
<td class="nump">$ 521,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transactional price remaining performance obligation</a></td>
<td class="nump">$ 279,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc. | Funding At Program Initiation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc. | Funding At Lead Candidate Identification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc. | Funding At Steady State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ResearchTermExtensionFee', window );">Research term extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementMilestonePayments', window );">Collaborative arrangement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_CollaborationAmendmentMember', window );">Collaboration Amendment | Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_InvestorAgreementDescription', window );">Investor agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">until the earlier of (i)&#160;the fifth anniversary of the expiration of the last to expire royalty term or the earlier termination of the collaboration agreement, as amended by the Collaboration Amendment, and (ii)&#160;the date after December&#160;31, 2021 on which the beneficial ownership of Sanofi Genzyme and its affiliates no longer represents at least 5% of the outstanding shares of common stock, Sanofi Genzyme and its affiliates will be bound by certain &#8220;standstill&#8221; provisions, including an agreement not to propose or support a proposal to acquire us.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_CollaborationAmendmentMember', window );">Collaboration Amendment | Minimum | Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage ownership interest owned by noncontrolling owners</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DiscoveryPeriodOfProgramsDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discovery period of programs development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DiscoveryPeriodOfProgramsDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended additional discovery period of programs development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_IncreaseDecreaseInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_IncreaseDecreaseInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InvestorAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investor agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InvestorAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum additional milestone payments to be receive upon achievement of certain criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum royalties and commercial milestone payments upon potential product sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfTargetedPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targeted programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfTargetedPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PercentageOfMaximumRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PercentageOfMaximumRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PotentialProceedsFromCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential proceeds from collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PotentialProceedsFromCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ResearchTermExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research term extension fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ResearchTermExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential maximum royalty percentage that will received for sales completed by collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_UpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_UpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtProgramInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtProgramInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtLeadCandidateIdentificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtLeadCandidateIdentificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAnAnnualDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAnAnnualDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_CollaborationAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_CollaborationAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775295520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">111,325,000<span></span>
</td>
<td class="nump">101,177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">111,325,000<span></span>
</td>
<td class="nump">101,177,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781118816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Manufacturing Facility</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2016, we purchased 12 acres of undeveloped land in Norton, Massachusetts. We are constructing a manufacturing facility at this site for drug substance for clinical and commercial use. As of September&#160;30, 2019 and December&#160;31, 2018, property, plant and equipment, net, on our condensed consolidated balance sheets reflect $278.2 million and $227.7 million, respectively, of land and associated costs related to the construction of our drug substance manufacturing facility.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are a party to legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred. </span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Securities Litigation</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On September 26, 2018, Caryl Hull Leavitt, individually and on behalf of all others similarly situated, filed a class action complaint for violation of federal securities laws against us, our Chief Executive Officer and our former Chief Financial Officer in the United States District Court for the Southern District of New York. By stipulation of the parties and Order of the Court dated November 20, 2018, the action was transferred to the United States District Court for the District of Massachusetts. On May 8, 2019, the Court entered an order appointing a&#160;lead&#160;plaintiff, and on July 3, 2019, lead&#160;plaintiff&#160;filed a consolidated class action complaint, or the Complaint. In addition to the originally named defendants, the Complaint also names as defendants certain of our other executive officers, and purports to be brought on behalf of a class of persons who acquired our securities&#160;between September 20, 2017 and September 12, 2018 and seeks to recover damages caused by defendants&#8217; alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The Complaint alleges, among other things, that the defendants made materially false and misleading statements related to the efficacy and safety of our product, ONPATTRO. The plaintiff seeks, among other things, the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed a motion to dismiss the Complaint in its entirety on July 31, 2019. The motion to dismiss was fully briefed on September 30, 2019.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. The complaint is brought on behalf of an alleged class of those who purchased our securities pursuant and/or traceable to our November 14, 2017 public stock offering. The complaint purports to allege claims arising under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, and generally alleges that the defendants violated the federal securities laws by, among other things, making material misstatements or omissions concerning the results of our APOLLO Phase 3 clinical trial of patisiran. The plaintiff seeks, among other things, the designation of the action as a class action, an award of unspecified compensatory damages, rescissory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that the allegations contained in the complaints are without merit and intend to defend the cases vigorously. We cannot predict at this point the length of time that these actions will be ongoing or the liabilities, if any, which may arise therefrom.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dicerna Litigation</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June&#160;10, 2015, we filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the Superior Court of Middlesex County, Massachusetts seeking to stop misappropriation by Dicerna of our confidential, proprietary and trade secret information related to the RNAi assets we purchased from Merck Sharp &amp; Dohme Corp., including certain N-acetylgalactosamine, or GalNAc, conjugate technology. In addition to permanent injunctive relief, we were also seeking monetary damages from Dicerna.</span></div>On April&#160;18, 2018, we and Dicerna entered into a settlement agreement resolving all ongoing litigation between the companies. Under the terms of the settlement agreement, Dicerna was required to pay us an aggregate of $25.0 million, all of which we had received as of January 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789419168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT REVENUES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Net Product Revenues</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net product revenues (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:46.684211%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">80,543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of World</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Product Revenues, Net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789294848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF BUSINESS</a></td>
<td class="text">NATURE OF BUSINESS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, commercial biopharmaceutical company with a sustainable pipeline of RNAi therapeutics to address the needs of patients who have limited or inadequate treatment options. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. In August 2018, we received approval for ONPATTRO</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#174;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (patisiran), our first product, from the United States Food and Drug Administration and began commercializing and generating product revenues in the U.S. In October 2018, we began commercializing and generating product revenues outside of the U.S. and, as of September 30, 2019, we have launched ONPATTRO in Japan, Canada and in several countries in Europe. Regulatory filings in additional markets in Europe and elsewhere are pending or planned for the remainder of 2019 and beyond.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784088128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Company's Marketable Debt Securities</a></td>
<td class="text"><div style="text-indent:54pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize our marketable debt securities as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:48.879765%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">90,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,289,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">298&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,289,577&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(44)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:48.879765%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(285)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">546,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">546,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(422)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of Fair Value of Marketable Debt Securities</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:69.783626%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.742690%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.742690%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">674,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">221,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">797,754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">662,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789394128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables present information about our assets that are measured at fair value on a recurring basis as of September&#160;30, 2019 and December&#160;31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.073421%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">655,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">655,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">134,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">134,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">634,514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">634,514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,607,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">135,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.073421%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">221,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">221,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">102,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">102,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">325,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">325,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">989,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>During the nine months ended September&#160;30, 2019 and 2018, there were no transfers between Level 1 and Level 2 financial assets. The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities. As of December&#160;31, 2018, the fair value of our long-term debt, computed pursuant to a discounted cash flow technique using a market interest rate, was $30.1 million and was considered a Level 3 fair value measurement. The effective interest rate reflected the current market rate as of the fair value date. On September 27, 2019, we repaid in full the $30.0 million long-term balance under our Credit Agreement with Wells Fargo Bank, National Association. Please read Note 9 for additional information regarding the Credit Agreement.In October 2017, we entered into a collaboration and license agreement with Vir Biotechnology, Inc., or Vir, at the time a private clinical-stage immunology company. As part of our upfront consideration, we received 5,000,000 shares of Vir common stock. On September 27, 2019, Vir implemented a 1-for-4.5 reverse split of its common stock, converting our 5,000,000 shares to 1,111,111 shares. On October 10, 2019, Vir completed its initial public offering, or IPO. As a result of the IPO, our common stock is now publicly traded common shares and is subject to a 180-day lock-up period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6959507600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text">EQUITY<div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offering</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, we sold an aggregate of 5,000,000 shares of our common stock through an underwritten public offering at a price to the public of $77.50 per share. As a result of the offering, we received aggregate net proceeds of $381.9 million after deducting underwriting discounts and commissions and other offering expenses of approximately $5.6 million.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regeneron Equity Placement</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 8, 2019, we executed the Regeneron SPA with Regeneron to sell 4,444,445 shares of our common stock, par value $0.01 per share for aggregate cash consideration of $400.0 million, or $90.00 per share, which we refer to as the Equity Transaction.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As a condition to consummating the transactions contemplated by the Regeneron SPA, we and Regeneron entered into an Investor Agreement dated April&#160;8, 2019, or the Investor Agreement. Under the Investor Agreement, until the expiration or termination of the Research Term under the Regeneron Master Agreement subject to extension by one year if the Research Term or Regeneron Master Agreement is terminated by Regeneron at will, or by up to two years if as of the expiration or termination of the Research Term Regeneron owns more than 19.99% of our outstanding shares, Regeneron and its affiliates will be bound by certain &#8220;standstill&#8221; provisions. The standstill provisions include agreements not to acquire more than 30% of our outstanding shares of common stock, call stockholder meetings, nominate directors other than those approved by our board of directors, subject to certain limited exceptions, or propose or support a proposal to acquire us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Further, under the Investor Agreement, Regeneron agreed to vote, and cause its affiliates to vote, all shares of our voting securities Regeneron is entitled to vote in a manner as recommended by our board of directors, except with respect to certain change of control transactions, liquidation or dissolution of our company, or, after the standstill term, any contested election of directors.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Investor Agreement, Regeneron agreed not to dispose of any of the purchased shares or any shares of common stock beneficially owned by it immediately after the closing of the Regeneron Master Agreement, until the earlier of (i)&#160;the four-year anniversary of the closing of the Equity Transaction and (ii)&#160;the termination of the Regeneron Collaboration, subject to limited exceptions, which we refer to as the Lock-Up Period. Following the expiration of the&#160;Lock-Up&#160;Period, if at any time Regeneron beneficially owns at least 9.9% of our outstanding shares, then until such time as Regeneron beneficially owns less than 5% of our outstanding shares, Regeneron will not dispose of any shares except (a)&#160;pursuant to a registered underwritten public offering pursuant to the Investor Agreement, (b)&#160;in a manner consistent with the volume limitations set forth in Rule 144 under the Securities Act, or (c)&#160;as otherwise approved by us.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Investor Agreement, following the&#160;Lock-Up&#160;Period, Regeneron will have three demand rights to require us to conduct a registered underwritten public offering with respect to the shares of common stock beneficially owned by Regeneron immediately after the closing of the Equity Transaction. In addition, following the&#160;Lock-Up&#160;Period, subject to certain conditions, Regeneron will be entitled to participate in registered underwritten public offerings by us if other selling stockholders are included in the registration. The rights and restrictions under the Investor Agreement are subject to termination upon the occurrence of certain events.</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Under the terms of the Regeneron SPA, if at the time of closing of the Equity Transaction a sufficient number of authorized shares of common stock under our Restated Certificate of Incorporation was not available, the Equity Transaction would have been settled in the form of our Series A redeemable convertible preferred stock. On April 25, 2019, following the receipt of stockholder approval at our annual meeting, a Certificate of Amendment was filed to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 125,000,000 to 250,000,000 shares, providing for a sufficient number of authorized shares of common stock available to be issued to Regeneron pursuant to the Equity Transaction.&#160;On May 21, 2019, subsequent to the expiration of the applicable pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Regeneron purchased 4,444,445 shares of our common stock for aggregate cash consideration of $400.0 million.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Because we had an obligation to Regeneron as of April 8, 2019 that may have resulted in the issuance of redeemable convertible preferred stock, we were required to follow the guidance in ASC 480 and mark-to-market the obligation to potentially issue this redeemable security until April 25, 2019, when it became known that the obligation would be fulfilled in common stock. The final mark-to-market adjustment of this obligation under ASC 480 resulted in us recording a gain of $9.4 million included in other income in the consolidated statements of comprehensive loss with the offsetting adjustment to equity netting against the $400.0 million proceeds that were received upon closing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781304064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Change in Contract Liability Balance Related to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Revenue recognized in the period from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in contract liability at the beginning of the period</a></td>
<td class="nump">$ 12,333<span></span>
</td>
<td class="nump">$ 3,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786280784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenues, Net - Summary of Net Product Revenues Of ONPATTRO (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 70,061<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 148,069<span></span>
</td>
<td class="nump">$ 53,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenues, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46,066<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">110,588<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenues, Net | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,591<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">80,543<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenues, Net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 12,475<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789350256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following common share equivalents (in thousands) were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787385808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2003 </div>
<div>RenewalOption</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>RenewalOption</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>RenewalOption</div>
</th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Net cash paid included in operating activities in cash flow | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=alny_BMRSixSevenFiveWestKendallLeaseMember', window );">BMR-675 West Kendall Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LeaseAgreementTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfLeaseExtensionOptions', window );">Number of lease extension options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal options period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">options to renew for two five-year terms each<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, operating lease, existence of option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=alny_ThirdStreetLeaseMember', window );">Third Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfLeaseExtensionOptions', window );">Number of lease extension options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal options period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to extend for two additional five-year terms<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, operating lease, existence of option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ExtendedLeaseExpirationDate', window );">Lease extended expiration date</a></td>
<td class="text">Jan. 31,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=alny_OneHundredAndOneMainStreetLeasesMember', window );">101 Main Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfLeaseExtensionOptions', window );">Number of lease extension options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal options period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to renew for one five-year term<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, operating lease, existence of option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ExtendedLeaseExpirationMonthAndYear', window );">Lease extended expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExtendedLeaseExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended lease expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExtendedLeaseExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExtendedLeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExtendedLeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LeaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LeaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfLeaseExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lease extension options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfLeaseExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=alny_BMRSixSevenFiveWestKendallLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=alny_BMRSixSevenFiveWestKendallLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=alny_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=alny_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=alny_OneHundredAndOneMainStreetLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=alny_OneHundredAndOneMainStreetLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787583040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Agreement - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Apr. 29, 2016</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit facility, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 29,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember', window );">Wells Fargo Bank, National Association</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage', window );">Cash collateral required for principal amount outstanding, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember', window );">Wells Fargo Bank, National Association | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember', window );">Wells Fargo Bank, National Association | Term Loan Facility | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash collateral required for principal amount outstanding, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784091792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reconciliation of Cash, Cash Equivalents and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Cash Cash Equivalents And Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 923,304<span></span>
</td>
<td class="nump">$ 420,146<span></span>
</td>
<td class="nump">$ 316,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included in prepaid expenses and other current assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in long-term other assets</a></td>
<td class="nump">2,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 925,750<span></span>
</td>
<td class="nump">$ 422,631<span></span>
</td>
<td class="nump">$ 318,746<span></span>
</td>
<td class="nump">$ 646,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781312272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Defined Benefit Plans - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanFundingStatusAxis=us-gaap_UnfundedPlanMember', window );">Unfunded Plan | Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanFundingStatusAxis=us-gaap_UnfundedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanFundingStatusAxis=us-gaap_UnfundedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791102176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ImpairmentOfMarketableDebtSecurities', window );">Impairment charges of marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ImpairmentOfMarketableDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ImpairmentOfMarketableDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787416208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Schedule of Revenue Recognized by Accounting Guidance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,061<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 148,069<span></span>
</td>
<td class="nump">$ 53,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 107,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">540,100<span></span>
</td>
<td class="nump">$ 521,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember', window );">Research Services Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">182,400<span></span>
</td>
<td class="nump">178,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember', window );">C5 License Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">109,200<span></span>
</td>
<td class="nump">93,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember', window );">C5 Co-Co Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">248,500<span></span>
</td>
<td class="nump">$ 249,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue recognized under ASC 808</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6777084960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALNYLAM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0602661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">675 West Kendall Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Henri A. Termeer Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">551-8200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01&#160;par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALNY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,489,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6592226384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the changes in accumulated other comprehensive (loss) income, by component, for the nine months ended September&#160;30, 2019 and 2018, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:32.356725%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695906%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.327485%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on Investment in Joint Venture</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Securities</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Total Accumulated Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Comprehensive (Loss) Income </span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(421)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(33,213)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,282)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">359&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,642)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net other comprehensive (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,158)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:32.356725%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695906%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.327485%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on Investment in Joint Venture</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (Losses) Gains from Debt<br/>Securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Accumulated Other<br/>Comprehensive (Loss) Income </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,641)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,433)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(590)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(590)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,041&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,041&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(33,392)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Amounts reclassified out of accumulated other comprehensive (loss) income relate to settlements of debt securities and are recorded as interest income in the condensed consolidated statements of comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776260576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents our inventory as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:72.707602%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">24,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791390416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 1,766,431<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 3,947,552<span></span>
</td>
<td class="num">$ (34,433)<span></span>
</td>
<td class="num">$ (2,147,685)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative effect adjustment from the adoption of new revenue standard</a></td>
<td class="nump">68,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">41,890<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">41,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">19,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(141,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">1,754,805<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">4,009,342<span></span>
</td>
<td class="num">(34,853)<span></span>
</td>
<td class="num">(2,220,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">1,766,431<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">3,947,552<span></span>
</td>
<td class="num">(34,433)<span></span>
</td>
<td class="num">(2,147,685)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(550,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2018</a></td>
<td class="nump">1,478,119<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">4,140,033<span></span>
</td>
<td class="num">(33,392)<span></span>
</td>
<td class="num">(2,629,531)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">1,754,805<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">4,009,342<span></span>
</td>
<td class="num">(34,853)<span></span>
</td>
<td class="num">(2,220,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">2,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">3,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">21,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(163,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,560)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">1,620,802<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">4,037,853<span></span>
</td>
<td class="num">(33,807)<span></span>
</td>
<td class="num">(2,384,249)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">13,497<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">13,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">88,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(245,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,282)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2018</a></td>
<td class="nump">1,478,119<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">4,140,033<span></span>
</td>
<td class="num">(33,392)<span></span>
</td>
<td class="num">(2,629,531)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,301,965<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">4,175,139<span></span>
</td>
<td class="num">(33,213)<span></span>
</td>
<td class="num">(2,840,972)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">101,177<span></span>
</td>
<td class="nump">101,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">$ 11,409<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">11,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">381,900<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">381,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">32,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(181,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,915)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">1,546,986<span></span>
</td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">4,601,662<span></span>
</td>
<td class="num">(32,853)<span></span>
</td>
<td class="num">(3,022,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,301,965<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">4,175,139<span></span>
</td>
<td class="num">(33,213)<span></span>
</td>
<td class="num">(2,840,972)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">101,177<span></span>
</td>
<td class="nump">101,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="num">$ (1,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(609,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 1,607,087<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">5,091,248<span></span>
</td>
<td class="num">(34,371)<span></span>
</td>
<td class="num">(3,450,903)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">111,325<span></span>
</td>
<td class="nump">111,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 1,546,986<span></span>
</td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">4,601,662<span></span>
</td>
<td class="num">(32,853)<span></span>
</td>
<td class="num">(3,022,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">6,182<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">6,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">4,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">390,577<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">390,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">30,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="num">(2,978)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,978)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(219,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(219,481)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">1,757,195<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="nump">5,034,284<span></span>
</td>
<td class="num">(35,831)<span></span>
</td>
<td class="num">(3,242,368)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under benefit plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">46,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(208,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,535)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 1,607,087<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">$ 5,091,248<span></span>
</td>
<td class="num">$ (34,371)<span></span>
</td>
<td class="num">$ (3,450,903)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">111,325<span></span>
</td>
<td class="nump">111,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6593251728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT REVENUES, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">PRODUCT REVENUES, NET</a></td>
<td class="text">PRODUCT REVENUES, NET<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net product revenues (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:46.684211%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">80,543&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of World</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Product Revenues, Net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019 and December&#160;31, 2018, net product revenue related receivables of $20.0 million and $13.1 million, respectively, were included in &#8220;Accounts receivable, net.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>alny-20190930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alny="http://www.alnylam.com/20190930"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alny-20190930.xsd" xlink:type="simple"/>
    <context id="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9a8cdc1b5f3342449f15e9e82f596399_I20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="ib290959e61784a1896b905564c991cdf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0e42c46e2c9e420489c577ce9a0935d6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd31099009a341cebcc213b46e1c6c76_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i290fb1f9477f4b0dad6a294dbebe5fe0_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ica700222a11442d3b8b92d9f887edb3c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2e4b5651a52648659bb33699e1f159aa_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="idc6569f4b7a54920b4b016ec2a2307d1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1ca8122b23ae48f2b7a30429c7434451_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia035051af8af48248146e9bb253e5b61_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id872e0d52c5f4349b6ad645fc3ff01c6_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icaba2b198691462eb220d545c5071fa7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i31f94264251c43368c4771d54ce4fbd2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iffcea211cbf84b608c3df605df16aac5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4af99066d2354ca1a75dbe6369056527_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1af6d69e893a4d178a9cfecc6e32e66d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i220bc1041a80494185ddcfda3b0920a1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3341252d93974bdca224a07c275ae6cc_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ibde364f980be4b1aa95846761f001d51_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ieb00a6eb479d40d3939afd5036703227_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib05e1ba0f35d45f5bd5774c207913ccb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifd648aa81acc49a38c586a7482708782_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9fd48e7dae264b53b2ee1bacea526327_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5a53da1f63ae4fd38c49af1968eb03e4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3e1d8229c0cc4d28a3d73367d8687475_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i29880daf69f1436f8c9e07a5d1f26e39_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1f06f86af24b4bb8b2e3262a34d11cd3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iaa8e567ccacd4802a6318a2e2c459b14_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id1f18bc840ab43f281968996981ebe97_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i092004fdf6b04a69ac3ae56810e7b8ef_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0ca4e4838440486c8f5a7b55f1575484_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i875fbab980f042debc104cf45c8ae36a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1efbe15735524508ab0312ffd4616e7b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i051b47be2e4f44b18624cfd7fb7d1e52_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia10915d8296543898e5c6c6185f06b70_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8a18a2febb21461088839dc562e86825_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i000b407bc82d4af584eae0ea4da200e8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4dda98ef75fa4c0cabaec8f6917de928_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if8260434ced747a89db3a4a3760f382a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icdb8b45ba98c4ea79afcd93e804e2e31_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i00290d9a0ceb4932b342087b2d02c362_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ia298b62308334655b29761118e628026_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if51590640cc3445e8236acd0882c53a5_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ib6b902bb76314b22b35d3d375909326c_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i017bcda5f3f84bd0b08d262246dc8609_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i3c9375ef392e4486bbab8ee684ac7c28_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i6c50c0a9426f4d279cde7bc33c6203d6_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i5cb5c2da414142a58bef1ad8643452f0_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i4d9c4ad3ea6f43f8b03c5853acc51d01_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i60ed32556e304de6860f08c6da60b133_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ic604e629a18e47f48644038e508838aa_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if084fb52c6fd4a039d5f4dc8424a4453_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i079b65915ef04049ab59dcf69c973f75_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="iade6d453882449f8b0ad8daf7e4d39e5_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i3a8833025058462db2992db44ec3934e_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ibddc1e81c5e54e42822e1311df259ceb_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ief21c0d90240476b8922ccee38864765_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i1a3e88d620de4614b17853b7a58ca2e2_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8b36842a761546ef807e31ee2522a096_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5ef4dd7f09d947d493d5f4436cf0c0e9_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ib15fa7b634fd4daea03b505c756c59bd_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ibb493b807d924cf39624accb949af88c_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id5a7aaddfaf542bbbf7a06985850a41f_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id9f25a7c241a4588906a002ff847246a_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i9c54b97117a54dc9a2281403a9143f40_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i20a7f979d1744d46907e2fe5ef13d747_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ib666c190ab3a4d4aa6556b9c46d1eb1d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i49ad1e878ba7413bba91fe1bdec91294_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i4d5fc643144f4f66a3f3e5fbd015f089_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i54e5da0497604cffa89334d054aa8689_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i47bf377672994a6989a0ffc4fda88279_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6977f9771bb9474f9b987ea4acb6e766_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia58cef5166244621bfaed56c877e6047_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i76fea3f3c89e4d38be0558a94f330d68_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iedca81ec08d84b71974e26397c92d1df_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic4a9dd2ed7f84b8eabd7dbe77bd4bede_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5944d6095a8a4e978f43fe95bdf38b47_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib789d44f74694f1ba05ae665b85e3c8d_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i94dc645833714139975f0211dc2191fb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ida54ff3bad294ce5853890d30053bb7c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i4c27321c10b343b58de158e6d3db20e5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id2a1f0c21c27441983ec53e357768237_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icfd9ee786c8c474d9a7bb46eff4d0397_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i97807f37924b4995a48c769fc07945fa_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i64a811b4311a4914940c20e54952a306_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie144870db8f9498eb7801f4559dd2d72_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i673aa3eee23e4a288c64b4dfedc553da_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i04e3a21a1c4c4bcdbb03dc8833f4924d_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ieb5884d7e33e4b7d94d106059300af24_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i21118dc8b808433e81625e7f2b7884b3_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie0b4cb7028ab4d418d05a21b47a3728a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1ae16923f0f84a86ad6008c568b4b1eb_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i83c1d7dbd6c148efb6c9867f8e130af1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8dd904aabd6f4f08942cf7251614b26f_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia18fdbb5b94847bb87d8d115277e9ea1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i33bd68ff20fc4287ac9b1020d2779301_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a1a333dbc9d46f196d16aaf2ceb4132_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i88c731ed1fbc417b9ee053536a59d9a6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idb229db5707849d4a22b3c3e18621842_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i841cbe61ae1c4ba5ac3531120ba0c867_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i7569b264a69c48a88a61d8ec84e9025a_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i46ff16a733d64c5fae19a59891cce764_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icc350c0de347466695b330f459fefc28_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide82e9762bef4fdeb0c81cbf70048f13_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5d7cf10b7b2548a080a4c2299f3c7795_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifb70ef125a034aa0830cee0808b5cfa1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i566f60a947954dc69ddaac57c3b30366_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie0bf8fb6901c49edba6c2026ee58fcc4_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i3bea475b1bd4453e8b3b41aa9c9a011b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ide622c05ddce4e44a17a894f34bccbba_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icef633268a6c4fcc928100d0671ed5e9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibfd6cf1430e34457b82db167b81278ef_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibc02df567f3e4ff6bf19fc1d69294ac4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia340b62c22e4415db15b4677cf672c04_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibf9a583b3eaa48f5ad28f2b7e2dc2657_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i146c5c0497e044de8cd9a05912301c3c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9592e8ff40504f85af6d1939889fd11b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="id7e703eff2264d08bab65003cdbeaad7_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i475658c0ca9e4d928c433d121b265c82_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if449ef4bea9a40ae916cb93478c18048_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45dfd0bcbe484904a18240c95809b63d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5715163b5bd44e09ae21778e01a08ad6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if50c807a1f0e4c1492220c3fbd4c4cac_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i992ffaac88eb4d129a8f61d7f3155127_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iae58e4687c76458cbd799a3532718cc8_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i828961f893674d5694c8381c4f2c012b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie2c0e609344340b0ac078896c7302e19_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if914afcf9e4744d0b11d5a1478378a35_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i527af3a6a1a443b0b18b74a5866a3b90_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i79eb574b077e440788e6310bda7ce3dc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i39121bec9968473c89779780093452eb_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia38c9fe25a9f40e79efe3342ecec48b2_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iae8470f847a3491dae7d1bcd2f3f6398_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i657c2557d02741b08dc2a2dfbc051fd5_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie781c80188954ce28b5095c7ad86743a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie89009e721c8458ea441dc7256bae44e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5faa958db3248cf8abd2d51854649c9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0133baa156a644908b72e47c2d43ec0a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id66ba49548de4a899fd6450c151c30c3_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i185ceb104d524ac2b0dd476c73f39d3b_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i28fd5aa0223e4864bd917a1eb955fbe1_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i80f0807ba74548b0a8cae142017dec3a_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5b1a8dc3c9da43c0b2be902403a125d8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib996cc6e2cef48baa147a3c936b7622d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i209d8f822ea54215a8a5a92d1710e4fa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3677fbfc08e94d57801b8fbdfc4f3d18_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6d661f5bbcaf4991993d92085c0405ea_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="if9d79f61ae80486795459192eaa096a6_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia9911e13cc954763aca179b898c772aa_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i05f229b2a3d4481b99dbd2a5d30a1bcf_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iea900a9c6d3a4cbab86b5bc952e69203_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2fae1adbaaf04d2681c00589c86c0041_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2c35a882679b407281d6fe08e0b51a82_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a80641a47214d5f91ecd50a0a248023_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i90acd6d92ec642f9b7b36589e3268571_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i757b55bca5a64fd58f1fab4d5d19add2_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:MdcoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i207df81799004a46ba28b23122e5111b_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ice65c0bb2b5e417888fde2ff078b534c_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-08</startDate>
            <endDate>2019-04-08</endDate>
        </period>
    </context>
    <context id="i5d3a888b47654db19c388966c89d70d3_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-08</startDate>
            <endDate>2019-04-08</endDate>
        </period>
    </context>
    <context id="i910f04c70f8f42eaa89bc212b0fcede9_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtProgramInitiationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="ie6314e00fa4e4a639121892a2b493f92_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtLeadCandidateIdentificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="i3e47a5ab3bd844aca1d5112c5e5bc4fe_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAnAnnualDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="ia89cc425b8ec4574a3b6d9187fd8d47b_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="if88df3d689a741d8b329bc0a7ffb25d6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9f99093d364045fda1a43bb5fcbfce58_D20190630-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-30</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i19f1516e126c4492b1083718d689a0b5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2e07bf9298b24bbcbbdd5c0c60d0efe0_D20190630-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-30</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibb5ab21b5e394f12b80ee7c85f5a6436_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i86d830c7785d42eca47ab825a3dd466e_D20190630-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-30</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6f42feab7e1d44078d72a7646ec908c5_D20190630-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-30</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idaea32819b574ef28e3693d2eb5e6e5b_D20190930-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1a8fa0c4e76a42f2852aac811eb5477f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie1583edbcfb14632bce947d08adc1711_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0a37ee0addcc471cbc26952515d07305_D20190930-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib0a05588cdc94fe990de15bb14b81d2e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2478295fa07f441eb5430e16d67ec61e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3b9efc823ea4a52a48884c8f7ef46ee_D20190930-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i561b9cbdf5134340b23a4852eff9113a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a69fc879d06480e8231d059d82c9ff1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i53189462639a41ea94d96ecc0862a2c7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i304e9e4a77f146f1b45c8803228f6a4d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i128a21da539642528efe8070e11f3e47_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i56c55aec91dc4c59ba2a9a3f39ee2da2_I20190117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-17</instant>
        </period>
    </context>
    <context id="i18255b8b8fa94a3c932e5d83d5508a09_I20190503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="i23a3a0ee563f4e42ad4529debd4b818a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CollaborationAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if894ca33791d422190136819871eb3fe_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:CollaborationAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7f917e7daa184219863485fd13588358_D20190425-20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-25</startDate>
            <endDate>2019-04-25</endDate>
        </period>
    </context>
    <context id="i2ab12e28db7e4641b70a2a645c6a28e8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9f78360553254ee782ee02d789c9d889_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i697b1bfc24074b85bf27cd5598d3b51b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4c50e4c814e74c9491d54d5e4e91af0f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3163fef4430b47c28ff4777546273453_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i45fc9bcd587c4f37b74ab016f6cbdefa_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie01382b3f2664b17976086250fb17c01_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie14a072a848f45a5a23bc9f805fbbd08_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i239343e7b44f41dabd006bd02fa42bff_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if099e69b9be14094b333354d839f0f79_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic860375e3027429092c256d65a2d7780_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icdc53aba859045ecb0ca135b483634d7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibe092ad14ecf40ecbc93697363251ede_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0949304a7dde4229b6e753cd9903c40e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4d0a82f69d8e49c7bf0facdafd02a08b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i891225af6803446f9581a304ba109390_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="idd2fc5c6f5de44f4ad84017a9d68a878_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8c36b06d4d7444b1b5923152fba320f9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i635b34a72c56410d8d1df7055596b6b8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia99a29ede5ec418db5992d141e96e1af_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3189a838fac44b6aa80a5b0128eeea48_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6fe3d4c3f27649a5b8cffd56fc6d60d6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic657523a72064bf8a77241824eec1de4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iea41bafdaa19451b99ca8455af31092b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i16e0f6431e4d44508c464f542f15baa9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4eb09fac19014b80be63710b35a8db33_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9de1d13c04544ccda16e21d30fb14653_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i782b647a38c84737b078e327971daeba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib04ae69b490e4a07b9dd11c6a1a057d8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40aef21a5b0742b6919605b695cba83a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i534eab2866fc4b1bb0f1e30546b2550e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0d0c030ef7f6469c8c51584431c73bee_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iedf54ff63ecd4190a0aebd37630638c0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib51284ca40ae4f409a968f2a88ae537c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i28d596b8dc524e17b6c9b06b62b6040d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6219fb42fe014e16a1c218a1ab221110_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8081f4ca6b924dd5986fc5e0a2f8b585_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5938ec1fdaa449c2b1ecc81f9993204c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i94c3b43b17584cae8dac039f9d951a2b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib8eaca78602548f881448af5a5dc5dc2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i13a256ed0c704bdaa3843a8e99ae65b0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i786e48af2f8048819a014a47ad5f3590_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i64cd7b4acbce48ee8c20aa3dc411db8a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a446afad065485689143f29fefeb88b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7cc9691ef8ec419190202c98ca260168_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51a9ec62896246148cc11c6a75758e7d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4fc8b8cbc9dc4a3fa34ac39e8ac315bd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6d00afa93a0d4d08987a2f888620c445_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40f9758c7a5442eb909c35e568f89d1a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6809fdac18e942108fea8b72dfefb89d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i563399d00a3f4495921402e83ebb9b19_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i77d6099e88b14f529fcdbf31508676b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie975d68357554af895cd61a0cde4dbcb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7fdecb33a35d4e5eb7f0e714d9cd1534_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iee8d158421a74475a932f3e1697894c8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2ecb9a3c8f1c431198624af0dce809c1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib4533404dc7f419c81cf7e77f58ea8c5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i1f6535ccbf5045358595e81d855d972e_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i9c5e31efccf54c278eb1d25e678417d7_I20190926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="iedd70bee38ec4be4894eb36e4bddfaf7_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="id9dfbac5853146558814da5e8f5ea8a7_D20190927-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-27</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i74014017f8ee43b3b9a7e4ef08932177_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iab3020f4366f48a4bbcc014e09a08814_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i21bcaecfc40942ca8fd4007f198b3c58_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if63df20ed74a495096a637566cb09eeb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i63b98f93930b4ca1a7e47371e33fbf42_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9d791afc3ff048e39ee8f08279c377d5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6057c3e479cc4cdba31104be591267b3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i14f2602865d142ab9138159f4fe344a7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i16dd0de9646a4fda905e58f333423af5_D20150401-20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:BMRSixSevenFiveWestKendallLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-04-30</endDate>
        </period>
    </context>
    <context id="i57addb2cc587477995144b49e9eba89b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:BMRSixSevenFiveWestKendallLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9fd9e2e99e294a098eb38e91d8de00b3_D20030925-20030926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2003-09-25</startDate>
            <endDate>2003-09-26</endDate>
        </period>
    </context>
    <context id="i65a3b729d2b6434facd1ef9436293344_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1997e78a21c14482b37dd96a0a0275a3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9c1b26358b0c4c7dbcbb8cdd284463c8_D20150501-20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="i8fc4dafdb8224f2fa05374c12dc848bb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:BMRSixSevenFiveWestKendallLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1856e4d8c9854c78af384a4826058c3a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2a15eda5822d49eeae29c67db90ce4d3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i387bd39383dc463f807be6d966c8ee8a_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">alny:OneHundredAndOneMainStreetLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ice75d291b75345eeb04d09221d4ac4bc_D20160429-20160429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-04-29</endDate>
        </period>
    </context>
    <context id="ia12206eca6a84503bf5e9fcc26bd4ded_D20160429-20160429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alny:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-04-29</endDate>
        </period>
    </context>
    <context id="ifb3e8a8fa91c4e08a54b904445e3b904_D20160429-20160429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-29</startDate>
            <endDate>2016-04-29</endDate>
        </period>
    </context>
    <context id="i8211fd2babc7426599d8a4da01554401_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alny:WellsFargoCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i436c9f5ba1394239990c555377c133a4_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-21</startDate>
            <endDate>2019-05-21</endDate>
        </period>
    </context>
    <context id="idc8680a0470f4515bbbb63de4581db15_I20190521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-21</instant>
        </period>
    </context>
    <context id="i41895d919e574902acb6169b0edb03fd_D20190408-20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-08</startDate>
            <endDate>2019-04-08</endDate>
        </period>
    </context>
    <context id="i5c4dc572daa54cea9409b772eff6e606_I20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="i48cd17bd102c404d9c2fb188602a9b17_I20190425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-25</instant>
        </period>
    </context>
    <context id="ia0fb16a3a7a347cf97e568dd2a32d15f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i756073bf9c7c485baa654d9c3b97871c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i0f962dd9c0f44fafacbd61a3c2eb05e8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c6c2484c92b4de1af5da63f0a53a5a3_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie27125284d00480e8f6436e54883feb0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id8c1e473ec654c44910204fe79355acb_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ib1a903160824485588e14c40fe27e4f4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib20fa348345c43e6aa0c88af9024338c_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i76aae8848c0147d7b950df899aa1ee06_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a29165453f749cf90320576aab15e8e_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9b94502431eb4c5aafa0614d51c18e74_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iebaaccb3176d4aea882b953a0bfbd222_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i635ef6dc444f45e2a67366c5fb673343_I20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="i4abb8539eed44421b7213ceef0389203_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alny:LandAndCostsRelatedToConstructionOfManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id20e2ef3281f455ba39063a9f09b371c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NortonMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alny:LandAndCostsRelatedToConstructionOfManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:DicernaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-18</startDate>
            <endDate>2018-04-18</endDate>
        </period>
    </context>
    <context id="i1a9655ab33ba47a3b214bdd3432435d3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanFundingStatusAxis">us-gaap:UnfundedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i920d2d842f894f7e86890f2d0f76a285_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia71b3c59a6854c088d21eef4ff92db76_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i22d215da162a4b1f870322c528da7252_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i668cb2e656af4447be63e110a6773f58_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i40c726db79a1419ca5405f2c9219f5d5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i730a5054c2f94c9685c25fdcab2d5d7a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if14817b988c44e9f97cb96e8be08c094_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i92f8703c144249dfa1533aa08a4f503a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i94bb522921334436b71c747686f4701a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i35867a636295441082ae888c09b539e8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8ca4613a2da84898a3f92d22c8ec8558_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic92b2ba692c74f76b138c30a332bc91c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie6d342895255493b9e648583464cf9bd_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i954eab77f4f9402dbb8b521337506e81_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ib9fea367ee9d4fe88b485027bf9fcb91_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i859a77e1c3ee4e5c8d583b9b6ac23528_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i285826056b0946b7ba9a170eaa6cc107_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="program">
        <measure>alny:Program</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewaloption">
        <measure>alny:RenewalOption</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y18yLTEtMS0xLTA_d841bbd0-351f-42ab-9f00-eb96e727fd5b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y180LTEtMS0xLTA_72add366-b9a9-407c-a3ed-eed3346a0d58">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y181LTEtMS0xLTA_7eed0625-d2c4-42d7-87d6-a47129c55022">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y184LTEtMS0xLTA_d78d2b9d-16c6-4d2a-8796-c04e4aec3d41">0001178670</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80L2ZyYWc6YzVmOWI1OWJkODhmNDNjYjk4OTE5MDViOGE1NGUyMjUvdGFibGU6YWM4NWEyYTMzODIxNDhlMDg0Yjc3ZDNhYjIwYTZjNmMvdGFibGVyYW5nZTphYzg1YTJhMzM4MjE0OGUwODRiNzdkM2FiMjBhNmM2Y185LTEtMS0xLTA_31cdae7b-584a-4ca3-a1ac-a2d70615195d">--12-31</dei:CurrentFiscalYearEndDate>
    <alny:InvestorAgreementDescription
      contextRef="if894ca33791d422190136819871eb3fe_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81Mi9mcmFnOjkyYTNmM2QwMWY0YTRkNjc5YmE4NzE3Nzg4MDUyYjAxL3RhYmxlOjczNDM5MGE3ZmE5YjQ3M2VhODdkNjUxZjZkY2ViOWUzL3RhYmxlcmFuZ2U6NzM0MzkwYTdmYTliNDczZWE4N2Q2NTFmNmRjZWI5ZTNfMS0xLTEtMS0w_18763693-775a-4ab9-baf6-1386ca7cd19d">until the earlier of (i)&#160;the fifth anniversary of the expiration of the last to expire royalty term or the earlier termination of the collaboration agreement, as amended by the Collaboration Amendment, and (ii)&#160;the date after December&#160;31, 2021 on which the beneficial ownership of Sanofi Genzyme and its affiliates no longer represents at least 5% of the outstanding shares of common stock, Sanofi Genzyme and its affiliates will be bound by certain &#x201c;standstill&#x201d; provisions, including an agreement not to propose or support a proposal to acquire us.</alny:InvestorAgreementDescription>
    <alny:DiscoveryPeriodOfProgramsDevelopment
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81Mi9mcmFnOjkyYTNmM2QwMWY0YTRkNjc5YmE4NzE3Nzg4MDUyYjAxL3RhYmxlOjczNDM5MGE3ZmE5YjQ3M2VhODdkNjUxZjZkY2ViOWUzL3RhYmxlcmFuZ2U6NzM0MzkwYTdmYTliNDczZWE4N2Q2NTFmNmRjZWI5ZTNfMi0xLTEtMS0w_16a7300e-935f-4b9e-a1a5-7090021e95f2">P5Y</alny:DiscoveryPeriodOfProgramsDevelopment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7f917e7daa184219863485fd13588358_D20190425-20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81Mi9mcmFnOjkyYTNmM2QwMWY0YTRkNjc5YmE4NzE3Nzg4MDUyYjAxL3RhYmxlOjkxYjFkYTZhNTQ3ZjQyYmY4OGI1ZWZiYTY1NjlhYzM0L3RhYmxlcmFuZ2U6OTFiMWRhNmE1NDdmNDJiZjg4YjVlZmJhNjU2OWFjMzRfMS0xLTEtMS0w_48ece2a5-869c-45a6-b6e4-45e11b8a1288"
      unitRef="shares">4444445000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="id9dfbac5853146558814da5e8f5ea8a7_D20190927-20190927"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMjg2L2ZyYWc6NmUyMzVlOWNiNmM5NDJmMWFlMWE0MjAwZGI2MmExM2YvdGFibGU6M2I5ZTllMThkODYzNGU0NGJmYmMxYjdlMGNiMDkwYmEvdGFibGVyYW5nZTozYjllOWUxOGQ4NjM0ZTQ0YmZiYzFiN2UwY2IwOTBiYV8wLTEtMS0xLTc5MzY_4263998f-4e5b-4ab4-a591-12c24b89dcec"
      unitRef="number">0.2222</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <alny:ImpairmentOfMarketableDebtSecurities
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82NC9mcmFnOjZlYzc3ZmI4ZTIzNjQyOTNhZWE4MTNiMTVjYWY4MDU4L3RhYmxlOjNmY2FiODQ2OTliZjQzNDhiODVlM2Y4ZWNjNjBlN2Q5L3RhYmxlcmFuZ2U6M2ZjYWI4NDY5OWJmNDM0OGI4NWUzZjhlY2M2MGU3ZDlfMS0xLTEtMS0w_4b0de892-bac3-4c6f-bfd0-ef997789beb3"
      unitRef="usd">0</alny:ImpairmentOfMarketableDebtSecurities>
    <alny:ImpairmentOfMarketableDebtSecurities
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82NC9mcmFnOjZlYzc3ZmI4ZTIzNjQyOTNhZWE4MTNiMTVjYWY4MDU4L3RhYmxlOjNmY2FiODQ2OTliZjQzNDhiODVlM2Y4ZWNjNjBlN2Q5L3RhYmxlcmFuZ2U6M2ZjYWI4NDY5OWJmNDM0OGI4NWUzZjhlY2M2MGU3ZDlfMS0yLTEtMS0w_f523bd1f-8b88-491b-a9e9-3a9dfd10e0bd"
      unitRef="usd">0</alny:ImpairmentOfMarketableDebtSecurities>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="i65a3b729d2b6434facd1ef9436293344_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNC0xLTEtMS0w_26ea3475-eee6-4293-b588-649a04b1d793">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="i57addb2cc587477995144b49e9eba89b_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNS0xLTEtMS0w_52d0bb59-5900-47dd-828e-8fa6d876b6b8">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="i1997e78a21c14482b37dd96a0a0275a3_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNi0xLTEtMS0w_b1d38623-484e-42e0-9d9d-47290d5b9987">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <alny:NumberOfLeaseExtensionOptions
      contextRef="i16dd0de9646a4fda905e58f333423af5_D20150401-20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNy0xLTEtMS0w_38194835-fa70-4512-8c22-c1129eea568c"
      unitRef="renewaloption">2</alny:NumberOfLeaseExtensionOptions>
    <alny:NumberOfLeaseExtensionOptions
      contextRef="i9fd9e2e99e294a098eb38e91d8de00b3_D20030925-20030926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOC0xLTEtMS0w_05abdb26-e2d5-4f03-b8df-94e345e29a41"
      unitRef="renewaloption">2</alny:NumberOfLeaseExtensionOptions>
    <alny:NumberOfLeaseExtensionOptions
      contextRef="i9c1b26358b0c4c7dbcbb8cdd284463c8_D20150501-20150531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOS0xLTEtMS0w_45eca64b-0786-4d18-93e7-369388527a7b"
      unitRef="renewaloption">1</alny:NumberOfLeaseExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8fc4dafdb8224f2fa05374c12dc848bb_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfNy0xLTEtMS05ODU1_57b355f2-d2e2-4f2b-9c64-375d23cb492c">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i1856e4d8c9854c78af384a4826058c3a_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOC0xLTEtMS05ODU1_334241ae-5c93-4486-8ada-c3114b645efc">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2a15eda5822d49eeae29c67db90ce4d3_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfOS0xLTEtMS05ODU2_a6d6fd84-18ee-4e45-9041-1e638e3e3645">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <alny:ExtendedLeaseExpirationMonthAndYear
      contextRef="i387bd39383dc463f807be6d966c8ee8a_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfMTAtMS0xLTEtMA_5db7cd60-8f75-4278-9c70-209721af81a5">2024-03</alny:ExtendedLeaseExpirationMonthAndYear>
    <alny:ExtendedLeaseExpirationMonthAndYear
      contextRef="i9c1b26358b0c4c7dbcbb8cdd284463c8_D20150501-20150531"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83MC9mcmFnOjQ2MzJmYTc3MjJiODQ4OTNhODliODE0M2VmNTdhYjk1L3RhYmxlOjk3NTE4NmQ4NDNmNzRiOWVhMzA2MzM3YmFjYWE5ZWQ1L3RhYmxlcmFuZ2U6OTc1MTg2ZDg0M2Y3NGI5ZWEzMDYzMzdiYWNhYTllZDVfMTEtMS0xLTEtMA_a5f768fd-3f4a-478d-be2e-f25beb7d362f">2021-06</alny:ExtendedLeaseExpirationMonthAndYear>
    <dei:DocumentType
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjM5_a03a8c78-a0f5-45c3-b41c-3c2466fa05de">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NmQwNjFlZTI3YzcwNGFkOTlhYWI4ZDZhN2QwMTMyYTQvdGFibGVyYW5nZTo2ZDA2MWVlMjdjNzA0YWQ5OWFhYjhkNmE3ZDAxMzJhNF8wLTAtMS0xLTU1OTE_74bbf66e-065d-49ec-8bfc-843643c83e5b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN180OTQ3ODAyMzI3MzM2_36f29565-2d4e-476b-8feb-9328dbe11883">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGUzZWRmMjYzNjA1NDAzM2JjZjQwMmVhNWRmMmQ4N2QvdGFibGVyYW5nZTo0ZTNlZGYyNjM2MDU0MDMzYmNmNDAyZWE1ZGYyZDg3ZF8wLTAtMS0xLTU1OTU_956155b1-7350-4db6-b028-c2074032111f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjYw_def41ee8-a7e2-4bda-81fd-046625a7202d">001-36407</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjYx_1fe5ab2e-09ce-4394-aa6e-bc17359e2a73">ALNYLAM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDQzYTk5MzFlOTYzNGEwYTk0NDNlNjg3Njg1MGUxNjgvdGFibGVyYW5nZTowNDNhOTkzMWU5NjM0YTBhOTQ0M2U2ODc2ODUwZTE2OF8wLTAtMS0xLTU2MTAvdGV4dHJlZ2lvbjowYmNjMGU5ZDUwNmE0NjFiYjI5NjBlODcxNjA4NTM4NV83Njk2NTgxMzk0NTE3_76e391a3-42b6-480e-a01e-ae4d7b616049">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDQzYTk5MzFlOTYzNGEwYTk0NDNlNjg3Njg1MGUxNjgvdGFibGVyYW5nZTowNDNhOTkzMWU5NjM0YTBhOTQ0M2U2ODc2ODUwZTE2OF8wLTEtMS0xLTU2MDQvdGV4dHJlZ2lvbjo1NjAyODkxMmMyYzc0NzNmODg2Y2E2NjEyMWE1Yjc3M183Njk2NTgxMzk0NDk1_d85410b7-c591-4d37-8989-7aa925005101">77-0602661</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NTYz_8aa17cda-f6c3-45e5-a437-f334adc08f04">675 West Kendall Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NTg4_8231dc9a-0b80-465a-862c-715f085e79b4">Henri A. Termeer Square</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NTk5_7a980b84-b540-42ca-9905-745b3f97dce0">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTAtMS0xLTU2MzQvdGV4dHJlZ2lvbjo5NWNlZGQwY2FhYmQ0NWM2YjM3NjViMTM2ZTlmNjE0ZF83Njk2NTgxMzk0NjAz_3bb3fa6f-b04f-4799-92dd-5085e080d3eb">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NTEyNTdjZTA4ZGY0NGZjMzllNmM0ZDQ2NDU3OGM2NjAvdGFibGVyYW5nZTo1MTI1N2NlMDhkZjQ0ZmMzOWU2YzRkNDY0NTc4YzY2MF8wLTEtMS0xLTU2NTAvdGV4dHJlZ2lvbjowMzAyZGJmOWZmZWM0ZjMxOWVjMWM2YWNiMGMxNDUxN183Njk2NTgxMzk0NDU5_9a70a2bf-6a45-4381-af20-37baf05538e3">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjY4_7d24202a-b4c8-47f7-a039-335988c278e3">617</dei:CityAreaCode>
    <dei:CityAreaCode
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2NjY4_cba741b9-46b2-4d8e-b3e9-787ee25b37f9">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2Njc4_12c3623a-e143-4084-8cbb-d07429e427e3">551-8200</dei:LocalPhoneNumber>
    <dei:LocalPhoneNumber
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2Njc4_adacebce-dd41-44ee-862c-06653e3d4f41">551-8200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGNhNTUwMmJhNmZjNDkwODhlODkyZGU1YjIwNGNkZGMvdGFibGVyYW5nZTo0Y2E1NTAyYmE2ZmM0OTA4OGU4OTJkZTViMjA0Y2RkY18xLTEtMS0xLTU2NjQ_fafd858b-6df0-4388-b013-0735779261c6">Common Stock, $0.01&#160;par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGNhNTUwMmJhNmZjNDkwODhlODkyZGU1YjIwNGNkZGMvdGFibGVyYW5nZTo0Y2E1NTAyYmE2ZmM0OTA4OGU4OTJkZTViMjA0Y2RkY18xLTMtMS0xLTU2NjE_aa35e2d9-fc07-4d5c-88cd-3a4467e23271">ALNY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6NGNhNTUwMmJhNmZjNDkwODhlODkyZGU1YjIwNGNkZGMvdGFibGVyYW5nZTo0Y2E1NTAyYmE2ZmM0OTA4OGU4OTJkZTViMjA0Y2RkY18xLTUtMS0xLTU2NjY_a0d7888f-406a-4aac-9041-0794e79ab323">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN183Njk2NTgxMzk2Njgz_60fc73b6-fce9-45c6-9da3-02c9641ca5f7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN184MjQ2MzM3MjEwNTc2_ef7090bd-cd8b-4562-a182-f0ac0a36ab03">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDcyNWI5MDFhYWNiNGU5NzhhZmU1ZjE5YmVjNTY4YzQvdGFibGVyYW5nZTowNzI1YjkwMWFhY2I0ZTk3OGFmZTVmMTliZWM1NjhjNF8wLTAtMS0xLTU2OTA_daba9f11-a9db-44eb-95df-1ae3d26ad5e2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDcyNWI5MDFhYWNiNGU5NzhhZmU1ZjE5YmVjNTY4YzQvdGFibGVyYW5nZTowNzI1YjkwMWFhY2I0ZTk3OGFmZTVmMTliZWM1NjhjNF8xLTMtMS0xLTU2OTI_6cf49de8-f2a5-4c92-82cb-93d13096ad3e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGFibGU6MDcyNWI5MDFhYWNiNGU5NzhhZmU1ZjE5YmVjNTY4YzQvdGFibGVyYW5nZTowNzI1YjkwMWFhY2I0ZTk3OGFmZTVmMTliZWM1NjhjNF8yLTEtMS0xLTU2OTQ_9ffed6a7-3204-4af2-8cda-563d111fb73d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN184MjQ2MzM3MjEwNTc5_bc3104f4-5883-444d-bccd-c2250a48d2e8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9a8cdc1b5f3342449f15e9e82f596399_I20191025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xL2ZyYWc6OTNjNTYzN2E2YjBiNDI0ODlhMjhhMzQ1NDcxNmJlZDcvdGV4dHJlZ2lvbjo5M2M1NjM3YTZiMGI0MjQ4OWEyOGEzNDU0NzE2YmVkN18yNzQ4Nzc5MDcxNjI4_8e65eb00-0c71-49ac-a38a-f709ed895ac2"
      unitRef="shares">111489744</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMy0xLTEtMS0w_f5e246dd-25ff-4ff6-a20b-eee09d9211d7"
      unitRef="usd">923304000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMy0zLTEtMS0w_5e2e5141-962d-4475-8ea5-679648350755"
      unitRef="usd">420146000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNC0xLTEtMS0w_3ed8334e-b006-4f00-b762-709cdecd59b0"
      unitRef="usd">797754000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNC0zLTEtMS0w_e06e68ec-4d92-4444-9bc9-6e025d4d5f37"
      unitRef="usd">662803000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNS0xLTEtMS0w_99ddf4ec-33c1-48bc-b424-74483aaa88aa"
      unitRef="usd">48109000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNS0zLTEtMS0w_e45dfe19-6c08-427d-b7b2-4d76e28fc5b5"
      unitRef="usd">18760000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNi0xLTEtMS0w_01ab0886-95f1-4db6-a7df-839ae86daa7b"
      unitRef="usd">54562000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNi0zLTEtMS0w_bb5e4c33-c893-4360-9e52-2a29dac54904"
      unitRef="usd">24068000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNy0xLTEtMS0w_aa714bb6-44a3-4284-97ba-1658b0eec4c9"
      unitRef="usd">73536000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfNy0zLTEtMS0w_d93d253f-198b-4396-b349-87750118e01e"
      unitRef="usd">74919000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOC0xLTEtMS0w_93d9862d-6dda-4c49-9d56-4dcb10695b36"
      unitRef="usd">1897265000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOC0zLTEtMS0w_90ceb5c1-a493-4618-9d21-7d3ee5d4cfe5"
      unitRef="usd">1200696000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOS0xLTEtMS0w_d87b04f7-75be-4910-8c53-34cbe5f8d818"
      unitRef="usd">396456000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfOS0zLTEtMS0w_a76f8484-1c94-4b53-92d8-c834500d9f0c"
      unitRef="usd">320658000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTAtMS0xLTEtMA_63162a4a-7ccc-4e15-bb7c-2dc56ee2e77e"
      unitRef="usd">223444000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTEtMS0xLTEtMA_2afa308f-97e8-46e3-9117-4f41ed8f1850"
      unitRef="usd">14825000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTEtMy0xLTEtMA_1614e027-16b6-42a1-b27e-91d42f8c2887"
      unitRef="usd">44825000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTItMS0xLTEtMA_01181ed3-16cf-4f75-9e42-395d5917154f"
      unitRef="usd">9632000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTItMy0xLTEtMA_0b348047-a4e1-4021-bec2-ac17ef45967d"
      unitRef="usd">8623000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTMtMS0xLTEtMA_51c4b41c-d7bf-48e8-9280-17d98ae79e9a"
      unitRef="usd">2541622000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTMtMy0xLTEtMA_f69ff540-3de0-4568-8e91-dc86627c736e"
      unitRef="usd">1574802000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTYtMS0xLTEtMA_6993998a-1436-4cc5-bedd-da175b69fe85"
      unitRef="usd">39392000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTYtMy0xLTEtMA_415afaa6-72ed-47fa-a1e3-402d534764b1"
      unitRef="usd">59708000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTctMS0xLTEtMA_97498ab9-ddaf-4f45-bec2-8d2f3be7cd93"
      unitRef="usd">177948000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTctMy0xLTEtMA_fa0fab48-fa29-44b9-9829-a7f37dd2071a"
      unitRef="usd">112719000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTgtMS0xLTEtMA_ae0b4fbb-fb95-4338-aa66-27e87c4cb2ce"
      unitRef="usd">28165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTktMS0xLTEtMA_38b82136-ac48-432e-a08b-bdd5142516c3"
      unitRef="usd">0</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMTktMy0xLTEtMA_c400a66a-7871-4bfb-bb58-37e75158d35f"
      unitRef="usd">3571000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjAtMS0xLTEtMA_f30648f0-8a5e-42ba-80c4-3861d14e05b7"
      unitRef="usd">107359000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjAtMy0xLTEtMA_a1cb1025-1cf1-4870-9f2e-6925573337ab"
      unitRef="usd">3496000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjEtMS0xLTEtMA_2e007876-3277-4574-be80-9ec72449da29"
      unitRef="usd">352864000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjEtMy0xLTEtMA_67fe0407-bf2e-4dab-bcc5-19052989643c"
      unitRef="usd">179494000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjItMS0xLTEtMA_f8c57b3e-b240-41f3-81f0-000c31f5ab56"
      unitRef="usd">276456000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjMtMS0xLTEtMA_dc1e4cf3-f323-411c-854c-4c1456b46496"
      unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjMtMy0xLTEtMA_0c2cb3f2-a15b-4df6-9f5b-ea5fbac4f055"
      unitRef="usd">57920000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjQtMS0xLTEtMA_c6447645-316d-4578-9516-6cdd4826c3f7"
      unitRef="usd">296179000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjQtMy0xLTEtMA_ded29d0b-872e-4740-9d46-f0509da29034"
      unitRef="usd">458000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjUtMS0xLTEtMA_1a2a7692-507c-4138-9c46-a5d5d673e871"
      unitRef="usd">0</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjUtMy0xLTEtMA_4d9bf921-64ea-43c3-9cb2-d089a66775a2"
      unitRef="usd">30000000</us-gaap:SecuredLongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjYtMS0xLTEtMA_072b9e0e-200b-430a-9fe1-8b97e3a383fd"
      unitRef="usd">9036000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjYtMy0xLTEtMA_e8646ea7-c5ec-4cea-ba61-4eaed141ecce"
      unitRef="usd">4965000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjctMS0xLTEtMA_21c849d2-7c2a-4b66-8391-2d81ec316ea7"
      unitRef="usd">934535000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjctMy0xLTEtMA_70606bd3-ee09-4cdb-95a1-6f06d81ce61b"
      unitRef="usd">272837000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjgtMS0xLTEtMA_ffa44f50-5806-4c33-89c0-49836775322c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMjgtMy0xLTEtMA_79a98d28-3180-49de-b17d-134dbf090f0e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjA_018679a5-754a-4b5c-b2cf-be84e0f059d9"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjA_0975cf92-c60c-43ae-a7de-1577968b0bbc"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNTI_19ae5d8f-0d7a-47b2-ad4f-2177cb8960da"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNTI_e3bf0285-7841-418a-945d-3fab01b44e94"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_40ccd47e-7f35-4183-b35e-1abaa8ce6e2b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_7a1ca825-948c-4d3b-b31f-9eece72c273c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_a888ec10-677f-4c7f-8b49-b875211708cd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMC0xLTEtNDY5MS90ZXh0cmVnaW9uOmFlY2Q5YzI4YjcwZTQwMzBhMDc1YzI1MTE2NTc1ZWI5Xzc2OTY1ODEzOTUwNjQ_ff8bd4ed-b590-4dd9-9857-8122334a786a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMS0xLTEtMA_3802835f-0926-49c5-a947-079f0926c18c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzAtMy0xLTEtMA_c78c92fb-c9fd-48f1-84ba-e6c10060dd8e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MDc_73e52c20-c57e-4874-8a6d-c0da8302278e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MDc_74bd10f0-d74d-4474-a176-748c49623d36"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MTY_2b6fc916-e6ae-4d8d-a7fc-1b08139bbd48"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MjY_2ebb89e0-9da2-4f22-983a-4f45c4a9ee9b"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MzY_3e101a77-6ba8-4033-b169-8a193d61e1f7"
      unitRef="shares">111325000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3MzY_f9ba635f-0030-40f6-836f-c4f2ae307579"
      unitRef="shares">111325000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3NDY_50769c7b-6717-4a4a-92e5-e729958966bb"
      unitRef="shares">101177000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMC0xLTEtNDY5My90ZXh0cmVnaW9uOmMwMDFkNjQxM2QxZTQ1OTNhMGRlMWRkMTg4Y2VjYWU1Xzc2OTY1ODEzOTQ3NDY_feef3572-4521-4e40-b457-65fec1f1eefb"
      unitRef="shares">101177000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMS0xLTEtMA_86dbcfd7-ca29-4ecc-abfc-3b79151af448"
      unitRef="usd">1113000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzEtMy0xLTEtMA_e33dc866-8e18-4bf7-9a2d-8a540275a39f"
      unitRef="usd">1011000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzItMS0xLTEtMA_d0c3b4a1-caf0-4c68-8567-1232a2de19d5"
      unitRef="usd">5091248000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzItMy0xLTEtMA_121b9833-3bef-429a-8d99-965207c7c00d"
      unitRef="usd">4175139000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzMtMS0xLTEtMA_15438dc6-99a4-4d25-b398-b48b29bf3dcf"
      unitRef="usd">-34371000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzMtMy0xLTEtMA_3253325c-7231-4e8f-a761-12bb6ebac4a1"
      unitRef="usd">-33213000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzQtMS0xLTEtMA_02ccbe99-17b9-437c-891e-5ea4190fdae9"
      unitRef="usd">-3450903000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzQtMy0xLTEtMA_837146d7-7f1d-4f9e-bce1-db77496e4740"
      unitRef="usd">-2840972000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzUtMS0xLTEtMA_77e0085c-c629-44da-86fe-f080e4d8ac87"
      unitRef="usd">1607087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzUtMy0xLTEtMA_daab6aab-d7c4-42ae-b47c-2a87a87c2dfc"
      unitRef="usd">1301965000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzYtMS0xLTEtMA_151401a8-f32a-4f8d-9374-84d8a3a1d9fe"
      unitRef="usd">2541622000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xNi9mcmFnOmRhMDU5MzkwMmM4ODRlNjI4ZmQxMTVhNjBjNDVhN2YxL3RhYmxlOmU4M2U1MzU3YjQ2YTQxMjg4NmYyNGYyNmE5YWE2YTRiL3RhYmxlcmFuZ2U6ZTgzZTUzNTdiNDZhNDEyODg2ZjI0ZjI2YTlhYTZhNGJfMzYtMy0xLTEtMA_7ef17e86-7715-4a0b-92d6-b57ce49722d8"
      unitRef="usd">1574802000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd31099009a341cebcc213b46e1c6c76_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy0xLTEtMS0w_e8d0d415-bb82-4034-83ad-51dafb686ff7"
      unitRef="usd">46066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i290fb1f9477f4b0dad6a294dbebe5fe0_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy0zLTEtMS0w_7ff6723b-4de9-4182-a917-04f45603e464"
      unitRef="usd">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica700222a11442d3b8b92d9f887edb3c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy01LTEtMS0w_67955aa3-3151-472a-b14a-68bed1f930a1"
      unitRef="usd">110588000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e4b5651a52648659bb33699e1f159aa_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMy03LTEtMS0w_5ab455b4-5df1-4624-b941-4227c34a86c2"
      unitRef="usd">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc6569f4b7a54920b4b016ec2a2307d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC0xLTEtMS0w_5e6c3bda-8509-4cfe-bf15-1dd4cd5a7ecf"
      unitRef="usd">23995000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ca8122b23ae48f2b7a30429c7434451_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC0zLTEtMS0w_54e5d02b-7ddf-403d-a7a5-17fa608ab373"
      unitRef="usd">1609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia035051af8af48248146e9bb253e5b61_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC01LTEtMS0w_0786bebd-6be5-4ed3-9836-d8879fe3f435"
      unitRef="usd">37481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id872e0d52c5f4349b6ad645fc3ff01c6_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNC03LTEtMS0w_3c5d79dc-e3c1-4304-b1d5-550b74947875"
      unitRef="usd">53415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS0xLTEtMS0w_c9a2b140-38b2-43c2-8ed5-31003fd68edc"
      unitRef="usd">70061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS0zLTEtMS0w_6bcc3829-7b71-4c88-bed5-8c87388a04ea"
      unitRef="usd">2069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS01LTEtMS0w_ceab7c29-fc23-482d-9933-de25e541bdb0"
      unitRef="usd">148069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNS03LTEtMS0w_37f43646-7d83-44c0-814e-bc1d097c6666"
      unitRef="usd">53875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy0xLTEtMS0w_6db34680-efd0-4a4c-be10-49f879c3982b"
      unitRef="usd">5213000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy0zLTEtMS0w_9821d23a-48db-463b-a2d6-9c1095bb66c3"
      unitRef="usd">137000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy01LTEtMS0w_001b81ad-0e79-42de-ad02-c5e00478ed43"
      unitRef="usd">12886000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfNy03LTEtMS0w_77968cec-7622-4c0b-97e7-80c6f3df1234"
      unitRef="usd">137000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC0xLTEtMS0w_946cbff7-27ae-4c37-ab51-efad8f9a327c"
      unitRef="usd">160796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC0zLTEtMS0w_153fe748-14fe-49e9-a7ca-c19f8c057b7c"
      unitRef="usd">139945000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC01LTEtMS0w_ff0b92bb-646f-43d5-9e20-ca7c8a104bf9"
      unitRef="usd">453813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOC03LTEtMS0w_97749a03-3720-4841-b671-e7bb0858d4f0"
      unitRef="usd">374384000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS0xLTEtMS0w_0476a779-5767-4f42-bada-1b46fedc11ea"
      unitRef="usd">120351000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS0zLTEtMS0w_ef9a864a-8190-4867-ae03-48a412390cc1"
      unitRef="usd">116545000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS01LTEtMS0w_fdcb7201-e828-4a7b-8f16-07717dfc9e2e"
      unitRef="usd">322728000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfOS03LTEtMS0w_9af39ab4-8f97-4cde-8b40-e6bac1432ce6"
      unitRef="usd">273671000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtMS0xLTEtMA_1b53cdc4-45b9-4472-801b-fd0df8072f99"
      unitRef="usd">286360000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtMy0xLTEtMA_ea40c06f-8bb8-4c34-a32e-0cd56c1f2ed4"
      unitRef="usd">256627000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtNS0xLTEtMA_65d9752a-b1e3-4e2b-8b9c-30b7393b186b"
      unitRef="usd">789427000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTAtNy0xLTEtMA_c579f330-80e0-40a4-8fe4-b60cb43ee5a0"
      unitRef="usd">648192000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtMS0xLTEtMA_20910e61-ddeb-472b-ab47-c9cd16ce0b66"
      unitRef="usd">-216299000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtMy0xLTEtMA_3e8d0d1a-648e-47f7-9f30-580aead3817b"
      unitRef="usd">-254558000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtNS0xLTEtMA_18adcd3c-559c-4698-b912-dd02210d2718"
      unitRef="usd">-641358000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTEtNy0xLTEtMA_647f740d-8f8c-4035-a846-6dac7549630a"
      unitRef="usd">-594317000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtMS0xLTEtMA_0aed29d4-3de7-41fd-bbab-a105b2ec5183"
      unitRef="usd">9889000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtMy0xLTEtMA_d30855e2-f9c5-4113-a60d-0bfe17afc972"
      unitRef="usd">6796000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtNS0xLTEtMA_c4f5dcc9-3bef-4a53-8106-cf75ff5f25e9"
      unitRef="usd">26195000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTMtNy0xLTEtMA_bfce9bc5-34c5-4dce-8bcd-a5d0ceeaee4a"
      unitRef="usd">18691000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtMS0xLTEtMA_87558b1f-0c81-4c37-9836-9b062a995221"
      unitRef="usd">-2519000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtMy0xLTEtMA_e64b1e95-1e5b-4cfd-984c-05e15012b221"
      unitRef="usd">2925000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtNS0xLTEtMA_5b2323d0-5a4e-4ceb-87bc-114c69751500"
      unitRef="usd">-2929000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTQtNy0xLTEtMA_8fe33f42-64d3-4c9a-83ed-77dfd865fc44"
      unitRef="usd">5468000</us-gaap:OtherNonoperatingIncomeExpense>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtMS0xLTEtMA_7a1c6275-f74b-4a39-b609-b00e1630ea51"
      unitRef="usd">0</alny:ChangeInFairValueOfLiabilityObligation>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtMy0xLTEtMA_897dc6d0-53b7-4825-8858-f103d59ae38f"
      unitRef="usd">0</alny:ChangeInFairValueOfLiabilityObligation>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtNS0xLTEtMA_f4bd5a00-132f-435a-bc64-c30c3c5c0c29"
      unitRef="usd">9422000</alny:ChangeInFairValueOfLiabilityObligation>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTUtNy0xLTEtMA_a4e97c13-7851-489b-b414-0e6dcf8e3e6a"
      unitRef="usd">0</alny:ChangeInFairValueOfLiabilityObligation>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtMS0xLTEtMA_c894593b-3d4e-4448-bd23-0858aa5aa811"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtMy0xLTEtMA_b6674db0-2926-4b44-9384-5667f568c2d5"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtNS0xLTEtMA_6aec7726-d661-4e86-8b13-cf935bacf805"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTYtNy0xLTEtMA_9dda0b90-4458-4f67-9470-0f6efe4710f3"
      unitRef="usd">20564000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctMS0xLTEtMA_407cf781-d776-46ce-a68f-85efe0a22354"
      unitRef="usd">7370000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctMy0xLTEtMA_522fdc79-ef3c-472b-9e17-25c85ff1efd9"
      unitRef="usd">9721000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctNS0xLTEtMA_7ad3d1a1-e6d4-4ba8-a1aa-76fe29a4bdd0"
      unitRef="usd">32688000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTctNy0xLTEtMA_fb209675-6ccf-40d5-8b2e-0643222e3428"
      unitRef="usd">44723000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtMS0xLTEtMA_d3af2f6e-93c7-47e5-b45a-e676542c79b1"
      unitRef="usd">-208929000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtMy0xLTEtMA_1a923487-2e26-4700-8506-06a8878fa276"
      unitRef="usd">-244837000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtNS0xLTEtMA_5d2817cb-e7d0-4fbb-85c4-e4343f2d1e26"
      unitRef="usd">-608670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTgtNy0xLTEtMA_f9864f5c-e8fd-49ac-b27c-21440ba6f7f3"
      unitRef="usd">-549594000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktMS0xLTEtMA_7101b1f8-028a-44cd-bf78-f4ee228990cc"
      unitRef="usd">-394000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktMy0xLTEtMA_6183ca93-21d2-428d-b03f-a8d3a51fff8b"
      unitRef="usd">445000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktNS0xLTEtMA_a7677fef-2659-4a81-bbe9-adcc48290a8b"
      unitRef="usd">1261000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMTktNy0xLTEtMA_208e0f8b-04a7-4cdb-8b1a-7b43ff0ebc92"
      unitRef="usd">462000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtMS0xLTEtMA_cffb5cab-81a9-4521-a724-cdb20e3583d3"
      unitRef="usd">-208535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtMy0xLTEtMA_b7f324b1-dffe-47c8-a109-9f6adb1eedbd"
      unitRef="usd">-245282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtNS0xLTEtMA_dc23a6f4-0429-4f45-9253-71a872ec5f71"
      unitRef="usd">-609931000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjAtNy0xLTEtMA_b6513247-5e86-4a8e-8fd3-f0ebe1cdae98"
      unitRef="usd">-550056000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtMS0xLTEtMA_b04eb59b-4308-4393-9c9f-9334ae3c85c5"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtMy0xLTEtMA_85111dc3-da66-4a1c-9bd2-e9d6ce0832ff"
      unitRef="usdPerShare">-2.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtNS0xLTEtMA_f6ee7ad2-0eab-4040-bd33-755b4e045876"
      unitRef="usdPerShare">-5.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjEtNy0xLTEtMA_3dc5f339-d46f-48cb-8be2-a0a31dfa17a2"
      unitRef="usdPerShare">-5.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItMS0xLTEtMA_86f02471-cf57-45ed-bef2-9da06db1b524"
      unitRef="shares">108701000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItMy0xLTEtMA_e739eae7-7fac-43bd-8ad7-622bc2afe0cc"
      unitRef="shares">100783000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItNS0xLTEtMA_7acc7a49-f5ad-4801-8fe8-39ba531dbbe7"
      unitRef="shares">108427000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjItNy0xLTEtMA_168fcdcc-fb0d-4b2f-a35a-7770fd50f76f"
      unitRef="shares">100430000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtMS0xLTEtMA_dfa621a5-77ab-467f-93f1-aabf0fb1fdfa"
      unitRef="usd">-208535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtMy0xLTEtMA_ff2825bb-8e43-405d-befc-d8b07e3d0ce3"
      unitRef="usd">-245282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtNS0xLTEtMA_6fb80732-9c3a-4944-b586-bffa64a564a7"
      unitRef="usd">-609931000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjQtNy0xLTEtMA_9878388b-a957-4194-88d1-bb02ca2491c0"
      unitRef="usd">-550056000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtMS0xLTEtMA_e4f9cbaf-167e-46cf-a593-dd105cff1441"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtMy0xLTEtMA_aad6b794-566a-4818-ae56-6467cf16ed47"
      unitRef="usd">415000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtNS0xLTEtMA_8cfde77b-e376-4d86-bb11-c3f7fb4ce81e"
      unitRef="usd">772000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjUtNy0xLTEtMA_65413823-6099-48bc-8c25-1dd29e10d0c5"
      unitRef="usd">1041000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtMS0xLTEtMA_79c22805-1415-4570-b1a1-37bfe4390a4e"
      unitRef="usd">1439000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtMy0xLTEtMA_4391b1da-5227-47df-8e0e-adc75b23dcbf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtNS0xLTEtMA_760335c8-4d03-4660-a9d2-6475a663d371"
      unitRef="usd">2281000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjYtNy0xLTEtMA_a648e16a-f724-4e48-81d3-a53789862a44"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctMS0xLTEtMA_fafb910c-d5ac-407b-8262-cbd1671385cd"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctMy0xLTEtMA_7177428e-d000-4252-b9a0-78df42937851"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctNS0xLTEtMA_008750e2-041d-47d4-903d-40a3bd185a74"
      unitRef="usd">4211000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjctNy0xLTEtMA_91cbd74f-8640-4a9a-8be4-3cde09c31e7a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtMS0xLTEtMA_6e69aa9a-fba2-4280-87de-3341af045361"
      unitRef="usd">-207075000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtMy0xLTEtMA_e01289f3-066b-4b39-8a43-144b7c530da5"
      unitRef="usd">-244867000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtNS0xLTEtMA_c4c173a6-1216-4ffc-a3cd-0bcae9069b52"
      unitRef="usd">-611089000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yMi9mcmFnOmY5MWFhZGU5YTk3ODRlMWZhMTRjNWQ2ZTUwMDNhNjM4L3RhYmxlOmNkMmVkM2ZlN2QzOTRmNjY5OTRkMDBhMzlmMzViYmU4L3RhYmxlcmFuZ2U6Y2QyZWQzZmU3ZDM5NGY2Njk5NGQwMGEzOWYzNWJiZThfMjgtNy0xLTEtMA_f48fe766-9891-467f-b8c1-8def61bf7ed6"
      unitRef="usd">-549015000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icaba2b198691462eb220d545c5071fa7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi0xLTEtMS01NDI_f5845ca4-c183-4de7-9f03-c3f103305949"
      unitRef="shares">101177000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icaba2b198691462eb220d545c5071fa7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi0zLTEtMS01NDI_77cc3cd6-b416-40db-99dc-645e1b5d79f3"
      unitRef="usd">1011000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31f94264251c43368c4771d54ce4fbd2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi01LTEtMS01NDI_39747f7a-7607-40c8-9bff-933ae5053dc8"
      unitRef="usd">4175139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffcea211cbf84b608c3df605df16aac5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi03LTEtMS01NDI_ff6e9696-ba8a-4a3b-b7bf-521910632920"
      unitRef="usd">-33213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4af99066d2354ca1a75dbe6369056527_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi05LTEtMS01NDI_557389a7-20a2-448f-be63-c9d848692fa3"
      unitRef="usd">-2840972000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMi0xMS0xLTEtNTQy_add762f2-565b-48bd-a5c6-1461ca3b9037"
      unitRef="usd">1301965000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy0xLTEtMS01NDI_41dabe39-82eb-44b0-afae-f826d991b59d"
      unitRef="shares">207000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy0zLTEtMS01NDI_81e5bf5c-6960-4e9d-a29f-a4fe38cf4e0f"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy01LTEtMS01NDI_162079e0-68ab-4c49-b713-1b3e6d6108cb"
      unitRef="usd">11406000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMy0xMS0xLTEtNTQy_ceb24c49-768c-498a-b8dd-cae4d0097104"
      unitRef="usd">11409000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNC0xLTEtMS01NDI_0ca07f57-ec80-4417-8ec2-e428e04d57d5"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNC01LTEtMS01NDI_3a82cd6c-b08e-4e9d-8119-ca773db16cc6"
      unitRef="usd">-58000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNC0xMS0xLTEtNTQy_4605d12c-97eb-418a-8e8e-4b806863fa37"
      unitRef="usd">-58000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNS0xLTEtMS01NDI_30b63b96-1d18-4ab0-a174-44fe9919bfd7"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNS01LTEtMS01NDI_985a6ec0-f25d-4612-9422-19c8a321aaf5"
      unitRef="usd">784000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNS0xMS0xLTEtNTQy_7ce42070-5d2a-4340-901a-c25e86b938d3"
      unitRef="usd">784000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi0xLTEtMS01NDI_5231a77b-f3e7-4097-a031-e64462da7388"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if921f569a8ed40d5ab7b3e4bb2e86a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi0zLTEtMS01NDI_e4617d25-7393-4ca1-b8c6-cf10a3e7e8ad"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi01LTEtMS01NDI_802d52f9-dec6-421b-ad21-747cf483c41f"
      unitRef="usd">381850000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNi0xMS0xLTEtNTQy_a965299f-832b-409d-805d-379dafd709f1"
      unitRef="usd">381900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic2c2edc4603a43609186b43d80dacfbe_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNy01LTEtMS01NDI_042630e7-c456-4bb6-9d52-1cbca64c8b87"
      unitRef="usd">32541000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfNy0xMS0xLTEtNTQy_eb2b2be5-2cc3-4cf4-b644-690ae30ef8bb"
      unitRef="usd">32541000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1af6d69e893a4d178a9cfecc6e32e66d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOC03LTEtMS01NDI_c1f431ee-e64d-437a-a94a-c2fe793e443c"
      unitRef="usd">360000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOC0xMS0xLTEtNTQy_ea3c4384-488b-4289-9927-642f69788e59"
      unitRef="usd">360000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i220bc1041a80494185ddcfda3b0920a1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOS05LTEtMS01NDI_ffe772dc-1b77-453e-a284-101e107d53f6"
      unitRef="usd">-181915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8eef83d26b6d4b94a94071b9bed77653_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfOS0xMS0xLTEtNTQy_8d08b1a9-a108-40d2-9fbd-e0bc80654e14"
      unitRef="usd">-181915000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3341252d93974bdca224a07c275ae6cc_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtMS0xLTEtNTQy_e5f4a689-02bd-4dc8-8a7b-eec1d3ff8f39"
      unitRef="shares">106400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3341252d93974bdca224a07c275ae6cc_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtMy0xLTEtNTQy_fe8dca6c-d81e-42ad-b354-0b8690d3adfd"
      unitRef="usd">1064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibde364f980be4b1aa95846761f001d51_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtNS0xLTEtNTQy_bc597501-9d3b-4c3d-82b2-7cfa4110d746"
      unitRef="usd">4601662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb00a6eb479d40d3939afd5036703227_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtNy0xLTEtNTQy_f319515c-1d77-40ed-80b1-e9613817459b"
      unitRef="usd">-32853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib05e1ba0f35d45f5bd5774c207913ccb_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtOS0xLTEtNTQy_535babb5-3eb1-4e59-97f4-03b805f910e3"
      unitRef="usd">-3022887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd648aa81acc49a38c586a7482708782_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTAtMTEtMS0xLTU0Mg_54863137-d20f-4287-8893-08babae2bf9d"
      unitRef="usd">1546986000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtMS0xLTEtNTQy_bb899cd0-235a-4c2d-bc1d-804fad569f2c"
      unitRef="shares">203000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtMy0xLTEtNTQy_799f78dc-a7b7-4bf5-923f-4f83a058d567"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtNS0xLTEtNTQy_842f1044-8679-48c1-8cd3-8ce3e2dfaef9"
      unitRef="usd">6180000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTEtMTEtMS0xLTU0Mg_6cb782d4-cb00-4938-a57e-65d6b98b6a69"
      unitRef="usd">6182000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTItMS0xLTEtNTQy_ca2bc661-30cf-48c9-867c-e9205aa82d9d"
      unitRef="shares">55000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTItNS0xLTEtNTQy_363babad-34ed-49df-b5dc-4f8be1f733bb"
      unitRef="usd">4022000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTItMTEtMS0xLTU0Mg_412435c7-e19a-4e06-9dca-e40e8fedea7f"
      unitRef="usd">4022000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTMtMS0xLTEtNTQy_2ed36301-88a2-486d-96b0-46483cd6dba2"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTMtNS0xLTEtNTQy_72ab8e59-f4c1-400f-ad0e-415e38009338"
      unitRef="usd">1089000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTMtMTEtMS0xLTU0Mg_458bfc5c-ff64-472f-a8fc-4fc16c6afaf4"
      unitRef="usd">1089000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtMS0xLTEtNTQy_b16085b0-7bad-4830-b440-85e7340409b1"
      unitRef="shares">4444000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i632bf0fa5ba0416486006fab0ab828b1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtMy0xLTEtNTQy_086522d7-22f6-4fc5-9f88-b8c75ca49fe7"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtNS0xLTEtNTQy_d78e8be1-9d27-49fa-bbda-7e5014797d46"
      unitRef="usd">390533000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTQtMTEtMS0xLTU0Mg_9f20d5d9-c0bc-44af-a28b-48f36130a8dd"
      unitRef="usd">390577000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib1dfb5f7e7ba4d169dd7771f1e2014a0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTUtNS0xLTEtNTQy_3c35e2c8-6a64-4a56-a159-f35d5fc2af6d"
      unitRef="usd">30798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTUtMTEtMS0xLTU0Mg_be146674-36c4-4576-be04-b59f48b03ac0"
      unitRef="usd">30798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9fd48e7dae264b53b2ee1bacea526327_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTYtNy0xLTEtNTQy_71da63b0-cb3b-4a6f-859e-0efe0b2b9738"
      unitRef="usd">-2978000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTYtMTEtMS0xLTU0Mg_78ed8170-958c-4d9d-9483-3c0fe377703b"
      unitRef="usd">-2978000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5a53da1f63ae4fd38c49af1968eb03e4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTctOS0xLTEtNTQy_49984ca0-4402-4110-98b1-bff7d6cb96e2"
      unitRef="usd">-219481000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i480d97ec647f4a6fa3367a13401e0900_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTctMTEtMS0xLTU0Mg_86ee08cc-d585-488d-bd95-0ceb588c59e1"
      unitRef="usd">-219481000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e1d8229c0cc4d28a3d73367d8687475_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtMS0xLTEtNTU4_a020572f-a3dd-4702-9421-d57f0ed43ec2"
      unitRef="shares">111114000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3e1d8229c0cc4d28a3d73367d8687475_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtMy0xLTEtNTQy_9533f997-2711-4ddc-a438-962cfca49b6e"
      unitRef="usd">1110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29880daf69f1436f8c9e07a5d1f26e39_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtNS0xLTEtNTU4_07ab0a13-7d76-461a-9644-50a84d6ccf85"
      unitRef="usd">5034284000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f06f86af24b4bb8b2e3262a34d11cd3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtNy0xLTEtNTQy_00901bbe-3105-4e2a-bceb-9087b70348a9"
      unitRef="usd">-35831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa8e567ccacd4802a6318a2e2c459b14_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtOS0xLTEtNTQy_c4bad202-48e0-4615-ba61-c9e4672b75e1"
      unitRef="usd">-3242368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1f18bc840ab43f281968996981ebe97_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTgtMTEtMS0xLTU0Mg_b44e8850-859e-4600-a609-d3478e294519"
      unitRef="usd">1757195000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktMS0xLTEtNTc1NQ_7b4fd297-fc0e-4808-a903-23e86e383c9a"
      unitRef="shares">191000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktMy0xLTEtNTQy_6e8d9887-d965-4cda-ad70-6d5c2f84c79f"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktNS0xLTEtNTc2Nw_74ad6e7f-98fe-4615-a09f-83ca3e1e6e72"
      unitRef="usd">9298000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMTktMTEtMS0xLTU0Mg_57845b48-6636-4861-be1b-63ee0ac54050"
      unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjAtMS0xLTEtNTc1OA_a1951ee6-144d-469d-99c2-fc06e74e8701"
      unitRef="shares">6000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtMS0xLTEtNTQy_b20ff0d5-d7e3-4a3b-9de4-686df1cd913a"
      unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i4c097b560b7348469ad0668ca30ae2c2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtMy0xLTEtNTQy_7ec3a149-f796-40d5-9d37-aa0aad41073d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtNS0xLTEtNTc3Mw_45f94e3d-8c47-4fb2-8265-04a796adf8c3"
      unitRef="usd">1001000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjEtMTEtMS0xLTU0Mg_225a4b42-1017-4587-a2cd-3824f5ed6d48"
      unitRef="usd">1002000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic98f393b510c46efa71e513979d5cfaf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjMtNS0xLTEtNTQy_4c65c43d-13db-4a6f-a67e-6687afc13400"
      unitRef="usd">46665000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjMtMTEtMS0xLTU0Mg_987ff9c4-fe9d-4347-8ffb-6c4068b4cf5b"
      unitRef="usd">46665000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i092004fdf6b04a69ac3ae56810e7b8ef_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjQtNy0xLTEtNTQy_5951a26e-a4fa-43e8-a702-846cfd414b76"
      unitRef="usd">1460000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjQtMTEtMS0xLTU0Mg_ae85a9c4-be9d-42e1-a265-232634316c80"
      unitRef="usd">1460000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0ca4e4838440486c8f5a7b55f1575484_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjUtOS0xLTEtNTU4_8dd57d72-e299-42bd-a20a-818802a9b06a"
      unitRef="usd">-208535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjUtMTEtMS0xLTU1OA_6cc4cf39-0165-4f2c-a6ae-ddd1a0c5d35c"
      unitRef="usd">-208535000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i875fbab980f042debc104cf45c8ae36a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtMS0xLTEtNTU4_a390f01e-ab3c-4ea0-93cc-156304abd6f7"
      unitRef="shares">111325000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i875fbab980f042debc104cf45c8ae36a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtMy0xLTEtNTU4_427e88bc-ef34-408c-acb6-ba09e673e21d"
      unitRef="usd">1113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1efbe15735524508ab0312ffd4616e7b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtNS0xLTEtNTU4_c560c2a0-02c4-4a15-a925-0590adbecd44"
      unitRef="usd">5091248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i051b47be2e4f44b18624cfd7fb7d1e52_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtNy0xLTEtNTU4_574654a2-e610-432a-b730-dce70c5b2d1d"
      unitRef="usd">-34371000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia10915d8296543898e5c6c6185f06b70_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtOS0xLTEtNTU4_0598eb5a-e3c9-4367-b3bf-84c4e7d12d28"
      unitRef="usd">-3450903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOjE4ODAzYzBkNGUwNTRlNjc4Zjg5MTI4MjM0MWU1NzFiL3RhYmxlcmFuZ2U6MTg4MDNjMGQ0ZTA1NGU2NzhmODkxMjgyMzQxZTU3MWJfMjYtMTEtMS0xLTU1OA_8575a108-a470-43a5-af70-01658c7dc6ae"
      unitRef="usd">1607087000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8a18a2febb21461088839dc562e86825_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi0xLTEtMS01MDk_2d0660a8-8d03-4225-9d73-b7d1894142b9"
      unitRef="shares">99667000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8a18a2febb21461088839dc562e86825_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi0zLTEtMS01MDk_3112bd12-5230-4449-829a-a77c1408455d"
      unitRef="usd">997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i000b407bc82d4af584eae0ea4da200e8_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi01LTEtMS01MDk_b6afaea0-5d26-4aef-9c42-bfaac8422078"
      unitRef="usd">3947552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dda98ef75fa4c0cabaec8f6917de928_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi03LTEtMS01MDk_9ef76488-ce91-4592-b970-7a5e2d8cf9be"
      unitRef="usd">-34433000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8260434ced747a89db3a4a3760f382a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi05LTEtMS01MDk_adc2aa08-59a5-4259-a640-b40e48154825"
      unitRef="usd">-2147685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icdb8b45ba98c4ea79afcd93e804e2e31_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMi0xMS0xLTEtNTA5_d9ec4da6-de8f-4dff-930e-def00b5619ed"
      unitRef="usd">1766431000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="i00290d9a0ceb4932b342087b2d02c362_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMy05LTEtMS01MDk_65953dc4-6344-4042-9af9-2293462b7542"
      unitRef="usd">68210000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMy0xMS0xLTEtNTA5_bd5dced0-73ac-45b4-9fed-b18f822dea41"
      unitRef="usd">68210000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC0xLTEtMS01MDk_fea64371-b778-4a1a-ab18-a79710aff578"
      unitRef="shares">795000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC0zLTEtMS01MDk_dfa8ced9-2fe3-40c4-89be-0b546db6737c"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC01LTEtMS01MDk_5534cae7-8901-4e64-b18b-ccf21bfacd49"
      unitRef="usd">41882000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNC0xMS0xLTEtNTA5_ea9912ab-0a4c-4cbc-9017-bf8f6c5ba133"
      unitRef="usd">41890000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNS0xLTEtMS01MDk_51ad22b7-16f8-4850-95a0-6f8b4a476bb1"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNS01LTEtMS01MDk_c8218906-cd83-48bf-8f7e-0f7d34f40556"
      unitRef="usd">-123000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNS0xMS0xLTEtNTA5_69fa89ec-736c-49e6-852f-7adafa9d1560"
      unitRef="usd">-123000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="ica6174c3bf6b4003b63f4246e38d451d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNi0xLTEtMS01MDk_1e9d7193-ee93-4382-b539-7db4ec7e38a8"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNi01LTEtMS01MDk_94fac340-6951-42d5-b0ff-c3e409a48555"
      unitRef="usd">568000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNi0xMS0xLTEtNTA5_5301ea2d-a9df-4b0d-bce1-06bb51daf19a"
      unitRef="usd">568000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if51590640cc3445e8236acd0882c53a5_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNy01LTEtMS01MDk_023a7d0f-0bed-4361-9b15-5361b8bc07cf"
      unitRef="usd">19463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfNy0xMS0xLTEtNTA5_904a12d2-22be-43b7-9795-44c8f78da42d"
      unitRef="usd">19463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib6b902bb76314b22b35d3d375909326c_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOC03LTEtMS01MDk_3e368fca-0286-48b9-a14e-3e1da05eedfb"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOC0xMS0xLTEtNTA5_1cd95c7a-6b80-447b-bee0-38b5513c7fef"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i00290d9a0ceb4932b342087b2d02c362_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOS05LTEtMS01MDk_20c39494-c21c-4176-8337-3e7df91d71e9"
      unitRef="usd">-141214000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia298b62308334655b29761118e628026_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfOS0xMS0xLTEtNTA5_d2730a4c-711a-4a12-9a02-f2b055106bd4"
      unitRef="usd">-141214000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i017bcda5f3f84bd0b08d262246dc8609_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtMS0xLTEtNTA5_d0769e88-c528-4467-9709-8eb17134e377"
      unitRef="shares">100468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i017bcda5f3f84bd0b08d262246dc8609_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtMy0xLTEtNTA5_4032e454-7b52-40fb-b540-18d1306b9b5b"
      unitRef="usd">1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c9375ef392e4486bbab8ee684ac7c28_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtNS0xLTEtNTA5_8c846c0b-7276-42e1-b971-2ab529c0470e"
      unitRef="usd">4009342000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c50c0a9426f4d279cde7bc33c6203d6_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtNy0xLTEtNTA5_35884b9b-fb66-49c2-817c-be12c0eb7d8f"
      unitRef="usd">-34853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cb5c2da414142a58bef1ad8643452f0_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtOS0xLTEtNTA5_4b08cc5f-8042-4921-a871-36996e37e8ec"
      unitRef="usd">-2220689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d9c4ad3ea6f43f8b03c5853acc51d01_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTAtMTEtMS0xLTUwOQ_ca26a6fe-088d-40c4-b8b5-e2eb84803033"
      unitRef="usd">1754805000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTEtMS0xLTEtNTA5_a91f37d8-701e-4229-b14b-d7be4124580a"
      unitRef="shares">53000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTEtNS0xLTEtNTA5_32a93571-ddf4-4c77-be7a-349fe66000bd"
      unitRef="usd">2561000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTEtMTEtMS0xLTUwOQ_9c7ada6c-9223-4199-96cb-c74b55898a6f"
      unitRef="usd">2561000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTItMS0xLTEtNTA5_0456ce41-ceb1-4125-8926-abe789569371"
      unitRef="shares">41000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTItNS0xLTEtNTA5_07777a72-ddbb-4005-89c9-3401e2e0427c"
      unitRef="usd">3124000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTItMTEtMS0xLTUwOQ_14ccb239-7091-4ca6-89e1-15b230964bb6"
      unitRef="usd">3124000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="ib01b3ec58427484795b7bb140e2a858f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTMtMS0xLTEtNTA5_77422cdb-09ac-4560-931b-6d5fc2002686"
      unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTMtNS0xLTEtNTA5_6412106a-477b-4bf0-b8dd-a7f9d67e0a91"
      unitRef="usd">829000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTMtMTEtMS0xLTUwOQ_866ac059-21c0-404c-b96f-9b9e801975c8"
      unitRef="usd">829000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b13c4e1d12349159516d7efe400472f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTQtNS0xLTEtNTA5_3a241fe4-d3d6-49ec-94db-8ae09b327bb0"
      unitRef="usd">21997000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTQtMTEtMS0xLTUwOQ_f7dd5e96-1136-4ffc-b25c-53e8be01c1dc"
      unitRef="usd">21997000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60ed32556e304de6860f08c6da60b133_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTUtNy0xLTEtNTA5_8b4847e5-270f-4d68-9447-682ed3416d95"
      unitRef="usd">1046000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTUtMTEtMS0xLTUwOQ_91016200-3f26-4ec7-a478-7e53c0bc2eb9"
      unitRef="usd">1046000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic604e629a18e47f48644038e508838aa_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTYtOS0xLTEtNTA5_592f7f4c-9470-4bf6-9e7e-84f71e6ca179"
      unitRef="usd">-163560000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibc3c4b1b5f294a8cbb0eba651ed320ec_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTYtMTEtMS0xLTUwOQ_0eaa0402-3cf9-4202-9c19-9725b6fe2f4d"
      unitRef="usd">-163560000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if084fb52c6fd4a039d5f4dc8424a4453_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctMS0xLTEtNTA5_43a2b922-3ab7-490d-aaf3-b97557448472"
      unitRef="shares">100569000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if084fb52c6fd4a039d5f4dc8424a4453_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctMy0xLTEtNTA5_e1722aaa-3f96-482a-bf34-25ce43ac3876"
      unitRef="usd">1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i079b65915ef04049ab59dcf69c973f75_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctNS0xLTEtNTA5_71f9f1f6-996d-4676-b610-42c3abb70291"
      unitRef="usd">4037853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iade6d453882449f8b0ad8daf7e4d39e5_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctNy0xLTEtNTA5_2ddf674d-e984-4a75-a9f7-17a40b8b5755"
      unitRef="usd">-33807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a8833025058462db2992db44ec3934e_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctOS0xLTEtNTA5_2df1cdeb-e393-4fa4-ba50-048491b431d1"
      unitRef="usd">-2384249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibddc1e81c5e54e42822e1311df259ceb_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTctMTEtMS0xLTUwOQ_7ff81dc1-7f95-4767-9b62-862d95993d76"
      unitRef="usd">1620802000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtMS0xLTEtMzg4Nw_2a864fac-1360-44a1-891d-aa9e9cc06130"
      unitRef="shares">261000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtMy0xLTEtNTA5_710848a6-ff05-41eb-9e16-46b972da367e"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtNS0xLTEtNTgwMQ_c3ff0d8c-4c02-4e79-b0e1-ff1bdd4ebcae"
      unitRef="usd">13494000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTgtMTEtMS0xLTUwOQ_56cf21c1-3adf-4ed1-84c4-89037d1d2166"
      unitRef="usd">13497000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktMS0xLTEtMzg4Nw_f7309858-6fc1-45ee-a64e-c1dee788dbd1"
      unitRef="shares">130000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktMy0xLTEtNTA5_6b9778f2-36cf-423b-af1e-0fd5fd9dfc91"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktNS0xLTEtNTgwNA_84a967d1-e37b-4dff-8afe-1da4f3e4c7fa"
      unitRef="usd">-546000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMTktMTEtMS0xLTUwOQ_938f6d42-a146-441c-b360-fe038a7be08f"
      unitRef="usd">-545000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="ief21c0d90240476b8922ccee38864765_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjAtMS0xLTEtMzg4OA_4400500e-7366-4549-942b-69ce25188a0c"
      unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjAtNS0xLTEtNTgwNw_c06628d1-0736-47fb-b5cc-56116bad5181"
      unitRef="usd">820000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjAtMTEtMS0xLTUwOQ_cdfa4afa-cc60-43ba-92a1-22333b0d4db0"
      unitRef="usd">820000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie10dd549a66a49738a2f1dfb13320661_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjEtNS0xLTEtNTgxMA_cc4099f3-fa9a-4268-a294-26fb335bda2c"
      unitRef="usd">88412000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjEtMTEtMS0xLTUwOQ_f2952f8a-e177-4fca-96d1-0606e2d7ede4"
      unitRef="usd">88412000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1a3e88d620de4614b17853b7a58ca2e2_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjItNy0xLTEtNTgxMw_09961051-62e2-4a4b-b4e2-5d0de782d80c"
      unitRef="usd">415000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjItMTEtMS0xLTUwOQ_4a7947a6-a668-43ba-be34-2ac7e9fd6961"
      unitRef="usd">415000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8b36842a761546ef807e31ee2522a096_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjMtOS0xLTEtNTA5_48e2e59f-4049-4a97-bee2-d2cf0dfee403"
      unitRef="usd">-245282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjMtMTEtMS0xLTUwOQ_f81142e1-6645-4a27-835d-be31f1d2e73c"
      unitRef="usd">-245282000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5ef4dd7f09d947d493d5f4436cf0c0e9_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtMS0xLTEtNTA5_4c82fc38-89c1-4762-a8d7-cfce3551d98c"
      unitRef="shares">100968000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5ef4dd7f09d947d493d5f4436cf0c0e9_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtMy0xLTEtNTA5_30e8f9ca-3ced-49d3-90fa-cf19f9f3af90"
      unitRef="usd">1009000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib15fa7b634fd4daea03b505c756c59bd_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtNS0xLTEtNTA5_d07b500a-8e75-4c5e-be18-000d42bb31a3"
      unitRef="usd">4140033000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb493b807d924cf39624accb949af88c_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtNy0xLTEtNTA5_1012f06c-c59a-4911-91fd-30e0bec32d78"
      unitRef="usd">-33392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5a7aaddfaf542bbbf7a06985850a41f_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtOS0xLTEtNTA5_8e9f1e19-fac8-4608-8cbf-1eb0867a185c"
      unitRef="usd">-2629531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yNS9mcmFnOmI1ZTMwMTBmNGMyNjQ5ZGZhZmYwZjBjZTkzMzJlZWZlL3RhYmxlOmI4NTk5MGJhZTdkMzQ5NmFiM2I3ZjM1NDliYzQxNGE2L3RhYmxlcmFuZ2U6Yjg1OTkwYmFlN2QzNDk2YWIzYjdmMzU0OWJjNDE0YTZfMjQtMTEtMS0xLTUwOQ_daa014e1-4174-4d4d-968d-3dd81f16b25c"
      unitRef="usd">1478119000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMy0xLTEtMS0w_b0688925-5369-40f8-b369-79b576314b2a"
      unitRef="usd">-609931000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMy0zLTEtMS0w_6b0bacf8-55ad-42b2-8cc7-980fb2f5c06a"
      unitRef="usd">-550056000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNS0xLTEtMS0w_ca515ddf-75a9-499e-be5b-9bc5f8a7495f"
      unitRef="usd">11733000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNS0zLTEtMS0w_9ebce384-6e99-44b3-aed2-37a489682ca5"
      unitRef="usd">5822000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <alny:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0xLTEtMS02NDE5_cfe6ae32-46d6-43c8-ba21-bf6ba92e3b81"
      unitRef="usd">27873000</alny:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <alny:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0zLTEtMS02NDIy_24e7ab7b-9756-4916-8fa9-bef6e0b0832b"
      unitRef="usd">0</alny:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <us-gaap:ShareBasedCompensation
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0xLTEtMS0w_7a049103-7bce-45f4-86a7-df558010a19f"
      unitRef="usd">108644000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNi0zLTEtMS0w_f7951162-7906-4553-ae8e-2d14b4f35804"
      unitRef="usd">129779000</us-gaap:ShareBasedCompensation>
    <alny:NonCashGainOnLitigationSettlement
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNy0xLTEtMS0w_2183137a-87f5-442c-8c94-d2866401d5ff"
      unitRef="usd">0</alny:NonCashGainOnLitigationSettlement>
    <alny:NonCashGainOnLitigationSettlement
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfNy0zLTEtMS0w_e36b5db5-db50-4fbb-b8ea-3b4b851a51e0"
      unitRef="usd">10000000</alny:NonCashGainOnLitigationSettlement>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOC0xLTEtMS0w_6033300e-2377-4b41-9149-bc506cbabddd"
      unitRef="usd">3268000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOC0zLTEtMS0w_e5d2d5b1-0328-4160-b90a-8bee995e7d0c"
      unitRef="usd">3612000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOS0xLTEtMS0w_3fbfff12-ab8d-4120-93f3-73bcf3e5a129"
      unitRef="usd">9422000</alny:ChangeInFairValueOfLiabilityObligation>
    <alny:ChangeInFairValueOfLiabilityObligation
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfOS0zLTEtMS0w_c7ebaab4-59ec-4974-9d13-71a30d256be5"
      unitRef="usd">0</alny:ChangeInFairValueOfLiabilityObligation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTEtMS0xLTEtMA_2e678d17-493c-4b32-814f-198bacfdc430"
      unitRef="usd">-4415000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTEtMy0xLTEtMA_8257a70d-4d21-4e93-b981-26b483c0c8f1"
      unitRef="usd">-2163000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTMtMS0xLTEtMA_20027108-7cb2-402e-a9c0-dbec38d091a3"
      unitRef="usd">29717000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTMtMy0xLTEtMA_402fedda-c071-4008-a8e9-ff742a04bcda"
      unitRef="usd">-30640000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMS0xLTEtODY4Ng_958be091-b251-4d46-b19a-fb6bc53defa7"
      unitRef="usd">-29064000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMy0xLTEtODY4Ng_79b67be6-f592-4f15-9b9e-21732cdc3fbd"
      unitRef="usd">-11597000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMS0xLTEtMA_6ba18211-de8b-4550-85d9-37c0e5bec1b3"
      unitRef="usd">28095000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTUtMy0xLTEtMA_554af603-f969-4ab6-bcb1-56655d63cb00"
      unitRef="usd">10354000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTYtMS0xLTEtMA_7b5256a1-53c9-4857-bfc3-302e385b9b6e"
      unitRef="usd">13662000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTYtMy0xLTEtMA_483cd071-52e5-4f3e-9f62-55d5b928b476"
      unitRef="usd">34125000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTctMS0xLTEtMA_7730fec4-92d8-490e-9af7-1dd0f8bed389"
      unitRef="usd">-3719000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTctMy0xLTEtMA_095c2bab-da8f-43f4-a66d-c56d418fead1"
      unitRef="usd">-650000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTgtMS0xLTEtMA_5d42ec3e-7aa0-4d37-9942-638115a66732"
      unitRef="usd">36348000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTgtMy0xLTEtMA_2f169da0-b89c-43d1-a64e-b777c7fa9b53"
      unitRef="usd">25242000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTktMS0xLTEtMA_0a236150-d4b5-432b-a716-793278ca6299"
      unitRef="usd">399584000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMTktMy0xLTEtMA_1842b880-bf0c-465c-afc4-9812fd93757c"
      unitRef="usd">-11503000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjAtMS0xLTEtMA_a919fe6d-6fec-4a07-b101-af7654968671"
      unitRef="usd">-82447000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjAtMy0xLTEtMA_cc512e3f-ff04-42ab-91bc-69dc0ee3fdb6"
      unitRef="usd">-412159000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjItMS0xLTEtMA_63d8504a-303b-4b36-a921-5eceb8ca9575"
      unitRef="usd">101351000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjItMy0xLTEtMA_8ce1d058-ee22-441c-9b0b-6e83b2a4dbe9"
      unitRef="usd">89374000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjMtMS0xLTEtMA_9e033774-61b5-4496-8862-2aa4d3135abd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjMtMy0xLTEtMA_07edb91c-d1c5-4e59-a576-4a21ea356223"
      unitRef="usd">14825000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMS0xLTEtNjQzNA_da272b29-c4c0-4d99-9402-7c8056f101e0"
      unitRef="usd">30000000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMy0xLTEtNjQzNw_0108cb76-a72f-4b02-b300-2157c4c93097"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjQtMS0xLTEtMA_a56628e8-7e6f-4e66-81db-29650a347426"
      unitRef="usd">1445632000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjQtMy0xLTEtMA_f92a453c-f96a-4430-bb1e-814cbe14f820"
      unitRef="usd">992385000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMS0xLTEtMA_54998a5f-f915-4975-8aa6-ab7feff9a174"
      unitRef="usd">1320156000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjUtMy0xLTEtMA_dadbf003-7110-4428-b3db-797918d64feb"
      unitRef="usd">1120565000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjYtMS0xLTEtMA_7130f64d-8581-48a4-9464-638ee183f49c"
      unitRef="usd">-196827000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjYtMy0xLTEtMA_14665ec9-3df2-4d64-8b7d-016e610fa7ba"
      unitRef="usd">23981000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjgtMS0xLTEtMA_0cb14d32-8a83-4cc6-acb6-b002ac51a8c9"
      unitRef="usd">30942000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjgtMy0xLTEtMA_678a8fb1-32f9-4948-9e80-9d043e2b1685"
      unitRef="usd">60092000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzEtMS0xLTEtNjY2NQ_6f7dea3b-194c-4368-94a1-342cc2b104d9"
      unitRef="usd">30000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzEtMy0xLTEtNjY2NQ_072a903b-dbfe-4a95-a549-9ff328d6c94c"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjktMS0xLTEtMA_3c0950f9-e22b-4950-9236-a1068c04aac6"
      unitRef="usd">381900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMjktMy0xLTEtMA_d00a86b8-b689-46cb-a4e5-61d38516c788"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzAtMS0xLTEtMA_4f4a60cb-70d2-42f8-85bc-11610f294929"
      unitRef="usd">400000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzAtMy0xLTEtMA_0e77fadc-c79d-4896-991b-e6a06a8b57f6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzItMS0xLTEtMA_dc4cb18f-a113-45fa-a82f-97d8da28e523"
      unitRef="usd">782842000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzItMy0xLTEtMA_d1f468ad-1218-4a44-afed-8d860be98efd"
      unitRef="usd">60092000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzMtMS0xLTEtMA_a32c7e6b-1e6c-4589-a924-1125cc0f1c20"
      unitRef="usd">-449000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzMtMy0xLTEtMA_65c4ad32-c22d-4825-abb8-5883915f523b"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzQtMS0xLTEtMA_2806b09c-3476-4719-b90d-476b1b33c789"
      unitRef="usd">503119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzQtMy0xLTEtMA_6a379a0b-0135-41ce-a608-a4fe2bb3136b"
      unitRef="usd">-328086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzUtMS0xLTEtMA_777de41a-73f2-4477-abd5-ba281eb4071c"
      unitRef="usd">422631000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="icdb8b45ba98c4ea79afcd93e804e2e31_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzUtMy0xLTEtMA_9cc4e542-0217-4244-873b-bb24a7d65bd9"
      unitRef="usd">646832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzYtMS0xLTEtMA_0a6e71a5-df1e-4739-b51f-ebcb1cdfd469"
      unitRef="usd">925750000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzYtMy0xLTEtMA_c803b7e0-d29c-470d-98a1-174418dcb7c5"
      unitRef="usd">318746000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzgtMS0xLTEtMA_39f720ec-b994-4ee3-8ece-50da5d035584"
      unitRef="usd">18923000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8yOC9mcmFnOjMxYzk5MTNlNjEwZDRhYTQ4ZjBiM2VhY2FlNzEzMGZiL3RhYmxlOmUzMDY1YTY4YjIyNDQxYzM5ZDIyZDYwYTA1ZmE5ZjY2L3RhYmxlcmFuZ2U6ZTMwNjVhNjhiMjI0NDFjMzlkMjJkNjBhMDVmYTlmNjZfMzgtMy0xLTEtMA_939260e7-5dfc-4011-9133-4eb8045402ca"
      unitRef="usd">19739000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNC9mcmFnOmNhYTYyNDg1Y2FiNDQ3MTY5ZGRjMGVlMDZkYjFhMDMzL3RleHRyZWdpb246Y2FhNjI0ODVjYWI0NDcxNjlkZGMwZWUwNmRiMWEwMzNfODI0NjMzNzIxMDM2MQ_38a0804d-739e-4e76-a7cf-601fccb7cc72">NATURE OF BUSINESS&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, commercial biopharmaceutical company with a sustainable pipeline of RNAi therapeutics to address the needs of patients who have limited or inadequate treatment options. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. In August 2018, we received approval for ONPATTRO&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; (patisiran), our first product, from the United States Food and Drug Administration and began commercializing and generating product revenues in the U.S. In October 2018, we began commercializing and generating product revenues outside of the U.S. and, as of September 30, 2019, we have launched ONPATTRO in Japan, Canada and in several countries in Europe. Regulatory filings in additional markets in Europe and elsewhere are pending or planned for the remainder of 2019 and beyond.&lt;/span&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzY5NjU4MTQwMjY1MQ_5158dbbf-4c4d-45a4-800d-4868b2146423">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2018, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 14, 2019. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018.&#160;Updates to our significant accounting policies, including the updated lease accounting policy due to the adoption of the new leasing accounting standard, are discussed below and under &#x201c;Recent Accounting Pronouncements.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable debt securities as of September&#160;30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to enable us to advance our &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Alnylam 2020&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We determine whether a contract is, or contains, a lease at inception. We classify each of our leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the condensed consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.&#160;Costs determined to be variable and not based on an index or rate are not included in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. We record expense to recognize fixed lease payments on a straight-line basis over the expected lease term. We have elected the practical expedient not to separate lease and non-lease components for real estate leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board, or FASB, issued a new leasing standard which generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the condensed consolidated balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new standard on January 1, 2019, using a modified retrospective basis and did not restate comparative periods. In addition, we did not elect the package of practical expedients permitted under the transition guidance that permits companies to carry forward prior conclusions related to (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. All our leases have been classified as operating leases under the new leasing standard.&#160;We elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the condensed consolidated balance sheets and recognize the associated lease payments in the condensed consolidated statements of comprehensive loss on a straight-line basis over the lease term. Please read Note 8 for additional disclosures related to accounting for leases under this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The adoption of ASC 842 had a material impact on our condensed consolidated balance sheet as the standard requires us to measure and recognize a right of use asset and lease liability.&#160;As most leases do not provide an implicit rate, our incremental borrowing rate was determined based on the information available at the date of adoption to measure our lease liability.&#160;Costs determined to be variable and not based on an index or rate were not included in the measurement of the lease liability.&#160;We recognized approximately $290.0 million of operating lease liabilities and approximately $230.0 million of operating lease right-of-use assets on our condensed consolidated balance sheet as of January 1, 2019, which are presented as separate line items on the condensed consolidated balance sheet.&#160;Had we not adopted the new leasing standard, we would not have had operating lease right-of-use assets or operating lease liabilities on our condensed consolidated balance sheet. The adoption of the standard did not have a material impact on our condensed consolidated statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued a new standard which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2017, the FASB issued a new standard that amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date.&#160;The new standard became effective for us on January 1, 2019. This standard did not have a significant impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued amendments that eliminate, add and modify certain disclosure requirements on fair value measurements. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued new accounting guidance to clarify the accounting for implementation costs in cloud computing arrangements (hosting arrangements). The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued guidance to clarify the interaction between the accounting guidance for collaborative arrangements and revenue from contracts with customers. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption, including adoption in any interim period, is permitted. This &lt;/span&gt;&lt;/div&gt;guidance is required to be applied retrospectively as of the date of our adoption of the new revenue standard on January 1, 2018. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzY5NjU4MTQxMzcyNg_a977bf96-76dd-41e0-9353-1c6c74b71ef4">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2018, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 14, 2019. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018.&#160;Updates to our significant accounting policies, including the updated lease accounting policy due to the adoption of the new leasing accounting standard, are discussed below and under &#x201c;Recent Accounting Pronouncements.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxOQ_89d45a83-ce3e-44f9-b489-cdadffde89cb">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <alny:LiquidityPolicyTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxNA_6f3ef34f-8c78-41f5-8ae3-08729ec610cf">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable debt securities as of September&#160;30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to enable us to advance our &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Alnylam 2020&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</alny:LiquidityPolicyTextBlock>
    <alny:LeasesPolicyPolicyTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxNQ_52ccbe41-4aff-49b4-aa14-3445697a350f">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We determine whether a contract is, or contains, a lease at inception. We classify each of our leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the condensed consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.&#160;Costs determined to be variable and not based on an index or rate are not included in &lt;/span&gt;&lt;/div&gt;the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. We record expense to recognize fixed lease payments on a straight-line basis over the expected lease term. We have elected the practical expedient not to separate lease and non-lease components for real estate leases.</alny:LeasesPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNzkxNg_0b120b24-050f-4bcd-a8be-edd04d42fe38">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board, or FASB, issued a new leasing standard which generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the condensed consolidated balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new standard on January 1, 2019, using a modified retrospective basis and did not restate comparative periods. In addition, we did not elect the package of practical expedients permitted under the transition guidance that permits companies to carry forward prior conclusions related to (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. All our leases have been classified as operating leases under the new leasing standard.&#160;We elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the condensed consolidated balance sheets and recognize the associated lease payments in the condensed consolidated statements of comprehensive loss on a straight-line basis over the lease term. Please read Note 8 for additional disclosures related to accounting for leases under this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The adoption of ASC 842 had a material impact on our condensed consolidated balance sheet as the standard requires us to measure and recognize a right of use asset and lease liability.&#160;As most leases do not provide an implicit rate, our incremental borrowing rate was determined based on the information available at the date of adoption to measure our lease liability.&#160;Costs determined to be variable and not based on an index or rate were not included in the measurement of the lease liability.&#160;We recognized approximately $290.0 million of operating lease liabilities and approximately $230.0 million of operating lease right-of-use assets on our condensed consolidated balance sheet as of January 1, 2019, which are presented as separate line items on the condensed consolidated balance sheet.&#160;Had we not adopted the new leasing standard, we would not have had operating lease right-of-use assets or operating lease liabilities on our condensed consolidated balance sheet. The adoption of the standard did not have a material impact on our condensed consolidated statement of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued a new standard which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2017, the FASB issued a new standard that amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date.&#160;The new standard became effective for us on January 1, 2019. This standard did not have a significant impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued amendments that eliminate, add and modify certain disclosure requirements on fair value measurements. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued new accounting guidance to clarify the accounting for implementation costs in cloud computing arrangements (hosting arrangements). The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued guidance to clarify the interaction between the accounting guidance for collaborative arrangements and revenue from contracts with customers. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption, including adoption in any interim period, is permitted. This &lt;/span&gt;&lt;/div&gt;guidance is required to be applied retrospectively as of the date of our adoption of the new revenue standard on January 1, 2018. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNTc0Ng_141a53e5-e662-4ffb-8c3d-94e63fde6029"
      unitRef="usd">290000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8zNy9mcmFnOmFjZDFhYjRjNmViMzRkYTFiOTZjMzg0ZDNjZTU1NDc4L3RleHRyZWdpb246YWNkMWFiNGM2ZWIzNGRhMWI5NmMzODRkM2NlNTU0NzhfNTc5OA_5f7ff493-9758-4359-ab9a-7d2b35704c07"
      unitRef="usd">230000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfNzY5NjU4MTM5NDcxNw_d762a457-288d-481c-8c9a-6cc003cb12bb">PRODUCT REVENUES, NET&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Net product revenues (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.684211%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Product Revenues, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019 and December&#160;31, 2018, net product revenue related receivables of $20.0 million and $13.1 million, respectively, were included in &#x201c;Accounts receivable, net.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfMjM2_027ea59d-2733-4b31-a1ec-8e439d039cd7">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Net product revenues (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.684211%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Product Revenues, Net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c54b97117a54dc9a2281403a9143f40_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi0xLTEtMS0w_82641eb6-41bf-4d65-ac27-fde38598aa08"
      unitRef="usd">33591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20a7f979d1744d46907e2fe5ef13d747_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi0zLTEtMS0w_4a3f5dd8-dc47-415d-81bb-fe838233bc0e"
      unitRef="usd">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib666c190ab3a4d4aa6556b9c46d1eb1d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi01LTEtMS0w_f401784b-5ad7-4d44-8f54-22712f671a98"
      unitRef="usd">80543000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49ad1e878ba7413bba91fe1bdec91294_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMi03LTEtMS0w_e85fbb22-624a-48d7-828f-fe9ac2040930"
      unitRef="usd">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d5fc643144f4f66a3f3e5fbd015f089_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy0xLTEtMS0w_b81e5476-3a37-410c-8112-d04062abed25"
      unitRef="usd">12475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54e5da0497604cffa89334d054aa8689_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy0zLTEtMS0w_30b9d837-0ec4-4e3e-8330-7766d92cf584"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47bf377672994a6989a0ffc4fda88279_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy01LTEtMS0w_f6604e8e-f7e3-440d-901a-c18d6114e588"
      unitRef="usd">30045000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6977f9771bb9474f9b987ea4acb6e766_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfMy03LTEtMS0w_19d1b115-71a7-4640-9655-1242f8830434"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd31099009a341cebcc213b46e1c6c76_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC0xLTEtMS0w_de7fe889-becd-42d0-8b01-ed4752f63147"
      unitRef="usd">46066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i290fb1f9477f4b0dad6a294dbebe5fe0_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC0zLTEtMS0w_c72c1e12-8c46-441c-89d2-60d1e9cf013e"
      unitRef="usd">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica700222a11442d3b8b92d9f887edb3c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC01LTEtMS0w_8b0511fe-75d9-4194-9fa9-b5dbc350d2f0"
      unitRef="usd">110588000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e4b5651a52648659bb33699e1f159aa_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RhYmxlOjYyM2E5MTQ5Y2RhZjQ0MDE5NTYwMWE4ZjA4MmUyOTAyL3RhYmxlcmFuZ2U6NjIzYTkxNDljZGFmNDQwMTk1NjAxYThmMDgyZTI5MDJfNC03LTEtMS0w_4e3a7929-0b2a-4b4a-b25f-40c62a888ab5"
      unitRef="usd">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia58cef5166244621bfaed56c877e6047_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfMTY3_10f7b5ab-2de8-4689-a5db-990c1366e06e"
      unitRef="usd">20000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i76fea3f3c89e4d38be0558a94f330d68_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80My9mcmFnOjgyN2RmZjA0ZDE3YTQ2NThiMmE4ZDRmOGQ2MTk2MWMzL3RleHRyZWdpb246ODI3ZGZmMDRkMTdhNDY1OGIyYThkNGY4ZDYxOTYxYzNfMTc0_e7c4b877-dc65-4bd3-b3ef-6aa91bcde58b"
      unitRef="usd">13100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzY5NjU4MTQyMTcyOA_17fcec0f-44fe-4d87-b9ea-620979574edd">COLLABORATION AGREEMENTS&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Net revenues from collaborators (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.929825%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir Biotechnology (Vir)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;The Medicines Company (MDCO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues from collaborators&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.029412%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.029412%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities included in &#x201c;Deferred revenue&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and nine months ended September&#160;30, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.794118%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.735294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.735294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts included in contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables provide the research and development expenses incurred by type that are directly attributable to our collaboration agreements by our collaboration partners for the periods indicated, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.597365%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trial and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;External services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.707602%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trial and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;External services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The research and development expenses incurred for each agreement listed in the tables above consist of costs incurred for external development and manufacturing services for which we are reimbursed and licensing payments made to the counterparty to such agreement. In addition, these expenses include a reasonable estimate of compensation and related costs as billed to our counterparties. As part of our revenue recognition policy adopted on January 1, 2018, the costs in the above table are considered an input in our determination of transaction price when they relate to consideration received for the delivery of goods or services. For the three and nine months ended September&#160;30, 2019 and 2018, we did not incur material selling, general and administrative expenses related to our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Regeneron Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On April&#160;8, 2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019, or the Effective Date. Upon closing of the Stock Purchase Agreement dated April 8, 2019, referred to as the Regeneron SPA, we issued 4,444,445 shares of common stock to Regeneron for aggregate cash consideration of $400.0 million, or $90.00 per share.&#160;Please read Note 10 for a full discussion regarding the Regeneron SPA. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 siRNA currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#x2019;s pozelimab (REGN3918), currently in Phase 1 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Regeneron Collaboration, we will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial five-year research period, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional two years, for a research term extension fee of up to $400.0 million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously-announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-directed clinical and preclinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Regeneron will lead development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron will alternate leadership on CNS and liver programs, with the lead party retaining global development and commercial responsibility. For CNS and liver programs, both we and Regeneron will have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#x201c;Licensee&#x201d; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#x201c;Licensee&#x201d; for the purposes of the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Under the C5 co-co collaboration agreement, we and Regeneron equally share costs and potential future profits on any monotherapy program. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $325.0 million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $400.0 million. We are also eligible to receive up to an additional $200.0 million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to 30 targets under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, with the potential for approximately $30.0 million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#x2019; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $150.0 million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Separately, the cemdisiran monotherapy co-co collaboration agreement is under the scope of ASC 808 as we and Regeneron are both active participants in the development and manufacturing activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The development and manufacturing activities are a combined unit of account under the scope of ASC 808 and are not deliverables under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The total transaction price is comprised of the&#160;$400.0 million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain ocular, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467836%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.906585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.412557%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.836141%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.412557%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.836141%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.331394%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.664625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Standalone Selling Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:0.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:95%;"&gt;ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;364,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;521,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:14.619883%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:98.000000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, the expected number of targets or indications expected to be pursued under each license, the probability of success, and the time needed to develop a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;For the Research Services Obligation and the C5 License Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period and during the quarter ended September 30, 2019, the transaction price increased $18.5 million from $521.6 million as of June 30, 2019 to $540.1 million as of September 30, 2019 resulting from additional variable consideration we expect to receive. For the C5 Co-Co Obligation accounted for under ASC 808, the transaction price allocated to this obligation is recognized using a &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;proportional performance method. Revenue recognized under this agreement, inclusive of the amount allocated to the C5 Co-Co Obligation and future cost reimbursements, is accounted for as collaboration revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.491228%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.454545%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.181818%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.969697%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.818182%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.272727%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.272727%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue Recognized During&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;402,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of&#160;September&#160;30, 2019, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation and C5 License Obligation that was unsatisfied is&#160;$279.8 million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. This amount excludes the transaction price allocated to the C5 Co-Co Obligation accounted for under ASC 808. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sanofi Genzyme Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaboration Amendment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On April&#160;8, 2019, we and Sanofi Genzyme entered into an amendment to our 2014 Sanofi Genzyme collaboration, which we refer to as the Collaboration Amendment.&#160;Under the Collaboration Amendment, we and Sanofi Genzyme agreed to conclude the research and option phase under our collaboration agreement. In connection and simultaneously with entering into the Collaboration Amendment, we and Sanofi Genzyme also entered into the Amended and Restated ALN-AT3 Global License Terms with respect to ALN-AT3 (fitusiran) and certain back-up products, which we refer to as the A&amp;amp;R AT3 License Terms. The A&amp;amp;R AT3 License Terms amend and restate the ALN-AT3 Global License Terms entered into by us and Sanofi Genzyme in January&#160;2018 to modify certain of the business terms. The material collaboration terms for fitusiran, as previously announced, will continue unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with entering into the Collaboration Amendment and the A&amp;amp;R AT3 License Terms, we agreed to advance, at our cost, a selected investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies. Following completion of such studies, we will transition, at our cost, such asset to Sanofi Genzyme. Thereafter, Sanofi Genzyme will fund all potential future development and commercialization costs for such asset. If this asset is developed and approved, we will be eligible to receive tiered double-digit royalties on global net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;No changes were made to our Exclusive License Agreement with Sanofi Genzyme, referred to as the Exclusive TTR License, pursuant to which we have global rights for the development and commercialization of ONPATTRO, together with vutrisiran and all back-up products, which remains in full force and effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Amended and Restated Investor Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the Collaboration Amendment, we and Sanofi Genzyme also entered into an Amended and Restated Investor Agreement, referred to as the A&amp;amp;R Investor Agreement, which amended and restated the Investor Agreement entered into by us and Sanofi Genzyme in February 2014, referred to as the Original Investor Agreement. Pursuant to the A&amp;amp;R Investor Agreement, Sanofi Genzyme was released from the lock-up restrictions under the Original Investor Agreement and was permitted to sell shares of our common stock in transactions approved by us or in fully bought block sale transactions satisfying the conditions set forth in the A&amp;amp;R Investor Agreement. As of January 17, 2019, Sanofi Genzyme owned 10,554,134 shares of our common stock and as of May 3, 2019, Sanofi Genzyme reported owning no shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the A&amp;amp;R Investor Agreement, until the earlier of (i)&#160;the fifth anniversary of the expiration of the last to expire royalty term or the earlier termination of the collaboration agreement, as amended by the Collaboration Amendment, and (ii)&#160;the date after December&#160;31, 2021 on which the beneficial ownership of Sanofi Genzyme and its affiliates no longer represents at least 5% of the outstanding shares of common stock, Sanofi Genzyme and its affiliates will be bound by certain &#x201c;standstill&#x201d; provisions, including an agreement not to propose or support a proposal to acquire us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTkwNTU_9af1af55-cd8c-47b5-86e3-3cab0f1357ab">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Net revenues from collaborators (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.929825%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir Biotechnology (Vir)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;The Medicines Company (MDCO)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues from collaborators&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedca81ec08d84b71974e26397c92d1df_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi0xLTEtMS0w_dc5199d7-4325-43d8-91cd-298c4e4749e6"
      unitRef="usd">1882000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4a9dd2ed7f84b8eabd7dbe77bd4bede_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi0zLTEtMS0w_50ae2796-0ce7-4bf5-9dce-5a518f76dfd2"
      unitRef="usd">-1560000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5944d6095a8a4e978f43fe95bdf38b47_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi01LTEtMS0w_2fc28a87-14ee-404b-88b7-27eaf5a78296"
      unitRef="usd">10382000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib789d44f74694f1ba05ae665b85e3c8d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMi03LTEtMS0w_2f0cdb6d-5be9-4985-8b74-4598182f2dc7"
      unitRef="usd">40370000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94dc645833714139975f0211dc2191fb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy0xLTEtMS0w_431e3b9a-a154-4a67-9475-f5b60a95f0b8"
      unitRef="usd">5869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida54ff3bad294ce5853890d30053bb7c_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy0zLTEtMS0w_225b0d2a-a393-40ce-b41c-d72aff2f68dd"
      unitRef="usd">2957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c27321c10b343b58de158e6d3db20e5_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy01LTEtMS0w_08c6f2fb-2dd3-426a-947a-6468bc0a0252"
      unitRef="usd">7888000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2a1f0c21c27441983ec53e357768237_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfMy03LTEtMS0w_cf112d4f-8990-4f94-a7ef-7db327d7e223"
      unitRef="usd">10313000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfd9ee786c8c474d9a7bb46eff4d0397_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC0xLTEtMS0w_00e77cfe-cd6f-4338-98d3-60ee6adf73dd"
      unitRef="usd">528000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97807f37924b4995a48c769fc07945fa_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC0zLTEtMS0w_1c0d8fdf-ecdb-4531-bf1f-5eecffa9575a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64a811b4311a4914940c20e54952a306_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC01LTEtMS0w_42698a48-c6ea-4fd1-9982-b06eea198e15"
      unitRef="usd">2273000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie144870db8f9498eb7801f4559dd2d72_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNC03LTEtMS0w_cb208043-b3d0-4398-9589-d9d4d5665504"
      unitRef="usd">1957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i673aa3eee23e4a288c64b4dfedc553da_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS0xLTEtMS0w_ef995863-477a-4546-8dae-7d2f7929c394"
      unitRef="usd">15261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04e3a21a1c4c4bcdbb03dc8833f4924d_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS0zLTEtMS0w_f29b47f5-5451-47b2-91bd-9d7f3abfd08d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb5884d7e33e4b7d94d106059300af24_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS01LTEtMS0w_cd91d33c-d554-4565-8d0b-15f206a62034"
      unitRef="usd">15961000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21118dc8b808433e81625e7f2b7884b3_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNS03LTEtMS0w_264e41a3-4fce-4421-883a-73c1d0a52df5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0b4cb7028ab4d418d05a21b47a3728a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi0xLTEtMS0w_85ff7c8b-d5d5-4433-8d72-9dc134dca8e8"
      unitRef="usd">455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ae16923f0f84a86ad6008c568b4b1eb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi0zLTEtMS0w_c45721ab-d09a-4e3e-81fc-ede132900b41"
      unitRef="usd">212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83c1d7dbd6c148efb6c9867f8e130af1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi01LTEtMS0w_c70016de-b992-4bae-95be-232f280cb023"
      unitRef="usd">977000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8dd904aabd6f4f08942cf7251614b26f_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNi03LTEtMS0w_f1ae6078-b8ef-413b-94df-088a7a0e06d5"
      unitRef="usd">775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc6569f4b7a54920b4b016ec2a2307d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy0xLTEtMS0w_d603b88b-cdec-4db8-b94a-7edc91ed0b0c"
      unitRef="usd">23995000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ca8122b23ae48f2b7a30429c7434451_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy0zLTEtMS0w_1728d111-83fe-46b3-8235-528bd035ebcb"
      unitRef="usd">1609000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia035051af8af48248146e9bb253e5b61_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy01LTEtMS0w_6d3bfe64-7af7-4099-9e00-6a4f4355b3e4"
      unitRef="usd">37481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id872e0d52c5f4349b6ad645fc3ff01c6_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmRlMTc5YjE1OWVhNDQ2MzZhZDBlODAyNjE5ZDJlOTgwL3RhYmxlcmFuZ2U6ZGUxNzliMTU5ZWE0NDYzNmFkMGU4MDI2MTlkMmU5ODBfNy03LTEtMS0w_7e6e453e-250f-4bfe-bbab-24ad23dd1d66"
      unitRef="usd">53415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTkwNTY_86eac86d-7d0d-4238-aa39-def1194edb5d">&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.029412%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.029412%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contract liabilities included in &#x201c;Deferred revenue&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and nine months ended September&#160;30, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.794118%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.735294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.735294%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts included in contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMS0xLTEtMS0w_c7ef4b83-c7d7-4fb3-b4c8-552c843a4e47"
      unitRef="usd">28107000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMS0zLTEtMS0w_26f8d10b-937e-426c-ab5b-e7b516821a57"
      unitRef="usd">5625000</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMi0xLTEtMS0w_0ed4f64d-4b8b-4ee1-a1a9-d1f6888d202d"
      unitRef="usd">158446000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYyYTcwMDIwZjU4YTQzODU5YTg3MTU5MDkyYjk4MzBmL3RhYmxlcmFuZ2U6ZjJhNzAwMjBmNThhNDM4NTlhODcxNTkwOTJiOTgzMGZfMi0zLTEtMS0w_de91e79a-ea32-4b16-92c3-68a8d4023bd5"
      unitRef="usd">3954000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYzMjIwMDE3N2RjYjQzYmNhZGJlYTczYTY4NDhkNmFiL3RhYmxlcmFuZ2U6ZjMyMjAwMTc3ZGNiNDNiY2FkYmVhNzNhNjg0OGQ2YWJfMS0xLTEtMS0w_5391ffd3-40cc-498b-902e-85c686f7d8e3"
      unitRef="usd">12333000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmYzMjIwMDE3N2RjYjQzYmNhZGJlYTczYTY4NDhkNmFiL3RhYmxlcmFuZ2U6ZjMyMjAwMTc3ZGNiNDNiY2FkYmVhNzNhNjg0OGQ2YWJfMS0zLTEtMS0w_a4ac17e1-b65c-499b-91af-095dc9d74b98"
      unitRef="usd">3954000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTkwNTc_377dd9c0-9779-42ae-a19b-01757a53c96b">The following tables provide the research and development expenses incurred by type that are directly attributable to our collaboration agreements by our collaboration partners for the periods indicated, in thousands:&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.597365%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.784773%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trial and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;External services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.707602%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.771930%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MDCO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Regeneron&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical trial and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;External services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia18fdbb5b94847bb87d8d115277e9ea1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xLTEtMS0w_0417a6d3-6cc7-4687-a528-919bb7a2e83c"
      unitRef="usd">3262000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i33bd68ff20fc4287ac9b1020d2779301_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0zLTEtMS0w_b47de0ca-b52f-46d8-82bf-b2f1b4ab5786"
      unitRef="usd">347000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4a1a333dbc9d46f196d16aaf2ceb4132_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC01LTEtMS0w_a04f1ecb-89b1-489a-b8a5-f5ada53deeb4"
      unitRef="usd">4843000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i88c731ed1fbc417b9ee053536a59d9a6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC03LTEtMS0w_d75df49a-adc7-4e97-98e5-dc591ee8df06"
      unitRef="usd">637000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb229db5707849d4a22b3c3e18621842_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC05LTEtMS0w_aeeb5348-daf6-46dd-8a1e-04395399f7e0"
      unitRef="usd">4308000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i841cbe61ae1c4ba5ac3531120ba0c867_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xMS0xLTEtMA_10a38c11-9b2b-4ea6-a688-244c2f1c89a8"
      unitRef="usd">937000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7569b264a69c48a88a61d8ec84e9025a_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xMy0xLTEtMA_aa117279-f7ca-477b-9cc3-303c75911ea9"
      unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i46ff16a733d64c5fae19a59891cce764_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNC0xNS0xLTEtMA_2c98ab50-5d42-46f4-80f0-5923556182cb"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc350c0de347466695b330f459fefc28_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xLTEtMS0w_2fe4bb2c-b1c7-43fe-913a-4ae070683202"
      unitRef="usd">110000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide82e9762bef4fdeb0c81cbf70048f13_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0zLTEtMS0w_95965e1b-281e-4d52-bdf3-2116bd8a321c"
      unitRef="usd">5992000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5d7cf10b7b2548a080a4c2299f3c7795_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS01LTEtMS0w_7f19928b-34c3-42b6-a099-108835925f28"
      unitRef="usd">20000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifb70ef125a034aa0830cee0808b5cfa1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS03LTEtMS0w_1f0c93ea-b0ac-4fa6-90a1-518945590f2e"
      unitRef="usd">959000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i566f60a947954dc69ddaac57c3b30366_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS05LTEtMS0w_a2285e62-ff14-43ce-89e2-0032ff5fc695"
      unitRef="usd">588000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie0bf8fb6901c49edba6c2026ee58fcc4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xMS0xLTEtMA_24d635d7-64fb-443d-a672-4f4daa6951d9"
      unitRef="usd">1000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3bea475b1bd4453e8b3b41aa9c9a011b_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xMy0xLTEtMA_5210a241-ca5f-4994-b876-b06e762adfd0"
      unitRef="usd">1023000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide622c05ddce4e44a17a894f34bccbba_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNS0xNS0xLTEtMA_60382ea2-ecae-4aca-94f1-c554d05e929e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icef633268a6c4fcc928100d0671ed5e9_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xLTEtMS0w_8da612a0-8241-48b4-9214-c2db5cc969b2"
      unitRef="usd">1588000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibfd6cf1430e34457b82db167b81278ef_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0zLTEtMS0w_9ae9eb9c-a1f5-4a68-b5f6-b2d3ea3ea5f8"
      unitRef="usd">398000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibc02df567f3e4ff6bf19fc1d69294ac4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi01LTEtMS0w_1304204b-5553-4c07-bec7-f6593e934395"
      unitRef="usd">2393000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia340b62c22e4415db15b4677cf672c04_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi03LTEtMS0w_800909fc-eb48-4145-ae17-05cbb14bb269"
      unitRef="usd">9518000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibf9a583b3eaa48f5ad28f2b7e2dc2657_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi05LTEtMS0w_e6e67e17-53eb-4d39-93a2-f54616e0f2fd"
      unitRef="usd">395000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i146c5c0497e044de8cd9a05912301c3c_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xMS0xLTEtMA_a2bc2365-a4c0-4539-a566-067a15837d84"
      unitRef="usd">2000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9592e8ff40504f85af6d1939889fd11b_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xMy0xLTEtMA_0ac71c4f-da25-4eed-afcb-ec57449684a9"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id7e703eff2264d08bab65003cdbeaad7_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNi0xNS0xLTEtMA_69a6131c-dd33-43d5-8b4d-a5d07cd87980"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i475658c0ca9e4d928c433d121b265c82_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xLTEtMS0w_779b4a1e-f29e-48a5-8185-b0e6153eb5df"
      unitRef="usd">4960000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if449ef4bea9a40ae916cb93478c18048_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0zLTEtMS0w_cf70ef2f-915d-4d2a-b257-325115a56abc"
      unitRef="usd">6737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i45dfd0bcbe484904a18240c95809b63d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy01LTEtMS0w_4370760b-9479-4ba0-9b41-77db083add4b"
      unitRef="usd">7256000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5715163b5bd44e09ae21778e01a08ad6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy03LTEtMS0w_30ecfa18-9b03-4d76-8a21-fe889e365809"
      unitRef="usd">11114000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if50c807a1f0e4c1492220c3fbd4c4cac_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy05LTEtMS0w_36697c9d-f94a-4082-804b-5b40934bc946"
      unitRef="usd">5291000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i992ffaac88eb4d129a8f61d7f3155127_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xMS0xLTEtMA_97f73c68-9c4d-4e80-889b-8ee60c74a6bc"
      unitRef="usd">940000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iae58e4687c76458cbd799a3532718cc8_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xMy0xLTEtMA_24353234-8f0e-48e0-9333-21d7466a6056"
      unitRef="usd">1823000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i828961f893674d5694c8381c4f2c012b_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOmZhNzAxYjc5MGZmYjQyOTNhMTcwOGUwNThiODM1Njk5L3RhYmxlcmFuZ2U6ZmE3MDFiNzkwZmZiNDI5M2ExNzA4ZTA1OGI4MzU2OTlfNy0xNS0xLTEtMA_f522ae3c-097f-4f34-8a9f-c75a3c17a3f8"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie2c0e609344340b0ac078896c7302e19_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xLTEtMS0w_a62684fa-51a9-4dda-b823-c4dd2ad3306b"
      unitRef="usd">11033000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if914afcf9e4744d0b11d5a1478378a35_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0zLTEtMS0w_2daabcbf-1a24-499e-9063-4782c058c773"
      unitRef="usd">2024000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i527af3a6a1a443b0b18b74a5866a3b90_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC01LTEtMS0w_174b62f2-63ad-486d-9fbd-29e84e19f029"
      unitRef="usd">5385000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i79eb574b077e440788e6310bda7ce3dc_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC03LTEtMS0w_e324ae5c-5997-470d-b1c8-afbec8cb5a6a"
      unitRef="usd">1152000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i39121bec9968473c89779780093452eb_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC05LTEtMS0w_b6d5458f-338a-4245-b33f-2457db68290a"
      unitRef="usd">32403000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia38c9fe25a9f40e79efe3342ecec48b2_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xMS0xLTEtMA_888797f6-a381-4e4d-8743-254a3c41e99d"
      unitRef="usd">1578000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iae8470f847a3491dae7d1bcd2f3f6398_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xMy0xLTEtMA_cc3bc439-de55-4d3b-8e2b-44d0305fabc6"
      unitRef="usd">6851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i657c2557d02741b08dc2a2dfbc051fd5_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNC0xNS0xLTEtMA_a2a40568-7f6f-4b51-beb8-336dbfa14aa7"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie781c80188954ce28b5095c7ad86743a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xLTEtMS0w_aef5f8e1-7342-4f3f-a00b-a087e1a30c0a"
      unitRef="usd">326000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie89009e721c8458ea441dc7256bae44e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0zLTEtMS0w_d96e8d55-a820-4337-83f2-1635e3fe85ce"
      unitRef="usd">6002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id5faa958db3248cf8abd2d51854649c9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS01LTEtMS0w_9b4fa0b7-af4c-4bfc-8d19-ec69bcba0119"
      unitRef="usd">268000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0133baa156a644908b72e47c2d43ec0a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS03LTEtMS0w_261bd0d3-04f5-41ca-b085-f3584de40703"
      unitRef="usd">1010000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id66ba49548de4a899fd6450c151c30c3_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS05LTEtMS0w_fe3b1c95-c74e-4ce9-b501-8a63488be7fa"
      unitRef="usd">5095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i185ceb104d524ac2b0dd476c73f39d3b_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xMS0xLTEtMA_2efa94cd-a0bb-4bfd-a6cd-814237f6b489"
      unitRef="usd">1000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i28fd5aa0223e4864bd917a1eb955fbe1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xMy0xLTEtMA_c05e511c-4c62-4d50-b016-9312e90366ed"
      unitRef="usd">7374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i80f0807ba74548b0a8cae142017dec3a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNS0xNS0xLTEtMA_729c4be1-850f-460e-acb8-11669d90ece0"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5b1a8dc3c9da43c0b2be902403a125d8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xLTEtMS0w_4b6f0f0e-940a-40d9-9683-19a68dd065e9"
      unitRef="usd">1681000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib996cc6e2cef48baa147a3c936b7622d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0zLTEtMS0w_009a5246-9ef5-4e66-88f7-8b1ad699abc5"
      unitRef="usd">458000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i209d8f822ea54215a8a5a92d1710e4fa_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi01LTEtMS0w_dac2c4b1-6ea7-4700-b71f-573de9f66d94"
      unitRef="usd">2733000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3677fbfc08e94d57801b8fbdfc4f3d18_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi03LTEtMS0w_f4dd60ca-73b9-422d-98b2-b61cd81889a1"
      unitRef="usd">9943000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6d661f5bbcaf4991993d92085c0405ea_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi05LTEtMS0w_42ca6077-4445-449b-9ecc-5ec11108fb2c"
      unitRef="usd">1145000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if9d79f61ae80486795459192eaa096a6_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xMS0xLTEtMA_cf823a25-f304-4727-85f9-662eba9876c0"
      unitRef="usd">2000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia9911e13cc954763aca179b898c772aa_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xMy0xLTEtMA_67273f49-2e82-43ac-b456-f0e092d2683e"
      unitRef="usd">980000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i05f229b2a3d4481b99dbd2a5d30a1bcf_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNi0xNS0xLTEtMA_e0e92904-2005-43b8-a376-e4feeb30c9a7"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iea900a9c6d3a4cbab86b5bc952e69203_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xLTEtMS0w_433ad709-757f-4497-9ac2-be258338c947"
      unitRef="usd">13040000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2fae1adbaaf04d2681c00589c86c0041_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0zLTEtMS0w_1d046e91-ff5e-4434-bb64-0bb0e1914722"
      unitRef="usd">8484000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2c35a882679b407281d6fe08e0b51a82_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy01LTEtMS0w_5d646a57-62c5-4135-9a7f-800d9c350e4e"
      unitRef="usd">8386000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4a80641a47214d5f91ecd50a0a248023_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy03LTEtMS0w_acf5931d-9128-4fd3-8768-cc6c2553f422"
      unitRef="usd">12105000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i90acd6d92ec642f9b7b36589e3268571_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy05LTEtMS0w_983737b3-a0e1-4c11-9a02-02ba7986e119"
      unitRef="usd">38643000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i757b55bca5a64fd58f1fab4d5d19add2_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xMS0xLTEtMA_40134867-cc56-4b92-9b5a-d639f807570a"
      unitRef="usd">1581000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i207df81799004a46ba28b23122e5111b_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xMy0xLTEtMA_9a976ad6-767b-4e77-b7d1-2ccca913dc3d"
      unitRef="usd">15205000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ice65c0bb2b5e417888fde2ff078b534c_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjExZjliOThkNTlmZDQ5Y2I4ZjBhZDI1NGQyOWFhMmM5L3RhYmxlcmFuZ2U6MTFmOWI5OGQ1OWZkNDljYjhmMGFkMjU0ZDI5YWEyYzlfNy0xNS0xLTEtMA_b7227736-5673-4ac0-bd15-b5d91f7cd72b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjc1Mg_bb85d702-c0d4-4636-96fa-afb84063d8c3"
      unitRef="shares">4444445</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjg0NA_19379a62-9d1a-4fb9-bf38-91fa589440b7"
      unitRef="usd">400000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i5d3a888b47654db19c388966c89d70d3_I20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjg1MQ_902da25d-3493-4d9f-9240-eb033fc9c473"
      unitRef="usdPerShare">90.00</us-gaap:SharesIssuedPricePerShare>
    <alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMjc0ODc3OTA4ODY5NQ_513a6445-1e75-4daa-a6ad-762787106806">P2Y</alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment>
    <alny:ResearchTermExtensionFee
      contextRef="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMzQyOA_41694ed3-b83c-4f17-b9b5-9d71e881cf54"
      unitRef="usd">400000000.0</alny:ResearchTermExtensionFee>
    <alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjIzMQ_61d804d9-6d97-4963-8b22-7ed673d748e7"
      unitRef="usd">325000000.0</alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale>
    <alny:UpfrontFeeReceived
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjU2OA_24f5fb03-9597-40fb-b86a-4f79098d62ce"
      unitRef="usd">400000000.0</alny:UpfrontFeeReceived>
    <alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjYyNA_aa043e89-3e4d-4ec9-950d-3b765e0998a3"
      unitRef="usd">200000000.0</alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria>
    <alny:NumberOfTargetedPrograms
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjgwNg_00db62ac-22af-4c2a-94bf-8203c1e19145"
      unitRef="program">30</alny:NumberOfTargetedPrograms>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="i910f04c70f8f42eaa89bc212b0fcede9_I20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjkzNA_a4707b25-ed5a-4f2e-8617-afc4e61b726b"
      unitRef="usd">2500000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="ie6314e00fa4e4a639121892a2b493f92_I20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNjk4OA_9e04e9c3-ef41-461b-9b1b-509db8c948d4"
      unitRef="usd">2500000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="i3e47a5ab3bd844aca1d5112c5e5bc4fe_I20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzA2Mg_a0cebe66-5690-440f-bdbe-ec03c8390bf4"
      unitRef="usd">30000000.0</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:CollaborativeArrangementMilestonePayments
      contextRef="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfODM5MQ_a03599f3-8728-4e2a-b4fe-a0a2b510fd7b"
      unitRef="usd">150000000.0</alny:CollaborativeArrangementMilestonePayments>
    <alny:RoyaltyRate
      contextRef="ia89cc425b8ec4574a3b6d9187fd8d47b_I20190408"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfODY0NQ_bc7cbb96-cf29-4233-85ee-00e2fefb8610"
      unitRef="number">0.20</alny:RoyaltyRate>
    <alny:PercentageOfMaximumRoyaltyPayments
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfOTUzNA_40c3eb48-d1f8-4b30-a188-e1f017e7b0c0"
      unitRef="number">0.20</alny:PercentageOfMaximumRoyaltyPayments>
    <alny:UpfrontFeeReceived
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTE4NDk_92bc266d-a6f3-49cb-bce5-4ed8d7462600"
      unitRef="usd">400000000.0</alny:UpfrontFeeReceived>
    <alny:ScheduleOfAllocatedTransactionPriceTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzY5NjU4MTQyMTY4Ng_50bdb728-3f02-46b8-8052-b3d87df6115e">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467836%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.906585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.412557%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.836141%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.412557%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.836141%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.331394%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.664625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Standalone Selling Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:0.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:95%;"&gt;ASC 606&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;364,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;521,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfAllocatedTransactionPriceTableTextBlock>
    <alny:StandaloneSellingPrice
      contextRef="if88df3d689a741d8b329bc0a7ffb25d6_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMi0yLTEtMS0xMTE0OA_c7d76e0c-b8db-4506-96dc-a690a66a795d"
      unitRef="usd">122000000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i9f99093d364045fda1a43bb5fcbfce58_D20190630-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMi00LTEtMS0xMTE2NQ_9f277005-3c1d-4a84-ae8f-401a76fb8656"
      unitRef="usd">178500000</alny:TransactionPrice>
    <alny:StandaloneSellingPrice
      contextRef="i19f1516e126c4492b1083718d689a0b5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMy0yLTEtMS0xMTE1Mw_e75916ae-a4cd-4162-9f1a-2d0c94866fac"
      unitRef="usd">97600000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i2e07bf9298b24bbcbbdd5c0c60d0efe0_D20190630-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfMy00LTEtMS0xMTE2OQ_8d633829-1ffd-4c9d-a19f-381a8f3c127f"
      unitRef="usd">93500000</alny:TransactionPrice>
    <alny:StandaloneSellingPrice
      contextRef="ibb5ab21b5e394f12b80ee7c85f5a6436_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfNC0yLTEtMS0xMTE1OQ_7086984a-0008-4f2e-b1c0-14bbbf9369e3"
      unitRef="usd">364600000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i86d830c7785d42eca47ab825a3dd466e_D20190630-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfNC00LTEtMS0xMTE3Mg_9a42a07f-9cff-45aa-a7d0-3f292b756df8"
      unitRef="usd">249600000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="i6f42feab7e1d44078d72a7646ec908c5_D20190630-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjJjNmM1NjA3NWQ4ZjQ4NWQ4ZjI1N2E3Y2NhMzBjZmFjL3RhYmxlcmFuZ2U6MmM2YzU2MDc1ZDhmNDg1ZDhmMjU3YTdjY2EzMGNmYWNfNS00LTEtMS0xMTE3Ng_e3c312b4-2ca6-4cca-8412-5c784ff5e3e4"
      unitRef="usd">521600000</alny:TransactionPrice>
    <alny:IncreaseDecreaseInTransactionPrice
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTA5OTUxMTY4MTg3MQ_93bdacd7-db50-4c33-a315-74f4ac0eb4e4"
      unitRef="usd">18500000</alny:IncreaseDecreaseInTransactionPrice>
    <alny:TransactionPrice
      contextRef="i6f42feab7e1d44078d72a7646ec908c5_D20190630-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTA5OTUxMTY4MTg4MQ_6453ad78-f253-42d8-95fd-2ba320af5708"
      unitRef="usd">521600000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTA5OTUxMTY4MTg5MQ_ea253594-8bd2-41b0-bd63-2e549687bdd2"
      unitRef="usd">540100000</alny:TransactionPrice>
    <alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfNzY5NjU4MTQ2MTU3MQ_7a6afe8b-11ac-48ec-bd9a-3c3779ac1894">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.491228%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.454545%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.181818%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.969697%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.818182%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.272727%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.406061%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.272727%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue Recognized During&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;540,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;402,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock>
    <alny:TransactionPrice
      contextRef="idaea32819b574ef28e3693d2eb5e6e5b_D20190930-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi0yLTEtMS0xMTI1Ng_8fc2c362-8487-433e-b0b6-a34474b09006"
      unitRef="usd">182400000</alny:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a8fa0c4e76a42f2852aac811eb5477f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi00LTEtMS0xMTI2Mg_32dc4bd6-0aab-4bd2-9fb5-046fef90af80"
      unitRef="usd">11100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1583edbcfb14632bce947d08adc1711_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi02LTEtMS0xMTI2OA_a0c78bfb-2002-407f-9977-fcc2fc5903cb"
      unitRef="usd">11800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if88df3d689a741d8b329bc0a7ffb25d6_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMi04LTEtMS0xMTI3NA_74dcd8ff-c2e8-421b-8df4-557ef68fa3fa"
      unitRef="usd">90600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i0a37ee0addcc471cbc26952515d07305_D20190930-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy0yLTEtMS0xMTI1OA_effcf8c4-b4f9-489b-a58b-d0945d7cfe24"
      unitRef="usd">109200000</alny:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0a05588cdc94fe990de15bb14b81d2e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy00LTEtMS0xMTI2NA_293be37e-2b9d-4d78-8d9d-375891bfde4b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2478295fa07f441eb5430e16d67ec61e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy02LTEtMS0xMTI3MA_e2e0cbb8-f2df-4ac2-92c0-7c0036427b87"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i19f1516e126c4492b1083718d689a0b5_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfMy04LTEtMS0xMTI3Ng_1929e634-f7ba-4307-86ba-dce714f63384"
      unitRef="usd">66500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="ie3b9efc823ea4a52a48884c8f7ef46ee_D20190930-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC0yLTEtMS0xMTI2MA_0fc5ec08-d6a9-478b-91d0-7b7663c08201"
      unitRef="usd">248500000</alny:TransactionPrice>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i561b9cbdf5134340b23a4852eff9113a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC00LTEtMS0xMTI2Ng_5c864ecb-5196-4232-8a38-3354277093ba"
      unitRef="usd">3600000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i4a69fc879d06480e8231d059d82c9ff1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC02LTEtMS0xMTI3Mg_f9de9d2a-8292-412f-9572-251ff3b2e9c6"
      unitRef="usd">3600000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibb5ab21b5e394f12b80ee7c85f5a6436_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNC04LTEtMS0xMTI3OA_451aba0f-05d7-4bf3-84cb-b47e65c91ba1"
      unitRef="usd">245000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS0yLTEtMS0xMTY0Ng_5e7adf45-0bdc-4084-9142-f3e522ca0a72"
      unitRef="usd">540100000</alny:TransactionPrice>
    <us-gaap:Revenues
      contextRef="i53189462639a41ea94d96ecc0862a2c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS00LTEtMS0xMTY0OA_ef392971-911f-4c2e-bb87-8d35f8201a51"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i304e9e4a77f146f1b45c8803228f6a4d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS02LTEtMS0xMTY1MA_ee26cabd-071e-4a23-892f-ba767c5bd590"
      unitRef="usd">15400000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i128a21da539642528efe8070e11f3e47_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RhYmxlOjAzOWI2NTY2ZjNhZTRiYWZiYmFjZjI3NDhjYWFjOTM0L3RhYmxlcmFuZ2U6MDM5YjY1NjZmM2FlNGJhZmJiYWNmMjc0OGNhYWM5MzRfNS04LTEtMS0xMTY1MQ_90efcea6-2c54-44f3-bdff-c34759cdcddc"
      unitRef="usd">402100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i128a21da539642528efe8070e11f3e47_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTY0OTI2NzQ2NTk3Nw_a6910d15-982f-4801-ae9f-3c74af233380"
      unitRef="usd">279800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56c55aec91dc4c59ba2a9a3f39ee2da2_I20190117"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTgzNTc_f83ffd44-85df-453f-97e3-4ed2f596b3ce"
      unitRef="shares">10554134</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i18255b8b8fa94a3c932e5d83d5508a09_I20190503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTg0NDE_bc54bc72-550d-444b-809c-1e9d7687700b"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i23a3a0ee563f4e42ad4529debd4b818a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV80OS9mcmFnOmQ5NWFlYzI0YzIxMjQ4ZjhhZWFmOTc3NmE2NDc1Zjk3L3RleHRyZWdpb246ZDk1YWVjMjRjMjEyNDhmOGFlYWY5Nzc2YTY0NzVmOTdfMTg4NTE_8555dc55-bacd-49ec-a822-07a5e6881fec"
      unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RleHRyZWdpb246MmRkZmQxNTBhNmM4NDBmZjliOTkwYTkyZWVlY2UwMzBfNzY5NjU4MTM5NDUyNw_6e5dcd01-f689-4cab-9d91-ddd3dfb5acc5">INVENTORY&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents our inventory as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.707602%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RleHRyZWdpb246MmRkZmQxNTBhNmM4NDBmZjliOTkwYTkyZWVlY2UwMzBfOTI_c458ee80-e550-4839-b7f9-5cbfff1e9b57">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents our inventory as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.707602%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMS0xLTEtMS0w_8b35e6f1-f73a-4dcd-b177-94ec298c63f0"
      unitRef="usd">11600000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMS0zLTEtMS0w_b0a41ef5-e797-4d06-be10-644a396c5d6f"
      unitRef="usd">8709000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMi0xLTEtMS0w_0d6977dc-feeb-49fd-a516-51ea31f0341f"
      unitRef="usd">42383000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMi0zLTEtMS0w_b749284a-4f32-445e-8fb0-14e798a98ed6"
      unitRef="usd">15262000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMy0xLTEtMS0w_e4208ade-d1e1-4169-a590-e4e5ffaa65eb"
      unitRef="usd">579000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfMy0zLTEtMS0w_02c50fdf-7224-4230-a5f0-a9c45c0c4caa"
      unitRef="usd">97000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfNC0xLTEtMS0w_0796cb97-02e8-4e39-add5-69794ff54f7c"
      unitRef="usd">54562000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81NS9mcmFnOjJkZGZkMTUwYTZjODQwZmY5Yjk5MGE5MmVlZWNlMDMwL3RhYmxlOjIzZmNkN2ViYjYwNTQyNmNiMjI3MWU4OWVmYmY4NTY3L3RhYmxlcmFuZ2U6MjNmY2Q3ZWJiNjA1NDI2Y2IyMjcxZTg5ZWZiZjg1NjdfNC0zLTEtMS0w_48219671-b8ac-4adc-817b-496f868529ce"
      unitRef="usd">24068000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfODI0NjMzNzIxNjE2Ng_7c0998f2-9f9d-411a-8d65-fae4e73ddb20">FAIR VALUE MEASUREMENTS&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables present information about our assets that are measured at fair value on a recurring basis as of September&#160;30, 2019 and December&#160;31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.073421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;634,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;634,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,607,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.073421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;325,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;325,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;989,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the nine months ended September&#160;30, 2019 and 2018, there were no transfers between Level 1 and Level 2 financial assets. The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities. As of December&#160;31, 2018, the fair value of our long-term debt, computed pursuant to a discounted cash flow technique using a market interest rate, was $30.1 million and was considered a Level 3 fair value measurement. The effective interest rate reflected the current market rate as of the fair value date. On September 27, 2019, we repaid in full the $30.0 million long-term balance under our Credit Agreement with Wells Fargo Bank, National Association. Please read Note 9 for additional information regarding the Credit Agreement.In October 2017, we entered into a collaboration and license agreement with Vir Biotechnology, Inc., or Vir, at the time a private clinical-stage immunology company. As part of our upfront consideration, we received 5,000,000 shares of Vir common stock. On September 27, 2019, Vir implemented a 1-for-4.5 reverse split of its common stock, converting our 5,000,000 shares to 1,111,111 shares. On October 10, 2019, Vir completed its initial public offering, or IPO. As a result of the IPO, our common stock is now publicly traded common shares and is subject to a 180-day lock-up period.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfODI0NjMzNzIxNjE2Nw_ae77c576-e12b-4902-aa26-8ee847695a49">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables present information about our assets that are measured at fair value on a recurring basis as of September&#160;30, 2019 and December&#160;31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.073421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;134,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;634,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;634,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,607,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;135,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.073421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.747430%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;102,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;325,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;325,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;989,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2ab12e28db7e4641b70a2a645c6a28e8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMi0yLTEtMS0w_0f687326-623c-4537-b4d7-9427f2c20a56"
      unitRef="usd">16975000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9f78360553254ee782ee02d789c9d889_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMi00LTEtMS0w_6774410f-0c9e-4734-a05a-5beac324946a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i697b1bfc24074b85bf27cd5598d3b51b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMi04LTEtMS0w_1165b2c0-f813-432d-a76f-994ed97c93ed"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4c50e4c814e74c9491d54d5e4e91af0f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy0yLTEtMS02Mjk5_c99d0d3a-bf4a-4341-bee9-2cc19e50d146"
      unitRef="usd">2105000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3163fef4430b47c28ff4777546273453_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy00LTEtMS02MzAy_00962567-281c-4eb2-9b7b-4f333b76d1b1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i45fc9bcd587c4f37b74ab016f6cbdefa_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy02LTEtMS02MzE3_44871bad-7187-4d98-9e4e-10a5f2fd264b"
      unitRef="usd">2105000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie01382b3f2664b17976086250fb17c01_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy04LTEtMS02MzIw_c1b1803f-8bb4-4cfa-b426-626c5be836d6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie14a072a848f45a5a23bc9f805fbbd08_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy0yLTEtMS0w_194dae23-c545-48c2-8618-a64c5c1c18af"
      unitRef="usd">655063000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i239343e7b44f41dabd006bd02fa42bff_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy00LTEtMS0w_f60f0252-ab4b-4ce8-a09d-b5e6b65f8aec"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if099e69b9be14094b333354d839f0f79_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy02LTEtMS0w_5844c7e0-d195-4c92-95f1-c59a5fae518f"
      unitRef="usd">655063000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic860375e3027429092c256d65a2d7780_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMy04LTEtMS0w_15472882-3c57-4da1-8fa4-95148501b24e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icdc53aba859045ecb0ca135b483634d7_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS0yLTEtMS0w_eb985dc5-036f-4ba3-9182-32abf72590f3"
      unitRef="usd">134440000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe092ad14ecf40ecbc93697363251ede_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS00LTEtMS0w_850bea90-dd82-45cb-9997-7b0ceb49f6ee"
      unitRef="usd">134440000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0949304a7dde4229b6e753cd9903c40e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS02LTEtMS0w_2adb0a7a-ea50-422e-bce0-75520284d2cd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d0a82f69d8e49c7bf0facdafd02a08b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNS04LTEtMS0w_f2d89db4-3933-41d3-a16e-9db4ad5915f5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i891225af6803446f9581a304ba109390_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy0yLTEtMS0w_8c34fe9e-68c2-4ee6-a2c7-769a474f0857"
      unitRef="usd">3053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd2fc5c6f5de44f4ad84017a9d68a878_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy00LTEtMS0w_5b2fcfaa-4779-4b4b-80c7-576a45280f34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c36b06d4d7444b1b5923152fba320f9_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy02LTEtMS0w_08cffbaf-54a4-488e-8484-e731e6298d0c"
      unitRef="usd">3053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i635b34a72c56410d8d1df7055596b6b8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfNy04LTEtMS0w_6f373fdc-33e1-4424-ba4b-001344702f93"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ab12e28db7e4641b70a2a645c6a28e8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC0yLTEtMS0w_119a7cd5-2505-4f16-be6b-1fbededab647"
      unitRef="usd">12512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f78360553254ee782ee02d789c9d889_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC00LTEtMS0w_ea5f956d-7409-4205-a04c-4e5ee88a11e3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia99a29ede5ec418db5992d141e96e1af_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC02LTEtMS0w_7921e5c6-fbe9-4a38-b668-1651f8ad159b"
      unitRef="usd">12512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i697b1bfc24074b85bf27cd5598d3b51b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOC04LTEtMS0w_20f7ba94-692e-4366-8f0a-7140e5acc2df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c50e4c814e74c9491d54d5e4e91af0f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS0yLTEtMS0w_5f0958a9-19fa-4c4f-92ce-903e8b9fddb2"
      unitRef="usd">87927000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3163fef4430b47c28ff4777546273453_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS00LTEtMS0w_1f129eaf-1c82-433e-82b6-a7bf5188a1e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45fc9bcd587c4f37b74ab016f6cbdefa_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS02LTEtMS0w_988137cc-9d39-4e37-9212-0983d5126486"
      unitRef="usd">87927000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie01382b3f2664b17976086250fb17c01_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfOS04LTEtMS0w_7411b9fa-09bf-4437-bf0e-81758ae26390"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3189a838fac44b6aa80a5b0128eeea48_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtMi0xLTEtMA_dc542374-e4f8-406d-a894-79bc19c73eb0"
      unitRef="usd">59748000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fe3d4c3f27649a5b8cffd56fc6d60d6_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtNC0xLTEtMA_8e519531-d1ad-42ad-bd0d-e870a19dbc9a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic657523a72064bf8a77241824eec1de4_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtNi0xLTEtMA_d2e3ea1d-6575-4d44-adb2-ada935acca7a"
      unitRef="usd">59748000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea41bafdaa19451b99ca8455af31092b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTAtOC0xLTEtMA_7e274c01-91d0-4733-9f14-7e42299edb22"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie14a072a848f45a5a23bc9f805fbbd08_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtMi0xLTEtMA_fbc91dab-cb82-4d42-8c11-c754b8617252"
      unitRef="usd">634514000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i239343e7b44f41dabd006bd02fa42bff_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtNC0xLTEtMA_c0ae0461-5441-4f9a-93ec-7624309ad348"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if099e69b9be14094b333354d839f0f79_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtNi0xLTEtMA_d5d39540-2d10-4d51-ad4e-482fb2244843"
      unitRef="usd">634514000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic860375e3027429092c256d65a2d7780_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTEtOC0xLTEtMA_5f78ffce-5b56-41a7-82df-5647119bbb27"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="icdc53aba859045ecb0ca135b483634d7_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItMi0xLTEtMA_c4374db8-d5a5-4d2e-afd8-109e6f902de4"
      unitRef="usd">1481000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibe092ad14ecf40ecbc93697363251ede_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItNC0xLTEtMA_db9fcc3d-7ed7-481c-8615-f0ae418c39ac"
      unitRef="usd">1481000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i0949304a7dde4229b6e753cd9903c40e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItNi0xLTEtMA_32e390df-77ff-4104-b5b0-35749b3e02ba"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i4d0a82f69d8e49c7bf0facdafd02a08b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTItOC0xLTEtMA_a305cd34-b23c-4aa9-b203-7c24d2e90e87"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16e0f6431e4d44508c464f542f15baa9_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtMi0xLTEtMA_fa271bab-afa5-4508-a89e-b53d7308bedf"
      unitRef="usd">1607818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4eb09fac19014b80be63710b35a8db33_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtNC0xLTEtMA_68344249-f15d-4dc1-9dde-d86aaf463ff7"
      unitRef="usd">135921000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9de1d13c04544ccda16e21d30fb14653_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtNi0xLTEtMA_72f7f6e2-de95-456d-818c-c8083f166600"
      unitRef="usd">1471897000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i782b647a38c84737b078e327971daeba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOmIzNDdiYjRiNTU3OTRkOTliNWViZWEzZTAyYTdhZDI5L3RhYmxlcmFuZ2U6YjM0N2JiNGI1NTc5NGQ5OWI1ZWJlYTNlMDJhN2FkMjlfMTMtOC0xLTEtMA_1c170133-eb29-4d84-a4c9-edb8d68c51a7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib04ae69b490e4a07b9dd11c6a1a057d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi0yLTEtMS0w_a6f3fcc1-2297-49c7-9c69-541a602c90ca"
      unitRef="usd">221281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i40aef21a5b0742b6919605b695cba83a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi00LTEtMS0w_fabf867a-a1c7-4b68-a0d6-fe633c926e07"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i534eab2866fc4b1bb0f1e30546b2550e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi02LTEtMS0w_a20a582c-f7ca-451f-be2c-69c6459c69f1"
      unitRef="usd">221281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d0c030ef7f6469c8c51584431c73bee_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMi04LTEtMS0w_a35ff95a-aa7a-41ca-aeb2-0f363b102c45"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iedf54ff63ecd4190a0aebd37630638c0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy0yLTEtMS0w_92d2b94a-bb4f-4dd8-9b63-6f301ccee0aa"
      unitRef="usd">102445000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib51284ca40ae4f409a968f2a88ae537c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy00LTEtMS0w_6b784180-cf91-48a9-b9c2-b6ee523b3cfd"
      unitRef="usd">102445000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i28d596b8dc524e17b6c9b06b62b6040d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy02LTEtMS0w_9753dbe0-ca61-4fe4-85bb-ffb6df2c40a3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6219fb42fe014e16a1c218a1ab221110_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMy04LTEtMS0w_067996e7-a6b0-468a-a10e-30cbf50f3da0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8081f4ca6b924dd5986fc5e0a2f8b585_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS0yLTEtMS0w_24f1e679-2ddf-4d3b-9789-86045022346f"
      unitRef="usd">8951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5938ec1fdaa449c2b1ecc81f9993204c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS00LTEtMS0w_02e2edec-be43-4ef9-8ca8-e94f22599772"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i94c3b43b17584cae8dac039f9d951a2b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS02LTEtMS0w_3ad7c2bb-63c5-451a-a130-704fc858e7c3"
      unitRef="usd">8951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8eaca78602548f881448af5a5dc5dc2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNS04LTEtMS0w_d8e679e5-7167-48fc-ab65-9cdbd8192550"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13a256ed0c704bdaa3843a8e99ae65b0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi0yLTEtMS0w_f719a370-72ae-4b19-934d-5dea37b86be4"
      unitRef="usd">57197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i786e48af2f8048819a014a47ad5f3590_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi00LTEtMS0w_f258f3ae-282d-4b65-ace5-2e000e2a95e3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64cd7b4acbce48ee8c20aa3dc411db8a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi02LTEtMS0w_51cc9733-bae8-42f2-9a74-f87b520222df"
      unitRef="usd">57197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a446afad065485689143f29fefeb88b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNi04LTEtMS0w_a38d7b95-7694-415f-9e32-7d61cd6048d6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cc9691ef8ec419190202c98ca260168_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy0yLTEtMS0w_a854ba59-f047-47ba-80e4-859111e14cb5"
      unitRef="usd">232410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51a9ec62896246148cc11c6a75758e7d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy00LTEtMS0w_d21ed719-9ca1-44e6-87c5-c4c049a5385b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fc8b8cbc9dc4a3fa34ac39e8ac315bd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy02LTEtMS0w_1ac3f55a-c955-42e8-9281-593a60193b52"
      unitRef="usd">232410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d00afa93a0d4d08987a2f888620c445_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfNy04LTEtMS0w_5f6b4768-7ff2-40a6-bd0a-9c16b6b20eab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40f9758c7a5442eb909c35e568f89d1a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC0yLTEtMS0w_ca1661f7-6730-4713-921e-0018bef67fe8"
      unitRef="usd">39018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6809fdac18e942108fea8b72dfefb89d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC00LTEtMS0w_81aed436-df60-4794-80d6-a013fb3ff9a1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i563399d00a3f4495921402e83ebb9b19_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC02LTEtMS0w_ade25e6f-3560-4dda-a115-0189ae2b0bf9"
      unitRef="usd">39018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77d6099e88b14f529fcdbf31508676b1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOC04LTEtMS0w_d4e5b170-1713-427a-a1b7-fcf03e63647d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib04ae69b490e4a07b9dd11c6a1a057d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS0yLTEtMS0w_c2c240c2-375b-4c9f-98be-2e388788a749"
      unitRef="usd">325227000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40aef21a5b0742b6919605b695cba83a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS00LTEtMS0w_8644cadb-8f5a-4cc3-9c5b-ef585864c9d0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i534eab2866fc4b1bb0f1e30546b2550e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS02LTEtMS0w_ed3724f3-fdee-4e91-b65b-6bc50dc08ead"
      unitRef="usd">325227000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d0c030ef7f6469c8c51584431c73bee_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfOS04LTEtMS0w_68966600-8039-4a20-96c2-414746f3609f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie975d68357554af895cd61a0cde4dbcb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtMi0xLTEtMA_ba377088-782a-43e5-9b20-a5bd652ae3f0"
      unitRef="usd">1206000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7fdecb33a35d4e5eb7f0e714d9cd1534_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtNC0xLTEtMA_516b7fbe-5be4-49e1-bb61-1ed004fb791f"
      unitRef="usd">1206000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iee8d158421a74475a932f3e1697894c8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtNi0xLTEtMA_b08d4871-461f-4c3c-a3ed-f227e17fab7e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2ecb9a3c8f1c431198624af0dce809c1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTAtOC0xLTEtMA_1634daf3-f1c6-4b12-9425-d06b47325f68"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iedf54ff63ecd4190a0aebd37630638c0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtMi0xLTEtMA_b9cc1984-2af2-453a-817e-0556b71a0544"
      unitRef="usd">1477000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib51284ca40ae4f409a968f2a88ae537c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtNC0xLTEtMA_8dd28453-a62e-4dd0-8d52-b64d09dd8197"
      unitRef="usd">1477000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i28d596b8dc524e17b6c9b06b62b6040d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtNi0xLTEtMA_1af3c19e-e704-4a14-9013-3b3cb56dc825"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i6219fb42fe014e16a1c218a1ab221110_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTEtOC0xLTEtMA_88470a46-a7c9-4aef-b8bd-e73ad2aef847"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie975d68357554af895cd61a0cde4dbcb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItMi0xLTEtMA_6ec07f20-bd52-4181-8b65-b1b23af2bb0f"
      unitRef="usd">989212000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7fdecb33a35d4e5eb7f0e714d9cd1534_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItNC0xLTEtMA_5cfb1ed8-e825-42f1-9f0f-58c1c25008d5"
      unitRef="usd">105128000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee8d158421a74475a932f3e1697894c8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItNi0xLTEtMA_32a97c21-1610-4755-bcb1-e0da5e7fa323"
      unitRef="usd">884084000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ecb9a3c8f1c431198624af0dce809c1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RhYmxlOjhiYmQxNWUxNDJkNTQ1NzQ5NmFhZGZlNmM0YzZmOGZiL3RhYmxlcmFuZ2U6OGJiZDE1ZTE0MmQ1NDU3NDk2YWFkZmU2YzRjNmY4ZmJfMTItOC0xLTEtMA_35f5c104-0ffa-40d1-ac91-1c4077680484"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfMjc0ODc3OTA3MDU2NA_3210a30f-64c0-4afe-8685-198469e73cb1"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfMjc0ODc3OTA3MDU2NA_55c91cd8-c464-4419-b7f0-c2020e28ee38"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib4533404dc7f419c81cf7e77f58ea8c5_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzU2_2cbeeaa1-1eee-4ce9-9e44-b8336add83ec"
      unitRef="usd">30100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfMzI5ODUzNDg5MTgxMg_48a8a139-feda-4909-b41e-b3e0764c5c46"
      unitRef="usd">30000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i1f6535ccbf5045358595e81d855d972e_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzY5NjU4MTM5ODQ0Mg_c102b49b-f9e0-49d7-828e-94fd39d9c213"
      unitRef="shares">5000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i9c5e31efccf54c278eb1d25e678417d7_I20190926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzY5NjU4MTM5ODQ1Mw_f6fe7c2e-adee-4627-8c26-e6a26c37c19f"
      unitRef="shares">5000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="iedd70bee38ec4be4894eb36e4bddfaf7_I20190927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV81OC9mcmFnOmMzZDQ2ZTk3NTZkYjQ2OTA5N2FkNjU0NjI4OTJiZTRjL3RleHRyZWdpb246YzNkNDZlOTc1NmRiNDY5MDk3YWQ2NTQ2Mjg5MmJlNGNfNzY5NjU4MTM5ODQ2NA_c93a4fe4-2f3f-495e-ad36-b182e9cc861c"
      unitRef="shares">1111111</us-gaap:InvestmentOwnedBalanceShares>
    <alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RleHRyZWdpb246MGU2MWVlNWZjMGI0NDZiNWJlNjJmNjk0YjBlYWM2N2NfODI0NjMzNzIxMDg5NA_560b2879-6238-465c-bf54-3fc623a68e87">MARKETABLE DEBT SECURITIES&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We obtain fair value measurement data for our marketable debt securities from independent pricing services. We perform validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand the methods and data sources used. Additionally, we perform our own review of prices received from the independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets. We did not record any impairment charges related to our marketable debt securities during the nine months ended September&#160;30, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:54pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize our marketable debt securities as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879765%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,289,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,289,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879765%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;546,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;546,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.783626%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.742690%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.742690%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;674,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;797,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;662,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We classify our debt security investments based on their contractual maturity dates. As of September&#160;30, 2019, the contract maturity for all of our available-for-sale debt securities was less than one year.&lt;/span&gt;&lt;/div&gt;</alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RleHRyZWdpb246MGU2MWVlNWZjMGI0NDZiNWJlNjJmNjk0YjBlYWM2N2NfNzY5NjU4MTM5NzI2MQ_92bb71df-86d7-49e5-bedd-209211d719d4">&lt;div style="text-indent:54pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize our marketable debt securities as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879765%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,289,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,289,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879765%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;546,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;546,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi0xLTEtMS0w_236f8442-dc65-4a37-b007-9fa756fd73b8"
      unitRef="usd">3053000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi0zLTEtMS0w_3c1b0190-b2ab-4be2-bbb0-8d0deee16b0e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi01LTEtMS0w_7e4e0d08-84e8-478a-9908-6bece2c08543"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74014017f8ee43b3b9a7e4ef08932177_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMi03LTEtMS0w_662a65fa-3519-4d0a-b6af-b1399d1c0185"
      unitRef="usd">3053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy0xLTEtMS0w_0d5272a9-e99b-41d0-bf3f-e6911b2431ab"
      unitRef="usd">29487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy0zLTEtMS0w_7fdc8978-4850-4336-ba73-8a08b1f061a4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy01LTEtMS0w_5fc6dbc1-3140-449a-a441-63483c82c5bc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab3020f4366f48a4bbcc014e09a08814_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfMy03LTEtMS0w_eeb9db78-f9a8-40c7-ae46-6c994e1b3d81"
      unitRef="usd">29487000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC0xLTEtMS0w_bb3b52c0-3872-41ec-bc26-53fb9f249674"
      unitRef="usd">89975000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC0zLTEtMS0w_0c3cc6c0-c7c9-4190-9a53-c1f7c76c1ffd"
      unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC01LTEtMS0w_475463fd-47f8-4cf4-b50b-34695d3ec404"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5dd5a11ef97c4a0b95fb143b6b42729d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNC03LTEtMS0w_0fdedb3a-b534-4025-9fa7-8e23fe594155"
      unitRef="usd">90032000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS0xLTEtMS0w_6576637a-937b-4fbd-b63c-7d2f061d4a2b"
      unitRef="usd">59737000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS0zLTEtMS0w_23c4d0b7-a8cb-485e-ae33-c5ecf93994f3"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS01LTEtMS0w_feab791d-5668-453c-be2d-2aa7fffaf036"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i21bcaecfc40942ca8fd4007f198b3c58_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNS03LTEtMS0w_a72fcba8-8cc4-4fac-8cbb-10c0568da743"
      unitRef="usd">59748000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if63df20ed74a495096a637566cb09eeb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi0xLTEtMS0w_45ccdd60-a78f-48aa-874a-693928dc6a38"
      unitRef="usd">1289294000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if63df20ed74a495096a637566cb09eeb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi0zLTEtMS0w_614dc29d-e76f-4882-aecd-0a08e0b2d75f"
      unitRef="usd">298000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if63df20ed74a495096a637566cb09eeb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi01LTEtMS0w_7ddfe03d-d772-4a9f-856b-781a507d7f2d"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if63df20ed74a495096a637566cb09eeb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNi03LTEtMS0w_e6f064cf-8ea5-49f0-815b-c3d886571412"
      unitRef="usd">1289577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy0xLTEtMS0w_6e3d4620-b857-4bd6-ab71-fc1658937bb7"
      unitRef="usd">1471546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy0zLTEtMS0w_7d768717-3121-468f-9b5f-4441fea176be"
      unitRef="usd">395000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy01LTEtMS0w_da493a52-ebaf-4aa2-b6e5-c8c2da270d11"
      unitRef="usd">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOmIxYTAxMzU1ZWQ1NzQ2ZThhOThhNjg2MGExNDA0NzA5L3RhYmxlcmFuZ2U6YjFhMDEzNTVlZDU3NDZlOGE5OGE2ODYwYTE0MDQ3MDlfNy03LTEtMS0w_90e3050e-8eff-4427-8f1e-9aa9dc7e13af"
      unitRef="usd">1471897000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi0xLTEtMS0w_32b531f0-95b4-4bf1-a7f9-72d2531cdcd5"
      unitRef="usd">8951000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi0zLTEtMS0w_d6a7089f-a98d-43f8-8f93-29deffc7c340"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi01LTEtMS0w_e18e19dd-379a-43ac-8ca1-bd37d03eac77"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63b98f93930b4ca1a7e47371e33fbf42_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMi03LTEtMS0w_66f7abe4-54de-43c4-a23f-ece1d42f1690"
      unitRef="usd">8951000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy0xLTEtMS0w_0e51b4bb-f76b-498a-b451-621ac9f81a4b"
      unitRef="usd">57197000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy0zLTEtMS0w_015d8819-ae68-4d83-8aeb-f974e0e137c7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy01LTEtMS0w_2b902612-9420-41a2-91a4-4fcccbbecf48"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d791afc3ff048e39ee8f08279c377d5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfMy03LTEtMS0w_28b09d32-5f87-4e5a-95c1-5cc58d774302"
      unitRef="usd">57197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC0xLTEtMS0w_6fe1d6ef-400e-44f1-8b9c-dace477a2363"
      unitRef="usd">232695000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC0zLTEtMS0w_b0fc4108-480f-4e28-9538-a735707667b3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC01LTEtMS0w_01c35c18-9c5b-4244-b3ae-4bb28d76671c"
      unitRef="usd">285000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6057c3e479cc4cdba31104be591267b3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNC03LTEtMS0w_ae2d0742-8fcb-440d-9973-3aeca4859954"
      unitRef="usd">232410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS0xLTEtMS0w_d7cf0d90-efe0-407d-a4c8-32eb6d06d719"
      unitRef="usd">39031000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS0zLTEtMS0w_97094c2f-8dcd-42ca-a551-9682dc9676e7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS01LTEtMS0w_9c6e7e3c-a997-424d-9cce-81bdbdfb0c0a"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14f2602865d142ab9138159f4fe344a7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNS03LTEtMS0w_b65e922f-f83f-454e-bfb3-8b8eff7e1570"
      unitRef="usd">39018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi0xLTEtMS0w_1ed5d96e-7c8e-4af3-b29a-c8c0d72051ce"
      unitRef="usd">546631000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi0zLTEtMS0w_10f32754-cd68-4e09-97c9-b3d7c865b56e"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi01LTEtMS0w_5a61384c-f03c-4f88-86e7-6e70e6a1f4ce"
      unitRef="usd">124000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b4184a62df84ea0bd011be2d3b6fde9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNi03LTEtMS0w_002a3ffb-0fa2-4f75-9bb9-e50440089a36"
      unitRef="usd">546508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy0xLTEtMS0w_5730b0ab-92a6-4124-8844-890376c75b95"
      unitRef="usd">884505000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy0zLTEtMS0w_701a19d4-67dd-485f-87cd-20e251a246c5"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy01LTEtMS0w_b9d26853-8c34-4355-992b-ecc511d1e368"
      unitRef="usd">422000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjZlNzg2OWM4ODAzNjQwMzdiMjAxNzdlZTc1ZmIyMDg1L3RhYmxlcmFuZ2U6NmU3ODY5Yzg4MDM2NDAzN2IyMDE3N2VlNzVmYjIwODVfNy03LTEtMS0w_f1c22cae-a77c-4db4-9c68-510a9f3b1365"
      unitRef="usd">884084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RleHRyZWdpb246MGU2MWVlNWZjMGI0NDZiNWJlNjJmNjk0YjBlYWM2N2NfNzY5NjU4MTM5NzI2Mg_352e5c25-92cb-4cdc-8ae9-7418a87c8687">&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.783626%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.742690%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.742690%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;674,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;797,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;662,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,471,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;884,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMS0xLTEtMS0w_f833a8a6-a2e8-414a-9973-317018c135b8"
      unitRef="usd">674143000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMS0zLTEtMS0w_bfb32911-71ee-498c-babd-f00630f39dcd"
      unitRef="usd">221281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMi0xLTEtMS0w_d86e45a7-195d-4e20-8ab1-e576c73958d0"
      unitRef="usd">797754000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMi0zLTEtMS0w_ae5aed73-173c-4c2b-93d3-f157717a501c"
      unitRef="usd">662803000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMy0xLTEtMS0w_698c2009-b432-47b4-92e1-3f0f6b76cc8c"
      unitRef="usd">1471897000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82MS9mcmFnOjBlNjFlZTVmYzBiNDQ2YjViZTYyZjY5NGIwZWFjNjdjL3RhYmxlOjYwZmFjMDk2MDIzZDRiMTliOTRlM2VmMTdjOGZjNTA4L3RhYmxlcmFuZ2U6NjBmYWMwOTYwMjNkNGIxOWI5NGUzZWYxN2M4ZmM1MDhfMy0zLTEtMS0w_4eeafee6-9e3e-4d23-a2cf-d726ca72eba5"
      unitRef="usd">884084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfNzY5NjU4MTM5ODk5NA_fee092ca-04d7-4f54-b7d5-951e4a0335d0">LEASES&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Overview of Significant Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We lease three facilities for office and laboratory space in Cambridge, Massachusetts that represent substantially all of our significant lease obligations.&#160;An overview of these significant leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;675 West Kendall Street&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We lease office and laboratory space located at 675 West Kendall Street, Cambridge, Massachusetts under a non-cancelable real property lease. In September 2019, we moved our corporate headquarters and research facility to this location from our 300 Third Street location. The lease commenced on May 1, 2018 and monthly rent payments became due commencing on February 1, 2019 upon substantial completion of the building improvements, and continue for 15 years, with options to renew for two five-year terms each. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;300 Third Street&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We lease office and laboratory space located at 300 Third Street, Cambridge, Massachusetts under a non-cancelable real property lease agreement dated as of September 26, 2003, as amended. The term of the lease expires on January&#160;31, 2034, with an option to extend for two additional five-year terms. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;101 Main Street&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We lease office space located on several floors at 101 Main Street, Cambridge, Massachusetts under non-cancelable real property lease agreements entered into in March and May 2015 that will expire in March 2024 and June 2021, respectively, each with an option to renew for one five-year term. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Lease Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Our facility leases described above generally contain customary provisions allowing the landlords to terminate the leases if we fail to remedy a breach of any of our obligations under any such lease within specified time periods, or upon our bankruptcy or insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The below table summarizes our costs included in operating expenses related to leases we have entered into through September&#160;30, 2019, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.349927%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.959004%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.959004%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Short-term lease costs were not material for the&#160;three and nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Net cash paid for the amounts included in the measurement of the operating lease liability in our condensed consolidated balance sheet and included in accrued expenses and other within operating activities in our condensed consolidated statement of cash flow was $24.8 million for the nine months ended September&#160;30, 2019.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September&#160;30, 2019 was 13.4 years and 8.2%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future lease payments for non-cancellable operating leases and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September&#160;30, 2019 is as follows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.286969%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713031%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;356,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(231,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total discounted lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;276,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the prior lease guidance, minimum payments under our non-cancelable facility leases, as of December&#160;31, 2018, were as follows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.286969%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713031%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;390,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;562,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <alny:LeaseAgreementTerm
      contextRef="i16dd0de9646a4fda905e58f333423af5_D20150401-20150430"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfNzQ5_f3cb767d-5907-47e4-b3a8-f0b119000eda">P15Y</alny:LeaseAgreementTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="i57addb2cc587477995144b49e9eba89b_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjc0ODc3OTA3Mjg2MQ_b8b39f9b-3d22-4bdc-b7a2-750359e53c2b">options to renew for two five-year terms each</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <alny:ExtendedLeaseExpirationDate
      contextRef="i9fd9e2e99e294a098eb38e91d8de00b3_D20030925-20030926"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMTMxMQ_2d4fd80f-6fb4-4cec-8f6d-1d62ebc57a37">2034-01-31</alny:ExtendedLeaseExpirationDate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="i65a3b729d2b6434facd1ef9436293344_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjc0ODc3OTA3MjkyNg_c971dc0d-d9b8-47fe-a332-d19830a564cc">option to extend for two additional five-year terms</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="i1997e78a21c14482b37dd96a0a0275a3_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjc0ODc3OTA3Mjk4Nw_f4935b24-75ad-42bd-aa48-c3451ff33458">option to renew for one five-year term</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMzM0NQ_68c24dc0-e7da-46b9-bece-e32a30fbc574">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The below table summarizes our costs included in operating expenses related to leases we have entered into through September&#160;30, 2019, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.349927%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.959004%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.959004%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMS0xLTEtMS0w_bbac65ed-7fb6-4290-af00-5475e2b90d62"
      unitRef="usd">9282000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMS0zLTEtMS0w_c78e5689-6df8-490c-ae55-632e550d3dfa"
      unitRef="usd">27863000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMi0xLTEtMS0w_c2cde969-91ea-49eb-a047-44ea3dd1e13f"
      unitRef="usd">3460000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMi0zLTEtMS0w_0c6e20e6-8ea3-4a6a-9e0c-e908397bd530"
      unitRef="usd">12993000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMy0xLTEtMS0w_10521210-443a-4bac-bebf-fe082d5f2518"
      unitRef="usd">12742000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjJlNjRlMTk1N2U3YTRiOTNiNjFmYjNkOTZlNTdmZDYzL3RhYmxlcmFuZ2U6MmU2NGUxOTU3ZTdhNGI5M2I2MWZiM2Q5NmU1N2ZkNjNfMy0zLTEtMS0w_07f8fc03-b3be-47c2-8300-865958a0577d"
      unitRef="usd">40856000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjgxMA_79df0be3-5128-4b9f-b8c8-87e5a5bb53a1"
      unitRef="usd">24800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjk0Nw_8398108e-26c2-493e-a360-226e7799f701">P13Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMjk1NA_8d99c8fb-98ca-47ea-94f6-af2b24fa785d"
      unitRef="number">0.082</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMzM0Ng_71743cd6-b856-4964-aa9e-3e4528ae31a5">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future lease payments for non-cancellable operating leases and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September&#160;30, 2019 is as follows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.286969%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713031%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;356,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total undiscounted lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;536,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(231,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total discounted lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;276,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMS0xLTEtMS0w_2ad40483-648d-439b-a1c4-036d6aa20b05"
      unitRef="usd">8223000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMi0xLTEtMS0w_f62bb06d-1c79-4a1d-abb5-c927876c5876"
      unitRef="usd">28700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMy0xLTEtMS0w_d6bb1543-0a16-4303-bcdd-90d35032fae3"
      unitRef="usd">36388000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNC0xLTEtMS0w_68663015-9355-402c-882f-561312dc0287"
      unitRef="usd">36510000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNS0xLTEtMS0w_218062c7-916a-48e0-8e67-2645024391c4"
      unitRef="usd">35576000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <alny:LesseeOperatingLeaseLiabilityPaymentsDueYearSix
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNi0xLTEtMS0w_fd4270c9-c10e-48a1-8bbc-8a6d53fe601c"
      unitRef="usd">34670000</alny:LesseeOperatingLeaseLiabilityPaymentsDueYearSix>
    <alny:LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfNy0xLTEtMS0w_51842d92-fbdd-46b6-a55c-daba7bc5ee7a"
      unitRef="usd">356208000</alny:LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfOC0xLTEtMS0w_dab6d7f6-bd11-47ef-8683-3e0447bba1b6"
      unitRef="usd">536275000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfOS0xLTEtMS0w_0eb797f5-63bc-4cba-ac17-09cb00bbc83c"
      unitRef="usd">231654000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTAtMS0xLTEtMA_73e560ee-88a7-4751-8ca7-8408f64a58c1"
      unitRef="usd">304621000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTItMS0xLTEtMA_049b4e96-299c-4b59-bd4a-8ae537d25889"
      unitRef="usd">28165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTMtMS0xLTEtMA_c84512f7-915f-4916-9036-62b2ca02bf5c"
      unitRef="usd">276456000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjM0NWYxNjk1MmYxMzQ0NTNiMzc4ZjdlMjA1NmU4YzI4L3RhYmxlcmFuZ2U6MzQ1ZjE2OTUyZjEzNDQ1M2IzNzhmN2UyMDU2ZThjMjhfMTQtMS0xLTEtMA_406fd56a-674b-460f-8c40-0119f644874b"
      unitRef="usd">304621000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RleHRyZWdpb246ZmU5OGE5MGQ1ODExNDQzZWE0Zjg4NDdmZWUzZDE3MzJfMzM0Nw_341e1838-4f95-4678-ab5f-8553b5d5cdf1">&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the prior lease guidance, minimum payments under our non-cancelable facility leases, as of December&#160;31, 2018, were as follows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.286969%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.713031%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;390,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;562,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfMS0xLTEtMS0w_f09cc295-8700-41e1-97f0-a1f675969b38"
      unitRef="usd">32228000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfMi0xLTEtMS0w_dfe55d66-bc06-4c57-ba67-7f03af233f79"
      unitRef="usd">34826000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfMy0xLTEtMS0w_8f798152-0414-4dd1-beaf-c06c829fac72"
      unitRef="usd">34410000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNC0xLTEtMS0w_1955b4d6-9800-465a-bfb0-06c3e1ee3edf"
      unitRef="usd">34826000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNS0xLTEtMS0w_2811f5c8-6b3a-4fc8-b426-0b905dbaac9f"
      unitRef="usd">35270000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNi0xLTEtMS0w_c267727d-6681-4a11-8b5e-885795c4639f"
      unitRef="usd">390455000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i0e42c46e2c9e420489c577ce9a0935d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV82Ny9mcmFnOmZlOThhOTBkNTgxMTQ0M2VhNGY4ODQ3ZmVlM2QxNzMyL3RhYmxlOjI1NGVjMWIyNzE0MDQxMjNhNzUwZDViMjA3ZDUyZDk0L3RhYmxlcmFuZ2U6MjU0ZWMxYjI3MTQwNDEyM2E3NTBkNWIyMDdkNTJkOTRfNy0xLTEtMS0w_97b4a321-1403-40c9-adf7-63e5cb58b2e5"
      unitRef="usd">562015000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <alny:CreditAgreementDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfNzY5NjU4MTM5ODA1Mw_ade149ac-8877-45c8-9d78-2826a7305a24">CREDIT AGREEMENT&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On April&#160;29, 2016, we entered into a Credit Agreement by and among Alnylam U.S., Inc., as the borrower, us, as a guarantor, and Wells Fargo Bank, National Association, as the lender.&#160;The Credit Agreement was entered into in connection with the planned build out of our drug substance manufacturing facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Credit Agreement provided for a $30.0 million term loan facility and was scheduled to mature on April&#160;29, 2021. On September 27, 2019, we repaid in full the $30.0 million outstanding principal amount under the Credit Agreement and the Credit Agreement terminated in accordance with its terms upon repayment of the outstanding indebtedness. Interest on borrowings under the Credit Agreement was calculated based on LIBOR plus 0.45%, except in the event of default.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The obligations of the borrower and us under the Credit Agreement were secured by cash collateral in an amount equal to, at any given time, at least 100% of the principal amount of all term loans outstanding under such Credit Agreement at such time. As of December&#160;31, 2018, we recorded $30.0 million of cash collateral in connection with the Credit Agreement as restricted investments.&lt;/span&gt;&lt;/div&gt;</alny:CreditAgreementDisclosureTextBlock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfMzY5_d2979219-02b5-4905-8ae0-58b7f3ef3373"
      unitRef="usd">30000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="ice75d291b75345eeb04d09221d4ac4bc_D20160429-20160429"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfNDA2_8e11f72f-3a49-4704-b8ba-28feec98f095">2021-04-29</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i010e5132fb454a8f9ef2ee2e7458409f_D20190927-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfMjc0ODc3OTA3NDE3Mw_48a8a139-feda-4909-b41e-b3e0764c5c46"
      unitRef="usd">30000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia12206eca6a84503bf5e9fcc26bd4ded_D20160429-20160429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfNjE4_2657429f-2dbd-4cd9-aec2-003908cb8a3b"
      unitRef="number">0.0045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage
      contextRef="ifb3e8a8fa91c4e08a54b904445e3b904_D20160429-20160429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfOTY2_5ee57c72-a708-4419-9fe9-9f6f27d4ff4f"
      unitRef="number">1</alny:CashCollateralRequiredForPrincipalAmountOutstandingPercentage>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i8211fd2babc7426599d8a4da01554401_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83My9mcmFnOmRjZjNiMDY3ODhiMDQ2ODVhMDQ2NmU3NDY2MDM2NDNhL3RleHRyZWdpb246ZGNmM2IwNjc4OGIwNDY4NWEwNDY2ZTc0NjYwMzY0M2FfMTA5OQ_7aceda3c-8173-4734-b670-5ce5e1cc8cf5"
      unitRef="usd">30000000.0</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNzY5NjU4MTQwMDgyMg_908391dc-f669-40bb-8ec3-121a0dd377a2">EQUITY&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2019, we sold an aggregate of 5,000,000 shares of our common stock through an underwritten public offering at a price to the public of $77.50 per share. As a result of the offering, we received aggregate net proceeds of $381.9 million after deducting underwriting discounts and commissions and other offering expenses of approximately $5.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Regeneron Equity Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 8, 2019, we executed the Regeneron SPA with Regeneron to sell 4,444,445 shares of our common stock, par value $0.01 per share for aggregate cash consideration of $400.0 million, or $90.00 per share, which we refer to as the Equity Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As a condition to consummating the transactions contemplated by the Regeneron SPA, we and Regeneron entered into an Investor Agreement dated April&#160;8, 2019, or the Investor Agreement. Under the Investor Agreement, until the expiration or termination of the Research Term under the Regeneron Master Agreement subject to extension by one year if the Research Term or Regeneron Master Agreement is terminated by Regeneron at will, or by up to two years if as of the expiration or termination of the Research Term Regeneron owns more than 19.99% of our outstanding shares, Regeneron and its affiliates will be bound by certain &#x201c;standstill&#x201d; provisions. The standstill provisions include agreements not to acquire more than 30% of our outstanding shares of common stock, call stockholder meetings, nominate directors other than those approved by our board of directors, subject to certain limited exceptions, or propose or support a proposal to acquire us.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Further, under the Investor Agreement, Regeneron agreed to vote, and cause its affiliates to vote, all shares of our voting securities Regeneron is entitled to vote in a manner as recommended by our board of directors, except with respect to certain change of control transactions, liquidation or dissolution of our company, or, after the standstill term, any contested election of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Investor Agreement, Regeneron agreed not to dispose of any of the purchased shares or any shares of common stock beneficially owned by it immediately after the closing of the Regeneron Master Agreement, until the earlier of (i)&#160;the four-year anniversary of the closing of the Equity Transaction and (ii)&#160;the termination of the Regeneron Collaboration, subject to limited exceptions, which we refer to as the Lock-Up Period. Following the expiration of the&#160;Lock-Up&#160;Period, if at any time Regeneron beneficially owns at least 9.9% of our outstanding shares, then until such time as Regeneron beneficially owns less than 5% of our outstanding shares, Regeneron will not dispose of any shares except (a)&#160;pursuant to a registered underwritten public offering pursuant to the Investor Agreement, (b)&#160;in a manner consistent with the volume limitations set forth in Rule 144 under the Securities Act, or (c)&#160;as otherwise approved by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Investor Agreement, following the&#160;Lock-Up&#160;Period, Regeneron will have three demand rights to require us to conduct a registered underwritten public offering with respect to the shares of common stock beneficially owned by Regeneron immediately after the closing of the Equity Transaction. In addition, following the&#160;Lock-Up&#160;Period, subject to certain conditions, Regeneron will be entitled to participate in registered underwritten public offerings by us if other selling stockholders are included in the registration. The rights and restrictions under the Investor Agreement are subject to termination upon the occurrence of certain events.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Under the terms of the Regeneron SPA, if at the time of closing of the Equity Transaction a sufficient number of authorized shares of common stock under our Restated Certificate of Incorporation was not available, the Equity Transaction would have been settled in the form of our Series A redeemable convertible preferred stock. On April 25, 2019, following the receipt of stockholder approval at our annual meeting, a Certificate of Amendment was filed to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 125,000,000 to 250,000,000 shares, providing for a sufficient number of authorized shares of common stock available to be issued to Regeneron pursuant to the Equity Transaction.&#160;On May 21, 2019, subsequent to the expiration of the applicable pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Regeneron purchased 4,444,445 shares of our common stock for aggregate cash consideration of $400.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Because we had an obligation to Regeneron as of April 8, 2019 that may have resulted in the issuance of redeemable convertible preferred stock, we were required to follow the guidance in ASC 480 and mark-to-market the obligation to potentially issue this redeemable security until April 25, 2019, when it became known that the obligation would be fulfilled in common stock. The final mark-to-market adjustment of this obligation under ASC 480 resulted in us recording a gain of $9.4 million included in other income in the consolidated statements of comprehensive loss with the offsetting adjustment to equity netting against the $400.0 million proceeds that were received upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNzM_27ad70fc-5234-481b-b898-f7a6114a9d9a"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i436c9f5ba1394239990c555377c133a4_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMTcx_cf1f434e-9209-4b5b-87a1-2336d99e1bb8"
      unitRef="usdPerShare">77.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMjUy_eaf3db34-f728-40c7-8ba3-71cf14558ac9"
      unitRef="usd">381900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzU1_d0f53e7e-def3-44c2-b3b2-45b6cf213446"
      unitRef="usd">5600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDU3_69d8f71f-00bd-40e0-8c13-142006b73a83"
      unitRef="usd">4444445</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idc8680a0470f4515bbbb63de4581db15_I20190521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDk4_cd6982f3-db37-4dbc-b13b-869c1795e39c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNTQ3_cc95ed1b-57e2-420d-9a12-19896879556c"
      unitRef="usd">400000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="idc8680a0470f4515bbbb63de4581db15_I20190521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNTU1_2100af95-a5d3-48a3-b315-588b4dafb4f5"
      unitRef="usdPerShare">90.00</us-gaap:SharesIssuedPricePerShare>
    <alny:DateOfAgreement
      contextRef="i304e9e4a77f146f1b45c8803228f6a4d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMTQ0Nw_ec4ae51e-b81e-488e-8823-6dc415ca426c">2019-04-08</alny:DateOfAgreement>
    <alny:AgreementExtensionPeriod
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMjc0ODc3OTA3NTgzMw_3e0e3d3f-97d7-45d9-9c55-1731c97863b7">P2Y</alny:AgreementExtensionPeriod>
    <alny:OwnershipPercentageOfSharesOutstanding
      contextRef="i41895d919e574902acb6169b0edb03fd_D20190408-20190408"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMTgyMg_cd2b33e4-3a9d-4c8d-a96a-10d17ea73783"
      unitRef="number">0.1999</alny:OwnershipPercentageOfSharesOutstanding>
    <alny:OwnershipPercentageSharesOfStocksOutstandingUpperLimit
      contextRef="i6bd260dc66034da5a186aaf7726d2fee_D20190408-20190408"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMjAwMQ_ffcb2518-5c60-41a0-bde2-572b1707b5b9"
      unitRef="number">0.30</alny:OwnershipPercentageSharesOfStocksOutstandingUpperLimit>
    <alny:BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod
      contextRef="i41895d919e574902acb6169b0edb03fd_D20190408-20190408"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzE2MA_668cebab-c84a-42a8-b8f6-66917c62893d"
      unitRef="number">0.099</alny:BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod>
    <alny:BeneficialOwnershipPercentageOfSharesOutstanding
      contextRef="i821641a6e4a94fd6a4f2b42dc65d06d2_D20190408-20190408"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzI1Mg_08119abc-35bb-464f-8bb4-2405a2521c5a"
      unitRef="number">0.05</alny:BeneficialOwnershipPercentageOfSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5c4dc572daa54cea9409b772eff6e606_I20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDQ1MA_537ef148-6cbb-485e-b972-6d7df39c4e54"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i48cd17bd102c404d9c2fb188602a9b17_I20190425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDQ1Ng_ee1c8b20-79c3-4734-93d9-624ede0f8c21"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDc5Nw_ff285fb0-bb72-40dd-84a3-356b5a0e408f"
      unitRef="usd">4444445</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNDg2Mw_d49c40ca-a83a-495c-b757-deb0f79bfc23"
      unitRef="usd">400000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <alny:GainLossOnSaleOfCommonStock
      contextRef="i7f917e7daa184219863485fd13588358_D20190425-20190425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfNTM0NQ_59e95704-fbaa-4d86-a889-d469a1500674"
      unitRef="usd">9400000</alny:GainLossOnSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i55bb269e5d0445609b3bb6004f1ec837_D20190521-20190521"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV83OS9mcmFnOmExZTljZGI5NGI1ZTRjNGM4NWYwOTk3YWM5M2MxZDYxL3RleHRyZWdpb246YTFlOWNkYjk0YjVlNGM0Yzg1ZjA5OTdhYzkzYzFkNjFfMzI5ODUzNDg4ODk1NA_d49c40ca-a83a-495c-b757-deb0f79bfc23"
      unitRef="usd">400000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RleHRyZWdpb246NWJkZGNjYmRlZGRkNDU1ZTg3ODhmMTg0NWE0ZDkyNDZfODI0NjMzNzIwODUwNg_dbfd66f1-6bf3-4b79-9a54-79ce810f51b5">STOCK-BASED COMPENSATION&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock-based compensation expenses included in operating costs and expenses, for the periods indicated, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.187683%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:11pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;129,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RleHRyZWdpb246NWJkZGNjYmRlZGRkNDU1ZTg3ODhmMTg0NWE0ZDkyNDZfMTg0_397f5be3-2553-4a64-a367-af3da51f203e">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock-based compensation expenses included in operating costs and expenses, for the periods indicated, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.187683%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.903226%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:11pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;108,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;129,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0fb16a3a7a347cf97e568dd2a32d15f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi0xLTEtMS0w_71beda30-8c8b-4387-93fb-19cce099f552"
      unitRef="usd">22737000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i756073bf9c7c485baa654d9c3b97871c_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi0zLTEtMS0w_d1c12d44-dcda-4f10-bb26-735bf73d5fbb"
      unitRef="usd">45784000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f962dd9c0f44fafacbd61a3c2eb05e8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi01LTEtMS0w_8dcd59e2-aa6f-4436-974c-0f20413e14e8"
      unitRef="usd">54144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c6c2484c92b4de1af5da63f0a53a5a3_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMi03LTEtMS0w_bae231af-95a0-4fa7-a847-712a0082b4a1"
      unitRef="usd">67537000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie27125284d00480e8f6436e54883feb0_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy0xLTEtMS0w_5b818e9c-608a-43a5-8115-eed70cf5822a"
      unitRef="usd">23272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id8c1e473ec654c44910204fe79355acb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy0zLTEtMS0w_c8421d9f-20f1-46c0-900c-133f705d4292"
      unitRef="usd">42170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib1a903160824485588e14c40fe27e4f4_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy01LTEtMS0w_60202d0c-efb8-4003-9a59-da5679efa3a8"
      unitRef="usd">54500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib20fa348345c43e6aa0c88af9024338c_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfMy03LTEtMS0w_24519e58-bea0-4ee3-ae3d-74b11598da07"
      unitRef="usd">62242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC0xLTEtMS0w_3d4eb521-35d5-4802-a18c-84ad482ca06a"
      unitRef="usd">46009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d7ae810fd9e49c89d0290c751519afb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC0zLTEtMS0w_58d18d62-34e6-46dd-82c0-f25ed4089171"
      unitRef="usd">87954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC01LTEtMS0w_59fe5ee6-7224-4020-93e6-286e156b137a"
      unitRef="usd">108644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84NS9mcmFnOjViZGRjY2JkZWRkZDQ1NWU4Nzg4ZjE4NDVhNGQ5MjQ2L3RhYmxlOjMzZDYxOWMxMjNmMTQ0ZTRiOTJhZjI2OWIxY2EzN2UzL3RhYmxlcmFuZ2U6MzNkNjE5YzEyM2YxNDRlNGI5MmFmMjY5YjFjYTM3ZTNfNC03LTEtMS0w_f7d08312-f668-483d-90dc-3cf95c007b86"
      unitRef="usd">129779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RleHRyZWdpb246ZWQyNGFmYzZiNzY0NDY3MmEwYjE0NmY2YjBkM2Q3ZGZfNzY5NjU4MTM5NzE5Mw_e44d6676-f130-461a-8876-96107e398e4c">NET LOSS PER COMMON SHARE&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding during the period. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. Potential common shares consist of shares issuable upon the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following common share equivalents (in thousands) were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RleHRyZWdpb246ZWQyNGFmYzZiNzY0NDY3MmEwYjE0NmY2YjBkM2Q3ZGZfODk5_53a7b632-c37d-49ad-99af-0f6d9473a4e2">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following common share equivalents (in thousands) were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i76aae8848c0147d7b950df899aa1ee06_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMi0xLTEtMS0w_553cf916-4e6c-4449-97e6-de0bcfca1c8e"
      unitRef="shares">13675000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a29165453f749cf90320576aab15e8e_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMi0zLTEtMS0w_ab1e3e1b-e017-430a-9815-b45a1b8f626c"
      unitRef="shares">12676000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9b94502431eb4c5aafa0614d51c18e74_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMy0xLTEtMS0w_6dc19446-cd74-4225-a517-688f0b47667b"
      unitRef="shares">668000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iebaaccb3176d4aea882b953a0bfbd222_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfMy0zLTEtMS0w_628e01d3-a75d-433e-bcf8-127315476aba"
      unitRef="shares">16000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfNC0xLTEtMS0w_fbf2fcd9-f292-481b-a5ef-faa2238363c9"
      unitRef="shares">14343000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV84OC9mcmFnOmVkMjRhZmM2Yjc2NDQ2NzJhMGIxNDZmNmIwZDNkN2RmL3RhYmxlOjNjMzdhYWY1MzllZDQ5NjQ5ZjU0YWEzNzI0M2I2ZTk4L3RhYmxlcmFuZ2U6M2MzN2FhZjUzOWVkNDk2NDlmNTRhYTM3MjQzYjZlOThfNC0zLTEtMS0w_29caada3-360a-46e4-b077-16db3503aa1f"
      unitRef="shares">12692000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RleHRyZWdpb246NGJjYjY0OWMyOTYxNGQxOWFhZDUwMzJmZTI5ZjkyMGZfODI0NjMzNzIwODY1OQ_dc8d08fc-27f4-4ecf-90f6-81183fc77aca">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;923,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;316,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash included in prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash included in long-term other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;925,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RleHRyZWdpb246NGJjYjY0OWMyOTYxNGQxOWFhZDUwMzJmZTI5ZjkyMGZfMzM2_993b42c3-11e3-4724-a3e3-a811ff8b020d">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.806452%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;923,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;316,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash included in prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash included in long-term other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;925,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMi0xLTEtMS0w_a4e36090-aa49-4f8f-b9fb-b5280885a4ef"
      unitRef="usd">923304000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMi0zLTEtMS0w_d7860505-45b7-492f-9cf7-4b2c7b6984fc"
      unitRef="usd">316608000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMy0xLTEtMS0w_85435244-0a98-4441-a26e-40c092852652"
      unitRef="usd">4000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfMy0zLTEtMS0w_03596949-b2d5-4797-b1b0-e39565534406"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNC0xLTEtMS0w_15306ff9-f823-4344-bb4c-16178f4a59d1"
      unitRef="usd">2442000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNC0zLTEtMS0w_3a3acd01-fd7d-481d-9100-b9039a55ba44"
      unitRef="usd">2138000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ib290959e61784a1896b905564c991cdf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNS0xLTEtMS0w_632dffa3-5b8e-4ac6-914e-a27f03980ab2"
      unitRef="usd">925750000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="id9f25a7c241a4588906a002ff847246a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85MS9mcmFnOjRiY2I2NDljMjk2MTRkMTlhYWQ1MDMyZmUyOWY5MjBmL3RhYmxlOjUxYzdhMzBiMDU0YjQyNDg4MDU1YTFmODZhNjY0NWU5L3RhYmxlcmFuZ2U6NTFjN2EzMGIwNTRiNDI0ODgwNTVhMWY4NmE2NjQ1ZTlfNS0zLTEtMS0w_77dc104d-f9ef-4bb9-afdd-9be23708ffad"
      unitRef="usd">318746000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfODI0NjMzNzIxMzc2OQ_f0273247-df79-4d41-83ed-d0d5dba8dab0">COMMITMENTS AND CONTINGENCIES&lt;div style="text-indent:9pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2016, we purchased 12 acres of undeveloped land in Norton, Massachusetts. We are constructing a manufacturing facility at this site for drug substance for clinical and commercial use. As of September&#160;30, 2019 and December&#160;31, 2018, property, plant and equipment, net, on our condensed consolidated balance sheets reflect $278.2 million and $227.7 million, respectively, of land and associated costs related to the construction of our drug substance manufacturing facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, we are a party to legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On September 26, 2018, Caryl Hull Leavitt, individually and on behalf of all others similarly situated, filed a class action complaint for violation of federal securities laws against us, our Chief Executive Officer and our former Chief Financial Officer in the United States District Court for the Southern District of New York. By stipulation of the parties and Order of the Court dated November 20, 2018, the action was transferred to the United States District Court for the District of Massachusetts. On May 8, 2019, the Court entered an order appointing a&#160;lead&#160;plaintiff, and on July 3, 2019, lead&#160;plaintiff&#160;filed a consolidated class action complaint, or the Complaint. In addition to the originally named defendants, the Complaint also names as defendants certain of our other executive officers, and purports to be brought on behalf of a class of persons who acquired our securities&#160;between September 20, 2017 and September 12, 2018 and seeks to recover damages caused by defendants&#x2019; alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The Complaint alleges, among other things, that the defendants made materially false and misleading statements related to the efficacy and safety of our product, ONPATTRO. The plaintiff seeks, among other things, the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed a motion to dismiss the Complaint in its entirety on July 31, 2019. The motion to dismiss was fully briefed on September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. The complaint is brought on behalf of an alleged class of those who purchased our securities pursuant and/or traceable to our November 14, 2017 public stock offering. The complaint purports to allege claims arising under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, and generally alleges that the defendants violated the federal securities laws by, among other things, making material misstatements or omissions concerning the results of our APOLLO Phase 3 clinical trial of patisiran. The plaintiff seeks, among other things, the designation of the action as a class action, an award of unspecified compensatory damages, rescissory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;We believe that the allegations contained in the complaints are without merit and intend to defend the cases vigorously. We cannot predict at this point the length of time that these actions will be ongoing or the liabilities, if any, which may arise therefrom.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Dicerna Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On June&#160;10, 2015, we filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc., or Dicerna, in the Superior Court of Middlesex County, Massachusetts seeking to stop misappropriation by Dicerna of our confidential, proprietary and trade secret information related to the RNAi assets we purchased from Merck Sharp &amp;amp; Dohme Corp., including certain N-acetylgalactosamine, or GalNAc, conjugate technology. In addition to permanent injunctive relief, we were also seeking monetary damages from Dicerna.&lt;/span&gt;&lt;/div&gt;On April&#160;18, 2018, we and Dicerna entered into a settlement agreement resolving all ongoing litigation between the companies. Under the terms of the settlement agreement, Dicerna was required to pay us an aggregate of $25.0 million, all of which we had received as of January 2019.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="i635ef6dc444f45e2a67366c5fb673343_I20160430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfOTA_155564fc-dd6a-4e3b-b92f-75a411433198"
      unitRef="sqft">12</us-gaap:AreaOfLand>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4abb8539eed44421b7213ceef0389203_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfMzU4_1c327830-9d92-4d51-9c46-21dee6f586c4"
      unitRef="usd">278200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id20e2ef3281f455ba39063a9f09b371c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfMzY1_8ed06e19-137d-4980-8c0c-261e7d70e748"
      unitRef="usd">227700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LossContingencySettlementAgreementDate
      contextRef="i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfNDAxMA_d69885fd-125c-451a-b6dd-2f811297fd55">April&#160;18, 2018</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV85NC9mcmFnOjE1N2NjMGY4ZWM0MDRmYmFhMzgwMjZhMjk1ZTkwMjJhL3RleHRyZWdpb246MTU3Y2MwZjhlYzQwNGZiYWEzODAyNmEyOTVlOTAyMmFfNDIxMw_88eed81a-5058-43cc-bbfc-790e14b302f6"
      unitRef="usd">25000000.0</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDAvZnJhZzpmNGE5ODlkMTVlNGU0ZTU1YmYzY2VjMDBlM2Q3YWQ5Zi90ZXh0cmVnaW9uOmY0YTk4OWQxNWU0ZTRlNTViZjNjZWMwMGUzZDdhZDlmXzgyNDYzMzcyMDkwNzM_f9d39085-d8a0-4df0-b918-03ef1ae5cba5">DEFINED BENEFIT PLANSWe maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The unfunded benefit obligation corresponds to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases and pension adjustments, offset by the fair value of the assets held by plan. The unfunded benefit obligation was approximately $4.0 million as of September&#160;30, 2019 and is recorded in other liabilities on the condensed consolidated balance sheet. The unfunded benefit obligation as of December&#160;31, 2018 and the total net periodic benefit cost for the three and nine months ended September&#160;30, 2019 and 2018 were not material.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1a9655ab33ba47a3b214bdd3432435d3_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDAvZnJhZzpmNGE5ODlkMTVlNGU0ZTU1YmYzY2VjMDBlM2Q3YWQ5Zi90ZXh0cmVnaW9uOmY0YTk4OWQxNWU0ZTRlNTViZjNjZWMwMGUzZDdhZDlmXzUwOA_0dc909ca-4770-4945-9a7e-4a13b367f669"
      unitRef="usd">4000000.0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90ZXh0cmVnaW9uOjRmZjYyMzJiNzhkYjRmYzA5MGYyZmVmZWYzYTE4MDAzXzgyNDYzMzcyMDg3Nzc_a5c4e7bc-5702-4fdc-b04d-4325c69fae28">OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the changes in accumulated other comprehensive (loss) income, by component, for the nine months ended September&#160;30, 2019 and 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.356725%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.327485%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized (Losses) Gains from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Total Accumulated Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Comprehensive (Loss) Income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.356725%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.327485%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized (Losses) Gains from Debt&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive (Loss) Income &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts reclassified out of accumulated other comprehensive (loss) income relate to settlements of debt securities and are recorded as interest income in the condensed consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90ZXh0cmVnaW9uOjRmZjYyMzJiNzhkYjRmYzA5MGYyZmVmZWYzYTE4MDAzXzQ1Mw_d8a341df-240f-4c45-bb1e-f243b323dd97">&lt;div style="text-indent:18pt;text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the changes in accumulated other comprehensive (loss) income, by component, for the nine months ended September&#160;30, 2019 and 2018, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.356725%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.327485%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Unrealized (Losses) Gains from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Total Accumulated Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"&gt;Comprehensive (Loss) Income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.356725%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.695906%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.327485%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized (Losses) Gains from Debt&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive (Loss) Income &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i920d2d842f894f7e86890f2d0f76a285_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtMS0xLTEtMA_93ef4bb9-0d6d-4966-a2af-269dfd3971ec"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia71b3c59a6854c088d21eef4ff92db76_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtMy0xLTEtMA_849c44a7-3d9e-4e16-af8e-61cdc94fd4c6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i22d215da162a4b1f870322c528da7252_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtNS0xLTEtMA_204d9182-5790-44ab-b7d6-b62ad5b89a6d"
      unitRef="usd">-421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i668cb2e656af4447be63e110a6773f58_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtNy0xLTEtMA_808cb8f4-9c9f-4289-ac29-4276c2da4539"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffcea211cbf84b608c3df605df16aac5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzEtOS0xLTEtMA_17ee9f84-658b-49d0-bbc7-8021cd426320"
      unitRef="usd">-33213000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItMS0xLTEtMA_1f991d44-117b-4f75-b140-2f87ea9a6d51"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItMy0xLTEtMA_f4dc51cd-15bc-4f46-b985-b58e5cb8c944"
      unitRef="usd">-4282000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItNS0xLTEtMA_a5ff62d3-ee89-4b93-ae49-9f692af59384"
      unitRef="usd">359000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItNy0xLTEtMA_4996ac94-64ba-4a83-a99a-9d6b9d981fdf"
      unitRef="usd">2281000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzItOS0xLTEtMA_cbd7925c-035a-4343-af69-f00859c1757b"
      unitRef="usd">-1642000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtMS0xLTEtMA_023bddbe-7433-465b-94bd-d9431c30cdde"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtMy0xLTEtMA_c0813cc6-f6d3-4b41-9c48-7f24b4354de9"
      unitRef="usd">-71000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtNS0xLTEtMA_8110b9f3-1096-40f3-a52c-fa897ab516ab"
      unitRef="usd">-413000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtNy0xLTEtMA_5864b55b-1e90-4b56-beef-14187f0e4916"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzMtOS0xLTEtMA_0aecc36d-a61f-42cd-b065-a39d4c7fbb59"
      unitRef="usd">-484000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib8ac79f2c1744ab8b129f28880c9b12f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtMS0xLTEtMA_dc190bca-330b-47d0-a02d-e039bf377fd2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia67d796dbaf94e2fab8b560647293242_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtMy0xLTEtMA_556c9b6e-061a-4f81-a228-d4d7fe16718c"
      unitRef="usd">-4211000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib77d993dc19343aea89f04cbca5dff69_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtNS0xLTEtMA_4f0be2c6-09dd-42c1-bdcf-142a983a4531"
      unitRef="usd">772000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3db276c4e9f44ed98bad147be30d52e6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtNy0xLTEtMA_82b362d1-b1a8-4ff6-8a7d-7c93091f2a57"
      unitRef="usd">2281000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzQtOS0xLTEtMA_f1204337-a7c7-4a59-b371-d23bdec8264e"
      unitRef="usd">-1158000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i40c726db79a1419ca5405f2c9219f5d5_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtMS0xLTEtMA_bafa6ce8-3ef4-4e73-8513-3879f17bfefb"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i730a5054c2f94c9685c25fdcab2d5d7a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtMy0xLTEtMA_16446eaa-d4dd-4490-9172-77efe4e5c708"
      unitRef="usd">-4211000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if14817b988c44e9f97cb96e8be08c094_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtNS0xLTEtMA_91ac64e4-198d-4cc9-8cdd-77eb7004332a"
      unitRef="usd">351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92f8703c144249dfa1533aa08a4f503a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtNy0xLTEtMA_8dc7cbdc-26e5-4307-a9f9-4cfd8747b657"
      unitRef="usd">2281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i051b47be2e4f44b18624cfd7fb7d1e52_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZToxOTA4MGFmODM4NWY0M2YwYTA5ODFkYTg3NjQ1YzAyNS90YWJsZXJhbmdlOjE5MDgwYWY4Mzg1ZjQzZjBhMDk4MWRhODc2NDVjMDI1XzUtOS0xLTEtMA_c77046ca-739c-4e0e-9161-ecb680950c0a"
      unitRef="usd">-34371000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i94bb522921334436b71c747686f4701a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtMS0xLTEtMA_9b1fc5ba-a575-4b3e-a2d8-6c26cd7ba630"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35867a636295441082ae888c09b539e8_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtMy0xLTEtMA_5c943923-1445-4f4f-b6be-e43fd62e97e7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ca4613a2da84898a3f92d22c8ec8558_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtNS0xLTEtMA_acdc3b5c-5128-4a04-a723-7f85b63380c6"
      unitRef="usd">-1641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic92b2ba692c74f76b138c30a332bc91c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtNy0xLTEtMA_c68ad6c2-f965-4a11-a70e-ca7704249fa2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dda98ef75fa4c0cabaec8f6917de928_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzEtOS0xLTEtMA_e1a5727b-ff4b-4125-aa7e-c0b88945f8bb"
      unitRef="usd">-34433000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItMS0xLTEtMA_89c00004-1df2-4dcf-9863-2d710af4f755"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItMy0xLTEtMA_70761d8c-0184-49f5-a247-1bf3e00bafbc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItNS0xLTEtMA_4e15b961-ea3c-4d8b-8e68-a01e7d51410e"
      unitRef="usd">-590000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie6d342895255493b9e648583464cf9bd_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItNy0xLTEtMA_c570e855-5d9d-4ba1-9376-40d0370a270e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzItOS0xLTEtMA_f797d83f-6c5b-4771-82c0-74fa5afa97d1"
      unitRef="usd">-590000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtMS0xLTEtMA_44f39125-daa2-4b7e-b2a3-d7ae187955c4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtMy0xLTEtMA_d9aed92d-4c41-4aaa-8241-a1f13a34c1a2"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtNS0xLTEtMA_d6e5ee61-8a22-4fbd-870d-874433fdf506"
      unitRef="usd">-1631000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie6d342895255493b9e648583464cf9bd_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtNy0xLTEtMA_f8ae2379-6521-4edf-84bd-77a8688fbc84"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzMtOS0xLTEtMA_3303d7b7-7722-4505-a843-1ce4125f92d6"
      unitRef="usd">-1631000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ida9992ae8ab84e09ae12d5b424deddf4_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtMS0xLTEtMA_266ae74e-fc40-49a6-9b87-77da8ab43a1f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i79ea58c433c241cd90421ddf064f1d05_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtMy0xLTEtMA_162a7352-e8ed-46c5-b0c9-9e5d21fc90b2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icafec2cacf59493aa033a544dbef3fe1_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtNS0xLTEtMA_20f1207b-61ac-4330-8d2c-a2d7d4538c4c"
      unitRef="usd">1041000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie6d342895255493b9e648583464cf9bd_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtNy0xLTEtMA_0a4bc789-2ce5-4874-828d-3db30f3bd211"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b90e287ae9d4833a89bb77e704ab070_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzQtOS0xLTEtMA_80bc3251-b63b-45e0-ae65-ba2f6ba9bf70"
      unitRef="usd">1041000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i954eab77f4f9402dbb8b521337506e81_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtMS0xLTEtMA_15797af7-c44f-47c8-9b15-6398f1cef356"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9fea367ee9d4fe88b485027bf9fcb91_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtMy0xLTEtMA_18945754-1b89-41a4-804c-1298044b589c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i859a77e1c3ee4e5c8d583b9b6ac23528_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtNS0xLTEtMA_91f2187b-7cf9-4c94-8cd6-e3828997d46e"
      unitRef="usd">-600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i285826056b0946b7ba9a170eaa6cc107_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtNy0xLTEtMA_4eb3a4f5-4f60-471c-bd9b-3a40fefdb8b2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb493b807d924cf39624accb949af88c_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0ZTgyYTc2ZDU3MTRmN2ZiZmU1MzYzYjllMDAwZmNlL3NlYzoyNGU4MmE3NmQ1NzE0ZjdmYmZlNTM2M2I5ZTAwMGZjZV8xMDMvZnJhZzo0ZmY2MjMyYjc4ZGI0ZmMwOTBmMmZlZmVmM2ExODAwMy90YWJsZTozMDZmMjc5YTk5NTM0MDg4YmVhMWZmZGJlZThiNTU2YS90YWJsZXJhbmdlOjMwNmYyNzlhOTk1MzQwODhiZWExZmZkYmVlOGI1NTZhXzUtOS0xLTEtMA_592804ba-43ad-4963-b591-20c27aed3836"
      unitRef="usd">-33392000</us-gaap:StockholdersEquity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776295728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Revenue from Collaborators (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,061<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 148,069<span></span>
</td>
<td class="nump">$ 53,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 107,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,995<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">37,481<span></span>
</td>
<td class="nump">53,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators | Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
<td class="num">(1,560)<span></span>
</td>
<td class="nump">10,382<span></span>
</td>
<td class="nump">40,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators | Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
<td class="nump">7,888<span></span>
</td>
<td class="nump">10,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators | The Medicines Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,261<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="nump">$ 775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">540,100<span></span>
</td>
<td class="nump">$ 521,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Research Services Obligation | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">182,400<span></span>
</td>
<td class="nump">178,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | C5 License Obligation | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">109,200<span></span>
</td>
<td class="nump">93,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | C5 Co-Co Obligation | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 248,500<span></span>
</td>
<td class="nump">$ 249,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue recognized under ASC 808</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_MdcoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_MdcoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789447776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the changes in accumulated other comprehensive (loss) income, by component, for the nine months ended September&#160;30, 2019 and 2018, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:32.356725%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695906%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.327485%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on Investment in Joint Venture</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Unrealized (Losses) Gains from Debt</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Securities</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Total Accumulated Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Comprehensive (Loss) Income </span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(421)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(33,213)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,282)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">359&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,642)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net other comprehensive (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,158)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:32.356725%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695906%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.327485%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on Investment in Joint Venture</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (Losses) Gains from Debt<br/>Securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total Accumulated Other<br/>Comprehensive (Loss) Income </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2017</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,641)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,433)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(590)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(590)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,041&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,041&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(32,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(33,392)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789349968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text">NET LOSS PER COMMON SHARE<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding during the period. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. Potential common shares consist of shares issuable upon the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following common share equivalents (in thousands) were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001178670-19-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178670-19-000005-xbrl.zip
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MR/)K DH?ZBBM,192"#+E<D,[+5EMWN+GM]7FK1H0!(H5 ZD4^), 'Y)Q+E%
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M:%&RDEQ9B#H!%XMVSCH50EU,SP<4I20H&;U7+C1?G:PD5Q8B4VQP-=AQ,L8
M#DJ(P3M"P!0M.?O9O.TU5Y:"*PO1*W7LE8J1UBH JV0L2-G8Y)TC]DIN>1>\
M6B!L/V1I*V<+5;68?*@I<3Z2,,9C@**UR-8O[Z;7RX'$_+:WIIS02TK"9P_1
MR>" E-7!I:"RS$U:N';__)1VR^9HA(.CJ2W]=*2SU\,X'.&D^XYNG#4/D_JD
MAI(T.F4K=M[!_A4CL#<X?_02!\/2?4:#B_/57!$W 8:<%657IYI[PIA=CN1<
MS! I4P.4_9I!BTVV" #9BF#0(U!POLX.I6!B+NP:P#5 [Z\9M- H(#H?,D!Q
M8%E#U$U!Z[['UD1OB$7&9ZL0K1FTQ Q:2&P0("<+QFOM)$@=@C-%*"ES4C+(
M$AN@@_X PM?=T2_=X832\6#8&QZ=[PS2]Y+FQW*VD6HHHX%2=,2L B2JRQOX
M(+(6PN@876J &EKS: DT$23EM)))BJA!1^,S2>/)9IVC$F0:H(G6/%H"9905
MRB+8B3&? &3P=?D13=HX9[W2K@'*:,VC)=!'J>1 Y.J.-PD<Y( NQCK?H4 6
M.KCFZZ-V3L/5)LY"!!&'\\(5[4+='#-PC \^.1M*$BZ *=A\0;3ZQ%F( K*
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MO';23RVOB*:Q=O:)><X_#,:TIF^S#*PBX6()*OBH(,848\XFB61%%E1(--_
MKJEY'RPK:P*,2D9#.D"1*GI!Y)(WI6:XZ.8JV"?FR?#)<,W=9IE5;[/7(CGG
M3:[+$",XC%X9U#F#M;0*9G7-RQ6WJ;: *H31D<S35?^S4^@L6$I!^&0:0.(U
MJY:.54KD++0G:64 M)$9%;7$:"++S9)GIC',6+6$+GO-JC]@5?AZ5LUKO4 D
MU,K+4/<IH:(\:1MT5L2*T)*)#6#5NJ-H3>?KCB+T!44"<A;9"2MO5-VE4TKF
M,SA7&K)K[IK.RTCGN]\IF*3QFG),)4JP6L5$ 5RN&T GZ613YF.NZ;R,=%[
M6M>H'9' G%,")U-,R@:CC#19."U,\\7&NM/T/JB,*% 8XWW**4"A$$1F2QW9
M1D<O63LW7V6L>7P?Y(4"YU4PK)A= 9AJ9"U(VFP=)2N;LLW)FL=+Q>,%;->C
M8Z"2O-*$@!SR@?<>DB^."EAJ0M?8>M1@N4A\]Z+"6!E#BKD8J:?;WBO-/#:*
M2@E27F]5UFA1L2;QBBL*0!O8$+N0A04OB$VRS,*$[%4*I:Q A\6:Q"LO)XR6
M/H!55@=D58P!<K"4DO!6H4JN 99XS:JE,XU:  4"=*Y(L$5&,,E[H97RQ2(T
M8?.!-:N6SE9)Y5')C$8'"\HH3X4\FR:2LM09@\N;O[<FTUTDU!F;C$%*0>8$
MR82("@/67=V(5,;9;&C&==GXL=BEYFZ#(5O2S0$,Z94QT4=?6%-,-YY19++7
MV1CA4<P66C!"K\'X?3!,2^@Y@,'AM49!9*PN0* P@U$A4\RU%]_C\EK.K]IM
M_J:MVN2#N9[PO4;S2_-5NX-YS%>M1>V^9ZL_/NZ>+HI9<[*YA:.'A%H[-KJ@
M5#6OVGH9O),4=?FXC)E<VOS/Q5)L 43XPK(^7ZODYI3?Z4J0CEQ&E!Z8--YJ
M\*9DJ8WW^GK*)HN\UNS#LK%F+>G^D%7*?"6K;I[Z/4-\&*4BY7-T!!9D=((5
MH.78TR('"W[YO=Q3[(Y>8^^,?CEO7ZX(40MX.J)_G=$@79'LLY-OG#K>HW0V
M&G4'1_,BV(U'VAR/:?*DA^/Q[0=Y,NSW:92ZV/L53_]PSXEE\5RA.*^M,$8K
M T3.*R*ALO,AA>Q]:!1;KC_^@TNL.6;GS^NJ,[]#F)W!Z=ED/#U#_@">K*G[
M@ZEK@XLREJ1 .!;P)A;E$@=6P6<=C8R-HN[*LN5.V[%N"'4A&4&0O 1RD )P
MV& @&P(*$HLH:^K^*.I>2D_:HCAY61^@.^G^B%VR?PAKM+0<2Q8 +2*XI'PI
MX)PS8)738'2C6+/VU?>1PF!*"I&]M'=ULUP7'6 4TA:;8J;2@"ZX>5!8K2G<
M7 J3D-JKJ(NR%J)TP=F:)F!$X2])R$91>.59LY:?7Z*P!!1.H0=?P*!!I6,*
MQ0M38LRB65U$O\>75R_W1U/*GO]0LOS@%K0LE%$Z:-#D(D !F9%I(BS_405!
MQ=*LB&7!E+E/TG=9^%M$"&1##)&-GP@0-?_#,;?7@>-M=T_Z.7^$\%S;W[O@
M;_)6:&=("^5 ,5%54L9FR[X[.^=%H_B[VI192\XO\3<GHS&B-T& H11%0JE-
M!*^MAKS$68O?P-_V<$#G;1R]I4G=K:"!W%T6ND1B"X=9 J4"@NF2@K;!,5>4
MD92I4719*KVWYNZ/YBZK2^8EH,N90*D0+3FC4PY!Z,1DOA_<O4NIN>;NW/KG
MLT"OB@W9$X3D(@='F#(6CO11^&:-J:\N7=82\PO<]4$J9;!8+S2 +<%XB6R(
M(THF;%B-$.D)C:ZV<:/Q;MFBT^%X5F*3"+PLG,E9E622+89]-13 [$%(AR%;
MC]ZM1D_X77%FJ73N/2&P3]I&83.'T  0931!:6E4B:B5*.M^S?F/0ZXM\%RS
M.+6)FH,EE8P%*;+/,A<GC#'!1AO7%GB).+.6G5\@,(: *E F0PFDSVR!@\H2
M) 5+$ILU,KI4%G@)V;Q:&?1UU1/TVG.(S]K!(GJ!)@JI/!$AK(;M??7R6=TG
M>%!+?GDZ'(R'(\K;TWG-H^Z8QC\\G>B^./)".D/213D+@7GD4RG9V))LMF*9
M=T9M$IG6,=8"QBZM<49IUJC"0BP>G5/LZ140)9D)&L7LI?+P2]O,[@FSV<G+
MB*7.0 ]@9 PAH0=CL&@I@EJ-[OY5)],Z*OL"LZ4E42QH29 !C/ )+!0#JD@3
M$9O5+W9/K!%0%(%CD;I\"D0O(EGMI(C:((?5>CV_;5DMT+(0*&226>HDP "D
ME)&M@))9B^EF.O=E@F0#NV*6A4#.JVC!H?;)@],N"N=)*Q><S$BQ6=,3U[)C
M 7F+ K!.,X @J,ZQBB%G*9-%B<*X?-FCYJ72L@$$6NTT[>^CC&])U=)R'JI'
M(!4E:\>K S8_008K#/_?I(A>XYHR:]&US/PU&@BC\M:65!,0HBB2M#!@HS+F
M*MVU*?Q=*M&UMK]WP5^111):4''%@@W))R.-!] R.1VI6?Q=;<JLD.2<'W\I
M%P.E6$TI P<GR'HB9NVL%I;C&+$2_&U^RO:RT"4:J3PDK+(3"HB P?JBT'LD
MHUUJ%%V62N^MN?NCN:M\KEF!/B>C@*2+-H4H;+0<-@D0^7YP=SVSJHG<M4J&
M$D$5$I*Y:U$F)3U*#IV4E'+MII>#+FN)^07N>N%E8<U@8U"0V09[CO4-"53%
M1^/-2G!W17*TEX4S)FA/2=;<$H"05)24$M,HA*"5@&;IS$5S9JET[CTA<("D
M(^@HG:GQ$OF,2>A00@Y&XE5N5%,(W BQN;; \XWT/6%"9I50!GSQ7@)X+ 8-
MQT\YJ481>,4YLY:=7R"PU*B,I2R2$Q!92&@/&CV%@&1-;%;(M(0$6H;)3/-C
M"X-'U;YQ3"* C5U #K01'&93M G-8LM]$GQKZEI(V47 %!-3F,@G)=C:Y012
MYNB;E0*R5%)S3=T?/7K.T;W%@EE8%IG&^B!!%Q4*%8K>-RM*6EFVK.7EEP1#
M2L$&2<77B?M!!J&$2L$G5%9(VZQ<S491]^ZW_YACOZ;$0,DJ'ZP"*\&G-$WP
M=<893^Z>C$'>>YG99 I#23[ZNJ8N*TS4!35+3QW(\U]IXCVA\+V7FTVFL,U"
ML.H,&D6&+'SPK@Y&>F^52 #-&I%<>=:LY>>7K+ H@25#<F@ %,4@0M*&.(0J
M/F39K*#_OLZ]7Q8R62]"R9BDIP!*"E\(?70J<QP>F4YK,JV'X9O);&.U#J&Z
M>UT @@E*@E#D-<48H@R-8O92B=6E;6;WA-G.95MW)?,^2BA&A9)R+!R!"6:@
MC;)1S+ZO9%I+VR\PFUC89NNU<<8 LIPU*5N)(F6"'--Z4& ),7,E4XI:HS89
MR%!T19"3D$/*TFAH%&9KH;: 1D\^UXFS2J(#< :#5D63M,'Y *E9PRE+)=3N
M"8$4VY^ .ODB$V@I@[>*O8?(B3BZ3<W20VO9L8"$5S!:@X"<7 $9DI>I.'*N
M&$_HDVG4ZDU+BM8<M\F3@HQD'\&P ?H2J"@B10[8B8A0?MNZ1$NYUNS#LL+V
MO#N@W?*$(YONY"FF;H\?[A(H[ W.'[VA7F_\%$='P]NGS*N-_^Z-]VG4?S[$
MP5?>\$\P@]$?3;9P0M?<4.ZZG.MCUZCEWSEU=N1/T$@6:[1)*18CN/T;;X(A
M+[,W)@>G+I?O<%(LG]?(U'WTG(ZPMSU]GANXO>Z.?ND.)Y2.!\/>\.A\9Y!^
M:*-V+2GF-&DF&=*22DK%0%+.4Y19&;+.@W0?M_E5=HW&OS6QRLY#DN?L1"2J
M,_$@$K .IZ@M0<RY8/F(QM)9UF5#P\T!C1QRB9C80NFZ&JFI$W(RLK$JAN4)
MN@8XO 7#LGAOXT#(ND%@\42@H^: Q1%0$9ZC7>D:L(WYSN =C2?UHOWS4_K^
MR53+(B<Q:J%$ 6UM 8\08TIUI0414-26UG!D&KF_D,G9H&0Y$%P"%#&8NA"S
MCC:"<NIJ5'JI,7G:'>"@5OL.U\+HK%Z]^#2J^0&D9$Q(J20.N$ ECL(R".&*
M##YJ]E0K -!<!Z"6!;=B=2Y*4': $(P(%JUVQMH412!JPKX=?XS;-Z]8N"SH
M6)8%O@3-U1\AH:P2P6DG2>L2"S1@XO5RB80YKNF079!8DBY%@"?-;<6S=E,N
M).U<;D#:Z+*(A#FFK@GCDN86$E*"E"-J*05'JR9(95W4RX_)4HJ$.4[#AZ*L
M4-Z:+$%A#%)[:4*!0AH W0H M$0B88XC^A&D![0J%P_$\CMSW492F05XR=2$
MS+FE$PES;%4V9\$H6+ ()6,0AHPO6FM0&HN9]@89 4*V+C\LKY9[SA#0YFB$
M@R.Z[9FF74._M/=>=C^\I'<T>-I]1V_8?_T/#3+V>M,+?W WD6D):(EKQ/Y=
M-]'TU(\*\#NZB8S#G*-*'$(Y<"X$(P$B! H4T8=XU=4G+\%=:J&^U."R9I=?
M">XG\OX[P TE!U(4^$\ %,%3U)Z"S#Z3$"Q8&%RA15"F=?5AZ08[OA+<_>/N
M*+^<C(@F=X"FT--N6O,5:%Z=:N> IC6H8^V,JCL_:2B8<NVP FU58%L,J]-4
M[Q;-Q;1-&8(CYU')5%<[4U&[G(-%@4(Y1GIUT-P=T#_.!IEUZN8@\Y<V=@<W
MP/T!,F@AZ)X-NI?0CFA [[$W/)UP+5UCUK_,G;JLDKW+4W:GI\S*FYTQ^UX+
M_+)93S(JJXV/@N-05_.4HT\Y*P]@=?)7@LS,!)E97MV\W-1AF66^7I&9&W+[
M.PR#+PDREAR]4AS/%F3\'"2I<O+@8P-Z3)=-B/V8;7N]L039I^ --T*/17,(
MRX;<"N.3;L &C MWPC]FH BEH8R&6T_F,(:0M6^R;"2#2(Q7 W9673J;^$-P
MTM[%K(/V=?$XJXL7+I)E!61375<.KYR8GCDQO79B?]J)Z:]W8GH^3BR1,UD%
M&9W18(BB@,SAI9(9,$%,4W2M !5:LP_+BNZRY*S:VN>CPM?@^,FIWX$C2J6$
MI806/7 CC,50*"DI&S-DR@W"<452G[_ZAJ]QU,78HSV&_G9?]//A( \'.W70
M(.+@[6XIQ ]7SWN^\\ONWBKRN$3-/L47##(!"8\&6!  L&W2]<.]YW$C4?5*
MRI)5Q)@<*&M"R!XY>&)/9@!$ ^9A+0V8/V9<CY04)2:K&(Z@<@2;:G ;78I:
MH/FTCTO^>*!^;.^1G(]Z FU3*":BU &4#H%C%V.,=BY)K7&6(;H<U74[.I!S
M6DO%Q*AL()/92!LK0M0Q6B&@2$I>SS+0C;IB#G]8MB;^^QGH>W1$ QH-![\>
MXZB/B<XFW82]\<X@7:5?< 'SD@$U&-DM-Z*3&P_RK#>,V.-8A'EZU$U/AKT>
MQJ^[_QQZ94U+?6V[NGGJ=[2KG+SU @4X4<!(YAB32F<"XV6.<C;M<DVFY2?3
M;:MSDQ_?L]"=],'D(-GN. A"88I6VA %Y2ATR5=6!X1OS3XL&U'&H\FCO8K.
M)3+U:[L[Z/;/^M_+@34%_\">04OXK[1G-T_]GN0-%E/).)61XYE$&( =I7.*
M2K%DA;VR9Z#,FJ;WEJ:W+27<2%OX'DOI4Y8N9BE4JNL8A*1*E+[NX(4A2M<L
MYN&'-?.:PCSD@%):U.A0@TLEN+H0;<X*M<K2S!9C< W(FZCP]^GEA,&H5SX?
MIBD0MSOK]FA,=5&-3783==&,X6D]=_O#*9=V!XDQ[LX38QR'>T['$I)+X#D(
M1FNJ@=$Q.._DY="!GP'LUP!_!\#^ZP'V<P-8E&!59D0Y"(."A55V77-/)T51
M&/(-RGQ:>H 7D]J6;%+@(045(9/$8C):700:C;/4-C\#>-V"O[,%?RW \VO!
MI)Q41GG(0H 7Y(L%;<F ][IP(UXU'_R2>KWNX.A9%7'88Y@W<Y^CE7'54=UW
M=(7T'20RWKTWSC[).B>4$GOA!!!8\0LHY((VABWWJGGCY8!Z(7XY2@Q"2RN\
M A9>QGN2#+DHW-P)2I/RRQL$]4(\=%2B[J7D-9@$FBRB2-YC"4*!UCZMFH=>
M#J@7XJL=@TO>@Z]KS+CL8C B%Q\"HB02MD&M>I-+R-W>687LXRS*[0^I=Y8I
M/QT-^T^&_=.SR90 NV4;1P,&??PKC5X>XZ@N_?[% FY39;M_VAN>$S-JF-Y>
M)NBOH@5PJ()DEVYT<1 2MWRMA*EDB9)C,&J0!5A16BS$6H08P%0G("E",LC1
MN; 2LI%UPQ[7) UP)[3@T&\RZJ8)Y2DQ5M%24$1,*6KI; 8D]%ZQ#]$H8HE9
M*;6V%(NDQ%U9B>O9;>-_E<EGD]K.)J-']<#LXJ^>RF:UH6(S!Y8<8!A2:)VV
M-ID2^8.&R]D:=AF7%*@#1]>J\QD-CT9X>EQ'=6X,MW2&HPG["1R/,1V?C6DR
M^;&S,^SM90&^9WP/8_2FKCJ4&1HEHU-2)Z(BM ]*-& 6S:^C(;_OY/S7'E<!
M*_[M?YUUI_UROYQ_,C_C.0[JS(PGPW%=U;['D.;]X9/A="&/=&D)VC@X*Y@F
M9W7!^WDE:B\C@^8WOR<K08J*5EYRRS81=1!68R@UEZ\.XRQ];NZ:08O-'C9D
M(X)*12<) MDW>"@U=U]&K13-AA% ^M;LP[)1J0+T9'@V79Z)'?-Y!_LW>;/5
M330:X.=9 3]>-$!+?E6RTB>G?L^H$ 9K#$:M&56'.BI95_=F)\_AAFG"Q,Q?
MD"U!HI?'=>K>%_N9=B?'-.H,!W5KE-H9U<58&_H<]XO;HTGW<@>6:I:>G@TR
MVY-J \X^W<YN4/@@Y7I:0UP&"XNLL@=5?(#BR%L?1%%9%&=1^0:L>7AMC*NO
MF)S7:&(XX*_C&XU^,Z6S_MG423P?CL>[@X\+)>X,_CGL#B:O^2.KYX:8:72R
MKL ;V#P;2,+[K"0+12BESOAPMO&H74>/'X';HM(=4/Z%!OQAVA+'F_GD[!+%
MAN"F% -E,DJK$*(LW@EVJ\DHG]$ITX"U7[\=MPY-7@U&A+WN!>6/[>X9=@>U
M+38$.6M]BHJLL5@X.JOSYC5)*3AX=KJ8!NQ?]^W([8^XC?4N76[36EKTF%PH
M*DD''%C[*!5_\]Z+%/AS:5"GZI([N,7WEG(;S"[8'+$$(%4JW,8*"TX%%KIJ
M=;!>O%M</-K1N1R"SDD&CF-JYW@H E),:'(I-JPTVG?N3!>/M\Y1.9N  CM>
MRL%'S+(Z8"VR88^\TGC?D0M>/,H@DE-LPEU 67?G1 /"L/L.2H9B<@-VYUQR
M-_U#>@]<75% U+W\V/.FP-%H4J;DA%%EDUT#%F1;>H?[8W:(D>"EB\'[!-6P
M!I=BL.0C"9]$:,!V6 UPG3^HOV[::5#7KU40<D%IM$84'J$8T80E$)?6"?X8
MO"!&HQ2[L;I<M+;1R>3 66\+."'Q:@/:YO8;+)%?<W/K/="&:Q%M7>7; $CA
M5<WGK*8QU@%ZWWC4ELJOS0\WGQ"LU*@R>O#!HZX=XDHE3ZEFUZ\B;HOT:_-#
MKLY;4Q%M4&P>B[-1:I]876JM8@I7J0LKAMS=^[7YX94QA%"M(D8_W4:5)$O^
MR*(D4\Y7$U>:D:&XY YN\0G*+A :CA2T3@IDRG6-"<D@"PM%9F%6!^O%N\7%
MHYVP4%()4S$!0HTM.,!@%90C%5U(KC3:B^U?7<S$8ILU*!^,,H;QCH$L>.,U
M6$@EQ+S2>"^B?W4QDTP,$$;G"I0 0N58Q\AJ4.J,L.2OEFUM,+B+=M.W1K'G
MU7L00R'4UA&%#(5#T,A-4R@72R@IAN:CMGB'^T-P\R:@<R23)@(RR6<VJ#%$
MBTEIH_PJXK;8/)^Y;67"KJ]N)V.C"&"CBQA0.D&(-B4IW"HBMX@\GS^%U\/N
MAT<C&@_/1HG&EU^/"?/T>7+WW>.?^<\EC+^)WVI'P<=?QY/S7H6"ND?'DT=@
M3B=_>]_-D^-'4HC_\[<'TY,>_SP^Q<'CG^/H(5]Z^?FRA,_*J<_38JH?#1XE
MJJGFM8C?N_K?7M?'T5%WT(K#R638?V3YN;BD2=U$8';-U1D]*I-'>#89SBX9
M35]E^DL<CK@66JFN+7<ZID>S#W^[<;]Z_>7W[J#2[)'@>^7N^+2'YXQ CXUN
M:WK?JXH)X:<0F**7U3/A.I[DV2-=5=U/E\<>3O+G!X/_28CKR[]XRJWK'T[O
M<'D7?OQ:?W]_H!]\ ISF9XZ8WAZ-AF>#7%]X.'HT.HK_Q>+UK[/_-L1/XK\_
M>_5W=6?ZA+VKWRXK?%9SD^%I+7LC#\]JS?_E\M'_=HJYYGI?UKWD>\]^N*Q[
M>8G6Q^=_.*W ;^'+[(2O?*G+8[/'*]PP6@7[W=[YH_^[SZ9@O-&A]QM[PSX.
M_N_ET3%;XT?2\X-.O[Z_K$;'%T\!OZI6J:9(O.KL[&]O;;S<W]S??OD-'%[&
M=WFY_>35WL[^SO;+C<W.UL;V_S[YQV;GV?;&D]UV>^?ERYW=SK<WTBN6W.W[
MJJ][WS<X/F9F3H:#OVYL_?3DI__\B[3B;Y=_E>#(;EGQ_,KW^^T;_FD(LE_)
MY*>[>^V-G]G7#8:#SEF??6/:N'*)>U2FNQ>BT08523+@C$;D4$\2)JU\I/3%
M_,>- 59I4M=/W1JR$J#++;0>7/7NZM?G<6OX[KG:>W>@VV?Y9/O=X;-PLGNR
M(P[WC\X/]I,ZW'JEV_M[_8XZ[![V7\GVQ<'%P4FOU][:?'_8[_2>ZT[OX&)X
MWGGV"MK];=WIOY"=BVUQ>)+[!_W#7F>_K=IJQQSN;[YO/SL\.7SM/SQ7A^<'
M;Y+=W>^<=/8/+CIJ6QV<_-+M;.V(W:W><?OD^+A]P>5LI0^=_C][AUOI77[V
M&O(_^+/JO8LG0\.ERLY)6Q_L'W;;SW9$^^0%[+[9/M]]MGW1V7HE^!G40?_U
MVX[TNG/R5G7VCSZT+_C_)VWS&PJ-/CG?0E%,"TS2K0@RM6K/I[5U7\A,#QY+
MT7HQ51\?$?D6E[^RS6M5M8S^23H%$KY2RGR;3E(_>>6,M_/123.!4@V:.OUP
M+5BN,*D_S4<_\0V^4A[=Y/H?$//?L_IV"_C*U^ 'F+?I+,-1'R=\-5<0!W0L
M)8>]B+W><!*''[YD65^<X8@;?N]\CTZ'HTDCC>S3;GSVRG+Y[SLG3WN'^SOZ
MX"*][SQ[^G9WOW=\\&8'#K<.CSOJQ?OV?IN?_<75-:_Y7F9PN#_D=]E4[3>O
M>^V3?-*YV!0';UZ8W3=/CP].CM]V^-GY.!OB?QYWGOKWS_<W)^V7XL/S_5=R
M=W_[-P<Q%FNI):S)+0B46CX6_@/:@DY>DXD/'O_G7X(#^[??-<U7C6N1S>8J
M[&A&RWGQ:G-O?WOO^<'&WO:ONWO[&[^^VGOY:K.SO[&_N\$">Y]5](;4&[M[
M&]+\5_[OC=VG&_O_V-ZXH;VO=??FD_UZN";MW\+C6^.F&X)-BCM6;.$K!=MP
MM#$YIHU_S9K]QF6'Q@;5R<'SEW(W[-&C7#M_N,3CC.?GA",:?,D@_3I]GNW+
MX81&FJ,_K?G$[OX+O;NU>=Z^V-'MB[;Z3=NB@K&FI3)0"YR-+5\HM@+7>8XD
MI?>:XTDZG4S[OBY#*BW^NE$1^-36;/RYV&-9J;R[MQ9[:[&W%GO?(/:FO>G=
MVIG>?+7W[-7%X9N]?ON$KSO9Y',VV6#^\^3PA%5>__5QIQ[KOP!6?9^J/7ZG
M3N_PV<$YFV759A/<WN*WZ7?Z7,;YX9MM68\=;AWIP\_4WJO?V!I+8Z)L.6U$
M"W*TK2B4;R4E' BMI)3E2NW!4JN]YK2;_;W-SLN=J:#[_]E[\Z:VDBQQ^ZO<
MT$R\416AI'-?JN9'A JPBVXDV2"7!__CR-4("XF1A&W\Z=_,*P'"@,TBB2N1
M76T;M-Z;RW/6/"?K>H_0]<:7N_Y"V0O#P4DQXS4IQH/B/DZ4E1R&K<')27>4
M I'%JV[4 .)F3.')!7HM=\I(8_JRR7>M)&;GY;D\_/K1^4"1]Q)HX3&@QFD@
M47  4LXQTP)#[%+(&8%H,4/Q8MV7C]MW=,G;#M/[W??"-]B^_U26;.^/4QVU
ME[W)OGU$P3-ML =0V6@J$D6!UMP#8U%4593'6D13L;'7.MQK-(LW?S?VFXVM
MG7>=W:W&WD&]V&UM;:S(QKLG]W_;^:;MN$AKHQB$XFJU%'I4')QZFY)97-'M
M%[OC4;%U5#I$?J_H/2\1-NMJ/-,'9GTL],.K8CT_R.=;F=WP2P+ Q4B@'PWN
M4<IG.QT.OB31=-V=.1%1USIZEMEO9?G/X?G6P*VFQ)I8W\WMM]\/.Y]9\_NK
M7CN]]_7.U_@[;&VW>JWC3U$Z?4+-U^^^Q7]_M+Z_QM<<M3N?OS??OV-1VL'#
MSE_Q][>PB=_A]K:-?]Y]_=#9P>WKUC=N=AH_2LROT6H_CM_#XOA\;9WLP-;Q
MJ^[A\6[\W+]Z[73=QPT:[YVV_KDF,6&KLT,^"NZ)0IH BJ,5GQJ7 0U1_,M3
M)U*G;TA5;7/;]_17/?0K(AQ_F;@QV1J_E8NQB!9B6:.T^/?9L#MRW;(Z<926
MJWUSUW9=>8_#3[K?_5[^_H.$KX(K)D/X*69 1W_;G>8F3VKPKK#1O6RZ[ES1
M=?OMCW2-MDCCO+W]^5OSI'E^^-U&^Z-UTM[^A _CO;2.=\Z;[W?0X;$E3?0#
M7;<_HX].,HJ@$< RA0!U1 "II )":X49A"S.:FU3"  YQ)RC->/K[L;^QL%&
M,>T3-%SMN[F^OXK68.,VBM[N0KU7[GFV.;+-D<7=O<1=P[FA'XVF_^S%*T K
M+.JB(G[>ZKCC^'GTP^M#V(J?V?S>Z[5.FO##]EO<BM?;?MV,XJ;QHZA#S<XN
M:N%6O/:CSQ^.W\(/)\WO[??O\.'W_<^M[?A9'4OCW>'FCX;$]QNBCK7>IY#@
MVZ^'^-71X<E;V'K?C/?0C&+MGVXSWO.'3B^:&G$<7OUH2!Q^_RBU1L(Z#0*W
MT9I@G@%-H[P+A%#M+)0!TMHF%ZQX[T?CXC^^[W2O5QR,A]Z/ZRLB^*J[_G%>
M_\^X_C_1CQ(3Y*S2 !H) >5, \FQ!0*Q "7S0IFX_O_V_6&W:&P4'3\\\='F
M/$A):*MB5U=L^6_%']O#J._W\^)_QL7_F7T46LFX[BDPC,;%CZT&46-D0%!F
M2%#"60]KFUOZQ R[[M.-Y5Y??"!ZNF1*CT][^&8X^-+MVU7V/J[\NCEN?/](
M3%P>F@=@( V "J6 PLX!EH@))73$F]IFL[$B?+RO73Q=C"DB]V88UV'W5/>*
MG6_>EDTTBW:(5J8?92?=>HJM-X/16/<^=$]7//ZQ/ )=>>A:M\0_FM\;YQ]>
M__ND_?[#R8?W\;N/F]_:[_\Y;B82O6]UFZ^;W^*U?&O=\-"]8Q^5%E!C$P#7
ME %*) (Z8 B(,#I QHCTI+8),:)XS2 4%V"15N#]O5@KG0'WVP*W=U)$&T.O
M5W9#SRT%AWX4#E,,L0:&6AE%>A! 0Z( (2R5,\>BW%!Y,I8R&=9H09%1T1XU
M&% G/3#$*R"D\!Y'W5P$5=ODZ)9TP^N__[Y(#3WUC>R].1KT<ZIHZ]C2CPA;
MPC'1P"-* (71KI+6&."@H%AYBL6"MU">D.L3HIVVWE@/G*,(4.K]Q+<#.6?$
M$T<#1;5-QA"0&,)?[:55U1NF<O0JA_#_^R^)D?AS5'1\SY^FY3+-*Z\7NWW;
M.TLF09%0?)N>49G[7F)6X36[J:QQ527%B=Y1J">:I<.R7V\Q+*?>#[TK3L^&
MH[.41SH>%/$5*20Z.7B)\&_F]V39IE,7#3O^8QWCG7 #_33>J B"Y.Y7_.KM
M=S^)^48<9(47$TO=H#Q"3"SBLU_LA<]SJ?PB>/T,/IYE.Z6F\F'^11MNLR(7
M<Y"O.^Z5N?@[VAX56ST]&MWC1&2>VE68VJ$N59Z#\Q,SZ/TVX\#-$[O2$WMQ
M?*;<LCO?[)'N?XH/](OW1]WXR/ZE6E3A"<^RX_9UF(Z SQ09C==6C :]KGM@
MC='[K5"Z,F45KIP!4_W_'&%3RJZ5= 9<U$MH';4Z[[XV3_Y]U#KY<-S:_ORU
MO7W4:V]_/O_P^ATZ/-[]&E_S^</KYHUZ"8=X![4ZC?/#DQW\X:0)VYT&;<?K
M;G?^_?E#YY]N\[@17[/_^1#%:YR-6!R__1AT<))) [@+, 49)# 0$0 %84(H
MS)'EDS/:D2D'XX']7"_^.\XLFIA4IWI8?-&],Y^.KA>CHY\EC%0//'F'5WV'
M3_66B=J2M_<]MG=S9GOO?-2:,(^= L%" :AC%DAI'2":4BX\)EB@R:GCO&WS
MMIWS\4L?U=&;)R\OA/:%LKJRQ0&6O;/?S>SLPX\:.B&E#(!"K@'5V@(%*8J"
M6U$OE#8$DVCW'?FBI4=._]]$>!=-/?SLQ\7>WM8*;?A[Q/RG[M/2<SWS_:DE
M13><KX(S>[?OT@$>7YCSPA[Y.%?QHC\77X]\>0(T^:R'5S42?D._%T=Z5(1N
MS[LBI:L/RY)AR1/^?V?=Y <?#PKCIR^(GSEUA:="3(/AM!#3U!<^XT>_-"$;
M=IR>3H68"A>?[7\J7WHZ]-:7K@2$B[):Y*CX+7Y>W/O%Z"Q:G*.C02K4<%'*
M:'RDQS]>^U=]_2K3)4[>/+V'W^N%[KOB-SRY1Q,)$I\WQ_$.TNO+E\8WI:N8
M?DZJGC8J+Z*\2#T:%PH63I^/KE6SG_R]\&RJK;/A,%[0I(A;4E_&>GPV6DG(
MS2M4^>G[1PZ#%<3PJ(MXE0JD<Z"<CJ8&MHI39#4+HK9YZ$<_DNG:W$TI-=_=
M^SY.4EK4HT?LVV^+N:2G ^7FPF\-KC\V+8+WL]CG2^-JXDU$S4EW/(YP\KV(
MG.&@GZ17[[SP49*=%[M))=2VS(?=UF,]*5OV W:O/F,V'+E_%E])(9L6O#F;
M=$XJ#D"G^"U-BO@S:N0;TQ>,C[JC>,7Z--6]632#)]=[B58_^OTYP#DSM&ED
MIQQ]6>"D\3G<_-XDS>.=KZUX3Q]]$%!!$_>0DR:"DV.@D<0@0&VA)EP;2#(X
M,SB?%9R15;KHQ;ORA;8V@G.8^L.5+!DF=>[61XNX6,$M3XQ.(F_C=PPO-*C(
MFI,X/.?UI+O&#XL*7QJ_3T4<I*_CHXNG-Z(JZ\LK<ZD59%E4LSS+D/*!<+S+
M.ZZO?!K]>?&R7[[@SNN[>%U27Z>OO>-2+U[9[9=2X2)#Q0!\H97/JN(;ZYBJ
M\O/D!K(A.89<+20K V\0Q1G#"TG+>.*5_R(M0XJ4ES&?M(R5J6:\1DZQ4M$I
MJ9+@^FDP/+^M,EG2*8=;TQ>LI )T42O'GK?>[[+F]JNC=.(E?B]K?3\Z2M?V
MX7B'1:4G?28]_'ZC#OC7UO==='C\^6LS=7K!Z1X_D_;K5R<?.O^<-#N][H?W
M2:DZ.OZAZPMN=QH?G39:!82 5LZDO%@#%',!(.V)PUP[YG%M<^]V>5#ENN G
M7><B8Q>ZF6:TND=NHV]5&K*5@4_C:B%.]('I:GR>H2Q'YCF6W[R&\T<]/0O$
MQR08W::A5VEWK_J*S OQ?F-W,+&Y)F"\-+PFOTYMJDS*JFJ]=[:^F6B[Y=S^
M=3:*-N1H->,D2]5VKZ5YM#N['[D-5#DO0<": 6H5!A+;U(?,(0)55'>)OU_7
MFRP?'[AU=FYW[U0)\9E$]R?1Q72^+F=S:S*9F4B_(M+Y;%YIN_/VHPK!.ZX%
M(!A20'6(1$HE^!B/2$(H&$'<4_IP52OW+"?&+#(.$7[B\:\7W=O#%-UP6VBW
M#.A&*Z8_*..Q9Z-)M"".RZ3!ZBV]N ;#\KMZY^G+OW;C5\>O+?KQA@8I /"E
M.RJMHK[NVZ[N)6=2:B&07CP:Z[[30S<J4@^"KKO];&J!R&_Z]UN=_CG<]/-P
MT^C(]WH7*Z'X+<YO&?:9=(TI8^UW!E1N"V\?^M%"H]T/58K3W:VR!)I;")Q]
M-)8@2 ,%3$H"**4.&&OC:L6804VEPU[>*4Y^%<^M<&A\73=[8URT[7APV1,9
MLTE/Y/I-:%]VO7Y59H9$8)[UNY-M6)XWB?;BM:VI=%0T+#(LE??%E*J F%=>
MXL 4)TI]W$U?A"!FM8@+VXVFY^C_U79;KZYWP^Z?G;C!>/J"6U+\RA,Q94[M
M07D5[;-QR?LXXU$MB$(]OAR^K&U[WOK^EK:^VZALIM8NN_2C])QY R& 5B!
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MSFNW/.>%K5ZX[5+#JHA^.57\=(4NIQQKY^VTP^4?*<O=_UDKCH;)0?%?R>Q
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M)P.2#-8V$:U+O(R8\'J:C]E-MB:L6X*;++-NSJP[OV0=XHAZB 5 /.5L8XV
MP<)'X#F*@[182E';I)EU55-/U\Y55IZPR3ZQE59*9U++,YX?B>?=654TY9!'
MG9-$/-M4R%XPD*0L((HYII! C(;:IJISDL][9T_8"P?<$C31#+BY .Y*_X2&
M4 FI )IZ!"C$4?_T%@-MD?"!,L6%JVW*.L>Y &:5U,]'>D=7X/S,[2KHTAJ-
M/"PKO *C]HQ=2!Z0ZKMRPFQIIXBR]'J0]&K.JN<,66HHLL )$]5SZ2506$*
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ML$Z1VB82HJYHKDZQPD'AC+G544<SYN:#N9G@IX9!&RKCVL$*4!J!IV3\28M
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M:5S;)+ >ETSF6X54SW5SCY;-[)=QK.9ENP26D4"89G(F23P["!X)ZFN-<J#
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MLIC*.FZ&1X9'AD>&1Z46489'AD>&QPI&8[.!7"T#^7H@UQL<__,,8&O3P9A
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M-#P+?;AZPRH _WP#NZU1.?C@+,U4\@0A,EJ01*IH/0CMCW?OG?2RW<QB;]I
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MZ!R+*6, H W$?R/=VRJCBNIFB9>FFOY>$9_+HYK];:-)47NHP7]-39=:@R&
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MVM:[3WN_'T=1N"#92&2DG$@PC@0*K# $"RE)"-$72F"B*YU$7D!>0%Y8;U[
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M9#39;VRJKPRY7&*]8!MA#TD 26"%20!GF*-DHV2C9*-DHV2C9*^&9,]CN#U
M=!X-M^6Z[ZY'Y)VP62?)B6=2$RE9)*&67&:@Q2HW :C-U7"[W9X9#3>LG5]T
M)#[  ')OLMA0_!-*MVI!*'[GPVE_> [P?+JUK\K.(H;/@^'OMZZ%X ^VCF4Y
M2(I2($;H@N%*.N(D#T2["%PQ:SV-&YL6$ZHPT19U^?5&?DRA1\E&R5Y'R7[<
MZ.K=;7/4Y^ZOSUT+IGXZCF63N$V,T*+0$6ER($'%2)1F3 >?BDK'BC[''R.E
M$G$?<1]Q'S6Z-IYEE&R4;)1LE&R4;)3L5DGVXP94T59[5-_[]?AI3-E+GSV)
ML3:J%<$3QWW9+"Z$"#3)%"C::BT+HMZMG'F5***1>A)JBD2-HU[E2'3@<WT,
MG1'T_:2\.!E>E#>3V/?C<2_WRI/^DQ\E+'5>ON:VEFD0F NWKIH;2C9*-DHV
M2O8J2'9+VPEOI?=GX\D'&$S&1\.MLFKUXGS_E>^EW<&V/^U-?+])G HWTU]?
M5SUNW)O (8P^]B),[;S7$(?O!LVG-"8?VG=SV7<[L[&XSWM;QS%*ZEP6Y3PZ
M3R37EGCN).$Z!R%42)[7W"K;E:Q] ZC:")Q((T@C*TPCJ""B9*-DHV2C9*-D
MHV2OAF2WM/LPFGXM,_UNA/8R=XIGZPDP8XC,T1.G:U:FIAIX,I! HNG7ONC>
MFI5('DQ.8-0$]49P4A"@]Q$Z[WQO,#M6&%,SEJ[EK67P'9.NUE7+0\E&R4;)
M1LE&R4;)1LE&R6Z]9X9Y =8FS6DQNS63@1FK1#!>V>@Y\+D3I1N[:GO6K-H=
M%"L+7@['XWV8'.0C_QE=*'.Y4'8G^^<ST?-/Q]0YS:AB1)<=(M++0((LCU0J
MNV@L3[9V)I'L=G<I!'L$>P3[M0)[5.-0LE&RUU&REUGOAFK< M2X&Y$PZ8V3
MQFOBM;;3(K< 0A+NHP&7DRY:'JIQ+0N#W:W(;67"8$66._TBTYCVL'1]:RTC
MT9C0M*[Z%DHV2C9*-DHV2C9*-DHV2C9*=LO.,DHV2O8*2_9<\Y."T%9R;S13
M4D.VU(!@ %QQ[JG3\\Q/NG.AP3Y,OOA$T1<ZER]T;W)P.#/O7%K@H%PFDDI'
MI'>&A+)[)/&8:<H DHJ-32[+";&WBP)P9!+B/N+^D\3]!YR;A[C_*+A_LQK,
M,B8Y,**U5 7YN2%6J%0#82RSQ,&(B,C?KA#8<BK!S*)6[;GO-[/R_+B6?1W"
MZ00^!!AU!.UV*FJT(V$A#$<)1LTWE&7KC(?]7NI<W>OTQ8NO$^7U-#P+?;AZ
MPRH _WSC]11DF9+)U"4G39).))6E%+IHC)&".]Z]=R7Q=C,YL>D!.AVR=W V
M&4_\H"X<XOY<N/_[U7"]J;X?+<]16&)=9$0:S8DO7$YBCB"48LG9@OJ,TJ[3
M[1NP]S"BV'+BP$2YMID,BZ?LQ5#-\A?T?]<#*]K-TK>MLT>@Z(:<3X;]LHSC
MG:8!-Q+SO,1\/D/,@H+-+GHB(B0B71+$T=J&/S.7718^.UJ(N4NI0UI&6D9:
M1EI&6EXQ6@Y,96^"%C(GF3QX*H*B*AJEHW(A(2VW@9;W9^WE1$W9(NJ)!:.(
MC I( &9).2))\A $\V)C4W:9I%TJ!%(S4C-2,U(S4G,;J'F>@&8(Q4H.EIKD
MN(Q9.,VECS$XZ7RV-GZ;F^>/8R))WY^D9VUG1AG/5$=2M"A?;&?&B&,YD6)3
MTP!1\&3LQJ807>$6',E$<D9R1G)&<FXW5JP<.2?EC2^WD'U6U>H*V7BJG556
M42]91G)N%3E?RS"UX#(#YLH!BI9(32VQ,63"(%"KC6=6U3RCKN:NJP1#?D9^
M1GY&?D9^7O;AG(.>7>:%H2.7S$MEK:/:4\ISMM)PJ3WZM=O RC?R?Y/WE$E@
M1#(CB4PR$:=M,9I3LBPS'7CE9=:5QG89PZ#S\I*(?YKX<NGEW]3[N/FO\N/R
M&F=6*D*1Q]'-F[CC5U^_WK^_MR_KPNA7%J;?&P YF?[.> -D1R?0\;'.>_"#
M\[+FG<%P4C[3C\K3@TZO7/>[D>]W3OUH.OWA!,90\275.>]5.1DT>]M,>\^]
M@1_$7GG[>%*>:&;-/+M:L:OU:?#@F!YSNS'/LFW^*XQ^VKS]<9>'>CANAM'\
MW,R>[WV$7S[UTN2D+$2YSXM[EOR9465=9E[9^/J'^%!NZVP"OUP<4OKMOUF-
M?=;7%V[VY\GH"S"\ Q)&X/\D/I<[^=GW/_GS\<9/UV[XXH,-_]I*WO?6"\0\
M[*TWVU-X:SAJAAG]7*BR@$]]6[UBOR)7VCD953+_GRHWIDAMQ9PJC]N5Z8N8
M_>LG_VW1:-D)-5\_H5LO]]^^W-KKO/KWUNN]K>V=-T>[VULO#[N=W?WMKZ#(
M2MW;]D'A^OW#G1>=\NCPX.7NBZVC\LOA4?EG;V?_Z+!S\&MG>^OPWYU?7Q[\
M]W#%[_:'W4$ABN'9V _2^,=5OYDW W^6>H7??OP:A#8_&A7@\JH_^-&[WF!J
M>/FSR?"7BR>FRDSSS(4"5"Z\[T_'\//E@UN68?-[KY)ML3O*]:;>^+3OSW_N
M#9HK;;[W H.=>^9<78$&B2]*FRXNZ0*EGTU?NZ$-3E\TXIDJ!H%3WW[+W_[]
MW[[HGEG)&?W>SZ;/V-^]J 1U3G[GGS_D=?]#4=D=C_/=O -W<^'<\B&Y>]5F
M_>,%7\CQPWN=[&-5O>T7N>KLE4\^&7=VBN"EZY5O=W#.7<IH,<?@JWOP#V]=
M@5-TOT+)^YVBO[4L5^*(<5H-]OF=O/?9Z =8-3P%#WT*[&UO I8D_]V:;?OQ
M22?WAY_&G3P:?N@,3Z':2H-WG>KV^EA,=QC__$#QDZ4)TSTO;MG?_U"+@TVJ
MO[M)]>*7Z%MG;?EK\J!!IONTOFA%F&BNIC'9*Z$\!P9*&B6\!Q\8^"BX#1"G
M(Z\<9=.F,>YA\CE>C8:Y-VE5QYB#[8N(T?N]SV__^E/M'>WW]]_O?/KCQ>N3
MMT>_RS_>/^_M\?^<O.6_]LMG_57^KO<E8O3FK[T7;]G;H[?R[?O=\_T7OY?/
MV%-_O-@]_^/%VT]OC[;8'Q]VU!_OW]Z*&-7HU/[[_YSLOS_I[95[W'_QZ_N]
MO_I_[KW_OS_WWS\_V7OQGP]OC_H?]M__D2^+$_<.Z:?C0+6UCBNBA'9$TFQ)
MJ(^,"\IHP63@?F-34]=UB\[@6,M>,=_?)>S!:!H1O04'=.4070='@5OCP25I
MA?#6A6 ,&"I]H(9>M %C#]H&#!']>Q']KRM$UX&6 U%P7"F?B.2!$QNC(<[2
M''A6D>J"Z$K1+E4:$?W[ O=K86HOSK88#DBLYK9/[\_&DR:6WYD,.R,H$!-[
M?>@,+JR/^FQ]W+S[K"8%] ;+LLR7;?RNT/>WR;YFS[AJJ1R\@--RY'M-1+[C
M!ZGC/PS+W?S5/-&M!Q];F"X@:?$!C-$[:RRS6[PUL[M;@[05XPCJXWV8H#HS
MASIS6:;?J#/1*Z92RL0H7PQ4YVJ9O@K$A:BR]48ZE3<V&>N:1ZG17TN5I@5&
M*@+? P#? ]AL"'S+!;XO=IR#$$%8232X GPR".(A<2*,E]9IRPLR%CNN:_GM
MRF?$O94SY5JLQLZ*=Z/&ULSN$8PG-?E[*NF=)G&ZF&_%GOMBOO7!CV%A8U"?
M]G#J1]!Q?7]P_O,-;-^]V/HKC'\]W?BCX<'EMK]L=AV!?Q[@[UUIO'S_Q8XZ
MCAFT!\&)U$D3*:(EP7-&0M;!.PXB6+:QR4W7FO9UIFHCACUH>6SKM-XG#84/
MK/7^!:-A\N,31,$EH.!?7U!P]_R82S ^F&+L&Z5K]Q]-"N\Y$B!KH(%:P</5
MN$*$P?8HP6OHRVW*E L)3PL7/YS"8-R@ 7IP5U2[O:H_KV-(GM=]W9[95@3N
M[U-?/QT;3PM24T%,B$"DRI)8[0U)6:G*PIZYZK"EMJNE1,\%>FR?,M ]IL<6
M@>XA-=1/Q]DXQ9CFQ#A:M%.EJH/6 N&)R2"S*&@G"]!QUS7F,9ILK"70H8OV
M3BOWFZ]Y,X-.OS?IO9LZ:L<PF?2;/AKH@&V_BOI5K\/^<%"KENKF'@Q>7FWM
MX=7.(GC/ ]ZS>>^<6<&$\<2:K(B4/!(;G22)6ZTE94GEC*X%]+"N+]8]<C+X
MW:)-B'@/C'A?U%40.J@4%"G_IT3F$$BPX(D(,EC%O&)0QY#1;CE%;6K5NB)8
MAV[4NU5A%R/T'50TZ!26_>'/'SL7[>/*-0WCGYV"$?$$?:KM5UC_OHX'!N-I
MI.Q@<@*C5\/QI,;)1@V$/X<!Y-YDYW/U00 "^AR ?K ]H\)J*H2@% @7QA 9
M9)V-(1T)45$=@P\II8U-T>6/,NYY+;T/Z&9=#^Q[3#<K8M_"L&]&F56))Q48
MH86]B"R"2\H6%VL^ #BGP"0:*_9IALFQ+5)HU]#S6A3:05%H>X-.]KU1YZ/O
MGS7-5?L]'WK]WN2\,PS]"S,6';$M[3UR-^?$=*MW![^6C?Y/W>>#_/)REP^N
M-AE!?1Y0GRWU$CD4&&6<^&!3 75.B1-9$"-"S *49]QM;+JN_$K% SHH6NR,
M7;:BN.SO__HP&$3_]FGV7PW#(>XO O>_*//10/ ^2*(<1"*=D<0E5G"?>4$3
M5SJ PEA<"]7Y-?1/-S8[^I];JJ?/WU&JV<^KHHRMJWXR-<KX:W_XZ?!RV S"
M]SP-IZX&3I5_MXXY:&,3,P6[10'P(#BQ3&;"G*VMJ%*492LW95<RA0VG5LD)
MO6P]<-G?OUC%_6G3P5(:#"(=+(P.SJ_HP')EO*&)R,09D> $"<Z6;=2A;'2D
MT>9:O-QE^G;M,M+!*OGE6\H;4X-]?*.7X'@,DW'3O^+2-X]]!5OV_6BDWJTA
M2XSE7>4PCR!"[V,=Y(7=!-MLM]Y9/]D=Q%%M'/ "IO_N#B[W^O755J-J,I=J
MLG?-4J64&T8M,3%P(BD'XEVD))6-%#91Q[PHJHGK&F90-UDE4Q4QKUU1E?EM
M,\2^16#?%[.LH%V&E#R)U!2SC!84]!8<R=E([JD,,?F-34&[6MXN ,"DJ94S
MSEJLP+X:#<M-I8M);/UBDY5WIVF_P&*UU>E]O8_3*H$)#/Q@TNE].!T-/T['
MPF,@O9WE =\Q[\.?-SOZZW!T>21^+2?BJ-GSK7Y_^,F7PX"@/Q?HO[E2> ]>
MO)7[[XZ=*CM85%L2N"K GZ0F@3E/<M A*I$@>],HO50_1D.6M0RO8W;5F@9I
MGC0I+&<(%)+"0DCA_!HI&!>T":!)5HX3F9DB+C@@G!G!8XHBA]3,55#NMB<$
M20%SKAYNY78''XN\#T?GZ+]>/__UY>;VL!GN=^OQ>UO'.GAF.6,D@0VUV1@E
M5B5'A(D45-E&%JKCVG:IPQPK=%P_6;![S$I?!+M%Z*<%[)22/FLJ2'9U*+4/
MFH08&%%:*Y6TB(%.6]4(==MA@6"'3NH'<E+#J>^E#DR+]:>I0\.:0'B12X0N
MA_535R\V_05D&(T@731JN&SFL-7L.T+[7-#^=E:/-4%QI7W!<A$+M%ME2,A1
M$$$Y"*N""QH*M(NNUECDNU)N:$3!]=%C$047@8(SJ1A6Q%2S,!0'16060%S6
MG!3MMD!@X3EI],:FD%W&%VS-KR4*HM]UOC3B4W]>DZO0_=I2??8A<^E>3?<:
MT7LN]([7=%@C:(8HB>/)$EF(FCB?#6$IT5SV- GK:O,QPVZ/?4#O!+IBGPCP
M/63R *+;@M'MBVY*G8H\^$"2MYE(D27Q6I>#H722S&;PB6UL:K7@)N%KB6WH
M>;VK8CHZ@Z]Z7F=*-]']VLXTX'LHJ5/WPG3W7W[9:83SN>#\W:RRJI+D$ 40
MXSTE,@E#G).<:&$94P79C>!%6=5=(1^C3?A:^AO0Z[H>X+=<IRN"WP.!WQ==
MEF>F72JX%ZR+19=-K.BR$DC95!--]BZHFC55#HQ\C#[A:PE^Z&R]T\I=QE(Z
M(_@(@S-TMJZ?]KI=+J5>Y'][DY/MLW%97QA=-8I%&)\+QO^<U6&IYT(S14F2
M0148YX%XPS0Q3G!CH]?<58>K<UUE<:0X^EW7#P-;WU@/T7#!:/A%J656\F!M
M46HS+4JM5I'X7*-1EO&<G##*Q&GE%L7^>NW09[_71VN?F;;JL_LPZ40_/NF<
MC8M2>[W3WE5;S7:X:,-PE&#4?$-9N\YXV.^ESN4-KQOZ+R7=H!R&VD'UU6CX
ML9<@/3]_4P[%[N KC581^.<!_O=;LVJP=\QET(GH7.<D>&I(J/OHL]%*.FVU
M81N;EG>E7'#SL@7(7YNP#5V\3Q0\EZ(Z(W@N#CR_:,TQ*L9!9)(SE41R'XAC
M(1+M4J107DA!;VQ*QKM,+3AMZ^FA9YM\Q/?3I\W">E9773KWAY\NFJ+U!A]A
M?$.=_KYFU7,Y;.X#]]_32?HQO$FM6YPVF9@M#IF\.AO%$U_S?X:Y<SJJ!N;D
MO-LY[=>&@#4E"/[?6>^T]@IJAYVY;MK08T93+IL^'0VW8MG5$;RZV.]7=;>W
M!FGG<J]1"9I+"=J]UD5$)*N*+DL$%:$.:M+$.\Z(@@C!1N^44;6PGG6%8FU2
M@MH(3V@EKB_T/68F$$+?XJ!O9BA1!):HL@2 <R(EB\0%&H@&*P+W,@5P&YO6
M=859<$^1M42^-EEXJZ+2CHJ!-^K%21,_J=;>0KM;KU]0?'FJ[,TQT=^$\M=7
M6[S[98<1QN>"\6L#7!Q0(8R11+.:"B2=)M9J3K@O$"Y8V>/:MO3Q9D6O90B\
M3<X;1+U556,1^QX$^V8J,PVDX(KBFE@LV ?*$:^,)M+S0F5":<Y%L=YEURZZ
M:\A:HAYZ9;]C=DO!AK-1;W+^^/KL^CDHVNJ:G6G"?UBP^R CLM\?V;]T=]Y_
M__M?^UO'R7/# W<DRE@+-9TC3E).3+14Z5RV$F@SGJN<*:Q50O_L4X:_!]9K
MOVG.(_(M!OG.9Y#OTW'9)QM#462]X9G(4$ O"$H)9\H4,"R;Y\QCVO1K"7WH
MH)W?0?O!C_Z$26TH5, C3#ICB%7976!B^]-V5RPUX6#KH^_UZU[_.AQ5L#^\
MVNP79>\1X^?"^-^OY:TKK;D%2PSH@N^@-;$L!<*=5M0+:237&YNL*Z7J:K'@
MML]KZ;I A^V:(.!2';:(@ ^+@%\\M]EQ+Y6(=:"))U(*2D(AM@*#,@9@,EM>
M;'OG>%=8=-VV0[E=0]=M%>II,[T+MVWOEIZ[>!7W23LNENFWW1JDO0MO_4'>
MN]KR+RB/"/^='MS:9D\Z9[W*!>&9(M(91:SWFOA@<CGNSC,CJXXK..TRI=&+
M@0[<IXR#CZKG(@X^DC]WKT:Q4LB4"F(8HT73Y98$46Q]XXQC-FF9(50<9 4'
ME;ZMZR(.KIPW=Q6:E/QPT:7DQUI'UI19=\+Y5VLLV^'9?5)5]VUJ6;)[>22P
MZOX[Z>#ZN#\F:-8R$:LL(])Z29S4LG:?!F!69.EJKRJGNY8ON&?) @2P35"'
M7N$U0L^6:M*(F8O#S)G^?E)K!=$1D3(GLNC,Q :3"&4:-*/9F^ W-KGH.GN[
M1G?9%0[K@)MM\B:O2+>2W!OX0>P]0+>2N3PWC]VMY#'<2JU;G#;9FBT.KES/
MBX?/,(J],=3PRG@RC']VAJ<5H&=G&4W.3Z?QE]K'I'8V&<#".IFL7UA]!:(N
MN^/Q68%%.,B')WX$XS>#(I"[Y8E!P<CJAVR>?NZ+%K4]_%!G7?EZ*[7N?US>
MUC^K:WY83\_!]/"@6C676G5M$!*-@<DD.+'>"B)CU,3'H$F@E/NHF+?1-?GU
M[E%F@:QE'/[)6IQK!IC+"L\@8"X=,+_8H=H4I,R!$<&S(]))2QQ82ERB4@ /
M3%NUL:EIESH$S#4P-5NL6[^&TVFR8M66)S#ZT.D/_0 SE%H:C;DS]E_MZ_@@
MOQP.WAV5K<5<TWEA^Z^=F5K2MWS_]V.=30(O F%.UKEWND"W] 7))8^Q(#>5
MR7VSEA2;7;4X"VG9.N2RO_]R&Q#YVZ[T?ZNH%C'_H3#__!KF4\.]JVU=4\A
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M;6/RX\X?PQ*:![1XL?GVCS7 Y''>#,V>BN;/0O@M;B^2[MJDHW$Q:6.3=+"
MR863),/4PDMRL34/< LE 7Z57(2+/ &W\"8T#I!A=M__DW/_X^# EB5LRRE3
M\'<9LYG#H^$4Z+:<]++?.OM;FWE2EHJ5:$'J#S_G7)!FS4JQZN=I#Z-1SAUK
M$A7*NK2<(]&B>N[1>4_F]7-VT&24S:(3TW&["FT8FA#G*$Y&PW$FC>P_F'%?
M;D1HR;D!]Y+2,VHRM.:)@:\6*PP*3\\>BO-<HF.06C 7R]JS\XPSSD6U"^J:
MF$=^ICB*FJ5<^]->DY]98C;-S4O+KTJ %CJD^.0_YS8W 6$8--^?CHOGHQCZ
M#>G_1OZU\-@-3G(]2CH;/!&_])I]+1=Z"N@[RYZ\M9;?UCJ_T7\MZ0*G ^^%
M%"\J=_9P[MO?6#XBN%=\9@'NA+[RQ5&2SC_19%4M>087H>JE0/4I=V%[XZ)#
M+YIGK8/F_9)6D(/=1RXK%=<0?ROXGV(\GKVLR9\=S)M5-"$8]$549#@J,QA^
M3+=QV#6YKNUL;_V)0]];2B"::T=7Q_U/)Q#GUHSB05Z>E]?@#,<W4:Z6=:J_
MFB\E-;6D:.DF+K18<',Z<W(NA$MI2VDX.CM8\+KE.?S+I\3MGDGRVGS[K*,Y
M!2G/!)&72(ZR.($]D7WKLQCOC="YT?SG:#CGD294VAH]9P3,-J20:S(GA0N\
MPR?M[ $;Y0@F[FP0P["@WXP0\G28V4&-39(K?[G-TJ;MSGVE<Z?HI-A7S09>
M9?7;/Q8,B^(_;5 VM[]XCF<]N=3 .72<J_WW.V=+?O19[^S-3,H%_BSY\HMM
M]V6V,O:_;[/7N@C>@S6?&)7<,V%(4LXGKX2.+@3>'O4!EL.I?='$+?9%VYD!
M; E4_#EKR'P;-/G83(E=C\&4()R T18%BE)2Q%-R2'L6D.%1LA2BQ-0\V: &
MP.3<3F8=P)%^._//\-?Y2,S#D8TW&4-VTKMQW,P \I@E1.QL?A1)94<=0P9Z
M''$8 &2=L4@%ZIC(?BBL0$+8;27D$OW]-@P!I9Y3D1L#I"R';2)SC7ZU\(ID
MS: 'NL2MK(46[_X7>.US@YEG]?:S&EK1J#^7-3#Y]J+W95J\43>,KIQ/M^BE
MQKMW-@][SJHSC;]9\G-+PIZK9.<U,B"4X5'\Y=6?5^T6)TNV-)C(IRWD,Y;Q
M7(_)\>%);V$0MY[$YBPV,#] Z\AZ;6S,BM;&7$I_[0U V9VV(?^E#/V1#;.M
M$+(:,"Z+V+,[M ]&Z<(8:U>,-%I6J<O)_SN>I]_E4P*.6JWD=&7F=6RTC847
M^456GV>:#8(ZHYP0=R[]KI>Q/KL=B\90-/=9/':6NK#<:?/NFE=_W+ZYZ;.B
MLXPG68V'JD)%IG[)5A]-RENR=383_>8(A,:'NWOV;:"^QW*P? G&#Q>KDPJ#
M-0LP9HO_%H=1ERCJ?,5%AX@9%!T,/^<U_VOM)AKS6=A;,IP7>],T70_WQ9Q*
MT,S]8D\WOH8VP61>R"Q_8SX@[9PM1LC<\/8%@,KTOGHR7YA7W6C7C>VS9 \]
MAGF]G7='R>.HKIW8S;)-Z+$P7A:\1MEO,\V7Y_#Q%(HN2GD.HER8I'H0^R5?
MQ682.^I-C_*:O?%!7M@Y."/?YU[3)J64I]JP1Y:_7H[N^+(F$,:SY;-S,\!%
M#RTY,PNFXPN<47GZY)6@EU#)\J*B&[%)%<#3 GAJ=YMS$IBE;6G1\'P5WEIV
M830IT-E%.$_H63X0IL74>4PJ+RUNTY>6#+]QJSHLW@2R,3PG&\V.,/-EFLM4
M=&:Y]-H29)Z2)8K7.\]/(^0L^6SQ\LQ]>4EH?N6@70A=+/7&37BZ%_)=;?N+
M?7U)VW/]+VE\Q>B'/D4RK"TYZQ:NZ&'VO(YFLG'&GY<]/HU[IPQ@X]?-:]?[
MPVG9W>MX.CGKQN_\=C <G_OU7Q?H%PMM!D1I/('9-&IBS5<4W^R'M\A8+6'Q
MBVI9G.EE=ZSB"ALO&1.S$/6IL/^S^<WAX@*7O9Z="YK83+H<< #J&OW3\XLT
M@?EJAX42-G?#SGS+^?,%I2[#Q&>P)QJ'U#!,^[%QY[=^["N*R'7*GMTFU[]7
M1G#2K(L%(ZOJ?153+L>4+LCIT6)+L;.H<AF,%(%I?5DN3C['5G O0J"B"^:D
M%3=L(W*GT*3I_+(S61,Z7,2T2IAFAAP_DZ"72UF(]^""[2+6SDA]41IK!O!=
M2;"I&< U W@U)+1F -<,X(>01/8MF;DWR$F^\+EKD_ VYEI";VG#IL;C638C
M.YOSDTEY/-.%9X'D4PKCTMXK,[7B\APC_4#UTO,YJU=GL2YO:<K9-VQI2G^V
MO%XR']F=;VGZIA&B%Z":/FLUT_>@ESYKU=(52<W%V[-HZ>'^29>^.?IPN(D_
M;#UG>[NO:1>T4"B'?]AZ<[3S\C7=WOU$M]^?/_]@9^L5^_#RP]%VCHSNAH/N
MUA[9>?D*ZGSPJ?MR#Y[?^[*SN_=E[VMW:;?(;5'.2?C\,2A)+1<*4:WS]J7$
M(^V-1=)[C)EWA#IW-DU72VZ)<=Y0SKCEQF)&&/$QAB2$Y_9LFNY?;W:VWCW;
M[;QY_O?S[KOGP*/=Y[O?L%'IM>^]Z\SOK=[8[N^/XGZIU$YJQ:RH0(]5IK8/
MM^E'3%6TP@1$53YBSC&"+(D@2I$S$S S/ER?O/WP;?-NG)S?N/NWDK TG(Z!
M&<HY%&4CROFBWF$.&@)9/;U4R3K?\&;7D-.7RQF<=CH9SCJJ.3NO_-(>WUT,
M^N-Q?#K[<.Z8S^5QR&T& CONVY.GO4%I;7EO:V@9LVY,[L6B@;1'>K=5:DVQ
M]>;:F>,#FXM<KDO-*2&7WW+E\U=?Q.M4@\I"O_%YO'Y%M?"Z8-@8_HV/UXH_
MZ(I?<X#]#6'H+D[]G=?&S&OS+2=U7EOAUM#[GBI??)*GOD![O!JAO_$DS]V#
M48R=[29I_'GQN9\Z/N$&YSG/@!&4C7CA('S3K55Z'H#T='.,ZZ<*SP/ (/83
MI:C5=HH)?#SI%'N],QOF!R%BV?[XED/EOV>@?T"O52GXT5*@[UL*ZD#7Z5ZG
M^VI,]VMH_EOZ^+^\CS&EZV0$BCS=9[()5M^BVRYTF=Q)OYTZ(N7L-+K[OOHF
M^5N!;OOON^VJ(B+?TU>-C#66]\_NJUNL!#-><&<4(<H*'KRQE&K",;.&<)8X
M;KW,ZI27>6E)&+O%DK!KHAS/O[3I+WF)6#ZL8-=^F2\48P_337VP=_2EOW.X
M=[)-GXOMW==BC[XY^'#X&F]O/1?=W;W/V^_AN<--J,>[DYW=S9/9,_"NZ0?Z
M3G8/7WW=V_WTI;O5/_SP\L51=^OU9RB?= \WO^SM'AQM;^V??-A]);:W_I.V
M>_C+G[O/)]MO\>>/FDI.HI.(DWSL6Y "64\52B$R+8RV%NLG&XRM"4/.K3%K
M,MD?Q(Q;$7BZN,=NHA7=#K=OI^I4.JET<J]T0K%5R2@3B.(\< G,$6F*(B;"
M@N*JT(F>T8F^B$XJ9]PS9WR=<P:W+(D0- J>*R .$9 FSJ$4-=.4,>=Q?++!
MY?E%R94P*F%4POCYPOW@",-)*3W8%=8QFX_SM5((Z8SG,H#V2L*%62[5_EA5
M+B%S+@';D2C-'1(V )<$SI%.@B-*%:%)*F(-V!\:KPG.*IU4.JETLH+"_>#H
MA!L+O*&5=E9QPIRSAJ1('#""(=3PUOX@U?Y8'<Y@<\Z(6B3G*$62<HNX!N+0
M5">P/TS>HIN7X:KVQUT1QET$<%+YWR\5P'D3FW38]\-1/US*N/1']]M5XG<-
M*S\\& \B><D9X3SQ)*5EB47 AH")2%B;&I5X0 A_LA25<+JL9I"(698]3-@C
M30A% <!=4NMBH.+)!J%K7(E[ /EOFV4KA4;?H?C?#)N_+].FPN!WP*#@402+
MN5$2<Y^2U88Q'K#@UFK9PN#5WO1E&/P:1\-@QP<5 >\= 1<^=H:="1K #T?/
M$<^'M&O&,%)*RF"H3T+S/*LU)?3W"H$5 A\W!'+E$H.YH:@QW$JCC<4I>9Z"
MU9HJ4_W##PH'E_S#$C@MZHB2B@QQC@."8;3($QTD(<!\.N>GX#7,JR988?"1
MPZ T*N=5*.*<X8HGXXQ6T7+KG8R@.=S KUDUP95 P(6WDYA '"$"*6+!%I8<
M(R.%0(1RFK1FF+.J":ZD4_,;L]()6:<KZ]7<'>;C5_YJ=P-H@6"\!B5/5C-)
MO;W8OHW!]3"<YGT&:MCO#COS@?)G"HS@O/^#L8P3'YWWE##'921>>B6K0_GA
MD&CWV9)#.425HM8&N>@#XC1@I!V,8@Q<"9HD(USED.$:EO)A10UO.257!.!J
M'DIEK%6<'@^.L:C!R9$$UIY*W.%@@[34\."BBR)%7#/I5X^6%EY^KZ@GD5"D
M/9>(\[Q-G0D421Q(-#YAPAYB)GWEI,I)*S"@E9-^#B=YJS"FE%I".*C:S&EG
M:#!):Q6#8[X&8QX472V",6 R"4)21$H$@S@Q')EDP:@2P7DF<* )/]D@!*\)
MK2ME5<JJE%4IZT%0%HW<"2F(%51R+85QCC%I3"2)"&-M71"P>KRT")'QR*PR
MU"#LJ$7<<8L<%0EQ["6U6FOK1#6C?G)P[=]EF^7+3A[Z]EVS?_YY )=LF[U9
M#H>8[Z+9] O#S5%EY4"%V0%F[:7V'(BUSN#\AMOSPQ>6SA?.Q=_F.'<KM(])
M$"DIYY(2EVP,0GJM5)28J_8X][/8=IOCW#>;0[?&;^:U[,;)L^8\BU4YS?W^
M]Y+?W6,?"4[*">L0#5$C+K5!%M1F9 SVA$D9L8QYM[2KCG+/,G.; 5<RQ;PF
MPFL3>6#:12R$MH8GQG"0N@RX)I21.N _=L ]_AB5YPZF%@I>"B"EP)!C,2%I
MK2'.ARBT V.)K9_?5VDVX&LPVQ>GS>1C[4>Q/?ZMG+[=R5D?%/\^&X0E<"@@
MLEZNDP48SZ'W_"%O\R-9S#<<R:)_-@1?<B0+O_,C69XMGR:XN3A,<&M^1LZJ
MG*"Q\[:=!$>O1??]"WC^%88_7[8/7X-6=G#PX?V+HYU=#V4]I]TM3SX<?F)G
M)\&'K4]D[_W?A]N';^#/\Y/NU@%,&BCK_9[H?O5T;W</=[_^#>6$I5-97I_
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M43.C&%[K9/DNQ6_!ZY8ND7))KW5Z ZC<<#J&>\9/YW.PS+BE05H: -GT?]/
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MB#5C[F/Y3,6[BG<KC'<B*)\(=LI1P;7%&EON*34F,:^4$56%^YF@MD@W5HD
M7FF'&/<,<>HDLM@81+#6#(QLD:C.6TA61*N(]K@1+3F%8R)46,RX!41CV,<(
MP*:=\.E&"Z KHMT9HBU2;TG"WK!HD</6(YZL1 9;@@31A@MA<*+QR08H<Q72
M*J0];D@34B:)K>&@D/'@I0G!6B^49XYA)F4-<?],2%M*-Z54BR@I2HEPQ)F/
M2)M($<:,IB02C)P RU/?1[)IA;0*:2L,:1&[I).3!A//30S.2D\QE3$*G;R_
M2;RW0MK=A0Z6<B\I#Y*)H)#DR2'.64!6*@H:&P<6 D0CP3S9(!72*J0];DAC
M+EJNA",N<"Y8U(XY3JPUWEA,B*OKA586[18YBH(2;"DGR%N1$#>&(Z>5!"-5
M1B6I#2E@0+LU3.]C67]%O(IX*XQX 6P=ZK$(P4>>3R@FRFK#$^/.>^=NDGI=
MD_;N&^R6DO8D9II&2U'T-B)NO44P>H!]0O" 1334Q/M,VOLUX:YND'NSKMN9
M',3+MT?_3J#^MGS07P6H?4R2,2HU6-D<S&M#-<$X8*E(###/:U;+2J)U;RF'
M3P<K";48Z:R=<NTX,I1PY&EP D8T+X+*BNG]>!=_S?3J%5@^4_'N1^"=2T'Z
M1#C#D8$MKIR&64(D_$NHTC'5&/#/!+6E5#T;373&(TN2  54:N1$ FN;!A8M
M_%\D_62#F0II%=(>.Z1Y3$,24B46>4K2)6*2)T&"D0:6&Z\JW(JBW2*'CS#,
M*>8."2$8XAXKY*)7*$EA6#0L;TKT9(.N,5.W#*UX]\CQSC*.G:2>TL@Y$:"^
M"<>E4CY)13VN>+>J>+?(\-,8P[@DCZ+C&G'"!;*1*(2%=X[D%6G2/-DP:X)4
M_:[BW2/'.Y>,%9HY,'HLUWD7<:H3=2K2X*D4=3.RGPIJBQR_**-4&<4$BP[Q
MP PRS%*4!)=$1IQH"MED%172*J0];D@C7'H!JII1$7,>HO;!6"P,H0P3SWR%
MM)\:6EC*\;/4><HDZ&=@E2(N -2LD!)AJ2P!5E)!<[!,*Z152'O<D&:$H5&G
MQ+' /&EADPS$,*.U2>'V.7XUX^5>@&Z1WH>M5\3SA(*E O$8 [+).Q2]4)P;
MJ7G>@K!N4U7AKL)=1A85%6;0 91*'K!VUDF!,?/!@9D:;F*45KB[;[A;3O S
M5A)&/ J!,<19$$@[#I@G E8^:&4TKG"WB@E^=Y#[''K_G*U2\X ^W[,W[([3
M?7AU?U\S6/W>(**#YCO!!2EWAQ/;[XQ:<.C800!LF<-#)S;XL-C;#QIX5WFH
M5W2^&XY"')470$=WQL-^+W3F8M5<;-_&X'H83ET_EAM^_2UL;Y?0^P-Z\H'R
M+%=""NVQMR;R8*CVG+% *'%4"J_K>:"K2;8G2_F92AG'\]E"B9J(>#X*5!,M
MD,-1DNPK%B'EHX:,7+T]>G[8Q%L1#%O--4>5D2HC/1A&2IR;F#B8><9R;*,A
MTCO#N-(>[#Q^DZU]*R/]#$9:)-?ZE#?"H@D9(@+B@5KDJ%"(44&(L$):YY]L
MR#5U+\<F54:JC%09:74FQH-C)"[RVGOG7>2:&PRZMJ8<>R,T-DZR4!EI11EI
MD0#-F<)*8H?R3F:(.XL1&$T$*14<U@SDD[LG&PHD1%9&JHQ4&:DRTBHSDE!$
M$,F<R!O^1&QLI$0I'3&Q6-L@*R.M*",M4M09CGE/8 T\A!G82$HB;2E!*6IM
M(I-9N<@GHZP1PBLE54JJE%0I:94I*0GL-5:6)!RY)]Q02K%G"1C*<V]ODG);
M*>EG4-)B@0&3TBAO DJ&6\2QIDB71:..PW!QYPV7^?@::E9OS\W*2)61*B-5
M1EK.F#8T)6N]UM'Q0*BQ.DD25&)$"$+KNK:?F[^PM C$J*28EV +>1X0CQHC
M,((<TC%*[!6W,L>+#*_Y"Y5V*NU4VEEIVK%1Z,BE5EY)+K1W01ECF6!4$>V]
MKH;0RC+2R=+1 WG &$<:S%G$=<3(,)9/\@SYO&DKL9!YST.]@IMQ5TZJG%0Y
MJ7+2$B=IJHTD21LF%0]"&NXUTWDY(O68T+IX=!7I:&DU51*4VL@\PF JH;S-
M/=+6).25L,P395G>K7)5MTM_!(14%F+]>V*AXK/E0$N+GI;ZR<.$B*-9*S;^
MQXW^O7%Z&=&=/'=D1_N]01D"V71BJ>OL@?9RX0D[G0QG]S?=7GYIQPEZIF^/
MQ_'I[,,Y%BO?>X, +WZ:AR3TQL=]>_*T-R@+K<I[?__<"Y.#I\:L&Y/[ON!I
MNXZMK5)S!UEOKIT1VN8BI>LEJX=>?LN5SU]Y4:XK10 'O_%QO$ZNNB@8-H9_
MX^.UWK7>M=ZUWJM8[VM6)-^08^]T7P8NOFN!]+4U;BGW>^I\L8:CSR@XZJX4
MG"X0=6<;2CX8=YX#DX?.VW@\B4<NCCH,K]W %)^1/JBA\<)!J+?66Z^Y]0%
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MN/3D>F?AOK[,YW]5V*?%P085VRRXC()SXDS3R704Y[!88@@GI]HQ![I3-;F
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M]4;CR?+16CX F<DY,&^0VA)6>.&56Y_#I3$Z\[W0R^#[WVFOS5\YLI_B?!L
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M%@OS]4<9,/(76Q2[9 '6FY&]*VASQ><N&[,%9M!L;T"*@H$M!+3*/G]E>-Q
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M9=,T[R?XX7@X@;G,\INFDRD\5P"VTQ\>SV<8!@EFHX=/]+XV*Y#OWXCV8@R
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MF(Z>I& MY\931Z+W (+&&$8QO^'QTJ7%&BO8W0O8+0Z6,(TTPL(@%SE#/";
M.6\UBH8G2H4Q2M'J>*AP5^&NJ9?./7.<.:)$/E2/.EB/F4DF !NPU%6"M[*8
MMSA<8C8HT%0.2>9S\722G:T,(X5Y\EKHJ#RK!*\B7D6\'#^DH_56@?%#!==)
M:\*YMDE8$3S\GU:"MXI@MSA9"CK;LE$@1:1"L((>62<%,CZXH(G):7&5X#VE
MDZ65]H8.CX[BR/=LOW-LC^-H98^4:B_T[] 9A%DJ9 S8 Z5RP5JF.;,Z&F.C
M%.XN NVKXK@/Q;%<2R<I8BQ30(NIC8@[8I!A/" 1(KSLM'21/WLNU!IYD/Y"
M3S-%JT+>$X$\(,@Q\V*:-.9 DHW%A%NN;!")"?.=$5@5[>X'[98*RU"A$P.@
MHYJ&7%A&(.N!-=,($A.I-2(^:,!IA;L*=RL,=Y+[H!RWWGF O1BUIQAH7O"<
MD.#T#0MI58;W S!OX0<5Q'NC&$/.1HTX3109JSA*6CE!,:4TI,KP*N15R"M%
M1RSGTB8;L!1<"ZD-X2Q1DV**3NL;'OU4AO>P:+=<<T2#RC("*6DXXD0D9"*C
M2 5)?)# VH.L#&\5':%/,BQT.#H>CNPD=@;#R3=64:]G9RNN,A3P*VE(3#H"
M,3;$8)J+4&MOJ<1$WD51\:HW[D-O+-<;L5IP9X5!"7.%N'(6:5SR40TA)!+N
MG7CVG#*ZQ@FN!V@U7N#GQCQ!K(E>4FTDY9)P[7WIHZ"$RI$UWYEZ7^'N?N!N
MX0@-E,2@\F&/MP1Q'B72R@ODN<?<6,&T<#5>H,)=A;NFHT#RVFGOO F>6Y8L
MX]8S$S7\382[(=Q5BO<#,&_A""6P6$D(B[P1 G$:-3)4$R0,LT#4#7."5HI7
M,:]B7G/X$S"VR<+FP($'K(U6.<%1:TFQY_R&68Z5XCTLW"T\H2))QY742*5$
M$<=6(A>P!<9'I)..XF@KQ5M)3^A3# DMC27WA_ ,@Z.8;W\\'(R'HQ@ZI>'T
M\:@WCBO<;[(>KMU-8ZYDE-!>6<&!?SF#C6<B"JF3-H'4>((5U2L[+Y8\I=X2
M*4E22"J&$5>$ 8TF$6%8.A>35"GJ9\^968/?ZP%;C2?XN2%/:FQ2L)[H:#@E
M6*=HM5,TI)@<@%YET:N(=@M'J28V!LXD"DEFM#,<Z=R*T&+"DF,I&4MJ/$&%
MNPIWS;F09,R8[#E@B7,C@!EP3*-FT3GCB*D,;V4Q;ZDQ7XA41)D0$QGS0LB9
M\T0@6#EC(W78)5,97H6\"GDE_$<%B8V)6CO"DZ F^> 2(P)KJ:0CE>&M(MHM
MI<[S*!Q1&)%LRG):VDX[A9)/F$7))%>A,KQ5]),^Q8C1XB>=C*(=3T<GW^L0
MK6=L*ZX['.8V2N.XP9%;K)P)H<11$8N%"C5T=%45R'(E44\]Y=A3Q)1PB'N3
MD-$N(AJ9UDIKJWBFRQ2DA#Y$AM73/&BKF/=$,"^WJ$N46.&PXM1)0XS$ OX5
MWEG-;G@(5/GRP\+=DD=4<NYM<$@G80'N/$/& _#%)+2 -[T)M=14A;L*=ZU'
ME/%H'=52)L\=<0XG$AD67+I<E.V&7>PKQ?L!F+?PB,; %.6)H11B1#P:@IP$
MS)/."QP\UM&&2O$JYE7,:Y+H _:8X9A4DEP:K[T@0G/.B%?,Q1MB7J5X#PMW
M"Y>HU$9*B3'2F!G$+<7(2#!P.>&*R\0D-JE2O%5TB7YKZ.BJND.7^M3%_TY[
MD^]VB=;CM!77'=$H$:1F0@G!;=)&^"")Q3Y$'IR_B]K[+XLD+13%J\_=7E46
MMVEJNKLQV>[AOXO"V/CH+%,*:XV4IA9Q%@4R#G2&%2Y(06UD"3][3M8HEO7\
MK(8+_-SXIL"$](XQRT0^>8Y.)1P5X<'X0 3C%=]6 ]^Z+^;X)HB$57(1"1<Y
MXB:"]>\D020&C'ERRI!4\:WB6\6WS-^B#MG8I\0JSI6PAM'$(I&YNR+W-SS2
MOLSVK]!V%]"V1-VP#EPK@K@D"7'//+(L!I0H59&H9)V*-?BI@EL%MP)N%*B;
ML<SK1#QGA!@M*1BI./BHL?'?&>M9P>T.P&UGP=N(9#S8?&I#O,R]+2@RG H4
M<,Z,9U0DJ2NXK:(;\QY.>'[TS+V)X\FHYR<19@GV?N<?1\-!/.D<%0=G)\$%
MQO^LIV%/46G$D 1/2;+H R<&6VRC"TQ)AB73_B[Z)"V$ZP7(UL:@_)/5R6?0
M'8-)/0J[G19Y><J[:;P'1<\1M;F.BF 6::(BPD)(IW*@+N?9^N>JGOS7D_^?
M'.N<(#2W3,Y!GCQQ;*R1.E&KM8V"J1LVBJ]8]Y!8M^3IU"' \@F&K*0Q9WYB
MI(.@R$D>L FYDZBJ6%>QKF)==@; UC#2Z> %Y9$H)[UQ8%I*ZB3F^#M+>U28
MNVN86U Z8A,#3A=15)@C;@E'!A.&F&/>"1F\IJ+&-U6@JT#7U#"BQ"3':8J8
M -!)2SPEVA+K*"6$?&?7RPIT=PQT2QY0K;G"EDMDE<^!G#$AIUT W&,V4/@5
MWJ] MXH>T*=8 W1W.+']53L8N_]%:H?EAJ,01^4&,(3.>-COA<Y\#ILWV[LQ
M>#\,ISGJ=?:!<P^U NOY/S_N<.1N)O.1ZN,'")'=&(_C9/S*]D9_V?XT;O;&
MOC\<3T>Q:N-;:>.M94^RC!ZK1#%RV:?"88F0SBVH'7&4V41S;N"SYT:;-5#'
M*W<>>9=;;D4 ;#5#-:I&JAII%29SM8*:JT:Z*XVT'-GLDR,Q:!0US2UQ$D$F
MX82$]F#C"XQU$,^>$RS6"%V]4H]5(U6-5#52U4CW%X9>-=+#:*2%C<2H-<I3
M@H@DN=ZZ //(.X(B#E9$E2RC[-ESK?D:UKQJI*J1JD:J&NE1:*3[S1VHRNBN
ME-'2\1D327B".<(I6<1Q(,AZ [K)<ZR4U)AKOKH)!#^',BJ';_\J)4+@W]#[
M_'RV$-WI41SU?/-[WHJ]P=26E?DW?&SV&&4R>X,0!_"4&AYD:78/I^-)+YW\
M>F1'^[U!,Y.T543E3DO7.1Z.>_GBOXQB'^[R.?[ZI1<F!S Y@%0'[;S0=95/
MYY;>>7;Q1:R#Y9I.XJ_M N'+O[,T7E]ZZ9U=J!O.[NDEN7KYKEG[?F\04?O,
MA)81$S%?M6:-EOX^&"UVQ7Y$;A3M)V03/,HOMO_%GHR?_>O4$[=75O2BJ?S>
M9X?]=;?/7M8' 'TX*L+W"^@(V'GY8WG$]I&,M',PREKL__0^XH_JV?/=4I)G
MF#HOLHH;3,;__I=]?GJ%5U=$U<4BNO%G=^_/C>W.?_YWX\WVQHN7[W:W7FS\
M^7:ML]5]L?[(GZV[L_OR;6=WI_-BI[OYLOOVY6;^Z>W.GUN;&[OPRZNM[D;W
MQ=;&GYVWN_#"]LON[MM'_LC_>#>PT]";Q/#/BZ#G^U7 RF'LO\_HN8;O,>T)
MM9XZQB3G 5L3F% :"R*YCI(U-!6^$\-&)IDB<1>C3Y$ /W4^.4&C<EYQDY3
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MXBY2Y)S+G7IPB#$2Z?"C]NRM=4JM4VJ=4NN4)]$IV0U6ZY0[ZA1RIE/R2N*
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M9"-CR M86\.,X8FMK-'+O7IJ:*RA\35!XVU\HT^-C;5O]!>P<>X;3=$Z94A
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M8-3-%_]]&(%M=K_%?Q]WPW@?)@>0;'\Z+W15"?C^PCLK5U_$.EBNR3C^>[I
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MS[%=^YE,N640T6O2X-;?MW;>KS>+O_Z[_K&Y_F;S4V?KS?K[[4:QU7KS4UF
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MPWN_Q(X"GV-Y_CP9Q\+9$6R0?AQ7K?".XKQY;);LPIT4\/Q5E^:S3\&+N4M
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MXO>[XCMD5\> 920&D:KIL\9(>^P1E22JH'!4')"04K6JKEWQ1CZ*.H*-W@5
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MDU_?&<>G?X[_[_O;_C: (#22R F9QAS/T>S0XAHS8U]S(].-8B]DKJ7OW#:
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M D:HC.A.JQJ<VHD,6N2H2N R$*WKD!)>*M*: /K.Z0.\4W&0\K)K?B)^"-"
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M!-?V1C/L7XHL*RYP_E9"S04JI#/D/_!%\*G._.B;5O#[8'8&4RCM11ES@C'
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M]5#4!HY%L/.;2%H$EODORS=&02L#>S^G?S3Z%X00HQFQV.,FPN  &[@;!#X
MJ!@)P!$H*VRGHLLXDTD"NBDCJB+E5*8$-B_#'+:)G)V-AGFP%>?"7DUF]4Q,
M9#TO2BP1H*E,'#1&0AMAZ#;5X/I9) VP_[)&MJ.$S9PI_^JRBK-><HL07/%F
MTS5@LAS3 [NLP:BH1!9@543I/"7BVE7>9K%/+NE%_YFEDNMD"+JE!Y-1Y=56
MD-C5U2P(-@%VM>FGM')8+WXF H30P2M,WX:JD?J8(3A#$41:WZ'G<N.1C+X*
MF>W>@59KM,KD6LCRRF07E^C;3=U*9UVFS0" +6>8Y3<3LBWZ+TUK- !!K*MQ
M:ZN+_4\R5C)?3EU0[6"$3QE,<D/R^7<;NWS.E&K'<Z('3;9E$V0L+F!2&X3"
MW% <#&B)!+14H2[:']*.;2<$G+ IWN +,R]39I'M,:,8Q:B_\M#T"3K9,-U-
M,H!+FI@%.<];E5%'$1KJ&FJ#PY@>KB39#'FJOEFX<.&)XPT5L3,M8L D3?Z2
MIG.95CC:)EL3@YNAV).&^]EFTT(D>34)W,B'#=*V/<&5+O&EIO7]S_Z F9I'
M?P6Z=/&\=OD/B=:W 'M6)<.U/V0ML9$ J(WZ*02K5EU:25/G^FO%ZER;ZBP#
MXFTB11?B74IJ??M&1H3GBS?=FDV[\K92G:[Z,.8<-^_TE@B!_UN,%4I6),S-
M>+.,T7Q-J5@&EV()",)C'Z=EK/Q'&FW-ZIH/(%Y<<&'G"^[/Q;Z)!01J,]TF
M8"$W' N*!S,BDEG69K/W;K:Y\:T6:WJ"%@#FMXO0:]-),3DO,!&Q:Q#F60;?
M.[">+UBB1=DUT25J=6TUIGZGZ7#-!5/?Q1H70D_/V*Z+6N2X-Y2#5Y$#8+27
M@,J5",Z+!"$PH 1;-'JK;Z8NDGWN62WYUITEJU[Q=SMO%AW?A6PPF<W?;U]N
M-.T@&FG:9P_13+>BURK:CO(M;#2DZJ,I4J."?R+YY'Q5,)E)E=H"7@X(TBT8
M2S+UC0[X'?*.7D!0L00CNL&_@6IM=34N?JT@UF*N?]\Y6*"ZVOAFR&]M1!^,
M5O2!>JF:"<<&<0!"HE=K9Q6-3U"/1<Y;!T[JH;*X9)E0VNBU+8A3$\N27Q0[
M% 3=6RNWFZEV>KBH1:"(?*VPOAM<!P-&ZVO3;*Y)>__8I_WAG/;[KK<^"5,>
M605_3!<3/'N:2YI[3:CE\HK]V"H[3+VXQL04QF@E#$P,>0CS:Q'X #'@*I.Q
MF#GVS0V=M@FA)9L]1/.X[=7LG,YL7&VG2@%MA+.2R4K3C/=7XOH+=KU&]MZ<
M.;E"SS[L(1 M:S5IW+<DO#4O2EV9&"4RGAXCU4G$UZ(Q G\(DWHALSVKV42L
MF+:^0#.R5=QSW;$Y 6C'NMU'*,+/8E]3GZ4DV[4RQJ(Q[A"(F]Q=>+!(-/A_
M4%<HCW*A]@1,M1 WGDS **\;:>@E$>/&B^AK+#9?2#NEYW'P<^Q.Q&4-BGDZ
MZM4TU*6^HCY=[&QG?/Z,"X!M $=FL5T";&*L0-H<?4NT63KI2_:<C'G<188:
MBT'ZP#)NCVYGN]Y]L\PM+*]>E3!:#+[G8K!-B\&T&'P'P4HG9TI51O_[C&7Y
M)1Y-&&"AK+_.C-'?T[-GF)9_W:U%[K <=_JM80[7M^$W<M&^ZM?#F[W=H-G#
M)QP]&4)9S!"4<9TV45=NOFZL^L[1NKJRV8)MSZCIE, \K6CW;9O[&O]O.DK=
M:>R:Y?8*0HKZ@8Z]FAS#XCW#^>]7LE:IZ;X:X&8"[-\"62USY @N^J-G*#7!
MW8[/F^4;8:K-0Q%M]L=*Z<(5 ML=&>VJCMH$EML0<?,)$:VONF5G8?U,11QL
M9? -/ME/6?\$+WT'-)9A/9$K"\:"6$;H63L9F^716$9VQ!9 :;.RG,5L#]R,
M^XKB>X0FN9?R30M-]W7'KY-/$L:U">-<5'K;BKL=OLIS$88K<K -F0AM81',
M!0'YZ6Z9IK<8_=V$&Z)K"]T-;''M>L%H3/6-R,8;^&)8I@L4-^YF&OS//P)/
M-X?($=B_!1*;>L,1[SIDPQD]^'#R_OV)]O/2W@1<R5C>5[VX;T(F T\NY:YC
MX;UO8OYIMG]LMG^Y;N_!]RM[#^8U!'XNV7?,N\R;/>W]/5IRQX'R_ !WIARL
MAH;'IY!YQ[V/ YV[9Z][I1.6!8^H>6]JKJJ+\$/FR))]]@A::0U4&*Z]<@6O
M;K57YMM>5+D4$<UJEG.YBZE-M&F24V\.9Z-NZT>)'\FV&2:#[(Y"\T:!E+,W
M'7OPO"RR3$Q9LTK_K[?OWYU\T@ZN[K2$!VZ V"7;9A$Y-F;;/#ZH/#'CYP#)
M/<\$G(<!T(9IEN)%M4*Q&-+FS#1,M&P2P]W>WCN1BM#G&9BV<9_%1 I+FL6:
MV,1WA>$6S6=UOG;33T>3AGJ[M"F7K/8[ZK5_BJNW?UVPS3J4T[\^M$$PN>4\
MEAO!FT*I(B=*[$_N#/HVQ0SW#A_TKK\].A"?F'L'UV_(O,XF&K@1-*^&P;$6
M$A"G$35,XFLWLB,-9.;O?(]ZNS5:YM7^9X8E^O&YY0WN,J,,$R3$[O-K=[*O
M77)W@_[[),O=)N[UR7*WKUN6*!$:J62XXZ)H5I"Z1-U&/;U[__[ST;OC@].W
M5^P<K%OU+V.NF*KT6Y-3AYAP)BJ0B>-L) ),A'HJM$D1R[S/DN,XTLF4I66[
M^1_?U["$ETR8:+.<HQNLL%X/YTIT*DH EEC\LE6G\SWQRQV711^6NW^]!%&"
MP,T) @XE"%"" -F'V]0I)_V"&')/\M4:0EWI(%'UK"W;L3YMLZK41S]9\)9B
M1MC>R<=W)\>:85Q5/4MUE>Y4/$266?KTYO=#57G.OVE8$>PG==X/\(U%@N@U
MW0ANZ\68XSB_7YYAJF%70G4U&62R^]T^;.BW?5D,2GF. ])$F>F?]F"%^+;S
M3+I:G%CUO3D9 (MP+R8D%^6J-,UNMX?,#^!M?D"SY_><E2FO+^6"/JO$/K'%
MY'Z8NRH5.\PNNYKR8IO5TA:2MIA@UD_2Y$V&?8+?$+O_DD3N#1;%(MJ2QTWJ
M0H0; ]'0'RE'1<GEEO:ZJT:W</2*TE7]QF\#-7"O0I+R3)317B1-?TBR^CAZ
M(\T^EH6=&0N[5JYT"X?>[K"'^<#*J##:KELCY7#6;=#-\8@W%(_FZ)BE#92]
M NK85[G+ SZ$1)43 705)2'$)ESL&%86ETUCP72LQI%.NDV5S7-QLU^S(6R[
M'2CG.%(F*]!V("1C-'..:7;]S'>57"% =[!+FY"5BE?4>4YO>^B$2$F)6(7)
MY4E67#1;\[I]1D+P\6O+2=0CY0"N)BS-<!-,O[OB8(TV@_:N?9=5#T5Y +%;
M*<>R)LN;F&0"BGIE,].J_O5Y:;[?2QZ\(;.9YS0 !X>7%6^8OJT2TM^2.=_\
MWYK)32&/_\S2&"0.=T;%\W,PL*XP'F;7;D-;?2K1%69K2"CRUF7F\=]X"@YV
MJ(K&/)YE<F:9.,QE7G^X7W4P;\OMRSU*3&[HQ>(3!?1)%0*Z<.+'#8=KR'SS
M>0FZ<5/29,5A&Z.FD,&3VXTSKY!ZT&Z[VG=%)W9<M'6$ELJ%7U_8A*W8]7+%
MBNO0($Y+N6-&%M:LY-;/;N>%V.TYKT>8SOLQWQ+4+]>B]K?XBX+@F&,G"[ET
MVP^6-E W$HZ[T@1\GY6\?]8.GN0EJT6(VO+-[F:YZ4]=V.[=G@41-Y+8QE/D
M5J9;[-INN])3X*I%^B^QECA<8KX15-@X$9KW?*'PPSG+&JL)Z OJX9SWMVZT
M[>/)/4V\9JGH]HIZ4-5=CA09*8M5F-OZ"RW+X?>O[N]9V+2T@P6'VBJ(CU5L
MZ ^.IYH5\.7EC<!826(AQ:_=M].#$GFPF&+IW7=Z>[GE@E,FJO]J&'CKV>Q=
M8GNW43;$M:KF.#:I(=LCMQ;/!Q/$7"CH7%\4,JXWZDT6;HX6!6"F+7%DZPL]
MZW;= EM,9&V#MDH2VE5+]T4#PAQ).%]9_&B_"AXM",/>P^4?J^#EFJV'/9!I
MR@I4G']M-["OVF7?A$]Z6^S4ALN[E5ILIN22XQO.7[4+<77ANK9X#&[;:WI4
MEU@-!%W(JDUJ[VUD%V?"@4#*(]2NJ H!!AA6ZB/ /(0DZ@ <"=&0I2FN@NM<
MUF\#U>[DQ=7(F:.01\583$!5@WXJ9'GMNCGTY_C@T[_:<,N\MH!T9>51VG&'
MMEWEZF/HVV1>A?Z"+U7T6AI-!5\LA2.8I$E]J8E_ET:&*G56-I^5P($6D':#
M"9=?KK+6YGYGHY5![ %=NZ!1Q7O4;5S=)RF?U^__730#>B<.>,U<Y\5,%*^"
M4?)O ,'RQ/.KQJGD5RSWV$9 ;Q?&E4:/C,%V_9PS9*]DTA@X#X;3L;?RLW*>
MEC/)YO_Z^7>U:^%IXO'R[O!%'&[+AC:6UE48;@[N6BAPTIQK9@M$ZU6TFV/"
MTO/MD<'8'WQQ^?Y5EV<!2FIY.G##<.^;JB '+;MA%#_AHO@:XDZU]#RF_33O
M7-$?PD<3%F+WN- *V- 4+/<9;RK/2(AJ5,*=N!F/YL-/STNSK(H%]=*99'((
M&'7 21K8B/,7VQ#+P?MC[>#44GZ5W6@)<0J&5K62"/CPTE-] BS-0FO^K9\6
M\RK#UPU2L-*2Y[&*D7#.X[[6$*PE.G8[8\FJ-K*V3%-^:UY[HS%ZIV))@<GS
MLF3C,C5 V)_74745[?^'3::O/JYZ&AZ:%#%J[]9H:>S(+J"!MG-3=:$+$"Z-
M!9]HDF9:XC91TZ9N#X8IT7&*!6WA<BY14$JT$+"FL%[1TB^0(^XF\Y9Q7/0G
MI#%X1)E5:1M5M=IY5RN2@O&  Y&O( M:XEG)HF9K*2I%-ZC5N79-[03!G[D(
MV[\[/M3$F6KR$&)1DP&/4&MW^;:!S"84BK41NLH-[;*$*!G;'-.WT&_QN.PA
MC&V1JYIR<&*!?KGV4U-4;B;.X\T6BBX)N_)V<9$Q^42&G9L^P PVGDI#M*H+
M-<_'@LX@**RT66)I:D\H=2J -"YF<$.+X8%ZL1!2(\@8@Q>UD)Y>,:-W_=J2
M'YK:DOMN*XA5K;KD^=F\FN/J(IM=<<>%6I=W-NODX88-+"X<]"7.E6W/;BU6
M!71%LA.6:2G*KAI86E68\R0K3\JP6GOT5%.-LK>AZNH)IO#W5W[9G6C%Q#R(
M1RZ*$D_:QA/;17DTN(YPB#65$LYD5=#>>-#U616F:X\-E]5ANN8H<>J!B5,N
M)4Y1XM1.0FQ4SF39W3&?B)WYPNKKD*FI,#A)91"[._>U/1\A71'/;ZM@]4!9
M'J>&A%17 N"\>N)J>!<Q$>C!RP7$8\*)[)(#>I$Q7$&N^E"XE 0";C^>M+N$
M]VH'F%H;7YIP-%#3:E*]NHY$6-1*PJV(Z:038?0T7ZEFH.*;9),FT#"O$-L-
M>B8*FS6M],/P\YR0]DR[:IZI)2TP>?)O/UFJ>B6#S2MGJS,;NXJEF&(B*!6Q
M,BS&E[%(<^G.VVV.GA6#A8YD*<!X,6D+L;%L81I$/<^VSWW-.X]\[7^ HW]$
M/#!$7G3G9LO34*>B2#2RYY*(B)F100ZY"KO@XU9=J?R^5;%"F' 70EKVCK6\
M6R3KZHG@Z.3(TI"R(G034>:X<MBU(ZJQ:,B%R[#P*V9%R769"8Z3-07K[F+%
M+1M;_1R3A>.BS].SHI3;.WD. VZ6BQN*R8*5B?"0S\")K6JL$ @?!I^S?QXW
MUL;FPH+#$+OX2\H'>C$@;RN8-HW_]QEJ"\,P5]6BNYEW!7MOE7FO*YM4IO+X
MG8-(G,6*>/D!(_3M\OS;)C'K221O1"TUV)P:TXX:PE7&=;9POOK:K.X==?7H
M\8+AO1(![#;K">EXD+/L$G?XX1:@;BT0S(UXGC7U<;ZCXZ3C_W9=L&HB)8U
M'>0YBM+5M<'_U\& 6*J50<Y#<+QEB4M#;:.B;;Q1'D/9[?WZ]/:-:*[=IF38
M35%,J61D,N?\4/N\6$@RD.&=JEM!O8F@\@@*$6/BP!TB4Z1=_4R >DWEYQME
MT=DC65PY_?LN=J<+5?#P.-NFA"LT4BT<2- P?N^4DF0AF;-WKJLJQ1/4!(C5
M#9OTK]*G%H[ XFV1L,]F=='24R@;>24L2O I-!$'G5;\9?NC/QOX_JO^="%I
MP':;9NSR99H+HHCO-MY?$(P<U[!U6_B =0G_B]LN-?[A2/J'+^KXZDW3'.D
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M<]B=P\R/+Z&[?V@:G2^ZGXJ+I(+.%R4NH/-%B1WH^'6:<S*/R#PBJ2#SB+B
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MG34LB)E)4^T++Y.1?*N13%L$;J?923WF&ZN=M(>+3[;CT.K3X%=1MTV-[7>
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MLPI_W)Z?H2JL OF?3%D)[=:%:*%B$ZY,>9D6,3:"EZ;P1ZE<0F.J<@&OP-]
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M+.;1Z7'\]'3,C8YV9[0[H]WY"_NBS^.#)P_>&SV:G3%)\;B3%/>!X/KB=6@
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MI+B*^I!V'68MSOW9CUX6=J8/O3!$N1"D+O%-:2 '_(DF;@2SB'0M^J&QG8D
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M-U_1^O>(N3+PX.PIO6MS4TNL<)SL'3[YVO"Z'#Y)Y5\NLG^AXV$NIK ^"Y-
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MGU 4_Z^D((^"_85K/OX[WT\6S&Z,SX,_[*RV!:.9#KIE/4M' #^^:AL$M.-
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MM+,]H<,:@+22QKYJ$JXZ(:!)8BO:<!E!V%8R1W63 1A@L=;!:*GYO>6VV&#
M$Q%5)BOI.[53Z3"AJX3=9-_PHGEY31XE>C7JOW\!!ZTT2Z#MBDEFN*VY=\QV
MDO.JG+74"?+L(_FPS/+@6J-OY?G=&!"(?BF>,>.*&OB'>%)22=:(/C0X)X<T
MVIO*$K-Y)"/3>RKO_D,6]$+5B-^I@S@.5J66\V 0QZ7%X]T7J!MJD%HUE5I:
M9P7)-E*E.*=-2RH+G6$2)\R/=HNZ@X(5B_6KAS9JH$P74T$BIC1VD,YW,][*
MQFM\]!$7@U74SBW]VJP=(Z#DRW+N!ZP::S1.33Y;/L^<=]S=S0.R.\- O3?H
MD?G2W7M=_7ZNO<^>L&;C]6E) +SIC[T1,K:8-=#;OW:*J& SJ;;+9!H3VZP^
M5!TIQ3SH2LGL^AL?#G?K=E=V$7[GR.U/__/J,VOGT]BABUY6B-H3JL5=;,P6
MFI1/X#((5:0,6LVHM(RQA:FXUZ!F7'.6<W+-5.0T9VA/O%FI7#+USS:4]%:"
ME#\!37+L&1[+AGVXW7<RWE#DX0/UPE"(;.,0,(PXA4RB*.D A677M)\>$?*U
M&^0CV(2:I&&MS65!N(,4,>V 7D!0,P+++:M!*^N1QOFY#XN=4^2U$SP*T]2L
M[V.5DZ@$&4U>9;7-S<OMNI8;/RJOP135\VQ)H:UE7 F3$Y9/191 PZ4.Y3NC
M#:9>]\NZIH\@*[&IQ&VWM*=5X9IV3EM8F_+: IYT/#?M"1)6#:T^FU;YH3BR
M3!=-RR%R(JZ(+R9<Q+7 D@F[G]+"5;KK#(3CH1JX7AGG1>B-'0Q#9@P5<' P
M^</0KH9/2 ](^1B;*T+/PR=]\+^OX!%U5T)&",X>]Y(I'66A['*'HN_3T\N:
M"74V$]>7[B%;2NW=[9*VHZUD3#QUY9U^CUVT"%VILJ:!,*' %(3M R;4-::3
MD5 F&7@D?X]BA[:R_<>2W!$ FF]Q''643*/%R7E<H0AK$A;82 B'L,SC?!J_
MMRSD3.*.@ !=Y]&3N-XIOI%V<3N>W)T_@ +%X[2)=.<)_:KPW73V3VM,@8WL
MI&U)OT'Y89]J[2/O7&?C(6-]#%1KL1UZ7:2JBEF,^!IP!3P6\/1A BL?#M>;
MECE<GAA"WL28O]0N<R)':ZMNE#SDELKL5CEEB&&3K*&S7R-"Y1,1*F<C0F5$
MJ#Q*8\MH]U4XYDX/PF$KXA]F/.G9,;</7B8\3S>=H)3)I]P$7CCE7C>DC"08
MX*UK-]W#7:'\@PF_>7FMJ1>($J8FNW(PFZ QQF]K7BRTS6#73^-7L-B,E4PZ
MWA7WE1*.XDJ.G40I6*CA5, ?O2/648YI6:?SG3">(VB4*U.N8A_*P<U/4I;@
M*QK"Z/#Q*"<Q1Q,@.AF!<;*FMLV5*#CC;,0MI'(7I\DOLP<SJCV'W?^.(V>7
ML+#D_<9),_"3W\J,:&5=PT\=NZYNXKBSQ0I79;0AM:7:9%GR1!9,F9=X\(-K
ML3/L32X66:-2W8_]Y KC;(KME4<DD#'5'D6I:'8L"@K]=S9^E,1!5A:*D%TB
MIL-)/" CH424E<3$7<$!"8';C4*R?4*2X89#N%I['HXVY$SG):8MV#$JD4'
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M[.!79:@9U5DX2=C!.GH47@QQG.8)VWLZ"F!3++@[H.BHD^6RS J?^X9K>=X
M3)H,[\X<;Z@8\[_@5XT/T&'D3%*+<XW P#+/RVM5,/A)1C 1N-,;\.A14W%B
M!^7&D;Q/4N7"T],RT$$>)&9@!(*.#+]A4@B]0-RY3V,P#8?>;]W62.TG(-"T
MK 6<PL%8$]X!/WAOE@T=A_A@IW+6!0/69#49Y^"1<\U!) P<*KR.O/,:!K(3
M1@42:_[#C0Y+LB[S'IQU^GZSK*H;OZ86;L(09'K )13'PTGD4$$';C*#)Z%W
MM-QVR.D=U!V\^-.K.]R ANK#FV[SU'6;8?ERM4:3?.RI/BJ5LRL6#U7UN.=4
M] "("G'1FA97OZDA.KLR7EN<QTG!3#!^;UNAKBU>AW#&Q6;W6-8Q\)(?7_3V
M"3#8@>8#1I8YSD$WDS"H34GGQ5697PD6.2&TVA[CS'[9FR0X(9+/!R1;RF"-
M,D*5T6^HB]FRA^),6K/G\FBFMGH\Q+RO[/1.?N@FE"60K]4]KQ5[-+#K"3:>
MJ-MVWQN\J+5-B:NAMQJ)8['IU'+A6(L'9DUV.3-=53/HCV"!ZDI3%^'8!S'W
MO_SB%\^#"(&LUM;Q,%[\VL^8DXLNX'U!?LCV7[27.*#1#CL0TK" Z"?@";,K
MTWU:Q6)^?JAL45Z+#\_"?5L\8/"\;D@][<3&]]0!Q@%LE&[%<%+Z3[K6+,N%
ME&S-=1A'RBM#F09,MF4R ]T')0Z-3PR9^(GOL:*1Y&X 0F6P]R=EB83U/1>"
M6$Q'?@G:W*6L!6?X>F.41X:9W3UI2F+9WQCA,:7H4"BW:2M\'72_L(H;>XK)
M^MM@@QH.H#1*$NV"Q-!4J:#WIG>-H>1?$TI^T'&UF"0DOZZAP@;H.)==Z+OH
M!XJCE2YPKAO^GJ:R%YXQ[W69Q(.$DX,8'F\Z.H/:,/KJH"/)1G8XF[M>:</M
M$]I3Y2X+FS!5"!%7]]8>6O%:P?8.IF'60WT?;AAT=^^\"?993\0!MY4/^X38
M_+=8E*GRT>NN##/=W4R4.%QN'!A=3;,_AMT!?3'N,I;\M!1PV/QT2J7]<;?^
MOGN.0_\PC+U3I,- &&NW)U/L,T(J[D19E(2GZ,N7EEAIEQRK*6]J,'++GW4U
MT&K%\VX[T692=X5)7D_R#;VYY1@@$WIETQ)QQC@\6Z5Y=9XM)3ERA:W7;=VE
M\O2FRUC9#5Z3<[A>U"1WZ[P'U1(Y@A(A#%I VEZ/6K:@$#6\#I8AUW:(2)E1
MQN2LZL:@R%:&(#P(Z^$_#:"EQ1DI<]2?;INPI5+M<G#9Z% >U1;F!32@SP7W
MPG*O;?Y1TD=]'@+=8A0JVDO33;JZ29D=B81 !/B[4^&S5NK-X!5U.?YDC#KB
MG>Z(=SH:\4XCWFE+@X>[9G^P3BFQ/I-',,U_R3!:DV8)NG<-VC=B$JC)!*+#
M)5EQM$,V ;OST==[?V&RVENZ'!.HLH2VQ;5%+P='5DRP@!F0GO0.^63AD#MP
M#F#RA7T%AJ@(9@E^V1N5)F@<O+GK4"6R#I,TUJ\FYY,&8!%@1HB==:P*3MU8
M,E<)$8$$[XE>(YQ3S -EB[;K\[5=='RG^3<5FHID82R-T"?DL(.]T!GKUCF?
M9&5O0F8*@E:M0N>24Y>)HWDF9X9//@Z$R3^G"3>5(1>!+3ELI4DJC8JN\(RC
M-@&J3-4!Z(FNCK,(0;6*LG#>*"]F0#7B&$C$SW#X94XP21W%S0_STRC2YII<
M(C%*0^YG,.D5YUJ0!J.W@>\4;#2RLQ0FUW$KG!@O!)L8SOSRV?CSC(;%6M$F
M3A,A:&?GC)+Q8",N3>J2\E?DON.,V!?@@2$BCN>>@0^4ES7QMY33:5LI(HP&
MP] R*BLYIO_)(2T+3"%H8LRRO7B+>?'"\Q,[DZ_6,!N9F9&PPP$;I%C>P@6F
M=I@FO%?&-%H6C^>&D"13.V4/W4]7015<']I4?MF@BRO8%XD- LH?U$1O)D2-
M$TZLE>F:#$O2)?-7<2DQ(YA8L027VU-_MP=T&F =CT)XW]&EN%O) _&6"6X6
M_GJ)TW(L5PMAE.C)I/)?V+<K3(,I*[)'9H),<10I.X",B@F&E5SF(8F037.#
MZ%40UFR^IV!>OS0// )%Y,@FYKT:T"9ZNZD=#H]6I:N<NU\F>N/K09#*T3P!
MIB=X'!_1SU\)E(@C%C?>%J/B0NB$9.QB*'SB@Z ^NVF*6 ;GT&?G?0Q!IP6N
MA<.H26[-UT0/B+$^ K8GK159HAXIP2HC=UW=E&Z"5%$OLF:-VH?88_IURQ8&
MY*&A$IXC//,H_L,(F?%:G.SR+MWS,YSEM=+&V#J!?Q,)F"FTQ:B99^&]X)_3
M2HRNB%$G96'OX/*<[XD<<^!J#G[O< ;(MP<R9;@%H,H6Q.P&G^)XI:ZLBT#C
M?5'*B77+[PT0_KUKS"@13H[@)"55O2UE$'RU#J;42+8&CV"]/PKQ$HP=-;H>
M?#^'AX&+$,Z4_G3XO;H"]JM@\R^KMFBPN.,S4</;F\H'<FF6"';BV6IBJCU^
M679#L<L9SO<]+Z805#J%%<LYYC&F'G0P-?4RTV&:N*F89%K 3WE&W099'Y!Q
M@3%<M3D>I:Z9<A[I,Q*\DK[$ S-#[U(.6GW9R%156?%O\AD\$PWMV'7[\UQV
M!*VX38'9TLO:/1)"'#R"6\S[^J8H8#;V^OXTC>7 S%5W]])D@<E&II;5:U]E
M55LSVFS322+J1GE8T)@B 2%A:DDBP,%> ]KAK%Z 7Y!4+)%@U8P+WM1BX1_1
M^\*2L!QE8"E0M,1#F7K346DU;%ODK&-W.CYYXT&%0_P#$>BF29-0:R7^KUT&
MG(1(;VRGLG78--=SNJ^;>2C@+,\!FE%WBE!AW3#4U5UD;=7.;UV6.7GAK#B?
M#X]&+M+L]>XX(G0/7==I["121N#>SL%8XUU81],;#&]WAW:!Q%$S]; G<?\&
MH?L,\CW#KI%&9AGZ!Z1GVGP[-&&XLV4DPT(#F^O8&2>X%$A>6E;A53K^+:*F
M'1VC%_A@\4@ _P&.BQ!9%K8)H21GH6/?4QZ8<1;ER34BQ 0[JH%FW"TWV(-$
M&FSF99Y*VZ\4A,-N.7@:>V/IUY*Q<>"PF]0HIU7=4 <4/ 1+":QR0]U6&'A5
MV54RY1/#2@MW*/6\D-@E83J0"_>J-TEW7]D<=>WN1PH?F!:,@*T2^?Y2D!C_
M!!*3E@L;.%>&:(;3EB99HO.35LFU$HD+U,?-5G?QI@/T2470-L[Y;7)=/H#:
MX@9O&;8]_K/\91']JRT,@3_B@:T@X_7+3W$T-T0LY>U(5@B<^JILJ#JH7+$$
M_H7XP-LDJK N:.0]74&H>^%8$ ?TAPI_LJ^^)^7,O'O-DUH29VDG2V(WULNG
MQ1Z_C4>2]Y/57(5ED0/O)^*(Z171Z37/LJ9&A_WHPI<]4ECX/;S.I99#>38"
M.\EX[G!JIP(CO"A=T\QE66)GH+3Z2)71E(@TG)CFVIBU#^H.&ST#4\PJ]>?/
M\='_AQ2IO>/7&2<$%QLY/^7X09O$QXJ;N,;<?QQ,_?*354G<;"ZZ9XUJH,QP
M8PB9/F@-1Q/R"[E=)!N.OZ\=9R#?)2D\()>5*T+=>^&H-QV=8J>9I4K.T82;
MJ4FY):J)>%LQ_\I),*^'%5S+E -97D#T8"T5,K$4NJU6Z_138'"N?0PQ_$=Y
MS2&$]T/^BM 7?P&#ZP-_E76YYT7*2DJ*%-:QP]&.)..4-FCJ,.-MR5?(<<1-
MY7"^<J#"]<>K'7;E<W/*L_#,8ZI5>??3B80I=W1K5(V],=+OX?7TAPEX3]_8
MK6!F;@CC6:(#;AX=1;L&),F/J/ A"3%J0]R0 S/5DZ(HT9*IK9%-4$-RHU#;
MD>(*-?"+('*\VCD>?=S\^F/6/@)RF]E6<_E^[P2.[?U#Z8 # VG-Y6>2&L^S
MW]LLS;2 (MEO7@YW*^ZJY5PZ'0O9,E&8!H5<QN>][3T1"XE+-],KUVZ)@Y/@
M=@,M8XFCK OD0K^X\U+N<>R*WLI!%'C$".;XTV".XQ',,8(Y;J%8V\_#@!6:
MEU+C?G1!YAW?];F/ 'VFJ:\/7L/0.W?L7GAN!"[26W$CGEDWXM$MUUUC\HNA
M2?<$UM4T(1R=!89Y"M[E3LLLYP2A1X54^7-XJ/^*VEF%U1I.R96VYT\,390+
M$,=71&6Z\P[S#P:35 +<7C-XDR+03C=6.*YMG=?++9O8PR2N:HPS>)314KS9
MF).F-?J@"#KQN^KJL*=.4L8$>@!GARMA@M&9&795$&=/"%9,I&$/:PM+TQT:
MY\\/B5Y[-PUO)VHJW03TB+'K/>3G0/^02SQ:@HB)$XA&TE%_.+,4:-7?-.S+
M^Q$_.>JEAN\NLX=%J#+(Y3-_TFQXIA-<$H/J3MJ^TTG-\^Q=*W68,<=E*M;/
MC:DM310E5C')$KU%SJ'HN+-+G8$1Y+G;?D:.N2V:#-W> ;A90(2H[(E:O@FA
M:->E&@:3NH_<[>$.])C<K'T<WF5@E@/L&$+-(Y[CT&UX9ZS\Q;("J\.]1-2<
MAZ@=R@M)-=INMWK8%.?@NKYX_>^7[U^^>;UF[6A_/2;6I+@16R>U79KI]O/%
M^\.N-505)JB=[O3%/]]:U!TWR\&=7C^_H!X[R<:=VSD)V#LXG6+S>S"&B=+P
M\)CXY[=51K.7X%"[RLRU-FY%KR[DFOFJ=TTP,"1:]J(O7H47Q1HVW#<7S%%"
M\X_P%;P1(,/(J!F/4/*Z.K(ZDF%>5@1[@Y$&.S^Z^2VUC3M_0'!#D#>'K]<2
MT\P[$MXUXDHZ1DG0@='@R< VZ&XND7--8FF]":/JA$B-3RX[9;HVO[?4=\0<
M=H*)\C^A\V#H,;0:TWF2S?+B ]7(^/8--35O<P[&\/2SKH@A#I&ZKRZ\#F9+
M56)9:F\B-Q'<*/Y$F$AH.F)0O00+UTP(8+#&Z K_W(PZHFS#(CS](JL[3"#.
M2-+CJ[:O9.:>=Z.U@.)@Q.^&M$X ;O1 7>Z!]J-7X,B49 UZQ!,*$QDZSS8/
MX8F# 2J.#T1:SW/]A JZ7#($N8471,\3"696#@EB!QO3^ZX,.1 3X]P?'*P$
M-J5-N-2Y1E2E)PBW";T>SLAQ;O)J]QW6#B5*[(\#9!WMXRD[TZ5CUFF?RH?0
MR7AD19,RJ5+ZQLMW/]#_:@%!JKG!%Q4\BK,*32RD-\PLS2P@XAU70C/3]V77
MV#^!#U#F%XV(]L1Q(V1(K3F3\(A"&L7)D_MHDKR90RQ3YBT8<)J&Z<RBA5C;
M;*1"MID,5J3-0O;!!2ZE9: MV!.@1>:[<)L%F#"O'&4?5A6Z1KR8E[D<>G-J
MU^?X63^$1;SEJX3\1.Q,=?/_/LT0BX)C'0K'2[H='Q8CPFSQMI:5,L%)0$+W
MQLO'%FJ2,+3(OYK%+%!%LZT9_2<53%R>_GP,MU(ZEU3&8R,V0NM'<)NV-K<(
M!#1=GX;L2QVVI4Z$8(F7;NF:TGD-KEZW]6/0*;5[21C#*2A95BY6)?P9ME]P
M;W,T[U&R6.5EAHQ-TOII'Y^YGDPJ;@/#NU.KCC*31$SYB]?/7US\^\TO[ZPW
MSGT!SQ''](H1^_C<SYR>PW,_?_4L$  ACM+(K9Q@==7-%H5E6DR2/)&NA 52
MP%-A("O<H^PU6EK6-<!R,]46=;PGP=,*ZF0WDU*@L11:4RR&7Z[,7*)I.4P&
MWYI06NS42MSBNUC*1.@ND"D="8=0'O75CP&QEOM)'+*YE)YID@FY=Q4W6&13
M<V<+>P;VH%=-$ 0;69\;Y=*//[U;RFN][#)]=?1%>SNP5J5L8EFN?&(8&CLN
M,51/Q;\Y'T+\I@B_3I](N"('#-G'68*$=.@Q+B9(*QF]OWC!?E8X"WO81%$;
M [=.@.C*4G@ 8GC'YV;:>46!FT;D&K@[L%*X1554I+67A29A%'#)S[GV]E2]
M+^2<KMN%!2&Z=>MZR/PD=@4#;#'F2TE_C] Y+/;R!.1-?2NQ]&]^?A'K)&-]
M]HL/$"];U;=,<AYRK"J;$IR:/9E%9/P9R\(:X'$BN/5A3TW0RU@W5' VIGTD
MV8;51)(44[.HDV9SR$[04\ICKI80]9)YN11N'K(4)/-4[=&0 A;3I"30/3';
M><_PV9!GA47U_LFIO?Z$V"PJ,&!J:Q*?O,*CD[(H04\N[$$U+\E-XGC+\;&[
M_DBMPG<>@U#[#1L+;T]3NN+"(%2?# *(VF4FA63L$L H:3]ZQY.F9T[$W)O@
MXUC0Y&3%>4A+D>[>@5*G-*U'.K_D4LMR*3@$J>I?&H5 LZAW?B!I $Z7,7H1
MQVMSX5L60:[4Y7H?@@,/VF^.H]5GH*9,75XFP?!A" 2A=J\E*ASKO_Y O.HJ
M<#?\U 9V>-7#SVLC+>>UN(<"QQ7./U@_^\IJ98:VT.75.YG3P&L;*'WTJ#H=
M&1Z)@-K#7JK&;GP\@-SE]]T$T_8,K\<ZVELAI8"P0#RW4D&R=7B;O67MG,M>
MA']I(5AW)?+4DZ1'Y*FO-'SFQ@J0HQ-H;A;8(9)GB39IX)AVW'Y0\(0M-&^%
M.O^#IPP^IWVR#I8&?O<:(7OR>&<#SH?MMIQ6+0_C\#K<8_5-@E1_8L](Z7T%
M!32+E+,8Y*DTJR5M.[YBOL*W!SU")$V]*M*J%" 2LKZY/FGAP4*)<Q<;3BY)
MXS7%:2BWIF)>$@U=]L$A(7P^)LY4KF6_!NQ<]UN.195C/Q]HX]N] 1Z\M6*\
MUB!YDDIS$<GYD=.]YB+0$%Z2 (]QE(.FF9!#IZ%#T LE-7KH6HC/?)2/6)P[
M8G%.1BS.B,79#:_Y(L>A!9?S6S)X4.IZ@@AQ.YV'SG-X1RW0=?/]7M$>/H_)
M)1=C.<LH\A6/9F&JRV[.*NFP2/:.[>V)RNG6U/9?\2HD]L3J.@T7=E9$5LS!
M+:1@&IU^S)(Q'C=\*%E3/;PACN4#O.\T]#)\BX19W]9F6P:IU'$;-*W#&2);
MAW+?[3T.\8;@(A6UH</Y&EZ,YS.BM[J<4W&], BVQWQ>W+G@VE3<JV=4]UU,
M<EY:KB4&!/$"+,'0#N=,D6-$.\9X67T)]%[<;40.N761R$+:0FE")@DE%K'O
M .\/,1LYS"BS=,KGK239L&=N*NE8BE+V-('MWI1J< Y0[9Y \L235MG93$H4
M=)HCFX":@1SL418%J=:5G]:M6E&J,R'$D<;1$ZN\4Z;054$)R8RK@W>S;^R>
MBA:$:_0X>R41;(#+85*[MY?##/<1B2<ZJ4N;L?R1]8E3WEQ)0887O BYX>*.
MN6?1G*17P[7X=P)8B)?$2=^]=MF-38GG8T_TWDF^L!$/OAX\S%WD^&XK\"N;
M)YQJ@S4=V@O>MMA'23PEEO&<&N6KE==6&RIL7PE1.@Z/POP$WE 3>_BDAT=[
M"UB&.3C3*</B$ML$1W<B=@6DR>"BS"QZE:PD]0L/AH^WCU9/^E YW<VZ>7CB
M904$3$2BA%NN19"<6)"B9,KY^Y@L7XH930+0U-F$EL7B*#F[@&^'"F;#:C6P
M09!C_7(MSM,CPBN5#6,K:ZIQI_"M>>WRWXFT[5+-K;>A=GEC/C=FMCF(N%+7
M/JIDD]&*+)+?2LV)4$RHJ[<@^O *-"JU?0":0/D>_O&;,$U@6H)V42#Z6*1\
M_XY"O<H#(.$>N.WO,(D_"<%*8F>P0\S*2R]JM.FL35+GHE$IMN?EE'CL4_?(
MD1BUSBNQX80X#AN>JZ2>?X\V30_>CL;6>B=\=7I6>^:R"/<%E?^YZ_G/E\4P
MMLR>S!;?X 73DE(G))B51U^2SL[WG_Y7^&M7G0(M/#O8/Z'/Q;S93[_WS(-_
MP:.#_;.-%]P_';S>?O2&U88NZU^Q?R%EXN(>^>N2S XW&8+/!FYI]#%+"[-R
M>3H0P6<_/9>!'844:[E+'QR^NIDO$IH'DDV-/=WAO&8ICJ-+Y/8H*6(%5PSN
M/U\MR\M\-36+#'Z83 ILV\XC@H3@0,>ID(34.$(/[0(RYU0\1@7;1K%&& YU
M6ZZPS2=!FX;:2JLP^/*=)4]JWXXZP_2=7G'SX]&]86G8$<*UI#MCK/33<]\W
MY]LB1P;X0X0Z,@Q94*Z27/*F\[*FF9K:DDX8J2RY+$ID7/$*B('Y+DHUV&*:
MQ?]]4[A30#YQ2X*G\/#18+-]+C/#(4%2T,0B.'1+/0)50"Y^_A S28P=ZT13
MF4@+)7F#]P<GS%2<6&4B/5S;F,$.7$E"UES$K-5@3V@P4]7FTN+J/PW<4$EI
M.JY;33-)]J.>*OC/=7BP2<]J#.(H;3FK[)4'_!59?J0+ 5'A\\:J"@1"V65+
M05M;<3KSJEM,4!/C/RH()8H/]?DAZP&L+F.=5RI9=";@4!::((51Z8)D^#(O
M(4XD1 2XPDTE7AQ/E:UE3M;3@VCQ\[>PA]\>[I\>+XX0XQV>;QJ=YJMPQCJ2
M,8"H8'9>? Q/ #WI67,FP<$':@2ONK]^2OMN'3<7/[_>^_?[MYUPGQV_(/P5
M$"Y61$G$4=?)@T9JD&F5D='%W"E_W?4$R 0>K=!1WW5VY5*G<,FY6=+U%'M)
M4IAB&ME-_6J8C*MDK 8)J3X[J8.O8&EFTN\9+GPGOY2XYKW6!(MI[D8= E3H
MA=W="-XZNC>7.3K5C'6%#ZGRL,LDD1Q9=&F=P/\,,]?TBMY->^GI6T+:.,R3
MDI<@K))-&*L56\0;GG6HYU^Q5"&<:_/-/BOP:M>5OUMKE_5W5?5*&@!*FK&(
MYR,!);P&MY?O?J@)'H>#S!$7J/W@-*R"SF5')FA %Z>U#[7DZ$N5*K<)#2>-
M03+3PF8MUXZ,(>+VAWPFG' ,N55L(<9.WCP!&6]!SAJ#/+W&*7@?0KEWGM2]
M\S0I["1;>PF.ABQ6U!+#FC7*Y2K*M\(HZAA&7%],7O%D _+0F)Y*.+M\YCKX
MC(8OR92TX?6DJWF#XOD== RT'<^S;E%DKWR9B)6M@%QO+JO&C$:5:2@SPHC;
M@1A+RY>Q\^KV9@.GA#?'A++H!3&8<*_")$>F,!F#U$O(VS8*YH)K2;@8]MS;
ML+):)V'4! >B'*_%PM;&"B]9?[VMG>^,Q&.XPD(@D>2K.B-3ZG)>_F5T2HT'
M@;!=!_K204L0%2WPVH[%P,UC]8=]=("'PZ@=>H&LMOB:F+4Y^&4/C#C4=RC#
M/,AVYJ4$&<%P2]=VX].3T8PB?SRUXD@LXF< 3UZD'K3F-M/Q=EZI+JR[J$V/
M%<=#2O_8T1>TW\SJ+,@[1CNAG'"3D]U13S#M:.(6+:RAH$MX&%,9_H->1 !'
MB <[J-3N=]#MRNU"4LG.4&]N^E!/KV"*O-,M&#ZYMOW38BB^NY5\[!WC]B^Q
M1%5<[N5FUGSWY 3^\@CD@SC GGZ_I0//@B4]/MI_0JM8$I%BMX>Z[ LS$8S1
M]IH..[I7VI+*B^T1=<Y$'!P(?#DW0"GV1Y)YX-@UC8$]%Z>T5/?)!&Y=4GC$
MS1YZY/%T-VF@LMUIZW.\(Z)E,Z+ER8AH&1$MH]U^*+OM2(F9RCAZ^?JY'^'H
ME IE&=2HK_N5U((GU;<)8E1"1AOT%Y)@EBVYV)XYY^['^MMN&! .3^>V*O2^
MNTX).DAHE;%C0K#2F<"J)0; 02T;DTJ]:R*NTMXRO5TU;Y3BOU2*/;*];,'-
MHK"9+1$/<F0YE Q0B=",QI"8>_$FB"GV!&I&=UHN#4L^$;$,^^ZCM&RAM-C\
M!.*YBLOD4A)&]9"0,#\.=1%W0Z!:N,KMQ9R]PX@."75OFZ+#6&X4F(=_OIL.
M2=?F$I0T;7-XO8:JA+Z45):F7:H;TN=%$?9J&315]2XL;0("PAOMS#8]W[#8
M$"M+6I7+/03<5I3MFOFD 3W1&;=UJYYO>%MOREHXK.3 <=%/I''/.V9'ZW7T
M:DH$PC,U1JG81JF ""(UO[<T&A3GA5,>5,:K\]R:/M,4LPYYDSW<GURPY#@0
M \[MT5)LT_,-RT0 BDH*X;HQ72X>;LP;=W +=U"AA#2/KN#<+[8V^+T6 ;>0
MJ\ 0!"?@6U_3GT0\"Y$_8*CEA@%J.P]M_\#I,,K-%LK-LF0"#1RDMJ0V!R*R
MTA9^'MBX=F3#<-U\W.@MW.BVF"57)2>- C*X+MD6:CAG)05MX[?U=<X#[4U
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M!M)1B0>1/Z#[2>_9]'!WKD2L::7R4TW\#2$<5'VJM!KC)95%V=DN8RQQ,48
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MT\>\B];<S\[K2(6+@[4Y6V4F8[I0.4[ZQ69SPL8!HV-LY79+)G#5M=$.*UY
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M?UW;EHW<X7%_W>CBTKW-1RII_ :$K6EE9%6H<9I(<%)8?S92>6C6<K]X:MQ
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MVAZ0<QXM.$[S"%AEVT9^G;32Z-' N0!#O0[1F-6@:=#:?B^L$^FF*]+W'01
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M#GWP":% #VG)9!9Q7IMU;3UB50\>_51WG)EV#$YO!;D]E8"77KGG?JC91\N
M^M3<:?.:9M+-\+3M5FI9I",?:FUVI3^=2[G+GJ/\^I3.ON;C&?_\8XQ[R]7E
M0()YB=7DQ6HU[+2\]SKY:%+;&RF9*2IT2I#^ V7QG62!NS^Q/W!C\N-'LW9@
MLA*SM,W7>$Z0[8"3(.ITK+VZ UT3Y[ML7Q26$H&SM5I5ZT3=5;+D,[MEX@@I
M1B8?@='[^+KD\PU8,N69BS9.:==+BD[,'I3/& N%ET[ @'6YI<)(W@6\#-XG
MLD,Q;G5HB'2$?58SRG10G$TF013NYI79GSLTN=M"J+-TBJP\XQ>NX'RNP!27
M==NN3Y8DNDU>V65[$9JTPVQ]X[POJW;N7#WT&\"?"K/$M#+Q*E28'NIEH$)"
MMM6<T9:]/'*#H+? \&6*HN!_!:L+<[UOS45X;&*I>-/12_C(M/,,!9:RKGZS
M%XICU*&,'5&'!;^;&_J+N1TV">GI]'+9-G9.'94C<2?%;;C/7#QEW9U)Z54@
M<6G$>X'1D,  8Z7HW1G]Q'1?.--/)]7=J>XF<$1_'W8_L=N#\Y"@KPIF.$P@
M_(M?9!\O673FK"-'O_Y3PH[0)1"OH#4%.<HH$ML$W%'4^8$?/J3WZ0 >\'E?
M(5_]*O5>O"R1HBH6/\0 L=',PINXV"3L$J,<2E_])0(!A>N.0C58&.DQV6&R
M?"R@#AZ*5O'P(QD_CW-)C40=E>E)=.I 05OS\X3D_8N$!4)^+3WON(>1YR@T
M+'7SJ?$P9R(X1Z(:5;AKM>_-B!2OK4+JA(AE,3U,?A\ /A^X!!LMDKH)WMV;
M(?2+%J^U7V)2#2Z+XG-"LC<T\5&<J&3U"BT8-ADJPUXIP[I_KU7&ZW3]$$]H
M]@TA&J(B%+AO^6CGT8B2BU@@<'A;LE12J@E_(X+%VJZ!V=!9W#G)56G=W\ +
MK"",NJ]J-^D]2\PEF%WV]0U@^?&M<-LM?HKGBBN64"LB:IJVF_L&$XLJ\57P
M?:.:)L;G*AS;N 4;OX(YKX+)7LM@9MX2T-[48NF2SY@_J8#.?5/A,,RH (__
MNE2V%BA&N4\7EB><>Y3M!<[E52W8!N G31_%S#-P9M(FYH13/Y^N G]!@"),
MEZ9!&R@ X8GO6W.@HI\*[[C"'4?B&O#F&5'%R-9Z^>CQ]-2=>P4%"\+(DTR.
M""89+27<#B[N'H,8$RV6C[B?;]) [#9()*I,1MID!*6AV_;9H23'13XMPT6.
M7%(\LP-E  3/G1O.7\+L2]U>[?Z,M2?BVC6U_\*8;*27F9H_[W0;CR 0LE(=
MY=TF_=0CW" =_=E#YVODWOXZ:S"^=GXEYB/2=1#<HQ+4V6_R^7R3=]CSZ7!F
MQ+UKU=_:083=S(8<\F_NL.0O2HT/]K:*#(S'?@_4XR*&#7$P*$/@"%$E;GE@
M7F83V$H8I@@];O0=947-Y9_D1!=/ Z'_^5)2#7>-J/6_Y["8WE/0"RV_*(F"
M1U4>0V[ZW2EV;B#+>2;\ARZR] V7O?\1;6\7,54U8]RP$(@E=<T$6A)>KMO0
MPX(D,*2)P,ID<_/!T%UAR?G;2/6KO"3:U"3'(CXKO0:75W0$5EP1<FU<I_*6
M(S"P3(4]'Z)A^-D2>GGE^E>"VU,KM?LYV#8P+UYQ\P?5)V1RRST!B_3PL-)8
MG!-TR+$_-..#^<;'_)H6>.[/#1@6A*;S97+L$,>0'5Z\ +<8WO7GUR_?O"B$
ME)SZ^L&C%4UYHAAOJ3),[2.2AU9W3>>PG;V->9[3:I ^]A$5\QM1,5\<43%'
M5,R?TK'95.SZ4W==LHN6P#,+*FGV9"JYL%#<P=(4B2"=.?>+D7JKQQ4;V(",
MK_Z*@DL$F:"="Z)LX/N-%EU[4]9[T[[MQ1.6K*F:XQOQG17O^+]0<WX8/N]M
MD:%&$0FPDKL/XB&*,RC&'S#_7.22_("JS:+3;9R+D01,B^H,L;M"0@>9"6TI
M%+\-15@I.(5W0B0JV"/<T29PXCS85(Y*,O9TY_(S]WT>?H>.MD\/[XJ([3M@
MX9V[A# ,=ITG"V$4Y.BB2<&1&N)>CUY9+0P+<=&Y<?IT\9JYD&IN./&:FP0V
ME@8)=:G9GU-P+/F62C>4S67*V<Q,9I,GBF82#5V@I'\_GFK-?8&N92?8*M%N
MV(PA"(27I['A@TOU[81 E=N0U$^NRVOB<>WZW(NBIA'XHFCH(K;Q&#,-Z%(U
MKB]KA-;T5^9FB6.?,Y3D/)E,-L'2V31'6F4ON?4(T\\CCZ.<X<4]([C7JHPA
MW!5V W5MIYYG1V:I??)*@6D/S5-WSS<NNZ^RS_9E*<E,JCJC #-+]6;KGR4I
MXW88$"Y0P"?-UMZPHT[N"A-6_KPS7&3QHJ%H]E?FW4V<GP=F3@NK^[9]:R+7
M1)Y%^1'J[2YD)M999D^E%MC>ES%.[/H]D9;Q,0 94?I'1)']31^]?,59C@+,
M='SB:]'QD*8-:I$#VM,1GH.#S#Z/Z+UI%VA%[/AJ\8VNJ;6=_B\F@N.S:W1(
M-8#'<R.VD4+;6"S=R-1(.AY#[,5Q<9%Z'[098%"9DE'>1UE3#J8G[%=A+J5[
MBRK:\>7$E-%]WM7K:[P,,?O>C%I$M/B]I4N]XZ2(&@NI"\*2<O,P^A<QOFJL
MM3>]*_2N>>B7\9GRQ,)]LI+L6VJ,Y9R<WA$IRSA>RIGTN\2D%)6L&7#BZ[1V
MO4A'*<Q_"L[ENC?A(Q5S$CP0@UGK&SYU>G_$V8?U;X@CC("17+<K\"HG1""6
ME46,:%TO5WDOC=2E((@,IE2GI2O4^EC5]3"3ZG_8_:ZE6=WVFOQB:?F-(#"*
M8*P_G"0&A9'>CDD=5;^>CNO(>AZ0KTA65?W2>DI=]A<HO#F"+9?ELD6G])]O
MF;-VK)3@QQW(NBFRAFR$&#P7'_4N^E__L@N9TN4@%FL["W^P>7MII])CP!>L
M)ETT9^[UN@@!"ZK/5&S@4BVTC>#01J<F0)$K(Q\I[:N2GV>J*N'L$G+*AP]^
M_25HK2.OZKBP3O+B[35KK<63SN))^&_G+447DMWP3,&8=U3A;$AG=71?">2,
MP8WU]FL%ICAH=#)2M-3(KMG*OTC57)%P$GSC0D@.L=6Q<.E<T/0-O2L0^P6>
MKWOCB]2>;P4 5(]#7%V[_5SS>$YA.<XQI_'0]LIX>N)"GQ/NJ2.2!R[6O4F7
MQ0],GELLGK=-',S+7"8X_G.S.D52%W_GJ"''=QI3"TW+&W<'QB_]^/Q-06GZ
M?;@DLY(^2B_X#0DQK>$BO3+X;OQW^WP1?^G=XB5UY+Z-WVW:*S9JWVV7WR\^
M(B\.!X,NPP84NO0(VN>CSW[,8[%GL7]YUBT'XA^-PV"'+89CW4X,)[ZAGT@_
M]2:\W59=.9XF_\V/DR,Q2]#OB(O2'KK+?LEA6@_]]'G,"EPZ$6L0V(KU1B4.
M'CHO*4-F5ZXSD'=#&LFJK.>7P8 S>A(9!>"*Z";^PD(&*/"GFGT0&\&Z>FF\
MFIC*3'RJ%'H\C<]G^=\C:Z6#%UZ0:I,[ODP.!G.>('BSZ<]V,CH-,VTZ_;>%
M<7(=R .AYBAZEQ2E>W$BP4TJPD?29IYZ 1%]@K';+TBWDCQ3+C-[,-."73 5
M&*C^XB,A$8,@DC4U*%TR6G,.4^=.W+7-9S$9+G='^J 4REXY@R"7U%>)<$*R
M$M#,\2CL6?H.?S6GV]C?T5,]N<3H.RG+]^"RA$,"Y 9?58P'T;R1MT+>.DV*
MO])0!J%O!>;S:J6?6>MOC)LWE73+-%)Y$/F/\%X1P@*!B.H#>),EV@GW26N#
ME5[+N<KUPW<^7XQV*YDV)YPB@M&IJIW 3RG&1G,GT,ZCOPGW 0/PM$XA$6/2
M-TAXMW&8\>#OKE<_G55,&*2EYWBP(<N CD0J&\6H.=3K0I-A,E=@+&FKI*#&
M-H(XU7GS:S=U/'OK:K-ABAI+Y3<'<'2T/OGR<VHYD183W$?U? XEU]3_H('#
MQ\D=4,>R1U<-%"'I%3 9?HCXFIF(;88&M]QM7OI26I+&7:,@HN)RR!@!0O-P
M2PUH7$*(__T6+=04K?8*EA!NCCJQMI"7V9I_($Q,H[40F&S!37%LJC-9US!E
M -%\]TVQ.$ #.,60V@[!]#J*H8=_NEZ3LBU57FM)*TH)E-B%-FU=M:GJ 47F
M&1C5>Q#)FASY3] 8E](DXFHJW!)&BE>Z-H,H$?157) QNTS5,=EVGRT41R&T
M?B?:XYZT#[^VIDBN[GB'CW]#XL<M,TKRK_1#$@L7U\:HI])+TUB_UJ>PVHLP
MZ\C,+O:D[0?M@B.\YK?":[X\PFN.\)H_I8'=DWS+UFJH*=BEFPJ21E\3/QTQ
M<-QDO2"IW<#["K"+J[);MI<WZXZ[^)I?APNK<;-IBV:GKJ(]:+?T?*!IZLSH
MHJ5.+92'FJ?&G@=_]YWU:5YG;W]R.[>E,@<?ZAWAG@C+,8BL:XR<#&:0XQTF
M/I&KJV;*-Z)] >%+1<-2\D:Z4>)"%923 &7-NH7$!3(8H2GX?R!WV8A4SC6H
M-5#;B^$LDJ5U]58B^[U@++3>YP%9N19R8C=6T*G?J F62LB1$X)':&B)[^XL
MXLX>X,0Y=-/=I[CP()\4Y2'I1(?^#QSV[8,40J5^?\)0)>$VS$'#HC>LW"P,
MSNCO@,Y8AA6!'K*V$P^RLZBX0\QA?([,W__X<ZB@/4$:4+,FH\.2=2]DD;.8
M19Q:B:,R2$Z6AK'(!_YMU<1-""<Q[<@^_8)1//RX>GU-B@?Q0/VSBS;A7Z$[
M^:&BP('QVD._NJSY79X_!Q-52-*YJM(F &\'Z7[V\H5)D_-Q&FD)_1)4LHT3
M>4ZZV8U7#ZOUB>%G7S)P+=1]@/"OER&PY4A?[LH*R24WS7+"WQ,(RQ19H( <
M&0(X$5)"EA44CY95C@\(",RK7N[#4(D7K9Q@]((-1QN,O]-"&6M2" B'RN0U
M.B+P1"[Y#C6V,U2.J;XOO)R<H.7PT$7%AY6<* K>5UO-O@ACEY,VF+."F?66
MRO1[%,9&PCLI6<W47QNG^L"#UF@D@\_X]CW-%Z3F-S/X/G\Y;1Z41@>F(-"6
MB<,M#I9VU[RXRX'JZYCRI>_'H-9]R! (F;F4QW$5!B([%23R^W^9$OZ8HS[Q
M%]#FTS=9WHQ>DUKM#;N<(9O?_Z()@L'X94:\)!3R;T,Q_V;@\1S+>5;JX&1W
MR#Q']7 >O%OWQM"BL$9R'J9Y+&4;8PYPYQK'%VZ;856'=D^ -N0.^KWTE(T2
M")+-0L%)Y5GA6U-"($L9> IXI3YT+99S%([J&!J'C'^AF9?@3 .4)8+R1D3S
MK'<Y_Z/GWS!V(A12,&12T^B9V+Z_='P $Q,2.FN1/3C%H_+:^YD_2L8".\-J
MH*PX'N0I%4>,@B6>PK\73ZO!'T%AM)FN#LN_.TCK[[=4[ 6\N1P.T!MG990L
M?8R;F+OC\\J JT;:&Y2NB-;-?6M$1S0SS\#&<*$U'TB,T#-4.T&?+4&K&E^C
MRD;C.RC17ZS8)%U*D4V6I1@O0U8&22RL<]L#D<QAX@L;Z<R8YMO%!5%U.XDJ
MN%<Z2#U_2'NV;[#WNV[DHTJ#+;&;XZFD"5PL7D>'CCK[WOA8=%>O,!KY8R%N
M7])'Z(ER80QJ'S-;?A^G>W&.A8D6X5ES4>.2BO_OE[)6_9.FI';/(=TS,90$
M2.JZ"<Q/4ZTKPMB<U<U-76Y)TO6'??2_2:ZV/6'7I<3;ZJLHUZXZY3SL?'2E
M:Y97)/HZ.SCZ--]?T@EB&@;2@XHT#ZPB+DOH7L$S8'=3GS;#."042G,>@;@P
ML(=/P\KHZ;_$)D,.E>$.-)K78;^OTV4OK#6+LYP[WI:T,^$83UBO<S76]<PB
MZ$179)1?XI@F:/8R[*_I=($X7>#9N0H9+'E*].LJ< G%_M%:>0%M@] DTE*B
M!_7P*\+<*@!^U:!M1X*FX5:.E#(QV^"7Q*E)EP;SL"J4]GL;$=TA]BA/)Y:S
M\28.+O2 <+.&]%M[0HL^SGO&ZS,F?)R6R:2+_2_@1HZ#),+)")U;#JNI1@7_
MD9&/^^+%:M^JC(79'3A-0RJA_I.MY-08^A*;H^@FJ-\D9<D:33\^/7^!F](A
M">YH4G^HW@;RM8K,[]B#EKIE!5"WO9VDN0'CQ1UL'?K+=P@D6%/J&6,V5+$J
MW.8V:538*#\1=Q#-4B5XO@.@NGV'P?S=BT&PY/U_#Y3+ZT1J\S/,@)#U9$]:
MQ'@@44M7(KL[5'MS5Y[&%^^:<LSJ,).Y(D^':0YV0_0MX-^B8/]C/'9O%Z\O
MRVZW^(\XY*\73]O+;0 ZDE&1<<3Z.SWN&<XIZ[7A5LD9?A*$B<.N<65I$BJ[
MQUAE99VVJ3S;7TFSSSY=G&7)/R,TE^C$*Q^CU"I0; 4],&*7>RXS0J;VX")/
M3YHUB#TN#'*J:PBQ;.X.I11[YES*R9L3Y2RFZQUWR&24MS!BS>W%Z#XDKB@D
M0:^#6T>DY[/$.R3.N4H^577F_%UT<RZK'3L5\O+XH5GW)CT/[WT=^)X!K\_B
MWS__[/01QS1;$8>-F[.["$D,G?:!D5FZP[0A[_)R=)B>//C[XGEC^!YC2_/^
MXRC<81'6.4=A&Z C6T[.TNW'R$(FGXN3#1Z?NYT>E4P8RBR)SR/%>#^LM>]9
M(HT\8&?8<-S')S%ZY,I/OM.3:<SN-B!BY2]=$-8?VGE+83557B$X(?3+G)RF
M;,:05YIX2]-QS #^F9#4[*NJ61@;;W<E9RW$3\GWCG%5BI]&W,SZAI*#) Q*
MV[34$"F^$X<>B=3O-;'[QWU\1MS>'8WP++K/Q,L?(US,1IS9(K?9A=KG#[;]
M#_X(9GH)TR2WH[JQ9MJV@\4<=3M[UV4^<!_=-&]XLT!&@SV8G_<E-V#P_[ K
M:.;RR3HSO@LD*MO'L6[VB_\_CNG;-G1QOPQQ59_&;?-+]*[BP/#WN*I'1-%O
M1!1]=404'1%%?THK%T[_BZ&VL_U<!/VX"$QBZ9NT?!_8\S?&29<;K>P^*]R]
MBRHTW<F;>+VVG1JXQ;6(CD?KD"QJX82:RUKX-JX@P0IB0?L@DD92,;6BW\G4
M\MI/*;(Z;H@NR9N,+3G]+I?F$W)U: 3M1%I*D@[QK*)4+X@7+W.R2B*5*\Y(
M;.4UB5XU#Q1IS,!S^I"Q&%"EKTW4J_VPW5)00 QTG$V31VPKP(7H%:U\P83D
MT2VQH:KOQ3@9*38\33XW-YNO;DP"-!-X2N@:P#DD*O(^A/,7UJ%?==4R>1\^
M,)B1I980$DE JOSS;/@'T@Y3J=+WE4-U/41C2KQ=9,%2%2C5">)M7EX$!Z3X
M"S&2CGW<<9"G)TOK(IS.F^\(<M!O^K<U P'68=L0AZD^*7>I(&M@S* ]\AJR
M369&XS:$QYK<6G67?K(1>8B<\#1X1FRH_M30JZC\[5G8.P^C@'@;H1PX/2_;
M#<HZ5V3MYK0_^%RX$5R+U#J=A='&MW.OJ=7%:\&;^,8U[1QT77)]W*S2.R@K
M &/%Y%?35#3R?2;BYUKZB()J*7390!-RLV76?7=!.%9_-*-9-K!B-2]0(3 K
M36"(3K+K-,O6*--JOE6%Z&!26B9]6^W'\ C3:,[5&QZ^D=@(80N?V1PEDO()
MV&BTPG)84A ^I0MFC!OGDGNNQ6<U>I&FZ"4S?OO1HARS-G\BC;QF&-Y-8ICR
M:I"N7-@%.@7VJ82EVC"Z5D0]J;K.K^OSWUJ3Q:RHE,LHA^_L*PHUC8TIC9I9
MG3#@PBK>.2I(E-.IT,)GPBH'<E?=.$9;JV)S2ZB:;BO9<.H@4?!X(F]@WA(2
M$R=*SPGE<B8\X''*2N1E1OF2C-A"&J'?"HW/DHKOS4GJ' ,*&6B0#<+N.9/%
M%PNWGPO:"UQ9CF8GKQ2,R;AL=FPB_*5&(TQ5_9RE5XL2\P@ ;PR57\697C<^
M2>X*4,"#+&;-#5,4[D/JRB5$Q.H2PEKD1E<9F$^@(C>31E!YCJC,TI.\&*.[
M D9FS9'G78^PI*Y"/ND1%C"*\I+A"\RG"9GT\L91RV]2DL2ZFN?/NDQ[N]G$
MN (<2%O**-(#*U,@F+!AY\X&B9YC&\G>8F!0/X 0\- /)ZBL7)()[X1>BGPA
M4T>T]W+17ITA7FU)L4+6BYY8GC2Y.Z)+_XM4Q?7,>M4W[,YE+3=][\R8[2"T
MI M@(W=+9W08W/W@0)3$P)500.KQ>8 1L$/&$(/2N-5'BTF;M9QYG]+G>JNC
M97&Q55:N12.N>IQCQ9P1W3[B92OVXRW4KTY0,(9D)3Z A^^Z$,)7Y'_3-JFH
M$5@P[33'PG5G?U<(C@!PLKM+OZL8I*P_>.)3%NA7Q<;8$LOCOFT(H</LPH1D
MCO/)J!U;%'S8I-$,,*/$(^H'.Z5J#\[W!Z1MW"TH")NLM]M]N%"'[3#WQJ@.
MSY+?F9R ZAS<[;QQA,]\)NF&AX6%6T3F6S MP7TX\"FW\H?^:^91'#+*0R^=
M5OZJE_.3*87*1<["&[5C"S$3X+!Y;AB><Y#IOUA9U?-]TD&$)Y(Y,S,/&-W
M&8YGG$-1Q.2ZZKMAI_[F!/"]!O1K=2!YDOH%/!H^@;-&3IW \;(9("'0<9'C
M'T,3I.S$G%9]4&1H=#N):#5/$C+T%5R11L"="$D$9T%-X&L!#%,5&E9?Q%4(
M?ILG*1KG[1ENKDS2U9H0^$?<!&36&=A /Z%<*K=PH0@ KVRB2[;X+C3_NA'<
M_MZII3\S;S?:=P/Q@?;JS2?VWV_(JSZ5:5)89IH.[TSR[MF0KB,CFELS]9I
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MX81P\5?5>F!&-58L<L>[KA4:(H,CF%'%N8/"5.*2#3AT'Z?KA:X&$8[B[7C
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MC"CR16-U;J<Z#)P%^S&.IY/K_P!02P,$%     @ <H!?3Z/*028+%   &,(
M !$   !A;&YY+3(P,3DP.3,P+GAS9.T]6W/B.-;O\RNT>=G9JJ&#N:23KNG>
M(N!T\PV7+)#NW:<I88O@:EMF?4F'^?7?D>0KQL(&,F86JG(!6^<BG:-SD8[E
M7__Y:IGHA3BN8=./5\J[^A4B5+-U@SY_O'J:/=1NK_[YZ:>??OU;K?;O^\D
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MX\6,KZ(1'03Y[.!T2I/J;C[ &[EH@WKDF3B%PPZNG'VP\<YW4 S@IT?FWI3
M?#>84O<,5S-MUW<*6)/]$9Z"M>CR-"@.ITITO CH*71Q II!B0.&:(D="VL$
M*&C0$3#OMK,*;+H\(BB%HO(8@1L;^&79S L86[&R +X.XE@-9B.[UPGZF;LJ
M40I'U8'W%%-[87PF] ]P.W)1;FU:N<CNAY.I\<I7.!Z,%_(-QODW0G5LFCR8
MEG>I('#EG1Q[2^+L2"J232IGN&L:E,WSF0/1"ZC_$%-_ 3S[3"WE'2D$6GD'
MP_@W7*L9STWCN9 ]W 57>=<&!E@NG:TB%ETPR04X!2>67/].A>#1*FENQXJ
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M1LF!U8N:_X757 S[$-!:OA4.^Q/52:PV;-#W=N_[X)<K5+O5R-3B1 H5:%%
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M/%3\]3K]3F7Q/?'>97[!A?S7PI]^^G]02P,$%     @ <H!?3SZ0%"8 )
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MY-F71_#E+I^ 9HRV(7%+;95@Y"E G5JSOR6^%3'.+@IF6O+(.<.(::;S/&A
MULF &/51&6N3JM-RO&W!K,6 <6V8P73/0XK1Q">[P@^-)H3F=;11YBVB^?!
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M[++FJLBB);&];RYCN$E7L_#8:,H".%@7\D%CB4":&G-S-:Z4C\8GPK?DOIY
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M+%E7B[5LOURQ-9H\AGEU+<[6+5X(4#T[U]!8+>N>^R\Q7(X7I)Q%V^0^;>$
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MRK3'B*P;>&[FF[R>KY&=0 T6ZF+TI/"[:/K< NXKZO%-Y_THZJ[6>Y+RUBA
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M<3>10YLJ\T%N]*:)W7"F)"$]]ZKV?A1,%T(*(=8L5B0++F8/;>*!=L651X*
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M+%1W+-=.KX%)X%ER79R-W<JE+G_^\]!N#[+K>RH?CO#OYZ,\(2-GE.F;WVF
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M!I>8)6 JZ)K7W:35PJ/(OF-B]"OUOFO*UER+PW*=WS;@$)41RC"OM6;:HV<
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M_(7%@6WNR=W6\%IKT8/],$W]67'-MLEKF;_@LAKMHV2\$/=!E73V*,% 1IU
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M09/*P0[87L^YWTHA#8+/K1 )X.I-Z0*Q96U>!XS'*<\;7+]=[:>G<AKDO[I
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MT]UT2I3S-Q"I&.'F@0O>&:DY5<X$#H'2!A9/O6I8TBXYQ6GJ<)=!RSN;Q7/
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MT@.?[AI5R8U 6X2,W@PH'*Z5:T=B:OYU8BJ@=S*@ 4*S*<WPVEX>Z@2(3=<
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M<WNSGN76JUE<KYVB@I3RCT"RH#4X#7#HW"U" SS8I@&FB^K>XO^==+KYZHO
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MRAD^(F-(WJR2MZ]LVJ ?I3\;S-(V?&F[0* )3MJ.UG\W_E9;:]=C5B'8 J4
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M7+\XY[Y!!#T Y*!?IEZ&B-A:A%#,OLY3#Z<"D'[& P!V 47C;_]I[B#Z]DG
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M +IDRI;R3JBL<XI9%]J^GFXJ,,UW".[P7>A<7H3>73T ^JCO7M^O5CX ,A\
MJ$W_8$,;P5*YM-ZR=2BYN:^(:MW$^2V(FMKVRR$T3]>TH4$ROCOB[:]?@@
MX$G9K/^_V42^4#[8M9G^:YFH!/SD!3ABU2"T#8ENP#?M4OUCJC]R2"7@-1-3
MN=).(;ORK3?LWN<!L!E]3^+_G\I&ON5]_0C"1P>$UX^!%". TOC;]@@F8@\
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MDP>'@1H0Y:5YHH<_OP?":-18$\%I)8/Y=?!<H8?-8R@<G=;I1ZV;W6D^ZA8
MDQ<>*ORE?N-'^EAYD6=GM4#\%:IDH-:I.0.+DN<5T>2U#][FL]H-_FUV*6R\
M]8YV,A-;Q[.\$AE,$X=JHI]WD'J>/)-J"SQL^<5MDT5,*;',JULP&BF!O)V3
M54VTF10D[L5"8DX)[3V575L;P0\Q'6TM&+YQ^DVJFM^*:3)&(0T+9.ZD\V-7
M<:_9AV6K2C$'8M(!3GR&,< 39!0(XL'D>>E?>R.,GB 7PFX2R@X1$@\Y$/YN
M7.++"4>XPEF=Q3Y\FZ*YIV7MH(V2Q2RK-]^B. 8_@K"%J5^M@D)2V*%"G]]$
MW"$&J0=GN-"^D'' 88MNM75FYZ,BPY@\7?Z%YSON\78H+/7S$H1L)CFG+YNK
M-E-!]G:<V3Q9&HJ[TU$2WH2N]]/!+?7QKMQT+#4HS*9V-U/&KP0&> @0AE0V
M8&++V ARS*/6:NX^)]% B48EB^$D@G]YI5;W:^^NOME,#J,[:7.Z2IVO,C\3
M2+KVL=T#6IS+F<\;%A*M+JW*E5F0^04X&_DD[A74_/6PT2HD5'\.8D3^X1J\
MF4=5M-Y5JS ;MR+0/P1+BC^IC/??FG&G_V,X@=2K.;%$705AZZJI EIX4/.&
M'Z5-@4,F4Q4#9A.QF4<XHIZVKU@9@S\W4#J)8&_G=B9N=:HW/JL \AL3Z)+5
MABQ-.\3H:G2'..4A,#MYS^PZ74'UM']%C(E"Q@XZ6Z40(HP[VOB\V-R+;O0L
M8TR[S03(',_#7J1_%*/R-8^VXKCRPWM;*3<HJ1#)H<BLS>IYVMQA.DOF7I3_
M6,H# I/TFF7X88 5+X@[\,DX909A/_67WJV])W97[]AI3N0VY 5H1\6VA9 [
M'D+9&6[?18$$M;1S*9&JJ)FX(<YK?>C 3<.L1.I(Q14>GLFQ!6LV^"$B!?KK
M:3R>T5C"L\#MC\IC3A@:CY!T']_[[X: )5H+4HXH_;C6DMNV4A[OX&7_0X6,
ME_<  E!_Z0WJE9J(#E*HR,;TW>-;I@XO>@]1Z",OSE&/QRN=E0HX'YS&]!8^
M\/L24XWOC_H2O]'W/1QPRAOB?+E6GS<6:]9/N0.W^U[-?T_W.<P'(J4XQG:C
M43(#&V\GO(B>6=+MR64)G_IV3%[>6T54V-, N"#&E^MH9H"E0D6Z4H1&3Y.=
MY2%#L6E['V>["H2_L6XYHF0;J/<S0OM?5,LLI6$\*>GR_1R:F+AQ5%Q3 USN
M:Z\[1<<_00IJ%G0!MXE@"M-J?!@VL@-3(NJH,^X25,,"SI<V7\_<*?&I,:IC
M\?42[>A4;<9#*Q3'M3IYO)Z.G,Z/I7@(8W^6/S&8#PLRKE^B'.B&,X&S'X^P
MZ$=@8!JRDVE@T:VGGP=RER[KUQUPJ7G+7[_Z</<2,NW#(HB;.S_O4M&5XF*7
M;VWN4%4C8*W3VO:1""LS[.+T0<]"O1A@-1"!5N?$@26J<4$CZ[%7N+KD+%9T
M94ZQA$Y=IAK45+%;:*C/UTV_V>)KQ[[DREJ,<3^RD;\YVR84NG'QD^>'CCZ^
MK9OL:ID;C/PJ>$3OM/S"1J>A=KB8D()JW,HQ29X.N.=2)5>[I.7.$_7$Y'7W
MN<JNZ(_AJ6;KJ481<,/1'%A9GKJ;@,1D(84 MXUKCB_9L)+7&!GETL\><6M@
M6(A# 1:\NDP^?"WC0L D0J2NN2R3J7.;N'IJ]ZRCFN_3I1Z[]0DE\TM2L1XA
MH/J*11WM 4'YQ[VY6]^M\0FUX116V&<H98<>WBDEP$(^%^:G-B$H<.[G:F=U
M[FY^^&F_U)[JG;ID>?XEWK=RI:7BGK72H+F>8,+5J=@2BT"]L6*"DTX*QKA6
M+MO+@6YD_1HT.$]OLO)N1+<I$:7D+]]B$UOZF^?UWA[L^VXUJF*DEU92:4O0
M*,UI#C[3;1R [RZ<##[HMH.I):K#^KM;4&\\5^\!F"[+[RJ@DH%KSS6G.G2K
M*PCLQ9SPOG=PR79)VV),Z:YLEMW(F^7?R$'I,IF5^LU6M\W,/;YVF!YD6A+P
M'41Y?3WK+8U:0_D:AL[OU;&T.;W8-*>Y*."L:I'M<(O\I;A\1P3E[+G@JP=L
MAU&-#2Z?X(:?2N_F??8L9]]I:!3FI[-A".,\[U>$5"<))^.(&1NBDMF%,?K3
MV@I]1[=2\X+GZ1 [L=?1O3TJW7WO]*!N#2%_KE"39])4X[N&ZDH?\7)K<>/U
M$(),I4EU1"Y"";_BHPD5X('L^)M@VL;Z@#'>:$.U%%&?Y A\,?I\>H!ST:!>
MCS IY'9KEEL!R\+-:FKD3F)CWTYX?.3 % D/KD["GM/C+<2!]G4*\PB8.3W>
M*1NY+^63QR*ZC"N4M-W-7;)&EWZT.%%ZREBC"EFQTI*SA',A_Q&6&Y8Y0D9&
M EJO'8X<;E%T?8#:JZC68V2A+@FS/,U=5";-A8Z/Y;(C/PRB^&3P5J/ F0AM
MY!( ]8R0@./S987JF+5=EX-B,+&KJ6U04QV]CRBNDL0[_JD4KHK\I#V#G")3
M9=<MMA@L1ZO+;J&3!T2?D=[85#-^D%5;GR( =.G6U?CVC,U:9N6WN0OIJ5:.
M.,P>'64?6QD0.R$/N?(!&'W58T0!\#)4*%SAFM/:X^G-WZ.SJN,%-#+-YWW%
M'JLCOD.F\H5[I/BX[U<E@8PK:+ K8_B[0S@U(@ W%F>;( *VW&NK[*^F6C9,
M@]05/-*W@%MS?3>6XK.F8\+J%"9_,H+@#LRQW%),B,[IN3!-^?&3V_U"W+SM
MOAXDD6%(Z2M8.%1$'*:7U>5:]/9 :, 7E45X4K"_<#9R,8+HJ@+79P8M+%J&
MG7^.";/M(O$P/;-X.LBRV*%_]MN/.)XQ8OE&8_1\ZE,SLO4\U"%$N\]U;_[(
M!?\/#2T5#U8A 1$.="QV"52M&.5*4JH'+HH[!M#L<PZ(]@K"+4#UGNJ!VC2%
MG\SN]1OAUP27,M]9S7WA]S"D$N.[U%1<)P,YUPY[N![=X(MH3WBH@(_\6E"F
M[K;>CE3-CW*?(+<&+^9$$,V\)*LTR!9P0]]54(H8EK]-]2*S\"+4P^Q9&231
M$>B?:7?GBI$"D\Z)\Q+> X OD7*85FJ30LL6N/G?[X[;?SD;Z^MUG(;H11]N
MU,EK]\HJQL@*7:=J>K#!RE=%PI;PJJ&$?E7]\O9OOK)NUD01^O0%'&^\+?\!
M1RP)")O6T8M;+EN<G'[PJ?,-7?< 5"Y@87\D\J[3B<@LWF6T^ [*@OBAS ^&
M(J@U,4TMDI#4KKQG"B$NFBE%"EU\!U=6$TF]H%OEAF16?K_#W+5O"$-))M7O
MR8R%<WHW53<BQ4J_?Z$O(]S."!GX%;O_:)D/4;02_77NY?M8\IZK8)%%D3YO
MCKR,D(G_M.=#0V?AO7T%:KI]K%60:',5< ]POT*IT6AJ9<@($?U'M3^E!6T)
M"QOFD[ZH-ISX&!DBQ@R?&!DA /GV@OR\JHR$2T3ZM1X,OD<9^-KJ[3&W5<[A
MTH2KGE*='_8] *Y4"[(<[-!": [Y4"^T[GR.&Y8UNH5$+H84)95.C+\<U&I8
M5JY<*M\EO'T,22A!(G^IW#X5MD$^YGP7GY K@:<&M_MS4@SV BCO\^WX32%)
MM;7(A,S=SIU*N!K6@^;D_6-6F<7 . KR<=,);J:\ Y9GQ!8T0M<,"'&&+BB<
M,E0 >=,=+\'1*O?>HK7$M:5C!J\1J]+]W,K8S-['H[02K&D1LGYA8>!GWOPH
MC'&A11HP/YG*B=/+YE$C9YQ!M 8-9VHT/U\XRJ L'>L^^8\ZY*9#F?CU.HT"
MI$$)"2HU1F3?V;OMNP"Z&2&95L6SNA\NZK65;9J_1SPW"S5"#Z4["*31WS)R
M$#1*F8!S^WDI&M 1[L380:TMI]3:GDXD2#>^^O< ']"V9(X67+H$WON?GS["
M#<,J[G1 *WICS9ZPS-5E+)C9FE,HE*W#[7W*LVOA;U<\Q9GS]<6=<3D*W,:!
M=G )>C2EMK9,VVS_"*,<&.O9$IA.@?7Z'K=@IB,LKU&Y;)CA>-O5<H @*UM:
MXQ0W&[96<5$DV5L:K%<$:P,#?2V\ *,FQ]1'@KP%YB3W@,[+*E+BHK4)#R6A
MQ4S96EQQPS D/45ID5BW8OQQ9F6'1:(NAGM V]M[@"]^9!3(/!7]PY5G:D^Q
MII9,L24WQ^ID>:/C):WYNH1G;O,4-?=NC0AQHU7V3G&6/*1%MQD:DOOELT:1
M5=8@'3OM]5OH=TXO2\X XK:S4CEHCZ]#:5 *<?V(8ZVN)\]&I@5UA/BG+XZ.
MZ_877][SIG!7CQ^6&,409ZMGF4=IY9Q;!9528\\ .HZ%)T>9C1G?A=$_FO/R
MI,:K!BU.0PAZ_-5OB*%J[4*$JUO!7.XJ4.&65:@+=S'/$WCN!6=KX_@?+-Z:
M/(((X:U>^(0]>K@NTV"U#A8I"4A/QQ&615R.G"N;\33+U)*%^, GB4=B"=_6
M$9EMTQ7/:-3J]BBQK!SVM/*IJFOK7%8M,BYYLG:SG?&%;'E+^7IR/KB#2+5D
M'*:*R4I%OO:]5HIYIK@!!X)AM76+7MG+\EW:=U=)/Y=EW=E;NG9K>NQ8OK$D
M;&732DE9U&B'Z5\5B;L=[T7&SQ6:WEXQ_*C?;M-W-([R.1+Q,-X]($2^Q/P>
M@--,<2-6!2DI+K:HCN-UJKGR2B+I=[<T>\_@T;3,@TRU HW,=M-)C2BV+GZ5
M73797R#55+Q*R]L(I(.C :&:?3/:"[%<QF+."N6QD[<=)#)?S&0BY0@<>L\R
M\P6I9NI!GG,)5BKE'2>Y;298&[X11.;LSCU ..PLEW9YQ'O F[%-B)$61W,8
M4YN 3N"QWB/O:U<J7)4;^1Q8X*I"UX%1#[^DC^M:*:9+Q-02NF:_',IT=44K
M2@^S73F%X1<^1@S[03>3AU U;DQ:L-"L-F -/XY>;VWA2<_ZBQ"S&SH)*W!L
MD;' !5:!:ZNA$#_T,DI@HDAY<XIQ:J,F]N@R8OMXAWKZ3L#ENEUM'&:D#,GU
MNWGA>ENX"8PNXG6>_I!M^/X3!T-H;<S@-!]\E8==&I"""LI[\^R.K"909GQ*
MI%)O5];[Y8E&L,ZBK>NEV-8WJ$[C$I]++;_Q?.N"(L_;9=UDOCL5FA1F['96
MM;>QSC9J"P!JZY?TM9>UI4R<&15$DI\O#!MLK.::KYIN*FGG)%I0+<I<;!3\
MQ*LC5CJ,4'SL&&^^X\C04&JOIQ9;33,]A&X=WZE+DAA+]MF=.C ]W$ ^I\7%
MA"K\384#5DLS3 >H],JM+V]!LO4.DPP,4B8UN>*?M:C%0Q@*&7ZNCL#4V\S(
M.U=U(+EQQ'I0?".R>GGXHSQAU2G1]!DWZU>#NTR^=T]6*+^4"5=( %QL(@^K
MPNVE&L(LXNO[7+Q:$3PMF.&I\QF99/=)5(PV\N:/"^V9,XG%=(Z"6:FA2$&-
MV$ LLYHX"V[3UJW^$.;GPGX>4*_8N5'1""EMD3D1[,87QJ7',VV.^3^:PZOT
M(T]PY>X!'HFK1V>8.#,[7AQ0R23WW)P$GMQG;VG'EUPSJP.M&OK"MQC9Q4B;
MQ[[R67X>:TH, :PVBCEY$*[HO'@-6>L'Y<G84"1G2Y%%)VBHL@LNE*L(8,L9
M1ST!V-6J/7D0V3!G+^RRP/>0B7C-L\1."O/!":?N6>/HFNZAK,]6K&\5EB\;
M0BYD&1"Z&Y^2#Y]?!&:%JDU:KS1/5+W <R8).WZV PDVDGCZ]8A.*KBC6AL^
MDV^MP@%XJ];M10R9/O]48XK44#&J^I(6=-KMWSEM7WO'*5$N^M:N^IWPF;OG
M;9A;[+?JL<I>LL*JQ"4S_Y[1D0#E0^2<'3>3DM#<^9E9\>KS,BIIL*XWYJ;G
M,%VL;X^O%FSH>%DN\'W-5.D1]ZH!B*?)=)I3T.D=G@$>W3,GT3V^UXKPY7#!
M/WJSH C)AD].T;7TFFRP2XI-,K5V"MU6=2=<!3;CR.Z@.IJ2G&6"^X PP^:
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MT"6=8W-</832!:0':^LXWLK0-WL")[?3F!^TG>,/O/)S'%][M<^%>?FH[1X
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M&T 3XG-@"60KZ+2%<)N'9"D89%.P0_*)R0[H#J2*>9YI$&MB,(&M^?X/1E*
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MJLL97^><[:7]9CDUI.=JWJL7%4?ZG=U^6-.! A5R5E)]-<!/D$!0=FAL)2[
M-[7Z-?]=MVA#\-S BY1/$6<5$@#[8<A)^W?UG7.;U63RHM,+"^:#N79J\HH7
MUJ;A3JM/K&6TC4^T>-T\B^\!G\\+S:T]$@C,&[<[7#]B1-1M=] _LG\8#XHS
MB9#_>CRG@I&58#R[9YQ3#+X1LPCOX4ST"?W0\G/PIG!.7>'P)R_<)O[W4J_+
M ^7'$RVHQ]*K@BW7+92!+[HJ'H'YKE*J9D9%B9R;'T.6LHT,3)Q7#QAWASHH
MC6H2^^@CY@%P&_G:] "''EGU&^S5&>NGM9&B8^ 4Y(R YZI#[*,]V.@XS^>C
M\E1D?=ICB;J9K$, _=\A):$Y>X2:53F1!L""Q3!MO5<?@@4[J%87T =_D"L8
MJ.F75U?5UJ60NJ0G;O@-TYCC9^NGBQD*0U$*.-T! N]/%1%UCOP==.34JR9+
M3MU1BU5'#)>N@.]=5XGID=>M=66VW1/[I^Y(8*!.7 L]J_&5F/ZW<6O&XV$<
M21K&"1HZ66'Y:%[.(FHT6]P32J+$OXG,?GH(DR==-W)&#9!OC,E81?K)HTX
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MQS*"N$#>3\6" D*+B]VI\!*H"1JH"Z^_WBX$6J.4 7@ -&8I\J[,*5Q0DZV
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MRC-EBT@S SB A?;V42X_GX? 4(N NC2IG7?D5?S>]2K7.M_4<9CR4)NDH/"
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M#-\<D3IC^U!XQ'+$&7=/#I[!&Z[\(5WM\[/G4@+A%RHWS# (1%^,.;WG$$I
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M/.\!WWUO/>LF_3:W*@)_>2*RC'</**R\";D'3!<ZHXI(.E/!PNX!X]-W$O>
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MD-(M!=A+&)M5XR/L?5*1_.L@D,(RR_,4K&2GHL4?S'O[L?U,'_'\A #]=%4
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MC)G7HZT[F^9PS-!*+NSNNXGKD-S-X>\O.\X#QFPQ&?-45HVO6-"TP6V-\(U
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MG*6Y)DNH/UT,[.'4^F[>^%1O-F%-=X*T%OY&O>QP_Z%4;=UPSA@I5!0%:+O
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M#[-A&P_WS.H.-M*D]G-J?>"%HQLQ2@^+7*64L%(:S]4*ADVTF_7[(O$RZ V
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MP@KRUMJ[H+U4'RUJ,'$J ,6VNJRWT=V?VE9@/W4^< R_TU(CW<L>UAOE]I#
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M$F;92#E^!5,:?7/'><['G5MAW%BS.$8'U#QX8:DL8P24<,6]-P[02$+DN3<
ME+DG@A&[--%<9;,+2U4[G\M(N#I^FK1JRVW?<#S@< ,@\#:7(-K1%X1))YC
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M\_G:N%*-!]4RE4L5G)#JC@*#/:P/N14-H.LI_EH!U0#2R;TDUS "[M[3)MT
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ME[_.D!O!B?^OK)2\?U#)]9)H>Z_"91=E!P(%ON=&3/XSG!0"'K%;Q8"6V\?
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M=-E8XZGB;9F'2+J;M*UXU-<T^5>^E7M1$YAX?"]@:1H3OEP_'+U,7IT5UGP
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M $RVNPV_E/L0.X3:O+X9-05/$\DW--B=]C)8TXH;["NQ"I""*W21RG+T%<&
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M!H[1;8[MZ_1"Z;:U('D\T9:.S%."'Q\>./<Z;L9MN)QJ-Q)R&RE*]/27BYC
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M$7UA)0G1:)XV/ES\U5D%5']=>H$*TX9RXZJ_.QR Z0#6P[25EXA)5"W''H]
MUBF<YCL^8/%G;\"W"#;/$\3J#7M&,7I4C-7E/,:TC)7FQX@BB5 65D1I]D\.
M^>7,K)S8=E[ACJ]BMJ:=A$LE>+C$9]1EVS"BX)1HY8=$+_$BL@LA9PD,T%<
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M\L!E:'IRM"H]H;MP%I=99I<1,'1GM%)XS%#I1_,W)L+2+.'-FW+UM[O[!O?
MU#@'W1&MFV$$WR^Q;]FN*VF;E"O=,Q"6<BL9_4(V6**/"D+A?ZX-XR$?=JBO
M42>NPW(:3[7_+-R_XP[O6EN1H#N\",]%=GPK@O-$LGW2+R__VZOP:3//I>G!
M')'Q-9K!MZNSY5%)U5[R;9KJ)-0*U9)C(9U&:&NT:!_2][1P[<&'MY1Y,HR/
MUZ1I+_\!/EZ6%(+W_@$6R79U/1.%IFO.M69@2/5S=J^5"3W [U$\*U[\H:AV
M'<J(BX'_)B]!?M45B-?*?TP:<@:<E6?PU-F@&1C[M"=+J,4"_I N@T=R/[,Y
MYB4&LTJ$D$C!<3RC7L<L+*>V-]L5] LO*QZM0)K,YE8%/PJ"6!U[']%YA^'W
M+_<Z.^/X_L]8IV$L]7^^A+_3:("L<#DWDIKV&A;N#<A-$ C%RU;>>3V24ZI0
MMA =H6,9T\"S&,%(/5#WZ40LK%?V9^^3G[1X=( &!<JL]7^ 9[MW+R<#5XL-
M XHG1S-6A^;ZKW]9>1<:OGD<'MOK^]S2TG3L42RE09]&M(:* 7LZGB8*^/L'
MEFS 69FXP'73N>MU5X+R=N78_[:Y"FWJC6?-L;SLMWX+\)UA"O/WR+OL+S1B
MO#$^0")1[!8>C&J=U*$_306:925<Q='!(J7ELW1?=68]D2,-M#P@/-LU+UF$
M%\-1N?;;W::8[$?JE(R(2@/O(*7V:0_\P%$S"[PT$7(HL%Y0<VCNGMOC_\ ;
M>[C ]7E22LQ;7*LE9-Y)B( K.OPS$#WU![Q(G3.2H$2OR!E*4.:IS=VLO=0:
M\:OZ*OCIRU(G7NB?1=&CH]]Q,S,KPC"[;>=(NI># GQK !RV[&^Y^*65'827
MF:I8V!>K*MM9NZ"B%<YT)S>:%Y:&B4V6N'&OH=+@^ND:(1!8'S7_9S 4WFH4
M(]&LRC=$S69Z=V2[R,JZW:<A VA3H,ST0@.E^@PGX3Y'PO9B7]U 4.)>*?.>
MAB'QX!]]W[*41[Q'B !V_SMO1F/J;)"!,4",?C TQ.C=[P-8^8]D[E9&M2^X
MU7-+I[>3,M0[Y2W%)9#\W33?T#^#4"L[@B5U@3]Q][KHFP.H6>P&/1,DLH.3
M6I7BC[1"V+=S(K[[C"L^:Q8U2:CY%ERQ7J_<*_OCL<+_!U;_GZGE.H+9O!.L
M4'>A%>*PO#.2Y8XCV8CW).J9F\PWS7_V>P .XX9.7P-YO"&]"S%48I8M*5XB
M5,,^CBVP6!]3GA>:G[,YFD+Q@GTBL[YN^&:?S?_?]$;;[/F>A<7[%2X8JV\N
MV3>JV5AGTJ+FO_*/Z#(_ZV@-T>G_\=?E>P)Q*(!"YRW6^MM5]X*6FXKD#;D2
M'E;6B2V$RGM!_I16Z^M#K:PAF?Z/W^N_U/WOP'5*.;E9!PFU(MDRNS0N+PLI
MU4^YS&\)M1(3)YG'JR%(1KJ)[2D/\51X_==2'STR'.NG!0#+I*''C'"<P*@J
MBR"JO.?Q9$/1S^O?^5\RDC?3E#&_Q:N6[2))#7N:]$0(W'7',GFC751<4+04
M4#Y<"'O!T:L*=Q5T?/.#D8'&_3?M<XU'J?_S%=$EEWWOI^&DE7.#0D?9DT)-
M?G[ZEJ[[?*'A,.I W#*\#<"#^04!L!;@HSY=2=2?858-$/YVXO$*KCL2.7.B
M_BI".3%MGJZN=Y?"_0Z[4ZG8]K\+)G1YF;IKB/M++N,UKMT3Y[Q]5<RG'+<1
M&6_S;3_S/_2485\,(8&!\2QJ**L*+J/5L;A[!&8N_[5XS^BR6O"F\8=:&\N,
MX/*RLF;#<8K^QPX:=;,.0D#0QUIDLWZ-X&_EHWP--W*QQQH?^)(J21CS:^YC
M7"='(VKE9&9^QH*]]S#V.?&.<$S6$46YGR.KY",U_?\V>K+J8'72\U?94X<F
MA/[ )HS9J]I0R4.87FQ!K?+TM_7B&%/"FY4^ -V?C_IB'5'NR\0GXJ R2Y$D
M@V$_AO\>'6;CN\]WKQ4KAQ$E$:8/ ET^SP0+E?XW8*TZ .67VU>P;U"PQ\40
M%BN(O)@4$XLHC*>?Q;.*9Z5W2Y*A%?*3QU+EH-G:H&(;AP0V7L"4WQ8\_07B
M1H&F E^6G/WH !/_2U3RJB P*8;)N\4R0V!5328%H\4#Q;]L>AO&CW6\M&]L
M']Q2@M4[HC4;3]?U$T50WDV?UQT*4CDAP2ZI;]]V$;YA>Z:6\?^SJ7+_I[Q*
MEF,8XI<3A'!KOE**_?%Z0/$)\QG%U4O<R!DI\IU&QD=8ZK _8&]_::J&[??'
M4"H+E7DM? E4L-*O=!FM9WR];H:\W23A_P#D4ES>.@'BND%$.UQT[P*[BI<E
MT?;$#8HGW/6C=LB74;VZ@V\^X#L@UUK5U8IN7"=XA)RH^H)P=UL^1-*//BK4
M&VC$RA\2=2E&%$4KB=&<5Z-[DFF!<'?,C>PX&R9K-9(#=JP^ :5<\9R"7T>+
M%A#,OAFDZT_N?;2$5%S:U'@<HA\XX)LZDE1G[V*GJ>YDGJ#'/6N^<2! <-YD
M'9K?T*B7-FBM?8+6;(V*3\M([LFIOROS*K*_<DPONM0Y5?UNGV!GX'&0! ;O
MY&\E%K0TZJV9LK^K2M7(\DZP_#U><GE=O'+9U;GP*+S$V)Y\[^+3XK+06>IA
M\B[ZY48BZM?*7'VSOH5IO8]I184C3DJRP>6X6^&-JM/3?P ;V_'/;DY.%+YA
M*)AOZLFOB%X_D#[+HH2R44HB?]+84)Z*!@WNR'&']2JY=!1\61-O+-L/:@S>
MFN+A(;-PHE^J[& CUWLO'U61-3;JV)T@<E/^H^$VS0,<A'^9L8(F>O /8-B.
MA",:FI(4'[V%K1<VQ0_9,IDF/HVAV51\C9?8\J!D>NOR;,T;>GS$-NU(MC*4
M*R"<[DZV)KCO6.6PHL.C.YPDN$Q\]G"6DQ!_./D\#I.T/W,N?CPS_F>QZAVD
M7W"Q\(2.=H*I 64-W!<0?T-:2PP>U*BTDI&1:%"\3?;PQ*P4650IY1J-9"@6
M.>57O$D47.S?(OO)[0<T4T8A@:<]9*1)VHIHKDFIM_XOI^[8C/6'K8ABEU%B
M:EM?88UI03:K;(T9[EBDP<(Z+: ^8 !;C]1^GVK-:O /<!Z,$4ZSL//P*3=:
M9.]<ED[E2?9ND$'V/.Q2ITYM?RC+[3#\NO3I>ONQ4%I9X(043=V48$K8/0OK
MW .5\G"HO;XX%)Z0(Q2P.&B739TNR&)R-LI3=D@<!N@T7H*J:GY$JS\VY(B5
MO&V;^H3,?M!3LB235N$,9>,#][8R"IVDPY:UCD0CJK6;<RX_MO/4@YH$V\0[
M%ZSBJJARB'JRD'GN+R8F9C6;4:2+9:&HL4'73W=ZKRG_6A"$,F;^ Q"T_@QR
M@+A/KVB1IDO-$Z5VPVR>^5P_'.@UY_<QD88Q!8HNZ@:MO\WI9B0)!V,\DSG:
MV*<B8./VC(YI]*],":LG%5"*U-RT%JY=]+*/!7&V#$P.4(E*18)U.^<&L>U9
MU:Q[,PE.3=$:K4V-$% WNQ8\H8\\N.?+JP6*C<1(S,6Y3OO$JA(<RY.5M[PC
MO)"T:FQ[*$&M\PG=BR;:=V+,A-"XL27P\3Q/),N:5Q@U8SJD#'(I4?-[''I8
M@IR +EP89TB"7SUL7"AN5'$83;Z#T1\TDA&M*+^.'@'CYF(?]Z:-'4G8X&"6
MT>U?G"S/J[S$WK5\3=,E7^R+1YE_57GR2(GVI_43K5?.)#R305;7A\+H$2/C
M0=F.6I 14$@\(F9BV5 ) A%"C84^.TK49Y3L$/[P0QC#57=IA/G/G2^!:-**
MP1=8I<B#[>#A,GF,<AVP8Q[J/\7J2D['%E?D6L/]A;9&'D,2XRAA!"GO"3(C
MSJS8I3XL,5DT6+XM?YBB]#RW[Y4\3[%H@41^0D]*?!IG62X)X:77M>3HVBJ9
M[<*?VIU[M$UU531UX1M:ZR0%$072L7WQD='#]VSO](RQ=#,"YOQDD+KH70'.
M(F9;6]4^Z39VP!N^Z*+BIOHH4PN9U>VK:W^M0%L;A^)3YY-[I__LO<3=]OD'
ML&K[T-6Y:C4!_?/D3+Q-"@351O5&V),Q*!)$#,69)KS52])B='#E':[MQ38\
M'6FX_88R@IBMZ_GGD"!6XGU<!'4_&?T4]'0!N3?@12W#VX*+B>F6%LC4M7$\
M;S\I +S5?YI\]OT'Z J*,*AN*%N1]2,:TGTYBUF686^WX]2G/'H!>K+\'>!\
M8J3ZB9LZG,U#BA+S.];J,C&@VKMZ4*&I04Y03&O& #[B )V++4<.VT=OO]4^
M9>.O&WFW_F'AS\)+W-\DE'<CC"]F_=4JE_7:(XO4O*\*O_2\&7TY[?APBHR-
M#\24VNA WVWO/W.[\. !F=;4>)!U#?EN($4SHJYI\@^1 ;B9E0CJ1Y&@9.7B
MM&G$K>)48L#F*!.E@6?CGJ ((LRXLH\"_+4QO$U!_!4ZIFE/<S/E1JB):-;6
M-OO]RO7.S^XY7$.D4ZO;93^)C'EXK:_!HHB?B@_"?EK3C50(CST39Y!6\\O\
M=B8>.B/8EZ%FH0V./Q-VDZ^K.5I?:O4<^ ? 'E)1JK %@!0 _I-NU[PK^['>
ML[Z\H>Y0*64AWGIO+_7$K;K:; C8-B^)^R?-:#KN^V[%5OV44NN'Y1W1TE:Q
MUGNO@']TQLW'[Q:)=L<R^T&0]/;>A$&)$#^NTJ'626<+ @%'MOKL#O6/,DSB
M\X%# B!NKXSOOD9'I0V[N28K_>>M18BH3G%(J8$%7J#UR7.F5/G@D)\J/Z:F
MVI_N-S(UQ(?YXSR,^T*<5Z)D1[E5Z<7N4/+L>^LC/WW2Z/K()[ %!?9,YN]O
M+][_=S!,=#?H6Y2=AKO7)=\Z\V=?4GA5N6W)Z(!N51O5XD8>03XX1"[S95";
M5M&H/-BFXE(78Z*#D>[6GCDZ@+_,CU?O:,C1JLO6:9_>RM[#AZ&WZ-BU ^K>
M2(M_3SPE#6Z?O==00]$-+I8S,FC]%2KZPX2_"'"E! UP,MH&+5O3>HC2<?DA
M3L(6K>77OZBD)+[/[5^V,+C][M%F/#$QXH1S(]D\KEC&D^\N$,!F9T8;]Q ,
MUK_[T</B\\*G"/^Y589:FPCUE>^]L:V/SXVPEE>_HWAZ5K)-=$1"G0*7*1QV
M!>_LY?@YOK,GLN!\]#)L8C1(E3=4;(%)UU<V"AB/5LOF[^D2N9G/U(LK;]-0
MZS0WHV+(OC!ZP-$LCTE.N?Q1.86EN20P%.2:][)$KW$"*)ASJ718!<^,?6?T
M-K+[W4_KJ:+FS^:*#=\XY@)'TC]7+;\G;5?0(ECTY[[DK/#F[*NI--2S%?.'
M")=Q+\#27+A6[#OW]D<B>;3S9?(IU_Q/7*4T@A.-5^^5M%H6.++"EMEW3G<(
M-Z!O:V\6+FZ<U24=&NN^.'2FA&[5)G[Y^A9(U$VH\M.!!>'Y#T 62+$G!;S\
M4KR?8-="7(6G<XY1<*E4EW#;F5!RMH)$RY)M92M8Z3Q0CC^R>!C!IELY+L,D
M#+X;:7\U5?G'B-4@NJM^)T-51YC19*&X2>1\;(_4\+U5;*ZV$9:5,S7-\#L5
M\W<%=,>\SM$IR&,""*?9#O ]O_,C9T Y&RTJ3P2D6MI55G]R?WI J<I-/110
MV=Q_9?Y?S[#*[;=M<,0Q@N;/8)N>L=YO#53*\G*TX$1!0_/GDA-6?B<K_]CR
M^E</0Y+AKKP8ZNX5?$QULHW5P^P<-#A"</GIC F)G%#W&\Y$(<19=[W/R[I7
M*K&_>$1A0DQ\O<=5MKDD#)?3F ^G?=GT8W^<B(7BLNR*]9?U^RB'DECR)>O"
MA#3+^W!CKHG/"IPP/NXF>#>JF.U02-'..2.+W4B:C76V&J(T^4/(4IB\*H=U
MG-(+G)';I3J6-L4H #8 <NXTP2LA4CBG0+XG0N!3C,SU.-0Y_:@"-$VWS'AR
M-W8"50)LOZ%D>DH?S/?SLO7>WX!G(W$9O.>41=7);A["&9V;\NYG 9I^33 V
M/U$D-+)JC-ZKT>JEK!V%(O7>?:QM+8//+; ?BES0?0UBPK'0"D/ZDE!'Z%'A
M%,G"C-OS4^%O5;6E":32BX^,%-\42M?=,%T&N*S5A.O<,<R8A4"309SS@>,,
M4Z05RH8L#@BD3' VJ9E&VV. ;I "P"?^YO7MQ_:'_6L%7O8MR6 )U?7OBX/I
MH&_?UT1@^]\6X^*6&,-_H12NN;WC#2?3F6LQ*ZG65XCI'<Q(CF>.620[O"&4
M@:UILD0[21B9YKCHP?S!L\6U9*_E/EOG/ L<D6*>F=5 1AO'3?3_F>> \XJ#
M)'Q18TI.+EP=*;BL2L_3 W(;C$94+8*=_ZS.A_>\L85:-])9?VLWNKRF\*KK
M=UCQ-2!YI;.J#E?.3P"+*5?0HA5=FM-# Q3N?3^OQO_![!'B5N"#^B/OCP>.
M#F?]ZQ/^?T?B\VD5TRB,54/F2$3\/WVHV%*"^2 3= /<33 #$!\7%Y>*G_G[
M:6GD>QS;YU<";(TNH ? EL%FXL,&YC0S=NUVCT$W$\5[MP=V7;^Y[)0FERIR
M*]??(Q^TV<R2.QQ7$+2<(_ ,_E*"FI#M<(->OW^U1#](B#K2"QPRF0M\@:G.
M*[%CI*.Z,CI*#I!LGV3<S0W9XZH([>;DAV6L*' ^7'BX]$O&_HHE"G!:0^W-
M^@D[VGG+U"4\)KMV[=>-B-9"UJ?2PJ^M-$:=G*Z+(T<VE9T'GA6(]N&HIU^F
MG4.P4J4E("/'4=UQTZ;6C(4 _4[#^F4U&XGQ7PF+E=ZG9LUF<)S(C\YOU )8
M[S4T6^-/%,#53>?X.7]>H617;*;.@V&Y/<U\W^91V"#AZ;NC9TKD@C-W!GW9
M@;,O/H9LVNP'-?#&.'D<LIRL;,C_ \BV^?VJ(9J9KSJM,%Q9QYT?^ %W8X&%
M@5T_R*5KD[47Y@=+V62>JWF.5WOJ7_KON^Y>0,[G*;]EGJ-.H8X@FGY>"M6=
M>@O71Z\[7@E-W$VLXMW(8K]< P5U)CH7%XQ^;MN3EPO!)WS\.&*-)[94C*I.
MF<.T?RSRAPD=N6L\'FGL:. I\F(L\,&[^I"%!K[[K2,BULUHUI2TLD>EEV_W
M@*L^\FF=8;#H:S<CZ<^!I/;&3)C5;GK>@R 2;S-_^4)].S&B[B3]A:#\"'6.
M)\%+:\WS-+1N/T4YYW9R2;+.>.?3M,.[&O3LQ#9'@:OA:: D-5V=5I3PIU>1
MA6 GZ6'MD#6EK8&B-Y0:H6;?1M,O%]>..M:"GO85J:_MH#1G/7WAGL)OCMO@
MDSQ%8#.*F>U1M5#@]E(2Y1#?2^[#\Q1NV6O-_ZZL:MVF2>CZU'A''7H0B/X#
M( 2O!VUKME%AM&-JIN>[3J]C);>3*#Q-T@[]9+2=,Q->M6V8S%M\1/'+K4^-
M0P6ED3V^_M(1YO!LDWIN?M5]H=2I=VH#3Z1 5'A9 [ZW O<VWNMH,,YM,;JY
M$%Z0:JQ07E ^040GOVU'(I&-<1#QS)R&!^.HA/!?$>%\O4-?4DG!=T->ISX7
M:;"%!_9O%L%!%I6J1RV"=7N-NB'B=H2RB:Q1WFA%C9)-9FY(*)/2N PCT?5[
M?Q(L;\_^H; :$;R0"O9)@>+B@D446,V04EG*.+'F4NL_3L-.@U8U)61Z'CCH
M"VLM43Y7*0#YN=3L^6:=P=O?*P50=D^T-:BPG>N^MPQE>YW;Z?FW'NIQQUMT
M;PGRRR*,KC&VKROGX0[RHG;9<">?%SF_U_AFE!(+=B/E!PFE8'\-]'E;(_[&
M*9-^)\VRP. :PS/E%-H1=Z/(VC#((+ABGC/)2&<!WQ21,OA<(TVC7AY4&OL9
M'F[_F\WOD +GQ"9<VK*#4F\GK<7P0HPGR\YU:$6MJK.E0#BY3*\5S<5EQ6UP
MLAQIQ:--[U:G/7(<(X5WN=^+,5(KG;NT&&IJ1V;!Q\L$,1'K<%L<7I>207+D
M1BN)P]SHP,!@TRWPW@3%'?7QD1;CP^7_ )WBYW^Y*]%-T_Z[\A=D/?E+<U+_
M $N683"M9!=S9Q-69D<I9G]&:6++AI8&C&<.FHEHU(T M+X/HH^L(OI5GR32
M N."^!BJH'CF\=227(=I%Z;/K"AP3D<CI9CV=4WP @F]?=6)%O>]KMQ;+ W"
M4LN.KWE8)[=4J-93V1<RVS5[]"R#Y6P>%>4<K-8L#A<6#4DQ3A&ZS''[QIR^
M=Y20?B["RPV#/3437[>=>\>/V5(:JNQ@OKHO8W^%!\\_8(4S><-B<!5#&%[3
MY"G#K^>@L86)R\-\S9\W)SD]DK23)-$"^$,R K^$#Q9F.JQHG23$V33LVFDS
M=9J^?+QV3WNJ[;25K(5L09SF]%L[)W1Q^WWC4[O4T,KXGQH/[I&N_P>($0K0
MG-D;AM-[(J=X:@ZVP<-5YA/VFLLU,+;ZE"^UG:VY$*^'8"#+5X)=$9,G'G92
M)(N71K.@J>J\Z<TIJUI4:D_L#<?MD=2H@(_#N_JWCR\<1(BUPTU,[U.1._(V
MVV-.R$C*?>*&UX$,I(1L"=E;&U[_M8Y*\FJL727EB:>/Z%]]D)-Y82Y9!^22
MGA<&23(R\8QV[5?UE?S(OX"0\6Z@^*.S>B6.]>)ZDNF#_RI2M7^[?[,EXC;]
M1H[^?9V!MXU*BN&@X$)J[-"P2T7XU%JKK#LA03S'VW1R("?;PY-9EL*FVS0/
M<2:"V\SW2,R-0=9*#CNR_.<"::G*;<'#;FNE$S9BJI=;ZBM]+#>+="*QWW0G
M_F@\'C!0.BA!@^DALH+&]$E[XG95FNO%MUO?H:5]GI&D<2-""]0CJBSR!8'O
M@KN)0F\SA 8C:J \0']1PD^"$+\@P@GXW8O>,JBG(V]:OP:[7FZJEF/:=I-+
MLV[-Q']7I<1^'XQ6\M05,1"H8PZ+8.EE2TMS@DG=YK4AX-1O;#I)>N^?E>DX
M_ 2V6D6L=M:?2],'DNS] Y *-3EQ ^'@F]UZ/?!PI1J;ZXX7$;-9D V2<_G-
M1NSX\R[&YY:S]?<Y@DOZX!^ [AYW)*[3@QC(%HZ[9WU3ISO2GNB)@%@E&S._
M_GIU79=0U>@T^/WI;R=I:_K!"LGW^^IJU)TKK.UM[5QE=E8Q,,]/NYH+?=#G
M(8+FB2/C33*DSIEA,^CVF'O]?W*:]^J.79MWCS^H(IW;@Y0JV'!463N8F>'*
M&T'#0H 7;QS='AVGD#+W/R[".!U<HW.(;XSKL#IYI?-[=L]#]'G7FL)63#LL
M3]0Z4AP8=;\*O^\[1\B>U,K\$O@C>1]=C=W2\XU:6)$H";/RG7%;7\NKZ26>
MEF"ON*W#PCH_KE^%!-1&]1*E<M_;!1IIW];>#3&R-XZOTX4VAMZ8^= 9SBM9
M50QS>R(Q3X"'!XZD7\GXLFD.%\OC'-D7-BH"E.ZI<4?//T!(QFHW"=&EDRIB
M&EA=,NG "6]NG<H:/V) QTIT(<!)&LG)JVW6D)R&T&Z["K"W-KR#R.YBX7OM
M;7:_ZBNJ> \;*-$F7SD'F9S@(RN"D]^/7^NE7MS#K&W:(&L&W]6>;" J0F]E
M]PKN^Y44[ELH3,*.^,$BKI\JV,QFFV\447XZ\"U2VJOQPCPC<.".12R@5#B0
M/.[0_59.72=&B;1>WPJ9Q$H/GNM,8EHV?-2ML?8A\.\2>*_\)>Y&&^YZ? 3J
M(YJ7P@Z631ZN@A)3K"I>V??]JJL37Z$B5>"P-TLF^$C$,XS6>3RS%"/CK/%7
MK<CFFN,RB>BYS,P*#:2F'D+E_&LBV$'G^"">-*++BLR_AF@B51F-XV@4!N+/
MJ;QG2QD(I_D*D^G"J?43?TGH>62U\6\]E2V1C 50 $,G$!TAPZAE.] A@5KC
MA15&E6#IS_5F$&W"4,XNY I#_;C"=IYD:KI[F/C#IK@E5B7R^27%IRC-QJ,9
M46JO?OYCY\"\_&")#_\ :["Z"G\Z;$>HT*.),R*085O2.2]"^00,X^ T$8JQ
M_.WN\TNG[W&RX4C1-<\>M8YO;.\W=R<BR%7H2*G5E.#ABKG!TCL=>M,[39A"
M0+/F@V!\0#;)A-8]5F'$O4T_(^*Y5A*;SHYQWZ??SUP]V) 0T<'^.L<6:LH1
MB@5\MY7K?1[<O"02M@3YTGB;Z6^Q_K*2:E]^[&S0[U!=3?^/]Y'$ODH,E\?V
MH"MV3M[S;:I6/_\H)ZY?_W?=^7LX-)@4.'CWV@C2E88^54_B>K)^<@@]+@BV
M7>39SAEH2#*20JL#-?70]'1+]3_RZI_@6QC>?I?X5&.+V:5&2E%-N=^R<(9_
M  TV6U[;BA6UK=A\<I 7SPO=>.&_1"U1R\FD-O[?D<'=Z,)M6 /19DM0F$?S
MPZY1)[\@+[?G5[)W4ZVH97N+&#X[BZ9()C*%(3T+?C-(Z6WV'9G]ZE.SV1?M
MR(E*AZ.[T7,_J)2>30(_/BZJ0<G*UI)-T)26<G7+W!(ZQ_CS_WUY^/^WA9)R
M2$T255<XZG@4JF/;"7NGB$OT(R8.%2(I6W9/"CG_ <*L,4:I65$[,]'K^Y?<
M6W7-TX+7X@)N97)LQH;1WE:?9S9<NK+V7/>3?S+O>@>MF83?2&)6-3&& D8J
MQ:L#I_W\?4X.V%_O4[T+0EZNQY3)FU*]$2%,Z*Z3BE4 .$LQ7DJ:Y5U&+793
MT_565$$2AR6[&V>W ;-$W&]^GE9^9 '4+?92L)1>=V_6<1CYK1M<?M')@.10
M0#:4FYJCCC9D3W.31E187PZ&>1O8SKK;>BJ]YI%E)AK.WHX"8.A7YSD5Q@]J
MPK_6$">[>058O RJTY-CK^2SUYEU]?'B6PC(6^+&8\Y0P3%M;8CM"M*Y39<0
MJ3%0(RXIWZ?[FJ9A)!<@]!-IX7NJ]OS.H6S38?EY0O= >7D.LXZ2IM;5+07.
M9HO2P?1Z%I-<RP2ZM>69H5U&=LHAQ,;,ZKIBW8$#"IL95T(1*)_7:?I %]N-
M6L3^ 7[L RUZJ-M9ZK$<;>NWYGM>6=7N_<!VH_,Q<'TI#/_14_"+33*:I"<;
MC,GW2;%0NE[]\X%'<<?D!.@AQ,71%$R/_PW'$=@%[)X9=0XW-:;2X!>( TOV
M1;73&%R6K \9$][-3@NV";T(F_]=9ZLZ*<<XOJ6R+;_S:UW&XU6XYH#B#//Y
M?:2DK_H3P*=?P.,NNJ_..J,M:Z<>1+_5U8:KJ":"1^H6R\LY_E+XL' LLH;T
M";6A<\)\3:+#(T,W+Q+OX9MLD5RAD0_92WP*-><!+4KF)$<3U_9-TP?UJ=ST
MU?G!HNIA.43N\:&!]'>]XUV"O.)+@P(]A!SZ]+CB+^+>)CS4UB"E !3$;&97
M_S^ONO__R_]5</_-_Q]02P,$%     @ <H!?3V.<4DP5R0  7P0( !4   !A
M;&YY+3(P,3DP.3,P7VQA8BYX;6S4O6MSW#B6+?I]?@5N3\2=J@BABP3!5]^9
M.2'+=H_NL2T?2]5].APW,O"4.)4B-213MN;77X!D/I7)!)@@E:<^N&R))-9>
M(!8W'GOO?_T?/Q_GX%F455;D__8G_\_>GX#(6<&S_/[?_O3[W4>8_.E__/L_
M_=.__E\0_N]WWSZ!]P5;/(J\!E>E(+7@X$=6/X"_<U'] 619/(*_%^4?V3.!
M\-^;FZZ*IY<RNW^H ?+\=/>WY5]"CL(T) $D**(0IU+ 1/HA3.)$\$2&*"+)
MQ?U?$H92Q@(,)4L#B FB,(T$AT*&,HDH%:D7-P^=9_D??]%_4%()H(S+J^:?
M__:GA[I^^LMOO_WX\>///VDY_W-1WO^&/"_X;7GUG[K+?[ZZ_D?07.VG:?I;
M\]O5I56V[T+U6/^W__WYTRU[$(\$9GE5DYSI!JKL+U7SPT\%(W7#^5%<X. 5
M^E]P>1G4/X(^@H'_YY\5_].__Q, +1UE,1??A 3Z_[]_NS[89/J;ON*W7-SK
MGOTJRJS@MS4IZT^$BKE"WSRM?GD2__:G*GM\FHOESQY*(?<_=EZ66T_5*%.-
MTH\TRG\^U-AO)\!WA+=^C=4!N,;<+ZXP]G'ZQ1G<.Z4/8GS &\V<#+E]H3[D
M?*IW=]74R=#'1^SJM2AJ,I_@M5@WLP%YKG_P2?VM:T8_J$=,FW8ZZ=Z *G[6
M(N>B5<NM1X.,_]N?U-]FBPK>$_(TN\Z?U7>O*%_>9Q6;%]6B%)>TJDO"ZEF0
M)&'"0_792@,!<912]3=/0ID($D9>P&,B9_7J]9Z)'/Y^NT32-&?<UI\L[*T/
MC-M25,6B9.LOWN-\WV=,?<'T-R_Y+2>/HGHBW0T*L'8.6AO^?045K+&"[TNT
M_]^__K:V\32.YU,R-S]/T@JV!6FNG8BBW*6C8#9T;(W/A@I)*MK8TCWE-^VZ
M_2;F=;7\"=0_@9[?^1K_;-+<;Z^Z_[)<FD-*=J17NBM^8X5RI)YJN-5!VO&T
MMKLNK-^<EG4%Y4^@*+DHE<.\QZS56UV5]>R;ZG;Q63Q24<XX8<Q+F(08!\K7
MQ2*%1"8<IA(A+@GE,HY,5&+GN>>F" TTLW&_RU#_&#_![I''LW)<ZZRJ,T;F
MX+,@^MUI)DG?WQ>/),L=#.@#MO<,7G7'QL!5_]H=M+N/G&2 'K!C.1@/_=IN
MX"V']%7Q^%CDMW7!_OA*RIM2=Y/@?R/SA5!.V^T#*<6,QU' I)? V(\1Q+X(
M(/74]%)$) ZC((X3B6P^W09MGMN ;2&#2F.^ $^D!,\:+O@ERP$OYG-25N!)
ME*#2X'^U^Z*;= $A,N7J;AA'&$,<)S%,DC2$C!*,J._1E*+9LRAI\4:=L-GV
MVW3#HN*C=H&9<^68UI%%N>/SMN53 5;: 5K(H,$,%&C0H';G<%E0Y-+Q,FEV
M4@?,@H==1\SFUF'?!;TNQQ=S<2.OM+S1HE2?[V=Q69;ZTZ._W-5ESK\H2P_\
M^D[]K5*.85;DU1VA<W&G)I+OE/U_S-2,+TA)+&',$@]BCU/EY 4(\LCW1.(Q
MGJ2)S?=D1*SG]AWZ)I0'KH9ELXZ\MK8H*SO!&[-[S83R3#IM=('=  \VT .2
M\ZU_W]0/2FKK!Y*#[9N^-\8!;1UHS',X]YV@$UQ*^)AP)Y7^"7C?_61,T>2P
M3\U[(;-<\'<B5W^IOZKQLUY>^*1^<UV+QVH6*1_7%VD"B:_>#<QC];<PC2$*
M9> '+*61Y#8?#:-6STW^.]"@0PTT[*WU,8T<-- MEQ7-.L%,VIU3.[)(.V'5
M6GNM6'*IHF8-3ZJ'5ESL*IO=S78:1>;YR^Q]QD29DZ_*K7Y4;]"B6<2JKG.V
M7+3$ 4GBU(>^3XF2)A_!-(HQI(@D41@'/*!&TF32V-DI4@L7[."]  JQF0(9
M4=PO/*Z)&UMO]G.F*0/?6[2&ZFWV>G;G49K#%)-QN-7JV[Q_?SY=K&U8:35:
MW]$HKY<&7J.[1L^81&YMK%FJK-4]IZXU7#Z3;*Y]RX]%>4OFXE:P19G5F:B^
M"6U;-L^:]VEGQHD"*2*:AI!'PH?8TR>D BH@1BCD*0N0Q,&P!85A@,Y-I&\7
MCX^D? &%5'/+QR>2O_Q+!3Z3\@]1-W/+]X+68&W:T*6$@;UGNUXP?I^,O176
MF:+[8V4,E$4)*V7.1D> ;8,F6@HXC=]QYOL#,;W1I/XT!@_/W$]\[C!UOLSK
MC&?SA5X.6#?XX2>;+[C@'Q4-6E,6[8?^1GX@99[E]]5R'?K=R_X'7/[,U*2>
M)J'4F_Q^$$00RR2 *9,42N%S0BBF*!0VPCTBUG/3]$VD@[5[S+XUD_4SZ;&1
M%?] 9X'O&J=#$9^ 39?Z/B;<2:5_ MYWOPI3-#GL@Z&F!<6C:+8D]01P>8R_
M/><S\SW*.0TE3#V>ZLT_Y:N3*(8XP9C@.*0L)7;G0'M:.S?1;L&"%5JPA&M[
M!K2/83/A=<;;R-)YD#*')\>L.'%[&+2OP8F/@QK8_OI J,E-PV3DDZ@J(?:<
M<J:ASZ6'FCF^4A!!?$A#1B"*A4^DCW#,F(V"'&KHW,2CQ>GB#/E!:LVDPP5A
M(ZO&(*ZL]>(8$2ZEXF!;DZK$,8MW!>+H]7;:P$6F'GE/YA^4\U*_-/,,24D<
MB9C#R/,IQ#R-8)I&/E0SR("KGWG(-PHLV?/L\U, !0^T^,Q&_#["^@?YB32,
M/J[7##B;/?68O![!U7((5X+]^;YX_DW=U8Y>]9?=0;OOB9.,TQY3ED.S[Y*!
M*T2,%0OUL/S^:S'/F)Y%+#\H*>8\]3&':>!AB&G*(4G5'P&EOHSBP$>IU:F-
MPTV=VUA=(P5+J(._UST$&ZZR.*%M[$6288S9+Y(<)</I&L?AUJ9=HCAJ]:L5
MAN-W#-.++Z*^(M7#U[)XSKC@[UY^KP2_SG5T6:6;NV1U]MRN1BQ?\UA&J4]1
M"DG@1Q!' 88DELKG#W@8I6G@$[OH47L(YZ8O&CZ0\^)'U1X&SI;0 5EA_XN=
MS SH%S/Y&9?MD65)@0<-V4OX@+Z 7[0%BO-?P<H(L+9B%-D:3J)+.1N 8E*9
M&\[2KOR=\*2!"Q[J8??-^LFMJ.MYLZ)R^:@E^/('*;M%W>:8^%=2UB\SST,Q
M1RR$"1,2X@ CF'C(@UX0)IP3'GJAW3J(7?OG)HAK^*!:X0>D,<!R><2R(PQ7
M3<:C=^Q)UYK9-?0+T((''?KV*]1&,30&.%QF&<:<T]472PC3+LH,X^?56LW
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MO2M1"M7$1Z)S -4OS0FE&?6#*,(BAJ&/ XACX4/JZWP+,2*1\!$.I6]W0/A
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M#7T?QDK@(S^(0N09%13L:>/<%/HJ5$,77A5@#=1B1>0 CP8K1*>S,[+L-<2
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MK%TPAR?%>JQW6Y_]=3,35V0_:.?K&NR'+QT^P'/5#R_ZK>0RY+''.0R34"?
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MSV4B&^>DN\UYXP[>Q.EQG//Z.I..^R:&[G9?<JX&3=4DTK@IFUIUBJ899DG
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M-^[HJ:HI'QF\:HRV56-!L='AYD/:64WF$;NCOX3S& U/6/%Y1-ZV"T2/V=
MWT!['<VRD?H$DODW73"T%/QCH:9^:N*7/9%YF_M] ](:[XRF$9-IY$%?)@SB
MV(LA\7$ 14PBE"0$B2 U=@).@G)N7_MF4L)6UH"R,Z?)>_2T- B0QJ)-T;C8
MD!6+[\!I_6CP19^L=T;^=#<=LS8$+"W1NYI@94M7*6/K\_UU^GZQ^!!/UC\3
M?7&=#"!7GU4GY/9^/T]K8;H/I1,FMKZ(;IXX^/P\$X)7>D-D64K[1EXUA;2;
MK?%9+) ,0B^"E/B!CL?&,"$A@9P1+_6E+U!@52/@:(OG]B&[D5(T1^&>.N07
M(!=U6V^\ZJFE,9!OLSUBIRR._,%98FTW<C<+MK=XVY,V3L_+FW'C^+3\D4:G
M/BMOQL&>D_*&-PX3G"_BQR5K$K5H&2N+7/V5M7'(7XMYQE[:/^_$S_J=GB'.
M(NQ%@4@]13CCRL,F,4Q2BF%*4L_W. F#-+;1'UL YR9'WP1K@OU7-H!M(^ST
MR+H[S.1I3)+'WE 1/PZ3>P%:X.![]W]M 6A,<'@8<"A[+O7,&L.D\C:4H5VU
M&_R<(3FR1274'0\ZG^2'G[7(=4V!CT+,O!C[-*0$>@E1"H>$#],P0C"(D8A0
M(CGWS3<2#K5R?C+6X@2JL4<@EDB!%%8)I0]Q:C"?=\'4R%JT(DEC!"N0X*,;
MDFQ2<#L@:Z)Y<\^;Y2R-]A$V^G-J'[IYP@3;1_!O9]L^=O$ +6R>PP6_Y+PI
M+D7F[W7ZOF=1OK0KNC=2J?%]21ZK]^)9S(LF6'.&O32.XR2%:M9)(::1=@.5
M5\AYJCQ!CR2,&_F")V X-QU=6@'(R@S EW9T>RMZJO74F0+XVA8+#1G8808R
M/'XWC"S2JQY86P!6)G3[F7J#<VD%>#]E#UAH_/@],=$7X)0QX>H3<1J9O1^0
M@8^>[O-RFNU;'Y\3'V5_C/M]]XK>E21O"Q]^$T]%6<]DQ *<Q@$,?>I#+'$(
MB9"Q^@,3'J,HQ,RHK$U?(^?V<5GB!&N@H$5J?F[[(*']WP97-(TL_@,8LCJH
M?8R"$PYI'WST9 >TCQFW>3C[Z+7#EB/;D+]U0?B/SU^R&0[5A!P'%*)$+SDB
M%$'"&8(I2UF2I#@43-HL.>YKY-R&^N>FQKK.^ A$&^I:K?#:+2GNI=1LV?!4
MHL;V]%IBUO@NP,>_P2_7[E;^^@APN;JWMYU)5_#Z+-U=I>N]=FB:?5()G26A
M27*Z7MZF,DC5AS[5:W$,XD1]Y:F'8IB&<:I3 WI18I4K[$ [YS;Z;Q>/CT3Y
MQLV>G,X/<IWK@#GE0NN@@E4JOP\_=0)9L96'I\WT9IMC?S_[9BKA@-.1A:++
MEZ\Q=OF8Q]DH.,*$V^SX^YN:.!E^K[VO<]_W7SY@X>HS9T6732A.0QXFG,!(
M(@)Q%"JIP#2%21*S"'M)Z!%_IB8JM#!:CEH_V>9%WGS^>.^S/JW]6?",9;D:
M_#J/-,EMTFIML,81CY/(PS#6*: Q2@E,(I; B,<L]@F6 3+/=3:,LTG<*85L
M&$$&2V;#S!Y9\S2H(3F]-M\-\[6J811,M/ZT=[BX6EAZ;7GO8M'&Y=,M +W&
MN+6HL^?7P[RXCR0K_T;F"W%95:*N+G.^+&VBO,3/2OT7I> W:J:H/$=]A$M=
M\*7(R^4_WY$JJSZI3KJNQ6,U0U2R!$D./9RJ:5^:IE"1&<*(A$GD!RA,DM#&
M]W.*[MP$3AL'&NLN0&M?DUUNPT*P-!$T:R*=5<U5FV:"QD[P75L*&E,MTUFY
M?0G,7- WZ]J11?Q->M7:[1V%?9?.LEN D[K8HW"[ZYB/T\BP;\A[0>OK)C]B
MDP]8/_KVJ11$M?\W4F9ZYJ +3?NS-"%1%%$?ID3[^SRA, VB%"*.(H](]2I@
MW^;S8-KPN2F_Q@VR%? +0)NA7C78M2H\=^A!:5P=WKHSS&1Z#(K'WE#0[%YO
ML-L*Z>V*W25P\*V/76M-M:7*I5P:MSVI$MHRLBMRUO</C.#HRBK<%9>LB1RY
M?";97#_]8U'>DKE8KYMJ1#,>!2+Q @HCSTLA9HD'TY1)R!BB:90$*.7"+-?,
M0 1&@VW2Y#-?U8,>]"IFF_YXM1'"]5@<N@UBVR]FBC8&UQ-%@73(]9IQAQTT
M8K>YG;*R!LJBA)6RQV%8R##JG :)6$*8-F1D&#^O D@&/F:"M"XSWT>IAV,U
MN0^4[&$OE)!&00J9B/W8"Z(@MCAI;=OZN?EQ@S(ZC)B88XRL*F>D?X,RIHQ)
M]X@Y3LYP37;0V_Y624F,5G:M'WJ^R43VKA(/?LC@X@7%H_A45-4R.6R6+]1C
MN]WO(J_>">64B/:Z._)35!]^UB51;60Y*5^:M8@OBAR=5K:8JY;NKW.EXZ*J
M9T$828D3'T94.=Z8J#]2(1",L21^Q$/E=GNS6A>R-_.X1\1J]95:(1YQ*UT9
M"6AC#<@:<T"M[;$N>3!:YYHY[F?292-_Y%KTX!=MYZ_KQ-VMJ6!MZ[)'N^L;
M<R_ MGE@:9_3*@MC=X+CB@RCP9VZ>L/8O.^I]#!ZD\,^-+_?_E6?7\^UTW/[
MI( H%/R#?O93F57MK&@]1^JVQ@.*/40]!GU?EXB3S(,I9C'D*$4^\Q(2^U;E
M'X: .+<)S.]_OOTSN%^9 :NE'4"L#!F\?#.HE\P^!6-S/[+&_WX+_KJ/] T+
M=A=VCI\+L9;R4TATJ=&#<$PJOJ<PM:NJ)SUKP K/K?;MR;S(Q:UH-/AKF3$Q
M\SD//5U)(?2U/QTG'DQH3"#2SG0HT]0/S;/N[6_CW,1NC1)T,$&#TV*%X "9
M!LLNIU,TLB:-QX[%*LGI+$VT%F+-EMUJ1S\/O6L:!VZ=;N6B'_O6^L212X<Y
MASK_N79:5[4;]V;@]Y)4<DP"&,8L@3AE(4Q%D$ ?>U'"$Y$$B55.)*-6STT1
M'92,L&/=S+MSSN7(TMG0V$W8-\,ZK,I(6+MO5BRY]-?,&I[40;/B8M<CL[MY
MF"@U2ZWO2"6X/LLL\JK]&'+"DE070/!X$"DOS(\@$5Q)$18^%UQY80FU4:']
MS9R;[#1)\"#5, ';P&FG. <H-9.8TXD:VQW3 #N.NOW@[2)_>F%%I[?M LK<
MZ4H_-2Z%Y$!+DRI'O[6[4G'DZF':L-&M57M,DZQ_T@1KDZ;N]'*)!%.,H\BG
M$$G?T_$_5,?_"!BF24C#).8LMEK(LFS_W-1D$_[R$#7<L !LFF G,;8]8Z8]
M(_(]LB@=K#G:\+[Y[YOZ092@?B#Y3J'2[^^+1_6]=;B,-9!.ET)F"V%2A1O(
MSZ[T#7W,,$ULWA_]B5N4I7K^UMGV+G04R3@,]<$CG?$QH@A2+")(91!RX6,:
M"J,@2-,&STWUV@&V =-.V8[R:R9E+ED;6;M:PM98MR)RW"^NFS+C4H:.MCFI
M[I@RL"LTQO<-3%N1Y3H;=REX5G\D3#_Z95T4YWT3&A%@#PD1$1C&NB0-\WV8
MTCA5_PQ3X<>QA[A5PGZ#-L]-7S3D)D%_ QK(#O7%9@4J;AV<8D*^F?(XIG1D
M\5FRV>(%'U=L;A1P>^\T&,6"'Z<Y+@R:G3;?A3D/KW)?6-PZT,M9IH5ITFPL
MCWW/TB2)!<$^% %7OHTO ET6,X0Q]Y@7<.2Q@%OY-GN;.3?%^2)JT*QH/)%,
M)\U99\\I5MESM(OYW'ZRU<^;J^6\^&'I^^QGW=#C.9G+L?V<%5E="ITE1H>^
M32\'3CV:_2U-Z\?T6OO*>^F_>IA.+/-'JWG71HK.C1F9/IQ5JL%Q5WP5I2S*
MQX]%V?A1U9UJL9URS_PT9D0O&<DTE! 3G7Z3!1Z,U<\$#4(48*/0#:>HSDV%
M5JG/]8K&AEG;BZ]+R_0V3V=;4U.LM>X":/OL1,E-%YMIV.0=-[+DN>NS$9:G
MG)+M4EO= )M4BIURN:O<;A]N)_156>O#$'73SE^%SL;\]) Q,K_\F54SRG$<
MA8C#I%GP3PF#Q*,<D@0E B6,,FYT5JNWE7,3XDU\9E+:3V*_-#JC9NRC!AO0
MP'<-SH%4&1G?(SWJ_@W94?_:E9S^!B:1$",;EY)@=O'@(*E2NX;O1?O_Z[PK
MGU3ILF39LP[SG7E1["5QX$.*PQ#B*(DA)93 D&(BO9#X:1C;91@P:=;H/9\T
MK< 2(RA7()O2D=:A2\<I-W.=G-$X63!1 Q/\L@3\JYXXKVA=@W8:(61,D>-0
MG^/M3AVS8\S$GN ;\WM/3/UWG3\MZNJ3=GJ";OM'>@D70I'L24$A1IA"BCB'
M+&&$*RF*D&>5O[VGK7-S/&ZS^SR32NW5!.+WO*"5*!NV00L=_-* !\&O W/L
M[6';3'L<<3BRY&SFOVN!7H".L1&VV0PX&24KW9[FWB;'W&&[#V:,Z[G%OMC+
MA[S.ZI=+SM4[5%VIO]Z4=\6/?!;+*/211)!Q3'2T7003'\>0!2Q" <$,8:/]
M^9XVSDTX6IB@PWD!-%+%(]!8S8N]'"*T7R,<T32R-@QBR*K8RQ$.3JCU<NC)
MDY5Z.6+:9J678Y<.'>8?L[DHKY3??U^4+S/N^VF$9 "3,/8@YE$ J9\D4) P
M"847\L W+N>TY_EG.KP;C& )TG9<;S-H.J8'\S+->#:D9,! WFOXR8-X^ZD3
M#^"])KT>O/LO<['-7'U<U(M2?,[R[''QN-RA>K\0LS2-<)1X>H,HUK5!"8(T
MIBD,.$IY$,5Q@D*;'"N&[5H-] GRI=SI-D[94C[,\) ]9B>\3;OIK*LZ-:!!
MAWJU"0T4[K$VHH\2-=[.].&FWW"K^B@?_7O7QV\_I5[<):V:S919RB7RD(Q@
MFE"D#[OX, DH@S0, LY2P4)DM+FQ__%GYT2T]<^^+_%9)NK?X<Y,3H8S,K;[
M8$S&P"IPNS:[K_^V:N$-*K_M6K>_YMNKJP8&*3&V>%PT 9)?1/U[7@HRS_Y;
M\.O\651ULT_2A5%V:UH>2>,X\ ,U,0BI_D- BB6!@G./R01Y";*+4K($<&XC
M?XVX#146U:] (Z[:'%\[Z5XLXY1L.\=,.,:D?&1IN;RYNKX &P: C2#M"Y.L
MR?K@7!,GX'[1<BBO3D.6;#%,&[,TD*%704M#GS-,)*^*QT=1ZGR;7XGRI9:)
MQT3*PD0OD7B2JVE5$$'*X@!*+XEDF 9>%!FMD_2V<FYRMP8)GC1*.T';3Z29
M:IU,S\C2M,%, W $@>FEP*6*[&]H4JGHM757#_HO'CCH6X7)GL4'*06K==&=
M6JF*X!](F:O95*6DYT;>D9_^#".=K9:&D*>*3(PC"BG52Z8!B4/?HS@,K*(6
M+=H^.X%800>BP0X(_\]%*\JM2U0_"/6SXJF)CBDDR,4/4(IGD2\$:#(6DY);
MRHI%5QF*S3@=,+8$K;EO8;>5R%K@8(G\ NB0#$6\0N]0F^P9<ZI8%LU/JV/V
MO+Q2MP&/&*9YZU+W:R=ZM2I!/8G]V--1V5RH/U ("8TC*%,O2A/$HH19);7I
M:^S<5&V-=2MWY\#EGEZ:S03*%7DC*])@WJSUQX00EX+3V]ZD"F-B^:ZD&-TS
M("OIEZ*LB_PSJ2K"'A8ZZ=QR:4)@E@8()9"*%$,<^ *2(/*A)R@)O=0+(]\H
M^+&_F7/3C1;H!=B":I%Z\S"?_3+ACJ61!:+%N,W/D%K9AXFR2%/JA+"),I7N
M?;-<564Y2D1OJM+#=T^7K?2H!5L)2X]??4*ZF]7VV^4JROF*5 \?Y\6/53""
M<JZ8SO$E(1-1"'%(&4P)0]#S9!K'0H0AP=9Y;TQ:/C?%;( /2'ICQ+*9;S4*
M=R/K:)L&9[U?OT9] 31NH(&#%7+'"7%LR'*>&<>H\>E3Y-APLC=7CM4#ANF3
M#G"\D1NQD$U(78(XE]S',$4RA3B-0YB$A$+.:<23E*8AM0H2V-O*N>E.$R9<
MR%?9[]QE'=Q/MIDDG4SAZ(O?IV<0=!3U:$292Q':W]"D@M-KZZZX]%\\>(?L
MJ10/(J]45[:%@Y9K4C.68DRY1Z! 2,N)(# 52, T14$2>>H/Z=L</^QIRTI4
M)CARN 45S(O*4C+Z:#7>-7-!UOA[9QL\;95*VURMO@"7=5UF=-&N*.F$#\U>
MOM,=MF-T.=YG.]C<U+MMQ^S>L^=V]):!2=67WLVG+!=-M;&9]%..D=#%; B&
M&,4"DM#WH!?R),)1+'QJE;GO=1/GYH^L$(+O&B-H0%JN,^\ATDPU3J-G9+&P
M9,8^4?I!XYTF27_=RK0)T@]:^2HY^N$KAP8<?1/WF5YLSNLOJJ-G<>A)03B#
MB:"1&MW,@T1$$0Q3Z24,>41ZS"[B:+N!<QO;77S-&B30*&UCCG9([!_9+J@9
M>5Q;LC(@[&B_Z2?''>T\=N+ H_U&O8X\.G#=B3D&WKU<5I6HK^:DJIKYK(B\
M6":,0T2B0(UEB6&24EV8,R7,XYB'J=%8/MK2N0WJ!AUHX W,(/"*2[./M1.&
M1A[;&^0XG^@?M7^43 &O&GN;/ &';#Z8)>#@#0,G_MV*9%>VICV J]<L<_XQ
MRTG.MM8OWV<54[/@12E6QQT\&OEI&""(*$XACCS][<<<2L3"B(=8>?96\02G
M CHW6;E=/#VUI:K('/ 5W.;@7%<J*%O:N)%']R^6"PVG=J/A:L2$G3/VDL5R
M4V5=LNEZW0\Y!RN#-O9BP-JD40[!N.+7Z1K'J9BF70AQQ."KU1)7SQUR*&>A
MM[)O9!/^^>%GK9=LBORF.8!;S;Q >694*6X2-D41$J'^QB+HJWF7CV*/Q+%Y
MQ>#>ILY-6ENP6DGG33(UL<0+VL/)5@=U>CGN5T>WS(VL>QUI-[(-"0<KJ.#&
M,6DV!W=<D3?5X9UC;YZS@SPFQ/0?YNE]PH0'>DPLV3[48W3'T"7J@OUQ754+
MP=\O2EWA6)19P1L/^\/CT[QX$>*=R(7,ZJ^JYV<R\%# > 0C2=2L6"8AI&&D
M=\,\R:* 422M2C]8MG]NRJN1JV]>6XFF>'S4!8JU16"1JSX M$4.GM1-EI-I
MVXXQ70\?C>[1%\LUK2UTT&('+?B+93:_I0&@LP!H$UPNIP_BSNU:NQV$B1?B
M!_'S>I5^V&-.3AO0'.C8LQFH=V]7F]61CQ(2^@'TTR;5N3Y<)&6H,Y]CBA$)
M:3@T:X!)^^>F?YL![$5S((:=>%+ MD/,=&]$FL=><-Q@N#UR9'C&8)1T #;D
MC90-P C"6R4#L.&G)Q> U6/L]RXOU<R Z]G!QSFYG_F1\#T_09"$,8$8AQXD
MB<\A9X$?BD3RD :FFY9;3SX[L5J" QJ=^2[E-EW'MR<'DS"VE)C9;[4?N=?6
M$S8BMY\WV0[D7C,VMQ[W7^"NPN<GH2<,794D+XA"'D@&]0%F70A+9QN+0ZC3
M$@DO1"&+PU/+>VXV>&X#]=.A:I0MZ--+>FZQ;>9!N.1PY'%^A+X1:DB9DC-V
M)<^M-M^\C.<^!DQJ>.Z]S_XKK_,J7Y:"7!5<S%C((NJI*0N-/*S7;7Q(&%,S
M&)%Z6,U=XL0W_LAO/OC<I*/)V*W! 8W._!N_1=;Q3_Q0"L;>RS.SWNH+O\_4
M$S[P6X^;[/N^SXC-S_O>WP_8H6I69[G@W5+MLA;OYR*O==VV?PA2SCSF\RCT
M&(P)BR!.HD3O4Q'H\900'*,H\&+C?2J#!L]MB'Y:[Q3H^KD;];H?->IFS_E%
MX;;8?S&AW6#KRC&9(P_V)=K5_M6*QP8P4(C!/]SS:+&;Y9C/B?:T5KPNM[0.
MO)^NMK8L6.K=X#)YSG3;7!96;6UVV=SG;OJU.O[#/!S**(QABKQF?PM#DOH$
MQI(F0H2!].C)4Z]S/:%U8-XP.#M0+]'#9UUG>(;J!.:<S+7&//;4V]Z;S[&.
M'5<RNF=H],>5T 5WY]=*KW[^3_$RHXP20GD$$R(\75.*ZR/C3/T14IIRAK%O
ME%CL8 OGIAA=I$.'$C0P@<)I&P&R2^3Q"=C)](SMG-DR,R *Y(#U)X>![#YW
MXCB0 V:]#@0Y=.$PMV!90.)&KG:@]<F.JZ*JJUE O83[$D,4$S5GXWX 4\(]
MF,2<!&F2Z,0V-FY!7V/G-LA_UZM1/W1JM?R^.;C=EF;5;K ^\I)5^C12^^]V
M"[B04C3G,Y3K+/+*-EE\;T>8N0VNZ!U9)%9%9Y3KL#[?TIPG:J"Z<QI,"''I
M-/2V-ZG38&+YKM-@=,]HYTV6%6Y)FK(XQ=#'20BQ%R601&I.$F"$4!BF*.16
MB;2,6SXW_3EV J(]^M =A'!^V&1H00IW'(\L0KH2Q8%T%..6EC!C:.)3)&]<
M3,*,DP$G1YQD ?PFU,0I8_5F?8I*!X(L2OVZS*(XC-.(IS"14LU_J."08C^$
MC$G"0B33U#=:V39L[]R$:@VWBV1K\-HITC&*S73((7$CJ\\&9QM0VU"T%JP[
M[3%DQ:7B'&MR4ITQM']774QO&Z8I[\A<^U:W#T+4GW07JLE$=S"#2DQ)&@4P
MI F&.)4Q3*(P4C0SX04I#6)J59?F<%/GIB0=4M! !4NL=DK20ZR9B+BA:V3]
MV,_4"$=<CK/A4C=Z6IM4,HY;O:L6!G<,$XJ_B^S^08G0Y;,HR;U8!D7=/BA7
M]691-P57LOS^':DR=IGS]]E\H:Z>(>IY"<4$ALB/(0Y0U/HD0>"'. J0CLVW
M$9%A,,Y-8)960-*:L0I>TF948%&I[[&:!NC#_ H^H-J:9H6'M_: 7(TV?;@?
M/+5G_E<W@U^RY6-^M1.L@1UL)F;C=]O(0K<T '06@'7HY6W;:1MF7(!WJQ[K
M3'&GA*=1Z5(E!R*95$%/8VM774]\VO"J@47>+(6UK]KEHGXH2EVG<!:*5*91
MPB!EF$.,*()IJ,-#L9\$,?=E%%CE,^QIZ]PT]&HCWO-BJ9QD!7>X$/;Q;:9V
MCE@<6=(Z F]; CL56R-U6V[P"!VNBPX>:F[RTH-'[-Y7@/#8+78J4I7U[&M9
M\ 6K*R5)MZ)\SIBHNJD(2S"+$I[ 5#"A0QT$3&-=73VF)")A@A)FM&34V\JY
M*4<'M/D\=TC-%**?RWYM<,;0V)MBK\EQ.)TS8J%'#-3]&T*@_K4K OT-3#+\
MC6Q<#GRSBP<<A;Y[R$I^6Y=Z'JC/\G4;*0C%//9$!$E ?(BE%\*4^1Q2KOZ=
MBL!/L%%-AIXVSFVX-RA!"[,]K&MQ)/< C?UCW1$Y(X_TU[P,*9AU@""+8\JG
M$S71R>26L*HEK#F=[.H,<C\%O<>.#]PZW4GC?NQ;AXN/7.JN9$11BSOQLWZG
M0/XQ\PE"5(@0!I$NLBZEA$3&$8R12(B/E> %ON4<J;?!<]._F[O_^/ -7-U\
M_OKMPW]\^')[_;</X-/-[2VX_/(>7%Y=_?[Y]T^7=Q_>@T,7GEYK8JL_C.=0
MSE@>?R)U*",$T)C!=XT:-+#=5G$W8FCL0A-;;;YYM8E]#)B4G-A[WXE)K=?I
M%]=E>=,D]7VDW"[NA3K\S,.0^#)21),P#%*92+M-^K[&SDV)--8V6]1& M/A
MY8][>393&5?LC:PPPXD;G@6[AY%1$F'O:^]M<F'W6'XP'7;?/<-41._VYZJO
M7M:/7G]#>< Y3T,.0QDG$&.E(C3!2D_"0 1(1(@G5C74^QH[-Q6Y_O*W#U_N
M;K[]PTXM>ODT4PM7+(VL%BN86VFB1_%!3!AQJ1:][4VJ%B:6[ZJ%T3U#SP8R
MG8D_DUF[Y_]1 38XEWC5'B)J<_RM*^UQSB*<1E!X(5,SICB$5$H*!::8B,CS
ME!,SR\6]?K*9OKB$9S32TG:D;8(<;\!=/O[_W+UK<^,XEB;\5Q@Q&[-5$48O
M 8(DL/W)Z716.R8K[;5=/=%O?5#@FM:T++DI*:L\OWX!DKI+%$"!--^-F<[*
MM$G@G ?$@P/@7*J8C&*MI9*1_62.)N4;M_"4#CJ\;F37^Y#UY?&XJU8U3FYI
M_JZB6KMUZM,N\OUU 7Q8I\J \O7L@1D>V4-WS0[Z:+<F_)T58QM1\&@ZKN^H
M-%:)L181R"#A ",D $LH AP20^LP,[O/S,=N/.QB:-;B2L+(BNA'ND?P<Z/.
MRU#IF !W .G 4_.T\B%)Z$@OO5+):2WW":'AR;:![T\O:C*Q),*F[R.,XB03
M4@$L= *PY QP*0B *>?:QH,8^\TOZGV[^:%-YSJPNQ0QJF7T#7??@:]Y1E\.
M2L>SV0N/%D'NQ]2^.,)]I]&>P]N/*708VW[TJ7:K\+?9]+=Y?2LJ<DD3!CF
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M7 ]M D/;^:%- %1;G-EXH!3VS,:EXY[/;#RP.#RS\7G9CZ.D&AO#ZX<J'*?
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MG.89<PMB/]G#T)AJ)62=!"^ZM2[[1DYWJ_TXD.>M]XOAZ9A-O)'QLN<;M;_
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M_3=UV'.R?P?=#]/]N[S400C&5M2'#??X8KZV49)R&B>:&P*1N>'V+ -4)@I
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MH,?&Q_4.>T:\UT?/!\+'-3P\_3WQ7$M;LTP ,\KS.,DAS !&RLQ:+F- &<4
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MOW6<>N6A;%:R5;BZ6<=^56QN;V?OIX_VFK8PU&C8<CS?FU)QG!%*S;HC<9P
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M^:?;V4)UNZ]OA7JQ#J4_5,6P-ES\FUK<:[/W-8819!E*"1!Q3LU>%&) -8)
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MX#S) +<NKVDN,ZTY(A(S'POS1#]#H]>;+=^PJ]H)+!I7[DNMW<).8>QF)P9
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M".K4>Q2)H,4H=SKHMP[E,=T.2E >?>BR4ACESM1F8!JEDJ$,90)P(3* ,YX
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MM!'5)XSD))X.UQU!4.J848X"=/Z"U <IGSB;$(CU%5Z31I,:N=E:VF#1-.>
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M;TO\PNKW^AHQL*AO2XQ.E7[;#M3>1RI6I;3P'_;PBIF/GU!EN7XQ40A3)H4
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M=X_D)C/>O&6R(TXN'91=AVK1?)']V&LJJ"72"B<,$)82@+6, 8\I GFF4Y5
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M#^:GGW_:_!_S#V>%^OFG/P%02P,$%     @ <H!?3^YY'P8 A0  $=P% !4
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M)UFB,2$$"(B5-8*#Y\F 8YH9%:3,MC\C9 L!G2#B6X?(H9QM%!Z"V&)+,4R
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M_>V*-0+)#*OC&:Q"XH^FLS46D4'FD+5"Y:3>DL=S.$JZ$CBNJ3SX'>P@<FI
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MJN.RR,:$$&V&S'Q +FQ!'.1ZI MQXX:5!H)7[U)I &E;#O.8/!>YWAZJ37]
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MBT91=7.DCS/,&Z3]8:-%VB3$+V)2 BEE(3.#.9<'L<Z^0]?8QOX(^-I7*@V
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M;MR[?PSU)X(6\)32V>>S3>+V0R&4BX5%M$I8QX K0PMCR=<A]QIRRHZ;Z,-
M)G5G"L<-'0^ LT%$TP#F3G!-O,%\F2YTL0K%H@IH(B1>=*U*L;5O+^V<2(9
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MQZ!L860"DT6LDF%D#\=4^$ 7GCM2.JZO^>2G\6!";!>EY^?"]A4F[ZQ(/H'
M$.NZ$KC$D*QI;36YY8J5IX3I(Z2.FXO3 $[[$F.[0#W?B1?%>YAK! KGJ_/D
MT^6F.L'&HH6CQ3%.N] 2KF(1$K0(*D;#?++#^3"[TSMN)7<#D.U5H.WB]F)G
M/K).QJS*TDN(M<&H4G5_UHZ1-I+!4VH/A3A(8\Y]"1ZWM+P!Y/8KTG:AN]FA
MKSY_F2V^(=Y(1YX(@:B$,<"DK[T],$*TPD#AP?$DC4;QE(A]B,YQ2]@; &HO
M FP7G^?[<-OZE.4A8'&0M">3AYL D1$O76:6Z8@NJ$$J]'8E=-P:]P80VH\(
MVX7H9@>^P]\WOUE-I).AU!I!IX2K'3(+>)T\!&V5"O0>&RK[MP-U(Y>_-X#&
M Z35+@3/M]CUJD303*!QD+'VIY.A-N;2" 9S$"G:PO5 U])=R.L&PN=S =2O
MO!I X8U2M-/% QEIFR7&NZ;S"1)[5],U7HP9.F?'":;%Q_GF6S;;<V(E[;U0
M1WHR20>#RJ$VL5907$B,N8 ^#S)[=>B%=4/^L[B7:@HC#>R9QVI$KZKNL$3#
MK?# A:S3FCGI <DSE* EFLBY'Z;NHPMQW;#[+"ZR>I=5 _B[W>:%H<F!$;7"
M5>(E0<)Y+\!%FY#VDDENF#["N_?5>1973_MSOP'H;,EB26A0QL3!,$\&2Z@C
MF+14(%T.' LMSS>53/1\[H7VE\.!"1ZOYKVU '@X8<5):QA+"5SP!E3D 5QA
M&;A+.<5D0I*#-)<Y.)>(/XMKG-YDTRO6GK@MP(NC#__^^NWQWS[<7DQ/W0"N
MO_U)F@ \L)C^:_]?A-6GU[/%[]?#^;+5TJ"ILQ=M!I5IUWG#':'1<N&-B*4,
M6P:_A:@>K*CZG>^7BZ]38M\OWWXCY^7-_&H^W%%:3[^>=Q6[8@.+OA17F^FE
M:B>6ZMNC (M&%4MV@!XF[W9W4AM)\#X42UMLKR%EUH"!1DLKT_7&M"1U;WS4
MQ"C% BA75.T(%,$6-*2?C;=^D$UW3<+( ]<&%O:B%\XW@)E;\9D:7)FGZ0QO
M^2FGB]U96:(U0@&+&$%Y*R%D1WO5:^%#;?:A!RH![G\Q(P]Y>UH<CXZ&!G;$
M2Z0GI^FYB#\OENOI?X6++HA'*=6F;8MYG;#(N$;GB@6)TH+2,D&,!0%9YC(+
MQ8T<)#.B(WWCZM_Q@;087JIC#S:\LX[+>3Q7Z[D:AG;%U+?5<UQ-K M1TY=!
M3LK6<>@6@DI(9U21HF1,\JY)_L"HPWTI&%>I-@/.IY-B WIU>Q+=)!;)I2>3
M7LA"QY7F"&0S"8@<:Y_EF/5 [N%6<L:MTFD&F#W*;&PE^6XQKQRK78N/YP],
MA23[7%H&UI1"#&*T$(\2I(U,Q<#2O0RR![3A=Q\U;HU-,^@:0"Y-=+7MTN/W
M<G0D.IM1^0+,D(&N%%KPTM ^"IPIG[0289")%CO0.&ZE33-H'5JZ8RO(KO.:
MK<U))@T>;65=?16+ X$\:FLUIM)-2_8X'GNPRY9FP#>4A [5EZ?])L1L8=ME
M\/<J'CQ)&)QWB=$!4+O$QL@AHB;SEQNFA$J.IT%49F<*QZV6:0:SPTJV 4_F
M_E7LU2HO,MJN^(<Y196X Y44V3"T&G N>@A,:,M"RO3;(3#;G<1Q*V>: ^U
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M-22QHH_-SFH?I)L#6"8A)$%&C 3OHJTI*O2*[/(ZP386H7.);)!&NX.NJLE
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M.3C'RX]A?M'*^06=F(O9-%_V=7Y_@_+C<H&Z,+O2E#?"D\EGM I!6NU!)9'
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MSV$ZGQ@LJ62O0-H:CW-*0L0DP";K,7$9K>^B>W<!RWTJQD%,/X*]CY(#N=Q
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M+J=A^1'7U>$_-WDGBDM6E)10-FDVQB,XPP4H825FI5B0W=)T'WI"MT T>][
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M2IYP?O6/-&]Q'YNV/WDU +I=!Y\FHPSS+()A=>Z+,1&"S *8,X@2E<<\2(K
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MS]]=5TSOHW=6$Z%+=3O+GEA@E!BJG(:<N*GSYG\G*AO))/4(DVVNAWK164N
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MJ3O"36$A9>CZE1XP\+*9VUG>#9RM?_?3<;D8?6! >"55YBB%Z-#V:PR4O19
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M V7;@>MM74[TJXZF*T2?]!R]\SO_+/> ]Q?R]S5"!Y>%[K-8?P4(![-:NVY
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MEXZ(U&>MC8ZH[S=E-Q>E8;/^K.?M]^K9T'4$MV%)@P]4FAB)8I82*3,G^ M
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MF:'*U)]-!!UJH5:_^W#!D"R+PH= <O"L=#>0N&&T),9X7AZHHT]3Y:S=2-'
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M@ 2/4IKWP!4Z:B>B): B C<"1\P&3R+76M"8)>/5AO9M364?/>E?7>Q1EC=
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M',9=TVFAC8$Q,*3TY13&0(%8&"B?(*:@.UC"N"'S5,0IL05^K/K/N>&E$IQ
M)JR$.HLE>RY<"A.T.8^]@:@W!],T@VG.H!LCD\7Z,GP3Z.U^+>CE)!$*\(%0
M6^&A#M %<7AMUMX+E4 .HT@0X7LL"P8Z 7-KSJ\#7@7FO1P@@VC'*)!R!><2
M2?;!T! QS#//.DH4$@0 PQJ YH>SWIZ8VI0D4L]M!7##I\(ZH*V.4&P,=H.5
M]36<VLJ8+6N_":CV#@RJXPV_OCIZW8G.AK8$8TF',#'I)!'PZ#T^(M1PCRW
MBIA(CA@@'  ]D<*F*(YB&21E3,SXS(2-I;8%],-T;;0,(,N-CCF#9DN. 5.,
M T@#<&[NXY2J*2>7D EO"\GMJZ/HM#V,NK01]8_YB>\?]5EX"H\"&;4*",=!
M".;,-> '(*)!SQLMV1@M@=%PQ@]C B20G3R#./;Z#W$>=4X/ ^CT((#>/6MV
M>GX%K[F%31=XVQ?CI_%81YX0T\+NWP4+]H0#K,J1 @70A0$%D!QGPOJ4"U)<
M>3VXS5@EZ_6$;[BD'J<E!UC!K%X6 WPI('&#+59+P?R^WQ83*YB@1N $1& J
MO@0IU%189 \^MJVG&CY!:\O!(-CQ^TXY<&D1%Y)B78%I>2-6+ 1Z!$ZS3L7@
MVX2C(*1^Z,_9,U+] 8? Y#!"X+3*]9LAL'>NW(J$_;/LW@$!0303#'%.K584
M:PJU$"/(I1'\U+ *B! :@DZ$%&Z!Q&37L!B6'K,>CB&B-D37N+@O7??EA/+"
MY! .UA.I.-:&>0,\*Y]R!?Q(0E3 &YYCN*$([#@"\B$L1>X+Q[> _?@PL+],
M_S<S*@N?(Q$8/$F %HL9N-3NH+=+&K1'S@^/NQFOASITA'QM Z^>Z,(];L$^
M58DNI3EN&I*GMXAD4FU'?/3RL!)@CT<J#O#5HY4=!EI7F3H 81M0>,91,E7_
M9B=JGY&?D8#H."X,PF:MVN_0FFGKH!U/K4&7C4'1G^'@C1P_TB4!_$/F?"!=
M&@[[2^Z/9_#D1A5+NTZ"52FU2VJ$.=?'"V>^&/GU* O%@DAQQV5Y5O- OOZW
ME^B9,7*X&]?^083(W]VX^M-C5D57?94:,5.O(WR5)1&CS^!*6X1]:1H%TNZT
ML4MZXAM 998)YSC_0AV::"! ^)X)L,\K.88X@+1OL:S _[AUJ(*7_UD(,-\'
M:J%B?Z1S\N^N].6@>$5++B6042#' D"*9PAX)!$+#J@JJ<5R=SCG] ZY0B"G
MGBUX6NV/LZN3NV=AM=S(A;.<'=F4,NAH^3*9/HKKDHQ#%P G<.9Z("P6V(HM
M,D -+).?3%G$=IYQ?CMDY-"VC9? .1(#R:H.B.$^OP+F_ \7)3CKH60+-=-R
MQK%N*SHM?W\Q94KF62[U@L/;>:I#'J8;T >H_B.DIKG/[]-K4)EHYW16H<7Y
MO>=F![\>M'"ZZN+O)(26">"=&W29I+GE@^K+<.V'?NP_7$<O>@.*4"[I8B"4
M]X,?M[PR\>9-LQ?U.^V^OSCA#/RQRJ3R4D4S7*IH.;;]LO>Z&>#QN,@7^_^C
MREO>_# %6!N;4_6VUJU5/2K(H4\Z^?T2@J53L&G/P'BXWC.D $ [R[:@\$'&
M6$LAP:71=LIX(HB^'(&;T;KG3(#^0USY>DT^0K&? ,Z[4=W?VEEBNUSX?Y=T
MSR5]==2#+.(_=UP V5C6)R#[?UB\%^3M,M_Y.SXY>!2/GDGEC<. PJ/W?\)/
M/G@][2H5/"$W]SPN\(R&? R;B%)@"RPMG[V?KCBU1V_ K?7)=;@5. B_ <SX
M^D6ZIZ[8;2FA$W!1X?BP!$3[V=?RRL]P!]#?1KSX'U!+ P04    " !R@%]/
M54?Z\OT'  #P*   %P   &%L;GEQ,S(P,3DQ,"UQ97@S,3(N:'1M[5IM;QNY
M$?[>7\&3T9P-Z%VRG4B. <=V<"JNB<]0F_;3@;N<E0ASEWLD5[+ZZSM#[NK%
MLF.Y=T"MY )8T7*'PR'GF9F'%,]^N/I\.?[WS36;NE2QFW]\^'ETR6J-5NM+
M[[+5NAI?L9_&?_^9]9OM#AL;GEGII,ZX:K6N/]58;>I</FBUYO-Y<]YK:C-I
MC6];I*K?4EI;: HG:N=GU(*?P,7Y7\Y^:#38E8Z+%#+'8@/<@6"%E=F$?1%@
M[UBC44I=ZGQAY&3J6+?=><>^:',G9SR\=](I.*_TG+7"\UG+#W(6:;$X/Q-R
MQJ1X7Y._MG_MH!DM; BMUBT4O*]-@;0/^MWFZ7'NAG,IW'30:;?_.JQYN?.S
M1&<.U1GL'+X&'5N:'-R[!E=RD@V\Q<.4FXG,&D[GJ!!UUX*N2C[B\=W$Z"(3
MC5@K;09F$AUVCX_KU1]K-]M'P_#NH.W_#4E!(^&I5(O!CV.9@F6?8,YN=<JS
M'\-;*_\#84#_. \3/,7.2F;0*"?<Z?HI7O_KI]&'T9CU.LWNYOP>GUF,*PUF
M+Z9V>7T['GT<75Z,1Y\_/3FW5S63_N,S&=7?''1.VL._09*P&UTHI[,ZB\$X
MF2R8FW+WYN#X[?#K_I.90-\-&KT3'#3G0F"T-10D;O"VDV^ ]>25+D/GJ)KA
M*S-M8S6[I\V34[^"(S;E,V &9A+FF.#<5%KV2\$-1I!:L%O(M7%,9^RC-BGK
MM!N_,)VP"Y4M%$_9S92;E,=0.!ES9>MLE,5-]/.[;][/W3WS\P=NT;OHQW3!
M[C(]5R F4 _N-L')0N/(F<9BAV-PF3&>+5B1.5, S@_+GZ^$Z'W.4GPRDBN6
M\!B;#-.I=,SI(+<ED$$,UG*S()&4WP&.NZ;38IM 8W!(Y<LHCD$"L318-E$L
MP^YHB0##YE,93YDMZ&/5?PX&2B4T@51:A?652O5<NBE.T.80>P-);XZF:8'3
MG&$WP:+%^C)\%^CM?2OH!9;(#/%!4%OAH8[017%\;=;>RRS!',:)&.+W6!4"
M=2+FUIQ?1[Q*RGLY0H;03E&@U K.)9+L@Z$Q8H1GG'62P-IG"<,:@>:'L]Z>
MF-LI2Y2>VPK@!B;2.J2KCG%J#':CE?4UG-K*F"UKOPNH]O<,JN,-O[XY>-OM
MG YM"<:2#E%BTDDB\=%[?,2X 8\MQ(J,%! &&""@(R7ME,1)+,6D3(F9GH6T
ML=*VP'Z4KHU6 62YT3$(;+;L$#$E $$:@'-]'T]Y-@%V@9GPME!@ V'K]'BC
M<WP(1[Y_YUB$I_ HB4EG >$T"*.<N0;\ $0RZ&6C)1NC)3@:S?AA3* $L9,7
M$,?^\4.<=[HG^P%TOA= [YTVNWV_@E=@<;.%WO;%^'D\UHDGQ+RPNW>A@AT!
MPJH<*5  71A4@,EQ)JU/N2@%F==#VXQ5LEY/^ 84]S@M.< *9O6R&-!+B8D;
M;;%:2>'W^[:(K!22&TD3D(&I^!*4D:;"$GOPL6T]U? )6EM @W"G[SOER*5E
M7"A.=06GY8U8L1#L$3C-.A7#;Q&0(*9^[ _B!:E^CT,@VH\0.*ER_68([)PK
MMR)A]RR[<T!@$,VD()QSJS-.-85;C!'BT@1^;D0%1 P-R2.II%L0,7EL6 I+
MCUD/QQ!1&Z)K7-R7KOMR0GEA<@P'ZXE4'&LCO &>E4\@0WZD,"KP#>04;B2"
M.XZ ? Q+F?O"\3U@/]X/["_3__6,J\+G2 (&) G28CE#E]I'Z.V2!NV0\\/C
MXXS70QT[8KZV@5='NG!/6[!+5>)+::!-0_+\%I%%U7;$1R^$E4![/%)I@&\>
MK6(_T+K*U $(VX"B,XZ2J?HWCZ+V!?F9"(B.X\(0;-:J_2-:4VT=MM-I->JR
M,2KZ+1R\L<,GNB2(?\R<#Z1+PW%_"?YXADYNLF)IUU&P:LKMDAI1SO7Q L(7
M([\>9:%8,"7O0)5G-0_DZ[][B5X8(_N[<3W>BQ#YO1M7?WHLJNBJKU(C9>IU
MA*^R)&'T!5QIB[ O3>-(VITV=DE/? .J3%/I',!7ZE"DD0#1>R'1/J_D$.,
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MS8C)B.UKCH<N0.XI(7.LCE+37EV+_I,O3>KOZH;&WA6=_P502P$"% ,4
M" !R@%]/@Y4ZL <F P#+;R< $0              @ $     86QN>2TR,#$Y
M,#DS,"YH=&U02P$"% ,4    " !R@%]/H\I!)@L4   8P@  $0
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<,C(N:'1M4$L%!@     +  L X (  -#Q!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781083344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net revenues from collaborators (in thousands) consist of the following:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:44.929825%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,882&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,560)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,370&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir Biotechnology (Vir)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,869&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">The Medicines Company (MDCO)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">775&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues from collaborators</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">53,415&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:65.205882%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.029412%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.029412%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,107&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">158,446&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three and nine months ended September&#160;30, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:65.794118%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.735294%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.735294%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Revenue recognized in the period from:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts included in contract liability at the beginning of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables provide the research and development expenses incurred by type that are directly attributable to our collaboration agreements by our collaboration partners for the periods indicated, in thousands:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:22.597365%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.784773%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,843&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">110&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,518&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">395&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,960&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,256&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,114&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:22.707602%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.771930%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi Genzyme</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MDCO</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vir</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Regeneron</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical trial and manufacturing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,033&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,578&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">External services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total research and development expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,484&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38,643&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,205&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research and development expenses incurred for each agreement listed in the tables above consist of costs incurred for external development and manufacturing services for which we are reimbursed and licensing payments made to the counterparty to such agreement. In addition, these expenses include a reasonable estimate of compensation and related costs as billed to our counterparties. As part of our revenue recognition policy adopted on January 1, 2018, the costs in the above table are considered an input in our determination of transaction price when they relate to consideration received for the delivery of goods or services. For the three and nine months ended September&#160;30, 2019 and 2018, we did not incur material selling, general and administrative expenses related to our collaboration agreements.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regeneron Collaboration</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On April&#160;8, 2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019, or the Effective Date. Upon closing of the Stock Purchase Agreement dated April 8, 2019, referred to as the Regeneron SPA, we issued 4,444,445 shares of common stock to Regeneron for aggregate cash consideration of $400.0 million, or $90.00 per share.&#160;Please read Note 10 for a full discussion regarding the Regeneron SPA. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 siRNA currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#8217;s pozelimab (REGN3918), currently in Phase 1 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Regeneron Collaboration, we will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial five-year research period, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional two years, for a research term extension fee of up to $400.0 million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously-announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-directed clinical and preclinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Regeneron will lead development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron will alternate leadership on CNS and liver programs, with the lead party retaining global development and commercial responsibility. For CNS and liver programs, both we and Regeneron will have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#8220;Licensee&#8221; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#8220;Licensee&#8221; for the purposes of the license agreement.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Under the C5 co-co collaboration agreement, we and Regeneron equally share costs and potential future profits on any monotherapy program. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $325.0 million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $400.0 million. We are also eligible to receive up to an additional $200.0 million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to 30 targets under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, with the potential for approximately $30.0 million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#8217; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $150.0 million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Separately, the cemdisiran monotherapy co-co collaboration agreement is under the scope of ASC 808 as we and Regeneron are both active participants in the development and manufacturing activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The development and manufacturing activities are a combined unit of account under the scope of ASC 808 and are not deliverables under ASC 606.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The total transaction price is comprised of the&#160;$400.0 million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain ocular, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467836%;"><tr><td style="width:1.0%;"/><td style="width:34.906585%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.412557%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.836141%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.412557%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.836141%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.331394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.664625%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Standalone Selling Price</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Guidance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">122,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">178,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">93,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:95%;">ASC 606</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">364,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">249,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">521,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:14.619883%;"><tr><td style="width:1.0%;"/><td style="width:98.000000%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, the expected number of targets or indications expected to be pursued under each license, the probability of success, and the time needed to develop a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the Research Services Obligation and the C5 License Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period and during the quarter ended September 30, 2019, the transaction price increased $18.5 million from $521.6 million as of June 30, 2019 to $540.1 million as of September 30, 2019 resulting from additional variable consideration we expect to receive. For the C5 Co-Co Obligation accounted for under ASC 808, the transaction price allocated to this obligation is recognized using a </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">proportional performance method. Revenue recognized under this agreement, inclusive of the amount allocated to the C5 Co-Co Obligation and future cost reimbursements, is accounted for as collaboration revenue.</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.491228%;"><tr><td style="width:1.0%;"/><td style="width:23.454545%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.181818%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.969697%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.818182%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.272727%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.406061%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.272727%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue Recognized During</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred Revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounting Guidance</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">182,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">90,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">109,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">66,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 606</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">248,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">245,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">540,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">402,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of&#160;September&#160;30, 2019, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation and C5 License Obligation that was unsatisfied is&#160;$279.8 million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. This amount excludes the transaction price allocated to the C5 Co-Co Obligation accounted for under ASC 808. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi Genzyme Collaboration</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Amendment</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April&#160;8, 2019, we and Sanofi Genzyme entered into an amendment to our 2014 Sanofi Genzyme collaboration, which we refer to as the Collaboration Amendment.&#160;Under the Collaboration Amendment, we and Sanofi Genzyme agreed to conclude the research and option phase under our collaboration agreement. In connection and simultaneously with entering into the Collaboration Amendment, we and Sanofi Genzyme also entered into the Amended and Restated ALN-AT3 Global License Terms with respect to ALN-AT3 (fitusiran) and certain back-up products, which we refer to as the A&amp;R AT3 License Terms. The A&amp;R AT3 License Terms amend and restate the ALN-AT3 Global License Terms entered into by us and Sanofi Genzyme in January&#160;2018 to modify certain of the business terms. The material collaboration terms for fitusiran, as previously announced, will continue unchanged.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with entering into the Collaboration Amendment and the A&amp;R AT3 License Terms, we agreed to advance, at our cost, a selected investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies. Following completion of such studies, we will transition, at our cost, such asset to Sanofi Genzyme. Thereafter, Sanofi Genzyme will fund all potential future development and commercialization costs for such asset. If this asset is developed and approved, we will be eligible to receive tiered double-digit royalties on global net sales.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">No changes were made to our Exclusive License Agreement with Sanofi Genzyme, referred to as the Exclusive TTR License, pursuant to which we have global rights for the development and commercialization of ONPATTRO, together with vutrisiran and all back-up products, which remains in full force and effect.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amended and Restated Investor Agreement</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Collaboration Amendment, we and Sanofi Genzyme also entered into an Amended and Restated Investor Agreement, referred to as the A&amp;R Investor Agreement, which amended and restated the Investor Agreement entered into by us and Sanofi Genzyme in February 2014, referred to as the Original Investor Agreement. Pursuant to the A&amp;R Investor Agreement, Sanofi Genzyme was released from the lock-up restrictions under the Original Investor Agreement and was permitted to sell shares of our common stock in transactions approved by us or in fully bought block sale transactions satisfying the conditions set forth in the A&amp;R Investor Agreement. As of January 17, 2019, Sanofi Genzyme owned 10,554,134 shares of our common stock and as of May 3, 2019, Sanofi Genzyme reported owning no shares of our common stock.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the A&amp;R Investor Agreement, until the earlier of (i)&#160;the fifth anniversary of the expiration of the last to expire royalty term or the earlier termination of the collaboration agreement, as amended by the Collaboration Amendment, and (ii)&#160;the date after December&#160;31, 2021 on which the beneficial ownership of Sanofi Genzyme and its affiliates no longer represents at least 5% of the outstanding shares of common stock, Sanofi Genzyme and its affiliates will be bound by certain &#8220;standstill&#8221; provisions, including an agreement not to propose or support a proposal to acquire us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6959507600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview of Significant Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease three facilities for office and laboratory space in Cambridge, Massachusetts that represent substantially all of our significant lease obligations.&#160;An overview of these significant leases are as follows:</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">675 West Kendall Street</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease office and laboratory space located at 675 West Kendall Street, Cambridge, Massachusetts under a non-cancelable real property lease. In September 2019, we moved our corporate headquarters and research facility to this location from our 300 Third Street location. The lease commenced on May 1, 2018 and monthly rent payments became due commencing on February 1, 2019 upon substantial completion of the building improvements, and continue for 15 years, with options to renew for two five-year terms each. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">300 Third Street</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease office and laboratory space located at 300 Third Street, Cambridge, Massachusetts under a non-cancelable real property lease agreement dated as of September 26, 2003, as amended. The term of the lease expires on January&#160;31, 2034, with an option to extend for two additional five-year terms. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">101 Main Street</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We lease office space located on several floors at 101 Main Street, Cambridge, Massachusetts under non-cancelable real property lease agreements entered into in March and May 2015 that will expire in March 2024 and June 2021, respectively, each with an option to renew for one five-year term. Exercise of these options was not determined to be reasonably certain and thus was not included in the operating lease liability on the condensed consolidated balance sheet as of September&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Lease Disclosures</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our facility leases described above generally contain customary provisions allowing the landlords to terminate the leases if we fail to remedy a breach of any of our obligations under any such lease within specified time periods, or upon our bankruptcy or insolvency.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The below table summarizes our costs included in operating expenses related to leases we have entered into through September&#160;30, 2019, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:65.349927%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.959004%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.959004%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Lease Cost</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,282&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27,863&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">40,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Short-term lease costs were not material for the&#160;three and nine months ended September&#160;30, 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash paid for the amounts included in the measurement of the operating lease liability in our condensed consolidated balance sheet and included in accrued expenses and other within operating activities in our condensed consolidated statement of cash flow was $24.8 million for the nine months ended September&#160;30, 2019.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September&#160;30, 2019 was 13.4 years and 8.2%, respectively.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Future lease payments for non-cancellable operating leases and a reconciliation to the carrying amount of the operating lease liability presented in the condensed consolidated balance sheet as of September&#160;30, 2019 is as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:86.286969%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining three months)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">35,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,670&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">356,208&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">536,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(231,654)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total discounted lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">304,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28,165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">276,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">304,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the prior lease guidance, minimum payments under our non-cancelable facility leases, as of December&#160;31, 2018, were as follows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:86.286969%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.713031%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">35,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">390,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">562,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alny-20190930.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 342,
   "dts": {
    "calculationLink": {
     "local": [
      "alny-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alny-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "alny-20190930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alny-20190930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alny-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "alny-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 423,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 8,
    "http://www.alnylam.com/20190930": 9,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 22
   },
   "keyCustom": 41,
   "keyStandard": 284,
   "memberCustom": 25,
   "memberStandard": 30,
   "nsprefix": "alny",
   "nsuri": "http://www.alnylam.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.alnylam.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - COLLABORATION AGREEMENTS",
     "role": "http://www.alnylam.com/role/COLLABORATIONAGREEMENTS",
     "shortName": "COLLABORATION AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - INVENTORY",
     "role": "http://www.alnylam.com/role/INVENTORY",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - MARKETABLE DEBT SECURITIES",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES",
     "shortName": "MARKETABLE DEBT SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - LEASES",
     "role": "http://www.alnylam.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:CreditAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - CREDIT AGREEMENT",
     "role": "http://www.alnylam.com/role/CREDITAGREEMENT",
     "shortName": "CREDIT AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:CreditAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - EQUITY",
     "role": "http://www.alnylam.com/role/EQUITY",
     "shortName": "EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - NET LOSS PER COMMON SHARE",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE",
     "shortName": "NET LOSS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146113 - Disclosure - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH",
     "role": "http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH",
     "shortName": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149114 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151115 - Disclosure - DEFINED BENEFIT PLANS",
     "role": "http://www.alnylam.com/role/DEFINEDBENEFITPLANS",
     "shortName": "DEFINED BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153116 - Disclosure - OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)",
     "role": "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies",
     "shortName": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - PRODUCT REVENUES, NET (Tables)",
     "role": "http://www.alnylam.com/role/PRODUCTREVENUESNETTables",
     "shortName": "PRODUCT REVENUES, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - COLLABORATION AGREEMENTS (Tables)",
     "role": "http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables",
     "shortName": "COLLABORATION AGREEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - INVENTORY (Tables)",
     "role": "http://www.alnylam.com/role/INVENTORYTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables",
     "shortName": "MARKETABLE DEBT SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - LEASES (Tables)",
     "role": "http://www.alnylam.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - NET LOSS PER COMMON SHARE (Tables)",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables",
     "shortName": "NET LOSS PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Tables)",
     "role": "http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables",
     "shortName": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354310 - Disclosure - OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation and Principles of Consolidation - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail",
     "shortName": "Basis of Presentation and Principles of Consolidation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "id5dcc5c5f3264c3591f7bcfc758ebdd4_I20190101",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Product Revenues, Net - Summary of Net Product Revenues Of ONPATTRO (Detail)",
     "role": "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail",
     "shortName": "Product Revenues, Net - Summary of Net Product Revenues Of ONPATTRO (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i9c54b97117a54dc9a2281403a9143f40_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Product Revenues, Net - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail",
     "shortName": "Product Revenues, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ia58cef5166244621bfaed56c877e6047_I20190930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Collaboration Agreements - Revenue from Collaborators (Detail)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
     "shortName": "Collaboration Agreements - Revenue from Collaborators (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "iedca81ec08d84b71974e26397c92d1df_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Collaboration Agreements - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
     "shortName": "Collaboration Agreements - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Collaboration Agreements - Change in Contract Liability Balance Related to Collaboration Agreements (Detail)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail",
     "shortName": "Collaboration Agreements - Change in Contract Liability Balance Related to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Collaboration Agreements - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
     "shortName": "Collaboration Agreements - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i475658c0ca9e4d928c433d121b265c82_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-5",
      "lang": null,
      "name": "alny:IncreaseDecreaseInTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i20dd038e16194a6ba76b31ab5bfe0fde_D20190930-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "alny:TransactionPrice",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Collaboration Agreements - Schedule of Transaction Price Allocated (Details)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
     "shortName": "Collaboration Agreements - Schedule of Transaction Price Allocated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfAllocatedTransactionPriceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "if88df3d689a741d8b329bc0a7ffb25d6_I20190930",
      "decimals": "-3",
      "lang": null,
      "name": "alny:StandaloneSellingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Collaboration Agreements - Schedule of Revenue Recognized by Accounting Guidance (Details)",
     "role": "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
     "shortName": "Collaboration Agreements - Schedule of Revenue Recognized by Accounting Guidance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Inventory - Schedule of Inventory (Detail)",
     "role": "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail",
     "shortName": "Inventory - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Detail)",
     "role": "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie975d68357554af895cd61a0cde4dbcb_I20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Marketable Debt Securities - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail",
     "shortName": "Marketable Debt Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Marketable Debt Securities - Summary of Company's Marketable Debt Securities (Detail)",
     "role": "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail",
     "shortName": "Marketable Debt Securities - Summary of Company's Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Marketable Debt Securities - Summary of Fair Value of Marketable Debt Securities (Detail)",
     "role": "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail",
     "shortName": "Marketable Debt Securities - Summary of Fair Value of Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "icdb8b45ba98c4ea79afcd93e804e2e31_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ia298b62308334655b29761118e628026_D20180101-20180331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Leases - Summary of Costs Included in Operating Expenses Related to Leases (Detail)",
     "role": "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail",
     "shortName": "Leases - Summary of Costs Included in Operating Expenses Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail)",
     "role": "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail",
     "shortName": "Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i0e42c46e2c9e420489c577ce9a0935d6_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Detail)",
     "role": "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i0e42c46e2c9e420489c577ce9a0935d6_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Credit Agreement - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
     "shortName": "Credit Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ice75d291b75345eeb04d09221d4ac4bc_D20160429-20160429",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Equity - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/EquityAdditionalInformationDetail",
     "shortName": "Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i7e210fbc6254492db46cc4dab7cb30a5_D20190101-20190131",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)",
     "role": "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail",
     "shortName": "Stock-Based Compensation - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ie1a9b10b43434d07b56b6207e00d9b4f_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Net Loss Per Common Share - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)",
     "role": "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail",
     "shortName": "Net Loss Per Common Share - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - Reconciliation of Cash, Cash Equivalents and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "role": "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "Reconciliation of Cash, Cash Equivalents and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "id9f25a7c241a4588906a002ff847246a_I20180930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "ib290959e61784a1896b905564c991cdf_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i5e6ba42cf3c140a2a684fe08a1b322e3_D20180418-20180418",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LossContingencySettlementAgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i1a9655ab33ba47a3b214bdd3432435d3_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - Defined Benefit Plans - Additional Information (Details)",
     "role": "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails",
     "shortName": "Defined Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i1a9655ab33ba47a3b214bdd3432435d3_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "id1f18bc840ab43f281968996981ebe97_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455428 - Disclosure - Other Comprehensive Loss and Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail)",
     "role": "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail",
     "shortName": "Other Comprehensive Loss and Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF BUSINESS",
     "role": "http://www.alnylam.com/role/NATUREOFBUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION",
     "role": "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION",
     "shortName": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - PRODUCT REVENUES, NET",
     "role": "http://www.alnylam.com/role/PRODUCTREVENUESNET",
     "shortName": "PRODUCT REVENUES, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20190930.htm",
      "contextRef": "i8fa535a2e1e54753aaeab1eac328bec2_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "alny_AccumulatedLossOnInvestmentInJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated loss on investment in joint venture.",
        "label": "Accumulated Loss On Investment In Joint Venture [Member]",
        "terseLabel": "Loss on Investment in Joint Venture"
       }
      }
     },
     "localname": "AccumulatedLossOnInvestmentInJointVentureMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_AgreementExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement extension period.",
        "label": "Agreement Extension Period",
        "terseLabel": "Agreement extension period"
       }
      }
     },
     "localname": "AgreementExtensionPeriod",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_AmortizationAndInterestAccretionRelatedToOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization and Interest Accretion Related to Operating Leases",
        "label": "Amortization and Interest Accretion Related to Operating Leases",
        "terseLabel": "Amortization and interest accretion related to operating leases"
       }
      }
     },
     "localname": "AmortizationAndInterestAccretionRelatedToOperatingLeases",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_BMRSixSevenFiveWestKendallLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BMR-675 West Kendall lease.",
        "label": "B M R Six Seven Five West Kendall Lease [Member]",
        "terseLabel": "BMR-675 West Kendall Lease"
       }
      }
     },
     "localname": "BMRSixSevenFiveWestKendallLeaseMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_BeneficialOwnershipPercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Beneficial ownership percentage of shares outstanding.",
        "label": "Beneficial Ownership Percentage Of Shares Outstanding",
        "terseLabel": "Beneficial ownership percentage of shares outstanding"
       }
      }
     },
     "localname": "BeneficialOwnershipPercentageOfSharesOutstanding",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Beneficial ownership percentage of shares outstanding following the expiration of lock-up period.",
        "label": "Beneficial Ownership Percentage Of Shares Outstanding Following The Expiration Of Lockup Period",
        "terseLabel": "Beneficial ownership percentage following the expiration of lock-up period"
       }
      }
     },
     "localname": "BeneficialOwnershipPercentageOfSharesOutstandingFollowingTheExpirationOfLockupPeriod",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_C5CoCoObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "C5 Co-Co obligation.",
        "label": "C5 Co Co Obligation [Member]",
        "terseLabel": "C5 Co-Co Obligation"
       }
      }
     },
     "localname": "C5CoCoObligationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_C5LicenseObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "C5 license obligation.",
        "label": "C5 License Obligation [Member]",
        "terseLabel": "C5 License Obligation"
       }
      }
     },
     "localname": "C5LicenseObligationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash cash equivalents and restricted cash.",
        "label": "Cash Cash Equivalents And Restricted Cash [Abstract]",
        "terseLabel": "Cash Cash Equivalents And Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.alnylam.com/20190930",
     "xbrltype": "stringItemType"
    },
    "alny_CashCollateralRequiredForPrincipalAmountOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash collateral required for principal amount outstanding, percentage.",
        "label": "Cash Collateral Required For Principal Amount Outstanding Percentage",
        "terseLabel": "Cash collateral required for principal amount outstanding, percentage"
       }
      }
     },
     "localname": "CashCollateralRequiredForPrincipalAmountOutstandingPercentage",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_ChangeInFairValueOfLiabilityObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in fair value of liability obligation.",
        "label": "Change In Fair Value Of Liability Obligation",
        "negatedTerseLabel": "Change in fair value of liability obligation",
        "terseLabel": "Change in fair value of liability obligation"
       }
      }
     },
     "localname": "ChangeInFairValueOfLiabilityObligation",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_ClinicalTrialAndManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical trial and manufacturing.",
        "label": "Clinical Trial And Manufacturing [Member]",
        "terseLabel": "Clinical trial and manufacturing"
       }
      }
     },
     "localname": "ClinicalTrialAndManufacturingMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CollaborationAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration amendment.",
        "label": "Collaboration Amendment [Member]",
        "terseLabel": "Collaboration Amendment"
       }
      }
     },
     "localname": "CollaborationAmendmentMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CollaborativeArrangementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement milestone payments.",
        "label": "Collaborative Arrangement Milestone Payments",
        "terseLabel": "Collaborative arrangement milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayments",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_CreditAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit agreement disclosure text block.",
        "label": "Credit Agreement Disclosure [Text Block]",
        "terseLabel": "CREDIT AGREEMENT"
       }
      }
     },
     "localname": "CreditAgreementDisclosureTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_DateOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of agreement.",
        "label": "Date Of Agreement",
        "verboseLabel": "Date of investor agreement"
       }
      }
     },
     "localname": "DateOfAgreement",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "alny_DicernaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dicerna Pharmaceuticals, Inc.",
        "label": "Dicerna Pharmaceuticals Inc [Member]",
        "terseLabel": "Dicerna Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "DicernaPharmaceuticalsIncMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_DiscoveryPeriodOfProgramsDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discovery period of programs development.",
        "label": "Discovery Period Of Programs Development",
        "terseLabel": "Discovery period of programs development"
       }
      }
     },
     "localname": "DiscoveryPeriodOfProgramsDevelopment",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_EquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity line items.",
        "label": "Equity [Line Items]",
        "terseLabel": "Equity [Line Items]"
       }
      }
     },
     "localname": "EquityLineItems",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_EquityTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity table.",
        "label": "Equity [Table]",
        "terseLabel": "Equity [Table]"
       }
      }
     },
     "localname": "EquityTable",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extended additional discovery period of programs development.",
        "label": "Extended Additional Discovery Period Of Programs Development",
        "terseLabel": "Extended additional discovery period of programs development"
       }
      }
     },
     "localname": "ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_ExtendedLeaseExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extended lease expiration date.",
        "label": "Extended Lease Expiration Date",
        "terseLabel": "Lease extended expiration date"
       }
      }
     },
     "localname": "ExtendedLeaseExpirationDate",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "alny_ExtendedLeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extended lease expiration month and year.",
        "label": "Extended Lease Expiration Month And Year",
        "terseLabel": "Lease extended expiration month and year"
       }
      }
     },
     "localname": "ExtendedLeaseExpirationMonthAndYear",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "alny_ExternalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "External services.",
        "label": "External Services [Member]",
        "terseLabel": "External services"
       }
      }
     },
     "localname": "ExternalServicesMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAnAnnualDiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funding an annual discovery.",
        "label": "Funding An Annual Discovery [Member]",
        "terseLabel": "Funding At Steady State"
       }
      }
     },
     "localname": "FundingAnAnnualDiscoveryMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAtLeadCandidateIdentificationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funding at lead candidate identification.",
        "label": "Funding At Lead Candidate Identification [Member]",
        "terseLabel": "Funding At Lead Candidate Identification"
       }
      }
     },
     "localname": "FundingAtLeadCandidateIdentificationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAtProgramInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funding at program initiation.",
        "label": "Funding At Program Initiation [Member]",
        "terseLabel": "Funding At Program Initiation"
       }
      }
     },
     "localname": "FundingAtProgramInitiationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_GainLossOnSaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (loss) on sale of common stock.",
        "label": "Gain Loss On Sale Of Common Stock",
        "terseLabel": "Gain on sale of common stock"
       }
      }
     },
     "localname": "GainLossOnSaleOfCommonStock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_GlobalStrategicCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global strategic collaboration.",
        "label": "Global Strategic Collaboration [Member]",
        "terseLabel": "Global Strategic Collaboration"
       }
      }
     },
     "localname": "GlobalStrategicCollaborationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ImpairmentOfMarketableDebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment of marketable debt securities.",
        "label": "Impairment Of Marketable Debt Securities",
        "terseLabel": "Impairment charges of marketable debt securities"
       }
      }
     },
     "localname": "ImpairmentOfMarketableDebtSecurities",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_IncreaseDecreaseInTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Transaction Price",
        "label": "Increase (Decrease) In Transaction Price",
        "terseLabel": "Change in Transaction Price"
       }
      }
     },
     "localname": "IncreaseDecreaseInTransactionPrice",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in marketable debt securities disclosure.",
        "label": "Investments In Marketable Debt Securities Disclosure [Text Block]",
        "terseLabel": "MARKETABLE DEBT SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_InvestorAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investor agreement description.",
        "label": "Investor Agreement Description",
        "terseLabel": "Investor agreement description"
       }
      }
     },
     "localname": "InvestorAgreementDescription",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LandAndCostsRelatedToConstructionOfManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Land and costs related to construction of manufacturing facility.",
        "label": "Land And Costs Related To Construction Of Manufacturing Facility [Member]",
        "terseLabel": "Land and Costs Related to the Construction of Manufacturing Facility"
       }
      }
     },
     "localname": "LandAndCostsRelatedToConstructionOfManufacturingFacilityMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_LeaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease agreement term.",
        "label": "Lease Agreement Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LeaseAgreementTerm",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_LeasesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leases policy.",
        "label": "Leases Policy Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesPolicyPolicyTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year seven and thereafter.",
        "label": "Lessee Operating Lease Liability Payments Due Year Seven And Thereafter",
        "negatedTerseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year six.",
        "label": "Lessee Operating Lease Liability Payments Due Year Six",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum additional milestone payments to be receive upon achievement of certain criteria.",
        "label": "Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria",
        "terseLabel": "Maximum additional milestone payments to be receive upon achievement of certain criteria"
       }
      }
     },
     "localname": "MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum royalties and commercial milestone payments upon potential product sale.",
        "label": "Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale",
        "terseLabel": "Maximum royalties and commercial milestone payments upon potential product sale"
       }
      }
     },
     "localname": "MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MdcoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Medicines Company.",
        "label": "Mdco [Member]",
        "terseLabel": "Mdco",
        "verboseLabel": "The Medicines Company"
       }
      }
     },
     "localname": "MdcoMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_NonCashGainOnLitigationSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash gain on litigation settlement.",
        "label": "Non Cash Gain On Litigation Settlement",
        "negatedLabel": "Gain on litigation settlement"
       }
      }
     },
     "localname": "NonCashGainOnLitigationSettlement",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_NortonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Norton, Massachusetts.",
        "label": "Norton Massachusetts [Member]",
        "terseLabel": "Norton, Massachusetts"
       }
      }
     },
     "localname": "NortonMassachusettsMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_NumberOfLeaseExtensionOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of lease extension options.",
        "label": "Number Of Lease Extension Options",
        "terseLabel": "Number of lease extension options"
       }
      }
     },
     "localname": "NumberOfLeaseExtensionOptions",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfTargetedPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of targeted programs.",
        "label": "Number Of Targeted Programs",
        "terseLabel": "Number of targeted programs"
       }
      }
     },
     "localname": "NumberOfTargetedPrograms",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_OneHundredAndOneMainStreetLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "101 Main Street leases.",
        "label": "One Hundred And One Main Street Leases [Member]",
        "terseLabel": "101 Main Street Lease"
       }
      }
     },
     "localname": "OneHundredAndOneMainStreetLeasesMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OtherCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other collaboration.",
        "label": "Other Collaborations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborationsMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OwnershipPercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership percentage of shares outstanding.",
        "label": "Ownership Percentage Of Shares Outstanding",
        "terseLabel": "Ownership percentage of shares outstanding"
       }
      }
     },
     "localname": "OwnershipPercentageOfSharesOutstanding",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_OwnershipPercentageSharesOfStocksOutstandingUpperLimit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership percentage shares of stocks outstanding upper limit.",
        "label": "Ownership Percentage Shares Of Stocks Outstanding Upper Limit",
        "terseLabel": "Ownership percentage of shares outstanding, upper limit"
       }
      }
     },
     "localname": "OwnershipPercentageSharesOfStocksOutstandingUpperLimit",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_PercentageOfMaximumRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of maximum royalty payments.",
        "label": "Percentage Of Maximum Royalty Payments",
        "terseLabel": "Maximum percentage of royalty payments"
       }
      }
     },
     "localname": "PercentageOfMaximumRoyaltyPayments",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_PotentialProceedsFromCollaborationArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential proceeds from collaboration arrangement.",
        "label": "Potential Proceeds From Collaboration Arrangement",
        "terseLabel": "Potential proceeds from collaboration arrangement"
       }
      }
     },
     "localname": "PotentialProceedsFromCollaborationArrangement",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RegeneronPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals, Incorporation.",
        "label": "Regeneron Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Regeneron Pharmaceuticals, Inc.",
        "verboseLabel": "Regeneron"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchServicesObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research services obligation.",
        "label": "Research Services Obligation [Member]",
        "terseLabel": "Research Services Obligation"
       }
      }
     },
     "localname": "ResearchServicesObligationMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchTermExtensionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research term extension fee.",
        "label": "Research Term Extension Fee",
        "terseLabel": "Research term extension fee"
       }
      }
     },
     "localname": "ResearchTermExtensionFee",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential maximum royalty percentage that will received for sales completed by collaboration partner.",
        "label": "Royalty Rate",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRate",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_SanofiGenzymeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Genzyme.",
        "label": "Sanofi Genzyme [Member]",
        "terseLabel": "Sanofi Genzyme"
       }
      }
     },
     "localname": "SanofiGenzymeMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ScheduleOfAllocatedTransactionPriceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Allocated Transaction Price",
        "label": "Schedule of Allocated Transaction Price [Table Text Block]",
        "terseLabel": "Schedule of Allocated Transaction Price Based on Accounting Guidance"
       }
      }
     },
     "localname": "ScheduleOfAllocatedTransactionPriceTableTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statement of reconciliation of cash, cash equivalents and restricted cash.",
        "label": "Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of research and development expenses incurred for collaboration agreements.",
        "label": "Schedule Of Research And Development Expenses Incurred For Collaboration Agreements Table [Text Block]",
        "terseLabel": "Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Revenue Recognized Based on Accounting Guidance",
        "label": "Schedule of Revenue Recognized Based on Accounting Guidance [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognized Based on Accounting Guidance"
       }
      }
     },
     "localname": "ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_StandaloneSellingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Standalone Selling Price",
        "label": "Standalone Selling Price",
        "terseLabel": "Standalone Selling Price"
       }
      }
     },
     "localname": "StandaloneSellingPrice",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term loan facility.",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ThirdStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third street lease.",
        "label": "Third Street Lease [Member]",
        "terseLabel": "Third Street Lease"
       }
      }
     },
     "localname": "ThirdStreetLeaseMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_TransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.",
        "label": "Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "TransactionPrice",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_UpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.",
        "label": "Upfront Fee Received",
        "terseLabel": "Upfront fee received"
       }
      }
     },
     "localname": "UpfrontFeeReceived",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_VirBiotechnologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vir biotechnology Inc.",
        "label": "Vir Biotechnology Inc [Member]",
        "terseLabel": "Vir Biotechnology",
        "verboseLabel": "Vir"
       }
      }
     },
     "localname": "VirBiotechnologyIncMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_WellsFargoCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Wells Fargo credit facility.",
        "label": "Wells Fargo Credit Facility [Member]",
        "terseLabel": "Wells Fargo Bank, National Association"
       }
      }
     },
     "localname": "WellsFargoCreditFacilityMember",
     "nsuri": "http://www.alnylam.com/20190930",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r114",
      "r163",
      "r166",
      "r271",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r115",
      "r163",
      "r167",
      "r273",
      "r283",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r15",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "verboseLabel": "Receivables included in \u201cAccounts receivable, net\u201d"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r116",
      "r117",
      "r164"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r50",
      "r55",
      "r56",
      "r172",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r55",
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized (Losses) Gains from Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r45",
      "r55",
      "r56",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r179",
      "r180",
      "r189",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense related to equity-classified awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Non-cash adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r180",
      "r185",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Undeveloped land acquired (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r111",
      "r253",
      "r263"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r43"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r122",
      "r137"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r119",
      "r123",
      "r137"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r121",
      "r137"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r99",
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r90"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r85",
      "r90",
      "r94"
     ],
     "calculation": {
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r224"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Revenue recognized in the period from:"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/COLLABORATIONAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "verboseLabel": "Net Revenues from Collaborators"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r149",
      "r256",
      "r268"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Common stock shares owned"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value per share, 250,000 and 125,000 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 111,325 shares issued and outstanding as of September 30, 2019; 101,177 shares issued and outstanding as of December 31, 2018"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r203",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r158",
      "r159",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities included in \u201cDeferred revenue\u201d"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r158",
      "r159",
      "r164"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r158",
      "r159",
      "r164"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amounts included in contract liability at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r170",
      "r177",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.",
        "label": "Cumulative Effect on Retained Earnings, Net of Tax",
        "terseLabel": "Cumulative effect adjustment from the adoption of new revenue standard"
       }
      }
     },
     "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r32",
      "r230"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r37",
      "r230"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "terseLabel": "Benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization, net"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Net Product Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/PRODUCTREVENUESNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Transfers between Level 1 and Level 2 financial assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r213",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r213",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Marketable Debt Securities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r177",
      "r214",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r216",
      "r217",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r170",
      "r171",
      "r177",
      "r214",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r170",
      "r171",
      "r177",
      "r214",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r170",
      "r171",
      "r177",
      "r214",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Gain on litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r100",
      "r251",
      "r257",
      "r270"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r110",
      "r195"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit (provision) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/INVENTORY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r42",
      "r143"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/InventoryScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r70",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r275",
      "r277",
      "r279",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Shares of Vir common stock"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r276",
      "r278",
      "r280",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r276",
      "r278",
      "r280",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r242",
      "r244"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Costs Included in Operating Expenses Related to Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "terseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019 (remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal options period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r254",
      "r266"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Line of Credit Facility [Abstract]",
        "terseLabel": "Line of Credit Facility [Abstract]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date the credit facility terminates, in CCYY-MM-DD format.",
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Line of credit facility, expiration date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencySettlementAgreementDate": {
     "auth_ref": [
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective date of a duly executed litigation settlement agreement.",
        "label": "Loss Contingency, Settlement Agreement, Date",
        "terseLabel": "Litigation settlement, settlement agreement date"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Percentage ownership interest owned by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r57",
      "r60",
      "r66",
      "r89",
      "r104",
      "r258",
      "r269"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r237",
      "r244"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total discounted lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail",
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Net cash paid included in operating activities in cash flow"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r241",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r240",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r53",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r55",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive (loss) income before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r63",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss), net of tax",
        "verboseLabel": "Net other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax",
        "negatedLabel": "Defined benefit pension plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r53"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedTerseLabel": "Proceeds from landlord lease incentive for tenant improvements"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r78",
      "r120"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Purchases of restricted investments"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Charge for 401(k) company stock match"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "DEFINED BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEFINEDBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2019 and December 31, 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Offering proceeds, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of common stock to Regeneron"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r81",
      "r187"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and other types of equity, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from maturity of restricted investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Revenues, Net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r57",
      "r60",
      "r84",
      "r111",
      "r113",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r27",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r146",
      "r267"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r55",
      "r56",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amounts reclassified from other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of term loan",
        "terseLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r192",
      "r286"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Total research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r9",
      "r90",
      "r94",
      "r252",
      "r264"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash (money market funds)"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r9",
      "r94"
     ],
     "calculation": {
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash included in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r12",
      "r94",
      "r284"
     ],
     "calculation": {
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash included in long-term other assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted common stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r155",
      "r265"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanFundingStatusAxis": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of funding for defined benefit plan designed to provide retirement benefits.",
        "label": "Retirement Plan Funding Status [Axis]",
        "terseLabel": "Retirement Plan Funding Status"
       }
      }
     },
     "localname": "RetirementPlanFundingStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanFundingStatusDomain": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of funding for defined benefit plan designed to provide retirement benefits.",
        "label": "Retirement Plan Funding Status [Domain]",
        "terseLabel": "Retirement Plan Funding Status"
       }
      }
     },
     "localname": "RetirementPlanFundingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r196",
      "r199"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue recognized under ASC 808"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue recognized under ASC 606"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "PRODUCT REVENUES, NET"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/PRODUCTREVENUESNET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transactional price remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r64",
      "r108",
      "r109",
      "r112"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Company's Marketable Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r259",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenue from Collaborators"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value of Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under Non-cancelable Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r21",
      "r22",
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/INVENTORYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r181",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69",
      "r142"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock at a price per share",
        "verboseLabel": "Shares issued price per share (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance of common stock under benefit plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r154",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r154",
      "r155",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of common stock options, net of tax withholdings (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance of common stock under benefit plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r154",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r154",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options, net of tax withholdings"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r118"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/EQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails",
      "http://www.alnylam.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r170",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored enterprise securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r170",
      "r177",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfundedPlanMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined benefit plan in which retirement benefits are payable directly from general assets of employer sponsoring plan.",
        "label": "Unfunded Plan [Member]",
        "terseLabel": "Unfunded Plan"
       }
      }
     },
     "localname": "UnfundedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r238",
      "r244"
     ],
     "calculation": {
      "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118644919&loc=SL5834089-161433"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32157-110900"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r287": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r288": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r289": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r291": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r292": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6958751744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (remaining three months)</a></td>
<td class="nump">$ 8,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">36,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">36,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">35,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix', window );">2024</a></td>
<td class="nump">34,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter', window );">2025 and thereafter</a></td>
<td class="num">(356,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease liability</a></td>
<td class="nump">536,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(231,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease liability</a></td>
<td class="nump">304,621<span></span>
</td>
<td class="nump">$ 290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">28,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 276,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year seven and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year six.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LesseeOperatingLeaseLiabilityPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6788233184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 46,009<span></span>
</td>
<td class="nump">$ 87,954<span></span>
</td>
<td class="nump">$ 108,644<span></span>
</td>
<td class="nump">$ 129,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">22,737<span></span>
</td>
<td class="nump">45,784<span></span>
</td>
<td class="nump">54,144<span></span>
</td>
<td class="nump">67,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 23,272<span></span>
</td>
<td class="nump">$ 42,170<span></span>
</td>
<td class="nump">$ 54,500<span></span>
</td>
<td class="nump">$ 62,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6957684240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Revenues, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 48,109<span></span>
</td>
<td class="nump">$ 18,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenues, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781308576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Cash Cash Equivalents And Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">923,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">316,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in long-term other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">925,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">318,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statement of reconciliation of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789302384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents our inventory as of September&#160;30, 2019 and December&#160;31, 2018, in thousands:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:72.707602%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">42,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">54,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">24,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6592226384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CREDIT AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CreditAgreementDisclosureTextBlock', window );">CREDIT AGREEMENT</a></td>
<td class="text">CREDIT AGREEMENT<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April&#160;29, 2016, we entered into a Credit Agreement by and among Alnylam U.S., Inc., as the borrower, us, as a guarantor, and Wells Fargo Bank, National Association, as the lender.&#160;The Credit Agreement was entered into in connection with the planned build out of our drug substance manufacturing facility.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement provided for a $30.0 million term loan facility and was scheduled to mature on April&#160;29, 2021. On September 27, 2019, we repaid in full the $30.0 million outstanding principal amount under the Credit Agreement and the Credit Agreement terminated in accordance with its terms upon repayment of the outstanding indebtedness. Interest on borrowings under the Credit Agreement was calculated based on LIBOR plus 0.45%, except in the event of default.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The obligations of the borrower and us under the Credit Agreement were secured by cash collateral in an amount equal to, at any given time, at least 100% of the principal amount of all term loans outstanding under such Credit Agreement at such time. As of December&#160;31, 2018, we recorded $30.0 million of cash collateral in connection with the Credit Agreement as restricted investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CreditAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit agreement disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CreditAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789321568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Cash Cash Equivalents And Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:73.806452%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">923,304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">316,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in long-term other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">925,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">318,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774960320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 32,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">34,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">34,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">34,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">35,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">390,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 562,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786221936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">14,343<span></span>
</td>
<td class="nump">12,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">13,675<span></span>
</td>
<td class="nump">12,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791575984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Loss and Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">$ 1,757,195<span></span>
</td>
<td class="nump">$ 1,546,986<span></span>
</td>
<td class="nump">$ 1,301,965<span></span>
</td>
<td class="nump">$ 1,620,802<span></span>
</td>
<td class="nump">$ 1,754,805<span></span>
</td>
<td class="nump">$ 1,766,431<span></span>
</td>
<td class="nump">$ 1,301,965<span></span>
</td>
<td class="nump">$ 1,766,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,642)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive (loss) income</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="num">(2,978)<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">1,607,087<span></span>
</td>
<td class="nump">1,757,195<span></span>
</td>
<td class="nump">1,546,986<span></span>
</td>
<td class="nump">1,478,119<span></span>
</td>
<td class="nump">1,620,802<span></span>
</td>
<td class="nump">1,754,805<span></span>
</td>
<td class="nump">1,607,087<span></span>
</td>
<td class="nump">1,478,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember', window );">Loss on Investment in Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(32,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,282)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(4,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized (Losses) Gains from Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,641)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
<td class="num">(1,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="nump">2,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">(35,831)<span></span>
</td>
<td class="num">(32,853)<span></span>
</td>
<td class="num">(33,213)<span></span>
</td>
<td class="num">(33,807)<span></span>
</td>
<td class="num">(34,853)<span></span>
</td>
<td class="num">(34,433)<span></span>
</td>
<td class="num">(33,213)<span></span>
</td>
<td class="num">(34,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive (loss) income</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="num">(2,978)<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance</a></td>
<td class="num">$ (34,371)<span></span>
</td>
<td class="num">$ (35,831)<span></span>
</td>
<td class="num">$ (32,853)<span></span>
</td>
<td class="num">$ (33,392)<span></span>
</td>
<td class="num">$ (33,807)<span></span>
</td>
<td class="num">$ (34,853)<span></span>
</td>
<td class="num">$ (34,371)<span></span>
</td>
<td class="num">$ (33,392)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787396352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers between Level 1 and Level 2 financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alny_VirBiotechnologyIncMember', window );">Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of Vir common stock | shares</a></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="nump">0.2222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember', window );">Term Loan Facility | Wells Fargo Bank, National Association</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alny_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=alny_WellsFargoCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6958562240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Schedule of Transaction Price Allocated (Details) - Global Strategic Collaboration - Regeneron Pharmaceuticals, Inc. - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 540,100<span></span>
</td>
<td class="nump">$ 521,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember', window );">Research Services Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">182,400<span></span>
</td>
<td class="nump">178,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember', window );">C5 License Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="nump">97,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">109,200<span></span>
</td>
<td class="nump">93,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember', window );">C5 Co-Co Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="nump">364,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 248,500<span></span>
</td>
<td class="nump">$ 249,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_StandaloneSellingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Standalone Selling Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_StandaloneSellingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781242192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2018, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 14, 2019. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018.&#160;Updates to our significant accounting policies, including the updated lease accounting policy due to the adoption of the new leasing accounting standard, are discussed below and under &#8220;Recent Accounting Pronouncements.&#8221;</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassification</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable debt securities as of September&#160;30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to enable us to advance our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We determine whether a contract is, or contains, a lease at inception. We classify each of our leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the condensed consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.&#160;Costs determined to be variable and not based on an index or rate are not included in </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. We record expense to recognize fixed lease payments on a straight-line basis over the expected lease term. We have elected the practical expedient not to separate lease and non-lease components for real estate leases.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board, or FASB, issued a new leasing standard which generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the condensed consolidated balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new standard on January 1, 2019, using a modified retrospective basis and did not restate comparative periods. In addition, we did not elect the package of practical expedients permitted under the transition guidance that permits companies to carry forward prior conclusions related to (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. All our leases have been classified as operating leases under the new leasing standard.&#160;We elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the condensed consolidated balance sheets and recognize the associated lease payments in the condensed consolidated statements of comprehensive loss on a straight-line basis over the lease term. Please read Note 8 for additional disclosures related to accounting for leases under this new standard.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The adoption of ASC 842 had a material impact on our condensed consolidated balance sheet as the standard requires us to measure and recognize a right of use asset and lease liability.&#160;As most leases do not provide an implicit rate, our incremental borrowing rate was determined based on the information available at the date of adoption to measure our lease liability.&#160;Costs determined to be variable and not based on an index or rate were not included in the measurement of the lease liability.&#160;We recognized approximately $290.0 million of operating lease liabilities and approximately $230.0 million of operating lease right-of-use assets on our condensed consolidated balance sheet as of January 1, 2019, which are presented as separate line items on the condensed consolidated balance sheet.&#160;Had we not adopted the new leasing standard, we would not have had operating lease right-of-use assets or operating lease liabilities on our condensed consolidated balance sheet. The adoption of the standard did not have a material impact on our condensed consolidated statement of comprehensive income.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued a new standard which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued a new standard that amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date.&#160;The new standard became effective for us on January 1, 2019. This standard did not have a significant impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued amendments that eliminate, add and modify certain disclosure requirements on fair value measurements. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued new accounting guidance to clarify the accounting for implementation costs in cloud computing arrangements (hosting arrangements). The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued guidance to clarify the interaction between the accounting guidance for collaborative arrangements and revenue from contracts with customers. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption, including adoption in any interim period, is permitted. This </span></div>guidance is required to be applied retrospectively as of the date of our adoption of the new revenue standard on January 1, 2018. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>342</ContextCount>
  <ElementCount>325</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NATUREOFBUSINESS</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION</Role>
      <ShortName>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - PRODUCT REVENUES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/PRODUCTREVENUESNET</Role>
      <ShortName>PRODUCT REVENUES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/COLLABORATIONAGREEMENTS</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - MARKETABLE DEBT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES</Role>
      <ShortName>MARKETABLE DEBT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - CREDIT AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CREDITAGREEMENT</Role>
      <ShortName>CREDIT AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/EQUITY</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2146113 - Disclosure - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH</Role>
      <ShortName>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149114 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151115 - Disclosure - DEFINED BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEFINEDBENEFITPLANS</Role>
      <ShortName>DEFINED BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2153116 - Disclosure - OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - PRODUCT REVENUES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/PRODUCTREVENUESNETTables</Role>
      <ShortName>PRODUCT REVENUES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/PRODUCTREVENUESNET</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - COLLABORATION AGREEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/COLLABORATIONAGREEMENTSTables</Role>
      <ShortName>COLLABORATION AGREEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/COLLABORATIONAGREEMENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/INVENTORY</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables</Role>
      <ShortName>MARKETABLE DEBT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/LEASES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASHTables</Role>
      <ShortName>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/RECONCILIATIONOFCASHCASHEQUIVALENTSANDRESTRICTEDCASH</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2354310 - Disclosure - OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>OTHER COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/OTHERCOMPREHENSIVELOSSANDACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation and Principles of Consolidation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BasisofPresentationandPrinciplesofConsolidationAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Product Revenues, Net - Summary of Net Product Revenues Of ONPATTRO (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/ProductRevenuesNetSummaryofNetProductRevenuesOfONPATTRODetail</Role>
      <ShortName>Product Revenues, Net - Summary of Net Product Revenues Of ONPATTRO (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Product Revenues, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/ProductRevenuesNetAdditionalInformationDetail</Role>
      <ShortName>Product Revenues, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Collaboration Agreements - Revenue from Collaborators (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsRevenuefromCollaboratorsDetail</Role>
      <ShortName>Collaboration Agreements - Revenue from Collaborators (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Collaboration Agreements - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail</Role>
      <ShortName>Collaboration Agreements - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Collaboration Agreements - Change in Contract Liability Balance Related to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsChangeinContractLiabilityBalanceRelatedtoCollaborationAgreementsDetail</Role>
      <ShortName>Collaboration Agreements - Change in Contract Liability Balance Related to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Collaboration Agreements - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail</Role>
      <ShortName>Collaboration Agreements - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Collaboration Agreements - Schedule of Transaction Price Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsScheduleofTransactionPriceAllocatedDetails</Role>
      <ShortName>Collaboration Agreements - Schedule of Transaction Price Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Collaboration Agreements - Schedule of Revenue Recognized by Accounting Guidance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CollaborationAgreementsScheduleofRevenueRecognizedbyAccountingGuidanceDetails</Role>
      <ShortName>Collaboration Agreements - Schedule of Revenue Recognized by Accounting Guidance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Inventory - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/InventoryScheduleofInventoryDetail</Role>
      <ShortName>Inventory - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FairValueMeasurementsFairValueofAssetsMeasuredonaRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value of Assets Measured on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Marketable Debt Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MarketableDebtSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Debt Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Marketable Debt Securities - Summary of Company's Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofCompanysMarketableDebtSecuritiesDetail</Role>
      <ShortName>Marketable Debt Securities - Summary of Company's Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Marketable Debt Securities - Summary of Fair Value of Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MarketableDebtSecuritiesSummaryofFairValueofMarketableDebtSecuritiesDetail</Role>
      <ShortName>Marketable Debt Securities - Summary of Fair Value of Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Leases - Summary of Costs Included in Operating Expenses Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LeasesSummaryofCostsIncludedinOperatingExpensesRelatedtoLeasesDetail</Role>
      <ShortName>Leases - Summary of Costs Included in Operating Expenses Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LeasesSummaryofFutureLeasePaymentsforNoncancellableOperatingLeasesandReconciliationtoCarryingAmountofOperatingLeaseLiabilityDetail</Role>
      <ShortName>Leases - Summary of Future Lease Payments for Non-cancellable Operating Leases and Reconciliation to Carrying Amount of Operating Lease Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetail</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Credit Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CreditAgreementAdditionalInformationDetail</Role>
      <ShortName>Credit Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/EquityAdditionalInformationDetail</Role>
      <ShortName>Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/StockBasedCompensationSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Net Loss Per Common Share - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NetLossPerCommonShareCommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail</Role>
      <ShortName>Net Loss Per Common Share - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - Reconciliation of Cash, Cash Equivalents and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/ReconciliationofCashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>Reconciliation of Cash, Cash Equivalents and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - Defined Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DefinedBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Defined Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="alny-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2455428 - Disclosure - Other Comprehensive Loss and Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OtherComprehensiveLossandAccumulatedOtherComprehensiveLossSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Other Comprehensive Loss and Accumulated Other Comprehensive Loss - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="alny-20190930.htm">alny-20190930.htm</File>
    <File>alny-20190930.xsd</File>
    <File>alny-20190930_cal.xml</File>
    <File>alny-20190930_def.xml</File>
    <File>alny-20190930_lab.xml</File>
    <File>alny-20190930_pre.xml</File>
    <File>alnyq3201910-qex311.htm</File>
    <File>alnyq3201910-qex312.htm</File>
    <File>alnyq3201910-qex321.htm</File>
    <File>alnyq3201910-qex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>alny-20190930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775201920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2018, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 14, 2019. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018.&#160;Updates to our significant accounting policies, including the updated lease accounting policy due to the adoption of the new leasing accounting standard, are discussed below and under &#8220;Recent Accounting Pronouncements.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassification</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable debt securities as of September&#160;30, 2019, together with the cash we expect to generate from product sales and under our alliances, will be sufficient to enable us to advance our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Alnylam 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LeasesPolicyPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We determine whether a contract is, or contains, a lease at inception. We classify each of our leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the condensed consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.&#160;Costs determined to be variable and not based on an index or rate are not included in </span></div>the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. We record expense to recognize fixed lease payments on a straight-line basis over the expected lease term. We have elected the practical expedient not to separate lease and non-lease components for real estate leases.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board, or FASB, issued a new leasing standard which generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the condensed consolidated balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new standard on January 1, 2019, using a modified retrospective basis and did not restate comparative periods. In addition, we did not elect the package of practical expedients permitted under the transition guidance that permits companies to carry forward prior conclusions related to (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. All our leases have been classified as operating leases under the new leasing standard.&#160;We elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the condensed consolidated balance sheets and recognize the associated lease payments in the condensed consolidated statements of comprehensive loss on a straight-line basis over the lease term. Please read Note 8 for additional disclosures related to accounting for leases under this new standard.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The adoption of ASC 842 had a material impact on our condensed consolidated balance sheet as the standard requires us to measure and recognize a right of use asset and lease liability.&#160;As most leases do not provide an implicit rate, our incremental borrowing rate was determined based on the information available at the date of adoption to measure our lease liability.&#160;Costs determined to be variable and not based on an index or rate were not included in the measurement of the lease liability.&#160;We recognized approximately $290.0 million of operating lease liabilities and approximately $230.0 million of operating lease right-of-use assets on our condensed consolidated balance sheet as of January 1, 2019, which are presented as separate line items on the condensed consolidated balance sheet.&#160;Had we not adopted the new leasing standard, we would not have had operating lease right-of-use assets or operating lease liabilities on our condensed consolidated balance sheet. The adoption of the standard did not have a material impact on our condensed consolidated statement of comprehensive income.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued a new standard which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued a new standard that amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date.&#160;The new standard became effective for us on January 1, 2019. This standard did not have a significant impact on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued amendments that eliminate, add and modify certain disclosure requirements on fair value measurements. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued new accounting guidance to clarify the accounting for implementation costs in cloud computing arrangements (hosting arrangements). The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard is effective for interim and annual periods beginning after December 15, 2019, however, early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued guidance to clarify the interaction between the accounting guidance for collaborative arrangements and revenue from contracts with customers. The amendments become effective for our fiscal year, including interim periods, beginning January 1, 2020. Early adoption, including adoption in any interim period, is permitted. This </span></div>guidance is required to be applied retrospectively as of the date of our adoption of the new revenue standard on January 1, 2018. We are currently evaluating the timing of our adoption and the expected impact this guidance could have on our condensed consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LeasesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LeasesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789414352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value of Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables present information about our assets that are measured at fair value on a recurring basis as of September&#160;30, 2019 and December&#160;31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value, in thousands:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.073421%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">655,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">655,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">134,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">134,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">87,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">59,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">634,514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">634,514&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,607,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">135,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,471,897&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:48.073421%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.747430%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">221,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">221,281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">102,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">102,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">57,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">325,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">325,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,477&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">989,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">884,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6958645520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 70,061<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 148,069<span></span>
</td>
<td class="nump">$ 53,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,213<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">160,796<span></span>
</td>
<td class="nump">139,945<span></span>
</td>
<td class="nump">453,813<span></span>
</td>
<td class="nump">374,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">120,351<span></span>
</td>
<td class="nump">116,545<span></span>
</td>
<td class="nump">322,728<span></span>
</td>
<td class="nump">273,671<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">286,360<span></span>
</td>
<td class="nump">256,627<span></span>
</td>
<td class="nump">789,427<span></span>
</td>
<td class="nump">648,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(216,299)<span></span>
</td>
<td class="num">(254,558)<span></span>
</td>
<td class="num">(641,358)<span></span>
</td>
<td class="num">(594,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">9,889<span></span>
</td>
<td class="nump">6,796<span></span>
</td>
<td class="nump">26,195<span></span>
</td>
<td class="nump">18,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(2,519)<span></span>
</td>
<td class="nump">2,925<span></span>
</td>
<td class="num">(2,929)<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ChangeInFairValueOfLiabilityObligation', window );">Change in fair value of liability obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,422<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">7,370<span></span>
</td>
<td class="nump">9,721<span></span>
</td>
<td class="nump">32,688<span></span>
</td>
<td class="nump">44,723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(208,929)<span></span>
</td>
<td class="num">(244,837)<span></span>
</td>
<td class="num">(608,670)<span></span>
</td>
<td class="num">(549,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) for income taxes</a></td>
<td class="nump">394<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (208,535)<span></span>
</td>
<td class="num">$ (245,282)<span></span>
</td>
<td class="num">$ (609,931)<span></span>
</td>
<td class="num">$ (550,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (5.63)<span></span>
</td>
<td class="num">$ (5.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)</a></td>
<td class="nump">108,701<span></span>
</td>
<td class="nump">100,783<span></span>
</td>
<td class="nump">108,427<span></span>
</td>
<td class="nump">100,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (208,535)<span></span>
</td>
<td class="num">$ (245,282)<span></span>
</td>
<td class="num">$ (609,931)<span></span>
</td>
<td class="num">$ (550,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Defined benefit pension plans</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(207,075)<span></span>
</td>
<td class="num">(244,867)<span></span>
</td>
<td class="num">(611,089)<span></span>
</td>
<td class="num">(549,015)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net Revenues from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23,995<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">37,481<span></span>
</td>
<td class="nump">53,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenues, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 46,066<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="nump">$ 110,588<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ChangeInFairValueOfLiabilityObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ChangeInFairValueOfLiabilityObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32157-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
